assay_strain,src_assay_id,description,cell_id,tid,assay_organism,curated_by,tissue_id,assay_tax_id,assay_id,assay_test_type,assay_cell_type,variant_id,assay_category,assay_tissue,assay_type,src_id,bao_format,doc_id,confidence_score,chembl_id,assay_subcellular_fraction,relationship_type
,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,12052,,Autocuration,,,1,,,,,,B,1,BAO_0000019,11087,8,CHEMBL615117,,H
,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,22226,,Autocuration,,,2,,,,,,F,1,BAO_0000219,684,0,CHEMBL615118,,U
,,,,22226,,Autocuration,,,3,,,,,,B,1,BAO_0000019,15453,0,CHEMBL615119,,U
,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,104729,Bos taurus,Autocuration,,9913.0,4,,,,,,B,1,BAO_0000249,17841,4,CHEMBL615120,,H
,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),163.0,80001,Homo sapiens,Intermediate,,9606.0,5,,143B,,,,F,1,BAO_0000219,17430,1,CHEMBL615121,,N
,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),163.0,80001,Homo sapiens,Intermediate,,9606.0,6,,143B,,,,F,1,BAO_0000219,17430,1,CHEMBL615122,,N
,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,163.0,80001,Mus musculus,Intermediate,,10090.0,7,,143B,,,,F,1,BAO_0000219,13799,1,CHEMBL615123,,N
,,In vitro cell cytotoxicity was determined against 143B cell line,163.0,80001,Homo sapiens,Expert,,9606.0,8,,143B,,,,F,1,BAO_0000219,17774,1,CHEMBL615124,,N
,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,163.0,80001,Homo sapiens,Intermediate,,9606.0,9,,143B,,,,F,1,BAO_0000219,3801,1,CHEMBL615125,,N
,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,163.0,80001,Homo sapiens,Intermediate,,9606.0,10,,143B,,,,F,1,BAO_0000219,17430,1,CHEMBL615126,,N
,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,163.0,80001,Homo sapiens,Intermediate,,9606.0,11,,143B,,,,F,1,BAO_0000219,17430,1,CHEMBL615127,,N
,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,163.0,80001,Homo sapiens,Expert,,9606.0,12,,143B,,,,F,1,BAO_0000219,17774,1,CHEMBL615128,,N
,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,50185,Staphylococcus aureus,Intermediate,,1280.0,13,,,,,,F,1,BAO_0000218,11324,1,CHEMBL857900,,N
,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,50185,Staphylococcus aureus,Intermediate,,1280.0,14,,,,,,F,1,BAO_0000218,11324,1,CHEMBL615129,,N
,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,50185,Staphylococcus aureus,Intermediate,,1280.0,15,,,,,,F,1,BAO_0000218,11324,1,CHEMBL615130,,N
,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,50185,Staphylococcus aureus,Intermediate,,1280.0,16,,,,,,F,1,BAO_0000218,11324,1,CHEMBL615131,,N
,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,100122,Rattus norvegicus,Expert,,10116.0,17,,,,,,A,1,BAO_0000357,11347,9,CHEMBL884521,,D
,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,12054,,Autocuration,,,18,,,,,,B,1,BAO_0000357,16474,8,CHEMBL615132,,H
,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,12054,,Autocuration,,,19,,,,,,B,1,BAO_0000019,10091,8,CHEMBL615133,,H
,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,12054,,Autocuration,,,20,,,,,,B,1,BAO_0000357,16474,8,CHEMBL615134,,H
,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,12054,,Autocuration,,,21,,,,,,B,1,BAO_0000357,16474,8,CHEMBL615135,,H
,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,12054,,Autocuration,,,22,,,,,,B,1,BAO_0000357,16474,8,CHEMBL615136,,H
,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,12054,,Autocuration,,,23,,,,,,B,1,BAO_0000357,16474,8,CHEMBL615137,,H
,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,12054,,Autocuration,,,24,,,,,,B,1,BAO_0000357,16474,8,CHEMBL615138,,H
,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,22226,,Autocuration,,,25,,,,,,B,1,BAO_0000219,14352,0,CHEMBL836324,,U
,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,12054,Oryctolagus cuniculus,Autocuration,,9986.0,26,,,,,,B,1,BAO_0000357,5646,8,CHEMBL615139,,H
,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,12054,Oryctolagus cuniculus,Autocuration,,9986.0,27,,,,,,B,1,BAO_0000357,5646,8,CHEMBL615140,,H
,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,12426,,Autocuration,,,28,,,,,,B,1,BAO_0000219,10997,8,CHEMBL615141,,H
,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,12054,soya bean,Autocuration,,3847.0,29,,,,,,B,1,BAO_0000357,6309,8,CHEMBL615142,,H
,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,12054,Glycine max,Autocuration,,3847.0,30,,,,,,B,1,BAO_0000357,167,8,CHEMBL615143,,H
,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,12054,Glycine max,Autocuration,,3847.0,31,,,,,,B,1,BAO_0000357,167,8,CHEMBL615144,,H
,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,12054,Glycine max,Autocuration,,3847.0,32,,,,,,B,1,BAO_0000357,11087,8,CHEMBL872867,,H
,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,12054,Glycine max,Autocuration,,3847.0,33,,,,,,B,1,BAO_0000357,11087,8,CHEMBL615145,,H
,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,12054,Glycine max,Autocuration,,3847.0,34,,,,,,B,1,BAO_0000357,13622,8,CHEMBL615146,,H
,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,12054,Glycine max,Autocuration,,3847.0,35,,,,,,B,1,BAO_0000357,13622,8,CHEMBL615147,,H
,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,22226,Rattus norvegicus,Autocuration,,10116.0,36,,,,,,A,1,BAO_0000019,11347,0,CHEMBL615148,,U
,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,22226,Escherichia coli,Autocuration,,562.0,37,,,,,,B,1,BAO_0000019,5926,0,CHEMBL615149,,U
,,Dissociation constant with dimeric 16S rRNA RNA construct B,,22226,,Autocuration,,,38,,,,,,B,1,BAO_0000019,4567,0,CHEMBL615150,,U
,,Dissociation constant towards 16S rRNA construct A,,22222,,Intermediate,,,39,,,,,,B,1,BAO_0000225,3782,3,CHEMBL615151,,M
,,Dissociation constant towards 16S rRNA construct B,,22222,,Intermediate,,,40,,,,,,B,1,BAO_0000225,3782,3,CHEMBL615152,,M
,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,100263,Escherichia coli,Expert,,562.0,41,,,,,,B,1,BAO_0000225,4466,3,CHEMBL615153,,M
,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,100263,Escherichia coli,Expert,,562.0,42,,,,,,B,1,BAO_0000225,6592,3,CHEMBL615154,,M
,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,13053,,Autocuration,,,43,,,,,,B,1,BAO_0000019,898,8,CHEMBL615155,,H
,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,13053,,Autocuration,,,44,,,,,,B,1,BAO_0000019,898,8,CHEMBL615156,,H
,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,20001,Homo sapiens,Autocuration,,9606.0,45,,,,,,B,1,BAO_0000019,13163,8,CHEMBL615157,,H
,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,20001,Homo sapiens,Autocuration,,9606.0,46,,,,,,B,1,BAO_0000019,13163,8,CHEMBL615158,,H
,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,12971,Rattus norvegicus,Expert,,10116.0,47,,,,,,B,1,BAO_0000019,10691,9,CHEMBL615159,,D
,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,12971,Rattus norvegicus,Expert,,10116.0,48,,,,,,B,1,BAO_0000019,10691,9,CHEMBL615172,,D
,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,12971,Rattus norvegicus,Expert,,10116.0,49,,,,,,B,1,BAO_0000019,10691,9,CHEMBL615173,,D
,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,12971,Rattus norvegicus,Expert,,10116.0,50,,,,,,B,1,BAO_0000019,10691,9,CHEMBL615174,,D
,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,13053,,Autocuration,,,51,,,,,,B,1,BAO_0000019,898,8,CHEMBL884518,,H
,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,11512,,Autocuration,,,52,,,,,,B,1,BAO_0000357,912,8,CHEMBL615175,,H
,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,11512,,Autocuration,,,53,,,,,,B,1,BAO_0000357,912,8,CHEMBL615176,,H
,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,11512,,Autocuration,,,54,,,,,,B,1,BAO_0000357,912,8,CHEMBL615177,,H
,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,104740,Rattus norvegicus,Autocuration,,10116.0,55,,,,,,B,1,BAO_0000249,15103,5,CHEMBL615178,Membranes,D
,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,506.0,80002,Homo sapiens,Intermediate,,9606.0,56,,1A9,,,,F,1,BAO_0000219,5116,1,CHEMBL615179,,N
,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,104835,Rattus norvegicus,Autocuration,,10116.0,57,,Oocytes,,,,F,1,BAO_0000219,14578,7,CHEMBL615180,,D
,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,104821,Rattus norvegicus,Autocuration,,10116.0,58,,Oocytes,,,,F,1,BAO_0000219,14578,7,CHEMBL615181,,D
,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,104848,Rattus norvegicus,Autocuration,,10116.0,59,,Oocytes,,,,F,1,BAO_0000219,14578,7,CHEMBL615182,,D
,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,506.0,80002,Homo sapiens,Expert,,9606.0,60,,1A9,,,,F,1,BAO_0000219,4787,1,CHEMBL615183,,N
,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,506.0,80002,Homo sapiens,Intermediate,,9606.0,61,,1A9,,,,F,1,BAO_0000219,4787,1,CHEMBL615184,,N
,,Cytotoxic activity against human ovarian cancer (1A9) cell line,506.0,80002,Homo sapiens,Intermediate,,9606.0,62,,1A9,,,,F,1,BAO_0000219,3547,1,CHEMBL615185,,N
,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,506.0,80002,Homo sapiens,Intermediate,,9606.0,63,,1A9,,,,F,1,BAO_0000219,3547,1,CHEMBL615186,,N
,,Effective dose of compound against replication of 1A9 cell line was evaluated,506.0,80002,Homo sapiens,Intermediate,,9606.0,64,,1A9,,,,F,1,BAO_0000219,6726,1,CHEMBL615187,,N
,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,506.0,80002,Homo sapiens,Expert,,9606.0,65,,1A9,,,,F,1,BAO_0000219,3455,1,CHEMBL885343,,N
,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),506.0,80002,Homo sapiens,Intermediate,,9606.0,66,,1A9,,,,F,1,BAO_0000219,5726,1,CHEMBL615188,,N
,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,506.0,80002,Homo sapiens,Intermediate,,9606.0,67,,1A9,,,,F,1,BAO_0000219,5726,1,CHEMBL615189,,N
,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,506.0,80002,Homo sapiens,Intermediate,,9606.0,68,,1A9,,,,F,1,BAO_0000219,5726,1,CHEMBL615190,,N
,,Inhibitory activity against Taxol resistant 1A9 cell lines,506.0,80002,Homo sapiens,Intermediate,,9606.0,69,,1A9,,,,F,1,BAO_0000219,3395,1,CHEMBL615191,,N
,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,506.0,80002,Homo sapiens,Expert,,9606.0,70,,1A9,,,,F,1,BAO_0000219,3415,1,CHEMBL615192,,N
,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,506.0,80002,Homo sapiens,Expert,,9606.0,71,,1A9,,,,F,1,BAO_0000219,3415,1,CHEMBL827083,,N
,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,506.0,80002,Homo sapiens,Expert,,9606.0,72,,1A9,,,,F,1,BAO_0000219,17099,1,CHEMBL615193,,N
,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,506.0,80002,Homo sapiens,Intermediate,,9606.0,73,,1A9,,,,F,1,BAO_0000219,17099,1,CHEMBL615194,,N
,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,506.0,80002,Homo sapiens,Intermediate,,9606.0,74,,1A9,,,,F,1,BAO_0000219,17099,1,CHEMBL615195,,N
,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,506.0,80002,Homo sapiens,Intermediate,,9606.0,75,,1A9,,,,F,1,BAO_0000219,17099,1,CHEMBL615196,,N
,,Inhibitory concentration against Jurkat cells,503.0,81072,Homo sapiens,Intermediate,,9606.0,76,,Jurkat,,,,F,1,BAO_0000219,17721,1,CHEMBL615197,,N
,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,22226,,Intermediate,,,77,,,,,,F,1,BAO_0000019,1229,0,CHEMBL615198,,U
,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,100121,Rattus norvegicus,Expert,,10116.0,78,,,,,,A,1,BAO_0000357,11347,9,CHEMBL615199,,D
,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,11231,,Expert,,,79,,,,,,B,1,BAO_0000357,17117,8,CHEMBL615200,,H
,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,11231,,Expert,,,80,,,,,,B,1,BAO_0000357,17117,8,CHEMBL615201,,H
,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,11231,,Expert,,,81,,,,,,B,1,BAO_0000357,17117,8,CHEMBL615202,,H
,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,11231,Candida albicans,Autocuration,,5476.0,82,,,,,,B,1,BAO_0000251,11375,8,CHEMBL615203,Microsomes,H
,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,11231,Candida albicans,Autocuration,,5476.0,83,,,,,,B,1,BAO_0000251,11375,8,CHEMBL615204,Microsomes,H
,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,11231,Saccharomyces cerevisiae,Autocuration,,4932.0,84,,,,,,B,1,BAO_0000251,11375,8,CHEMBL615205,Microsomes,H
,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,11231,Saccharomyces cerevisiae,Autocuration,,4932.0,85,,,,,,B,1,BAO_0000251,11375,8,CHEMBL615206,Microsomes,H
,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,12083,Sus scrofa,Autocuration,2107.0,9823.0,86,,,,,Liver,B,1,BAO_0000251,11375,8,CHEMBL615207,Microsomes,H
,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,11231,Rattus norvegicus,Autocuration,,10116.0,87,,,,,,B,1,BAO_0000019,791,8,CHEMBL827084,,H
,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,11231,Rattus norvegicus,Autocuration,,10116.0,88,,,,,,B,1,BAO_0000019,791,8,CHEMBL615208,,H
,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,11231,Rattus norvegicus,Autocuration,,10116.0,89,,,,,,B,1,BAO_0000019,791,8,CHEMBL615209,,H
,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,12083,Rattus norvegicus,Autocuration,2107.0,10116.0,90,,,,,Liver,B,1,BAO_0000251,11375,9,CHEMBL615210,Microsomes,D
,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,12083,Rattus norvegicus,Autocuration,2107.0,10116.0,91,,,,,Liver,B,1,BAO_0000251,11375,9,CHEMBL615211,Microsomes,D
,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,12083,Rattus norvegicus,Autocuration,2107.0,10116.0,92,,,,,Liver,B,1,BAO_0000251,153,9,CHEMBL615212,Microsomes,D
,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,11377,,Expert,,,93,,,,,,B,1,BAO_0000357,8269,8,CHEMBL615213,,H
,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,11377,,Expert,,,94,,,,,,B,1,BAO_0000357,8269,8,CHEMBL615273,,H
,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,726.0,81020,Homo sapiens,Expert,,9606.0,95,,HepG2,,,,F,1,BAO_0000219,17653,1,CHEMBL615274,,N
,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,726.0,81020,Homo sapiens,Intermediate,,9606.0,96,,HepG2,,,,F,1,BAO_0000219,14277,1,CHEMBL615275,,N
,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,726.0,81020,Homo sapiens,Intermediate,,9606.0,97,,HepG2,,,,F,1,BAO_0000219,1717,1,CHEMBL615276,,N
,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,726.0,81020,Homo sapiens,Intermediate,,9606.0,98,,HepG2,,,,F,1,BAO_0000219,14091,1,CHEMBL615277,,N
,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,726.0,81020,Homo sapiens,Intermediate,,9606.0,99,,HepG2,,,,F,1,BAO_0000219,14091,1,CHEMBL615326,,N
,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,50606,Hepatitis B virus,Expert,,10407.0,100,,,,,,F,1,BAO_0000218,17653,1,CHEMBL883130,,N
,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,726.0,81020,Homo sapiens,Intermediate,,9606.0,101,,HepG2,,,,F,1,BAO_0000219,13105,1,CHEMBL884519,,N
,,Concentration required to inhibit 50% of 2.2.15 cell line,726.0,81020,Homo sapiens,Intermediate,,9606.0,102,,HepG2,,,,F,1,BAO_0000219,1717,1,CHEMBL615327,,N
,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,726.0,81020,Homo sapiens,Intermediate,,9606.0,103,,HepG2,,,,A,1,BAO_0000219,13105,1,CHEMBL615328,,N
,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,50587,Homo sapiens,Intermediate,,9606.0,104,,2.2.15,,,,F,1,BAO_0000218,13600,1,CHEMBL615329,,N
,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,50587,Homo sapiens,Intermediate,,9606.0,105,,2.2.15,,,,F,1,BAO_0000218,13467,1,CHEMBL615330,,N
,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,50606,Hepatitis B virus,Expert,,10407.0,106,,2.2.15,,,,F,1,BAO_0000218,17477,1,CHEMBL615331,,N
,,In vitro anti-HBV activity in 2.2.15 cells,,50587,Homo sapiens,Intermediate,,9606.0,107,,2.2.15,,,,F,1,BAO_0000218,1593,1,CHEMBL615332,,N
,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,50587,Homo sapiens,Intermediate,,9606.0,108,,2.2.15,,,,F,1,BAO_0000218,1593,1,CHEMBL615333,,N
,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,50587,Homo sapiens,Intermediate,,9606.0,109,,2.2.15,,,,F,1,BAO_0000218,15089,1,CHEMBL615334,,N
,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,50587,Homo sapiens,Intermediate,,9606.0,110,,2.2.15,,,,F,1,BAO_0000218,15089,1,CHEMBL615335,,N
,,Cytotoxicity in 2.2.15 cells,,50587,Homo sapiens,Intermediate,,9606.0,111,,2.2.15,,,,F,1,BAO_0000218,1593,1,CHEMBL615336,,N
,,Cytotoxicity in 2.2.15 cells; Not determined,,50587,Homo sapiens,Intermediate,,9606.0,112,,2.2.15,,,,F,1,BAO_0000218,1593,1,CHEMBL615337,,N
,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,50587,Homo sapiens,Intermediate,,9606.0,113,,2.2.15,,,,F,1,BAO_0000218,13600,1,CHEMBL615338,,N
,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,50587,Homo sapiens,Intermediate,,9606.0,114,,2.2.15,,,,F,1,BAO_0000218,13467,1,CHEMBL615339,,N
,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,50587,Homo sapiens,Intermediate,,9606.0,115,,2.2.15,,,,F,1,BAO_0000218,13467,1,CHEMBL615340,,N
,,Antiviral activity against HBV was determined in 2.215 cell line,726.0,81020,Homo sapiens,Intermediate,,9606.0,116,,HepG2,,,,F,1,BAO_0000219,14764,1,CHEMBL615341,,N
,,Inhibition of 20-HETE synthesis in human renal microsomes,,22226,Homo sapiens,Autocuration,,9606.0,117,,,,,,B,1,BAO_0000251,6531,0,CHEMBL615342,Microsomes,U
,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,22226,,Autocuration,,,118,,,,,,B,1,BAO_0000019,17322,0,CHEMBL615343,,U
,,Inhibitory concentration against 2008 (ovarian) cells,388.0,80612,Homo sapiens,Intermediate,,9606.0,119,,2008,,,,F,1,BAO_0000219,17072,1,CHEMBL615344,,N
,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,388.0,80612,Homo sapiens,Intermediate,,9606.0,120,,2008,,,,F,1,BAO_0000219,16936,1,CHEMBL615345,,N
,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),388.0,80612,Homo sapiens,Intermediate,,9606.0,121,,2008,,,,F,1,BAO_0000219,16936,1,CHEMBL615346,,N
,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,388.0,80612,Homo sapiens,Intermediate,,9606.0,122,,2008,,,,F,1,BAO_0000219,17146,1,CHEMBL615347,,N
,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,388.0,80612,Homo sapiens,Intermediate,,9606.0,123,,2008,,,,F,1,BAO_0000219,17146,1,CHEMBL615348,,N
,,In vitro inhibition of 2008/R ovarian cancer cell line,561.0,80613,Homo sapiens,Intermediate,,9606.0,124,,2008/R,,,,F,1,BAO_0000219,10797,1,CHEMBL827085,,N
,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,561.0,80613,Homo sapiens,Intermediate,,9606.0,125,,2008/R,,,,F,1,BAO_0000219,10797,1,CHEMBL615349,,N
,,In vitro inhibition of 2008/S ovarian cancer cell line,389.0,80614,Homo sapiens,Intermediate,,9606.0,126,,2008/S,,,,F,1,BAO_0000219,10797,1,CHEMBL615350,,N
,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,389.0,80614,Homo sapiens,Intermediate,,9606.0,127,,2008/S,,,,F,1,BAO_0000219,10797,1,CHEMBL615351,,N
,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,100256,Homo sapiens,Expert,,9606.0,128,,,,,,B,1,BAO_0000220,4823,2,CHEMBL615352,,S
,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,100256,Homo sapiens,Intermediate,,9606.0,129,,,,,,B,1,BAO_0000220,12912,2,CHEMBL615353,,S
,,Inhibition of chymotrypsin-like activity of 20S proteasome,,100256,,Expert,,,130,,,,,,B,1,BAO_0000220,2957,2,CHEMBL615354,,S
,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,100256,,Expert,,,131,,,,,,B,1,BAO_0000220,2957,2,CHEMBL615355,,S
,,Inhibitory activity against 20S proteosome,,100256,,Intermediate,,,132,,,,,,B,1,BAO_0000220,3260,2,CHEMBL615356,,S
,,Compound was tested for inhibitory activity against tryptase,,22226,Homo sapiens,Autocuration,,9606.0,133,,,,,,B,1,BAO_0000019,3451,0,CHEMBL615357,,U
,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,726.0,81020,Homo sapiens,Intermediate,,9606.0,134,,HepG2,,,,F,1,BAO_0000219,13885,1,CHEMBL615358,,N
,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,726.0,81020,Homo sapiens,Intermediate,,9606.0,135,,HepG2,,,,F,1,BAO_0000219,13885,1,CHEMBL827086,,N
,,Compound was tested for the inhibition of Alpha-glucosidase,,22226,,Autocuration,,,136,,,,,,B,1,BAO_0000019,3676,0,CHEMBL615359,,U
,,Inhibitory concentration against human neutrophil elastase (HNE),,235,,Autocuration,,,137,,,,,,B,1,BAO_0000357,6043,8,CHEMBL615360,,H
,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,22226,Rattus norvegicus,Autocuration,948.0,10116.0,138,,,,,Heart,F,1,BAO_0000218,11140,0,CHEMBL615361,,U
,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,19640,,Autocuration,,,139,,,,,,F,1,BAO_0000019,10543,8,CHEMBL615362,,H
,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,19640,,Expert,,,140,,,,,,F,1,BAO_0000019,10543,8,CHEMBL615363,,H
,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,19640,,Autocuration,,,141,,,,,,B,1,BAO_0000357,10543,8,CHEMBL615364,,H
,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,19640,,Expert,,,142,,,,,,F,1,BAO_0000019,10543,8,CHEMBL615365,,H
,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,524.0,80360,Mus musculus,Intermediate,,10090.0,143,,P338,,,,F,1,BAO_0000219,11365,1,CHEMBL615366,,N
,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,524.0,80360,Mus musculus,Intermediate,,10090.0,144,,P338,,,,F,1,BAO_0000219,11365,1,CHEMBL615367,,N
,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,554.0,80384,Homo sapiens,Intermediate,,9606.0,145,,PBL,,,,F,1,BAO_0000219,11803,1,CHEMBL615368,,N
,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,22226,Ovis aries,Autocuration,,9940.0,146,,,,,,F,1,BAO_0000019,11803,0,CHEMBL615369,,U
,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,22226,Ovis aries,Autocuration,,9940.0,147,,,,,,F,1,BAO_0000019,11803,0,CHEMBL615370,,U
,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,191,,Autocuration,,,148,,,,,,B,1,BAO_0000357,12278,8,CHEMBL615673,,H
,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,22226,Homo sapiens,Autocuration,,9606.0,149,,,,,,F,1,BAO_0000019,8249,0,CHEMBL615674,,U
,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,22226,Homo sapiens,Autocuration,,9606.0,150,,,,,,F,1,BAO_0000019,8249,0,CHEMBL615675,,U
,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,635.0,22226,Homo sapiens,Autocuration,,9606.0,151,,CCRF-CEM,,,,F,1,BAO_0000219,8249,0,CHEMBL615676,,U
,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,635.0,22226,Homo sapiens,Autocuration,,9606.0,152,,CCRF-CEM,,,,F,1,BAO_0000219,8249,0,CHEMBL615677,,U
,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,635.0,22226,Homo sapiens,Autocuration,,9606.0,153,,CCRF-CEM,,,,F,1,BAO_0000219,8249,0,CHEMBL615678,,U
,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,635.0,22226,Homo sapiens,Autocuration,,9606.0,154,,CCRF-CEM,,,,F,1,BAO_0000219,8249,0,CHEMBL615679,,U
,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,22226,Homo sapiens,Autocuration,,9606.0,155,,,,,,F,1,BAO_0000019,8249,0,CHEMBL615680,,U
,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,22226,Homo sapiens,Autocuration,,9606.0,156,,,,,,F,1,BAO_0000019,8249,0,CHEMBL615681,,U
,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,104290,,Autocuration,,,157,,,,,,B,1,BAO_0000249,16992,6,CHEMBL857972,,H
,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,50264,Streptococcus pyogenes,Intermediate,,1314.0,158,,,,,,F,1,BAO_0000218,10543,1,CHEMBL857899,,N
,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,50527,Human herpesvirus 3,Intermediate,,10335.0,159,,,,,,F,1,BAO_0000218,17833,1,CHEMBL615371,,N
,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,468.0,50527,vericilla zoster virus,Expert,,10335.0,160,,HEL,,,,F,1,BAO_0000218,17290,1,CHEMBL615372,,N
,,Antiviral activity against 07/1 strain of VZV; ND: No data,,50527,vericilla zoster virus,Intermediate,,10335.0,161,,,,,,F,1,BAO_0000218,17290,1,CHEMBL615373,,N
,,Antiviral activity against 07/1 strain of VZV; ND=No data,,50527,vericilla zoster virus,Intermediate,,10335.0,162,,,,,,F,1,BAO_0000218,17290,1,CHEMBL615374,,N
,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,50145,escherichia cloac,Intermediate,,561.0,163,,,,,,F,1,BAO_0000218,10932,1,CHEMBL615375,,N
,,Ratio of Ki at A2 to Ki at A1 receptors,,22226,,Autocuration,,,164,,,,,,B,1,BAO_0000019,9707,0,CHEMBL615376,,U
,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,11143,Candida albicans,Expert,,5476.0,165,,,,,,B,1,BAO_0000249,2346,8,CHEMBL615377,,H
,,"Inhibition of 1,3-beta-glucan synthase",,18077,Candida glabrata CBS 138,Expert,,284593.0,166,,,,,,B,1,BAO_0000357,2205,8,CHEMBL615378,,H
,,Inhibition of growth of 1-87 human tumor cell line,832.0,80609,Homo sapiens,Intermediate,,9606.0,167,,1-87 tumor cell line,,,,F,1,BAO_0000219,11900,1,CHEMBL615379,,N
,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,12166,Rattus norvegicus,Expert,,10116.0,168,,,,,,B,1,BAO_0000219,14864,9,CHEMBL615380,,D
,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,100171,Glycine max,Autocuration,,3847.0,169,,,,,,B,1,BAO_0000357,16474,9,CHEMBL615381,,D
,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,100171,Glycine max,Autocuration,,3847.0,170,,,,,,B,1,BAO_0000357,16474,9,CHEMBL615382,,D
,,% inhibition against soybean 1-lipoxygenase (SLO),,100171,Glycine max,Autocuration,,3847.0,171,,,,,,B,1,BAO_0000357,16474,9,CHEMBL615383,,D
,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,100171,Glycine max,Autocuration,,3847.0,172,,,,,,B,1,BAO_0000357,16474,9,CHEMBL615384,,D
,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,100171,Glycine max,Autocuration,,3847.0,173,,,,,,B,1,BAO_0000357,3094,9,CHEMBL615385,,D
,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,100171,Glycine max,Autocuration,,3847.0,174,,,,,,B,1,BAO_0000357,3094,9,CHEMBL615386,,D
,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,100171,Glycine max,Autocuration,,3847.0,175,,,,,,B,1,BAO_0000357,3094,9,CHEMBL615387,,D
,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,100171,Glycine max,Autocuration,,3847.0,176,,,,,,B,1,BAO_0000357,3094,9,CHEMBL615388,,D
,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,100171,Glycine max,Autocuration,,3847.0,177,,,,,,B,1,BAO_0000357,3094,9,CHEMBL615214,,D
,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,100171,Glycine max,Autocuration,,3847.0,178,,,,,,B,1,BAO_0000357,3094,9,CHEMBL827087,,D
,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,100171,Glycine max,Autocuration,,3847.0,179,,,,,,B,1,BAO_0000357,3094,9,CHEMBL615215,,D
,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,100171,Glycine max,Autocuration,,3847.0,180,,,,,,B,1,BAO_0000357,3094,9,CHEMBL615216,,D
,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,100171,Glycine max,Autocuration,,3847.0,181,,,,,,B,1,BAO_0000357,3094,9,CHEMBL615217,,D
,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,100171,Glycine max,Autocuration,,3847.0,182,,,,,,B,1,BAO_0000357,3094,9,CHEMBL615218,,D
,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,100171,Glycine max,Autocuration,,3847.0,183,,,,,,B,1,BAO_0000357,3094,9,CHEMBL615219,,D
,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,22226,Mus musculus,Autocuration,,10090.0,184,,,,,,B,1,BAO_0000019,10413,0,CHEMBL615220,,U
,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),294.0,80049,Mus musculus,Intermediate,,10090.0,185,,C3H 10T1/2,,,,F,1,BAO_0000219,16929,1,CHEMBL615221,,N
,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,22226,,Intermediate,,,186,,,,,,F,1,BAO_0000019,1229,0,CHEMBL615222,,U
,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,11489,,Autocuration,,,187,,,,,,B,1,BAO_0000357,16587,8,CHEMBL615223,,H
,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,11862,,Autocuration,,,188,,,,,,B,1,BAO_0000357,16587,8,CHEMBL615224,,H
,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,11862,,Autocuration,,,189,,,,,,B,1,BAO_0000357,16587,8,CHEMBL615225,,H
,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,11489,,Autocuration,,,190,,,,,,B,1,BAO_0000357,16587,8,CHEMBL615226,,H
,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,11862,,Autocuration,,,191,,,,,,B,1,BAO_0000357,16587,8,CHEMBL615227,,H
,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,12347,Bos taurus,Expert,,9913.0,192,,,,,,F,1,BAO_0000019,8058,9,CHEMBL615228,,D
,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,100120,Rattus norvegicus,Expert,,10116.0,193,,,,,,B,1,BAO_0000357,9065,9,CHEMBL615229,,D
,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,100120,Rattus norvegicus,Expert,2369.0,10116.0,194,,,,,Adrenal gland,B,1,BAO_0000357,8865,9,CHEMBL615230,,D
,,Inhibition of rat adrenal 11-beta-hydroxylase,,100120,Rattus norvegicus,Expert,,10116.0,195,,,,,,B,1,BAO_0000357,9066,9,CHEMBL615231,,D
,,Inhibition of rat adrenal 11-beta-hydroxylase,,100120,Rattus norvegicus,Expert,,10116.0,196,,,,,,B,1,BAO_0000357,8394,9,CHEMBL884520,,D
,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,100120,Rattus norvegicus,Expert,,10116.0,197,,,,,,B,1,BAO_0000357,8394,9,CHEMBL615232,,D
,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,10328,,Autocuration,,,198,,,,,,B,1,BAO_0000019,6431,8,CHEMBL615233,,H
,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,11490,,Autocuration,,,199,,,,,,B,1,BAO_0000357,6431,8,CHEMBL827088,,H
,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,11490,,Autocuration,,,200,,,,,,B,1,BAO_0000357,6431,8,CHEMBL615234,,H
,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,11134,,Autocuration,,,201,,,,,,F,1,BAO_0000019,9295,8,CHEMBL615235,,H
,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,12052,,Autocuration,,,202,,,,,,B,1,BAO_0000019,10193,8,CHEMBL615236,,H
,,Compound was tested in vitro for inhibition of 12-LO human platelet,,11134,,Autocuration,,,203,,,,,,B,1,BAO_0000019,13622,8,CHEMBL615237,,H
,,Inhibitory concentration against human platelet 12-lipoxygenase,,11134,,Autocuration,,,204,,,,,,F,1,BAO_0000019,12079,8,CHEMBL615238,,H
,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,11134,,Autocuration,,,205,,,,,,B,1,BAO_0000019,13622,8,CHEMBL615239,,H
,,Inhibitory concentration against human platelet 12-lipoxygenase,,11134,Homo sapiens,Autocuration,,9606.0,206,,,,,,F,1,BAO_0000019,12079,9,CHEMBL615240,,D
,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,11835,,Expert,,,207,,,,,,B,1,BAO_0000019,13500,8,CHEMBL615241,,H
,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,11601,,Expert,,,208,,,,,,B,1,BAO_0000357,13723,8,CHEMBL615242,,H
,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,11134,,Autocuration,,,209,,,,,,B,1,BAO_0000019,16474,8,CHEMBL615243,,H
,,Inhibitory activity against human platelet 12-lipoxygenase,,11134,,Autocuration,,,210,,,,,,B,1,BAO_0000019,1630,8,CHEMBL615244,,H
,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,11134,,Autocuration,,,211,,,,,,B,1,BAO_0000019,167,8,CHEMBL615245,,H
,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,11134,,Autocuration,,,212,,,,,,B,1,BAO_0000019,16474,8,CHEMBL615246,,H
,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,11134,,Autocuration,,,213,,,,,,B,1,BAO_0000019,167,8,CHEMBL615247,,H
,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,11134,,Autocuration,,,214,,,,,,B,1,BAO_0000019,16474,8,CHEMBL615248,,H
,,Inhibitory activity towards porcine 12-lipoxygenase,,11601,,Autocuration,,,215,,,,,,B,1,BAO_0000357,10091,8,CHEMBL615249,,H
,,Tested for inhibition against porcine 12-LO,,11601,,Autocuration,,,216,,,,,,B,1,BAO_0000357,11966,8,CHEMBL615250,,H
,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,12052,,Autocuration,,,217,,,,,,B,1,BAO_0000019,951,8,CHEMBL615251,,H
,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,12052,,Autocuration,,,218,,,,,,B,1,BAO_0000019,10997,8,CHEMBL615252,,H
,,In vitro inhibition of rat platelet 12-lipoxygenase,,12052,,Expert,,,219,,,,,,B,1,BAO_0000019,10193,8,CHEMBL828340,,H
,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,12052,,Autocuration,,,220,,,,,,B,1,BAO_0000019,10193,8,CHEMBL615253,,H
,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,12052,,Autocuration,,,221,,,,,,B,1,BAO_0000019,10193,8,CHEMBL615254,,H
,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,12052,,Autocuration,,,222,,,,,,B,1,BAO_0000019,10193,8,CHEMBL615255,,H
,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,12052,,Autocuration,,,223,,,,,,B,1,BAO_0000019,10193,8,CHEMBL615256,,H
,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,12052,,Autocuration,,,224,,,,,,B,1,BAO_0000019,10193,8,CHEMBL615257,,H
,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,12052,,Autocuration,,,225,,,,,,B,1,BAO_0000019,11087,8,CHEMBL615258,,H
,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,621.0,80007,Homo sapiens,Intermediate,,9606.0,226,,41M,,,,F,1,BAO_0000219,15569,1,CHEMBL615259,,N
,,In vitro antitumor activity against 41M cell line.,621.0,80007,Homo sapiens,Expert,,9606.0,227,,41M,,,,F,1,BAO_0000219,12989,1,CHEMBL615260,,N
,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,621.0,80007,Homo sapiens,Intermediate,,9606.0,228,,41M,,,,F,1,BAO_0000219,16745,1,CHEMBL615261,,N
,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,621.0,80007,Homo sapiens,Intermediate,,9606.0,229,,41M,,,,F,1,BAO_0000219,15569,1,CHEMBL615262,,N
,,In vitro antitumor activity against 41McisR cell line.,621.0,80007,Homo sapiens,Expert,,9606.0,230,,41M,,,,F,1,BAO_0000219,12989,1,CHEMBL615263,,N
,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,621.0,80007,Homo sapiens,Expert,,9606.0,231,,41M,,,,F,1,BAO_0000219,12989,1,CHEMBL838393,,N
,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,621.0,80007,Homo sapiens,Intermediate,,9606.0,232,,41M,,,,F,1,BAO_0000219,16745,1,CHEMBL615264,,N
,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,84,Homo sapiens,Expert,,9606.0,233,,,,,,B,1,BAO_0000357,6210,9,CHEMBL615265,,D
,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,68,Homo sapiens,Expert,,9606.0,234,,,,,,B,1,BAO_0000357,6210,9,CHEMBL615266,,D
,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,68,,Expert,,,235,,,,,,B,1,BAO_0000357,6226,8,CHEMBL615267,,H
,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,10201,,Expert,,,236,,,,,,B,1,BAO_0000357,17855,8,CHEMBL615268,,H
,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,10201,,Expert,,,237,,,,,,B,1,BAO_0000357,17855,8,CHEMBL615269,,H
,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,10201,,Expert,,,238,,,,,,B,1,BAO_0000357,17855,8,CHEMBL615270,,H
,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,12220,,Autocuration,,,239,,,,,,B,1,BAO_0000357,10413,8,CHEMBL615271,,H
,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,11303,Escherichia coli,Autocuration,,562.0,240,,,,,,B,1,BAO_0000357,10413,8,CHEMBL615272,,H
,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,11303,Escherichia coli,Autocuration,,562.0,241,,,,,,B,1,BAO_0000357,10413,8,CHEMBL615103,,H
,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,11303,Escherichia coli,Autocuration,,562.0,242,,,,,,B,1,BAO_0000357,10413,8,CHEMBL615104,,H
,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,12220,,Autocuration,,,243,,,,,,B,1,BAO_0000357,10413,8,CHEMBL615105,,H
,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,12220,,Autocuration,,,244,,,,,,B,1,BAO_0000357,10413,8,CHEMBL872866,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,11303,Sus scrofa,Autocuration,,9823.0,245,,,,,,B,1,BAO_0000357,7587,8,CHEMBL615106,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,11303,Sus scrofa,Autocuration,,9823.0,246,,,,,,B,1,BAO_0000019,7587,8,CHEMBL615107,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,11303,Sus scrofa,Autocuration,,9823.0,247,,,,,,B,1,BAO_0000357,7587,8,CHEMBL615108,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,11303,Sus scrofa,Autocuration,,9823.0,248,,,,,,B,1,BAO_0000357,7587,8,CHEMBL615109,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,11303,Sus scrofa,Autocuration,,9823.0,249,,,,,,B,1,BAO_0000357,7587,8,CHEMBL615110,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,11303,Sus scrofa,Autocuration,,9823.0,250,,,,,,B,1,BAO_0000019,7587,8,CHEMBL840105,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,11303,Sus scrofa,Autocuration,,9823.0,251,,,,,,B,1,BAO_0000019,7587,8,CHEMBL615111,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,11303,Sus scrofa,Autocuration,,9823.0,252,,,,,,B,1,BAO_0000019,7587,8,CHEMBL615112,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,11303,Sus scrofa,Autocuration,,9823.0,253,,,,,,B,1,BAO_0000019,7587,8,CHEMBL615113,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,11303,Sus scrofa,Autocuration,,9823.0,254,,,,,,B,1,BAO_0000019,7587,8,CHEMBL615114,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,11303,Sus scrofa,Autocuration,,9823.0,255,,,,,,B,1,BAO_0000357,7587,8,CHEMBL615115,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,11303,Sus scrofa,Autocuration,,9823.0,256,,,,,,B,1,BAO_0000019,7587,8,CHEMBL615116,,H
,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,11303,,Autocuration,,,257,,,,,,B,1,BAO_0000357,7323,8,CHEMBL615698,,H
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,22226,Sus scrofa,Autocuration,,9823.0,258,,,,,,B,1,BAO_0000019,7587,0,CHEMBL615699,,U
,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,22226,Sus scrofa,Autocuration,,9823.0,259,,,,,,B,1,BAO_0000019,7587,0,CHEMBL615700,,U
,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,100249,Saccharomyces cerevisiae,Expert,,4932.0,260,,,,,,B,1,BAO_0000357,13750,8,CHEMBL615701,,H
,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,22226,Rattus norvegicus,Autocuration,,10116.0,261,,,,,,B,1,BAO_0000019,7662,0,CHEMBL615702,,U
,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,22226,Rattus norvegicus,Autocuration,,10116.0,262,,,,,,B,1,BAO_0000019,7662,0,CHEMBL615703,,U
,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,22226,Rattus norvegicus,Autocuration,,10116.0,263,,,,,,B,1,BAO_0000019,7662,0,CHEMBL615704,,U
,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,104698,,Autocuration,,,264,,,,,,F,1,BAO_0000019,12211,6,CHEMBL615705,,H
,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,104698,,Autocuration,,,265,,,,,,F,1,BAO_0000019,12211,6,CHEMBL615706,,H
,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,266,,,,,Ileum,F,1,BAO_0000221,12211,9,CHEMBL615707,,D
,,Stimulatory activity of intragastric pressure was tested in the rat,,10623,,Expert,,,267,,,,,,F,1,BAO_0000019,12211,8,CHEMBL615708,,H
,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,121,,Autocuration,,,268,,,,,,B,1,BAO_0000357,15453,8,CHEMBL615709,,H
,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,22226,Rattus norvegicus,Autocuration,,10116.0,269,,,,,,F,1,BAO_0000218,11884,0,CHEMBL615710,,U
,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,12688,,Autocuration,,,270,,,,,,F,1,BAO_0000019,7185,8,CHEMBL615711,,H
,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,121,Homo sapiens,Expert,,9606.0,271,,,,,,B,1,BAO_0000357,6876,9,CHEMBL615712,,D
,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,121,Homo sapiens,Expert,,9606.0,272,,,,,,B,1,BAO_0000357,6876,9,CHEMBL836325,,D
,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,12198,,Autocuration,,,273,,,,,,F,1,BAO_0000019,11863,8,CHEMBL615713,,H
,,Inhibition constant of high-affinity 5-HT uptake,,12198,,Autocuration,,,274,,,,,,B,1,BAO_0000357,11863,8,CHEMBL615714,,H
,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,12198,,Autocuration,,,275,,,,,,F,1,BAO_0000019,11863,8,CHEMBL615715,,H
,,Maximum rate was determined for high affinity transport of 5-HT,,12198,,Autocuration,,,276,,,,,,F,1,BAO_0000019,11863,8,CHEMBL615716,,H
,,Compound was tested for agonistic activity against 5-HT uptake,,104714,,Autocuration,,,277,,,,,,F,1,BAO_0000019,4639,4,CHEMBL615717,,H
,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,10577,,Expert,,,278,,,,,,B,1,BAO_0000019,15796,8,CHEMBL881818,,H
,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,105,Bos taurus,Expert,,9913.0,279,,,,,,B,1,BAO_0000357,15796,8,CHEMBL884540,,H
,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,104744,Rattus norvegicus,Autocuration,,10116.0,280,,,,,,B,1,BAO_0000224,12801,5,CHEMBL615718,,D
,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,104744,,Autocuration,,,281,,,,,,B,1,BAO_0000224,12801,4,CHEMBL615719,,H
,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,104744,,Autocuration,,,282,,,,,,B,1,BAO_0000249,12120,4,CHEMBL615720,Membranes,H
,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,104744,,Autocuration,,,283,,,,,,B,1,BAO_0000249,12120,4,CHEMBL615721,Membranes,H
,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744,,Autocuration,,,284,,,,,,B,1,BAO_0000019,11963,4,CHEMBL615722,,H
,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,51,,Autocuration,,,285,,,,,,F,1,BAO_0000019,11701,8,CHEMBL615723,,H
,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,286,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL615724,,H
,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,287,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL615725,,H
,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,288,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL615726,,H
,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,10576,,Autocuration,,,289,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615727,,H
,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,105570,Cavia porcellus,Intermediate,,10141.0,290,,,,,,F,1,BAO_0000019,11574,9,CHEMBL615728,,D
,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,279,,Autocuration,,,291,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL857971,,H
,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,292,,,,,,B,1,BAO_0000357,15363,8,CHEMBL615729,,H
,,Efficacy against 5-hydroxytryptamine 2A receptor,,12687,Rattus norvegicus,Expert,,10116.0,293,,,,,,F,1,BAO_0000019,15363,9,CHEMBL615730,,D
,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,12687,,Expert,,,294,,,,,,F,1,BAO_0000019,15329,8,CHEMBL615731,,H
,,Relative potency towards 5-HT2A receptor of rat tail artery,,12687,,Expert,,,295,,,,,,F,1,BAO_0000019,15329,8,CHEMBL615732,,H
,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,12687,,Expert,,,296,,,,,,F,1,BAO_0000019,15329,8,CHEMBL615733,,H
,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,12687,,Expert,,,297,,,,,,F,1,BAO_0000019,15329,8,CHEMBL615734,,H
,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,12687,,Autocuration,,,298,,,,,,F,1,BAO_0000019,15329,8,CHEMBL615735,,H
,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,12687,,Expert,,,299,,,,,,F,1,BAO_0000019,15329,8,CHEMBL615736,,H
,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,300,,,,,Ileum,F,1,BAO_0000221,273,9,CHEMBL615737,,D
,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,20033,Cavia porcellus,Intermediate,2116.0,10141.0,301,,,,,Ileum,F,1,BAO_0000221,273,9,CHEMBL615738,,D
,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,302,,,,,Ileum,F,1,BAO_0000221,273,9,CHEMBL615739,,D
,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,10623,,Autocuration,,,303,,,,,,B,1,BAO_0000357,12092,8,CHEMBL615278,,H
,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,10623,Rattus norvegicus,Expert,,10116.0,304,,,,,,F,1,BAO_0000019,1317,9,CHEMBL615279,,D
,,Binding affinity against 5-hydroxytryptamine 4 receptor,,168,,Expert,,,305,,,,,,B,1,BAO_0000357,12409,8,CHEMBL615280,,H
,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,22226,Gallus gallus,Autocuration,,9031.0,306,,,,,,B,1,BAO_0000019,11126,0,CHEMBL615281,,U
,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,22226,Homo sapiens,Autocuration,,9606.0,307,,,,,,F,1,BAO_0000019,11126,0,CHEMBL615282,,U
,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,22226,Homo sapiens,Autocuration,,9606.0,308,,,,,,F,1,BAO_0000019,11126,0,CHEMBL615283,,U
,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,649.0,80156,Homo sapiens,Autocuration,,9606.0,309,,HL-60,,,,B,1,BAO_0000219,11126,1,CHEMBL615284,,N
,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,22226,Homo sapiens,Autocuration,,9606.0,310,,,,,,B,1,BAO_0000019,11126,0,CHEMBL615285,,U
,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,22226,Homo sapiens,Autocuration,,9606.0,311,,,,,,B,1,BAO_0000019,11126,0,CHEMBL615286,,U
,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,104703,Homo sapiens,Autocuration,,9606.0,312,,Oocytes,,,,B,1,BAO_0000219,17807,7,CHEMBL615287,,D
,,Chymotryptic inhibitory activity against 26S proteasome,,100256,,Intermediate,,,313,,,,,,F,1,BAO_0000220,16575,2,CHEMBL615288,,S
,,Inhibitory activity against 26S proteasome degradation of IkB,,100256,,Intermediate,,,314,,,,,,B,1,BAO_0000220,15407,2,CHEMBL615289,,S
,,In vitro inhibition of 2780/DOX ovarian cancer cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,315,,A2780,,,,F,1,BAO_0000219,10797,1,CHEMBL615290,,N
,,In vitro inhibition of 2780/S ovarian cancer cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,316,,A2780,,,,F,1,BAO_0000219,10797,1,CHEMBL884522,,N
,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,22226,Homo sapiens,Autocuration,,9606.0,317,,,,,,F,1,BAO_0000019,3469,0,CHEMBL615291,,U
,,Association constant for binding to AATT 28-mer AATT hairpin,,22222,,Intermediate,,,318,,,,,,B,1,BAO_0000225,16037,3,CHEMBL615292,,M
,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,22222,,Intermediate,,,319,,,,,,B,1,BAO_0000225,16037,3,CHEMBL615293,,M
,,Reaction Rate Parameter for 28-mer AATT hairpin,,22222,,Intermediate,,,320,,,,,,B,1,BAO_0000225,16037,3,CHEMBL615294,,M
,,Reaction Rate Parameter for 28-mer AATT hairpin,,22222,,Intermediate,,,321,,,,,,B,1,BAO_0000225,16037,3,CHEMBL615295,,M
,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,22226,Homo sapiens,Autocuration,,9606.0,322,,,,,,F,1,BAO_0000019,16524,0,CHEMBL825021,,U
,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,22226,Homo sapiens,Autocuration,,9606.0,323,,,,,,F,1,BAO_0000019,16524,0,CHEMBL615296,,U
,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,22226,Homo sapiens,Autocuration,,9606.0,324,,,,,,F,1,BAO_0000019,16524,0,CHEMBL615297,,U
,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,22226,Cricetulus griseus,Autocuration,,10029.0,325,,,,,,F,1,BAO_0000019,16758,0,CHEMBL615298,,U
,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,22226,Cricetulus griseus,Autocuration,,10029.0,326,,,,,,F,1,BAO_0000019,16758,0,CHEMBL615299,,U
,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,22226,Cricetulus griseus,Autocuration,,10029.0,327,,,,,,F,1,BAO_0000019,16758,0,CHEMBL615300,,U
,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,241,,Autocuration,,,328,,,,,,B,1,BAO_0000357,14360,8,CHEMBL615301,,H
,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,241,Homo sapiens,Expert,,9606.0,329,,,,,,B,1,BAO_0000357,14360,9,CHEMBL615302,,D
,,Selectivity ratio of ID50 in liver and heart,,22226,Rattus norvegicus,Autocuration,,10116.0,330,,,,,,B,1,BAO_0000019,9964,0,CHEMBL615303,,U
,,"Selectivity, ratio of relative ID50 in liver and heart",,12132,,Autocuration,,,331,,,,,,B,1,BAO_0000019,9964,8,CHEMBL615304,,H
,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,12132,,Autocuration,,,332,,,,,,B,1,BAO_0000019,9964,8,CHEMBL615305,,H
,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132,,Autocuration,,,333,,,,,,B,1,BAO_0000218,9964,8,CHEMBL615306,,H
,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132,,Autocuration,,,334,,,,,,B,1,BAO_0000218,9964,8,CHEMBL615307,,H
,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132,,Autocuration,,,335,In vivo,,,,,B,1,BAO_0000218,9964,8,CHEMBL615308,,H
,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132,,Autocuration,,,336,In vivo,,,,,F,1,BAO_0000218,9964,8,CHEMBL615309,,H
,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,22226,,Autocuration,,,337,,,,,,B,1,BAO_0000019,9964,0,CHEMBL615310,,U
,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,12132,,Autocuration,,,338,,,,,,B,1,BAO_0000019,9964,8,CHEMBL615311,,H
,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,22226,Homo sapiens,Autocuration,,9606.0,339,,,,,,B,1,BAO_0000019,9964,0,CHEMBL615312,,U
,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,12132,,Autocuration,,,340,,,,,,B,1,BAO_0000019,9964,8,CHEMBL615313,,H
,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,12132,,Autocuration,,,341,,,,,,F,1,BAO_0000019,9964,8,CHEMBL615314,,H
,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,12132,,Autocuration,,,342,,,,,,B,1,BAO_0000019,9964,8,CHEMBL615315,,H
,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,22226,Rattus norvegicus,Autocuration,,10116.0,343,,,,,,B,1,BAO_0000218,9964,0,CHEMBL615316,,U
,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,12132,,Autocuration,,,344,In vivo,,,,,B,1,BAO_0000218,9964,8,CHEMBL615317,,H
,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132,,Autocuration,,,345,,,,,,B,1,BAO_0000218,9964,8,CHEMBL615318,,H
,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,22226,Rattus norvegicus,Autocuration,,10116.0,346,,,,,,B,1,BAO_0000218,9964,0,CHEMBL615319,,U
,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,12132,,Autocuration,,,347,,,,,,B,1,BAO_0000019,9964,8,CHEMBL615320,,H
,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,12132,,Autocuration,,,348,,,,,,F,1,BAO_0000019,9964,8,CHEMBL615321,,H
,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,22226,Rattus norvegicus,Autocuration,,10116.0,349,,,,,,B,1,BAO_0000019,3796,0,CHEMBL615322,,U
,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,19690,Escherichia coli,Autocuration,,562.0,350,,,,,,B,1,BAO_0000357,4251,8,CHEMBL615323,,H
,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,19690,Escherichia coli,Autocuration,,562.0,351,,,,,,B,1,BAO_0000357,4251,8,CHEMBL615407,,H
,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,19690,Escherichia coli,Autocuration,,562.0,352,,,,,,B,1,BAO_0000357,4251,8,CHEMBL857267,,H
,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,19690,Escherichia coli,Autocuration,,562.0,353,,,,,,B,1,BAO_0000357,4251,8,CHEMBL615408,,H
,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,19690,,Autocuration,,,354,,,,,,B,1,BAO_0000357,166,8,CHEMBL615409,,H
,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,19690,,Autocuration,,,355,,,,,,B,1,BAO_0000357,17861,8,CHEMBL615410,,H
,,Inhibition constant against 3-dehydroquinate synthase,,19690,,Autocuration,,,356,,,,,,B,1,BAO_0000357,166,8,CHEMBL615411,,H
,,Association rate constant against 3-dehydroquinate synthase,,19690,,Autocuration,,,357,,,,,,B,1,BAO_0000357,166,8,CHEMBL615412,,H
,,Rate constant against 3-dehydroquinate synthase,,19690,,Autocuration,,,358,,,,,,B,1,BAO_0000357,166,8,CHEMBL615413,,H
,,Inhibitory activity against fuc-TVII,,22226,,Autocuration,,,359,,,,,,B,1,BAO_0000019,3548,0,CHEMBL615414,,U
,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,12236,Rattus norvegicus,Autocuration,2107.0,10116.0,360,,,,,Liver,B,1,BAO_0000251,9877,9,CHEMBL615415,Microsomes,D
,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,12236,Rattus norvegicus,Autocuration,2107.0,10116.0,361,,,,,Liver,B,1,BAO_0000251,9877,9,CHEMBL615416,Microsomes,D
,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,12236,Rattus norvegicus,Autocuration,2107.0,10116.0,362,,,,,Liver,B,1,BAO_0000251,9877,9,CHEMBL615417,Microsomes,D
,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,12236,Rattus norvegicus,Autocuration,2107.0,10116.0,363,,,,,Liver,B,1,BAO_0000251,9877,9,CHEMBL615418,Microsomes,D
,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,12236,Rattus norvegicus,Autocuration,2107.0,10116.0,364,,,,,Liver,B,1,BAO_0000251,9877,9,CHEMBL615419,Microsomes,D
,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,12236,Rattus norvegicus,Autocuration,2107.0,10116.0,365,,,,,Liver,B,1,BAO_0000251,9877,9,CHEMBL615420,Microsomes,D
,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,12236,Rattus norvegicus,Autocuration,2107.0,10116.0,366,,,,,Liver,B,1,BAO_0000251,9877,9,CHEMBL615421,Microsomes,D
,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,12236,Rattus norvegicus,Autocuration,2107.0,10116.0,367,,,,,Liver,B,1,BAO_0000251,9877,9,CHEMBL615422,Microsomes,D
,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,12236,Rattus norvegicus,Autocuration,2107.0,10116.0,368,,,,,Liver,B,1,BAO_0000251,9877,9,CHEMBL615423,Microsomes,D
,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,12236,Rattus norvegicus,Autocuration,2107.0,10116.0,369,,,,,Liver,B,1,BAO_0000251,9877,9,CHEMBL872868,Microsomes,D
,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,12236,Rattus norvegicus,Autocuration,2107.0,10116.0,370,,,,,Liver,B,1,BAO_0000251,9877,9,CHEMBL615424,Microsomes,D
,,Inhibitory activity against 3-phosphoglycerate kinase.,,104832,,Autocuration,,,371,,,,,,B,1,BAO_0000224,3003,4,CHEMBL825022,,H
,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,104832,,Autocuration,,,372,,,,,,B,1,BAO_0000224,3003,4,CHEMBL615425,,H
,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,104832,,Autocuration,,,373,,,,,,B,1,BAO_0000224,3003,4,CHEMBL615426,,H
,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,10612,Homo sapiens,Expert,,9606.0,374,,,,,,B,1,BAO_0000357,17185,9,CHEMBL615427,,D
,,Cytotoxicity on 3677 melanoma cells,844.0,80616,Homo sapiens,Intermediate,,9606.0,375,,3677 melanoma cell line,,,,F,1,BAO_0000219,6072,1,CHEMBL615428,,N
,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,844.0,80616,Homo sapiens,Intermediate,,9606.0,376,,3677 melanoma cell line,,,,F,1,BAO_0000219,6072,1,CHEMBL615429,,N
,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,700.0,80617,Mus musculus,Intermediate,,10090.0,377,,MC-38,,,,F,1,BAO_0000219,5018,1,CHEMBL615430,,N
,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,22226,Homo sapiens,Intermediate,,9606.0,378,,,,,,F,1,BAO_0000019,2852,0,CHEMBL615431,,U
,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,798.0,22226,,Autocuration,,,379,,B16,,,,F,1,BAO_0000218,8663,0,CHEMBL615432,,U
,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,798.0,22226,,Autocuration,,,380,,B16,,,,F,1,BAO_0000218,8663,0,CHEMBL615433,,U
,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,12464,Human rhinovirus 14,Expert,,12131.0,381,,,,,,F,1,BAO_0000019,3245,9,CHEMBL615434,,D
,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,50085,Human rhinovirus sp.,Intermediate,,169066.0,382,,,,,,F,1,BAO_0000218,3245,1,CHEMBL615435,,N
,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,50679,human rhinovirus type 14,Intermediate,,169066.0,383,,,,,,F,1,BAO_0000218,3877,1,CHEMBL615436,,N
,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,50679,human rhinovirus type 14,Intermediate,,169066.0,384,,,,,,F,1,BAO_0000218,3877,1,CHEMBL615437,,N
,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,12464,Human rhinovirus 14,Expert,,12131.0,385,,,,,,F,1,BAO_0000019,5861,9,CHEMBL615438,,D
,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,12464,Human rhinovirus 14,Expert,,12131.0,386,,,,,,F,1,BAO_0000019,5861,9,CHEMBL615439,,D
,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,12464,Human rhinovirus 14,Expert,,12131.0,387,,,,,,F,1,BAO_0000019,5861,9,CHEMBL615440,,D
,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,12464,Human rhinovirus 14,Expert,,12131.0,388,,,,,,F,1,BAO_0000019,5861,9,CHEMBL615441,,D
,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,50665,Enterovirus,Intermediate,,12059.0,389,,,,,,F,1,BAO_0000218,13748,1,CHEMBL615641,,N
,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,50665,Enterovirus,Intermediate,,12059.0,390,,,,,,F,1,BAO_0000218,13748,1,CHEMBL872065,,N
,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,50665,Enterovirus,Intermediate,,12059.0,391,,,,,,F,1,BAO_0000218,13748,1,CHEMBL825023,,N
,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,50665,Enterovirus,Intermediate,,12059.0,392,,,,,,F,1,BAO_0000218,13748,1,CHEMBL615642,,N
,,Inhibition of human rhinovirus 3C protease,,12464,Human rhinovirus B,Expert,,147712.0,393,,,,,,B,1,BAO_0000357,13748,8,CHEMBL615643,,H
,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,22226,Homo sapiens,Autocuration,,9606.0,394,,,,,,B,1,BAO_0000019,17699,0,CHEMBL615644,,U
,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),833.0,80619,Mus musculus,Intermediate,,10090.0,395,,3EM 37,,,,F,1,BAO_0000218,7145,1,CHEMBL615645,,N
,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),833.0,80619,Mus musculus,Intermediate,,10090.0,396,,3EM 37,,,,F,1,BAO_0000218,7145,1,CHEMBL615646,,N
,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),833.0,80619,Mus musculus,Intermediate,,10090.0,397,,3EM 37,,,,F,1,BAO_0000218,7145,1,CHEMBL615647,,N
,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),833.0,80619,Mus musculus,Intermediate,,10090.0,398,,3EM 37,,,,F,1,BAO_0000218,7145,1,CHEMBL615648,,N
,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,833.0,80619,Mus musculus,Intermediate,,10090.0,399,,3EM 37,,,,F,1,BAO_0000218,7145,1,CHEMBL615649,,N
,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,833.0,80619,Mus musculus,Intermediate,,10090.0,400,,3EM 37,,,,F,1,BAO_0000218,7145,1,CHEMBL615650,,N
,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,847.0,80620,Mus musculus,Intermediate,,10090.0,401,,3LL cell line,,,,F,1,BAO_0000218,5325,1,CHEMBL615651,,N
,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,847.0,80620,Mus musculus,Intermediate,,10090.0,402,,3LL cell line,,,,F,1,BAO_0000218,5325,1,CHEMBL615652,,N
,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,847.0,80620,Mus musculus,Expert,,10090.0,403,,3LL cell line,,,,F,1,BAO_0000218,5325,1,CHEMBL615653,,N
,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,847.0,80620,Mus musculus,Intermediate,,10090.0,404,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615654,,N
,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,847.0,80620,Mus musculus,Intermediate,,10090.0,405,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615655,,N
,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,847.0,80620,Mus musculus,Intermediate,,10090.0,406,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL825024,,N
,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,847.0,80620,Mus musculus,Intermediate,,10090.0,407,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615656,,N
,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,847.0,80620,Mus musculus,Intermediate,,10090.0,408,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615657,,N
,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,847.0,80620,Mus musculus,Intermediate,,10090.0,409,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615658,,N
,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,847.0,80620,Mus musculus,Intermediate,,10090.0,410,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615659,,N
,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,847.0,80620,Mus musculus,Intermediate,,10090.0,411,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615660,,N
,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,847.0,80620,Mus musculus,Intermediate,,10090.0,412,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615661,,N
,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,847.0,80620,Mus musculus,Intermediate,,10090.0,413,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615662,,N
,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,847.0,80620,Mus musculus,Intermediate,,10090.0,414,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615663,,N
,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,847.0,80620,Mus musculus,Intermediate,,10090.0,415,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615664,,N
,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,847.0,80620,Mus musculus,Intermediate,,10090.0,416,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615665,,N
,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,847.0,80620,Mus musculus,Intermediate,,10090.0,417,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615666,,N
,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,418,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615667,,N
,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,419,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615668,,N
,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,420,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615669,,N
,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,421,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615670,,N
,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,422,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL836739,,N
,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,423,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615671,,N
,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,424,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615672,,N
,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,425,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615791,,N
,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,426,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615792,,N
,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,427,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615793,,N
,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,428,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615794,,N
,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,847.0,80620,Mus musculus,Intermediate,,10090.0,429,,3LL cell line,,,,F,1,BAO_0000219,16169,1,CHEMBL615795,,N
,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,971.0,80621,Homo sapiens,Intermediate,,9606.0,430,,3LLD122,,,,F,1,BAO_0000219,15547,1,CHEMBL615590,,N
,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,22226,,Autocuration,,,431,,,,,,F,1,BAO_0000218,8663,0,CHEMBL615591,,U
,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,22226,,Autocuration,,,432,,,,,,F,1,BAO_0000218,8663,0,CHEMBL615592,,U
,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,22226,,Autocuration,,,433,,,,,,F,1,BAO_0000218,8663,0,CHEMBL615593,,U
,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,22226,,Autocuration,,,434,,,,,,F,1,BAO_0000218,8663,0,CHEMBL615594,,U
,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,723.0,80951,Mus musculus,Intermediate,,10090.0,435,,NIH3T3,,,,F,1,BAO_0000219,4504,1,CHEMBL615595,,N
,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,723.0,80951,Mus musculus,Intermediate,,10090.0,436,,NIH3T3,,,,F,1,BAO_0000219,4504,1,CHEMBL615596,,N
,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,723.0,11169,,Expert,,,437,,NIH3T3,,,,F,1,BAO_0000219,12695,8,CHEMBL615597,,H
,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,723.0,80951,Mus musculus,Intermediate,,10090.0,438,,NIH3T3,,,,F,1,BAO_0000219,12695,1,CHEMBL615598,,N
,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,723.0,80951,Mus musculus,Intermediate,,10090.0,439,,NIH3T3,,,,F,1,BAO_0000219,12695,1,CHEMBL615599,,N
,,Effective dose against murine 3T3 fibroblasts cells,723.0,80951,Mus musculus,Expert,,10090.0,440,,NIH3T3,,,,F,1,BAO_0000219,17642,1,CHEMBL615600,,N
,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,723.0,80951,Mus musculus,Expert,,10090.0,441,,NIH3T3,,,,F,1,BAO_0000219,17642,1,CHEMBL615601,,N
,,Cytotoxic effect on 3T3 cells,723.0,80951,Mus musculus,Expert,,10090.0,442,,NIH3T3,,,,F,1,BAO_0000219,12340,1,CHEMBL615602,,N
,,Cytotoxic effect on 3T3 cells,723.0,80951,Mus musculus,Expert,,10090.0,443,,NIH3T3,,,,F,1,BAO_0000219,12340,1,CHEMBL615603,,N
,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,723.0,80951,Mus musculus,Intermediate,,10090.0,444,,NIH3T3,,,,F,1,BAO_0000219,12716,1,CHEMBL615604,,N
,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,723.0,80951,Mus musculus,Intermediate,,10090.0,445,,NIH3T3,,,,F,1,BAO_0000219,6277,1,CHEMBL615605,,N
,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,723.0,80951,Mus musculus,Intermediate,,10090.0,446,,NIH3T3,,,,F,1,BAO_0000219,6277,1,CHEMBL615606,,N
,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,723.0,80951,Mus musculus,Expert,,10090.0,447,,NIH3T3,,,,F,1,BAO_0000219,6277,1,CHEMBL884526,,N
,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,723.0,80951,Mus musculus,Expert,,10090.0,448,,NIH3T3,,,,F,1,BAO_0000219,6277,1,CHEMBL615607,,N
,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,723.0,80951,Mus musculus,Intermediate,,10090.0,449,,NIH3T3,,,,F,1,BAO_0000219,6277,1,CHEMBL615608,,N
,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,723.0,80951,Mus musculus,Expert,,10090.0,450,,NIH3T3,,,,F,1,BAO_0000219,6277,1,CHEMBL615609,,N
,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,723.0,80951,Mus musculus,Expert,,10090.0,451,,NIH3T3,,,,F,1,BAO_0000219,6277,1,CHEMBL615682,,N
,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,723.0,80951,Mus musculus,Intermediate,,10090.0,452,,NIH3T3,,,,F,1,BAO_0000219,6277,1,CHEMBL615683,,N
,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,723.0,80951,Mus musculus,Expert,,10090.0,453,,NIH3T3,,,,F,1,BAO_0000218,17780,1,CHEMBL615684,,N
,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,104860,Mus musculus,Autocuration,,10090.0,454,,,,,,F,1,BAO_0000219,12751,7,CHEMBL615685,,D
,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,723.0,80951,Mus musculus,Expert,,10090.0,455,,NIH3T3,,,,F,1,BAO_0000219,12380,1,CHEMBL615686,,N
,,Inhibitory activity against 3T3 cell line,723.0,80951,Mus musculus,Intermediate,,10090.0,456,,NIH3T3,,,,F,1,BAO_0000219,14892,1,CHEMBL615687,,N
,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,723.0,80951,Mus musculus,Intermediate,,10090.0,457,,NIH3T3,,,,F,1,BAO_0000219,12695,1,CHEMBL884523,,N
,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,11169,,Expert,,,458,,,,,,F,1,BAO_0000019,12695,8,CHEMBL615688,,H
,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,723.0,80951,Mus musculus,Intermediate,,10090.0,459,,NIH3T3,,,,F,1,BAO_0000219,12695,1,CHEMBL615689,,N
,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,723.0,80951,Mus musculus,Intermediate,,10090.0,460,,NIH3T3,,,,F,1,BAO_0000219,12695,1,CHEMBL615690,,N
,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,11169,,Expert,,,461,,,,,,F,1,BAO_0000019,12695,8,CHEMBL615691,,H
,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,11169,,Expert,,,462,,,,,,F,1,BAO_0000019,12695,8,CHEMBL615692,,H
,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,723.0,80951,Mus musculus,Intermediate,,10090.0,463,,NIH3T3,,,,F,1,BAO_0000219,6277,1,CHEMBL615693,,N
,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,723.0,80951,Mus musculus,Expert,,10090.0,464,,NIH3T3,,,,F,1,BAO_0000219,6277,1,CHEMBL615324,,N
,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,723.0,9,Homo sapiens,Expert,,9606.0,465,,NIH3T3,,,,F,1,BAO_0000219,4959,9,CHEMBL615325,,D
,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),723.0,9,Homo sapiens,Expert,,9606.0,466,,NIH3T3,,,,F,1,BAO_0000219,4959,9,CHEMBL615490,,D
,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,723.0,188,Homo sapiens,Expert,,9606.0,467,,NIH3T3,,,,F,1,BAO_0000219,4959,9,CHEMBL615491,,D
,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),723.0,188,Homo sapiens,Expert,,9606.0,468,,NIH3T3,,,,F,1,BAO_0000219,4959,9,CHEMBL615492,,D
,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,723.0,80951,Mus musculus,Intermediate,,10090.0,469,,NIH3T3,,,,F,1,BAO_0000219,12082,1,CHEMBL615493,,N
,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,723.0,80951,Mus musculus,Intermediate,,10090.0,470,,NIH3T3,,,,F,1,BAO_0000219,12082,1,CHEMBL615494,,N
,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,723.0,80951,Mus musculus,Intermediate,,10090.0,471,,NIH3T3,,,,F,1,BAO_0000219,12082,1,CHEMBL615495,,N
,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,723.0,80951,Mus musculus,Intermediate,,10090.0,472,,NIH3T3,,,,F,1,BAO_0000219,12082,1,CHEMBL615496,,N
,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,723.0,80951,Mus musculus,Intermediate,,10090.0,473,,NIH3T3,,,,F,1,BAO_0000219,2643,1,CHEMBL615497,,N
,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,723.0,80951,Mus musculus,Expert,,10090.0,474,,NIH3T3,,,,F,1,BAO_0000219,11926,1,CHEMBL615498,,N
,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,723.0,80951,Mus musculus,Intermediate,,10090.0,475,,NIH3T3,,,,A,1,BAO_0000219,15204,1,CHEMBL615499,,N
,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,723.0,80951,Mus musculus,Expert,,10090.0,476,,NIH3T3,,,,F,1,BAO_0000219,15992,1,CHEMBL835522,,N
,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,723.0,80951,Mus musculus,Intermediate,,10090.0,477,,NIH3T3,,,,F,1,BAO_0000219,16279,1,CHEMBL615500,,N
,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,80951,Mus musculus,Intermediate,,10090.0,478,,NIH3T3,,,,F,1,BAO_0000219,16279,1,CHEMBL615501,,N
,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,80951,Mus musculus,Intermediate,,10090.0,479,,NIH3T3,,,,F,1,BAO_0000219,16279,1,CHEMBL615502,,N
,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,80951,Mus musculus,Intermediate,,10090.0,480,,NIH3T3,,,,F,1,BAO_0000219,16279,1,CHEMBL615503,,N
,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,80951,Mus musculus,Intermediate,,10090.0,481,,NIH3T3,,,,F,1,BAO_0000219,16279,1,CHEMBL615504,,N
,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,80951,Mus musculus,Intermediate,,10090.0,482,,NIH3T3,,,,F,1,BAO_0000219,16279,1,CHEMBL615505,,N
,,Inhibition of swiss 3T3 mouse fibroblast proliferation,723.0,80951,Mus musculus,Expert,,10090.0,483,,NIH3T3,,,,F,1,BAO_0000219,12831,1,CHEMBL615506,,N
,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,723.0,80951,Mus musculus,Intermediate,,10090.0,484,,NIH3T3,,,,F,1,BAO_0000219,13497,1,CHEMBL615507,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,620.0,80006,,Intermediate,,,485,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615508,,N
,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,620.0,80006,Mus musculus,Intermediate,,10090.0,486,,3T3-L1,,,,F,1,BAO_0000219,13618,1,CHEMBL615509,,N
,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,620.0,80006,Mus musculus,Intermediate,,10090.0,487,,3T3-L1,,,,F,1,BAO_0000219,11902,1,CHEMBL615510,,N
,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,620.0,80006,Mus musculus,Intermediate,,10090.0,488,,3T3-L1,,,,F,1,BAO_0000219,11902,1,CHEMBL615511,,N
,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,620.0,80006,Mus musculus,Intermediate,,10090.0,489,,3T3-L1,,,,F,1,BAO_0000219,11902,1,CHEMBL615512,,N
,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",620.0,80006,Mus musculus,Intermediate,,10090.0,490,,3T3-L1,,,,F,1,BAO_0000218,14840,1,CHEMBL615513,,N
,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",620.0,80006,Mus musculus,Intermediate,,10090.0,491,,3T3-L1,,,,F,1,BAO_0000218,14840,1,CHEMBL615514,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,620.0,80006,,Intermediate,,,492,,3T3-L1,,,,F,1,BAO_0000219,13715,1,CHEMBL615515,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,620.0,80006,,Intermediate,,,493,,3T3-L1,,,,F,1,BAO_0000219,13715,1,CHEMBL615516,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,620.0,80006,,Intermediate,,,494,,3T3-L1,,,,F,1,BAO_0000219,13715,1,CHEMBL615517,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,620.0,80006,,Intermediate,,,495,,3T3-L1,,,,F,1,BAO_0000219,13715,1,CHEMBL615518,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,620.0,80006,,Intermediate,,,496,,3T3-L1,,,,F,1,BAO_0000219,13715,1,CHEMBL615519,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,620.0,80006,,Intermediate,,,497,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615520,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,620.0,80006,,Intermediate,,,498,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615521,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,620.0,80006,,Intermediate,,,499,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615522,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,620.0,80006,,Intermediate,,,500,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615523,,N
,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,620.0,80006,,Expert,,,501,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615524,,N
,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,620.0,80006,,Expert,,,502,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615525,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,620.0,80006,,Intermediate,,,503,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615526,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,620.0,80006,,Intermediate,,,504,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615527,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,620.0,80006,,Intermediate,,,505,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615528,,N
,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,620.0,80006,,Expert,,,506,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615529,,N
,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,620.0,80006,,Expert,,,507,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615530,,N
,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,620.0,80006,,Expert,,,508,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615531,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,620.0,80006,,Intermediate,,,509,,3T3-L1,,,,F,1,BAO_0000219,13715,1,CHEMBL615532,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,620.0,80006,,Intermediate,,,510,,3T3-L1,,,,F,1,BAO_0000219,13715,1,CHEMBL615533,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,620.0,80006,,Intermediate,,,511,,3T3-L1,,,,F,1,BAO_0000219,13715,1,CHEMBL615534,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,620.0,80006,,Intermediate,,,512,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615535,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,620.0,80006,,Intermediate,,,513,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615536,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,620.0,80006,,Intermediate,,,514,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615537,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,620.0,80006,,Intermediate,,,515,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL615538,,N
,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,620.0,80006,,Intermediate,,,516,,3T3-L1,,,,F,1,BAO_0000218,13715,1,CHEMBL836166,,N
,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,620.0,11214,,Expert,,,517,,3T3-L1,,,,F,1,BAO_0000219,6411,8,CHEMBL615539,,H
,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,620.0,80006,Mus musculus,Intermediate,,10090.0,518,,3T3-L1,,,,F,1,BAO_0000219,6411,1,CHEMBL615540,,N
,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,620.0,11214,,Expert,,,519,,3T3-L1,,,,F,1,BAO_0000219,6411,8,CHEMBL615541,,H
,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,620.0,80006,Mus musculus,Expert,,10090.0,520,,3T3-L1,,,,F,1,BAO_0000219,3966,1,CHEMBL615542,,N
,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,620.0,80006,Mus musculus,Intermediate,,10090.0,521,,3T3-L1,,,,F,1,BAO_0000219,3966,1,CHEMBL615543,,N
,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,620.0,80006,Mus musculus,Expert,,10090.0,522,,3T3-L1,,,,F,1,BAO_0000219,15556,1,CHEMBL615544,,N
,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,620.0,80006,Mus musculus,Expert,,10090.0,523,,3T3-L1,,,,F,1,BAO_0000219,5845,1,CHEMBL615545,,N
,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,620.0,80006,Mus musculus,Expert,,10090.0,524,,3T3-L1,,,,F,1,BAO_0000219,14422,1,CHEMBL615546,,N
,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,620.0,80006,Mus musculus,Expert,,10090.0,525,,3T3-L1,,,,F,1,BAO_0000219,5845,1,CHEMBL615547,,N
,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,620.0,80006,Mus musculus,Expert,,10090.0,526,,3T3-L1,,,,F,1,BAO_0000219,14508,1,CHEMBL615548,,N
,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,620.0,80006,Mus musculus,Expert,,10090.0,527,,3T3-L1,,,,F,1,BAO_0000219,14508,1,CHEMBL615549,,N
,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,620.0,80006,Mus musculus,Expert,,10090.0,528,,3T3-L1,,,,F,1,BAO_0000219,14508,1,CHEMBL615550,,N
,,Inhibitory activity against rat fibroblast (3Y1) cell line,1118.0,80622,Rattus norvegicus,Intermediate,,10116.0,529,,3Y1 cell line,,,,F,1,BAO_0000219,6349,1,CHEMBL615551,,N
,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,1118.0,80622,Rattus norvegicus,Expert,,10116.0,530,,3Y1 cell line,,,,F,1,BAO_0000219,15899,1,CHEMBL615552,,N
,,Cytotoxicity in 3Y1 cells.,1118.0,80622,Rattus norvegicus,Expert,,10116.0,531,,3Y1 cell line,,,,F,1,BAO_0000219,15899,1,CHEMBL615553,,N
,,Cytostatic effect in 3Y1 cells.,1118.0,80622,Rattus norvegicus,Expert,,10116.0,532,,3Y1 cell line,,,,F,1,BAO_0000219,15899,1,CHEMBL615554,,N
,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",1118.0,80622,Rattus norvegicus,Intermediate,,10116.0,533,,3Y1 cell line,,,,F,1,BAO_0000219,15899,1,CHEMBL615555,,N
,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,1118.0,80622,Rattus norvegicus,Expert,,10116.0,534,,3Y1 cell line,,,,F,1,BAO_0000219,17038,1,CHEMBL615556,,N
,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,22226,,Autocuration,,,535,,,,,,B,1,BAO_0000019,12421,0,CHEMBL615557,,U
,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,22226,,Autocuration,,,536,,,,,,B,1,BAO_0000019,12947,0,CHEMBL615558,,U
,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,22226,,Autocuration,,,537,,,,,,B,1,BAO_0000019,12947,0,CHEMBL872066,,U
,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,11607,Sus scrofa,Expert,,9823.0,538,,,,,,B,1,BAO_0000019,4896,9,CHEMBL615559,,D
,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,11607,,Autocuration,,,539,,,,,,B,1,BAO_0000019,6148,8,CHEMBL615560,,H
,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,11607,,Autocuration,,,540,,,,,,B,1,BAO_0000019,16432,8,CHEMBL615561,,H
,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,11607,,Expert,,,541,,,,,,B,1,BAO_0000019,4978,8,CHEMBL857062,,H
,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,11607,,Expert,,,542,,,,,,B,1,BAO_0000019,4978,8,CHEMBL615562,,H
,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,11607,,Autocuration,,,543,,,,,,B,1,BAO_0000019,3723,8,CHEMBL615563,,H
,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,11607,,Autocuration,,,544,,,,,,B,1,BAO_0000357,3518,8,CHEMBL615564,,H
,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,11607,,Autocuration,,,545,,,,,,B,1,BAO_0000019,4164,8,CHEMBL615565,,H
,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,11607,,Autocuration,,,546,,,,,,B,1,BAO_0000019,3518,8,CHEMBL615566,,H
,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,11607,Sus scrofa,Expert,,9823.0,547,,,,,,B,1,BAO_0000019,4164,9,CHEMBL615567,,D
,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,11607,,Autocuration,,,548,,,,,,B,1,BAO_0000019,3518,8,CHEMBL615568,,H
,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,11607,,Autocuration,,,549,,,,,,B,1,BAO_0000357,3518,8,CHEMBL615569,,H
,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,11607,,Autocuration,,,550,,,,,,B,1,BAO_0000019,4978,8,CHEMBL615570,,H
,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,11607,,Autocuration,,,551,,,,,,B,1,BAO_0000019,4978,8,CHEMBL615571,,H
,,Binding affinity against melatonin (MT1) receptor (pC1),,104733,,Autocuration,,,552,,,,,,B,1,BAO_0000224,6455,4,CHEMBL615572,,H
,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,22226,,Autocuration,,,553,,,,,,B,1,BAO_0000019,2222,0,CHEMBL615573,,U
,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,22226,,Autocuration,,,554,,,,,,B,1,BAO_0000019,13020,0,CHEMBL615574,,U
,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,22226,,Autocuration,,,555,,,,,,B,1,BAO_0000019,13021,0,CHEMBL615575,,U
,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,10619,,Autocuration,,,556,,,,,,B,1,BAO_0000357,14532,8,CHEMBL615576,,H
,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,10619,,Autocuration,,,557,,,,,,B,1,BAO_0000357,14118,8,CHEMBL615577,,H
,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,51,,Autocuration,10000000.0,,558,,,,,Hippocampus,B,1,BAO_0000221,11884,8,CHEMBL615578,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,51,,Expert,,,559,,,,,,B,1,BAO_0000357,13969,8,CHEMBL615579,,H
,,Binding affinity for 5-hydroxytryptamine 1A receptor,,51,,Expert,,,560,,,,,,B,1,BAO_0000357,13392,8,CHEMBL615580,,H
,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,51,,Expert,,,561,,,,,,B,1,BAO_0000019,14430,8,CHEMBL615581,,H
,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51,,Autocuration,10000000.0,,562,,,,,Hippocampus,B,1,BAO_0000221,12248,8,CHEMBL615582,,H
,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51,,Autocuration,10000000.0,,563,,,,,Hippocampus,B,1,BAO_0000221,12249,8,CHEMBL615583,,H
,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,564,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL615584,,H
,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,565,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL833691,,H
,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,566,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL615585,,H
,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,567,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL615586,,H
,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,568,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL884524,,H
,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51,,Autocuration,10000000.0,,569,,,,,Hippocampus,B,1,BAO_0000221,12249,8,CHEMBL615587,,H
,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,51,,Autocuration,10000000.0,,570,,,,,Hippocampus,B,1,BAO_0000221,11799,8,CHEMBL615588,,H
,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,10576,Rattus norvegicus,Expert,,10116.0,571,,,,,,B,1,BAO_0000249,14331,9,CHEMBL615589,Membranes,D
,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,51,Bos taurus,Expert,10000000.0,9913.0,572,,,,,Hippocampus,B,1,BAO_0000221,11884,8,CHEMBL615442,,H
,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,51,,Autocuration,10000000.0,,573,,,,,Hippocampus,B,1,BAO_0000221,14331,8,CHEMBL615443,,H
,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,51,,Autocuration,10000000.0,,574,,,,,Hippocampus,B,1,BAO_0000221,11701,8,CHEMBL615444,,H
,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,51,,Expert,10000000.0,,575,,,,,Hippocampus,B,1,BAO_0000221,11701,8,CHEMBL615445,,H
,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,51,,Autocuration,10000000.0,,576,,,,,Hippocampus,B,1,BAO_0000221,12248,8,CHEMBL615446,,H
,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,449.0,51,,Autocuration,,,577,,CHO,,,,B,1,BAO_0000219,12248,8,CHEMBL615447,,H
,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51,,Expert,10000000.0,,578,,,,,Hippocampus,B,1,BAO_0000221,12248,8,CHEMBL615448,,H
,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51,,Expert,10000000.0,,579,,,,,Hippocampus,B,1,BAO_0000221,12249,8,CHEMBL615449,,H
,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,51,,Autocuration,,,580,,CHO,,,,B,1,BAO_0000219,12248,8,CHEMBL615450,,H
,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,51,,Expert,10000000.0,,581,,,,,Hippocampus,B,1,BAO_0000221,11799,8,CHEMBL615451,,H
,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,51,,Autocuration,,,582,,,,,,B,1,BAO_0000357,634,8,CHEMBL615452,,H
,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,583,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL615453,,H
,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,584,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL615454,,H
,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,585,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL615455,,H
,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,586,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL615456,,H
,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,587,,,,,Hippocampus,B,1,BAO_0000221,9995,8,CHEMBL615457,,H
,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,51,,Expert,10000000.0,,588,,,,,Hippocampus,B,1,BAO_0000218,12210,8,CHEMBL615458,,H
,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,Expert,10000000.0,,589,,,,,Hippocampus,B,1,BAO_0000221,13311,8,CHEMBL615459,,H
,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",449.0,51,Homo sapiens,Expert,,9606.0,590,,CHO,,,,B,1,BAO_0000219,2331,9,CHEMBL615460,,D
,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,51,Cavia porcellus,Autocuration,,10141.0,591,,,,,,F,1,BAO_0000019,1375,8,CHEMBL615461,,H
,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,51,Cavia porcellus,Autocuration,,10141.0,592,,,,,,F,1,BAO_0000019,1375,8,CHEMBL615462,,H
,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,51,Cavia porcellus,Autocuration,10000000.0,10141.0,593,,,,,Hippocampus,F,1,BAO_0000221,11574,8,CHEMBL615463,,H
,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,51,Cavia porcellus,Autocuration,2116.0,10141.0,594,,,,,Ileum,B,1,BAO_0000221,12867,8,CHEMBL615464,,H
,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,51,Cavia porcellus,Autocuration,2116.0,10141.0,595,,,,,Ileum,B,1,BAO_0000221,12867,8,CHEMBL615465,,H
,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,51,Cavia porcellus,Autocuration,2116.0,10141.0,596,,,,,Ileum,B,1,BAO_0000221,12867,8,CHEMBL615466,,H
,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,51,Cavia porcellus,Autocuration,2116.0,10141.0,597,,,,,Ileum,B,1,BAO_0000221,12867,8,CHEMBL615467,,H
,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,51,Cavia porcellus,Autocuration,2116.0,10141.0,598,,,,,Ileum,B,1,BAO_0000221,12867,8,CHEMBL615468,,H
,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,51,Cavia porcellus,Autocuration,2116.0,10141.0,599,,,,,Ileum,B,1,BAO_0000221,12867,8,CHEMBL615469,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor,,51,Cavia porcellus,Autocuration,,10141.0,600,,,,,,B,1,BAO_0000357,11574,8,CHEMBL615470,,H
,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,51,Cavia porcellus,Autocuration,,10141.0,601,,,,,,B,1,BAO_0000357,13114,8,CHEMBL615471,,H
,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,51,Cavia porcellus,Autocuration,,10141.0,602,,,,,,B,1,BAO_0000357,13181,8,CHEMBL615472,,H
,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,106,Cavia porcellus,Autocuration,10000000.0,10141.0,603,,,,,Hippocampus,B,1,BAO_0000221,10639,8,CHEMBL883242,,H
,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,106,Cavia porcellus,Autocuration,10000000.0,10141.0,604,,,,,Hippocampus,F,1,BAO_0000221,10639,8,CHEMBL615473,,H
,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),449.0,11863,Cricetulus griseus,Autocuration,,10029.0,605,,CHO,,,,B,1,BAO_0000218,11883,8,CHEMBL615474,,H
,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,606,,,,,,B,1,BAO_0000357,17785,8,CHEMBL615475,,H
,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,308.0,51,,Autocuration,,,607,,HeLa,,,,F,1,BAO_0000219,1558,8,CHEMBL615476,,H
,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,308.0,51,,Autocuration,,,608,,HeLa,,,,F,1,BAO_0000219,1558,8,CHEMBL615477,,H
,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,609,,,,,,F,1,BAO_0000019,15740,8,CHEMBL615478,,H
,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,449.0,51,,Autocuration,,,610,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615160,,H
,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,449.0,51,,Expert,,,611,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615161,,H
,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,449.0,51,,Autocuration,,,612,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615162,,H
,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,449.0,51,,Autocuration,,,613,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615163,,H
,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,51,,Expert,,,614,,CHO,,,,B,1,BAO_0000219,17624,8,CHEMBL615164,,H
,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,51,,Expert,,,615,,CHO,,,,B,1,BAO_0000219,17624,8,CHEMBL615165,,H
,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,449.0,51,,Autocuration,,,616,,CHO,,,,B,1,BAO_0000219,17624,8,CHEMBL615166,,H
,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,51,,Autocuration,,,617,,,,,,F,1,BAO_0000219,14256,8,CHEMBL615167,,H
,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,308.0,51,Homo sapiens,Expert,,9606.0,618,,HeLa,,,,B,1,BAO_0000219,3445,9,CHEMBL615168,,D
,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,308.0,51,Homo sapiens,Expert,,9606.0,619,,HeLa,,,,B,1,BAO_0000219,3445,9,CHEMBL615169,,D
,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,449.0,51,Homo sapiens,Expert,,9606.0,620,,CHO,,,,B,1,BAO_0000219,17200,9,CHEMBL615170,,D
,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,449.0,51,Homo sapiens,Expert,,9606.0,621,,CHO,,,,B,1,BAO_0000219,17200,9,CHEMBL615171,,D
,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,622,,,,,,F,1,BAO_0000019,15180,8,CHEMBL615694,,H
,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,623,,,,,,F,1,BAO_0000019,15180,8,CHEMBL615695,,H
,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,51,,Autocuration,,,624,,,,,,F,1,BAO_0000019,16026,8,CHEMBL615696,,H
,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,449.0,51,,Autocuration,,,625,,CHO,,,,F,1,BAO_0000219,2759,8,CHEMBL615697,,H
,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),449.0,51,Homo sapiens,Expert,,9606.0,626,,CHO,,,,F,1,BAO_0000219,2759,9,CHEMBL859410,,D
,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),449.0,51,,Autocuration,,,627,,CHO,,,,F,1,BAO_0000219,2759,8,CHEMBL615841,,H
,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),449.0,51,Homo sapiens,Expert,,9606.0,628,,CHO,,,,F,1,BAO_0000219,2759,9,CHEMBL615842,,D
,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,449.0,51,,Autocuration,,,629,,CHO,,,,F,1,BAO_0000219,2759,8,CHEMBL835003,,H
,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),449.0,51,,Autocuration,,,630,,CHO,,,,F,1,BAO_0000219,2759,8,CHEMBL615843,,H
,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),449.0,51,Homo sapiens,Expert,,9606.0,631,,CHO,,,,F,1,BAO_0000219,2759,9,CHEMBL615979,,D
,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),449.0,51,,Autocuration,,,632,,CHO,,,,F,1,BAO_0000219,2759,8,CHEMBL615980,,H
,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),449.0,51,Homo sapiens,Expert,,9606.0,633,,CHO,,,,F,1,BAO_0000219,2759,9,CHEMBL615981,,D
,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,51,Homo sapiens,Expert,,9606.0,634,,,,,,F,1,BAO_0000019,3445,9,CHEMBL615982,,D
,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,51,Homo sapiens,Expert,,9606.0,635,,,,,,F,1,BAO_0000019,5272,9,CHEMBL615983,,D
,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,51,Homo sapiens,Expert,,9606.0,636,,,,,,F,1,BAO_0000019,5272,9,CHEMBL615984,,D
,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,51,Homo sapiens,Expert,,9606.0,637,,,,,,F,1,BAO_0000019,5272,9,CHEMBL615985,,D
,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,449.0,51,,Autocuration,,,638,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615986,,H
,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,449.0,51,,Autocuration,,,639,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615987,,H
,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,449.0,51,,Autocuration,,,640,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615988,,H
,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,449.0,51,,Expert,,,641,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615989,,H
,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,449.0,51,,Autocuration,,,642,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615990,,H
,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,449.0,51,,Autocuration,,,643,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615991,,H
,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,449.0,51,,Autocuration,,,644,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615992,,H
,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,449.0,51,,Autocuration,,,645,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615993,,H
,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,449.0,51,,Expert,,,646,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615994,,H
,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,449.0,51,,Autocuration,,,647,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615995,,H
,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,449.0,51,,Autocuration,,,648,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615996,,H
,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,449.0,51,,Autocuration,,,649,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615997,,H
,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51,,Autocuration,,,650,,,,,,F,1,BAO_0000019,6563,8,CHEMBL615998,,H
,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51,,Autocuration,,,651,,,,,,F,1,BAO_0000019,6563,8,CHEMBL615999,,H
,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,51,,Autocuration,,,652,,,,,,F,1,BAO_0000019,6563,8,CHEMBL616000,,H
,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,51,,Autocuration,,,653,,HEK293,,,,F,1,BAO_0000219,17296,8,CHEMBL616001,,H
,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,51,Homo sapiens,Expert,,9606.0,654,,,,,,F,1,BAO_0000019,6876,9,CHEMBL616002,,D
,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,51,,Expert,,,655,,,,,,F,1,BAO_0000019,6876,8,CHEMBL616003,,H
,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,51,Homo sapiens,Expert,,9606.0,656,,,,,,F,1,BAO_0000019,5272,9,CHEMBL616004,,D
,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,51,Homo sapiens,Expert,,9606.0,657,,,,,,F,1,BAO_0000019,5272,9,CHEMBL616005,,D
,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,51,,Autocuration,,,658,,,,,,F,1,BAO_0000019,5548,8,CHEMBL616006,,H
,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,51,,Expert,,,659,,,,,,F,1,BAO_0000019,5548,8,CHEMBL616007,,H
,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,51,,Autocuration,,,660,,,,,,F,1,BAO_0000019,5548,8,CHEMBL616008,,H
,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,51,,Autocuration,,,661,,,,,,F,1,BAO_0000019,5548,8,CHEMBL616009,,H
,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,51,,Expert,,,662,,,,,,F,1,BAO_0000019,5929,8,CHEMBL616010,,H
,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,51,Homo sapiens,Expert,,9606.0,663,,,,,,F,1,BAO_0000019,5929,9,CHEMBL616011,,D
,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,51,Homo sapiens,Expert,,9606.0,664,,,,,,F,1,BAO_0000019,5929,9,CHEMBL615740,,D
,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,51,,Autocuration,,,665,,,,,,F,1,BAO_0000019,16245,8,CHEMBL615741,,H
,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,51,,Expert,,,666,,,,,,F,1,BAO_0000019,5640,8,CHEMBL615742,,H
,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,51,,Autocuration,,,667,,,,,,F,1,BAO_0000019,5640,8,CHEMBL615743,,H
,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,449.0,51,,Autocuration,,,668,,CHO,,,,F,1,BAO_0000219,14509,8,CHEMBL615744,,H
,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,449.0,51,,Expert,,,669,,CHO,,,,F,1,BAO_0000219,14509,8,CHEMBL615745,,H
,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,51,,Autocuration,,,670,,,,,,B,1,BAO_0000357,15331,8,CHEMBL615746,,H
,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,51,,Autocuration,,,671,,,,,,B,1,BAO_0000357,15331,8,CHEMBL615747,,H
,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51,,Autocuration,,,672,,,,,,F,1,BAO_0000019,6563,8,CHEMBL615748,,H
,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,51,,Autocuration,,,673,,,,,,F,1,BAO_0000019,6563,8,CHEMBL615749,,H
,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,51,,Autocuration,,,674,,,,,,F,1,BAO_0000019,6563,8,CHEMBL615750,,H
,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,51,Homo sapiens,Expert,,9606.0,675,,,,,,F,1,BAO_0000019,6563,9,CHEMBL616259,,D
,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51,,Autocuration,,,676,,,,,,F,1,BAO_0000019,6563,8,CHEMBL616260,,H
,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,51,Homo sapiens,Expert,,9606.0,677,,,,,,F,1,BAO_0000019,5272,9,CHEMBL616261,,D
,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,51,Homo sapiens,Expert,,9606.0,678,,,,,,F,1,BAO_0000019,5272,9,CHEMBL616262,,D
,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,51,Homo sapiens,Expert,,9606.0,679,,,,,,F,1,BAO_0000019,5272,9,CHEMBL616263,,D
,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,51,Homo sapiens,Expert,,9606.0,680,,,,,,F,1,BAO_0000019,5272,9,CHEMBL616264,,D
,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,51,Homo sapiens,Expert,,9606.0,681,,,,,,F,1,BAO_0000019,5272,9,CHEMBL616265,,D
,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,51,Homo sapiens,Expert,,9606.0,682,,,,,,F,1,BAO_0000019,5272,9,CHEMBL616266,,D
,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,51,Homo sapiens,Expert,,9606.0,683,,,,,,F,1,BAO_0000019,5272,9,CHEMBL616267,,D
,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,51,Homo sapiens,Expert,,9606.0,684,,,,,,F,1,BAO_0000019,5272,9,CHEMBL616268,,D
,,Inhibition of human 5-hydroxytryptamine 1A receptor,,51,Homo sapiens,Expert,,9606.0,685,,,,,,B,1,BAO_0000357,16146,9,CHEMBL616269,,D
,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,51,,Autocuration,,,686,,CHO,,,,B,1,BAO_0000219,17624,8,CHEMBL884528,,H
,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,722.0,105,,Expert,,,687,,HEK293,,,,B,1,BAO_0000219,13706,9,CHEMBL616270,,D
,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,449.0,51,,Autocuration,,,688,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL616271,,H
,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,449.0,51,,Autocuration,,,689,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL616272,,H
,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,51,,Expert,,,690,,,,,,B,1,BAO_0000357,6861,8,CHEMBL616273,,H
,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,51,Homo sapiens,Expert,,9606.0,691,,,,,,B,1,BAO_0000357,17200,9,CHEMBL616274,,D
,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,449.0,51,,Autocuration,,,692,,CHO,,,,B,1,BAO_0000219,17624,8,CHEMBL616275,,H
,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,51,,Autocuration,,,693,,CHO,,,,B,1,BAO_0000219,17624,8,CHEMBL616276,,H
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,22226,Rattus norvegicus,Autocuration,,10116.0,694,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616277,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,22226,Rattus norvegicus,Autocuration,,10116.0,695,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616278,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,22226,Rattus norvegicus,Autocuration,,10116.0,696,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616279,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,22226,Rattus norvegicus,Autocuration,,10116.0,697,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616280,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,22226,Rattus norvegicus,Autocuration,,10116.0,698,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616281,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,22226,Rattus norvegicus,Autocuration,,10116.0,699,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616282,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,22226,Rattus norvegicus,Autocuration,,10116.0,700,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616283,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,22226,Rattus norvegicus,Autocuration,,10116.0,701,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616284,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,22226,Rattus norvegicus,Autocuration,,10116.0,702,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616285,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,22226,Rattus norvegicus,Autocuration,,10116.0,703,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616286,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,22226,Rattus norvegicus,Autocuration,,10116.0,704,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616287,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,22226,Rattus norvegicus,Autocuration,,10116.0,705,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616288,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,22226,Rattus norvegicus,Autocuration,,10116.0,706,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL616289,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,22226,Rattus norvegicus,Autocuration,,10116.0,707,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL615610,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,22226,Rattus norvegicus,Autocuration,,10116.0,708,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL615611,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,22226,Rattus norvegicus,Autocuration,,10116.0,709,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL615612,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,22226,Rattus norvegicus,Autocuration,,10116.0,710,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL615613,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,22226,Rattus norvegicus,Autocuration,,10116.0,711,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL615614,,U
,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,22226,Rattus norvegicus,Autocuration,,10116.0,712,In vivo,,,,,F,1,BAO_0000218,12058,0,CHEMBL615615,,U
,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,105093,,Autocuration,,,713,,,,,,B,1,BAO_0000019,11440,4,CHEMBL615616,,H
,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,11923,,Autocuration,1898.0,,714,,,,,Hypothalamus,B,1,BAO_0000249,6238,8,CHEMBL615617,,H
,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,10577,,Autocuration,,,715,,,,,,B,1,BAO_0000019,10046,8,CHEMBL615618,,H
,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,10577,,Autocuration,,,716,,,,,,B,1,BAO_0000019,10046,8,CHEMBL615619,,H
,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,10577,,Expert,,,717,,,,,,B,1,BAO_0000019,10046,8,CHEMBL615620,,H
,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,55,,Autocuration,,,718,,,,,,B,1,BAO_0000357,167,8,CHEMBL615621,,H
,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,55,,Autocuration,,,719,,,,,,B,1,BAO_0000357,167,8,CHEMBL615622,,H
,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,12166,,Autocuration,,,720,,,,,,F,1,BAO_0000019,11520,8,CHEMBL615623,,H
,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,12166,,Autocuration,,,721,,,,,,F,1,BAO_0000019,11520,8,CHEMBL615624,,H
,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,12166,,Autocuration,,,722,,,,,,F,1,BAO_0000019,11520,8,CHEMBL615625,,H
,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,12166,,Autocuration,,,723,,,,,,F,1,BAO_0000019,11520,8,CHEMBL767045,,H
,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,55,Cavia porcellus,Autocuration,,10141.0,724,,,,,,F,1,BAO_0000019,135,8,CHEMBL615626,,H
,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,55,Cavia porcellus,Autocuration,,10141.0,725,,,,,,F,1,BAO_0000019,135,8,CHEMBL615627,,H
,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,55,Cavia porcellus,Autocuration,,10141.0,726,,,,,,B,1,BAO_0000019,11311,8,CHEMBL615628,,H
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,55,Cavia porcellus,Autocuration,,10141.0,727,,,,,,B,1,BAO_0000357,10193,8,CHEMBL615629,,H
,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,55,Homo sapiens,Expert,,9606.0,728,,,,,,B,1,BAO_0000357,12281,9,CHEMBL615630,,D
,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,55,,Autocuration,,,729,,,,,,B,1,BAO_0000219,11311,8,CHEMBL615631,,H
,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,17087,,Autocuration,,,730,,,,,,F,1,BAO_0000218,12576,8,CHEMBL615632,,H
,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,17087,,Autocuration,,,731,,,,,,B,1,BAO_0000357,12281,8,CHEMBL615633,,H
,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,17087,,Autocuration,,,732,,,,,,F,1,BAO_0000218,12576,8,CHEMBL615634,,H
,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,55,Sus scrofa,Expert,,9823.0,733,,,,,,B,1,BAO_0000019,11089,8,CHEMBL615635,,H
,,In vitro inhibition of rat 5-Lipoxygenase,,12166,,Expert,,,734,,,,,,B,1,BAO_0000357,11006,8,CHEMBL615636,,H
,,Inhibitory activity against 5-Lipoxygenase,,12166,Rattus norvegicus,Expert,,10116.0,735,,,,,,B,1,BAO_0000357,11481,9,CHEMBL615637,,D
,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,702.0,12166,,Expert,,,736,,RBL-1,,,,B,1,BAO_0000219,10864,8,CHEMBL615638,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),702.0,12166,,Autocuration,,,737,,RBL-1,,,,B,1,BAO_0000219,3595,8,CHEMBL615639,,H
,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,702.0,12166,,Autocuration,,,738,,RBL-1,,,,B,1,BAO_0000219,11311,8,CHEMBL615640,,H
,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,12166,,Autocuration,,,739,,,,,,B,1,BAO_0000019,11311,8,CHEMBL615796,,H
,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,12166,,Autocuration,,,740,,,,,,B,1,BAO_0000219,11311,8,CHEMBL615845,,H
,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,12166,,Autocuration,,,741,,,,,,B,1,BAO_0000357,11006,8,CHEMBL615846,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,702.0,12166,,Autocuration,,,742,,RBL-1,,,,B,1,BAO_0000219,3595,8,CHEMBL615847,,H
,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,12166,,Autocuration,,,743,,,,,,B,1,BAO_0000357,11311,8,CHEMBL615848,,H
,,Ratio of IC50 against 5-LO and COX,,22226,Rattus norvegicus,Autocuration,,10116.0,744,,,,,,B,1,BAO_0000019,11481,0,CHEMBL615849,,U
,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,12166,,Autocuration,,,745,,,,,,B,1,BAO_0000357,11006,8,CHEMBL615850,,H
,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,12166,,Autocuration,,,746,,,,,,B,1,BAO_0000357,11006,8,CHEMBL615851,,H
,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,12166,,Autocuration,,,747,,,,,,B,1,BAO_0000219,11311,8,CHEMBL615852,,H
,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,12166,,Autocuration,,,748,,,,,,F,1,BAO_0000019,11006,8,CHEMBL615853,,H
,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,120,,Autocuration,2367.0,,749,,,,,Prostate gland,B,1,BAO_0000357,4288,8,CHEMBL884527,,H
,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,22226,Columba livia,Autocuration,,8932.0,750,,,,,,B,1,BAO_0000019,7587,0,CHEMBL872871,,U
,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,22226,Columba livia,Autocuration,,8932.0,751,,,,,,B,1,BAO_0000019,7587,0,CHEMBL615854,,U
,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,22226,Columba livia,Autocuration,,8932.0,752,,,,,,B,1,BAO_0000019,7587,0,CHEMBL767046,,U
,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,10732,,Autocuration,,,753,,,,,,B,1,BAO_0000357,11249,8,CHEMBL615855,,H
,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,12198,Rattus norvegicus,Expert,,10116.0,754,,,,,,F,1,BAO_0000019,8003,9,CHEMBL615856,,D
,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,12198,Rattus norvegicus,Expert,,10116.0,755,,,,,,F,1,BAO_0000019,8003,9,CHEMBL615857,,D
,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,12198,Rattus norvegicus,Expert,,10116.0,756,,,,,,F,1,BAO_0000019,8003,9,CHEMBL615858,,D
,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,10576,,Expert,10000000.0,,757,,,,,Hippocampus,B,1,BAO_0000221,12416,8,CHEMBL615859,,H
,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,51,,Autocuration,,,758,,,,,,B,1,BAO_0000357,16293,8,CHEMBL615860,,H
,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,22226,Oryctolagus cuniculus,Autocuration,,9986.0,759,,,,,,B,1,BAO_0000019,13047,0,CHEMBL615861,,U
,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,22226,Oryctolagus cuniculus,Autocuration,,9986.0,760,,,,,,B,1,BAO_0000019,13047,0,CHEMBL615862,,U
,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,22226,Oryctolagus cuniculus,Autocuration,,9986.0,761,,,,,,B,1,BAO_0000019,13047,0,CHEMBL615863,,U
,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,22226,Oryctolagus cuniculus,Autocuration,,9986.0,762,,,,,,B,1,BAO_0000019,13047,0,CHEMBL615864,,U
,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,104744,,Autocuration,10000000.0,,763,,,,,Hippocampus,B,1,BAO_0000221,10085,4,CHEMBL615865,,H
,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,104744,,Autocuration,10000000.0,,764,,,,,Hippocampus,B,1,BAO_0000221,10085,4,CHEMBL615866,,H
,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,104744,,Autocuration,10000000.0,,765,,,,,Hippocampus,B,1,BAO_0000221,10085,4,CHEMBL615867,,H
,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,104744,,Autocuration,,,766,,,,,,B,1,BAO_0000249,9841,4,CHEMBL615868,Membranes,H
,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,104744,Rattus norvegicus,Autocuration,,10116.0,767,,,,,,B,1,BAO_0000249,8822,5,CHEMBL615869,,D
,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,104744,Rattus norvegicus,Autocuration,,10116.0,768,,,,,,B,1,BAO_0000019,9806,5,CHEMBL615870,,D
,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,104744,Rattus norvegicus,Autocuration,,10116.0,769,,,,,,B,1,BAO_0000019,9806,5,CHEMBL615871,,D
,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,104744,,Autocuration,,,770,,,,,,B,1,BAO_0000224,8868,4,CHEMBL615872,,H
,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,104744,,Autocuration,10000000.0,,771,,,,,Hippocampus,B,1,BAO_0000221,9036,4,CHEMBL833492,,H
,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,104744,,Autocuration,10000000.0,,772,,,,,Hippocampus,B,1,BAO_0000221,11374,4,CHEMBL615873,,H
,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,104744,,Autocuration,,,773,,,,,,B,1,BAO_0000224,10881,4,CHEMBL615479,,H
,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,104744,,Autocuration,,,774,,,,,,B,1,BAO_0000019,8822,4,CHEMBL615480,,H
,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,104744,Rattus norvegicus,Autocuration,,10116.0,775,,,,,,B,1,BAO_0000249,9806,5,CHEMBL615481,,D
,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744,,Autocuration,,,776,,,,,,B,1,BAO_0000019,15463,4,CHEMBL872869,,H
,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744,,Autocuration,,,777,,,,,,B,1,BAO_0000019,15463,4,CHEMBL615482,,H
,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,104744,,Autocuration,955.0,,778,,,,,Brain,B,1,BAO_0000221,14542,4,CHEMBL615483,,H
,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,104744,,Autocuration,955.0,,779,,,,,Brain,B,1,BAO_0000221,14542,4,CHEMBL615484,,H
,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,104744,,Autocuration,,,780,,,,,,B,1,BAO_0000019,8569,4,CHEMBL615485,,H
,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,104744,Rattus norvegicus,Autocuration,,10116.0,781,,,,,,B,1,BAO_0000224,10062,5,CHEMBL615486,,D
,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,104744,,Autocuration,,,782,,,,,,B,1,BAO_0000224,4771,4,CHEMBL615487,,H
,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,104744,,Autocuration,,,783,,,,,,B,1,BAO_0000224,10062,4,CHEMBL615488,,H
,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,104744,,Autocuration,,,784,,,,,,B,1,BAO_0000224,10062,4,CHEMBL615489,,H
,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,104744,,Autocuration,,,785,,,,,,B,1,BAO_0000224,10062,4,CHEMBL615389,,H
,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,104744,,Autocuration,,,786,,,,,,B,1,BAO_0000019,15463,4,CHEMBL615390,,H
,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,104744,,Autocuration,,,787,,,,,,B,1,BAO_0000019,15463,4,CHEMBL615391,,H
,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,104744,,Autocuration,,,788,,,,,,B,1,BAO_0000224,9098,4,CHEMBL615392,,H
,,Affinity for 5-hydroxytryptamine 1 receptor,,22226,Rattus norvegicus,Autocuration,,10116.0,789,,,,,,B,1,BAO_0000019,3070,0,CHEMBL615393,,U
,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,104744,,Autocuration,955.0,,790,,,,,Brain,B,1,BAO_0000221,14542,4,CHEMBL615394,,H
,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,104744,,Autocuration,955.0,,791,,,,,Brain,B,1,BAO_0000221,14542,4,CHEMBL615395,,H
,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,104744,,Autocuration,,,792,,,,,,B,1,BAO_0000224,6398,4,CHEMBL615396,,H
,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,104744,,Autocuration,955.0,,793,,,,,Brain,B,1,BAO_0000221,1344,4,CHEMBL615397,,H
,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744,,Autocuration,,,794,,,,,,B,1,BAO_0000019,11963,4,CHEMBL615398,,H
,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,22226,Rattus norvegicus,Autocuration,,10116.0,795,,,,,,B,1,BAO_0000019,8908,0,CHEMBL615399,,U
,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,104744,,Autocuration,,,796,,,,,,B,1,BAO_0000019,9098,4,CHEMBL615400,,H
,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,104744,Rattus norvegicus,Autocuration,,10116.0,797,,,,,,B,1,BAO_0000019,8841,5,CHEMBL615401,,D
,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,22226,Rattus norvegicus,Autocuration,,10116.0,798,,,,,,B,1,BAO_0000019,8814,0,CHEMBL615402,,U
,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,104744,,Autocuration,,,799,,,,,,B,1,BAO_0000019,11752,4,CHEMBL615403,,H
,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,104744,,Autocuration,955.0,,800,,,,,Brain,B,1,BAO_0000221,11642,4,CHEMBL615404,,H
,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,104744,,Autocuration,,,801,,,,,,B,1,BAO_0000019,11642,4,CHEMBL615781,,H
,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,104744,,Autocuration,955.0,,802,,,,,Brain,B,1,BAO_0000220,9231,4,CHEMBL615782,,H
,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,104744,,Autocuration,955.0,,803,,,,,Brain,B,1,BAO_0000221,11351,4,CHEMBL615783,,H
,,Compound was tested for binding affinity against 5-HT1 receptor,,22226,,Autocuration,,,804,,,,,,B,1,BAO_0000019,4639,0,CHEMBL873481,,U
,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,22226,,Autocuration,,,805,,,,,,B,1,BAO_0000019,1205,0,CHEMBL615784,,U
,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,10576,,Expert,,,806,,,,,,B,1,BAO_0000357,10025,8,CHEMBL615785,,H
,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,10576,,Autocuration,,,807,,,,,,F,1,BAO_0000249,13241,8,CHEMBL615786,,H
,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,10576,,Autocuration,,,808,In vivo,,,,,F,1,BAO_0000218,16245,8,CHEMBL615787,,H
,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,10576,,Autocuration,,,809,In vivo,,,,,F,1,BAO_0000218,16245,8,CHEMBL615788,,H
,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,810,,,,,,F,1,BAO_0000019,12438,8,CHEMBL767044,,H
,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,10576,,Autocuration,,,811,In vivo,,,,,F,1,BAO_0000218,16245,8,CHEMBL615789,,H
,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,10576,,Autocuration,,,812,In vivo,,,,,F,1,BAO_0000218,16245,8,CHEMBL615790,,H
,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,10576,,Autocuration,,,813,,,,,,F,1,BAO_0000019,15740,8,CHEMBL615813,,H
,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,10576,,Autocuration,,,814,,,,,,F,1,BAO_0000219,15535,8,CHEMBL615814,,H
,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,51,,Expert,,,815,,,,,,F,1,BAO_0000219,15535,8,CHEMBL615815,,H
,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,10576,,Autocuration,,,816,,,,,,F,1,BAO_0000219,15535,8,CHEMBL615816,,H
,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,10576,,Expert,,,817,,,,,,B,1,BAO_0000249,9888,8,CHEMBL615817,,H
,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,10576,,Autocuration,10000000.0,,818,,,,,Hippocampus,B,1,BAO_0000221,10085,8,CHEMBL615818,,H
,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,10576,,Autocuration,10000000.0,,819,,,,,Hippocampus,B,1,BAO_0000221,10085,8,CHEMBL615819,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,10576,,Expert,,,820,,,,,,B,1,BAO_0000249,17331,8,CHEMBL615820,Membranes,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,821,,,,,Hippocampus,B,1,BAO_0000221,10845,9,CHEMBL615821,,D
,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,822,,,,,Hippocampus,B,1,BAO_0000221,10845,9,CHEMBL615822,,D
,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,10576,,Expert,10000000.0,,823,,,,,Hippocampus,B,1,BAO_0000221,10845,8,CHEMBL615823,,H
,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,824,,,,,Hippocampus,B,1,BAO_0000221,10845,9,CHEMBL615824,,D
,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,825,,,,,Hippocampus,B,1,BAO_0000221,10845,9,CHEMBL615825,,D
,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,10576,,Expert,,,826,,,,,,B,1,BAO_0000357,13730,8,CHEMBL615826,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,10576,,Expert,,,827,,,,,,B,1,BAO_0000249,13508,8,CHEMBL615827,,H
,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,10576,,Expert,10000000.0,,828,,,,,Hippocampus,B,1,BAO_0000249,13508,8,CHEMBL615828,,H
,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,Expert,10000000.0,,829,,,,,Hippocampus,B,1,BAO_0000221,12073,8,CHEMBL615829,,H
,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,10576,,Autocuration,10000000.0,,830,,,,,Hippocampus,B,1,BAO_0000221,4671,8,CHEMBL615830,,H
,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,10576,,Expert,10000000.0,,831,,,,,Hippocampus,B,1,BAO_0000221,13631,8,CHEMBL615831,,H
,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,832,,,,,,B,1,BAO_0000357,12438,8,CHEMBL615832,,H
,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,10576,,Autocuration,,,833,,,,,,B,1,BAO_0000019,10483,8,CHEMBL615833,,H
,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,10576,,Autocuration,10000000.0,,834,,,,,Hippocampus,B,1,BAO_0000221,10483,8,CHEMBL615834,,H
,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,10576,,Intermediate,,,835,,,,,,B,1,BAO_0000249,12352,8,CHEMBL615835,,H
,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,10576,,Autocuration,10000000.0,,836,,,,,Hippocampus,B,1,BAO_0000249,14732,8,CHEMBL615836,,H
,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,10576,Rattus norvegicus,Expert,,10116.0,837,,,,,,B,1,BAO_0000019,11049,9,CHEMBL615837,,D
,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,10576,Rattus norvegicus,Expert,,10116.0,838,,,,,,B,1,BAO_0000019,11049,9,CHEMBL615838,,D
,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,10576,,Expert,,,839,,,,,,B,1,BAO_0000249,13657,8,CHEMBL615839,,H
,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,10576,,Autocuration,,,840,,,,,,B,1,BAO_0000019,11473,8,CHEMBL884525,,H
,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,10576,,Autocuration,,,841,,,,,,B,1,BAO_0000249,2014,8,CHEMBL615840,,H
,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,Expert,10000000.0,,842,,,,,Hippocampus,B,1,BAO_0000221,3086,8,CHEMBL615405,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,10576,,Expert,,,843,,,,,,B,1,BAO_0000019,15854,8,CHEMBL615406,,H
,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,10576,,Expert,10000000.0,,844,,,,,Hippocampus,B,1,BAO_0000221,10922,8,CHEMBL615900,,H
,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,10576,,Expert,10000000.0,,845,,,,,Hippocampus,B,1,BAO_0000221,13346,8,CHEMBL615901,,H
,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,10576,,Expert,,,846,,,,,,B,1,BAO_0000357,15311,8,CHEMBL615902,,H
,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,10576,,Autocuration,10000000.0,,847,,,,,Hippocampus,B,1,BAO_0000221,10922,8,CHEMBL615903,,H
,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,10576,,Autocuration,,,848,,,,,,B,1,BAO_0000357,10025,8,CHEMBL615904,,H
,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,10576,,Expert,,,849,,,,,,B,1,BAO_0000357,10025,8,CHEMBL615905,,H
,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,10576,,Autocuration,,,850,,,,,,B,1,BAO_0000019,9742,8,CHEMBL615906,,H
,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,10576,,Autocuration,,,851,,,,,,F,1,BAO_0000019,9742,8,CHEMBL615907,,H
,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,10576,,Expert,,,852,,,,,,B,1,BAO_0000019,12304,8,CHEMBL615908,,H
,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,10576,,Autocuration,10000000.0,,853,,,,,Hippocampus,B,1,BAO_0000221,15789,8,CHEMBL615909,,H
,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,10576,,Autocuration,,,854,,,,,,B,1,BAO_0000019,9912,8,CHEMBL615910,,H
,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,10576,,Autocuration,,,855,,,,,,B,1,BAO_0000019,9912,8,CHEMBL615911,,H
,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,10576,,Autocuration,,,856,,,,,,B,1,BAO_0000019,9912,8,CHEMBL615912,,H
,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,10576,,Expert,,,857,,,,,,B,1,BAO_0000019,16693,8,CHEMBL615913,,H
,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,10576,,Expert,,,858,,,,,,B,1,BAO_0000357,13276,8,CHEMBL615914,,H
,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,10576,,Autocuration,10000000.0,,859,,,,,Hippocampus,B,1,BAO_0000221,12678,8,CHEMBL615915,,H
,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,10576,,Autocuration,,,860,,,,,,B,1,BAO_0000357,11825,8,CHEMBL615916,,H
,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,10576,,Expert,,,861,,,,,,B,1,BAO_0000357,12443,8,CHEMBL615917,,H
,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,10576,,Expert,,,862,,,,,,B,1,BAO_0000357,13830,8,CHEMBL615918,,H
,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,10576,,Expert,10000000.0,,863,,,,,Hippocampus,B,1,BAO_0000249,14286,8,CHEMBL615919,,H
,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,864,,,,,Hippocampus,B,1,BAO_0000221,14356,9,CHEMBL615920,,D
,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,865,,,,,,B,1,BAO_0000357,15306,8,CHEMBL615921,,H
,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,10576,,Expert,,,866,,,,,,B,1,BAO_0000357,15306,8,CHEMBL615922,,H
,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,10576,Rattus norvegicus,Expert,,10116.0,867,,,,,,F,1,BAO_0000249,16616,9,CHEMBL881290,,D
,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,10576,,Autocuration,10000000.0,,868,,,,,Hippocampus,B,1,BAO_0000221,3651,8,CHEMBL615923,,H
,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,Autocuration,10000000.0,,869,,,,,Hippocampus,F,1,BAO_0000221,14331,8,CHEMBL615924,,H
,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,Autocuration,10000000.0,,870,,,,,Hippocampus,F,1,BAO_0000221,14331,8,CHEMBL615925,,H
,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,10576,Rattus norvegicus,Expert,,10116.0,871,,,,,,B,1,BAO_0000357,14178,9,CHEMBL615926,,D
,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,10576,Rattus norvegicus,Expert,,10116.0,872,,,,,,B,1,BAO_0000019,10639,9,CHEMBL615927,,D
,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576,,Autocuration,10000000.0,,873,,,,,Hippocampus,B,1,BAO_0000221,12306,8,CHEMBL615928,,H
,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,10576,Rattus norvegicus,Expert,,10116.0,874,,,,,,B,1,BAO_0000357,1348,9,CHEMBL615929,,D
,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,10576,,Autocuration,10000000.0,,875,,,,,Hippocampus,B,1,BAO_0000221,13605,8,CHEMBL615930,,H
,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,51,,Autocuration,,,876,,CHO,,,,B,1,BAO_0000219,17624,8,CHEMBL615931,,H
,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,449.0,51,,Autocuration,,,877,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615932,,H
,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,449.0,51,,Autocuration,,,878,,CHO,,,,F,1,BAO_0000219,17624,8,CHEMBL615933,,H
,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,879,,,,,,B,1,BAO_0000357,15267,8,CHEMBL615934,,H
,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,51,,Autocuration,,,880,,,,,,B,1,BAO_0000357,16532,8,CHEMBL615935,,H
,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51,,Autocuration,,,881,,,,,,F,1,BAO_0000019,6563,8,CHEMBL615936,,H
,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,449.0,51,,Autocuration,,,882,,CHO,,,,B,1,BAO_0000219,4751,8,CHEMBL615937,,H
,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,883,,,,,,B,1,BAO_0000357,15463,8,CHEMBL615938,,H
,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,51,,Autocuration,,,884,,,,,,B,1,BAO_0000357,3805,8,CHEMBL615797,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,885,,,,,,B,1,BAO_0000357,5640,8,CHEMBL615798,,H
,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,51,,Autocuration,,,886,,,,,,B,1,BAO_0000357,6563,8,CHEMBL872870,,H
,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,51,,Autocuration,,,887,,,,,,B,1,BAO_0000357,5548,8,CHEMBL615799,,H
,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,888,,,,,,B,1,BAO_0000357,6347,8,CHEMBL615800,,H
,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,51,,Autocuration,,,889,,HEK293,,,,F,1,BAO_0000219,17296,8,CHEMBL615801,,H
,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,51,,Autocuration,,,890,,,,,,B,1,BAO_0000019,13047,8,CHEMBL615802,,H
,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,51,,Autocuration,,,891,,,,,,B,1,BAO_0000357,15740,8,CHEMBL615803,,H
,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,51,,Expert,,,892,,,,,,F,1,BAO_0000019,5640,8,CHEMBL835002,,H
,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,51,,Autocuration,,,893,,,,,,F,1,BAO_0000019,5640,8,CHEMBL615804,,H
,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,308.0,51,,Expert,,,894,,HeLa,,,,B,1,BAO_0000219,17211,8,CHEMBL615805,,H
,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,449.0,51,,Autocuration,,,895,,CHO,,,,B,1,BAO_0000219,4751,8,CHEMBL615806,,H
,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,51,Homo sapiens,Expert,,9606.0,896,,,,,,B,1,BAO_0000357,6491,9,CHEMBL615807,,D
,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,51,,Autocuration,,,897,,,,,,B,1,BAO_0000357,4707,8,CHEMBL615808,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor,,51,Homo sapiens,Expert,,9606.0,898,,,,,,B,1,BAO_0000357,13910,9,CHEMBL615809,,D
,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,308.0,51,,Autocuration,,,899,,HeLa,,,,B,1,BAO_0000219,16190,8,CHEMBL615810,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,900,,,,,,B,1,BAO_0000357,16633,8,CHEMBL615811,,H
,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,449.0,51,,Autocuration,,,901,,CHO,,,,B,1,BAO_0000219,11898,8,CHEMBL615812,,H
,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,51,,Autocuration,,,902,,CHO,,,,B,1,BAO_0000219,11898,8,CHEMBL615751,,H
,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,903,,,,,,B,1,BAO_0000357,14331,8,CHEMBL615752,,H
,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,449.0,51,,Expert,,,904,,CHO,,,,B,1,BAO_0000219,17624,8,CHEMBL615753,,H
,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,449.0,51,,Autocuration,,,905,,CHO,,,,B,1,BAO_0000219,17624,8,CHEMBL615754,,H
,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,906,,,,,,B,1,BAO_0000357,3307,8,CHEMBL615755,,H
,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,449.0,51,Homo sapiens,Expert,,9606.0,907,,CHO,,,,B,1,BAO_0000219,6563,9,CHEMBL615756,,D
,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,908,,,,,,B,1,BAO_0000019,14165,8,CHEMBL615757,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,51,,Autocuration,,,909,,,,,,B,1,BAO_0000357,5732,8,CHEMBL615758,,H
,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,51,,Expert,,,910,,,,,,B,1,BAO_0000357,13366,8,CHEMBL615759,,H
,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,911,,,,,,B,1,BAO_0000357,17626,8,CHEMBL615760,,H
,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,308.0,51,,Expert,,,912,,HeLa,,,,B,1,BAO_0000219,6588,8,CHEMBL615761,,H
,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,51,,Autocuration,,,913,,,,,,B,1,BAO_0000357,16209,8,CHEMBL872104,,H
,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,914,,,,,,B,1,BAO_0000357,15463,8,CHEMBL615762,,H
,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,915,,,,,,B,1,BAO_0000357,15463,8,CHEMBL615763,,H
,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,51,,Autocuration,,,916,,,,,,B,1,BAO_0000357,14770,8,CHEMBL615764,,H
,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),1167.0,51,,Autocuration,,,917,,Cell line,,,,B,1,BAO_0000219,16245,8,CHEMBL615765,,H
,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,51,,Autocuration,,,918,,,,,,B,1,BAO_0000019,16245,8,CHEMBL615766,,H
,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,919,,,,,,B,1,BAO_0000357,5548,8,CHEMBL615767,,H
,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,Expert,,,920,,,,,,B,1,BAO_0000357,5548,8,CHEMBL615768,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,921,,,,,,B,1,BAO_0000357,5548,8,CHEMBL615769,,H
,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,51,,Expert,,,922,,,,,,B,1,BAO_0000357,6876,8,CHEMBL615770,,H
,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,923,,,,,,B,1,BAO_0000357,2598,8,CHEMBL615771,,H
,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,51,,Expert,,,924,,,,,,B,1,BAO_0000357,17785,8,CHEMBL615772,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,925,,,,,,B,1,BAO_0000357,6013,8,CHEMBL615773,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,51,,Expert,,,926,,,,,,B,1,BAO_0000357,5929,8,CHEMBL615774,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,927,,,,,,B,1,BAO_0000357,16633,8,CHEMBL615775,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,51,,Autocuration,,,928,,,,,,B,1,BAO_0000357,1558,8,CHEMBL615776,,H
,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,Expert,,,929,,,,,,B,1,BAO_0000357,16026,8,CHEMBL615777,,H
,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,51,,Autocuration,,,930,,,,,,B,1,BAO_0000219,12469,8,CHEMBL615778,,H
,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,51,Homo sapiens,Expert,,9606.0,931,,,,,,B,1,BAO_0000357,15874,9,CHEMBL615779,,D
,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,51,,Autocuration,,,932,,,,,,B,1,BAO_0000357,15874,8,CHEMBL615780,,H
,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,933,,,,,,B,1,BAO_0000357,3935,8,CHEMBL616298,,H
,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,934,,,,,,B,1,BAO_0000357,15818,8,CHEMBL616299,,H
,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,485.0,51,,Autocuration,,,935,,CHO-K1,,,,B,1,BAO_0000219,13706,8,CHEMBL616300,,H
,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,485.0,51,,Expert,,,936,,CHO-K1,,,,F,1,BAO_0000219,13729,8,CHEMBL616301,,H
,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,937,,,,,,B,1,BAO_0000019,15413,8,CHEMBL616302,,H
,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,51,,Autocuration,,,938,,,,,,B,1,BAO_0000019,15413,8,CHEMBL616117,,H
,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,51,,Autocuration,,,939,,,,,,B,1,BAO_0000019,15413,8,CHEMBL616118,,H
,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,51,,Autocuration,,,940,,,,,,B,1,BAO_0000019,15413,8,CHEMBL616119,,H
,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,308.0,51,Homo sapiens,Expert,,9606.0,941,,HeLa,,,,B,1,BAO_0000219,3445,9,CHEMBL616120,,D
,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,942,,,,,,B,1,BAO_0000357,15740,8,CHEMBL616121,,H
,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,51,,Autocuration,,,943,,,,,,B,1,BAO_0000357,15740,8,CHEMBL616122,,H
,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,944,,,,,,B,1,BAO_0000357,17626,8,CHEMBL616123,,H
,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,51,Homo sapiens,Expert,,9606.0,945,,,,,,B,1,BAO_0000357,4234,9,CHEMBL616124,,D
,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,51,,Expert,,,946,,,,,,B,1,BAO_0000357,5640,8,CHEMBL616125,,H
,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,51,Rattus norvegicus,Expert,,10116.0,947,,,,,,B,1,BAO_0000357,5272,8,CHEMBL616126,,H
,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,449.0,51,,Autocuration,,,948,,CHO,,,,B,1,BAO_0000219,4622,8,CHEMBL616127,,H
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,51,,Expert,,,949,,,,,,B,1,BAO_0000019,17085,8,CHEMBL616128,,H
,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,51,,Autocuration,,,950,,,,,,B,1,BAO_0000357,3025,8,CHEMBL616129,,H
,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,51,,Expert,,,951,,,,,,B,1,BAO_0000357,15315,8,CHEMBL616130,,H
,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,51,,Autocuration,,,952,,,,,,B,1,BAO_0000357,15267,8,CHEMBL616131,,H
,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,308.0,51,,Autocuration,,,953,,HeLa,,,,B,1,BAO_0000219,17158,8,CHEMBL616132,,H
,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,308.0,51,Homo sapiens,Expert,,9606.0,954,,HeLa,,,,B,1,BAO_0000219,14214,9,CHEMBL616133,,D
,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,955,,,,,,B,1,BAO_0000357,17133,8,CHEMBL616134,,H
,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,51,,Autocuration,,,956,,,,,,B,1,BAO_0000357,16532,8,CHEMBL616135,,H
,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,51,Homo sapiens,Expert,,9606.0,957,,,,,,B,1,BAO_0000357,2391,9,CHEMBL616136,,D
,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,51,,Autocuration,,,958,,,,,,B,1,BAO_0000019,14447,8,CHEMBL616137,,H
,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,51,,Autocuration,,,959,,,,,,B,1,BAO_0000019,14447,8,CHEMBL872105,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,51,,Autocuration,,,960,,,,,,B,1,BAO_0000357,15086,8,CHEMBL616138,,H
,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,51,Homo sapiens,Expert,,9606.0,961,,,,,,B,1,BAO_0000357,13051,9,CHEMBL616139,,D
,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,51,,Autocuration,,,962,,,,,,F,1,BAO_0000019,16026,8,CHEMBL616140,,H
,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,51,,Expert,,,963,,,,,,B,1,BAO_0000019,17085,8,CHEMBL616141,,H
,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,964,,,,,,B,1,BAO_0000357,17133,8,CHEMBL616142,,H
,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,51,,Autocuration,,,965,,,,,,B,1,BAO_0000357,17133,8,CHEMBL616143,,H
,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,308.0,51,,Autocuration,,,966,,HeLa,,,,B,1,BAO_0000219,17211,8,CHEMBL616144,,H
,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,308.0,51,,Autocuration,,,967,,HeLa,,,,B,1,BAO_0000219,17211,8,CHEMBL616145,,H
,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,308.0,51,,Autocuration,,,968,,HeLa,,,,B,1,BAO_0000219,17211,8,CHEMBL616012,,H
,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,308.0,51,,Autocuration,,,969,,HeLa,,,,B,1,BAO_0000219,17211,8,CHEMBL616013,,H
,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,51,,Autocuration,,,970,,,,,,F,1,BAO_0000019,16394,8,CHEMBL616014,,H
,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,51,,Autocuration,,,971,,,,,,F,1,BAO_0000019,16394,8,CHEMBL616015,,H
,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,51,,Autocuration,,,972,,,,,,F,1,BAO_0000019,16394,8,CHEMBL616016,,H
,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,51,,Autocuration,,,973,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL616017,,H
,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,51,,Autocuration,,,974,,,,,,B,1,BAO_0000019,16394,8,CHEMBL616018,,H
,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,51,,Autocuration,,,975,,,,,,F,1,BAO_0000019,15740,8,CHEMBL616019,,H
,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,51,,Autocuration,,,976,,,,,,F,1,BAO_0000019,15740,8,CHEMBL616020,,H
,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,977,,,,,,B,1,BAO_0000357,15740,8,CHEMBL858018,,H
,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,51,,Autocuration,,,978,,HEK293,,,,F,1,BAO_0000219,17296,8,CHEMBL616021,,H
,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,51,,Expert,,,979,,,,,,F,1,BAO_0000019,5640,8,CHEMBL616022,,H
,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,51,,Autocuration,,,980,,,,,,F,1,BAO_0000019,5640,8,CHEMBL616023,,H
,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,51,,Autocuration,,,981,,,,,,F,1,BAO_0000019,5640,8,CHEMBL616024,,H
,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,51,,Autocuration,,,982,,,,,,F,1,BAO_0000019,5640,8,CHEMBL616025,,H
,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,449.0,51,,Autocuration,,,983,,CHO,,,,F,1,BAO_0000219,2759,8,CHEMBL616026,,H
,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,51,,Autocuration,,,984,,,,,,F,1,BAO_0000019,16394,8,CHEMBL616027,,H
,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,51,Homo sapiens,Expert,,9606.0,985,,,,,,F,1,BAO_0000019,16394,9,CHEMBL616028,,D
,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,51,Homo sapiens,Expert,,9606.0,986,,,,,,F,1,BAO_0000019,3445,9,CHEMBL616029,,D
,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,449.0,51,,Expert,,,987,,CHO,,,,B,1,BAO_0000219,4316,8,CHEMBL616030,,H
,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,51,,Expert,,,988,,,,,,B,1,BAO_0000019,4316,8,CHEMBL616031,,H
,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,51,Homo sapiens,Expert,,9606.0,989,,,,,,F,1,BAO_0000019,15180,9,CHEMBL616032,,D
,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,51,Homo sapiens,Expert,,9606.0,990,,,,,,F,1,BAO_0000019,15180,9,CHEMBL616033,,D
,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51,,Autocuration,,,991,,,,,,F,1,BAO_0000019,15042,8,CHEMBL616034,,H
,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51,,Autocuration,,,992,,,,,,F,1,BAO_0000019,15042,8,CHEMBL616035,,H
,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,993,,,,,,F,1,BAO_0000019,15042,8,CHEMBL616036,,H
,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51,,Autocuration,,,994,,,,,,F,1,BAO_0000019,15042,8,CHEMBL616037,,H
,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51,,Autocuration,,,995,,,,,,F,1,BAO_0000019,15042,8,CHEMBL616038,,H
,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51,,Autocuration,,,996,,,,,,F,1,BAO_0000019,15042,8,CHEMBL616039,,H
,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,997,,,,,,F,1,BAO_0000019,15042,8,CHEMBL616040,,H
,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,308.0,51,Homo sapiens,Expert,,9606.0,998,,HeLa,,,,F,1,BAO_0000219,15180,9,CHEMBL616041,,D
,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,308.0,51,Homo sapiens,Expert,,9606.0,999,,HeLa,,,,F,1,BAO_0000219,15180,9,CHEMBL616042,,D
,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,308.0,51,Homo sapiens,Expert,,9606.0,1000,,HeLa,,,,F,1,BAO_0000219,15180,9,CHEMBL616043,,D
,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,51,,Autocuration,,,1001,,,,,,F,1,BAO_0000019,16245,8,CHEMBL616044,,H
,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,51,,Autocuration,,,1002,,,,,,F,1,BAO_0000019,16026,8,CHEMBL616045,,H
,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,51,,Autocuration,,,1003,,HEK293,,,,F,1,BAO_0000219,17296,8,CHEMBL616046,,H
,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),449.0,51,,Autocuration,,,1004,,CHO,,,,F,1,BAO_0000219,2759,8,CHEMBL616047,,H
,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,449.0,51,,Autocuration,,,1005,,CHO,,,,F,1,BAO_0000219,2759,8,CHEMBL616048,,H
,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),449.0,51,Homo sapiens,Expert,,9606.0,1006,,CHO,,,,F,1,BAO_0000219,2759,9,CHEMBL616049,,D
,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),449.0,51,,Autocuration,,,1007,,CHO,,,,F,1,BAO_0000219,2759,8,CHEMBL616050,,H
,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,51,,Expert,,,1008,,,,,,F,1,BAO_0000219,15419,8,CHEMBL616051,,H
,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,51,,Autocuration,,,1009,,,,,,F,1,BAO_0000219,15419,8,CHEMBL616212,,H
,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,51,,Autocuration,,,1010,,,,,,F,1,BAO_0000019,16026,8,CHEMBL616213,,H
,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,51,,Expert,,,1011,In vitro,,,,,B,1,BAO_0000219,1414,8,CHEMBL616214,,H
,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,51,,Expert,,,1012,In vitro,,,,,B,1,BAO_0000219,1414,8,CHEMBL616215,,H
,,Binding activity radioligand.,,51,,Autocuration,,,1013,,,,,,B,1,BAO_0000357,12861,8,CHEMBL616216,,H
,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,51,,Autocuration,,,1014,,,,,,B,1,BAO_0000019,12861,8,CHEMBL616217,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1015,,,,,,B,1,BAO_0000357,5104,8,CHEMBL616218,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1016,,,,,,B,1,BAO_0000357,5105,8,CHEMBL616219,,H
,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1017,,,,,,B,1,BAO_0000357,16312,8,CHEMBL616220,,H
,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,51,Homo sapiens,Expert,,9606.0,1018,,,,,,B,1,BAO_0000357,15180,9,CHEMBL833493,,D
,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1019,,,,,,B,1,BAO_0000357,5033,8,CHEMBL616221,,H
,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,449.0,51,Homo sapiens,Expert,,9606.0,1020,,CHO,,,,B,1,BAO_0000219,16909,9,CHEMBL616222,,D
,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1021,,,,,,F,1,BAO_0000019,2590,8,CHEMBL616223,,H
,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,51,,Autocuration,,,1022,,,,,,F,1,BAO_0000019,2590,8,CHEMBL616224,,H
,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,51,,Expert,,,1023,,,,,,B,1,BAO_0000019,16394,8,CHEMBL616225,,H
,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,722.0,51,Homo sapiens,Expert,,9606.0,1024,,HEK293,,,,B,1,BAO_0000219,4540,9,CHEMBL616226,,D
,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,722.0,51,,Autocuration,,,1025,,HEK293,,,,B,1,BAO_0000219,17296,8,CHEMBL616227,,H
,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,722.0,51,,Autocuration,,,1026,,HEK293,,,,B,1,BAO_0000219,17296,8,CHEMBL616228,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,722.0,51,,Autocuration,,,1027,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL616229,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,722.0,51,,Autocuration,,,1028,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL616230,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,722.0,51,,Autocuration,,,1029,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL616231,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,1030,,,,,,B,1,BAO_0000357,6166,8,CHEMBL616232,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,722.0,51,,Autocuration,,,1031,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL616233,,H
,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,722.0,51,,Autocuration,,,1032,,HEK293,,,,B,1,BAO_0000219,4199,8,CHEMBL857973,,H
,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,51,,Autocuration,,,1033,,,,,,B,1,BAO_0000219,15316,8,CHEMBL616234,,H
,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1034,,,,,,B,1,BAO_0000357,14875,8,CHEMBL616235,,H
,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,308.0,51,,Expert,,,1035,,HeLa,,,,B,1,BAO_0000219,14727,8,CHEMBL616236,,H
,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,51,,Expert,,,1036,,,,,,B,1,BAO_0000019,14727,8,CHEMBL616237,,H
,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,722.0,51,,Autocuration,,,1037,,HEK293,,,,B,1,BAO_0000219,15146,8,CHEMBL616238,,H
,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,722.0,51,,Autocuration,,,1038,,HEK293,,,,B,1,BAO_0000219,5213,8,CHEMBL616239,,H
,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,51,,Autocuration,,,1039,,,,,,B,1,BAO_0000219,16429,8,CHEMBL616240,,H
,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,308.0,51,Homo sapiens,Expert,,9606.0,1040,,HeLa,,,,B,1,BAO_0000219,15042,9,CHEMBL616241,,D
,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,722.0,51,,Autocuration,,,1041,,HEK293,,,,B,1,BAO_0000219,14818,8,CHEMBL616242,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",722.0,51,,Autocuration,,,1042,,HEK293,,,,B,1,BAO_0000219,4829,8,CHEMBL616243,,H
,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,51,,Expert,,,1043,,,,,,B,1,BAO_0000357,17200,9,CHEMBL616244,,D
,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,51,Homo sapiens,Autocuration,,9606.0,1044,,,,,,B,1,BAO_0000357,13051,9,CHEMBL616245,,D
,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,106,,Autocuration,,,1045,,,,,,B,1,BAO_0000357,5486,8,CHEMBL616246,,H
,,Binding affinity against 5-HT1D receptor,,105,,Autocuration,,,1046,,,,,,B,1,BAO_0000357,5254,8,CHEMBL616247,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor,,105,,Autocuration,,,1047,,,,,,B,1,BAO_0000357,5254,8,CHEMBL616248,,H
,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,107,,Autocuration,,,1048,,,,,,B,1,BAO_0000357,15331,8,CHEMBL616249,,H
,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,10576,Homo sapiens,Autocuration,,9606.0,1049,,,,,,B,1,BAO_0000357,13506,8,CHEMBL616250,,H
,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1050,,,,,,B,1,BAO_0000357,15267,8,CHEMBL616251,,H
,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,11863,,Autocuration,,,1051,In vivo,,,,,F,1,BAO_0000218,16616,8,CHEMBL616252,,H
,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,11863,,Autocuration,,,1052,In vivo,,,,,F,1,BAO_0000218,16616,8,CHEMBL616253,,H
,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,11863,,Autocuration,,,1053,In vivo,,,,,F,1,BAO_0000218,16616,8,CHEMBL616254,,H
,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,11863,Mus musculus,Expert,,10090.0,1054,,,,,,F,1,BAO_0000218,16616,9,CHEMBL616255,,D
,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,11863,Mus musculus,Expert,,10090.0,1055,,,,,,F,1,BAO_0000218,16616,9,CHEMBL832872,,D
,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,11863,Mus musculus,Expert,,10090.0,1056,,,,,,F,1,BAO_0000218,16616,9,CHEMBL616256,,D
,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,11863,Mus musculus,Expert,,10090.0,1057,,,,,,F,1,BAO_0000218,16616,9,CHEMBL616257,,D
,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,11863,Mus musculus,Expert,,10090.0,1058,,,,,,F,1,BAO_0000218,16616,9,CHEMBL616258,,D
,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,11863,Mus musculus,Expert,,10090.0,1059,,,,,,F,1,BAO_0000218,16616,9,CHEMBL616384,,D
,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,11863,,Autocuration,10000000.0,,1060,,,,,Hippocampus,B,1,BAO_0000221,10297,8,CHEMBL616385,,H
,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,11863,,Expert,,,1061,,,,,,B,1,BAO_0000357,13704,8,CHEMBL616386,,H
,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,11863,Mus musculus,Expert,10000000.0,10090.0,1062,,,,,Hippocampus,B,1,BAO_0000221,10297,9,CHEMBL616387,,D
,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,11863,,Autocuration,10000000.0,,1063,,,,,Hippocampus,B,1,BAO_0000221,10297,8,CHEMBL616388,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,11863,Mus musculus,Expert,10000000.0,10090.0,1064,,,,,Hippocampus,B,1,BAO_0000221,10297,9,CHEMBL616389,,D
,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,11863,,Autocuration,10000000.0,,1065,,,,,Hippocampus,B,1,BAO_0000221,10297,8,CHEMBL616390,,H
,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,11863,,Autocuration,,,1066,,,,,,B,1,BAO_0000357,217,8,CHEMBL616391,,H
,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,11863,Mus musculus,Expert,10000000.0,10090.0,1067,,,,,Hippocampus,B,1,BAO_0000221,10297,9,CHEMBL616392,,D
,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,51,Sus scrofa,Autocuration,,9823.0,1068,,,,,,B,1,BAO_0000357,4921,8,CHEMBL616393,,H
,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,51,Sus scrofa,Autocuration,,9823.0,1069,,,,,,B,1,BAO_0000357,4921,8,CHEMBL616394,,H
,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,51,Sus scrofa,Autocuration,,9823.0,1070,,,,,,B,1,BAO_0000019,4996,8,CHEMBL616395,,H
,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,51,Sus scrofa,Autocuration,,9823.0,1071,,,,,,B,1,BAO_0000357,12918,8,CHEMBL616396,,H
,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,51,Sus scrofa,Autocuration,,9823.0,1072,,,,,,B,1,BAO_0000019,5333,8,CHEMBL872907,,H
,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,51,Sus scrofa,Autocuration,,9823.0,1073,,,,,,B,1,BAO_0000019,4437,8,CHEMBL616397,,H
,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,51,Sus scrofa,Autocuration,,9823.0,1074,,,,,,B,1,BAO_0000019,1742,8,CHEMBL616398,,H
,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,51,Sus scrofa,Expert,,9823.0,1075,,,,,,B,1,BAO_0000357,16688,8,CHEMBL616399,,H
,,Binding activity radioligand.,,51,Sus scrofa,Autocuration,,9823.0,1076,,,,,,B,1,BAO_0000357,12861,8,CHEMBL857065,,H
,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,51,Sus scrofa,Expert,,9823.0,1077,,,,,,B,1,BAO_0000019,12861,8,CHEMBL616400,,H
,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,51,Sus scrofa,Autocuration,,9823.0,1078,,,,,,B,1,BAO_0000019,12861,8,CHEMBL616401,,H
,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,10624,,Expert,,,1079,,,,,,B,1,BAO_0000019,12490,8,CHEMBL616402,,H
,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,51,Sus scrofa,Expert,,9823.0,1080,,,,,,B,1,BAO_0000019,11828,8,CHEMBL616403,,H
,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,51,Sus scrofa,Autocuration,10000000.0,9823.0,1081,,,,,Hippocampus,B,1,BAO_0000221,11866,8,CHEMBL616404,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,51,Sus scrofa,Autocuration,,9823.0,1082,,,,,,B,1,BAO_0000249,12827,8,CHEMBL616405,,H
,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,51,Sus scrofa,Autocuration,,9823.0,1083,,,,,,B,1,BAO_0000019,12918,8,CHEMBL616406,,H
,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,51,Sus scrofa,Expert,,9823.0,1084,,,,,,F,1,BAO_0000019,12919,8,CHEMBL616407,,H
,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,51,Oryctolagus cuniculus,Autocuration,,9986.0,1085,,,,,,B,1,BAO_0000019,13047,8,CHEMBL616408,,H
,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,10576,Rattus norvegicus,Expert,,10116.0,1086,,,,,,B,1,BAO_0000249,15796,9,CHEMBL616409,,D
,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1087,,,,,Hippocampus,B,1,BAO_0000221,3651,9,CHEMBL616410,,D
,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,10576,,Autocuration,,,1088,,,,,,B,1,BAO_0000357,188,8,CHEMBL616411,,H
,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,10576,Rattus norvegicus,Expert,,10116.0,1089,,,,,,F,1,BAO_0000249,16616,9,CHEMBL616412,Membranes,D
,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1090,,,,,Hippocampus,F,1,BAO_0000249,16616,9,CHEMBL616413,Membranes,D
,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576,,Autocuration,10000000.0,,1091,,,,,Hippocampus,B,1,BAO_0000221,12306,8,CHEMBL616414,,H
,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1092,,,,,Hippocampus,B,1,BAO_0000221,17167,9,CHEMBL616415,,D
,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,10576,,Autocuration,,,1093,,,,,,B,1,BAO_0000019,14776,8,CHEMBL616416,,H
,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,10576,,Expert,,,1094,,,,,,B,1,BAO_0000357,12158,8,CHEMBL616417,,H
,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,10576,,Autocuration,,,1095,,,,,,B,1,BAO_0000357,13481,8,CHEMBL616418,,H
,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,10576,,Autocuration,,,1096,In vitro,,,,,B,1,BAO_0000219,13427,8,CHEMBL616419,,H
,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,10576,,Autocuration,,,1097,,,,,,B,1,BAO_0000357,10210,8,CHEMBL616420,,H
,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,10576,,Autocuration,,,1098,,,,,,B,1,BAO_0000249,10205,8,CHEMBL616421,Membranes,H
,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,10576,,Autocuration,,,1099,,,,,,B,1,BAO_0000249,10205,8,CHEMBL616422,Membranes,H
,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,10576,,Expert,,,1100,,,,,,B,1,BAO_0000249,10205,8,CHEMBL616423,Membranes,H
,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,10576,Rattus norvegicus,Expert,,10116.0,1101,,,,,,B,1,BAO_0000357,12280,9,CHEMBL616424,,D
,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,10576,,Expert,,,1102,,,,,,B,1,BAO_0000357,17386,8,CHEMBL616425,,H
,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,10576,,Expert,,,1103,,,,,,B,1,BAO_0000357,13654,8,CHEMBL616426,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,10576,,Autocuration,10000000.0,,1104,,,,,Hippocampus,B,1,BAO_0000221,14423,8,CHEMBL616427,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,10576,,Autocuration,10000000.0,,1105,,,,,Hippocampus,B,1,BAO_0000221,15412,8,CHEMBL616428,,H
,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,Autocuration,10000000.0,,1106,,,,,Hippocampus,B,1,BAO_0000221,12073,8,CHEMBL616290,,H
,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,10576,Rattus norvegicus,Expert,,10116.0,1107,,,,,,B,1,BAO_0000357,4101,9,CHEMBL616052,,D
,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1108,,,,,,B,1,BAO_0000357,10062,8,CHEMBL616053,,H
,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,10576,,Autocuration,,,1109,,,,,,B,1,BAO_0000249,6238,8,CHEMBL616054,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1110,,,,,,B,1,BAO_0000357,16273,8,CHEMBL616055,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,10576,,Autocuration,,,1111,,,,,,B,1,BAO_0000357,11139,8,CHEMBL616056,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,10576,,Expert,,,1112,,,,,,B,1,BAO_0000019,16796,8,CHEMBL616057,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,10576,Rattus norvegicus,Expert,955.0,10116.0,1113,,,,,Brain,B,1,BAO_0000221,9548,9,CHEMBL616058,,D
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,10576,,Autocuration,955.0,,1114,,,,,Brain,B,1,BAO_0000221,10381,8,CHEMBL616059,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,10576,,Autocuration,,,1115,,,,,,B,1,BAO_0000249,13408,8,CHEMBL616060,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1116,,,,,Hippocampus,B,1,BAO_0000221,13825,9,CHEMBL616061,,D
,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,10576,,Expert,10000000.0,,1117,,,,,Hippocampus,B,1,BAO_0000221,11147,8,CHEMBL616062,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,10576,,Autocuration,,,1118,,,,,,B,1,BAO_0000249,10552,8,CHEMBL616063,,H
,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,10576,,Autocuration,2435.0,,1119,,,,,Striatum,B,1,BAO_0000249,10552,8,CHEMBL616064,,H
,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,10576,Rattus norvegicus,Expert,,10116.0,1120,,,,,,B,1,BAO_0000249,17136,9,CHEMBL616065,Membranes,D
,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,10576,Rattus norvegicus,Expert,,10116.0,1121,,,,,,B,1,BAO_0000249,5778,9,CHEMBL616066,Membranes,D
,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,10576,,Autocuration,10000000.0,,1122,,,,,Hippocampus,B,1,BAO_0000221,13481,8,CHEMBL616067,,H
,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,10576,,Autocuration,10000000.0,,1123,,,,,Hippocampus,B,1,BAO_0000221,13481,8,CHEMBL616068,,H
,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,10576,,Intermediate,10000000.0,,1124,,,,,Hippocampus,B,1,BAO_0000221,13630,8,CHEMBL616069,,H
,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,10576,,Expert,,,1125,,,,,,B,1,BAO_0000249,16245,8,CHEMBL616070,,H
,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576,,Autocuration,10000000.0,,1126,,,,,Hippocampus,B,1,BAO_0000221,14509,8,CHEMBL616071,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,10576,,Expert,10000000.0,,1127,,,,,Hippocampus,B,1,BAO_0000221,14509,8,CHEMBL616072,,H
,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,10576,,Autocuration,10000000.0,,1128,,,,,Hippocampus,B,1,BAO_0000221,14509,8,CHEMBL616073,,H
,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,10576,,Autocuration,10000000.0,,1129,,,,,Hippocampus,B,1,BAO_0000221,14509,8,CHEMBL616074,,H
,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,10576,,Expert,,,1130,,,,,,B,1,BAO_0000019,14256,8,CHEMBL616075,,H
,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1131,,,,,,B,1,BAO_0000357,11139,8,CHEMBL616076,,H
,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,10576,Rattus norvegicus,Expert,,10116.0,1132,,,,,,B,1,BAO_0000019,11047,9,CHEMBL616077,,D
,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,10576,Rattus norvegicus,Expert,,10116.0,1133,,,,,,B,1,BAO_0000019,11047,9,CHEMBL616078,,D
,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,10576,Rattus norvegicus,Expert,,10116.0,1134,,,,,,B,1,BAO_0000019,11047,9,CHEMBL616079,,D
,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,485.0,10576,Rattus norvegicus,Expert,,10116.0,1135,,CHO-K1,,,,B,1,BAO_0000219,2395,9,CHEMBL616080,,D
,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1136,,,,,,B,1,BAO_0000357,9699,8,CHEMBL616081,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1137,,,,,Hippocampus,B,1,BAO_0000221,12028,9,CHEMBL616082,,D
,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,10576,,Autocuration,10000000.0,,1138,,,,,Hippocampus,B,1,BAO_0000221,12028,8,CHEMBL616083,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,10576,,Autocuration,,,1139,,,,,,B,1,BAO_0000019,5815,8,CHEMBL616084,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,10576,,Expert,,,1140,,,,,,B,1,BAO_0000019,16616,8,CHEMBL616085,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,10576,,Autocuration,,,1141,,,,,,B,1,BAO_0000019,5815,8,CHEMBL616086,,H
,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,10576,,Autocuration,10000000.0,,1142,,,,,Hippocampus,B,1,BAO_0000221,2761,8,CHEMBL616087,,H
,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,10576,,Expert,,,1143,,,,,,B,1,BAO_0000357,13133,8,CHEMBL616088,,H
,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,10576,,Autocuration,,,1144,,,,,,B,1,BAO_0000019,10444,8,CHEMBL616089,,H
,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,10576,Rattus norvegicus,Expert,,10116.0,1145,,,,,,B,1,BAO_0000357,13278,9,CHEMBL616090,,D
,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,10576,,Autocuration,,,1146,,,,,,B,1,BAO_0000357,15874,8,CHEMBL616091,,H
,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,10576,,Autocuration,2435.0,,1147,,,,,Striatum,B,1,BAO_0000249,10552,8,CHEMBL616092,Membranes,H
,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,10576,,Autocuration,,,1148,,,,,,B,1,BAO_0000357,11130,8,CHEMBL616093,,H
,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,10576,,Autocuration,,,1149,In vivo,,,,,B,1,BAO_0000218,11130,8,CHEMBL616094,,H
,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,10576,,Autocuration,955.0,,1150,,,,,Brain,B,1,BAO_0000221,14542,8,CHEMBL616095,,H
,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,10576,Rattus norvegicus,Expert,,10116.0,1151,,,,,,B,1,BAO_0000357,13670,9,CHEMBL616096,,D
,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,10576,,Expert,,,1152,,,,,,B,1,BAO_0000249,9888,8,CHEMBL616097,,H
,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,10576,Rattus norvegicus,Expert,,10116.0,1153,,,,,,B,1,BAO_0000249,3678,9,CHEMBL616098,Membranes,D
,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576,,Autocuration,10000000.0,,1154,,,,,Hippocampus,B,1,BAO_0000221,11332,8,CHEMBL616099,,H
,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576,,Autocuration,10000000.0,,1155,,,,,Hippocampus,B,1,BAO_0000221,11332,8,CHEMBL616100,,H
,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,10576,,Expert,,,1156,,,,,,B,1,BAO_0000357,1185,8,CHEMBL616101,,H
,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,10576,,Expert,,,1157,,,,,,B,1,BAO_0000249,2014,8,CHEMBL616102,,H
,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1158,,,,,,B,1,BAO_0000357,1185,8,CHEMBL616103,,H
,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,10576,,Expert,,,1159,,,,,,B,1,BAO_0000019,14429,8,CHEMBL616104,,H
,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,10576,,Expert,,,1160,,,,,,B,1,BAO_0000019,16288,8,CHEMBL616105,,H
,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,10576,Rattus norvegicus,Expert,,10116.0,1161,,,,,,B,1,BAO_0000019,5432,9,CHEMBL616106,,D
,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,10576,,Autocuration,,,1162,,,,,,B,1,BAO_0000019,14429,8,CHEMBL616107,,H
,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,10576,,Expert,,,1163,,,,,,B,1,BAO_0000357,13672,8,CHEMBL616108,,H
,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,10576,,Expert,10000000.0,,1164,,,,,Hippocampus,B,1,BAO_0000221,11296,8,CHEMBL616109,,H
,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,10576,,Autocuration,,,1165,,,,,,B,1,BAO_0000357,11296,8,CHEMBL616110,,H
,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,449.0,10576,,Expert,,,1166,,CHO,,,,B,1,BAO_0000219,14749,8,CHEMBL616111,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,10576,,Expert,,,1167,,,,,,B,1,BAO_0000019,15086,8,CHEMBL616112,,H
,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,10576,,Autocuration,10000000.0,,1168,,,,,Hippocampus,B,1,BAO_0000221,13462,8,CHEMBL616113,,H
,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1169,,,,,,B,1,BAO_0000019,15363,8,CHEMBL616114,,H
,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1170,,,,,,B,1,BAO_0000019,15363,8,CHEMBL616115,,H
,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1171,,,,,,B,1,BAO_0000357,10796,8,CHEMBL616116,,H
,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,10576,,Expert,955.0,,1172,,,,,Brain,B,1,BAO_0000221,12816,8,CHEMBL615844,,H
,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,10576,,Expert,10000000.0,,1173,,,,,Hippocampus,B,1,BAO_0000221,13542,8,CHEMBL615939,,H
,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,10576,,Expert,,,1174,,,,,,B,1,BAO_0000019,13308,8,CHEMBL615940,,H
,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,10576,,Expert,10000000.0,,1175,,,,,Hippocampus,B,1,BAO_0000221,13541,8,CHEMBL615941,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,10576,,Autocuration,10000000.0,,1176,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615942,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,10576,,Autocuration,10000000.0,,1177,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615943,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,10576,,Autocuration,10000000.0,,1178,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615944,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,10576,,Autocuration,10000000.0,,1179,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615945,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,10576,,Autocuration,10000000.0,,1180,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615946,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,10576,,Autocuration,10000000.0,,1181,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615947,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,10576,,Autocuration,10000000.0,,1182,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615948,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,10576,,Autocuration,10000000.0,,1183,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615949,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,10576,,Autocuration,10000000.0,,1184,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615950,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,10576,,Autocuration,10000000.0,,1185,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615951,,H
,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,10576,,Autocuration,10000000.0,,1186,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615952,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,10576,,Autocuration,10000000.0,,1187,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615953,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,10576,,Autocuration,10000000.0,,1188,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615954,,H
,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1189,,,,,Hippocampus,B,1,BAO_0000221,10058,9,CHEMBL615955,,D
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,10576,,Autocuration,10000000.0,,1190,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615956,,H
,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,10576,,Autocuration,10000000.0,,1191,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL615957,,H
,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,10576,,Expert,,,1192,,,,,,B,1,BAO_0000019,12879,8,CHEMBL615958,,H
,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,10576,,Expert,,,1193,,,,,,B,1,BAO_0000019,11964,8,CHEMBL615959,,H
,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,10576,,Autocuration,,,1194,,,,,,B,1,BAO_0000019,11964,8,CHEMBL615960,,H
,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,10576,,Autocuration,,,1195,,,,,,B,1,BAO_0000019,11964,8,CHEMBL615961,,H
,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,10576,,Expert,955.0,,1196,,,,,Brain,B,1,BAO_0000221,9548,8,CHEMBL615962,,H
,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,10576,,Expert,,,1197,,,,,,B,1,BAO_0000019,9098,8,CHEMBL615963,,H
,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,10576,,Autocuration,,,1198,,,,,,B,1,BAO_0000019,9098,8,CHEMBL615964,,H
,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,10576,,Autocuration,,,1199,,,,,,B,1,BAO_0000019,9098,8,CHEMBL615965,,H
,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,449.0,10576,,Expert,,,1200,,CHO,,,,B,1,BAO_0000219,13248,8,CHEMBL615966,,H
,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,10576,,Expert,,,1201,,,,,,B,1,BAO_0000249,3147,8,CHEMBL615967,,H
,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,10576,,Expert,,,1202,,,,,,B,1,BAO_0000019,13949,8,CHEMBL615968,,H
,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),449.0,10576,,Autocuration,,,1203,,CHO,,,,B,1,BAO_0000218,11883,8,CHEMBL615969,,H
,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,10576,,Autocuration,,,1204,,,,,,B,1,BAO_0000218,11883,8,CHEMBL615970,,H
,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,10576,Rattus norvegicus,Expert,,10116.0,1205,,,,,,B,1,BAO_0000357,11883,9,CHEMBL615971,,D
,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,10576,,Expert,,,1206,,,,,,B,1,BAO_0000249,15535,8,CHEMBL615972,Membranes,H
,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,10576,,Autocuration,,,1207,,,,,,B,1,BAO_0000249,15535,8,CHEMBL615973,,H
,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,10576,,Autocuration,,,1208,,,,,,B,1,BAO_0000249,15535,8,CHEMBL615974,,H
,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,449.0,51,Homo sapiens,Expert,,9606.0,1209,,CHO,,,,B,1,BAO_0000219,16372,9,CHEMBL615975,,D
,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,10576,,Expert,,,1210,,,,,,B,1,BAO_0000249,14608,8,CHEMBL615976,,H
,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1211,,,,,Hippocampus,B,1,BAO_0000221,4795,9,CHEMBL872106,,D
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,10576,,Autocuration,,,1212,,,,,,B,1,BAO_0000357,13863,8,CHEMBL615977,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,10576,,Autocuration,,,1213,,,,,,B,1,BAO_0000357,13863,8,CHEMBL615978,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,10576,,Autocuration,,,1214,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616166,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,10576,,Autocuration,,,1215,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616167,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,10576,,Autocuration,,,1216,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616168,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,10576,,Autocuration,,,1217,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616169,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,10576,,Autocuration,,,1218,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616170,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,10576,,Autocuration,,,1219,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616171,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,10576,,Autocuration,,,1220,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616172,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,10576,,Autocuration,,,1221,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616173,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,10576,,Autocuration,,,1222,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616174,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,10576,,Autocuration,,,1223,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616175,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,10576,,Autocuration,,,1224,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616176,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,10576,,Autocuration,,,1225,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616177,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,10576,,Autocuration,,,1226,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616178,,H
,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,10576,,Autocuration,,,1227,,,,,,B,1,BAO_0000019,9742,8,CHEMBL616179,,H
,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1228,,,,,,B,1,BAO_0000357,12073,8,CHEMBL616180,,H
,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,10576,,Autocuration,,,1229,,,,,,B,1,BAO_0000357,4101,8,CHEMBL616181,,H
,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,10576,,Autocuration,,,1230,,,,,,B,1,BAO_0000019,15360,8,CHEMBL616182,,H
,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,10000000.0,,1231,,,,,Hippocampus,B,1,BAO_0000221,11576,8,CHEMBL616183,,H
,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,10576,,Expert,,,1232,,,,,,B,1,BAO_0000019,5834,8,CHEMBL615874,,H
,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,485.0,10576,Rattus norvegicus,Expert,,10116.0,1233,,CHO-K1,,,,B,1,BAO_0000219,2395,9,CHEMBL615875,,D
,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,10576,,Autocuration,,,1234,,,,,,B,1,BAO_0000019,1375,8,CHEMBL615876,,H
,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,10576,,Autocuration,,,1235,,,,,,B,1,BAO_0000019,1375,8,CHEMBL615877,,H
,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,10576,,Autocuration,,,1236,,,,,,B,1,BAO_0000357,3967,8,CHEMBL615878,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,10576,,Expert,,,1237,,,,,,B,1,BAO_0000357,12884,8,CHEMBL615879,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,10576,,Expert,,,1238,,,,,,B,1,BAO_0000357,2343,8,CHEMBL615880,,H
,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,10576,,Autocuration,,,1239,,,,,,B,1,BAO_0000019,11511,8,CHEMBL615881,,H
,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,10576,Rattus norvegicus,Expert,,10116.0,1240,,,,,,B,1,BAO_0000019,11511,9,CHEMBL615882,,D
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,10576,,Autocuration,,,1241,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615883,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,10576,,Autocuration,,,1242,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615884,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,10576,,Autocuration,,,1243,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615885,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,10576,,Autocuration,,,1244,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615886,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,10576,,Autocuration,,,1245,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615887,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,10576,,Autocuration,,,1246,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615888,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,10576,,Autocuration,,,1247,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615889,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,10576,,Autocuration,,,1248,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615890,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,10576,,Autocuration,,,1249,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615891,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,10576,,Autocuration,,,1250,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615892,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,10576,,Autocuration,,,1251,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615893,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,10576,,Autocuration,,,1252,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615894,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,10576,,Autocuration,,,1253,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615895,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,10576,,Autocuration,,,1254,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615896,,H
,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,10576,,Autocuration,,,1255,In vivo,,,,,F,1,BAO_0000218,16394,8,CHEMBL615897,,H
,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,10576,Rattus norvegicus,Expert,,10116.0,1256,,,,,,F,1,BAO_0000249,16616,9,CHEMBL615898,Membranes,D
,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,10576,,Autocuration,,,1257,,,,,,B,1,BAO_0000019,16796,8,CHEMBL615899,,H
,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,10576,,Autocuration,,,1258,,,,,,B,1,BAO_0000019,16796,8,CHEMBL616291,,H
,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,10576,,Autocuration,,,1259,,,,,,B,1,BAO_0000357,15629,8,CHEMBL616292,,H
,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,10576,,Autocuration,,,1260,,,,,,F,1,BAO_0000249,13241,8,CHEMBL616293,,H
,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,Expert,10000000.0,,1261,,,,,Hippocampus,B,1,BAO_0000221,12073,8,CHEMBL616294,,H
,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,10576,,Autocuration,10000000.0,,1262,,,,,Hippocampus,B,1,BAO_0000249,14286,8,CHEMBL616295,,H
,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,10576,,Autocuration,955.0,,1263,,,,,Brain,B,1,BAO_0000221,14542,8,CHEMBL616296,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,10576,,Autocuration,,,1264,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616297,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,10576,,Autocuration,,,1265,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616605,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,10576,,Autocuration,,,1266,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616606,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,10576,,Autocuration,,,1267,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616607,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,10576,,Expert,,,1268,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616608,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,10576,,Autocuration,,,1269,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616609,,H
,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,10576,Rattus norvegicus,Expert,,10116.0,1270,,,,,,F,1,BAO_0000019,13630,9,CHEMBL616610,,D
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,10576,,Autocuration,,,1271,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616611,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,10576,,Expert,,,1272,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616612,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,10576,,Autocuration,,,1273,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616613,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,10576,,Expert,,,1274,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616614,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,10576,,Autocuration,,,1275,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616615,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,10576,,Expert,,,1276,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616616,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,10576,,Autocuration,,,1277,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616617,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,10576,,Autocuration,,,1278,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616618,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,10576,,Autocuration,,,1279,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616619,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,10576,,Expert,,,1280,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616620,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,10576,,Expert,,,1281,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616621,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,10576,,Autocuration,,,1282,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616622,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,10576,,Expert,,,1283,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616146,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,10576,,Autocuration,,,1284,,,,,,F,1,BAO_0000019,13630,8,CHEMBL832873,,H
,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,10576,,Autocuration,,,1285,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616147,,H
,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,10576,,Autocuration,,,1286,,,,,,F,1,BAO_0000019,13630,8,CHEMBL872872,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,10576,,Autocuration,,,1287,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616148,,H
,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,10576,,Autocuration,10000000.0,,1288,,,,,Hippocampus,B,1,BAO_0000221,9783,8,CHEMBL616149,,H
,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,10576,,Expert,10000000.0,,1289,,,,,Hippocampus,B,1,BAO_0000221,9783,8,CHEMBL616150,,H
,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,10576,Rattus norvegicus,Expert,,10116.0,1290,,,,,,B,1,BAO_0000249,14331,9,CHEMBL616151,Membranes,D
,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,10576,,Expert,10000000.0,,1291,,,,,Hippocampus,B,1,BAO_0000221,15260,8,CHEMBL872873,,H
,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,10576,,Autocuration,10000000.0,,1292,,,,,Hippocampus,B,1,BAO_0000221,15260,8,CHEMBL616670,,H
,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,10576,,Autocuration,10000000.0,,1293,,,,,Hippocampus,B,1,BAO_0000221,15260,8,CHEMBL616671,,H
,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,10576,Rattus norvegicus,Expert,,10116.0,1294,,,,,,F,1,BAO_0000249,16616,9,CHEMBL884861,,D
,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,10576,,Autocuration,,,1295,,,,,,B,1,BAO_0000357,15629,8,CHEMBL616672,,H
,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,10576,,Autocuration,,,1296,,,,,,B,1,BAO_0000019,15086,8,CHEMBL616673,,H
,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,10576,,Expert,,,1297,,,,,,F,1,BAO_0000019,5717,8,CHEMBL616674,,H
,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,10576,,Autocuration,,,1298,,,,,,B,1,BAO_0000357,12652,8,CHEMBL616675,,H
,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,10576,,Autocuration,10000000.0,,1299,,,,,Hippocampus,B,1,BAO_0000221,14608,8,CHEMBL616676,,H
,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576,,Autocuration,10000000.0,,1300,,,,,Hippocampus,B,1,BAO_0000221,12306,8,CHEMBL616677,,H
,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576,,Autocuration,10000000.0,,1301,,,,,Hippocampus,B,1,BAO_0000221,12306,8,CHEMBL616678,,H
,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,10576,Rattus norvegicus,Expert,,10116.0,1302,,,,,,B,1,BAO_0000357,15247,9,CHEMBL616679,,D
,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,10576,,Expert,10000000.0,,1303,,,,,Hippocampus,B,1,BAO_0000221,17529,8,CHEMBL616680,,H
,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,Autocuration,10000000.0,,1304,,,,,Hippocampus,B,1,BAO_0000221,14826,8,CHEMBL616681,,H
,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,Autocuration,10000000.0,,1305,,,,,Hippocampus,B,1,BAO_0000221,14826,8,CHEMBL616682,,H
,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,10000000.0,,1306,,,,,Hippocampus,B,1,BAO_0000221,13241,8,CHEMBL616683,,H
,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,10000000.0,,1307,,,,,Hippocampus,B,1,BAO_0000221,14093,8,CHEMBL616684,,H
,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,10576,,Autocuration,10000000.0,,1308,,,,,Hippocampus,B,1,BAO_0000221,14093,8,CHEMBL616685,,H
,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,10576,,Autocuration,955.0,,1309,,,,,Brain,B,1,BAO_0000221,14442,8,CHEMBL616686,,H
,,Affinity for 5-hydroxytryptamine 1A receptor site,,10576,,Autocuration,,,1310,,,,,,B,1,BAO_0000357,9919,8,CHEMBL616687,,H
,,Affinity for 5-hydroxytryptamine 1A receptor site,,10576,,Autocuration,,,1311,,,,,,B,1,BAO_0000357,9919,8,CHEMBL616688,,H
,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,10576,,Autocuration,10000000.0,,1312,,,,,Hippocampus,B,1,BAO_0000221,11440,8,CHEMBL616689,,H
,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,10576,,Autocuration,,,1313,,,,,,B,1,BAO_0000357,11257,8,CHEMBL616690,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,10576,,Expert,,,1314,,,,,,B,1,BAO_0000357,10330,8,CHEMBL616691,,H
,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1315,,,,,Hippocampus,B,1,BAO_0000221,17331,9,CHEMBL616692,,D
,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,10576,,Expert,,,1316,,,,,,B,1,BAO_0000249,16567,8,CHEMBL616693,,H
,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,10576,Rattus norvegicus,Expert,,10116.0,1317,,,,,,B,1,BAO_0000019,12058,9,CHEMBL616694,,D
,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,10576,,Autocuration,10000000.0,,1318,,,,,Hippocampus,B,1,BAO_0000221,9699,8,CHEMBL616695,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,10576,,Autocuration,,,1319,,,,,,B,1,BAO_0000357,9547,8,CHEMBL616696,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,10576,,Autocuration,,,1320,,,,,,B,1,BAO_0000357,10330,8,CHEMBL616697,,H
,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1321,,,,,,B,1,BAO_0000357,14331,8,CHEMBL616698,,H
,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,10576,Rattus norvegicus,Expert,,10116.0,1322,,,,,,B,1,BAO_0000019,14060,9,CHEMBL616949,,D
,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,10576,,Autocuration,10000000.0,,1323,,,,,Hippocampus,B,1,BAO_0000221,14744,8,CHEMBL616950,,H
,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,10576,,Autocuration,,,1324,,,,,,B,1,BAO_0000357,13506,8,CHEMBL832875,,H
,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10576,,Expert,955.0,,1325,,,,,Brain,B,1,BAO_0000221,10862,8,CHEMBL616951,,H
,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10576,,Expert,955.0,,1326,,,,,Brain,B,1,BAO_0000221,10862,8,CHEMBL616952,,H
,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,10576,,Expert,,,1327,,,,,,B,1,BAO_0000357,10062,8,CHEMBL616953,,H
,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,10576,,Autocuration,,,1328,,,,,,B,1,BAO_0000357,12073,8,CHEMBL616954,,H
,,GTPgammaS radioligand binding assay,,106,,Autocuration,,,1329,,,,,,B,1,BAO_0000357,14875,8,CHEMBL616955,,H
,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,106,,Autocuration,,,1330,,,,,,B,1,BAO_0000357,2391,8,CHEMBL616956,,H
,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,106,,Autocuration,,,1331,,,,,,F,1,BAO_0000019,2391,8,CHEMBL616957,,H
,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,106,,Autocuration,,,1332,,,,,,F,1,BAO_0000019,2391,8,CHEMBL616958,,H
,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,106,,Autocuration,,,1333,,,,,,B,1,BAO_0000357,2391,8,CHEMBL616959,,H
,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,106,,Autocuration,,,1334,,,,,,B,1,BAO_0000357,2391,8,CHEMBL616960,,H
,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,106,,Autocuration,,,1335,,,,,,F,1,BAO_0000019,2391,8,CHEMBL616961,,H
,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,308.0,106,,Expert,,,1336,,HeLa,,,,B,1,BAO_0000219,17211,8,CHEMBL616962,,H
,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,308.0,106,,Autocuration,,,1337,,HeLa,,,,B,1,BAO_0000219,17211,8,CHEMBL616963,,H
,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,106,Homo sapiens,Expert,,9606.0,1338,,,,,,B,1,BAO_0000357,6491,9,CHEMBL616524,,D
,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,449.0,106,,Autocuration,,,1339,,CHO,,,,B,1,BAO_0000219,16190,8,CHEMBL616525,,H
,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,106,,Autocuration,,,1340,,,,,,B,1,BAO_0000019,14165,8,CHEMBL872908,,H
,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,106,,Autocuration,,,1341,,,,,,B,1,BAO_0000019,14165,8,CHEMBL616526,,H
,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,106,Homo sapiens,Expert,,9606.0,1342,,,,,,B,1,BAO_0000357,4234,9,CHEMBL616527,,D
,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,106,,Expert,,,1343,,,,,,B,1,BAO_0000219,6328,8,CHEMBL616528,,H
,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,106,,Autocuration,,,1344,,,,,,B,1,BAO_0000357,14770,8,CHEMBL616529,,H
,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,106,,Autocuration,,,1345,,,,,,B,1,BAO_0000357,2598,8,CHEMBL616530,,H
,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,106,,Expert,,,1346,,,,,,B,1,BAO_0000357,6897,8,CHEMBL616531,,H
,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,106,,Autocuration,,,1347,,,,,,B,1,BAO_0000357,6897,8,CHEMBL616532,,H
,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,106,,Autocuration,,,1348,,,,,,B,1,BAO_0000357,6013,8,CHEMBL616533,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,106,,Expert,,,1349,,,,,,B,1,BAO_0000357,5843,8,CHEMBL616534,,H
,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,106,,Expert,,,1350,,,,,,B,1,BAO_0000357,14454,8,CHEMBL616535,,H
,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,106,,Autocuration,,,1351,,,,,,B,1,BAO_0000357,16209,8,CHEMBL616536,,H
,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,106,,Autocuration,,,1352,,,,,,B,1,BAO_0000357,3935,8,CHEMBL616537,,H
,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,485.0,106,,Expert,,,1353,,CHO-K1,,,,F,1,BAO_0000219,13729,8,CHEMBL616538,,H
,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,106,,Expert,,,1354,,,,,,F,1,BAO_0000019,14251,8,CHEMBL616539,,H
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,106,,Expert,,,1355,,,,,,B,1,BAO_0000019,17085,8,CHEMBL616540,,H
,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,106,,Autocuration,,,1356,,,,,,B,1,BAO_0000357,3025,8,CHEMBL616429,,H
,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,106,,Expert,,,1357,,,,,,B,1,BAO_0000357,15315,8,CHEMBL616430,,H
,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,106,Homo sapiens,Expert,,9606.0,1358,,,,,,B,1,BAO_0000219,14214,9,CHEMBL616431,,D
,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,106,Homo sapiens,Expert,,9606.0,1359,,,,,,B,1,BAO_0000357,3804,9,CHEMBL616432,,D
,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,106,Homo sapiens,Expert,,9606.0,1360,,,,,,B,1,BAO_0000357,2391,9,CHEMBL616433,,D
,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,106,Homo sapiens,Expert,,9606.0,1361,,,,,,B,1,BAO_0000357,4175,9,CHEMBL616434,,D
,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,449.0,106,,Autocuration,,,1362,,CHO,,,,B,1,BAO_0000219,17296,8,CHEMBL616435,,H
,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,106,,Expert,,,1363,,,,,,B,1,BAO_0000019,17085,8,CHEMBL616436,,H
,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,308.0,106,,Autocuration,,,1364,,HeLa,,,,B,1,BAO_0000219,17211,8,CHEMBL616437,,H
,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,308.0,106,,Autocuration,,,1365,,HeLa,,,,B,1,BAO_0000219,17211,8,CHEMBL616438,,H
,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,308.0,106,,Autocuration,,,1366,,HeLa,,,,B,1,BAO_0000219,17211,8,CHEMBL616439,,H
,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,106,Homo sapiens,Expert,,9606.0,1367,,,,,,B,1,BAO_0000357,15926,9,CHEMBL616440,,D
,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,485.0,106,,Autocuration,,,1368,,CHO-K1,,,,B,1,BAO_0000219,16312,8,CHEMBL616441,,H
,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,106,,Expert,,,1369,,,,,,B,1,BAO_0000357,5843,8,CHEMBL616442,,H
,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,106,,Autocuration,,,1370,,,,,,B,1,BAO_0000357,5843,8,CHEMBL616443,,H
,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,485.0,106,,Expert,,,1371,,CHO-K1,,,,B,1,BAO_0000219,16312,8,CHEMBL616444,,H
,,Binding activity against human 5-hydroxytryptamine 1B receptor,,106,Homo sapiens,Expert,,9606.0,1372,,,,,,B,1,BAO_0000357,15926,9,CHEMBL616445,,D
,,Binding activity against human 5-hydroxytryptamine 1B receptor,,106,Homo sapiens,Expert,,9606.0,1373,,,,,,B,1,BAO_0000357,15926,9,CHEMBL616446,,D
,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,449.0,106,Homo sapiens,Expert,,9606.0,1374,,CHO,,,,B,1,BAO_0000219,4540,9,CHEMBL616447,,D
,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,106,,Autocuration,,,1375,,,,,,B,1,BAO_0000357,6166,8,CHEMBL616448,,H
,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,449.0,106,,Autocuration,,,1376,,CHO,,,,B,1,BAO_0000219,17296,8,CHEMBL616449,,H
,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,449.0,106,,Autocuration,,,1377,,CHO,,,,B,1,BAO_0000219,17296,8,CHEMBL616450,,H
,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,449.0,106,,Autocuration,,,1378,,CHO,,,,B,1,BAO_0000219,17296,8,CHEMBL857974,,H
,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,449.0,106,,Autocuration,,,1379,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL616451,,H
,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,449.0,106,,Autocuration,,,1380,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL616452,,H
,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,449.0,106,,Autocuration,,,1381,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL616453,,H
,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,449.0,106,,Autocuration,,,1382,,CHO,,,,B,1,BAO_0000219,4199,8,CHEMBL616454,,H
,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,106,Homo sapiens,Expert,,9606.0,1383,,,,,,B,1,BAO_0000357,14875,9,CHEMBL616455,,D
,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,449.0,106,,Autocuration,,,1384,,CHO,,,,B,1,BAO_0000219,15146,8,CHEMBL616456,,H
,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,106,,Autocuration,,,1385,,,,,,B,1,BAO_0000357,5213,8,CHEMBL616457,,H
,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,449.0,106,,Autocuration,,,1386,,CHO,,,,B,1,BAO_0000219,14818,8,CHEMBL616458,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",449.0,106,,Autocuration,,,1387,,CHO,,,,B,1,BAO_0000219,4829,8,CHEMBL616459,,H
,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,106,,Expert,,,1388,,,,,,F,1,BAO_0000019,14454,8,CHEMBL616460,,H
,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,106,,Expert,,,1389,,,,,,F,1,BAO_0000019,14454,8,CHEMBL616461,,H
,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",449.0,106,,Autocuration,,,1390,,CHO,,,,F,1,BAO_0000219,14875,8,CHEMBL616462,,H
,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",449.0,106,,Autocuration,,,1391,,CHO,,,,F,1,BAO_0000219,14875,8,CHEMBL616463,,H
,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,105,,Autocuration,,,1392,,,,,,F,1,BAO_0000019,15250,8,CHEMBL616464,,H
,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,449.0,105,,Autocuration,,,1393,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL616465,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,17105,,Autocuration,,,1394,,,,,,B,1,BAO_0000357,15086,8,CHEMBL832874,,H
,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,106,Oryctolagus cuniculus,Autocuration,,9986.0,1395,,,,,,F,1,BAO_0000019,3025,8,CHEMBL616184,,H
,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,106,Oryctolagus cuniculus,Autocuration,,9986.0,1396,,,,,,B,1,BAO_0000019,14998,8,CHEMBL616185,,H
,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,106,Oryctolagus cuniculus,Intermediate,,9986.0,1397,,,,,,B,1,BAO_0000019,14998,8,CHEMBL616186,,H
,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,106,Oryctolagus cuniculus,Autocuration,,9986.0,1398,,,,,,B,1,BAO_0000019,14998,8,CHEMBL616187,,H
,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,10577,,Expert,,,1399,,,,,,B,1,BAO_0000357,13969,8,CHEMBL616188,,H
,,Binding affinity for 5-hydroxytryptamine 1B receptor,,10577,,Intermediate,,,1400,,,,,,B,1,BAO_0000357,13392,9,CHEMBL873475,,D
,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,10577,Rattus norvegicus,Expert,2435.0,10116.0,1401,,,,,Striatum,B,1,BAO_0000019,3651,9,CHEMBL616189,,D
,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,10577,,Expert,,,1402,,,,,,B,1,BAO_0000357,10025,8,CHEMBL616190,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,10576,,Autocuration,,,1403,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616191,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,10576,,Autocuration,,,1404,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616192,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,10576,,Autocuration,,,1405,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616193,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,10576,,Autocuration,,,1406,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616194,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,10576,,Autocuration,,,1407,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616195,,H
,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,10576,,Autocuration,,,1408,,,,,,B,1,BAO_0000357,13863,8,CHEMBL616196,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,10576,,Autocuration,10000000.0,,1409,,,,,Hippocampus,B,1,BAO_0000249,4622,8,CHEMBL616197,,H
,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,10576,,Intermediate,,,1410,,,,,,B,1,BAO_0000019,14911,8,CHEMBL616198,,H
,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,10576,,Autocuration,10000000.0,,1411,,,,,Hippocampus,B,1,BAO_0000221,12678,8,CHEMBL616199,,H
,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,10576,,Expert,10000000.0,,1412,,,,,Hippocampus,B,1,BAO_0000221,12678,8,CHEMBL616200,,H
,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,10576,,Expert,10000000.0,,1413,,,,,Hippocampus,B,1,BAO_0000221,14235,8,CHEMBL616201,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,10576,,Expert,10000000.0,,1414,,,,,Hippocampus,B,1,BAO_0000221,14949,8,CHEMBL616202,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,10576,,Expert,10000000.0,,1415,,,,,Hippocampus,B,1,BAO_0000221,14949,8,CHEMBL616203,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,10576,,Expert,10000000.0,,1416,,,,,Hippocampus,B,1,BAO_0000221,14949,8,CHEMBL616204,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,10576,,Expert,10000000.0,,1417,,,,,Hippocampus,B,1,BAO_0000221,14949,8,CHEMBL616205,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,10576,,Expert,10000000.0,,1418,,,,,Hippocampus,B,1,BAO_0000221,14949,8,CHEMBL616206,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,10576,,Expert,,,1419,,,,,,B,1,BAO_0000249,16118,8,CHEMBL616207,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,10576,,Autocuration,,,1420,,,,,,B,1,BAO_0000249,3268,8,CHEMBL616208,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,10576,,Autocuration,,,1421,,,,,,B,1,BAO_0000249,3268,8,CHEMBL616209,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,10576,,Expert,,,1422,,,,,,B,1,BAO_0000357,16117,8,CHEMBL616210,,H
,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,10576,,Expert,10000000.0,,1423,,,,,Hippocampus,B,1,BAO_0000221,9783,8,CHEMBL616211,,H
,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,10576,,Autocuration,10000000.0,,1424,,,,,Hippocampus,B,1,BAO_0000221,9783,8,CHEMBL616504,,H
,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1425,,,,,Hippocampus,B,1,BAO_0000221,14356,9,CHEMBL616505,,D
,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1426,,,,,,F,1,BAO_0000019,15740,8,CHEMBL616506,,H
,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576,,Autocuration,10000000.0,,1427,,,,,Hippocampus,B,1,BAO_0000221,12306,8,CHEMBL872107,,H
,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1428,,,,,Hippocampus,B,1,BAO_0000221,13348,9,CHEMBL616507,,D
,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,10576,,Autocuration,,,1429,,,,,,B,1,BAO_0000249,10394,8,CHEMBL616303,,H
,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,10576,,Autocuration,10000000.0,,1430,,,,,Hippocampus,B,1,BAO_0000221,15260,8,CHEMBL616304,,H
,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10576,,Expert,10000000.0,,1431,,,,,Hippocampus,B,1,BAO_0000221,10046,8,CHEMBL616305,,H
,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,10576,,Intermediate,10000000.0,,1432,,,,,Hippocampus,F,1,BAO_0000221,15260,8,CHEMBL616306,,H
,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1433,,,,,,B,1,BAO_0000357,12851,8,CHEMBL616307,,H
,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1434,,,,,Hippocampus,B,1,BAO_0000221,2148,9,CHEMBL881829,,D
,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,10576,,Expert,,,1435,,,,,,B,1,BAO_0000357,13134,8,CHEMBL616308,,H
,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,10576,,Autocuration,,,1436,,,,,,B,1,BAO_0000019,12462,8,CHEMBL616309,,H
,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,10576,,Expert,,,1437,,,,,,B,1,BAO_0000019,12462,8,CHEMBL616310,,H
,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,449.0,10576,,Autocuration,,,1438,,CHO,,,,B,1,BAO_0000219,12462,8,CHEMBL616311,,H
,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,10576,,Expert,,,1439,,,,,,B,1,BAO_0000357,11933,8,CHEMBL616312,,H
,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,10576,,Autocuration,,,1440,,,,,,B,1,BAO_0000357,11933,8,CHEMBL616313,,H
,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1441,,,,,Hippocampus,B,1,BAO_0000221,403,9,CHEMBL616314,,D
,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,Autocuration,10000000.0,,1442,,,,,Hippocampus,B,1,BAO_0000221,15538,8,CHEMBL616315,,H
,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,10576,,Autocuration,10000000.0,,1443,,,,,Hippocampus,B,1,BAO_0000221,15538,8,CHEMBL616567,,H
,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,10576,,Autocuration,10000000.0,,1444,,,,,Hippocampus,B,1,BAO_0000221,15538,8,CHEMBL616568,,H
,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,10576,,Intermediate,,,1445,,,,,,B,1,BAO_0000019,12464,8,CHEMBL616569,,H
,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,10576,,Expert,,,1446,,,,,,B,1,BAO_0000357,1455,8,CHEMBL616570,,H
,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,10576,,Autocuration,,,1447,,,,,,B,1,BAO_0000357,12652,8,CHEMBL616571,,H
,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,10576,,Autocuration,10000000.0,,1448,,,,,Hippocampus,B,1,BAO_0000221,12639,8,CHEMBL616572,,H
,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,10576,,Expert,,,1449,,,,,,B,1,BAO_0000249,13949,8,CHEMBL616573,,H
,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,10576,Rattus norvegicus,Expert,,10116.0,1450,,,,,,B,1,BAO_0000357,12463,9,CHEMBL616574,,D
,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,10576,,Expert,10000000.0,,1451,,,,,Hippocampus,B,1,BAO_0000221,14829,8,CHEMBL616575,,H
,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,10576,,Autocuration,10000000.0,,1452,,,,,Hippocampus,B,1,BAO_0000221,14829,8,CHEMBL872108,,H
,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,10576,,Autocuration,,,1453,,,,,,B,1,BAO_0000357,12092,8,CHEMBL616576,,H
,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,10576,,Autocuration,,,1454,,,,,,B,1,BAO_0000249,403,8,CHEMBL616577,,H
,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,10576,,Autocuration,,,1455,,,,,,B,1,BAO_0000249,403,8,CHEMBL616578,,H
,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,10576,,Expert,,,1456,,,,,,B,1,BAO_0000357,3967,8,CHEMBL616579,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,10576,Rattus norvegicus,Expert,,10116.0,1457,,,,,,B,1,BAO_0000019,12771,9,CHEMBL616580,,D
,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,10576,,Autocuration,,,1458,,,,,,B,1,BAO_0000019,15086,8,CHEMBL616581,,H
,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,Autocuration,10000000.0,,1459,,,,,Hippocampus,B,1,BAO_0000221,14909,8,CHEMBL616582,,H
,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,Expert,10000000.0,,1460,,,,,Hippocampus,B,1,BAO_0000221,14949,8,CHEMBL616583,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1461,,,,,Hippocampus,B,1,BAO_0000221,2309,9,CHEMBL616584,,D
,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,10576,,Expert,,,1462,,,,,,B,1,BAO_0000357,4170,8,CHEMBL616585,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1463,,,,,Hippocampus,B,1,BAO_0000221,11642,9,CHEMBL616586,,D
,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,10576,,Autocuration,10000000.0,,1464,,,,,Hippocampus,B,1,BAO_0000221,11642,8,CHEMBL616587,,H
,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,10576,,Autocuration,10000000.0,,1465,,,,,Hippocampus,B,1,BAO_0000221,12953,8,CHEMBL616588,,H
,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,10576,,Autocuration,10000000.0,,1466,,,,,Hippocampus,B,1,BAO_0000221,12953,8,CHEMBL616589,,H
,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576,,Expert,10000000.0,,1467,,,,,Hippocampus,B,1,BAO_0000221,12953,8,CHEMBL616590,,H
,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",449.0,10576,,Expert,,,1468,,CHO,,,,B,1,BAO_0000219,12903,8,CHEMBL616591,,H
,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,10576,,Expert,,,1469,,,,,,B,1,BAO_0000357,12536,8,CHEMBL616592,,H
,,The inhibition activity of 5-HT1A at 1 uM,,10576,,Autocuration,,,1470,,,,,,B,1,BAO_0000357,10058,8,CHEMBL616593,,H
,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",485.0,10576,,Expert,,,1471,,CHO-K1,,,,B,1,BAO_0000219,12902,8,CHEMBL616594,,H
,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,10576,,Expert,,,1472,,,,,,B,1,BAO_0000249,14057,8,CHEMBL616595,,H
,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,10576,,Autocuration,,,1473,,,,,,B,1,BAO_0000357,11296,8,CHEMBL616596,,H
,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,10576,,Autocuration,10000000.0,,1474,,,,,Hippocampus,B,1,BAO_0000221,11296,8,CHEMBL616597,,H
,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,10576,,Expert,10000000.0,,1475,,,,,Hippocampus,B,1,BAO_0000221,11296,8,CHEMBL616598,,H
,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,10576,Rattus norvegicus,Expert,,10116.0,1476,,,,,,F,1,BAO_0000249,16616,9,CHEMBL616599,Membranes,D
,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1477,,,,,Hippocampus,F,1,BAO_0000249,16616,9,CHEMBL616600,Membranes,D
,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,10576,,Autocuration,,,1478,,,,,,B,1,BAO_0000019,16567,8,CHEMBL616601,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,10576,,Autocuration,,,1479,,,,,,B,1,BAO_0000019,16567,8,CHEMBL616602,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,10576,,Autocuration,,,1480,,,,,,B,1,BAO_0000019,16567,8,CHEMBL616603,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,10576,,Autocuration,,,1481,,,,,,B,1,BAO_0000019,16567,8,CHEMBL616604,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,10576,,Autocuration,,,1482,,,,,,B,1,BAO_0000249,17136,8,CHEMBL616316,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,10576,,Autocuration,,,1483,,,,,,B,1,BAO_0000249,17136,8,CHEMBL616317,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,10576,Rattus norvegicus,Expert,,10116.0,1484,,,,,,B,1,BAO_0000019,16616,9,CHEMBL616318,,D
,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,10576,,Autocuration,10000000.0,,1485,,,,,Hippocampus,B,1,BAO_0000221,17331,8,CHEMBL616319,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,10576,,Autocuration,10000000.0,,1486,,,,,Hippocampus,B,1,BAO_0000221,17331,8,CHEMBL616320,,H
,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1487,,,,,Hippocampus,B,1,BAO_0000221,17167,9,CHEMBL616321,,D
,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,10576,,Autocuration,,,1488,,,,,,F,1,BAO_0000019,15740,8,CHEMBL616322,,H
,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,10576,,Autocuration,,,1489,,,,,,F,1,BAO_0000019,15740,8,CHEMBL616323,,H
,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,10576,,Autocuration,,,1490,,,,,,B,1,BAO_0000357,4671,8,CHEMBL616324,,H
,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,10576,,Autocuration,10000000.0,,1491,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL616325,,H
,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,10576,,Autocuration,10000000.0,,1492,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL616326,,H
,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,10576,,Autocuration,10000000.0,,1493,,,,,Hippocampus,B,1,BAO_0000221,10058,8,CHEMBL616327,,H
,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,10576,,Autocuration,,,1494,,,,,,B,1,BAO_0000357,12073,8,CHEMBL616328,,H
,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,10576,,Autocuration,,,1495,,,,,,B,1,BAO_0000249,2759,8,CHEMBL858110,,H
,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,10576,,Autocuration,,,1496,,,,,,F,1,BAO_0000249,2759,8,CHEMBL616329,,H
,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,10576,,Autocuration,,,1497,,,,,,B,1,BAO_0000249,2759,8,CHEMBL616330,,H
,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,10576,,Autocuration,,,1498,,,,,,F,1,BAO_0000249,2759,8,CHEMBL616331,,H
,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,10576,,Autocuration,,,1499,,,,,,F,1,BAO_0000249,2759,8,CHEMBL616332,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,10576,,Autocuration,955.0,,1500,,,,,Brain,B,1,BAO_0000249,9737,8,CHEMBL857063,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,10576,,Autocuration,,,1501,,,,,,B,1,BAO_0000019,9737,8,CHEMBL616333,,H
,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,10576,,Expert,,,1502,,,,,,F,1,BAO_0000019,5717,8,CHEMBL616334,,H
,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,10576,,Autocuration,10000000.0,,1503,,,,,Hippocampus,B,1,BAO_0000221,12253,8,CHEMBL616335,,H
,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,10576,,Autocuration,,,1504,,,,,,B,1,BAO_0000019,14025,8,CHEMBL616336,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,10576,,Expert,,,1505,,,,,,B,1,BAO_0000249,10425,8,CHEMBL616337,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,10576,,Autocuration,,,1506,,,,,,B,1,BAO_0000019,14998,8,CHEMBL616338,,H
,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,10576,,Autocuration,10000000.0,,1507,,,,,Hippocampus,B,1,BAO_0000221,13694,8,CHEMBL616339,,H
,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,10576,,Autocuration,10000000.0,,1508,,,,,Hippocampus,B,1,BAO_0000221,13694,8,CHEMBL616340,,H
,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,10576,,Autocuration,,,1509,,,,,,B,1,BAO_0000357,4342,8,CHEMBL616341,,H
,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,10576,Rattus norvegicus,Expert,,10116.0,1510,,,,,,B,1,BAO_0000357,12936,9,CHEMBL616342,,D
,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,10576,Rattus norvegicus,Expert,,10116.0,1511,,,,,,B,1,BAO_0000019,13144,9,CHEMBL616343,,D
,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,10576,,Expert,,,1512,,,,,,B,1,BAO_0000019,13343,8,CHEMBL616344,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,10576,,Expert,,,1513,,,,,,B,1,BAO_0000357,12132,8,CHEMBL616345,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,10576,,Expert,,,1514,,,,,,B,1,BAO_0000019,15419,8,CHEMBL616346,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,10576,,Autocuration,10000000.0,,1515,,,,,Hippocampus,B,1,BAO_0000221,1479,8,CHEMBL616347,,H
,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,10576,,Expert,,,1516,,,,,,B,1,BAO_0000019,14287,8,CHEMBL616348,,H
,,Binding affinity at 5-hydroxytryptamine 1A receptor,,10576,,Expert,,,1517,,,,,,B,1,BAO_0000357,13116,8,CHEMBL616349,,H
,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,10576,Rattus norvegicus,Expert,,10116.0,1518,,,,,,B,1,BAO_0000249,2759,9,CHEMBL616152,Membranes,D
,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,10576,,Autocuration,,,1519,,,,,,B,1,BAO_0000249,2759,8,CHEMBL616153,,H
,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,10576,,Expert,,,1520,,,,,,B,1,BAO_0000019,14748,8,CHEMBL616154,,H
,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,10576,,Autocuration,,,1521,,,,,,B,1,BAO_0000019,12304,8,CHEMBL616155,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1522,,,,,Hippocampus,B,1,BAO_0000221,12409,9,CHEMBL616156,,D
,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,10576,Rattus norvegicus,Expert,10000000.0,10116.0,1523,,,,,Hippocampus,B,1,BAO_0000221,12409,9,CHEMBL616157,,D
,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,10576,,Autocuration,10000000.0,,1524,,,,,Hippocampus,B,1,BAO_0000221,13267,8,CHEMBL616158,,H
,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,10576,,Autocuration,,,1525,,,,,,B,1,BAO_0000357,15194,8,CHEMBL616159,,H
,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,10576,,Expert,,,1526,,,,,,B,1,BAO_0000357,14256,8,CHEMBL616160,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,10576,,Autocuration,,,1527,,,,,,B,1,BAO_0000019,16567,8,CHEMBL616161,,H
,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,10576,,Autocuration,,,1528,,,,,,F,1,BAO_0000019,15740,8,CHEMBL616162,,H
,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,12687,Rattus norvegicus,Expert,,10116.0,1529,,,,,,B,1,BAO_0000357,13278,9,CHEMBL616163,,D
,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,10626,,Expert,,,1530,,,,,,B,1,BAO_0000249,1970,8,CHEMBL616164,Membranes,H
,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,10576,,Autocuration,955.0,,1531,,,,,Brain,B,1,BAO_0000221,10034,8,CHEMBL616165,,H
,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,51,Rattus norvegicus,Autocuration,,10116.0,1532,,,,,,B,1,BAO_0000019,13348,8,CHEMBL616355,,H
,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,10576,,Autocuration,,,1533,,,,,,F,1,BAO_0000019,13630,8,CHEMBL616356,,H
,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10576,,Autocuration,955.0,,1534,,,,,Brain,B,1,BAO_0000221,10862,8,CHEMBL616357,,H
,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,10576,,Autocuration,,,1535,,,,,,B,1,BAO_0000019,12058,8,CHEMBL616358,,H
,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1536,,,,,,B,1,BAO_0000357,4639,8,CHEMBL616359,,H
,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,51,,Expert,,,1537,,,,,,B,1,BAO_0000357,15453,8,CHEMBL616360,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,51,,Expert,,,1538,,,,,,B,1,BAO_0000357,4820,8,CHEMBL616361,,H
,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1539,,,,,,B,1,BAO_0000357,1089,8,CHEMBL616362,,H
,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,51,,Autocuration,,,1540,,,,,,B,1,BAO_0000249,386,8,CHEMBL616363,Brain membranes,H
,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,51,,Autocuration,,,1541,,,,,,B,1,BAO_0000357,6011,8,CHEMBL616364,,H
,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1542,,,,,,B,1,BAO_0000357,5014,8,CHEMBL616365,,H
,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,51,,Expert,,,1543,,,,,,B,1,BAO_0000357,4402,8,CHEMBL616366,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,51,,Expert,,,1544,,,,,,B,1,BAO_0000357,17066,8,CHEMBL872906,,H
,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,51,,Autocuration,,,1545,,,,,,B,1,BAO_0000357,17515,8,CHEMBL616367,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1546,,,,,,B,1,BAO_0000357,2474,8,CHEMBL616368,,H
,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,51,,Autocuration,,,1547,,,,,,B,1,BAO_0000357,4775,8,CHEMBL616369,,H
,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,51,Homo sapiens,Expert,,9606.0,1548,,,,,,B,1,BAO_0000357,14294,9,CHEMBL616370,,D
,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,51,Homo sapiens,Expert,,9606.0,1549,,,,,,B,1,BAO_0000357,14294,9,CHEMBL616371,,D
,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,51,,Autocuration,,,1550,,CHO,,,,B,1,BAO_0000219,12249,8,CHEMBL616372,,H
,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,51,,Expert,,,1551,,,,,,B,1,BAO_0000219,11376,8,CHEMBL616373,,H
,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,Autocuration,,,1552,In vivo,,,,,B,1,BAO_0000218,2474,8,CHEMBL616374,,H
,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,Autocuration,10000000.0,,1553,,,,,Hippocampus,B,1,BAO_0000221,13311,8,CHEMBL616375,,H
,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,51,,Autocuration,,,1554,,,,,,B,1,BAO_0000357,4373,8,CHEMBL616376,,H
,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,51,,Expert,,,1555,,,,,,B,1,BAO_0000357,1633,8,CHEMBL857064,,H
,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,51,,Autocuration,,,1556,,,,,,B,1,BAO_0000357,11866,8,CHEMBL616377,,H
,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,51,,Autocuration,,,1557,,,,,,B,1,BAO_0000357,4373,8,CHEMBL616378,,H
,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,51,,Autocuration,,,1558,,,,,,B,1,BAO_0000357,4687,8,CHEMBL616379,,H
,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,11863,,Autocuration,,,1559,,,,,,B,1,BAO_0000357,16946,8,CHEMBL616380,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,11863,,Autocuration,,,1560,,,,,,B,1,BAO_0000357,13291,8,CHEMBL616381,,H
,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,11863,,Autocuration,,,1561,,,,,,B,1,BAO_0000357,14159,8,CHEMBL616382,,H
,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,11863,,Autocuration,,,1562,,,,,,B,1,BAO_0000357,10812,8,CHEMBL616383,,H
,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,449.0,11863,Mus musculus,Expert,,10090.0,1563,,CHO,,,,B,1,BAO_0000219,3032,9,CHEMBL616350,,D
,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,11863,,Autocuration,,,1564,,,,,,B,1,BAO_0000357,16655,8,CHEMBL616351,,H
,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,11863,,Autocuration,,,1565,,,,,,B,1,BAO_0000357,14532,8,CHEMBL616352,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor,,11863,,Autocuration,,,1566,,,,,,B,1,BAO_0000357,13944,8,CHEMBL616353,,H
,,Binding affinity against serotonergic 5-HT1a receptor,,11863,,Autocuration,,,1567,,,,,,B,1,BAO_0000357,13033,8,CHEMBL616354,,H
,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,11863,,Autocuration,,,1568,,,,,,B,1,BAO_0000357,10321,8,CHEMBL616508,,H
,,Binding affinity for 5-hydroxytryptamine 1A receptor,,11863,Mus musculus,Expert,,10090.0,1569,,,,,,B,1,BAO_0000357,2968,9,CHEMBL616559,,D
,,Binding affinity at 5-hydroxytryptamine 1A receptor,,11863,,Autocuration,,,1570,,,,,,B,1,BAO_0000357,13964,8,CHEMBL616560,,H
,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,11863,,Autocuration,,,1571,,,,,,B,1,BAO_0000357,15527,8,CHEMBL616561,,H
,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,11863,,Autocuration,,,1572,,CHO,,,,B,1,BAO_0000219,12248,8,CHEMBL616562,,H
,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,11863,,Autocuration,,,1573,,CHO,,,,B,1,BAO_0000219,12249,8,CHEMBL616563,,H
,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,11863,,Autocuration,,,1574,,,,,,B,1,BAO_0000357,15120,8,CHEMBL616564,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,11863,,Autocuration,,,1575,,,,,,B,1,BAO_0000357,13313,8,CHEMBL616565,,H
,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,11863,,Autocuration,,,1576,,,,,,B,1,BAO_0000218,2613,8,CHEMBL616566,,H
,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,11863,,Autocuration,,,1577,,,,,,B,1,BAO_0000357,16700,8,CHEMBL616989,,H
,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,11863,,Autocuration,,,1578,,,,,,B,1,BAO_0000357,2201,8,CHEMBL857975,,H
,,Binding affinity against 5-hydroxytryptamine 1A receptor,,11863,Mus musculus,Expert,,10090.0,1579,,,,,,B,1,BAO_0000357,1274,9,CHEMBL616990,,D
,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,11863,,Autocuration,,,1580,,,,,,B,1,BAO_0000357,1317,8,CHEMBL616991,,H
,,Tested against 5-hydroxytryptamine 1A receptor,,11863,,Autocuration,,,1581,,,,,,B,1,BAO_0000357,12146,8,CHEMBL616992,,H
,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,11863,,Autocuration,,,1582,,,,,,B,1,BAO_0000357,14059,8,CHEMBL616993,,H
,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,106,Oryctolagus cuniculus,Expert,,9986.0,1583,,,,,,B,1,BAO_0000019,14025,8,CHEMBL616994,,H
,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,106,Oryctolagus cuniculus,Autocuration,,9986.0,1584,,,,,,B,1,BAO_0000019,14025,8,CHEMBL616995,,H
,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,722.0,105571,Gorilla gorilla,Intermediate,,9593.0,1585,,HEK293,,,,B,1,BAO_0000219,14447,9,CHEMBL616996,,D
,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,106,Cavia porcellus,Autocuration,,10141.0,1586,In vivo,,,,,F,1,BAO_0000218,3025,8,CHEMBL616997,,H
,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,106,Cavia porcellus,Autocuration,,10141.0,1587,In vivo,,,,,F,1,BAO_0000218,3025,8,CHEMBL616998,,H
,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,106,Cavia porcellus,Autocuration,,10141.0,1588,,,,,,F,1,BAO_0000019,15329,8,CHEMBL616999,,H
,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,106,Cavia porcellus,Autocuration,,10141.0,1589,,,,,,F,1,BAO_0000019,15329,8,CHEMBL617000,,H
,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,106,Cavia porcellus,Autocuration,,10141.0,1590,,,,,,F,1,BAO_0000019,15847,8,CHEMBL617001,,H
,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,106,Cavia porcellus,Autocuration,,10141.0,1591,,,,,,F,1,BAO_0000019,15847,8,CHEMBL858111,,H
,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,106,,Autocuration,,,1592,,,,,,F,1,BAO_0000019,14165,8,CHEMBL617002,,H
,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,106,,Autocuration,,,1593,,,,,,F,1,BAO_0000019,14214,8,CHEMBL617003,,H
,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,106,,Autocuration,,,1594,,,,,,F,1,BAO_0000019,14214,8,CHEMBL617004,,H
,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,106,Homo sapiens,Expert,,9606.0,1595,,,,,,F,1,BAO_0000019,14214,9,CHEMBL617005,,D
,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,485.0,106,Homo sapiens,Expert,,9606.0,1596,,CHO-K1,,,,F,1,BAO_0000219,13729,9,CHEMBL616623,,D
,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,449.0,106,,Autocuration,,,1597,,CHO,,,,F,1,BAO_0000219,3025,8,CHEMBL616624,,H
,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,106,,Autocuration,,,1598,,,,,,B,1,BAO_0000357,2391,8,CHEMBL883243,,H
,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,106,,Autocuration,,,1599,,,,,,F,1,BAO_0000019,2391,8,CHEMBL616625,,H
,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",449.0,106,,Expert,,,1600,,CHO,,,,F,1,BAO_0000219,14956,8,CHEMBL616626,,H
,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,449.0,106,,Autocuration,,,1601,,CHO,,,,F,1,BAO_0000219,2598,8,CHEMBL616627,,H
,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,449.0,106,,Autocuration,,,1602,,CHO,,,,F,1,BAO_0000219,2598,8,CHEMBL616628,,H
,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,449.0,106,,Autocuration,,,1603,,CHO,,,,F,1,BAO_0000219,2598,8,CHEMBL616629,,H
,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,449.0,106,,Autocuration,,,1604,,CHO,,,,F,1,BAO_0000219,2598,8,CHEMBL616630,,H
,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,106,,Expert,,,1605,,,,,,F,1,BAO_0000019,14956,8,CHEMBL616631,,H
,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,106,,Autocuration,,,1606,,,,,,F,1,BAO_0000019,14956,8,CHEMBL616632,,H
,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,106,Homo sapiens,Expert,,9606.0,1607,,,,,,B,1,BAO_0000357,14214,9,CHEMBL616633,,D
,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,449.0,106,,Expert,,,1608,,CHO,,,,B,1,BAO_0000219,3463,8,CHEMBL616634,,H
,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,106,,Autocuration,,,1609,,,,,,B,1,BAO_0000357,15331,8,CHEMBL616635,,H
,,Binding affinity against 5-hydroxytryptamine 1B receptor,,106,Homo sapiens,Expert,,9606.0,1610,,,,,,B,1,BAO_0000357,16146,9,CHEMBL885358,,D
,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,449.0,106,Homo sapiens,Expert,,9606.0,1611,,CHO,,,,B,1,BAO_0000219,14159,9,CHEMBL616636,,D
,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,449.0,106,,Expert,,,1612,,CHO,,,,B,1,BAO_0000219,14158,8,CHEMBL616637,,H
,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,106,,Autocuration,,,1613,,,,,,B,1,BAO_0000357,14159,8,CHEMBL616638,,H
,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,449.0,106,,Expert,,,1614,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL616639,,H
,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,449.0,106,,Expert,,,1615,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL616640,,H
,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,449.0,106,,Expert,,,1616,,CHO,,,,B,1,BAO_0000219,15331,8,CHEMBL616641,,H
,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,449.0,106,,Expert,,,1617,,CHO,,,,B,1,BAO_0000219,15332,8,CHEMBL616642,,H
,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,449.0,106,,Expert,,,1618,,CHO,,,,B,1,BAO_0000219,14956,8,CHEMBL616643,,H
,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,106,,Autocuration,,,1619,,,,,,B,1,BAO_0000357,3805,8,CHEMBL616644,,H
,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,106,,Autocuration,,,1620,,,,,,B,1,BAO_0000357,14875,8,CHEMBL616645,,H
,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,105,Oryctolagus cuniculus,Autocuration,,9986.0,1621,,,,,,F,1,BAO_0000019,14454,8,CHEMBL616646,,H
,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,105,Oryctolagus cuniculus,Expert,,9986.0,1622,,,,,,F,1,BAO_0000019,14454,8,CHEMBL616647,,H
,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,105,,Autocuration,,,1623,,,,,,B,1,BAO_0000357,16288,8,CHEMBL616509,,H
,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,105,,Autocuration,,,1624,,,,,,B,1,BAO_0000357,16288,8,CHEMBL616510,,H
,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1625,,,,,,B,1,BAO_0000357,16312,8,CHEMBL616511,,H
,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,105,Bos taurus,Expert,,9913.0,1626,,,,,,B,1,BAO_0000357,1348,8,CHEMBL616512,,H
,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,105,Bos taurus,Autocuration,,9913.0,1627,,,,,,B,1,BAO_0000357,5834,8,CHEMBL616513,,H
,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,105,Bos taurus,Autocuration,2435.0,9913.0,1628,,,,,Striatum,B,1,BAO_0000019,13366,8,CHEMBL616514,,H
,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,105,Bos taurus,Expert,,9913.0,1629,,,,,,B,1,BAO_0000357,1414,8,CHEMBL616515,,H
,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,105,Bos taurus,Autocuration,,9913.0,1630,,,,,,B,1,BAO_0000019,14998,8,CHEMBL616516,,H
,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,105,Bos taurus,Autocuration,,9913.0,1631,,,,,,B,1,BAO_0000357,11473,8,CHEMBL616517,,H
,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,105,Bos taurus,Autocuration,,9913.0,1632,,,,,,B,1,BAO_0000357,11473,8,CHEMBL616518,,H
,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,105,Bos taurus,Autocuration,,9913.0,1633,,,,,,B,1,BAO_0000357,10639,8,CHEMBL616519,,H
,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,105,Bos taurus,Autocuration,,9913.0,1634,,,,,,B,1,BAO_0000357,10639,8,CHEMBL616520,,H
,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,105,Bos taurus,Autocuration,,9913.0,1635,,,,,,B,1,BAO_0000357,1375,8,CHEMBL616521,,H
,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,105,Bos taurus,Autocuration,,9913.0,1636,,,,,,B,1,BAO_0000357,1375,8,CHEMBL616522,,H
,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,105,Bos taurus,Autocuration,,9913.0,1637,,,,,,B,1,BAO_0000357,16532,8,CHEMBL884531,,H
,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,105,Bos taurus,Autocuration,,9913.0,1638,,,,,,B,1,BAO_0000357,11147,8,CHEMBL616523,,H
,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,105,Bos taurus,Autocuration,2435.0,9913.0,1639,,,,,Striatum,B,1,BAO_0000019,13366,8,CHEMBL616731,,H
,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,105,Bos taurus,Autocuration,,9913.0,1640,,,,,,B,1,BAO_0000019,10444,8,CHEMBL616732,,H
,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,105,Bos taurus,Autocuration,,9913.0,1641,,,,,,B,1,BAO_0000357,16532,8,CHEMBL616733,,H
,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,105,Bos taurus,Autocuration,,9913.0,1642,,,,,,B,1,BAO_0000357,16532,8,CHEMBL616734,,H
,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,105,Bos taurus,Autocuration,,9913.0,1643,,,,,,B,1,BAO_0000249,12827,8,CHEMBL616735,,H
,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,105,Bos taurus,Autocuration,,9913.0,1644,,,,,,B,1,BAO_0000249,12827,8,CHEMBL616736,,H
,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,105,Bos taurus,Expert,,9913.0,1645,,,,,,F,1,BAO_0000019,12919,8,CHEMBL616737,,H
,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,105,Bos taurus,Autocuration,,9913.0,1646,,,,,,B,1,BAO_0000019,14025,8,CHEMBL616738,,H
,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,105,Bos taurus,Expert,,9913.0,1647,,,,,,F,1,BAO_0000019,12919,8,CHEMBL616739,,H
,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,105,Bos taurus,Expert,,9913.0,1648,,,,,,F,1,BAO_0000019,12919,8,CHEMBL616740,,H
,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,105,Bos taurus,Expert,,9913.0,1649,,,,,,F,1,BAO_0000019,12919,8,CHEMBL616741,,H
,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,722.0,105,Gorilla gorilla,Autocuration,,9593.0,1650,,HEK293,,,,B,1,BAO_0000219,14447,8,CHEMBL616742,,H
,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,105570,Cavia porcellus,Intermediate,,10141.0,1651,,,,,,B,1,BAO_0000019,1375,9,CHEMBL616743,,D
,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,105570,Cavia porcellus,Intermediate,,10141.0,1652,,,,,,B,1,BAO_0000019,1375,9,CHEMBL616744,,D
,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,105570,Cavia porcellus,Intermediate,,10141.0,1653,,,,,,F,1,BAO_0000019,12409,9,CHEMBL616745,,D
,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,105570,Cavia porcellus,Intermediate,,10141.0,1654,,,,,,F,1,BAO_0000019,12409,9,CHEMBL616746,,D
,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,105570,Cavia porcellus,Intermediate,,10141.0,1655,,,,,,F,1,BAO_0000019,12409,9,CHEMBL616747,,D
,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,105570,Cavia porcellus,Intermediate,,10141.0,1656,,,,,,F,1,BAO_0000019,12409,9,CHEMBL616748,,D
,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,105570,Cavia porcellus,Intermediate,,10141.0,1657,,,,,,F,1,BAO_0000019,12409,9,CHEMBL616648,,D
,,Binding affinity against 5-hydroxytryptamine 1D receptor,,105570,Cavia porcellus,Intermediate,,10141.0,1658,,,,,,B,1,BAO_0000357,11574,9,CHEMBL616649,,D
,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,105570,Cavia porcellus,Intermediate,,10141.0,1659,,,,,,B,1,BAO_0000357,1558,9,CHEMBL616650,,D
,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,105570,Cavia porcellus,Intermediate,,10141.0,1660,,,,,,F,1,BAO_0000218,12409,9,CHEMBL616651,,D
,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,105570,Cavia porcellus,Intermediate,,10141.0,1661,,,,,,F,1,BAO_0000218,12409,9,CHEMBL616652,,D
,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,105570,Cavia porcellus,Intermediate,,10141.0,1662,,,,,,F,1,BAO_0000218,12409,9,CHEMBL616653,,D
,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,105570,Cavia porcellus,Intermediate,,10141.0,1663,,,,,,F,1,BAO_0000218,12409,9,CHEMBL616654,,D
,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,105570,Cavia porcellus,Intermediate,,10141.0,1664,,,,,,B,1,BAO_0000019,12253,9,CHEMBL616655,,D
,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,105570,Cavia porcellus,Intermediate,,10141.0,1665,,,,,,B,1,BAO_0000357,12936,9,CHEMBL616656,,D
,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,105,Cavia porcellus,Autocuration,,10141.0,1666,,,,,,B,1,BAO_0000019,13181,8,CHEMBL616657,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,105570,Cavia porcellus,Intermediate,2435.0,10141.0,1667,,,,,Striatum,B,1,BAO_0000357,12409,9,CHEMBL616658,,D
,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,105570,Cavia porcellus,Intermediate,,10141.0,1668,,,,,,B,1,BAO_0000357,10639,9,CHEMBL616659,,D
,,Binding affinity against 5-hydroxytryptamine 1D receptor,,51,,Autocuration,,,1669,,,,,,B,1,BAO_0000357,5254,8,CHEMBL616660,,H
,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,106,,Autocuration,,,1670,,,,,,B,1,BAO_0000357,13051,8,CHEMBL616661,,H
,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,105,,Expert,,,1671,,,,,,F,1,BAO_0000019,3463,8,CHEMBL616662,,H
,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1672,,,,,,F,1,BAO_0000019,15315,8,CHEMBL616663,,H
,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1673,,,,,,F,1,BAO_0000019,6011,8,CHEMBL616664,,H
,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",449.0,105,Homo sapiens,Expert,,9606.0,1674,,CHO,,,,F,1,BAO_0000219,14159,9,CHEMBL881820,,D
,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",449.0,105,,Autocuration,,,1675,,CHO,,,,F,1,BAO_0000219,14159,8,CHEMBL616665,,H
,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,449.0,105,,Expert,,,1676,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL616666,,H
,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,449.0,105,,Autocuration,,,1677,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL616667,,H
,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",449.0,105,,Expert,,,1678,,CHO,,,,F,1,BAO_0000219,15331,8,CHEMBL616668,,H
,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",449.0,105,Homo sapiens,Expert,,9606.0,1679,,CHO,,,,F,1,BAO_0000219,15332,9,CHEMBL616669,,D
,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",449.0,105,,Expert,,,1680,,CHO,,,,F,1,BAO_0000219,15332,8,CHEMBL617040,,H
,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",449.0,105,,Autocuration,,,1681,,CHO,,,,F,1,BAO_0000219,3294,8,CHEMBL617041,,H
,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",449.0,105,,Expert,,,1682,,CHO,,,,F,1,BAO_0000219,14158,8,CHEMBL617042,,H
,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",449.0,105,,Expert,,,1683,,CHO,,,,F,1,BAO_0000219,14956,8,CHEMBL617043,,H
,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1684,,,,,,F,1,BAO_0000019,12469,8,CHEMBL617044,,H
,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,449.0,105,,Expert,,,1685,,CHO,,,,F,1,BAO_0000219,3463,8,CHEMBL617045,,H
,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",449.0,105,Homo sapiens,Expert,,9606.0,1686,,CHO,,,,F,1,BAO_0000219,15250,9,CHEMBL617046,,D
,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",449.0,105,Homo sapiens,Expert,,9606.0,1687,,CHO,,,,F,1,BAO_0000219,15250,9,CHEMBL617047,,D
,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,105,,Expert,,,1688,,,,,,F,1,BAO_0000019,14956,8,CHEMBL617048,,H
,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,105,,Autocuration,,,1689,,,,,,F,1,BAO_0000019,14159,8,CHEMBL616897,,H
,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,105,Homo sapiens,Expert,,9606.0,1690,,,,,,F,1,BAO_0000019,14159,9,CHEMBL616898,,D
,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,449.0,105,Homo sapiens,Expert,,9606.0,1691,,CHO,,,,F,1,BAO_0000219,14499,9,CHEMBL858201,,D
,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1692,,,,,,F,1,BAO_0000019,15315,8,CHEMBL616899,,H
,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,105,,Autocuration,,,1693,In vitro,,,,,B,1,BAO_0000219,3294,8,CHEMBL616900,,H
,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,449.0,105,,Expert,,,1694,,CHO,,,,B,1,BAO_0000219,3463,8,CHEMBL616901,,H
,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,105,,Autocuration,,,1695,,,,,,B,1,BAO_0000357,15331,8,CHEMBL616902,,H
,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,105,Homo sapiens,Expert,,9606.0,1696,,CHO,,,,B,1,BAO_0000219,14159,9,CHEMBL616903,,D
,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,449.0,105,,Expert,,,1697,,CHO,,,,B,1,BAO_0000219,14158,8,CHEMBL616904,,H
,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1698,,,,,,B,1,BAO_0000357,14159,8,CHEMBL616905,,H
,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,449.0,105,,Expert,,,1699,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL616906,,H
,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,449.0,105,,Expert,,,1700,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL616907,,H
,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,449.0,105,,Expert,,,1701,,CHO,,,,B,1,BAO_0000219,15331,8,CHEMBL616908,,H
,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,105,Homo sapiens,Expert,,9606.0,1702,,CHO,,,,B,1,BAO_0000219,15332,9,CHEMBL616909,,D
,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,105,Homo sapiens,Expert,,9606.0,1703,,CHO,,,,B,1,BAO_0000219,14499,9,CHEMBL616910,,D
,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,449.0,105,,Expert,,,1704,,CHO,,,,B,1,BAO_0000219,15332,8,CHEMBL616911,,H
,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,105,,Expert,,,1705,,CHO,,,,B,1,BAO_0000219,14956,8,CHEMBL616912,,H
,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,105,,Autocuration,,,1706,,,,,,B,1,BAO_0000357,3805,8,CHEMBL616913,,H
,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,449.0,105,Homo sapiens,Expert,,9606.0,1707,,CHO,,,,B,1,BAO_0000219,6011,9,CHEMBL616914,,D
,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,449.0,105,,Autocuration,,,1708,,CHO,,,,B,1,BAO_0000219,16190,8,CHEMBL616915,,H
,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,105,,Autocuration,,,1709,,,,,,B,1,BAO_0000019,14165,8,CHEMBL616916,,H
,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,105,Homo sapiens,Expert,,9606.0,1710,,,,,,B,1,BAO_0000357,4234,9,CHEMBL616917,,D
,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,105,,Autocuration,,,1711,,,,,,B,1,BAO_0000357,15527,8,CHEMBL616918,,H
,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,105,,Expert,,,1712,,,,,,B,1,BAO_0000219,6328,8,CHEMBL616919,,H
,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,105,,Autocuration,,,1713,,,,,,B,1,BAO_0000357,16209,8,CHEMBL616920,,H
,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,105,,Autocuration,,,1714,,,,,,B,1,BAO_0000357,14770,8,CHEMBL872914,,H
,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,105,,Autocuration,,,1715,,,,,,B,1,BAO_0000357,2598,8,CHEMBL616921,,H
,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,105,,Expert,,,1716,,,,,,B,1,BAO_0000357,6897,8,CHEMBL616922,,H
,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1717,,,,,,B,1,BAO_0000357,6013,8,CHEMBL616923,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,105,,Expert,,,1718,,,,,,B,1,BAO_0000357,5843,8,CHEMBL616924,,H
,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,105,,Expert,,,1719,,,,,,B,1,BAO_0000357,14454,8,CHEMBL875909,,H
,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,105,,Autocuration,,,1720,,,,,,B,1,BAO_0000357,14454,8,CHEMBL616925,,H
,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,105,,Autocuration,,,1721,,,,,,B,1,BAO_0000357,14454,8,CHEMBL616926,,H
,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1722,,,,,,B,1,BAO_0000357,15818,8,CHEMBL616927,,H
,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,485.0,105,,Expert,,,1723,,CHO-K1,,,,F,1,BAO_0000219,13729,8,CHEMBL616928,,H
,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,105,Homo sapiens,Expert,,9606.0,1724,In vitro,,,,,B,1,BAO_0000219,6011,9,CHEMBL616929,,D
,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,105,Homo sapiens,Expert,,9606.0,1725,,,,,,B,1,BAO_0000357,4234,9,CHEMBL616930,,D
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,105,,Expert,,,1726,,,,,,B,1,BAO_0000019,17085,8,CHEMBL616931,,H
,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,105,,Autocuration,,,1727,,,,,,B,1,BAO_0000357,3025,8,CHEMBL616932,,H
,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,105,,Expert,,,1728,,,,,,B,1,BAO_0000357,15315,8,CHEMBL616933,,H
,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,105,Homo sapiens,Expert,,9606.0,1729,,,,,,B,1,BAO_0000219,14214,9,CHEMBL616934,,D
,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,105,Homo sapiens,Expert,,9606.0,1730,,,,,,B,1,BAO_0000357,3804,9,CHEMBL616935,,D
,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,105,,Autocuration,,,1731,,,,,,B,1,BAO_0000357,16700,8,CHEMBL616936,,H
,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,105,Homo sapiens,Expert,,9606.0,1732,,,,,,B,1,BAO_0000357,2391,9,CHEMBL616937,,D
,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,105,Homo sapiens,Expert,,9606.0,1733,,,,,,B,1,BAO_0000357,4175,9,CHEMBL616938,,D
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1734,,,,,,B,1,BAO_0000019,17085,8,CHEMBL616939,,H
,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,105,,Expert,,,1735,,,,,,B,1,BAO_0000019,17085,8,CHEMBL616940,,H
,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,105,Homo sapiens,Expert,,9606.0,1736,,,,,,B,1,BAO_0000357,15926,9,CHEMBL616941,,D
,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,485.0,105,,Autocuration,,,1737,,CHO-K1,,,,B,1,BAO_0000219,16312,8,CHEMBL616942,,H
,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,485.0,105,,Autocuration,,,1738,,CHO-K1,,,,B,1,BAO_0000219,16312,8,CHEMBL616943,,H
,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,449.0,104802,,Autocuration,,,1739,,CHO,,,,B,1,BAO_0000219,14956,4,CHEMBL616944,,H
,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,105,,Autocuration,,,1740,,,,,,F,1,BAO_0000019,3294,8,CHEMBL616945,,H
,,Binding activity radioligand.,,105,,Autocuration,,,1741,,,,,,B,1,BAO_0000357,12861,8,CHEMBL616946,,H
,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,105,,Autocuration,,,1742,,,,,,B,1,BAO_0000019,12861,8,CHEMBL616947,,H
,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,485.0,105,,Expert,,,1743,,CHO-K1,,,,B,1,BAO_0000219,16312,8,CHEMBL616948,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1744,,,,,,B,1,BAO_0000357,5104,8,CHEMBL616851,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1745,,,,,,B,1,BAO_0000357,5105,8,CHEMBL616852,,H
,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1746,,,,,,B,1,BAO_0000357,14499,8,CHEMBL616853,,H
,,Binding activity against human 5-hydroxytryptamine 1D receptor,,105,Homo sapiens,Expert,,9606.0,1747,,,,,,B,1,BAO_0000357,15926,9,CHEMBL616854,,D
,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,449.0,105,Homo sapiens,Expert,,9606.0,1748,,CHO,,,,B,1,BAO_0000219,4540,9,CHEMBL616855,,D
,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,449.0,105,,Autocuration,,,1749,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL616856,,H
,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,105,,Autocuration,,,1750,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL616857,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1751,,,,,,B,1,BAO_0000357,6166,8,CHEMBL616858,,H
,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,449.0,105,,Autocuration,,,1752,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL616859,,H
,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,449.0,105,,Autocuration,,,1753,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL616860,,H
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,722.0,105,,Autocuration,,,1754,,HEK293,,,,B,1,BAO_0000219,17451,8,CHEMBL616861,,H
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,722.0,105,,Autocuration,,,1755,,HEK293,,,,B,1,BAO_0000219,17451,8,CHEMBL616541,,H
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,722.0,105,,Autocuration,,,1756,,HEK293,,,,B,1,BAO_0000219,17451,8,CHEMBL616542,,H
,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,449.0,105,,Autocuration,,,1757,,CHO,,,,B,1,BAO_0000219,4199,8,CHEMBL616543,,H
,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,105,Homo sapiens,Expert,,9606.0,1758,,,,,,B,1,BAO_0000357,14875,9,CHEMBL616544,,D
,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,449.0,105,,Autocuration,,,1759,,CHO,,,,B,1,BAO_0000219,15146,8,CHEMBL616545,,H
,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,105,,Autocuration,,,1760,,,,,,B,1,BAO_0000357,5213,8,CHEMBL616546,,H
,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,449.0,105,,Autocuration,,,1761,,CHO,,,,B,1,BAO_0000219,14818,8,CHEMBL616547,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",449.0,105,,Autocuration,,,1762,,CHO,,,,B,1,BAO_0000219,4829,8,CHEMBL616548,,H
,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,105,,Expert,,,1763,,,,,,F,1,BAO_0000019,14454,8,CHEMBL616549,,H
,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,105,,Expert,,,1764,,,,,,F,1,BAO_0000019,14454,8,CHEMBL616550,,H
,,Binding affinity against 5-HT2C receptor,,108,,Autocuration,,,1765,,,,,,B,1,BAO_0000357,5254,8,CHEMBL857066,,H
,,Binding affinity against 5-hydroxytryptamine 1D receptor,,108,,Autocuration,,,1766,,,,,,B,1,BAO_0000357,5254,8,CHEMBL616551,,H
,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,10577,,Autocuration,,,1767,,,,,,B,1,BAO_0000357,10639,8,CHEMBL616552,,H
,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,10577,,Autocuration,,,1768,,,,,,F,1,BAO_0000019,10639,8,CHEMBL832876,,H
,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,10577,,Expert,,,1769,,,,,,B,1,BAO_0000019,12352,8,CHEMBL616553,,H
,,Binding affinity towards 5-HT1B was determined,,10577,,Autocuration,,,1770,,,,,,B,1,BAO_0000357,9098,8,CHEMBL616554,,H
,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,10577,,Expert,,,1771,,,,,,B,1,BAO_0000019,14430,8,CHEMBL616555,,H
,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,10577,,Expert,,,1772,,,,,,B,1,BAO_0000019,13657,8,CHEMBL616556,,H
,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,10577,,Autocuration,,,1773,,,,,,B,1,BAO_0000019,13657,8,CHEMBL616557,,H
,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,10577,,Expert,,,1774,,,,,,B,1,BAO_0000019,15854,8,CHEMBL616558,,H
,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,10577,Rattus norvegicus,Expert,,10116.0,1775,,,,,,B,1,BAO_0000019,10639,9,CHEMBL616749,,D
,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,10577,,Autocuration,,,1776,,,,,,B,1,BAO_0000357,10025,8,CHEMBL616750,,H
,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,10577,,Autocuration,,,1777,,,,,,B,1,BAO_0000357,10025,8,CHEMBL616751,,H
,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,10577,,Autocuration,,,1778,,,,,,B,1,BAO_0000249,14286,8,CHEMBL616752,,H
,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,10577,,Autocuration,2435.0,,1779,,,,,Striatum,B,1,BAO_0000019,3651,8,CHEMBL616753,,H
,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,10577,Rattus norvegicus,Expert,,10116.0,1780,,,,,,B,1,BAO_0000357,14178,9,CHEMBL616754,,D
,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,10577,,Autocuration,,,1781,,,,,,B,1,BAO_0000019,10639,8,CHEMBL616755,,H
,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,10577,,Autocuration,2435.0,,1782,,,,,Striatum,B,1,BAO_0000019,13605,8,CHEMBL616756,,H
,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,10577,,Autocuration,2435.0,,1783,,,,,Striatum,B,1,BAO_0000019,5834,8,CHEMBL616757,,H
,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,10577,,Autocuration,2435.0,,1784,,,,,Striatum,B,1,BAO_0000357,10922,8,CHEMBL616758,,H
,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,10577,,Autocuration,,,1785,,,,,,B,1,BAO_0000249,14286,8,CHEMBL616759,,H
,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,10577,,Autocuration,,,1786,,,,,,B,1,BAO_0000357,11825,8,CHEMBL616760,,H
,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,10577,,Autocuration,2435.0,,1787,,,,,Striatum,B,1,BAO_0000019,14826,8,CHEMBL616761,,H
,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,10577,,Autocuration,2435.0,,1788,,,,,Striatum,B,1,BAO_0000019,9699,8,CHEMBL616762,,H
,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,10577,,Autocuration,,,1789,,,,,,B,1,BAO_0000019,14423,8,CHEMBL616763,,H
,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,10577,,Expert,,,1790,,,,,,B,1,BAO_0000357,10062,8,CHEMBL872909,,H
,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,10577,,Autocuration,,,1791,,,,,,B,1,BAO_0000357,10062,8,CHEMBL616764,,H
,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,10577,Rattus norvegicus,Expert,,10116.0,1792,,,,,,B,1,BAO_0000357,12280,9,CHEMBL616765,,D
,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,10577,,Autocuration,2435.0,,1793,,,,,Striatum,B,1,BAO_0000357,15412,8,CHEMBL616766,,H
,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,10577,,Autocuration,2435.0,,1794,,,,,Striatum,B,1,BAO_0000357,15412,8,CHEMBL616767,,H
,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,10577,,Autocuration,,,1795,,,,,,B,1,BAO_0000357,10062,8,CHEMBL616768,,H
,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,10577,,Autocuration,,,1796,,,,,,B,1,BAO_0000357,11147,8,CHEMBL616769,,H
,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,10577,,Autocuration,,,1797,,,,,,B,1,BAO_0000019,9547,8,CHEMBL616770,,H
,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,10577,,Autocuration,,,1798,,,,,,B,1,BAO_0000019,10444,8,CHEMBL616771,,H
,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,10577,,Autocuration,2435.0,,1799,,,,,Striatum,B,1,BAO_0000019,12469,8,CHEMBL616772,,H
,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,10577,,Expert,,,1800,,,,,,B,1,BAO_0000019,9098,8,CHEMBL616773,,H
,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,10577,,Autocuration,,,1801,,,,,,B,1,BAO_0000019,9098,8,CHEMBL616774,,H
,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,10577,,Autocuration,,,1802,,,,,,B,1,BAO_0000357,9699,8,CHEMBL616775,,H
,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,10577,,Autocuration,,,1803,,,,,,B,1,BAO_0000249,10394,8,CHEMBL616776,,H
,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,10577,,Autocuration,,,1804,,,,,,B,1,BAO_0000357,12092,8,CHEMBL616777,,H
,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,10577,,Autocuration,,,1805,,,,,,B,1,BAO_0000357,16700,8,CHEMBL616778,,H
,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,10577,Rattus norvegicus,Expert,,10116.0,1806,,,,,,B,1,BAO_0000249,403,9,CHEMBL616779,,D
,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,10577,Rattus norvegicus,Expert,,10116.0,1807,,,,,,B,1,BAO_0000357,12771,9,CHEMBL616780,,D
,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,10577,,Autocuration,,,1808,,,,,,B,1,BAO_0000019,11642,8,CHEMBL616781,,H
,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,10577,,Autocuration,,,1809,,,,,,B,1,BAO_0000357,12953,8,CHEMBL616782,,H
,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,10577,,Autocuration,,,1810,,,,,,B,1,BAO_0000357,12953,8,CHEMBL616783,,H
,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,10577,,Expert,2435.0,,1811,,,,,Striatum,B,1,BAO_0000019,12953,8,CHEMBL616784,,H
,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,10577,,Autocuration,,,1812,,,,,,B,1,BAO_0000357,12953,8,CHEMBL616785,,H
,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,10577,,Autocuration,955.0,,1813,,,,,Brain,B,1,BAO_0000249,9737,8,CHEMBL857067,,H
,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,10577,,Autocuration,,,1814,,,,,,B,1,BAO_0000019,9737,8,CHEMBL616786,,H
,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,10577,,Autocuration,955.0,,1815,,,,,Brain,B,1,BAO_0000249,9737,8,CHEMBL616787,,H
,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,10577,,Autocuration,,,1816,,,,,,B,1,BAO_0000357,12827,8,CHEMBL616788,,H
,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,10577,,Autocuration,,,1817,,,,,,B,1,BAO_0000357,5033,8,CHEMBL616789,,H
,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,10577,Rattus norvegicus,Expert,,10116.0,1818,,,,,,B,1,BAO_0000019,9786,9,CHEMBL616790,,D
,,Binding affinity at 5-hydroxytryptamine 1B receptor,,10577,,Expert,,,1819,,,,,,B,1,BAO_0000357,13116,8,CHEMBL616791,,H
,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,10577,,Autocuration,,,1820,,,,,,B,1,BAO_0000019,16429,8,CHEMBL616792,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,10577,Rattus norvegicus,Expert,,10116.0,1821,,,,,,B,1,BAO_0000249,12409,9,CHEMBL616793,,D
,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,10577,,Autocuration,,,1822,,,,,,B,1,BAO_0000357,15194,8,CHEMBL616794,,H
,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,10577,,Autocuration,,,1823,,,,,,B,1,BAO_0000357,15194,8,CHEMBL616795,,H
,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,104686,,Autocuration,,,1824,,,,,,B,1,BAO_0000019,5486,4,CHEMBL616796,,H
,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,106,,Autocuration,,,1825,,,,,,B,1,BAO_0000357,4639,8,CHEMBL616797,,H
,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,106,,Autocuration,,,1826,,,,,,B,1,BAO_0000249,386,8,CHEMBL616798,Brain membranes,H
,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,106,,Autocuration,,,1827,,,,,,B,1,BAO_0000357,2474,8,CHEMBL616799,,H
,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,106,,Autocuration,,,1828,,,,,,B,1,BAO_0000357,6011,8,CHEMBL616800,,H
,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,106,,Autocuration,,,1829,,,,,,B,1,BAO_0000357,5014,8,CHEMBL616801,,H
,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,106,,Autocuration,,,1830,,,,,,B,1,BAO_0000357,17515,8,CHEMBL616802,,H
,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,106,,Autocuration,,,1831,,,,,,B,1,BAO_0000357,4373,8,CHEMBL616803,,H
,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,106,,Expert,,,1832,,,,,,B,1,BAO_0000357,1633,8,CHEMBL857068,,H
,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,106,,Autocuration,,,1833,,,,,,B,1,BAO_0000357,1633,8,CHEMBL616804,,H
,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,106,,Autocuration,,,1834,,,,,,B,1,BAO_0000357,4373,8,CHEMBL616805,,H
,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,106,,Autocuration,,,1835,,,,,,B,1,BAO_0000357,4687,8,CHEMBL616806,,H
,,Binding affinity against 5-hydroxytryptamine 1B receptor,,106,,Autocuration,,,1836,,,,,,B,1,BAO_0000357,11574,8,CHEMBL616807,,H
,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,106,,Autocuration,,,1837,,,,,,B,1,BAO_0000357,10321,8,CHEMBL616808,,H
,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,106,,Autocuration,,,1838,,,,,,B,1,BAO_0000357,15527,8,CHEMBL616809,,H
,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,106,,Autocuration,,,1839,,,,,,B,1,BAO_0000357,17200,8,CHEMBL616810,,H
,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,104802,,Autocuration,,,1840,,,,,,B,1,BAO_0000224,14423,4,CHEMBL616811,,H
,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,108,Bos taurus,Autocuration,,9913.0,1841,,,,,,B,1,BAO_0000357,5834,8,CHEMBL616812,,H
,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,108,Sus scrofa,Autocuration,,9823.0,1842,,,,,,B,1,BAO_0000357,11473,8,CHEMBL616813,,H
,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,108,Sus scrofa,Autocuration,,9823.0,1843,,,,,,B,1,BAO_0000357,11473,8,CHEMBL616814,,H
,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,108,Sus scrofa,Autocuration,,9823.0,1844,,,,,,B,1,BAO_0000357,10639,8,CHEMBL616815,,H
,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,108,Sus scrofa,Autocuration,,9823.0,1845,,,,,,B,1,BAO_0000357,10639,8,CHEMBL616816,,H
,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,108,Sus scrofa,Autocuration,,9823.0,1846,,,,,,B,1,BAO_0000357,14331,8,CHEMBL616817,,H
,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,108,Sus scrofa,Autocuration,,9823.0,1847,,,,,,B,1,BAO_0000357,10796,8,CHEMBL616818,,H
,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,108,Sus scrofa,Expert,,9823.0,1848,,,,,,B,1,BAO_0000357,9098,8,CHEMBL616819,,H
,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,108,Sus scrofa,Expert,,9823.0,1849,,,,,,B,1,BAO_0000357,14331,8,CHEMBL616820,,H
,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,108,Sus scrofa,Expert,,9823.0,1850,,,,,,B,1,BAO_0000019,11828,8,CHEMBL616821,,H
,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,108,Sus scrofa,Autocuration,,9823.0,1851,,,,,,B,1,BAO_0000357,11866,8,CHEMBL616822,,H
,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,108,Oryctolagus cuniculus,Autocuration,,9986.0,1852,,,,,,B,1,BAO_0000019,13047,8,CHEMBL616823,,H
,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,12689,Rattus norvegicus,Autocuration,,10116.0,1853,,,,,,B,1,BAO_0000357,188,9,CHEMBL616824,,D
,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,12689,Rattus norvegicus,Autocuration,,10116.0,1854,,,,,,B,1,BAO_0000357,11825,9,CHEMBL616825,,D
,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,12689,Rattus norvegicus,Autocuration,,10116.0,1855,,,,,,B,1,BAO_0000357,11825,9,CHEMBL616826,,D
,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,12689,Rattus norvegicus,Expert,,10116.0,1856,,,,,,B,1,BAO_0000019,11624,9,CHEMBL616827,,D
,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,12689,Rattus norvegicus,Autocuration,,10116.0,1857,,,,,,B,1,BAO_0000357,11139,9,CHEMBL616828,,D
,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,12689,Rattus norvegicus,Autocuration,,10116.0,1858,,,,,,B,1,BAO_0000357,11147,9,CHEMBL616829,,D
,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,12689,Rattus norvegicus,Autocuration,,10116.0,1859,,,,,,B,1,BAO_0000019,10444,9,CHEMBL616830,,D
,,Binding affinity against 5-hydroxytryptamine 1C receptor,,12689,Rattus norvegicus,Expert,,10116.0,1860,,,,,,B,1,BAO_0000357,11624,9,CHEMBL616831,,D
,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,12689,Rattus norvegicus,Autocuration,,10116.0,1861,,,,,,B,1,BAO_0000019,11662,9,CHEMBL616832,,D
,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,12689,Rattus norvegicus,Autocuration,,10116.0,1862,,,,,,B,1,BAO_0000019,11662,9,CHEMBL616833,,D
,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,12689,Rattus norvegicus,Expert,,10116.0,1863,,,,,,B,1,BAO_0000019,11662,9,CHEMBL616834,,D
,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,12689,Rattus norvegicus,Autocuration,,10116.0,1864,,,,,,B,1,BAO_0000019,11662,9,CHEMBL829595,,D
,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,12689,Rattus norvegicus,Autocuration,,10116.0,1865,,,,,,B,1,BAO_0000357,9098,9,CHEMBL616835,,D
,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,12689,Rattus norvegicus,Autocuration,,10116.0,1866,,,,,,B,1,BAO_0000249,10394,9,CHEMBL872910,,D
,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,12689,,Expert,,,1867,,,,,,B,1,BAO_0000357,11933,8,CHEMBL616836,,H
,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,12689,Rattus norvegicus,Autocuration,,10116.0,1868,,,,,,B,1,BAO_0000357,12092,9,CHEMBL616837,,D
,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,12689,Rattus norvegicus,Autocuration,,10116.0,1869,,,,,,B,1,BAO_0000019,12253,9,CHEMBL616466,,D
,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,722.0,12689,Rattus norvegicus,Autocuration,,10116.0,1870,,HEK293,,,,B,1,BAO_0000219,12253,9,CHEMBL616467,,D
,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,108,,Autocuration,,,1871,,,,,,B,1,BAO_0000357,1558,8,CHEMBL616468,,H
,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,108,,Autocuration,,,1872,,,,,,B,1,BAO_0000357,2474,8,CHEMBL616469,,H
,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,108,,Autocuration,,,1873,,,,,,B,1,BAO_0000357,2474,8,CHEMBL616470,,H
,,Binding affinity against 5-hydroxytryptamine 1C receptor,,12689,,Autocuration,,,1874,,,,,,B,1,BAO_0000357,11574,8,CHEMBL616471,,H
,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,12689,,Autocuration,,,1875,,,,,,B,1,BAO_0000357,1558,8,CHEMBL616472,,H
,,Binding affinity against 5-hydroxytryptamine 1C receptor,,12689,,Autocuration,,,1876,,,,,,B,1,BAO_0000357,13944,8,CHEMBL616473,,H
,,Binding affinity against serotonergic 5-HT1c receptor,,12689,,Autocuration,,,1877,,,,,,B,1,BAO_0000357,13033,8,CHEMBL616474,,H
,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,12689,,Autocuration,,,1878,,,,,,B,1,BAO_0000357,10321,8,CHEMBL616475,,H
,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,12689,,Autocuration,,,1879,,,,,,B,1,BAO_0000357,11866,8,CHEMBL616476,,H
,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,105,Oryctolagus cuniculus,Autocuration,,9986.0,1880,,,,,,B,1,BAO_0000019,14454,8,CHEMBL616477,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,104686,,Autocuration,,,1881,,,,,,B,1,BAO_0000224,11574,4,CHEMBL616478,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,104686,,Autocuration,,,1882,,,,,,B,1,BAO_0000224,11574,4,CHEMBL616479,,H
,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,104686,,Autocuration,,,1883,,,,,,B,1,BAO_0000019,13631,4,CHEMBL616480,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,104686,Rattus norvegicus,Autocuration,,10116.0,1884,,,,,,B,1,BAO_0000019,9630,5,CHEMBL616481,,D
,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,104686,Rattus norvegicus,Autocuration,,10116.0,1885,,,,,,B,1,BAO_0000249,8822,5,CHEMBL616482,,D
,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,104686,Rattus norvegicus,Autocuration,955.0,10116.0,1886,,,,,Brain,B,1,BAO_0000221,9064,5,CHEMBL884713,,D
,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,104686,,Autocuration,,,1887,,,,,,B,1,BAO_0000224,8868,4,CHEMBL616483,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,104686,,Autocuration,,,1888,,,,,,B,1,BAO_0000224,9064,4,CHEMBL616484,,H
,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,104686,,Autocuration,,,1889,,,,,,B,1,BAO_0000019,9806,4,CHEMBL616485,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,104686,,Autocuration,,,1890,,,,,,B,1,BAO_0000224,9098,4,CHEMBL616486,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,104686,,Autocuration,,,1891,,,,,,B,1,BAO_0000224,8868,4,CHEMBL616487,,H
,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,104686,,Autocuration,,,1892,,,,,,B,1,BAO_0000224,12765,4,CHEMBL616488,,H
,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686,,Autocuration,,,1893,,,,,,B,1,BAO_0000019,11049,4,CHEMBL616489,,H
,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686,,Autocuration,,,1894,,,,,,B,1,BAO_0000019,11049,4,CHEMBL616490,,H
,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,104686,,Autocuration,,,1895,,,,,,B,1,BAO_0000019,11049,4,CHEMBL616491,,H
,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,104686,,Autocuration,,,1896,,,,,,B,1,BAO_0000019,11049,4,CHEMBL616492,,H
,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686,,Autocuration,,,1897,,,,,,B,1,BAO_0000019,11049,4,CHEMBL616493,,H
,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,104686,,Autocuration,,,1898,,,,,,B,1,BAO_0000019,11473,4,CHEMBL616494,,H
,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,104686,,Autocuration,,,1899,,,,,,B,1,BAO_0000019,11473,4,CHEMBL616495,,H
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,104686,,Autocuration,,,1900,,,,,,B,1,BAO_0000019,3086,4,CHEMBL616496,,H
,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686,,Autocuration,,,1901,,,,,,B,1,BAO_0000019,11049,4,CHEMBL616497,,H
,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686,,Autocuration,,,1902,,,,,,B,1,BAO_0000019,11049,4,CHEMBL616498,,H
,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,104686,,Autocuration,,,1903,,,,,,B,1,BAO_0000019,10639,4,CHEMBL616499,,H
,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,104686,,Autocuration,,,1904,,,,,,B,1,BAO_0000019,10922,4,CHEMBL616500,,H
,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,104686,Rattus norvegicus,Autocuration,955.0,10116.0,1905,,,,,Brain,B,1,BAO_0000221,9064,5,CHEMBL616501,,D
,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,104686,,Autocuration,955.0,,1906,,,,,Brain,B,1,BAO_0000221,10748,4,CHEMBL616502,,H
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,104686,,Autocuration,,,1907,,,,,,B,1,BAO_0000249,11614,4,CHEMBL884529,Membranes,H
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,104686,,Autocuration,,,1908,,,,,,B,1,BAO_0000249,11615,4,CHEMBL616503,Membranes,H
,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,1909,,,,,,B,1,BAO_0000224,11615,4,CHEMBL616964,,H
,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,104686,,Autocuration,,,1910,,,,,,B,1,BAO_0000249,11614,4,CHEMBL616965,Membranes,H
,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,104686,,Autocuration,,,1911,,,,,,B,1,BAO_0000224,11702,4,CHEMBL616966,,H
,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,104686,,Autocuration,,,1912,,,,,,B,1,BAO_0000224,11702,4,CHEMBL616967,,H
,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,104686,Rattus norvegicus,Autocuration,,10116.0,1913,,,,,,B,1,BAO_0000224,11702,5,CHEMBL616968,,D
,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,104686,,Autocuration,,,1914,,,,,,B,1,BAO_0000224,11702,4,CHEMBL616969,,H
,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,104686,,Autocuration,,,1915,,,,,,B,1,BAO_0000019,13346,4,CHEMBL884530,,H
,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,1916,,,,,,B,1,BAO_0000224,10025,4,CHEMBL616970,,H
,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,104686,,Autocuration,,,1917,,,,,,B,1,BAO_0000224,10025,4,CHEMBL616971,,H
,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,104686,,Autocuration,,,1918,,,,,,B,1,BAO_0000224,10025,4,CHEMBL616972,,H
,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,104686,,Autocuration,,,1919,,,,,,B,1,BAO_0000224,9036,4,CHEMBL616973,,H
,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,104686,,Autocuration,,,1920,,,,,,B,1,BAO_0000224,9036,4,CHEMBL616974,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,104686,,Autocuration,,,1921,,,,,,B,1,BAO_0000019,9161,4,CHEMBL616975,,H
,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,104686,,Autocuration,,,1922,,,,,,B,1,BAO_0000019,12304,4,CHEMBL616976,,H
,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,104686,,Autocuration,,,1923,,,,,,B,1,BAO_0000224,13276,4,CHEMBL616977,,H
,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,104686,,Autocuration,,,1924,,,,,,B,1,BAO_0000224,11825,4,CHEMBL616978,,H
,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,104686,,Autocuration,,,1925,,,,,,B,1,BAO_0000224,12443,4,CHEMBL616979,,H
,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,1926,,,,,,B,1,BAO_0000224,13830,4,CHEMBL616980,,H
,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,104686,,Autocuration,,,1927,,,,,,B,1,BAO_0000249,9592,4,CHEMBL616981,Membranes,H
,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,104686,,Autocuration,,,1928,,,,,,B,1,BAO_0000249,9592,4,CHEMBL616982,Membranes,H
,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,104686,,Autocuration,,,1929,,,,,,B,1,BAO_0000224,10881,4,CHEMBL616983,,H
,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,104686,,Autocuration,,,1930,,,,,,B,1,BAO_0000019,13605,4,CHEMBL616984,,H
,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,104686,Rattus norvegicus,Autocuration,,10116.0,1931,,,,,,B,1,BAO_0000224,11624,5,CHEMBL616985,,D
,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,104686,,Autocuration,,,1932,,,,,,B,1,BAO_0000224,4101,4,CHEMBL616986,,H
,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,104686,,Autocuration,,,1933,,,,,,B,1,BAO_0000224,4101,4,CHEMBL616987,,H
,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,104686,,Autocuration,,,1934,,,,,,B,1,BAO_0000019,15360,4,CHEMBL616988,,H
,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,104686,,Autocuration,,,1935,,,,,,B,1,BAO_0000019,11576,4,CHEMBL617243,,H
,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,104686,,Autocuration,,,1936,,,,,,B,1,BAO_0000019,5834,4,CHEMBL617244,,H
,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,485.0,104686,Rattus norvegicus,Autocuration,,10116.0,1937,,CHO-K1,,,,B,1,BAO_0000219,2395,5,CHEMBL617245,,D
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,104686,,Autocuration,,,1938,,,,,,B,1,BAO_0000249,11965,4,CHEMBL617246,Membranes,H
,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,104686,,Autocuration,,,1939,,,,,,B,1,BAO_0000224,3967,4,CHEMBL617546,,H
,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,104686,,Autocuration,,,1940,,,,,,B,1,BAO_0000249,11130,4,CHEMBL617547,Brain membranes,H
,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,104686,,Autocuration,,,1941,In vitro,,,,,B,1,BAO_0000219,13427,4,CHEMBL617548,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,1942,,,,,,B,1,BAO_0000224,9443,4,CHEMBL617549,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,104686,,Autocuration,,,1943,,,,,,B,1,BAO_0000224,9443,4,CHEMBL617550,,H
,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,104686,,Autocuration,,,1944,,,,,,B,1,BAO_0000224,11825,4,CHEMBL617551,,H
,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,104686,,Autocuration,,,1945,,,,,,B,1,BAO_0000249,12120,4,CHEMBL617552,Membranes,H
,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,104686,,Autocuration,,,1946,,,,,,B,1,BAO_0000249,12120,4,CHEMBL617553,Membranes,H
,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,104686,,Autocuration,1515.0,,1947,,,,,Thoracic aorta,F,1,BAO_0000019,11963,4,CHEMBL617554,,H
,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,1948,,,,,,B,1,BAO_0000019,9069,4,CHEMBL617555,,H
,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,104686,,Autocuration,,,1949,,,,,,B,1,BAO_0000224,8868,4,CHEMBL617556,,H
,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,10624,,Autocuration,,,1950,,,,,,B,1,BAO_0000357,17200,8,CHEMBL617557,,H
,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,10624,,Autocuration,,,1951,,,,,,B,1,BAO_0000357,17200,8,CHEMBL617558,,H
,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,17106,,Expert,,,1952,,,,,,B,1,BAO_0000357,13969,8,CHEMBL617559,,H
,,Binding affinity for 5-hydroxytryptamine 1D receptor,,17106,,Expert,,,1953,,,,,,B,1,BAO_0000357,13392,9,CHEMBL617560,,D
,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,17106,,Autocuration,,,1954,,,,,,B,1,BAO_0000249,1742,8,CHEMBL617561,,H
,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,17106,,Autocuration,,,1955,,,,,,B,1,BAO_0000249,1742,8,CHEMBL617562,,H
,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,17106,,Autocuration,2435.0,,1956,,,,,Striatum,B,1,BAO_0000357,14331,8,CHEMBL617563,,H
,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,17106,,Autocuration,,,1957,,,,,,F,1,BAO_0000019,12861,8,CHEMBL617564,,H
,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,17106,,Expert,,,1958,,,,,,B,1,BAO_0000019,12861,8,CHEMBL617565,,H
,,Binding activity radioligand.,,17106,,Autocuration,,,1959,,,,,,B,1,BAO_0000357,12861,8,CHEMBL856076,,H
,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,17106,,Autocuration,,,1960,,,,,,B,1,BAO_0000019,12861,8,CHEMBL617566,,H
,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,17106,,Expert,,,1961,,,,,,B,1,BAO_0000019,12861,8,CHEMBL875911,,H
,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,17106,,Autocuration,,,1962,,,,,,B,1,BAO_0000019,12861,8,CHEMBL617567,,H
,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,17106,,Autocuration,,,1963,,,,,,B,1,BAO_0000249,675,8,CHEMBL617568,,H
,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,17106,,Expert,,,1964,,,,,,B,1,BAO_0000019,12490,8,CHEMBL617569,,H
,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,17106,,Expert,,,1965,,,,,,B,1,BAO_0000249,11828,8,CHEMBL617570,,H
,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,17106,,Autocuration,,,1966,,,,,,B,1,BAO_0000357,11866,8,CHEMBL617571,,H
,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,105,Sus scrofa,Autocuration,,9823.0,1967,,,,,,B,1,BAO_0000357,773,8,CHEMBL617572,,H
,,The compound was tested for intrinsic activity against 5-HT1D receptor,,105,Oryctolagus cuniculus,Expert,,9986.0,1968,,,,,,B,1,BAO_0000357,13047,8,CHEMBL617573,,H
,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,105,Oryctolagus cuniculus,Autocuration,,9986.0,1969,,,,,,B,1,BAO_0000019,13047,8,CHEMBL617574,,H
,,The compound was tested for binding affinity against 5-HT1D receptor,,105,Oryctolagus cuniculus,Expert,,9986.0,1970,,,,,,B,1,BAO_0000357,13047,8,CHEMBL617575,,H
,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,10578,,Autocuration,,,1971,,,,,,B,1,BAO_0000357,188,8,CHEMBL617576,,H
,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,10578,,Autocuration,,,1972,,,,,,F,1,BAO_0000019,10639,8,CHEMBL617577,,H
,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,10578,,Autocuration,,,1973,,,,,,F,1,BAO_0000019,12438,8,CHEMBL617578,,H
,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,10578,,Autocuration,,,1974,,,,,,B,1,BAO_0000357,12438,8,CHEMBL617579,,H
,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,10578,,Expert,,,1975,,,,,,B,1,BAO_0000019,15854,8,CHEMBL617580,,H
,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,10578,,Autocuration,,,1976,,,,,,B,1,BAO_0000249,10394,8,CHEMBL617581,,H
,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,10578,,Autocuration,,,1977,,,,,,B,1,BAO_0000357,12092,8,CHEMBL617582,,H
,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,10578,,Expert,,,1978,,,,,,B,1,BAO_0000019,3389,8,CHEMBL617583,,H
,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,105,,Autocuration,,,1979,,,,,,B,1,BAO_0000357,6011,8,CHEMBL617584,,H
,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1980,,,,,,B,1,BAO_0000357,4639,8,CHEMBL617585,,H
,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,105,,Autocuration,,,1981,,,,,,B,1,BAO_0000357,2474,8,CHEMBL875912,,H
,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1982,,,,,,B,1,BAO_0000357,5014,8,CHEMBL617586,,H
,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,105,,Autocuration,,,1983,,,,,,B,1,BAO_0000357,17515,8,CHEMBL617587,,H
,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,105,,Autocuration,,,1984,,,,,,B,1,BAO_0000357,11866,8,CHEMBL617588,,H
,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1985,,,,,,B,1,BAO_0000357,4687,8,CHEMBL857980,,H
,,Tested against 5-hydroxytryptamine 1D receptor,,105,,Autocuration,,,1986,,,,,,B,1,BAO_0000357,12146,8,CHEMBL617589,,H
,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,105,,Autocuration,,,1987,,,,,,B,1,BAO_0000357,10321,8,CHEMBL617590,,H
,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,722.0,105,,Autocuration,,,1988,,HEK293,,,,B,1,BAO_0000219,13267,8,CHEMBL617591,,H
,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,105,Homo sapiens,Expert,,9606.0,1989,,,,,,B,1,BAO_0000357,1274,9,CHEMBL617592,,D
,,,,105,,Autocuration,,,1990,,,,,,B,1,BAO_0000357,15250,8,CHEMBL617593,,H
,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,485.0,106,,Autocuration,,,1991,,CHO-K1,,,,B,1,BAO_0000219,13706,8,CHEMBL617594,,H
,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,485.0,105,,Autocuration,,,1992,,CHO-K1,,,,B,1,BAO_0000219,13706,8,CHEMBL617595,,H
,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,722.0,105,,Autocuration,,,1993,,HEK293,,,,B,1,BAO_0000219,13706,8,CHEMBL617596,,H
,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,722.0,105,,Autocuration,,,1994,,HEK293,,,,B,1,BAO_0000219,13706,8,CHEMBL617597,,H
,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,105,,Autocuration,,,1995,,,,,,B,1,BAO_0000019,13047,8,CHEMBL617598,,H
,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,105,,Autocuration,,,1996,,,,,,B,1,BAO_0000357,13366,8,CHEMBL872916,,H
,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,105,,Expert,,,1997,,,,,,B,1,BAO_0000357,13366,8,CHEMBL617599,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,105,,Autocuration,,,1998,,,,,,B,1,BAO_0000357,1558,8,CHEMBL617091,,H
,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",485.0,105,,Expert,,,1999,,CHO-K1,,,,B,1,BAO_0000219,12902,8,CHEMBL617092,,H
,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,485.0,105,,Autocuration,,,2000,,CHO-K1,,,,B,1,BAO_0000219,13706,8,CHEMBL617093,,H
,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,105,,Autocuration,,,2001,,,,,,F,1,BAO_0000019,13706,8,CHEMBL617094,,H
,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,105,,Autocuration,,,2002,,,,,,F,1,BAO_0000019,13706,8,CHEMBL617095,,H
,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,105,,Autocuration,,,2003,,,,,,F,1,BAO_0000019,14251,8,CHEMBL617096,,H
,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,105,,Autocuration,,,2004,,,,,,F,1,BAO_0000019,14251,8,CHEMBL617097,,H
,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,105,,Autocuration,,,2005,,,,,,F,1,BAO_0000019,14251,8,CHEMBL617098,,H
,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,105,,Autocuration,,,2006,,,,,,B,1,BAO_0000357,13313,8,CHEMBL617301,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,105,,Autocuration,,,2007,,,,,,B,1,BAO_0000357,13313,8,CHEMBL617302,,H
,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,105,,Autocuration,,,2008,,,,,,B,1,BAO_0000357,13366,8,CHEMBL617303,,H
,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,105,,Expert,,,2009,,,,,,B,1,BAO_0000357,13051,8,CHEMBL617304,,H
,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",449.0,105,,Expert,,,2010,,CHO,,,,B,1,BAO_0000219,12903,8,CHEMBL617305,,H
,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,105,Homo sapiens,Autocuration,,9606.0,2011,,,,,,B,1,BAO_0000219,12469,9,CHEMBL617306,,D
,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,17106,,Autocuration,,,2012,,,,,,B,1,BAO_0000357,5619,8,CHEMBL617307,,H
,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,105,Oryctolagus cuniculus,Autocuration,,9986.0,2013,,,,,,B,1,BAO_0000019,13047,8,CHEMBL617308,,H
,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,105,,Autocuration,,,2014,,,,,,B,1,BAO_0000357,16633,8,CHEMBL617309,,H
,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,105,,Autocuration,,,2015,,,,,,B,1,BAO_0000357,16633,8,CHEMBL617310,,H
,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,105,,Autocuration,,,2016,,,,,,B,1,BAO_0000357,16633,8,CHEMBL617311,,H
,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,105,,Autocuration,,,2017,,,,,,B,1,BAO_0000357,16633,8,CHEMBL617312,,H
,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,105,,Autocuration,,,2018,,,,,,B,1,BAO_0000357,3269,8,CHEMBL617313,,H
,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,105,,Expert,,,2019,,,,,,B,1,BAO_0000357,12409,8,CHEMBL617314,,H
,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,106,,Autocuration,,,2020,,,,,,F,1,BAO_0000019,13706,8,CHEMBL617315,,H
,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,722.0,106,,Autocuration,,,2021,,HEK293,,,,B,1,BAO_0000219,13706,8,CHEMBL617316,,H
,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,722.0,106,,Autocuration,,,2022,,HEK293,,,,B,1,BAO_0000219,13706,8,CHEMBL617317,,H
,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",449.0,106,,Autocuration,,,2023,,CHO,,,,B,1,BAO_0000219,12903,8,CHEMBL617318,,H
,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,106,,Autocuration,,,2024,,,,,,B,1,BAO_0000019,13047,8,CHEMBL617319,,H
,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,106,,Expert,,,2025,,,,,,B,1,BAO_0000357,13366,9,CHEMBL617320,,D
,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,106,,Expert,,,2026,,,,,,B,1,BAO_0000357,13366,9,CHEMBL617321,,D
,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,106,,Expert,,,2027,,,,,,B,1,BAO_0000357,13366,9,CHEMBL617322,,D
,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,106,,Autocuration,,,2028,,,,,,B,1,BAO_0000357,13366,8,CHEMBL616862,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,106,,Autocuration,,,2029,,,,,,B,1,BAO_0000357,13366,8,CHEMBL616863,,H
,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,449.0,106,,Autocuration,,,2030,,CHO,,,,B,1,BAO_0000219,12469,8,CHEMBL616864,,H
,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,485.0,106,,Autocuration,,,2031,,CHO-K1,,,,B,1,BAO_0000219,13706,8,CHEMBL616865,,H
,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,485.0,106,,Autocuration,,,2032,,CHO-K1,,,,B,1,BAO_0000219,13706,8,CHEMBL616866,,H
,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,106,,Autocuration,,,2033,,,,,,F,1,BAO_0000019,13706,8,CHEMBL616867,,H
,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",485.0,106,,Expert,,,2034,,CHO-K1,,,,B,1,BAO_0000219,12902,8,CHEMBL616868,,H
,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,105,,Expert,,,2035,,,,,,B,1,BAO_0000357,13051,8,CHEMBL616869,,H
,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",449.0,106,,Expert,,,2036,,CHO,,,,B,1,BAO_0000219,12903,8,CHEMBL616870,,H
,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,485.0,105,,Autocuration,,,2037,,CHO-K1,,,,F,1,BAO_0000219,1558,8,CHEMBL616871,,H
,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,485.0,105,,Autocuration,,,2038,,CHO-K1,,,,F,1,BAO_0000219,1558,8,CHEMBL616872,,H
,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,485.0,105,,Autocuration,,,2039,,CHO-K1,,,,F,1,BAO_0000219,1558,8,CHEMBL616873,,H
,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,485.0,105,,Autocuration,,,2040,,CHO-K1,,,,F,1,BAO_0000219,1558,8,CHEMBL616838,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,105,,Autocuration,,,2041,,,,,,B,1,BAO_0000357,1558,8,CHEMBL616839,,H
,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,106,Oryctolagus cuniculus,Autocuration,,9986.0,2042,,,,,,B,1,BAO_0000019,13047,8,CHEMBL616840,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,105,,Autocuration,,,2043,,,,,,B,1,BAO_0000357,13313,8,CHEMBL616841,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,105,,Autocuration,,,2044,,,,,,B,1,BAO_0000357,13313,8,CHEMBL616842,,H
,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,105,,Expert,,,2045,,,,,,B,1,BAO_0000357,12409,8,CHEMBL857976,,H
,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,449.0,10618,,Autocuration,,,2046,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL616843,,H
,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,10618,Homo sapiens,Expert,,9606.0,2047,,,,,,B,1,BAO_0000357,1348,9,CHEMBL616844,,D
,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,10618,,Autocuration,,,2048,,,,,,B,1,BAO_0000357,1348,8,CHEMBL616845,,H
,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,10618,Homo sapiens,Expert,,9606.0,2049,,,,,,B,1,BAO_0000357,4234,9,CHEMBL616846,,D
,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,10618,,Autocuration,,,2050,,,,,,B,1,BAO_0000357,16209,8,CHEMBL616847,,H
,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,10618,,Autocuration,,,2051,,,,,,B,1,BAO_0000019,10444,8,CHEMBL616848,,H
,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,10618,,Autocuration,,,2052,,,,,,B,1,BAO_0000357,3935,8,CHEMBL616849,,H
,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,10618,,Autocuration,,,2053,,,,,,B,1,BAO_0000357,15818,8,CHEMBL872911,,H
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,10618,,Autocuration,,,2054,,,,,,B,1,BAO_0000019,17085,8,CHEMBL616850,,H
,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,449.0,10618,Homo sapiens,Expert,,9606.0,2055,,CHO,,,,B,1,BAO_0000219,12936,9,CHEMBL616699,,D
,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,10618,,Autocuration,,,2056,,,,,,B,1,BAO_0000357,6166,8,CHEMBL616700,,H
,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,10618,,Autocuration,,,2057,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL616701,,H
,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,449.0,10618,,Autocuration,,,2058,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL616702,,H
,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,449.0,10618,,Autocuration,,,2059,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL616703,,H
,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,10618,,Autocuration,,,2060,,,,,,B,1,BAO_0000357,13181,8,CHEMBL616704,,H
,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,449.0,10618,,Autocuration,,,2061,,CHO,,,,B,1,BAO_0000219,4199,8,CHEMBL616705,,H
,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,10618,,Autocuration,,,2062,,,,,,B,1,BAO_0000357,14875,8,CHEMBL616706,,H
,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,449.0,10618,,Autocuration,,,2063,,CHO,,,,B,1,BAO_0000219,15146,8,CHEMBL616707,,H
,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,10618,,Autocuration,,,2064,,,,,,B,1,BAO_0000357,5213,8,CHEMBL616708,,H
,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,10618,,Autocuration,,,2065,,,,,,B,1,BAO_0000357,12146,8,CHEMBL616709,,H
,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,449.0,10618,,Autocuration,,,2066,,CHO,,,,B,1,BAO_0000219,13267,8,CHEMBL616710,,H
,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,449.0,10618,,Autocuration,,,2067,,CHO,,,,B,1,BAO_0000219,14818,8,CHEMBL616711,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",449.0,10618,,Autocuration,,,2068,,CHO,,,,B,1,BAO_0000219,4829,8,CHEMBL616712,,H
,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,10618,,Autocuration,,,2069,,,,,,B,1,BAO_0000357,4373,8,CHEMBL616713,,H
,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,10618,,Autocuration,,,2070,,,,,,B,1,BAO_0000357,4373,8,CHEMBL616714,,H
,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,10618,,Autocuration,,,2071,,,,,,B,1,BAO_0000357,14159,8,CHEMBL616715,,H
,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,10618,,Autocuration,,,2072,,,,,,B,1,BAO_0000357,16633,8,CHEMBL616716,,H
,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,279,,Autocuration,,,2073,,,,,,F,1,BAO_0000019,17085,8,CHEMBL616717,,H
,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,279,,Expert,,,2074,,,,,,F,1,BAO_0000019,17085,8,CHEMBL616718,,H
,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,279,,Autocuration,,,2075,,,,,,F,1,BAO_0000019,16209,8,CHEMBL875905,,H
,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,279,,Autocuration,,,2076,,,,,,F,1,BAO_0000019,16209,8,CHEMBL616719,,H
,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,279,,Expert,,,2077,,,,,,F,1,BAO_0000019,17085,8,CHEMBL616720,,H
,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,279,,Autocuration,,,2078,,,,,,B,1,BAO_0000357,14159,8,CHEMBL616721,,H
,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,449.0,279,,Autocuration,,,2079,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL616722,,H
,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,279,,Autocuration,,,2080,,,,,,B,1,BAO_0000357,3805,8,CHEMBL616723,,H
,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,449.0,279,,Autocuration,,,2081,,CHO,,,,B,1,BAO_0000219,16190,8,CHEMBL616724,,H
,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,279,,Autocuration,,,2082,,,,,,B,1,BAO_0000357,16190,8,CHEMBL616725,,H
,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,279,,Autocuration,,,2083,,,,,,B,1,BAO_0000357,16209,8,CHEMBL616726,,H
,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,279,,Autocuration,,,2084,,,,,,B,1,BAO_0000357,16209,8,CHEMBL616727,,H
,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,279,,Autocuration,,,2085,,,,,,B,1,BAO_0000357,16209,8,CHEMBL616728,,H
,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,279,,Autocuration,,,2086,,,,,,B,1,BAO_0000357,6866,8,CHEMBL616729,,H
,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,279,,Expert,,,2087,,,,,,B,1,BAO_0000019,17085,8,CHEMBL616730,,H
,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,279,,Autocuration,,,2088,,,,,,B,1,BAO_0000357,16312,8,CHEMBL617125,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,279,,Autocuration,,,2089,,,,,,B,1,BAO_0000357,6166,8,CHEMBL857977,,H
,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,279,,Autocuration,,,2090,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL617126,,H
,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,449.0,279,,Autocuration,,,2091,,CHO,,,,B,1,BAO_0000219,4199,8,CHEMBL617127,,H
,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,279,,Autocuration,,,2092,,,,,,B,1,BAO_0000357,14875,8,CHEMBL617128,,H
,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,449.0,279,,Autocuration,,,2093,,CHO,,,,B,1,BAO_0000219,15146,8,CHEMBL617129,,H
,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,279,,Autocuration,,,2094,,,,,,B,1,BAO_0000357,5213,8,CHEMBL617130,,H
,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,449.0,279,,Autocuration,,,2095,,CHO,,,,B,1,BAO_0000219,14818,8,CHEMBL617131,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",449.0,279,,Autocuration,,,2096,,CHO,,,,B,1,BAO_0000219,4829,8,CHEMBL617132,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",449.0,279,,Autocuration,,,2097,,CHO,,,,B,1,BAO_0000219,4829,8,CHEMBL617133,,H
,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,279,,Autocuration,,,2098,,,,,,B,1,BAO_0000357,4373,8,CHEMBL617134,,H
,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,279,,Autocuration,,,2099,,,,,,B,1,BAO_0000357,4373,8,CHEMBL617135,,H
,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,279,,Autocuration,,,2100,,,,,,B,1,BAO_0000357,5014,8,CHEMBL617136,,H
,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,104686,,Autocuration,,,2101,,,,,,B,1,BAO_0000019,11662,4,CHEMBL617137,,H
,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,104686,,Autocuration,,,2102,,,,,,B,1,BAO_0000019,11662,4,CHEMBL617138,,H
,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,104686,,Autocuration,,,2103,,,,,,B,1,BAO_0000019,11662,4,CHEMBL617139,,H
,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2104,,,,,,B,1,BAO_0000019,14093,8,CHEMBL617140,,H
,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,104686,,Autocuration,,,2105,In vivo,,,,,F,1,BAO_0000218,11200,4,CHEMBL617141,,H
,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686,,Autocuration,,,2106,,,,,,F,1,BAO_0000019,11200,4,CHEMBL858112,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,17005,,Intermediate,,,2107,,,,,,B,1,BAO_0000019,12352,8,CHEMBL617142,,H
,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,22226,Bos taurus,Autocuration,,9913.0,2108,,,,,,B,1,BAO_0000019,13657,0,CHEMBL617143,,U
,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,22226,Bos taurus,Autocuration,,9913.0,2109,,,,,,B,1,BAO_0000019,14331,0,CHEMBL617144,,U
,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,22226,Bos taurus,Autocuration,,9913.0,2110,,,,,,B,1,BAO_0000019,14331,0,CHEMBL617145,,U
,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,22226,,Autocuration,,,2111,,,,,,B,1,BAO_0000019,14331,0,CHEMBL617146,,U
,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,104784,Cavia porcellus,Autocuration,,10141.0,2112,,,,,,B,1,BAO_0000019,12685,4,CHEMBL617147,,H
,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,104784,Cavia porcellus,Autocuration,,10141.0,2113,,,,,,B,1,BAO_0000019,14389,4,CHEMBL617148,,H
,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,104784,Cavia porcellus,Autocuration,,10141.0,2114,,,,,,B,1,BAO_0000019,14386,4,CHEMBL617149,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,104784,,Autocuration,,,2115,,,,,,B,1,BAO_0000224,5732,4,CHEMBL617150,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,104784,,Autocuration,,,2116,,,,,,B,1,BAO_0000224,16293,4,CHEMBL617151,,H
,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,104784,,Autocuration,,,2117,,,,,,B,1,BAO_0000224,2078,4,CHEMBL617201,,H
,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,10209,,Autocuration,,,2118,,,,,,B,1,BAO_0000357,5486,8,CHEMBL617202,,H
,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,104826,,Autocuration,,,2119,In vivo,,,,,B,1,BAO_0000218,11820,4,CHEMBL617203,,H
,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,104826,,Autocuration,,,2120,,,,,,B,1,BAO_0000019,10297,4,CHEMBL617204,,H
,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,104826,,Autocuration,,,2121,,,,,,B,1,BAO_0000224,13704,4,CHEMBL617205,,H
,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,104826,Mus musculus,Autocuration,,10090.0,2122,,,,,,B,1,BAO_0000019,10297,5,CHEMBL617206,,D
,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,104826,,Autocuration,,,2123,In vivo,,,,,B,1,BAO_0000218,11820,4,CHEMBL617207,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,104826,Mus musculus,Autocuration,,10090.0,2124,,,,,,B,1,BAO_0000019,10297,5,CHEMBL617208,,D
,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,104826,,Autocuration,,,2125,,,,,,B,1,BAO_0000224,11555,4,CHEMBL617209,,H
,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,104826,,Autocuration,,,2126,,,,,,B,1,BAO_0000224,11555,4,CHEMBL617210,,H
,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,104826,,Autocuration,,,2127,,,,,,B,1,BAO_0000224,11555,4,CHEMBL617211,,H
,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,104826,Mus musculus,Autocuration,,10090.0,2128,,,,,,B,1,BAO_0000019,10297,5,CHEMBL617212,,D
,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,104784,Sus scrofa,Autocuration,,9823.0,2129,,,,,,B,1,BAO_0000224,16688,4,CHEMBL617213,,H
,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,104784,Sus scrofa,Autocuration,,9823.0,2130,,,,,,B,1,BAO_0000224,16688,4,CHEMBL617214,,H
,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,22226,,Autocuration,,,2131,,,,,,B,1,BAO_0000221,5333,0,CHEMBL617215,,U
,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,22226,,Autocuration,,,2132,,,,,,B,1,BAO_0000221,4437,0,CHEMBL617216,,U
,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,17005,Sus scrofa,Autocuration,,9823.0,2133,,,,,,B,1,BAO_0000357,5033,8,CHEMBL617217,,H
,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2134,,,,,,B,1,BAO_0000019,15267,4,CHEMBL617218,,H
,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2135,,,,,,B,1,BAO_0000019,15267,4,CHEMBL872913,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,104826,,Autocuration,,,2136,,,,,,B,1,BAO_0000019,11820,4,CHEMBL617219,,H
,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2137,,,,,,B,1,BAO_0000224,9069,4,CHEMBL873482,,H
,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,104686,Rattus norvegicus,Autocuration,,10116.0,2138,,,,,,B,1,BAO_0000019,9162,5,CHEMBL617220,,D
,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,104686,,Autocuration,,,2139,,,,,,B,1,BAO_0000019,9162,4,CHEMBL617221,,H
,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,104686,,Autocuration,,,2140,,,,,,B,1,BAO_0000019,9162,4,CHEMBL617222,,H
,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,104686,,Autocuration,,,2141,,,,,,F,1,BAO_0000019,10428,4,CHEMBL875906,,H
,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,104686,,Autocuration,,,2142,,,,,,B,1,BAO_0000019,9628,4,CHEMBL617223,,H
,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2143,,,,,,B,1,BAO_0000224,12704,4,CHEMBL617224,,H
,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,104686,Rattus norvegicus,Autocuration,,10116.0,2144,,,,,,B,1,BAO_0000224,15453,5,CHEMBL617225,,D
,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,104686,,Autocuration,,,2145,,,,,,B,1,BAO_0000224,188,4,CHEMBL617226,,H
,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,104686,,Autocuration,,,2146,,,,,,B,1,BAO_0000224,10349,4,CHEMBL617227,,H
,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,104686,,Autocuration,,,2147,,,,,,B,1,BAO_0000224,10349,4,CHEMBL617228,,H
,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,104686,,Autocuration,,,2148,,,,,,B,1,BAO_0000224,8868,4,CHEMBL617229,,H
,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,104686,,Autocuration,,,2149,,,,,,B,1,BAO_0000224,10025,4,CHEMBL617230,,H
,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,104686,,Autocuration,,,2150,,,,,,B,1,BAO_0000224,10025,4,CHEMBL617231,,H
,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,104686,,Autocuration,,,2151,,,,,,B,1,BAO_0000224,11702,4,CHEMBL617232,,H
,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2152,,,,,,B,1,BAO_0000224,11702,4,CHEMBL617233,,H
,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,104686,,Autocuration,,,2153,,,,,,B,1,BAO_0000224,11702,4,CHEMBL617234,,H
,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,104686,,Autocuration,,,2154,,,,,,F,1,BAO_0000019,11702,4,CHEMBL617235,,H
,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,104686,,Autocuration,,,2155,,,,,,F,1,BAO_0000019,11702,4,CHEMBL617236,,H
,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,104686,,Autocuration,10000000.0,,2156,,,,,Hippocampus,B,1,BAO_0000221,10085,4,CHEMBL617237,,H
,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,104686,,Autocuration,10000000.0,,2157,,,,,Hippocampus,B,1,BAO_0000221,10085,4,CHEMBL617238,,H
,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,104686,Rattus norvegicus,Autocuration,955.0,10116.0,2158,,,,,Brain,B,1,BAO_0000221,9630,5,CHEMBL617239,,D
,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,104686,,Autocuration,,,2159,,,,,,B,1,BAO_0000019,11070,4,CHEMBL617240,,H
,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,104686,,Autocuration,,,2160,,,,,,B,1,BAO_0000249,9841,4,CHEMBL617241,Membranes,H
,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,104686,,Autocuration,,,2161,,,,,,B,1,BAO_0000249,9841,4,CHEMBL875907,Membranes,H
,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,104686,,Autocuration,,,2162,,,,,,B,1,BAO_0000019,13291,4,CHEMBL617242,,H
,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,104686,,Autocuration,,,2163,,,,,,F,1,BAO_0000019,10590,4,CHEMBL617152,,H
,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,104686,Rattus norvegicus,Autocuration,955.0,10116.0,2164,,,,,Brain,B,1,BAO_0000221,9064,5,CHEMBL617153,,D
,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,104686,Rattus norvegicus,Autocuration,,10116.0,2165,,,,,,B,1,BAO_0000249,12268,5,CHEMBL617154,Membranes,D
,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,104686,,Autocuration,955.0,,2166,,,,,Brain,B,1,BAO_0000221,13508,4,CHEMBL617155,,H
,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,104686,,Autocuration,,,2167,,,,,,F,1,BAO_0000019,11279,4,CHEMBL617156,,H
,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,104686,,Autocuration,,,2168,,,,,,F,1,BAO_0000019,11200,4,CHEMBL617157,,H
,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686,,Autocuration,,,2169,,,,,,F,1,BAO_0000019,11200,4,CHEMBL617158,,H
,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,104686,,Autocuration,,,2170,,,,,,F,1,BAO_0000019,11200,4,CHEMBL617159,,H
,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,104686,,Autocuration,,,2171,,,,,,F,1,BAO_0000019,11200,4,CHEMBL617160,,H
,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686,,Autocuration,,,2172,,,,,,F,1,BAO_0000019,11200,4,CHEMBL858113,,H
,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,104686,,Autocuration,955.0,,2173,,,,,Brain,B,1,BAO_0000220,9231,4,CHEMBL617247,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,104686,,Autocuration,,,2174,,,,,,B,1,BAO_0000019,9737,4,CHEMBL617248,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,104686,,Autocuration,955.0,,2175,,,,,Brain,B,1,BAO_0000249,9737,4,CHEMBL617249,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,104686,,Autocuration,,,2176,,,,,,B,1,BAO_0000019,9737,4,CHEMBL617250,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,104686,,Autocuration,,,2177,,,,,,B,1,BAO_0000019,9737,4,CHEMBL617251,,H
,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,104686,Rattus norvegicus,Autocuration,,10116.0,2178,,,,,,B,1,BAO_0000019,11828,5,CHEMBL617252,,D
,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,104686,,Autocuration,,,2179,,,,,,B,1,BAO_0000019,12253,4,CHEMBL617006,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,104686,,Autocuration,,,2180,,,,,,B,1,BAO_0000019,12253,4,CHEMBL617007,,H
,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,104686,,Autocuration,,,2181,,,,,,F,1,BAO_0000019,11279,4,CHEMBL617008,,H
,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,104686,,Autocuration,,,2182,,,,,,B,1,BAO_0000019,11866,4,CHEMBL617009,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,104686,Rattus norvegicus,Autocuration,,10116.0,2183,,,,,,B,1,BAO_0000224,14424,5,CHEMBL617010,,D
,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,104686,Rattus norvegicus,Autocuration,,10116.0,2184,,,,,,B,1,BAO_0000019,15180,5,CHEMBL857978,,D
,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,104686,Rattus norvegicus,Autocuration,,10116.0,2185,,,,,,B,1,BAO_0000019,15180,5,CHEMBL617011,,D
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,104686,Rattus norvegicus,Autocuration,,10116.0,2186,,,,,,B,1,BAO_0000019,9786,5,CHEMBL617012,,D
,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,104686,,Autocuration,,,2187,,,,,,B,1,BAO_0000224,12132,4,CHEMBL617013,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,104686,,Autocuration,,,2188,,,,,,B,1,BAO_0000249,5486,4,CHEMBL617014,,H
,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2189,,,,,,B,1,BAO_0000019,15316,4,CHEMBL617015,,H
,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,104686,,Autocuration,,,2190,,,,,,B,1,BAO_0000019,16429,4,CHEMBL617016,,H
,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,104686,,Autocuration,,,2191,,,,,,B,1,BAO_0000224,14617,4,CHEMBL617017,,H
,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,104686,,Autocuration,955.0,,2192,,,,,Brain,B,1,BAO_0000221,11351,4,CHEMBL617018,,H
,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,104686,,Autocuration,,,2193,,,,,,F,1,BAO_0000019,11279,4,CHEMBL617019,,H
,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,Autocuration,,,2194,,,,,,B,1,BAO_0000019,9523,4,CHEMBL617020,,H
,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,Autocuration,,,2195,,,,,,B,1,BAO_0000019,9523,4,CHEMBL617021,,H
,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,Autocuration,,,2196,,,,,,B,1,BAO_0000019,9523,4,CHEMBL617022,,H
,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,Autocuration,,,2197,,,,,,B,1,BAO_0000019,9523,4,CHEMBL617023,,H
,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,Autocuration,,,2198,,,,,,B,1,BAO_0000019,9523,4,CHEMBL617024,,H
,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,Autocuration,,,2199,,,,,,B,1,BAO_0000019,9523,4,CHEMBL617025,,H
,,Hill coefficient of compound was determined,,105075,,Autocuration,,,2200,,,,,,B,1,BAO_0000224,9523,4,CHEMBL617026,,H
,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,22226,,Autocuration,,,2201,,,,,,B,1,BAO_0000019,4771,0,CHEMBL617027,,U
,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,104686,Rattus norvegicus,Autocuration,,10116.0,2202,,,,,,B,1,BAO_0000019,5033,5,CHEMBL617028,,D
,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,12687,,Expert,,,2203,,,,,,B,1,BAO_0000019,10845,8,CHEMBL617029,,H
,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,12687,,Expert,,,2204,,,,,,B,1,BAO_0000019,10845,8,CHEMBL875908,,H
,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,12687,,Autocuration,,,2205,,,,,,B,1,BAO_0000357,16288,8,CHEMBL617030,,H
,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,12687,,Autocuration,,,2206,,,,,,B,1,BAO_0000019,16288,8,CHEMBL617031,,H
,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,12687,,Autocuration,,,2207,,,,,,B,1,BAO_0000019,16190,8,CHEMBL617032,,H
,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,104686,Rattus norvegicus,Autocuration,,10116.0,2208,,,,,,B,1,BAO_0000224,12463,5,CHEMBL617033,,D
,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,104686,,Autocuration,,,2209,,,,,,B,1,BAO_0000224,9699,4,CHEMBL617034,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,104686,,Autocuration,,,2210,,,,,,B,1,BAO_0000224,9699,4,CHEMBL617035,,H
,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,104686,,Autocuration,,,2211,,,,,,B,1,BAO_0000019,11662,4,CHEMBL617036,,H
,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,104784,,Autocuration,,,2212,,,,,,B,1,BAO_0000224,1205,4,CHEMBL617037,,H
,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,22226,,Autocuration,,,2213,,,,,,B,1,BAO_0000219,11376,0,CHEMBL617038,,U
,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,104784,,Autocuration,,,2214,,,,,,B,1,BAO_0000219,11376,4,CHEMBL617039,,H
,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,104784,,Autocuration,,,2215,,,,,,B,1,BAO_0000224,4639,4,CHEMBL617161,,H
,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,104784,,Autocuration,,,2216,,,,,,B,1,BAO_0000224,2222,4,CHEMBL617162,,H
,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,104784,,Autocuration,,,2217,,,,,,B,1,BAO_0000224,1558,4,CHEMBL617163,,H
,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,104784,,Autocuration,,,2218,,,,,,B,1,BAO_0000224,1089,4,CHEMBL617164,,H
,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,104784,,Autocuration,,,2219,,,,,,B,1,BAO_0000249,386,4,CHEMBL617165,Brain membranes,H
,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,104784,,Autocuration,,,2220,,,,,,B,1,BAO_0000224,2474,4,CHEMBL617166,,H
,,Binding affinity towards 5-HT2 receptor,,104784,,Autocuration,,,2221,,,,,,B,1,BAO_0000224,17066,4,CHEMBL617167,,H
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,104784,,Autocuration,,,2222,,,,,,B,1,BAO_0000224,959,4,CHEMBL872912,,H
,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,104784,,Autocuration,,,2223,,,,,,B,1,BAO_0000224,6398,4,CHEMBL617168,,H
,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,104686,,Autocuration,,,2224,,,,,,B,1,BAO_0000224,11889,4,CHEMBL617169,,H
,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,104784,,Autocuration,,,2225,,,,,,B,1,BAO_0000224,4221,4,CHEMBL617170,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,104784,,Autocuration,,,2226,,,,,,B,1,BAO_0000224,11026,4,CHEMBL617171,,H
,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,104784,,Autocuration,,,2227,,,,,,B,1,BAO_0000224,11866,4,CHEMBL617172,,H
,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,104784,,Autocuration,,,2228,,,,,,B,1,BAO_0000224,4221,4,CHEMBL617173,,H
,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,22226,,Autocuration,,,2229,,,,,,B,1,BAO_0000019,13950,0,CHEMBL617174,,U
,,5-hydroxytryptamine 2 receptor binding affinity,,104784,,Autocuration,,,2230,,,,,,B,1,BAO_0000224,1263,4,CHEMBL617175,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,17005,,Autocuration,,,2231,,,,,,B,1,BAO_0000357,13291,8,CHEMBL617176,,H
,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,17005,,Autocuration,,,2232,,,,,,B,1,BAO_0000357,10812,8,CHEMBL617177,,H
,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,104784,,Autocuration,,,2233,,,,,,B,1,BAO_0000224,13020,4,CHEMBL617178,,H
,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,104784,,Autocuration,,,2234,,,,,,B,1,BAO_0000224,13021,4,CHEMBL617179,,H
,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,104784,,Autocuration,,,2235,,,,,,B,1,BAO_0000224,13020,4,CHEMBL617180,,H
,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,17005,,Autocuration,,,2236,,,,,,B,1,BAO_0000357,14532,8,CHEMBL617181,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor,,17005,,Autocuration,,,2237,,,,,,B,1,BAO_0000357,13944,8,CHEMBL617182,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor,,17005,,Autocuration,,,2238,,,,,,B,1,BAO_0000357,14331,8,CHEMBL617183,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,17005,,Autocuration,,,2239,,,,,,B,1,BAO_0000357,14118,8,CHEMBL617184,,H
,,Binding affinity against serotonergic 5-HT2 receptor,,17005,,Autocuration,,,2240,,,,,,B,1,BAO_0000357,13033,8,CHEMBL617185,,H
,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,17005,,Autocuration,,,2241,,,,,,B,1,BAO_0000357,10321,8,CHEMBL617186,,H
,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,17005,,Autocuration,,,2242,,,,,,B,1,BAO_0000357,12918,8,CHEMBL617187,,H
,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,17005,,Autocuration,,,2243,,,,,,B,1,BAO_0000357,15120,8,CHEMBL617188,,H
,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,17005,,Autocuration,,,2244,,,,,,B,1,BAO_0000218,2613,8,CHEMBL617189,,H
,,Inhibitory activity against cloned human 5-HT2 receptor,,104784,Homo sapiens,Autocuration,,9606.0,2245,,,,,,B,1,BAO_0000224,13378,5,CHEMBL617190,,D
,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",449.0,104784,Homo sapiens,Autocuration,,9606.0,2246,,CHO,,,,B,1,BAO_0000219,2331,5,CHEMBL617191,,D
,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",449.0,104784,Homo sapiens,Autocuration,,9606.0,2247,,CHO,,,,B,1,BAO_0000219,2331,5,CHEMBL617192,,D
,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",449.0,104784,Homo sapiens,Autocuration,,9606.0,2248,,CHO,,,,B,1,BAO_0000219,2331,5,CHEMBL617193,,D
,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",449.0,104784,Homo sapiens,Autocuration,,9606.0,2249,,CHO,,,,B,1,BAO_0000219,2331,5,CHEMBL617194,,D
,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,104784,,Autocuration,,,2250,,,,,,B,1,BAO_0000224,4170,4,CHEMBL617195,,H
,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,104784,,Autocuration,,,2251,,,,,,B,1,BAO_0000224,15453,4,CHEMBL881830,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,17005,,Autocuration,,,2252,,,,,,B,1,BAO_0000357,1479,8,CHEMBL617196,,H
,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,104686,,Autocuration,,,2253,,,,,,B,1,BAO_0000224,11139,4,CHEMBL617197,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,17005,,Expert,,,2254,,,,,,B,1,BAO_0000357,13969,8,CHEMBL617198,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,17005,,Expert,,,2255,,,,,,B,1,BAO_0000357,13392,8,CHEMBL873476,,H
,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,17005,,Expert,,,2256,,,,,,B,1,BAO_0000019,14430,8,CHEMBL617199,,H
,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,107,Cavia porcellus,Autocuration,,10141.0,2257,,,,,,B,1,BAO_0000357,13181,8,CHEMBL617200,,H
,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,51,,Autocuration,,,2258,,,,,,B,1,BAO_0000357,17200,8,CHEMBL617484,,H
,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,107,,Autocuration,,,2259,,,,,,B,1,BAO_0000357,17200,8,CHEMBL617485,,H
,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,51,,Autocuration,,,2260,,,,,,B,1,BAO_0000357,17200,8,CHEMBL617486,,H
,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,107,,Autocuration,,,2261,,,,,,B,1,BAO_0000357,13463,8,CHEMBL858022,,H
,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,449.0,107,,Autocuration,,,2262,,CHO,,,,B,1,BAO_0000219,6347,8,CHEMBL617049,,H
,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,449.0,107,Homo sapiens,Expert,,9606.0,2263,,CHO,,,,F,1,BAO_0000219,6857,9,CHEMBL617050,,D
,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,107,,Autocuration,,,2264,,,,,,F,1,BAO_0000219,4176,8,CHEMBL617051,,H
,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,107,,Autocuration,,,2265,,,,,,F,1,BAO_0000219,4176,8,CHEMBL617052,,H
,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,107,,Autocuration,,,2266,,,,,,F,1,BAO_0000219,4176,8,CHEMBL617053,,H
,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",449.0,107,,Autocuration,,,2267,,CHO,,,,B,1,BAO_0000219,6347,8,CHEMBL617054,,H
,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",449.0,107,,Autocuration,,,2268,,CHO,,,,B,1,BAO_0000219,6347,8,CHEMBL617055,,H
,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,107,,Autocuration,,,2269,,,,,,B,1,BAO_0000357,15331,8,CHEMBL882924,,H
,,Inhibition of human 5-hydroxytryptamine 2A receptor,,107,Homo sapiens,Expert,,9606.0,2270,,,,,,B,1,BAO_0000357,16146,9,CHEMBL617056,,D
,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,107,,Autocuration,,,2271,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL617057,,H
,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,107,,Expert,,,2272,,,,,,B,1,BAO_0000219,13631,8,CHEMBL617058,,H
,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,107,,Autocuration,,,2273,,,,,,B,1,BAO_0000357,3805,8,CHEMBL617059,,H
,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,449.0,107,,Autocuration,,,2274,,CHO,,,,B,1,BAO_0000219,4011,8,CHEMBL617060,,H
,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,449.0,107,,Expert,,,2275,,CHO,,,,B,1,BAO_0000219,4012,8,CHEMBL617061,,H
,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,307.0,107,,Expert,,,2276,,L929,,,,B,1,BAO_0000219,6366,8,CHEMBL617062,,H
,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,107,,Expert,,,2277,,CHO,,,,B,1,BAO_0000219,15949,8,CHEMBL617063,,H
,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,107,,Autocuration,,,2278,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617064,,H
,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,107,,Autocuration,,,2279,,,,,,F,1,BAO_0000019,13481,8,CHEMBL617065,,H
,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,449.0,107,,Autocuration,,,2280,,CHO,,,,B,1,BAO_0000219,6347,8,CHEMBL617066,,H
,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,449.0,107,,Autocuration,,,2281,,CHO,,,,B,1,BAO_0000219,6347,8,CHEMBL617067,,H
,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,107,,Autocuration,,,2282,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617068,,H
,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,107,,Autocuration,,,2283,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617069,,H
,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,107,,Autocuration,,,2284,,,,,,F,1,BAO_0000019,13481,8,CHEMBL617070,,H
,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,107,,Autocuration,,,2285,,,,,,B,1,BAO_0000357,14442,8,CHEMBL617071,,H
,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,107,,Autocuration,,,2286,,,,,,B,1,BAO_0000357,14442,8,CHEMBL872915,,H
,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,107,,Autocuration,,,2287,,,,,,B,1,BAO_0000357,14755,8,CHEMBL617072,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,107,,Autocuration,,,2288,,,,,,B,1,BAO_0000357,16441,8,CHEMBL617073,,H
,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,107,,Autocuration,,,2289,,,,,,B,1,BAO_0000357,14744,8,CHEMBL617074,,H
,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,107,,Expert,,,2290,,CHO,,,,B,1,BAO_0000219,16659,8,CHEMBL617075,,H
,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2291,,,,,,B,1,BAO_0000357,3307,8,CHEMBL617076,,H
,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,107,Homo sapiens,Expert,,9606.0,2292,,,,,,B,1,BAO_0000019,6857,9,CHEMBL617077,,D
,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,107,,Expert,,,2293,,,,,,B,1,BAO_0000357,5635,8,CHEMBL617078,,H
,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,107,Homo sapiens,Expert,,9606.0,2294,,,,,,B,1,BAO_0000357,4234,9,CHEMBL617079,,D
,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,107,,Autocuration,,,2295,,,,,,B,1,BAO_0000357,15527,8,CHEMBL617080,,H
,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,449.0,107,,Expert,,,2296,,CHO,,,,B,1,BAO_0000219,6588,8,CHEMBL617081,,H
,,Binding affinity towards human 5-HT2A receptor in BEK cells,,107,,Expert,,,2297,,,,,,B,1,BAO_0000219,13631,8,CHEMBL617082,,H
,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2298,,,,,,B,1,BAO_0000357,17723,8,CHEMBL617083,,H
,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,107,,Autocuration,,,2299,,,,,,B,1,BAO_0000357,14770,8,CHEMBL617084,,H
,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,107,Homo sapiens,Expert,,9606.0,2300,,,,,,B,1,BAO_0000357,16293,9,CHEMBL617085,,D
,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,107,,Autocuration,,,2301,,,,,,B,1,BAO_0000357,16209,8,CHEMBL617086,,H
,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,107,,Autocuration,,,2302,,,,,,B,1,BAO_0000219,12469,8,CHEMBL617087,,H
,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2303,,,,,,B,1,BAO_0000357,15363,8,CHEMBL617088,,H
,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2304,,,,,,B,1,BAO_0000357,15363,8,CHEMBL617089,,H
,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,107,,Expert,,,2305,,,,,,B,1,BAO_0000019,16441,8,CHEMBL617090,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,107,,Autocuration,,,2306,,,,,,B,1,BAO_0000357,8,8,CHEMBL617513,,H
,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,722.0,107,,Autocuration,,,2307,,HEK293,,,,B,1,BAO_0000219,4176,8,CHEMBL617514,,H
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2308,,,,,,B,1,BAO_0000019,17085,8,CHEMBL617515,,H
,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,107,,Autocuration,,,2309,,,,,,B,1,BAO_0000357,17200,8,CHEMBL617516,,H
,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,107,Homo sapiens,Expert,,9606.0,2310,,,,,,B,1,BAO_0000357,17200,9,CHEMBL617517,,D
,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,449.0,107,Homo sapiens,Expert,,9606.0,2311,,CHO,,,,B,1,BAO_0000219,4013,9,CHEMBL617518,,D
,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2312,,,,,,B,1,BAO_0000357,5088,8,CHEMBL617519,,H
,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,107,Homo sapiens,Expert,,9606.0,2313,,,,,,B,1,BAO_0000357,5088,9,CHEMBL617520,,D
,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,107,,Autocuration,,,2314,,,,,,B,1,BAO_0000357,5088,8,CHEMBL617521,,H
,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,107,Homo sapiens,Expert,,9606.0,2315,,,,,,B,1,BAO_0000357,5088,9,CHEMBL617522,,D
,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,107,,Autocuration,,,2316,,,,,,B,1,BAO_0000357,5088,8,CHEMBL617523,,H
,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,107,,Autocuration,,,2317,,,,,,B,1,BAO_0000357,5088,8,CHEMBL617524,,H
,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,104686,,Autocuration,,,2318,,,,,,B,1,BAO_0000019,9786,4,CHEMBL617525,,H
,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,104686,Rattus norvegicus,Autocuration,,10116.0,2319,,,,,,B,1,BAO_0000019,9205,5,CHEMBL617526,,D
,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,104686,,Autocuration,,,2320,,,,,,B,1,BAO_0000224,11257,4,CHEMBL617527,,H
,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,104686,,Autocuration,,,2321,,,,,,B,1,BAO_0000019,9362,4,CHEMBL617528,,H
,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,104686,,Autocuration,,,2322,,,,,,B,1,BAO_0000019,9362,4,CHEMBL617529,,H
,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,104686,,Autocuration,,,2323,,,,,,B,1,BAO_0000224,10590,4,CHEMBL617530,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,104686,,Autocuration,,,2324,,,,,,B,1,BAO_0000019,10468,4,CHEMBL617531,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,104686,,Autocuration,,,2325,,,,,,B,1,BAO_0000019,13050,4,CHEMBL617532,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,104686,,Autocuration,,,2326,,,,,,B,1,BAO_0000019,11624,4,CHEMBL617533,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,104686,,Autocuration,,,2327,,,,,,B,1,BAO_0000019,10468,4,CHEMBL617534,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,104686,,Autocuration,,,2328,,,,,,B,1,BAO_0000224,10330,4,CHEMBL617535,,H
,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,104686,,Autocuration,,,2329,,,,,,B,1,BAO_0000224,10062,4,CHEMBL617536,,H
,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2330,,,,,,B,1,BAO_0000224,11642,4,CHEMBL617537,,H
,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2331,,,,,,B,1,BAO_0000224,10062,4,CHEMBL617538,,H
,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,104686,,Autocuration,,,2332,In vitro,,,,,B,1,BAO_0000219,13427,4,CHEMBL617539,,H
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,104686,Rattus norvegicus,Autocuration,,10116.0,2333,,,,,,B,1,BAO_0000224,12280,5,CHEMBL617540,,D
,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,104686,Rattus norvegicus,Autocuration,,10116.0,2334,,,,,,B,1,BAO_0000224,4101,5,CHEMBL617541,,D
,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2335,,,,,,B,1,BAO_0000224,10062,4,CHEMBL617542,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,104686,,Autocuration,,,2336,,,,,,B,1,BAO_0000224,11147,4,CHEMBL617543,,H
,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,485.0,104686,Rattus norvegicus,Autocuration,,10116.0,2337,,CHO-K1,,,,B,1,BAO_0000219,2395,5,CHEMBL617544,,D
,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,485.0,104686,Rattus norvegicus,Autocuration,,10116.0,2338,,CHO-K1,,,,B,1,BAO_0000219,2395,5,CHEMBL617545,,D
,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,104686,Rattus norvegicus,Autocuration,,10116.0,2339,,,,,,B,1,BAO_0000019,9098,5,CHEMBL617413,,D
,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,104686,,Autocuration,,,2340,,,,,,B,1,BAO_0000019,9098,4,CHEMBL617414,,H
,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,104686,Rattus norvegicus,Autocuration,,10116.0,2341,,,,,,B,1,BAO_0000019,9098,5,CHEMBL617415,,D
,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2342,,,,,,B,1,BAO_0000224,9443,4,CHEMBL617416,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,104686,,Autocuration,,,2343,,,,,,B,1,BAO_0000224,9443,4,CHEMBL617417,,H
,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,104686,,Autocuration,,,2344,,,,,,B,1,BAO_0000019,9699,4,CHEMBL617418,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,104686,,Autocuration,,,2345,,,,,,B,1,BAO_0000019,9699,4,CHEMBL617419,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,104686,,Autocuration,,,2346,,,,,,B,1,BAO_0000224,9098,4,CHEMBL617420,,H
,,Affinity for 5-hydroxytryptamine 2 receptor,,104686,Rattus norvegicus,Autocuration,,10116.0,2347,,,,,,B,1,BAO_0000224,3070,5,CHEMBL617421,,D
,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,104686,,Autocuration,,,2348,,,,,,B,1,BAO_0000224,9547,4,CHEMBL617422,,H
,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,104686,,Autocuration,,,2349,,,,,,B,1,BAO_0000019,10444,4,CHEMBL617423,,H
,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,104686,,Autocuration,,,2350,,,,,,B,1,BAO_0000019,14617,4,CHEMBL617424,,H
,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,104686,,Autocuration,,,2351,,,,,,B,1,BAO_0000019,14617,4,CHEMBL617425,,H
,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,104686,,Autocuration,,,2352,,,,,,B,1,BAO_0000224,11130,4,CHEMBL617426,,H
,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,104686,,Autocuration,,,2353,In vivo,,,,,B,1,BAO_0000218,11130,4,CHEMBL617427,,H
,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,104686,,Autocuration,955.0,,2354,,,,,Brain,B,1,BAO_0000221,14542,4,CHEMBL617428,,H
,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,104686,,Autocuration,,,2355,,,,,,B,1,BAO_0000224,2797,4,CHEMBL617429,,H
,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,104686,,Autocuration,,,2356,,,,,,B,1,BAO_0000019,11332,4,CHEMBL617430,,H
,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,104686,,Autocuration,,,2357,,,,,,B,1,BAO_0000019,11332,4,CHEMBL617431,,H
,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,104686,,Autocuration,1870.0,,2358,,,,,Frontal cortex,B,1,BAO_0000019,10752,4,CHEMBL617432,,H
,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2359,,,,,,B,1,BAO_0000224,1185,4,CHEMBL617433,,H
,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2360,,,,,,B,1,BAO_0000224,1185,4,CHEMBL617434,,H
,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,104686,Rattus norvegicus,Autocuration,,10116.0,2361,,,,,,B,1,BAO_0000224,11624,5,CHEMBL617435,,D
,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,104686,,Autocuration,,,2362,,,,,,B,1,BAO_0000019,1344,4,CHEMBL617436,,H
,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,104686,Rattus norvegicus,Autocuration,2435.0,10116.0,2363,,,,,Striatum,B,1,BAO_0000019,15453,5,CHEMBL617437,,D
,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,104686,,Autocuration,,,2364,,,,,,B,1,BAO_0000019,11662,4,CHEMBL617438,,H
,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,104686,,Autocuration,,,2365,,,,,,B,1,BAO_0000019,11662,4,CHEMBL617439,,H
,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2366,,,,,,B,1,BAO_0000224,10796,4,CHEMBL617440,,H
,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2367,,,,,,B,1,BAO_0000224,9069,4,CHEMBL617441,,H
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,104686,Rattus norvegicus,Autocuration,,10116.0,2368,,,,,,B,1,BAO_0000019,8814,5,CHEMBL872918,,D
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,104686,Rattus norvegicus,Autocuration,,10116.0,2369,,,,,,B,1,BAO_0000019,8908,5,CHEMBL617442,,D
,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,104686,,Autocuration,,,2370,,,,,,B,1,BAO_0000019,9098,4,CHEMBL617443,,H
,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,104686,,Autocuration,,,2371,,,,,,B,1,BAO_0000019,9098,4,CHEMBL617444,,H
,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,104686,,Autocuration,,,2372,,,,,,B,1,BAO_0000019,9098,4,CHEMBL617445,,H
,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,104686,,Autocuration,,,2373,,,,,,B,1,BAO_0000019,9098,4,CHEMBL617446,,H
,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,104686,,Autocuration,,,2374,,,,,,B,1,BAO_0000249,9098,4,CHEMBL617447,,H
,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,104686,,Autocuration,,,2375,,,,,,B,1,BAO_0000019,9098,4,CHEMBL617448,,H
,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,104686,,Autocuration,,,2376,,,,,,B,1,BAO_0000019,9098,4,CHEMBL617449,,H
,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,104686,,Autocuration,,,2377,,,,,,B,1,BAO_0000019,9161,4,CHEMBL617450,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,104686,,Autocuration,,,2378,,,,,,B,1,BAO_0000019,9161,4,CHEMBL617451,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,104686,,Autocuration,,,2379,,,,,,B,1,BAO_0000019,9161,4,CHEMBL617452,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,104686,,Autocuration,,,2380,,,,,,B,1,BAO_0000019,9161,4,CHEMBL617453,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,104686,,Autocuration,,,2381,,,,,,B,1,BAO_0000019,9161,4,CHEMBL617660,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,104686,,Autocuration,,,2382,,,,,,B,1,BAO_0000019,9161,4,CHEMBL617661,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,104686,,Autocuration,,,2383,,,,,,B,1,BAO_0000019,9161,4,CHEMBL617662,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,104686,,Autocuration,,,2384,,,,,,B,1,BAO_0000019,9161,4,CHEMBL872919,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,104686,,Autocuration,,,2385,,,,,,B,1,BAO_0000019,9161,4,CHEMBL617663,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,104686,,Autocuration,,,2386,,,,,,B,1,BAO_0000019,9161,4,CHEMBL617664,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,104686,,Autocuration,,,2387,,,,,,B,1,BAO_0000019,9161,4,CHEMBL617665,,H
,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,104686,,Autocuration,,,2388,,,,,,B,1,BAO_0000019,9161,4,CHEMBL617666,,H
,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,104686,,Autocuration,,,2389,,,,,,B,1,BAO_0000019,12094,4,CHEMBL617667,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,104686,,Autocuration,,,2390,,,,,,B,1,BAO_0000249,12018,4,CHEMBL617668,,H
,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,104686,,Autocuration,,,2391,,,,,,B,1,BAO_0000249,10394,4,CHEMBL617669,,H
,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2392,,,,,,B,1,BAO_0000224,15260,4,CHEMBL617670,,H
,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,104686,Rattus norvegicus,Autocuration,,10116.0,2393,,,,,,B,1,BAO_0000224,11624,5,CHEMBL617671,,D
,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2394,,,,,,B,1,BAO_0000224,13654,4,CHEMBL617672,,H
,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,104686,,Autocuration,,,2395,,,,,,B,1,BAO_0000019,9541,4,CHEMBL617673,,H
,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,104686,,Autocuration,,,2396,,,,,,B,1,BAO_0000224,11933,4,CHEMBL617674,,H
,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,104686,,Autocuration,,,2397,,,,,,B,1,BAO_0000019,15538,4,CHEMBL617675,,H
,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,104686,,Autocuration,,,2398,,,,,,B,1,BAO_0000019,15538,4,CHEMBL617676,,H
,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,104686,,Autocuration,,,2399,,,,,,B,1,BAO_0000019,15538,4,CHEMBL617677,,H
,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2400,,,,,,B,1,BAO_0000019,8841,5,CHEMBL617678,,D
,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,104686,,Autocuration,,,2401,,,,,,B,1,BAO_0000224,1455,4,CHEMBL617679,,H
,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,104686,,Autocuration,,,2402,,,,,,B,1,BAO_0000224,1455,4,CHEMBL617680,,H
,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,104686,,Autocuration,,,2403,,,,,,B,1,BAO_0000019,11752,4,CHEMBL617681,,H
,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,104686,,Autocuration,955.0,,2404,,,,,Brain,B,1,BAO_0000221,11642,4,CHEMBL617682,,H
,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,104686,,Autocuration,,,2405,,,,,,B,1,BAO_0000224,12092,4,CHEMBL617683,,H
,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,104686,,Autocuration,,,2406,,,,,,B,1,BAO_0000224,3967,4,CHEMBL617684,,H
,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,104686,Rattus norvegicus,Autocuration,,10116.0,2407,,,,,,B,1,BAO_0000224,12771,5,CHEMBL617685,,D
,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,104686,,Autocuration,,,2408,,,,,,B,1,BAO_0000019,11642,4,CHEMBL617686,,H
,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,104686,,Autocuration,,,2409,,,,,,B,1,BAO_0000224,11628,4,CHEMBL617687,,H
,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,104686,,Autocuration,,,2410,,,,,,B,1,BAO_0000224,13654,4,CHEMBL617688,,H
,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686,,Autocuration,,,2411,,,,,,F,1,BAO_0000019,11200,4,CHEMBL617689,,H
,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686,,Autocuration,,,2412,,,,,,F,1,BAO_0000019,11200,4,CHEMBL617690,,H
,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,104686,,Autocuration,,,2413,In vivo,,,,,F,1,BAO_0000218,11200,4,CHEMBL617691,,H
,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,104686,,Autocuration,,,2414,In vivo,,,,,F,1,BAO_0000218,11200,4,CHEMBL617692,,H
,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,104686,,Autocuration,,,2415,In vivo,,,,,F,1,BAO_0000218,11200,4,CHEMBL617693,,H
,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,104686,,Autocuration,,,2416,In vivo,,,,,F,1,BAO_0000218,11200,4,CHEMBL617694,,H
,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,12687,,Expert,955.0,,2417,,,,,Brain,B,1,BAO_0000221,15436,8,CHEMBL857985,,H
,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,12687,Rattus norvegicus,Expert,,10116.0,2418,,,,,,B,1,BAO_0000019,15436,9,CHEMBL617695,,D
,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,12687,,Autocuration,,,2419,,,,,,B,1,BAO_0000019,14025,8,CHEMBL617696,,H
,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,12687,,Autocuration,,,2420,,,,,,B,1,BAO_0000357,4342,8,CHEMBL617697,,H
,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,12687,Rattus norvegicus,Expert,,10116.0,2421,,,,,,B,1,BAO_0000019,13735,9,CHEMBL617257,,D
,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,12687,Rattus norvegicus,Expert,,10116.0,2422,,,,,,B,1,BAO_0000357,5816,9,CHEMBL617258,,D
,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,12687,,Expert,,,2423,,,,,,B,1,BAO_0000019,14287,8,CHEMBL617259,,H
,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,12687,,Autocuration,,,2424,,,,,,B,1,BAO_0000357,15738,8,CHEMBL617260,,H
,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,12687,Rattus norvegicus,Expert,,10116.0,2425,,,,,,B,1,BAO_0000357,15738,9,CHEMBL617261,,D
,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,12687,,Autocuration,,,2426,,,,,,B,1,BAO_0000019,15026,8,CHEMBL617262,,H
,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,12687,,Expert,,,2427,,,,,,B,1,BAO_0000019,16647,8,CHEMBL617263,,H
,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,12687,,Autocuration,,,2428,,,,,,B,1,BAO_0000019,16647,8,CHEMBL617264,,H
,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,12687,Rattus norvegicus,Expert,,10116.0,2429,,,,,,B,1,BAO_0000019,13345,9,CHEMBL617265,,D
,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2430,,,,,,B,1,BAO_0000249,1543,8,CHEMBL617266,Membranes,H
,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,12687,,Autocuration,,,2431,,,,,,B,1,BAO_0000019,12444,8,CHEMBL617267,,H
,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,12687,,Expert,,,2432,,,,,,B,1,BAO_0000019,16404,8,CHEMBL617268,,H
,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,449.0,12687,,Autocuration,,,2433,,CHO,,,,B,1,BAO_0000219,16404,8,CHEMBL617269,,H
,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,12687,,Expert,,,2434,,,,,,B,1,BAO_0000357,15577,8,CHEMBL617323,,H
,,Serotonergic activity of the compound.,,12687,,Autocuration,,,2435,,,,,,B,1,BAO_0000357,15577,8,CHEMBL617324,,H
,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,12687,,Autocuration,,,2436,,,,,,B,1,BAO_0000249,2495,8,CHEMBL617325,,H
,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,12687,Rattus norvegicus,Expert,,10116.0,2437,,,,,,B,1,BAO_0000019,15042,9,CHEMBL617326,,D
,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,12687,,Expert,,,2438,,,,,,B,1,BAO_0000249,15026,8,CHEMBL617327,,H
,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12687,Rattus norvegicus,Expert,,10116.0,2439,,,,,,F,1,BAO_0000019,12919,9,CHEMBL617328,,D
,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12687,Rattus norvegicus,Expert,,10116.0,2440,,,,,,F,1,BAO_0000019,12919,9,CHEMBL617329,,D
,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12687,Rattus norvegicus,Expert,,10116.0,2441,,,,,,F,1,BAO_0000019,12919,9,CHEMBL617330,,D
,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687,,Autocuration,,,2442,,,,,,B,1,BAO_0000357,15194,8,CHEMBL617331,,H
,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,12687,,Autocuration,,,2443,,,,,,B,1,BAO_0000357,15194,8,CHEMBL617332,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,107,,Expert,,,2444,,,,,,B,1,BAO_0000357,4820,8,CHEMBL617333,,H
,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,107,,Autocuration,,,2445,,,,,,B,1,BAO_0000357,6736,8,CHEMBL617334,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,107,,Autocuration,,,2446,,,,,,B,1,BAO_0000357,5163,8,CHEMBL617335,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,107,,Autocuration,,,2447,,,,,,B,1,BAO_0000357,5163,8,CHEMBL617336,,H
,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,107,,Autocuration,,,2448,,,,,,B,1,BAO_0000357,6011,8,CHEMBL617337,,H
,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,107,Homo sapiens,Expert,,9606.0,2449,,,,,,B,1,BAO_0000357,14294,9,CHEMBL617338,,D
,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2450,,,,,,B,1,BAO_0000357,5014,8,CHEMBL617339,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,107,,Expert,,,2451,,,,,,B,1,BAO_0000357,17066,8,CHEMBL617340,,H
,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,107,,Autocuration,,,2452,,,,,,B,1,BAO_0000357,17515,8,CHEMBL617341,,H
,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,107,,Expert,,,2453,,,,,,B,1,BAO_0000357,6736,8,CHEMBL617342,,H
,,Affinity for 5-hydroxytryptamine 2A receptor,,107,,Expert,,,2454,,,,,,B,1,BAO_0000357,5163,8,CHEMBL617343,,H
,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,723.0,107,,Expert,,,2455,,NIH3T3,,,,B,1,BAO_0000219,16911,8,CHEMBL617344,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,107,,Expert,,,2456,,,,,,B,1,BAO_0000357,6841,8,CHEMBL617345,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,107,,Expert,,,2457,,,,,,B,1,BAO_0000357,6119,8,CHEMBL617346,,H
,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2458,,,,,,B,1,BAO_0000357,3962,8,CHEMBL617347,,H
,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,107,,Autocuration,,,2459,,,,,,B,1,BAO_0000357,4373,8,CHEMBL617348,,H
,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,107,,Autocuration,,,2460,,,,,,B,1,BAO_0000357,4373,8,CHEMBL617349,,H
,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2461,,,,,,F,1,BAO_0000019,3962,8,CHEMBL617350,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,107,,Expert,,,2462,,,,,,B,1,BAO_0000357,1633,8,CHEMBL872339,,H
,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,107,,Autocuration,,,2463,,,,,,B,1,BAO_0000357,4373,8,CHEMBL617351,,H
,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,107,,Expert,,,2464,,,,,,B,1,BAO_0000357,6576,8,CHEMBL617352,,H
,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2465,,,,,,B,1,BAO_0000357,4687,8,CHEMBL617353,,H
,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2466,,,,,,B,1,BAO_0000357,16946,8,CHEMBL617354,,H
,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2467,,,,,,B,1,BAO_0000357,14159,8,CHEMBL617355,,H
,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,449.0,107,Mus musculus,Expert,,10090.0,2468,,CHO,,,,B,1,BAO_0000219,3032,8,CHEMBL617356,,H
,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2469,,,,,,B,1,BAO_0000357,16655,8,CHEMBL617357,,H
,,Binding affinity at 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2470,,,,,,B,1,BAO_0000357,13964,8,CHEMBL617358,,H
,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,107,,Expert,,,2471,,,,,,B,1,BAO_0000357,16989,8,CHEMBL617359,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,107,,Autocuration,,,2472,,,,,,B,1,BAO_0000357,16117,8,CHEMBL617360,,H
,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,107,,Autocuration,,,2473,,,,,,B,1,BAO_0000357,16700,8,CHEMBL875913,,H
,,Affinity against 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2474,,,,,,B,1,BAO_0000357,3269,8,CHEMBL617361,,H
,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,107,Homo sapiens,Expert,,9606.0,2475,,,,,,B,1,BAO_0000357,1274,9,CHEMBL617362,,D
,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,107,,Autocuration,,,2476,,,,,,B,1,BAO_0000357,1317,8,CHEMBL617363,,H
,,Tested against 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2477,,,,,,B,1,BAO_0000357,12146,8,CHEMBL617364,,H
,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,105075,,Autocuration,,,2478,,,,,,B,1,BAO_0000224,12652,4,CHEMBL617365,,H
,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,105075,,Autocuration,,,2479,,,,,,B,1,BAO_0000224,12652,4,CHEMBL617366,,H
,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,105075,,Autocuration,,,2480,,,,,,B,1,BAO_0000224,12652,4,CHEMBL617367,,H
,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,105075,,Autocuration,,,2481,,,,,,B,1,BAO_0000224,12652,4,CHEMBL617368,,H
,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,107,,Autocuration,,,2482,,,,,,B,1,BAO_0000357,16647,8,CHEMBL617369,,H
,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,722.0,227,Homo sapiens,Expert,,9606.0,2483,,HEK293,,,,B,1,BAO_0000219,15851,9,CHEMBL617370,,D
,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,449.0,227,Homo sapiens,Expert,,9606.0,2484,,CHO,,,,F,1,BAO_0000219,6857,9,CHEMBL617371,,D
,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,227,,Autocuration,,,2485,,,,,,B,1,BAO_0000357,3805,8,CHEMBL617372,,H
,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,227,Homo sapiens,Expert,,9606.0,2486,,,,,,B,1,BAO_0000357,6491,9,CHEMBL617373,,D
,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,227,,Autocuration,,,2487,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617374,,H
,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,227,,Autocuration,,,2488,,,,,,F,1,BAO_0000019,13481,8,CHEMBL617375,,H
,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,227,,Autocuration,,,2489,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617376,,H
,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,227,,Autocuration,,,2490,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617377,,H
,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,227,,Autocuration,,,2491,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617378,,H
,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,227,,Autocuration,,,2492,,,,,,F,1,BAO_0000019,13481,8,CHEMBL617379,,H
,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,227,,Autocuration,,,2493,,,,,,B,1,BAO_0000357,14442,8,CHEMBL617380,,H
,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,227,,Autocuration,,,2494,,,,,,B,1,BAO_0000357,14442,8,CHEMBL617381,,H
,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,227,,Autocuration,,,2495,,,,,,B,1,BAO_0000357,14442,8,CHEMBL617382,,H
,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2496,,,,,,B,1,BAO_0000357,12369,8,CHEMBL617383,,H
,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,107,,Expert,,,2497,,,,,,B,1,BAO_0000357,12369,8,CHEMBL617384,,H
,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,107,,Expert,,,2498,,,,,,B,1,BAO_0000357,12369,8,CHEMBL617385,,H
,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,107,,Autocuration,,,2499,,,,,,B,1,BAO_0000019,14447,8,CHEMBL617386,,H
,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,107,,Autocuration,,,2500,,,,,,B,1,BAO_0000019,14447,8,CHEMBL617387,,H
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,107,,Autocuration,,,2501,,NIH3T3,,,,B,1,BAO_0000219,17451,8,CHEMBL617388,,H
,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,107,,Autocuration,,,2502,,CHO,,,,F,1,BAO_0000219,6857,8,CHEMBL617389,,H
,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,107,Homo sapiens,Expert,,9606.0,2503,,CHO,,,,F,1,BAO_0000219,6857,9,CHEMBL617390,,D
,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,104817,,Autocuration,,,2504,,,,,,B,1,BAO_0000224,5635,4,CHEMBL617391,,H
,,Binding activity radioligand.,,107,,Autocuration,,,2505,,,,,,B,1,BAO_0000357,12861,8,CHEMBL617392,,H
,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,107,,Autocuration,,,2506,,,,,,B,1,BAO_0000019,12861,8,CHEMBL617393,,H
,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,307.0,107,,Autocuration,,,2507,,L929,,,,B,1,BAO_0000219,5105,8,CHEMBL617394,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,307.0,107,,Expert,,,2508,,L929,,,,B,1,BAO_0000219,5104,8,CHEMBL617395,,H
,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,307.0,107,,Expert,,,2509,,L929,,,,B,1,BAO_0000219,5105,8,CHEMBL617396,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,307.0,107,,Autocuration,,,2510,,L929,,,,B,1,BAO_0000219,5105,8,CHEMBL617397,,H
,,Binding affinity against 5-HT2A receptor,,107,,Autocuration,,,2511,,,,,,B,1,BAO_0000357,5254,8,CHEMBL617398,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor,,107,,Autocuration,,,2512,,,,,,B,1,BAO_0000357,5254,8,CHEMBL617399,,H
,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,722.0,107,,Autocuration,,,2513,,HEK293,,,,B,1,BAO_0000219,13267,8,CHEMBL617400,,H
,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,722.0,107,,Autocuration,,,2514,,HEK293,,,,B,1,BAO_0000219,13267,8,CHEMBL617401,,H
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,722.0,107,Homo sapiens,Expert,,9606.0,2515,,HEK293,,,,B,1,BAO_0000219,14157,9,CHEMBL617402,,D
,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,107,Homo sapiens,Expert,,9606.0,2516,,HEK293,,,,B,1,BAO_0000219,12936,9,CHEMBL617403,,D
,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,107,,Expert,,,2517,,,,,,B,1,BAO_0000357,14068,8,CHEMBL617404,,H
,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,107,Homo sapiens,Expert,,9606.0,2518,,HEK293,,,,B,1,BAO_0000219,12936,9,CHEMBL857981,,D
,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,107,Homo sapiens,Expert,,9606.0,2519,,HEK293,,,,B,1,BAO_0000219,12936,9,CHEMBL617405,,D
,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,722.0,107,Homo sapiens,Expert,,9606.0,2520,,HEK293,,,,B,1,BAO_0000219,4540,9,CHEMBL617253,,D
,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,107,,Expert,,,2521,,,,,,B,1,BAO_0000357,6166,8,CHEMBL617254,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,722.0,107,,Autocuration,,,2522,,HEK293,,,,B,1,BAO_0000219,17296,8,CHEMBL617255,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,722.0,107,,Autocuration,,,2523,,HEK293,,,,B,1,BAO_0000219,17296,8,CHEMBL617256,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,722.0,107,,Autocuration,,,2524,,HEK293,,,,B,1,BAO_0000219,17296,8,CHEMBL616874,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,722.0,107,Homo sapiens,Expert,,9606.0,2525,,HEK293,,,,B,1,BAO_0000219,15779,9,CHEMBL616875,,D
,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,722.0,107,,Expert,,,2526,,HEK293,,,,B,1,BAO_0000219,14391,8,CHEMBL616876,,H
,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",722.0,107,,Expert,,,2527,,HEK293,,,,B,1,BAO_0000219,15851,8,CHEMBL616877,,H
,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,722.0,107,Homo sapiens,Expert,,9606.0,2528,,HEK293,,,,B,1,BAO_0000219,15851,9,CHEMBL616878,,D
,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,722.0,107,,Expert,,,2529,,HEK293,,,,B,1,BAO_0000219,3832,8,CHEMBL616879,,H
,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,722.0,107,,Expert,,,2530,,HEK293,,,,B,1,BAO_0000219,3833,8,CHEMBL616880,,H
,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,107,Homo sapiens,Expert,,9606.0,2531,,HEK293,,,,B,1,BAO_0000219,12936,9,CHEMBL616881,,D
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,723.0,107,,Autocuration,,,2532,,NIH3T3,,,,B,1,BAO_0000219,17451,8,CHEMBL616882,,H
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,107,,Autocuration,,,2533,,NIH3T3,,,,B,1,BAO_0000219,17451,8,CHEMBL616883,,H
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,107,,Autocuration,,,2534,,NIH3T3,,,,B,1,BAO_0000219,17451,8,CHEMBL616884,,H
,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,722.0,107,,Autocuration,,,2535,,HEK293,,,,B,1,BAO_0000219,4199,8,CHEMBL616885,,H
,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,485.0,107,,Autocuration,,,2536,,CHO-K1,,,,B,1,BAO_0000219,1883,8,CHEMBL616886,,H
,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,485.0,107,,Expert,,,2537,,CHO-K1,,,,B,1,BAO_0000219,1883,8,CHEMBL616887,,H
,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,107,Homo sapiens,Expert,,9606.0,2538,,,,,,B,1,BAO_0000357,14875,9,CHEMBL616888,,D
,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,722.0,107,,Autocuration,,,2539,,HEK293,,,,B,1,BAO_0000219,15146,8,CHEMBL616889,,H
,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,722.0,107,,Autocuration,,,2540,,HEK293,,,,B,1,BAO_0000219,5213,8,CHEMBL616890,,H
,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,449.0,107,Homo sapiens,Expert,,9606.0,2541,,CHO,,,,B,1,BAO_0000219,16404,9,CHEMBL616891,,D
,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,722.0,107,,Autocuration,,,2542,,HEK293,,,,B,1,BAO_0000219,14818,8,CHEMBL616892,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",722.0,107,,Autocuration,,,2543,,HEK293,,,,B,1,BAO_0000219,4829,8,CHEMBL616893,,H
,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,723.0,10620,,Autocuration,,,2544,,NIH3T3,,,,F,1,BAO_0000219,12652,8,CHEMBL616894,,H
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,723.0,107,,Expert,,,2545,,NIH3T3,,,,B,1,BAO_0000219,4682,8,CHEMBL616895,,H
,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,10620,,Autocuration,,,2546,,,,,,F,1,BAO_0000019,12652,8,CHEMBL616896,,H
,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,10621,,Autocuration,,,2547,,,,,,B,1,BAO_0000357,4921,8,CHEMBL617099,,H
,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,10621,,Autocuration,,,2548,,,,,,B,1,BAO_0000357,4921,8,CHEMBL617100,,H
,,Binding affinity against rabbit aorta 5-HT2A receptor,,107,Oryctolagus cuniculus,Autocuration,,9986.0,2549,,,,,,B,1,BAO_0000357,16312,8,CHEMBL884532,,H
,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,107,Oryctolagus cuniculus,Expert,,9986.0,2550,,,,,,B,1,BAO_0000357,14998,8,CHEMBL617101,,H
,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,107,Oryctolagus cuniculus,Expert,,9986.0,2551,,,,,,B,1,BAO_0000357,14025,8,CHEMBL617102,,H
,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,107,Oryctolagus cuniculus,Autocuration,,9986.0,2552,,,,,,B,1,BAO_0000019,13047,8,CHEMBL617103,,H
,,The compound was tested for binding affinity against 5-HT2A receptor,,107,Oryctolagus cuniculus,Expert,,9986.0,2553,,,,,,B,1,BAO_0000357,13047,8,CHEMBL617104,,H
,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,485.0,10576,,Autocuration,,,2554,,CHO-K1,,,,B,1,BAO_0000219,1883,8,CHEMBL857979,,H
,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,12687,,Autocuration,,,2555,,,,,,B,1,BAO_0000019,13463,8,CHEMBL857502,,H
,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,12687,,Autocuration,,,2556,,,,,,B,1,BAO_0000019,13463,8,CHEMBL617105,,H
,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,12687,,Autocuration,945.0,,2557,,,,,Stomach,B,1,BAO_0000019,13463,8,CHEMBL858021,,H
,,Binding affinity for 5-HT 2A in rat stomach fundus,,12687,Rattus norvegicus,Expert,945.0,10116.0,2558,,,,,Stomach,B,1,BAO_0000019,13463,9,CHEMBL875910,,D
,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,12687,,Autocuration,,,2559,,,,,,B,1,BAO_0000019,13463,8,CHEMBL617106,,H
,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,723.0,12687,,Expert,,,2560,,NIH3T3,,,,B,1,BAO_0000219,16326,8,CHEMBL617107,,H
,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2561,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617108,,H
,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2562,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617109,,H
,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2563,,,,,,B,1,BAO_0000357,15740,8,CHEMBL617110,,H
,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,12687,,Autocuration,,,2564,,,,,,B,1,BAO_0000357,16633,8,CHEMBL617111,,H
,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,12687,Rattus norvegicus,Expert,,10116.0,2565,,,,,,F,1,BAO_0000019,17200,9,CHEMBL617112,,D
,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2566,,,,,,B,1,BAO_0000357,17133,8,CHEMBL617113,,H
,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2567,,,,,,B,1,BAO_0000357,17133,8,CHEMBL617114,,H
,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2568,,,,,,B,1,BAO_0000357,17133,8,CHEMBL617115,,H
,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,12687,,Autocuration,,,2569,,,,,,F,1,BAO_0000219,17200,8,CHEMBL617116,,H
,,Efficacy at 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2570,,,,,,F,1,BAO_0000019,15363,8,CHEMBL617117,,H
,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,12687,,Autocuration,,,2571,,,,,,B,1,BAO_0000357,17200,8,CHEMBL617118,,H
,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,12687,Rattus norvegicus,Expert,,10116.0,2572,,,,,,B,1,BAO_0000357,17200,9,CHEMBL617119,,D
,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,12687,Rattus norvegicus,Expert,,10116.0,2573,,,,,,B,1,BAO_0000357,17200,9,CHEMBL617120,,D
,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,12687,Rattus norvegicus,Expert,,10116.0,2574,,,,,,F,1,BAO_0000219,17200,9,CHEMBL617121,,D
,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,12687,,Autocuration,,,2575,,,,,,F,1,BAO_0000219,17200,8,CHEMBL617122,,H
,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2576,,,,,,B,1,BAO_0000019,17211,8,CHEMBL617123,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,12687,,Expert,,,2577,,,,,,B,1,BAO_0000019,17331,8,CHEMBL617124,,H
,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,12687,,Expert,,,2578,,,,,,B,1,BAO_0000249,13565,8,CHEMBL617600,,H
,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,12687,,Expert,,,2579,,,,,,B,1,BAO_0000357,13730,8,CHEMBL617601,,H
,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,12687,,Expert,,,2580,,,,,,B,1,BAO_0000019,12416,8,CHEMBL882923,,H
,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2581,,,,,,B,1,BAO_0000357,15295,8,CHEMBL617602,,H
,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,12687,,Autocuration,,,2582,,,,,,B,1,BAO_0000019,1742,8,CHEMBL617603,,H
,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2583,,,,,,B,1,BAO_0000357,15295,8,CHEMBL617604,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,12687,,Expert,,,2584,,,,,,B,1,BAO_0000019,14970,8,CHEMBL617605,,H
,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,12687,,Expert,,,2585,,,,,,B,1,BAO_0000019,16693,8,CHEMBL617606,,H
,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,12687,Rattus norvegicus,Expert,,10116.0,2586,,,,,,B,1,BAO_0000019,14776,9,CHEMBL617607,,D
,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,Autocuration,,,2587,,,,,,B,1,BAO_0000249,14286,8,CHEMBL617455,,H
,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,12687,Rattus norvegicus,Expert,,10116.0,2588,,,,,,B,1,BAO_0000019,17200,9,CHEMBL617456,,D
,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,12687,,Expert,,,2589,,,,,,B,1,BAO_0000357,15306,8,CHEMBL617457,,H
,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,12687,Rattus norvegicus,Expert,,10116.0,2590,,,,,,B,1,BAO_0000357,14178,9,CHEMBL617458,,D
,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,12687,Rattus norvegicus,Expert,,10116.0,2591,,,,,,B,1,BAO_0000019,14229,9,CHEMBL617459,,D
,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,12687,,Expert,,,2592,,,,,,B,1,BAO_0000357,12884,8,CHEMBL617460,,H
,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,12687,,Expert,,,2593,,,,,,B,1,BAO_0000357,13149,8,CHEMBL617461,,H
,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,12687,Rattus norvegicus,Expert,,10116.0,2594,,,,,,B,1,BAO_0000019,15295,9,CHEMBL617462,,D
,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,12687,,Autocuration,,,2595,,,,,,B,1,BAO_0000357,15740,8,CHEMBL617463,,H
,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,12687,,Autocuration,,,2596,,,,,,B,1,BAO_0000019,15185,8,CHEMBL617464,,H
,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,12687,,Autocuration,,,2597,,,,,,B,1,BAO_0000019,15185,8,CHEMBL617465,,H
,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,12687,,Expert,,,2598,,,,,,B,1,BAO_0000019,17529,8,CHEMBL617466,,H
,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,12687,,Autocuration,,,2599,,,,,,B,1,BAO_0000019,14826,8,CHEMBL617467,,H
,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,12687,,Expert,,,2600,,,,,,B,1,BAO_0000019,17211,8,CHEMBL617468,,H
,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,12687,,Autocuration,,,2601,,,,,,B,1,BAO_0000019,14826,8,CHEMBL617469,,H
,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2602,,,,,,B,1,BAO_0000019,14093,8,CHEMBL617470,,H
,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,12687,,Autocuration,,,2603,,,,,,B,1,BAO_0000019,14093,8,CHEMBL617471,,H
,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,723.0,12687,,Expert,,,2604,,NIH3T3,,,,B,1,BAO_0000219,13246,8,CHEMBL617472,,H
,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,12687,,Expert,,,2605,,,,,,B,1,BAO_0000357,13246,8,CHEMBL617473,,H
,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,12687,Rattus norvegicus,Expert,,10116.0,2606,,,,,,B,1,BAO_0000019,15436,9,CHEMBL617474,,D
,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,12687,Rattus norvegicus,Expert,,10116.0,2607,,,,,,B,1,BAO_0000019,15436,9,CHEMBL617475,,D
,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,12687,,Autocuration,955.0,,2608,,,,,Brain,B,1,BAO_0000221,14442,8,CHEMBL617476,,H
,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,12687,,Expert,,,2609,,,,,,B,1,BAO_0000357,12457,8,CHEMBL617477,,H
,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,723.0,12687,,Expert,,,2610,,NIH3T3,,,,B,1,BAO_0000219,12457,8,CHEMBL617478,,H
,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,12687,,Autocuration,,,2611,,,,,,F,1,BAO_0000221,14755,8,CHEMBL617479,,H
,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,12687,,Autocuration,,,2612,,,,,,B,1,BAO_0000357,4707,8,CHEMBL617480,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor,,12687,,Expert,,,2613,,,,,,B,1,BAO_0000357,13297,8,CHEMBL617481,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,12687,,Expert,,,2614,,,,,,B,1,BAO_0000019,17331,8,CHEMBL617482,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,12687,,Autocuration,,,2615,,,,,,B,1,BAO_0000019,4664,8,CHEMBL617483,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,12687,,Autocuration,,,2616,,,,,,B,1,BAO_0000357,16633,8,CHEMBL621528,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,723.0,12687,Rattus norvegicus,Expert,,10116.0,2617,,NIH3T3,,,,B,1,BAO_0000219,4664,9,CHEMBL621529,,D
,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,12687,,Expert,,,2618,,,,,,B,1,BAO_0000357,16133,8,CHEMBL621530,,H
,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687,,Expert,,,2619,,,,,,B,1,BAO_0000357,16133,8,CHEMBL621531,,H
,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,12687,Rattus norvegicus,Expert,,10116.0,2620,,,,,,B,1,BAO_0000019,14060,9,CHEMBL621532,,D
,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,12687,,Expert,,,2621,,,,,,B,1,BAO_0000357,16326,8,CHEMBL621533,,H
,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,12687,,Expert,,,2622,,CHO,,,,B,1,BAO_0000219,16659,8,CHEMBL621534,,H
,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,12687,,Autocuration,,,2623,,,,,,B,1,BAO_0000019,14776,8,CHEMBL621535,,H
,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,12687,,Autocuration,,,2624,,,,,,B,1,BAO_0000357,13481,8,CHEMBL621536,,H
,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2625,,,,,,B,1,BAO_0000357,17386,8,CHEMBL621537,,H
,,Binding affinity for 5-hydroxytryptamine 2A receptor,,12687,Rattus norvegicus,Expert,,10116.0,2626,,,,,,B,1,BAO_0000357,6611,9,CHEMBL621538,,D
,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,12687,,Autocuration,,,2627,,,,,,B,1,BAO_0000019,14423,8,CHEMBL621539,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,12687,,Autocuration,,,2628,,,,,,B,1,BAO_0000019,15412,8,CHEMBL621540,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,12687,,Autocuration,,,2629,,,,,,B,1,BAO_0000019,15412,8,CHEMBL621541,,H
,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,12687,,Autocuration,,,2630,,,,,,B,1,BAO_0000019,6238,8,CHEMBL621542,,H
,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,12687,,Expert,,,2631,,,,,,B,1,BAO_0000357,6648,8,CHEMBL621543,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,12687,,Expert,,,2632,,,,,,B,1,BAO_0000357,5667,8,CHEMBL621544,,H
,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,12687,Rattus norvegicus,Expert,,10116.0,2633,,,,,,B,1,BAO_0000357,6611,9,CHEMBL621545,,D
,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687,,Autocuration,,,2634,,,,,,B,1,BAO_0000357,13481,8,CHEMBL621546,,H
,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,12687,,Autocuration,,,2635,,,,,,B,1,BAO_0000357,13481,8,CHEMBL621547,,H
,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,723.0,12687,,Expert,,,2636,,NIH3T3,,,,B,1,BAO_0000219,15558,8,CHEMBL618692,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2637,,,,,,B,1,BAO_0000357,6013,8,CHEMBL618693,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,12687,,Autocuration,,,2638,,,,,,B,1,BAO_0000357,16633,8,CHEMBL872922,,H
,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,12687,,Autocuration,,,2639,,,,,,B,1,BAO_0000357,6013,8,CHEMBL618694,,H
,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,12687,Rattus norvegicus,Expert,,10116.0,2640,,,,,,B,1,BAO_0000357,6013,9,CHEMBL618695,,D
,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,12687,,Autocuration,,,2641,,,,,,B,1,BAO_0000357,6013,8,CHEMBL618696,,H
,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,12687,,Expert,,,2642,,,,,,B,1,BAO_0000357,6013,8,CHEMBL618697,,H
,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,12687,,Autocuration,,,2643,,,,,,B,1,BAO_0000357,6013,8,CHEMBL618892,,H
,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,12687,,Autocuration,,,2644,,,,,,B,1,BAO_0000357,6013,8,CHEMBL618893,,H
,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2645,,,,,,B,1,BAO_0000357,16293,8,CHEMBL618894,,H
,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,723.0,12687,,Expert,,,2646,,NIH3T3,,,,B,1,BAO_0000219,17175,8,CHEMBL618895,,H
,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,12687,Rattus norvegicus,Expert,,10116.0,2647,,,,,,B,1,BAO_0000357,13278,9,CHEMBL618896,,D
,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,12687,,Autocuration,5383.0,,2648,,,,,Caudate-putamen,B,1,BAO_0000019,3682,8,CHEMBL618897,,H
,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,12687,,Autocuration,,,2649,,,,,,B,1,BAO_0000357,2014,8,CHEMBL618898,,H
,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,12687,,Autocuration,,,2650,,,,,,B,1,BAO_0000357,2014,8,CHEMBL618899,,H
,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,12687,,Autocuration,,,2651,,,,,,B,1,BAO_0000357,4932,8,CHEMBL618900,,H
,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,12687,,Autocuration,,,2652,,,,,,B,1,BAO_0000019,4932,8,CHEMBL618901,,H
,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2653,,,,,,B,1,BAO_0000357,3935,8,CHEMBL618902,,H
,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,12687,Rattus norvegicus,Expert,10000000.0,10116.0,2654,,,,,Hippocampus,B,1,BAO_0000221,5432,9,CHEMBL618903,,D
,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2655,,,,,,B,1,BAO_0000357,15818,8,CHEMBL618904,,H
,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,12687,,Autocuration,,,2656,,,,,,B,1,BAO_0000357,13672,8,CHEMBL618905,,H
,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,12687,,Autocuration,,,2657,,,,,,B,1,BAO_0000357,13672,8,CHEMBL618906,,H
,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,723.0,12687,,Expert,,,2658,,NIH3T3,,,,B,1,BAO_0000219,14749,8,CHEMBL618907,,H
,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,12687,,Autocuration,,,2659,,,,,,B,1,BAO_0000019,13462,8,CHEMBL618908,,H
,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2660,,,,,,B,1,BAO_0000357,15740,8,CHEMBL617909,,H
,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,12687,,Expert,,,2661,,,,,,B,1,BAO_0000019,16647,8,CHEMBL617910,,H
,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,12687,,Autocuration,955.0,,2662,,,,,Brain,B,1,BAO_0000221,13345,8,CHEMBL617911,,H
,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,Autocuration,,,2663,,,,,,B,1,BAO_0000249,16740,8,CHEMBL872923,,H
,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,Autocuration,,,2664,,,,,,B,1,BAO_0000249,16740,8,CHEMBL617912,,H
,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,12687,Rattus norvegicus,Expert,,10116.0,2665,,,,,,B,1,BAO_0000019,15535,9,CHEMBL617913,,D
,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,Expert,,,2666,,,,,,B,1,BAO_0000249,16740,8,CHEMBL617914,,H
,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,Autocuration,,,2667,,,,,,B,1,BAO_0000249,16740,8,CHEMBL617915,,H
,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,Autocuration,,,2668,,,,,,B,1,BAO_0000249,16740,8,CHEMBL617916,,H
,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,12687,Rattus norvegicus,Expert,,10116.0,2669,,,,,,B,1,BAO_0000019,4795,9,CHEMBL617917,,D
,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,12687,,Expert,,,2670,,,,,,B,1,BAO_0000019,8,8,CHEMBL617918,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,12687,,Autocuration,,,2671,,,,,,B,1,BAO_0000019,8,8,CHEMBL617919,,H
,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,12687,Rattus norvegicus,Expert,,10116.0,2672,,,,,,B,1,BAO_0000019,17200,9,CHEMBL617920,,D
,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,12687,Rattus norvegicus,Expert,,10116.0,2673,,,,,,B,1,BAO_0000019,2148,9,CHEMBL617921,,D
,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,105102,Rattus norvegicus,Expert,,10116.0,2674,,,,,,B,1,BAO_0000224,13345,5,CHEMBL617922,,D
,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,12687,,Autocuration,,,2675,,,,,,B,1,BAO_0000357,5088,8,CHEMBL617923,,H
,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687,,Autocuration,,,2676,,,,,,B,1,BAO_0000357,5088,8,CHEMBL617924,,H
,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,12687,,Autocuration,,,2677,,,,,,B,1,BAO_0000357,17133,8,CHEMBL617925,,H
,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,12687,Rattus norvegicus,Expert,,10116.0,2678,,,,,,B,1,BAO_0000357,17133,9,CHEMBL617926,,D
,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,12687,,Autocuration,,,2679,,,,,,B,1,BAO_0000357,16532,8,CHEMBL617927,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,12687,,Autocuration,,,2680,,,,,,B,1,BAO_0000357,15086,8,CHEMBL617928,,H
,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12687,Rattus norvegicus,Expert,,10116.0,2681,,,,,,B,1,BAO_0000019,2309,9,CHEMBL617929,,D
,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,12687,,Expert,,,2682,,,,,,B,1,BAO_0000019,12953,8,CHEMBL617930,,H
,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,12687,,Autocuration,,,2683,,,,,,B,1,BAO_0000019,12953,8,CHEMBL617931,,H
,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,12687,,Autocuration,,,2684,,,,,,B,1,BAO_0000019,12953,8,CHEMBL617932,,H
,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,449.0,12687,,Autocuration,,,2685,,CHO,,,,B,1,BAO_0000219,16659,8,CHEMBL617933,,H
,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,12687,,Autocuration,,,2686,,,,,,B,1,BAO_0000019,16740,8,CHEMBL617934,,H
,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,12687,,Autocuration,,,2687,,,,,,B,1,BAO_0000019,16740,8,CHEMBL617935,,H
,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,12687,,Autocuration,,,2688,,,,,,B,1,BAO_0000357,17133,8,CHEMBL617936,,H
,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,12687,,Autocuration,,,2689,,,,,,B,1,BAO_0000019,17211,8,CHEMBL617937,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,12687,,Autocuration,,,2690,,,,,,B,1,BAO_0000019,17331,8,CHEMBL617938,,H
,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,12687,,Autocuration,,,2691,,,,,,B,1,BAO_0000218,16633,8,CHEMBL617939,,H
,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,12687,,Autocuration,,,2692,,,,,,B,1,BAO_0000218,16633,8,CHEMBL617940,,H
,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,12687,,Autocuration,,,2693,,,,,,B,1,BAO_0000218,16633,8,CHEMBL617941,,H
,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,12687,,Expert,,,2694,,,,,,B,1,BAO_0000357,15026,8,CHEMBL617942,,H
,,Ratio of pKi of 5-HT2A to that of D2 receptor,,12687,,Expert,,,2695,,,,,,B,1,BAO_0000357,15026,8,CHEMBL617943,,H
,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,105093,,Expert,,,2696,,,,,,B,1,BAO_0000224,16404,4,CHEMBL617944,,H
,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,105093,,Expert,,,2697,,,,,,B,1,BAO_0000224,16404,4,CHEMBL617945,,H
,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,105075,,Expert,,,2698,,,,,,B,1,BAO_0000224,16404,4,CHEMBL617946,,H
,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,12687,,Autocuration,,,2699,,,,,,B,1,BAO_0000357,16404,8,CHEMBL617947,,H
,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,12687,,Expert,,,2700,,,,,,B,1,BAO_0000357,16326,8,CHEMBL617948,,H
,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,12687,,Autocuration,,,2701,,,,,,F,1,BAO_0000019,15847,8,CHEMBL858116,,H
,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,12687,,Autocuration,,,2702,,,,,,F,1,BAO_0000019,15847,8,CHEMBL617949,,H
,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,12687,,Autocuration,,,2703,,,,,,F,1,BAO_0000019,15329,8,CHEMBL617950,,H
,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,12687,,Expert,1515.0,,2704,,,,,Thoracic aorta,F,1,BAO_0000019,16404,8,CHEMBL617951,,H
,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,12687,,Expert,1515.0,,2705,,,,,Thoracic aorta,F,1,BAO_0000019,16404,8,CHEMBL617952,,H
,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,12687,,Autocuration,1515.0,,2706,,,,,Thoracic aorta,F,1,BAO_0000019,16404,8,CHEMBL617953,,H
,,Binding activity radioligand.,,12687,,Autocuration,,,2707,,,,,,B,1,BAO_0000357,12861,8,CHEMBL617954,,H
,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12687,,Expert,,,2708,,,,,,B,1,BAO_0000019,12861,8,CHEMBL617955,,H
,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,12687,,Autocuration,,,2709,,,,,,B,1,BAO_0000019,12861,8,CHEMBL857071,,H
,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,12687,,Expert,,,2710,,,,,,B,1,BAO_0000019,12490,8,CHEMBL617270,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,339.0,12687,,Autocuration,,,2711,,N1E-115,,,,B,1,BAO_0000219,12827,8,CHEMBL617271,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,339.0,12687,,Autocuration,,,2712,,N1E-115,,,,B,1,BAO_0000219,12827,8,CHEMBL617272,,H
,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,12687,,Autocuration,,,2713,,,,,,B,1,BAO_0000019,12918,8,CHEMBL617273,,H
,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,12687,Rattus norvegicus,Expert,,10116.0,2714,,,,,,F,1,BAO_0000019,12919,9,CHEMBL617274,,D
,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,2715,,,,,,B,1,BAO_0000357,17723,8,CHEMBL617275,,H
,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,2716,,,,,,B,1,BAO_0000357,6013,8,CHEMBL617276,,H
,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,2717,,,,,,B,1,BAO_0000357,16293,8,CHEMBL617277,,H
,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,108,,Expert,,,2718,,,,,,B,1,BAO_0000019,3857,8,CHEMBL617278,,H
,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,108,,Expert,,,2719,,,,,,B,1,BAO_0000019,3857,8,CHEMBL617279,,H
,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,108,,Expert,,,2720,,,,,,B,1,BAO_0000019,3857,8,CHEMBL617280,,H
,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,2721,,,,,,B,1,BAO_0000357,15363,8,CHEMBL617281,,H
,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,2722,,,,,,B,1,BAO_0000357,15363,8,CHEMBL617282,,H
,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,108,,Expert,,,2723,,,,,,B,1,BAO_0000019,16441,8,CHEMBL617283,,H
,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,108,,Expert,,,2724,,,,,,B,1,BAO_0000019,16441,8,CHEMBL617284,,H
,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,722.0,108,,Autocuration,,,2725,,HEK293,,,,B,1,BAO_0000219,4176,8,CHEMBL617285,,H
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,2726,,,,,,B,1,BAO_0000019,17085,8,CHEMBL617286,,H
,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,108,Homo sapiens,Expert,,9606.0,2727,,,,,,B,1,BAO_0000357,17200,9,CHEMBL617287,,D
,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,108,,Expert,,,2728,,,,,,B,1,BAO_0000357,5088,8,CHEMBL617288,,H
,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,108,,Autocuration,,,2729,,,,,,B,1,BAO_0000357,5088,8,CHEMBL617289,,H
,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,108,,Autocuration,,,2730,,,,,,B,1,BAO_0000357,5088,8,CHEMBL872917,,H
,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,108,,Autocuration,,,2731,,,,,,B,1,BAO_0000357,5088,8,CHEMBL617290,,H
,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,449.0,108,,Autocuration,,,2732,,CHO,,,,B,1,BAO_0000219,16659,8,CHEMBL617291,,H
,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,449.0,108,,Autocuration,,,2733,,CHO,,,,B,1,BAO_0000219,16659,8,CHEMBL617292,,H
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,108,,Autocuration,,,2734,,NIH3T3,,,,B,1,BAO_0000219,17451,8,CHEMBL617293,,H
,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,108,Homo sapiens,Expert,,9606.0,2735,,CHO,,,,F,1,BAO_0000219,6857,9,CHEMBL617294,,D
,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,108,,Expert,,,2736,,,,,,B,1,BAO_0000019,3857,8,CHEMBL617295,,H
,,Binding activity radioligand.,,108,,Autocuration,,,2737,,,,,,B,1,BAO_0000357,12861,8,CHEMBL617296,,H
,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,108,,Autocuration,,,2738,,,,,,B,1,BAO_0000019,12861,8,CHEMBL617297,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,449.0,108,,Expert,,,2739,,CHO,,,,B,1,BAO_0000219,5104,8,CHEMBL617298,,H
,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,449.0,108,,Expert,,,2740,,CHO,,,,B,1,BAO_0000219,5105,8,CHEMBL617299,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,449.0,108,,Autocuration,,,2741,,CHO,,,,B,1,BAO_0000219,5105,8,CHEMBL617300,,H
,,Binding affinity against 5-HT2C receptor,,108,,Autocuration,,,2742,,,,,,B,1,BAO_0000357,5254,8,CHEMBL617454,,H
,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,722.0,108,,Autocuration,,,2743,,HEK293,,,,B,1,BAO_0000219,13267,8,CHEMBL617505,,H
,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,722.0,108,Homo sapiens,Expert,,9606.0,2744,,HEK293,,,,B,1,BAO_0000219,14157,9,CHEMBL617506,,D
,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,722.0,108,Homo sapiens,Expert,,9606.0,2745,,HEK293,,,,B,1,BAO_0000219,12936,9,CHEMBL617507,,D
,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,108,,Expert,,,2746,,,,,,B,1,BAO_0000357,14068,8,CHEMBL617508,,H
,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,722.0,108,Homo sapiens,Expert,,9606.0,2747,,HEK293,,,,B,1,BAO_0000219,12936,9,CHEMBL857982,,D
,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,722.0,108,Homo sapiens,Expert,,9606.0,2748,,HEK293,,,,B,1,BAO_0000219,4540,9,CHEMBL617509,,D
,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,722.0,108,Homo sapiens,Expert,,9606.0,2749,,HEK293,,,,B,1,BAO_0000219,4540,9,CHEMBL617510,,D
,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,108,,Autocuration,,,2750,,,,,,B,1,BAO_0000357,6166,8,CHEMBL617511,,H
,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,722.0,108,,Autocuration,,,2751,,HEK293,,,,B,1,BAO_0000219,17296,8,CHEMBL617512,,H
,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,722.0,108,,Autocuration,,,2752,,HEK293,,,,B,1,BAO_0000219,17296,8,CHEMBL617749,,H
,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,108,,Autocuration,,,2753,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL617750,,H
,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,108,,Autocuration,,,2754,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL617751,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,722.0,108,,Expert,,,2755,,HEK293,,,,B,1,BAO_0000219,14391,8,CHEMBL617752,,H
,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",722.0,108,,Autocuration,,,2756,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL617753,,H
,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",722.0,108,,Expert,,,2757,,HEK293,,,,B,1,BAO_0000219,15851,8,CHEMBL617754,,H
,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,722.0,108,Homo sapiens,Expert,,9606.0,2758,,HEK293,,,,B,1,BAO_0000219,15851,9,CHEMBL617755,,D
,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",722.0,108,,Autocuration,,,2759,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL617756,,H
,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,722.0,108,,Expert,,,2760,,HEK293,,,,B,1,BAO_0000219,3832,8,CHEMBL617757,,H
,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,722.0,108,,Expert,,,2761,,HEK293,,,,B,1,BAO_0000219,3833,8,CHEMBL617758,,H
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,723.0,108,,Autocuration,,,2762,,NIH3T3,,,,B,1,BAO_0000219,17451,8,CHEMBL617759,,H
,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,722.0,108,,Autocuration,,,2763,,HEK293,,,,B,1,BAO_0000219,4199,8,CHEMBL617760,,H
,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,485.0,108,,Expert,,,2764,,CHO-K1,,,,B,1,BAO_0000219,1883,8,CHEMBL617761,,H
,,Binding affinity against 5-hydroxytryptamine 2C receptor,,108,Homo sapiens,Expert,,9606.0,2765,,,,,,B,1,BAO_0000357,4321,9,CHEMBL617762,,D
,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,2766,,,,,,B,1,BAO_0000357,14875,8,CHEMBL617763,,H
,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,722.0,108,,Autocuration,,,2767,,HEK293,,,,B,1,BAO_0000219,15146,8,CHEMBL857983,,H
,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,722.0,108,,Autocuration,,,2768,,HEK293,,,,B,1,BAO_0000219,5213,8,CHEMBL617764,,H
,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,308.0,108,,Autocuration,,,2769,,HeLa,,,,B,1,BAO_0000219,16404,8,CHEMBL617765,,H
,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,108,,Autocuration,,,2770,,,,,,F,1,BAO_0000019,13267,8,CHEMBL617766,,H
,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,108,,Autocuration,10000000.0,,2771,,,,,Hippocampus,F,1,BAO_0000221,13267,8,CHEMBL617767,,H
,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,722.0,108,,Autocuration,,,2772,,HEK293,,,,B,1,BAO_0000219,14818,8,CHEMBL617768,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",722.0,108,,Autocuration,,,2773,,HEK293,,,,B,1,BAO_0000219,4829,8,CHEMBL617769,,H
,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,11864,,Autocuration,,,2774,,,,,,B,1,BAO_0000357,13463,8,CHEMBL858023,,H
,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,11864,,Autocuration,945.0,,2775,,,,,Stomach,B,1,BAO_0000019,13463,8,CHEMBL617770,,H
,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,11864,,Autocuration,945.0,,2776,,,,,Stomach,B,1,BAO_0000019,13463,8,CHEMBL617771,,H
,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,625.0,11864,,Autocuration,,,2777,,A9,,,,F,1,BAO_0000219,12652,8,CHEMBL617772,,H
,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,723.0,11864,,Autocuration,,,2778,,NIH3T3,,,,B,1,BAO_0000219,4682,8,CHEMBL617773,,H
,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,723.0,11864,,Autocuration,,,2779,,NIH3T3,,,,B,1,BAO_0000219,4682,8,CHEMBL617850,,H
,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,723.0,11864,,Autocuration,,,2780,,NIH3T3,,,,B,1,BAO_0000219,4682,8,CHEMBL617851,,H
,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,11864,,Autocuration,,,2781,,,,,,F,1,BAO_0000019,12652,8,CHEMBL617852,,H
,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,12689,Mus musculus,Autocuration,945.0,10090.0,2782,,,,,Stomach,B,1,BAO_0000019,13463,8,CHEMBL858024,,H
,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,12689,Rattus norvegicus,Expert,945.0,10116.0,2783,,,,,Stomach,B,1,BAO_0000019,13463,9,CHEMBL617853,,D
,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,108,,Expert,,,2784,,,,,,B,1,BAO_0000357,13969,8,CHEMBL617854,,H
,,Binding affinity for 5-hydroxytryptamine 2C receptor,,108,Sus scrofa,Expert,,9823.0,2785,,,,,,B,1,BAO_0000357,13392,8,CHEMBL873477,,H
,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,108,,Expert,,,2786,,,,,,B,1,BAO_0000357,13392,8,CHEMBL617855,,H
,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,108,,Expert,,,2787,,,,,,B,1,BAO_0000019,14430,8,CHEMBL617856,,H
,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,108,,Autocuration,,,2788,,,,,,B,1,BAO_0000019,1742,8,CHEMBL617857,,H
,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,108,,Autocuration,,,2789,,,,,,B,1,BAO_0000249,14286,8,CHEMBL617858,,H
,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,2790,,,,,,B,1,BAO_0000357,5619,8,CHEMBL617859,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,2791,,,,,,B,1,BAO_0000357,15086,8,CHEMBL617860,,H
,,Binding activity radioligand.,,108,,Autocuration,,,2792,,,,,,B,1,BAO_0000357,12861,8,CHEMBL617861,,H
,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,108,,Expert,,,2793,,,,,,B,1,BAO_0000019,12861,8,CHEMBL617862,,H
,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,108,,Autocuration,,,2794,,,,,,B,1,BAO_0000019,12861,8,CHEMBL617863,,H
,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,108,,Autocuration,,,2795,,,,,,B,1,BAO_0000249,12827,8,CHEMBL617864,,H
,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,108,,Autocuration,,,2796,,,,,,B,1,BAO_0000249,12827,8,CHEMBL617649,,H
,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,108,Sus scrofa,Expert,,9823.0,2797,,,,,,F,1,BAO_0000019,12919,8,CHEMBL617650,,H
,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,108,Sus scrofa,Expert,,9823.0,2798,,,,,,F,1,BAO_0000019,12919,8,CHEMBL617651,,H
,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,108,Sus scrofa,Autocuration,,9823.0,2799,,,,,,B,1,BAO_0000357,16429,8,CHEMBL617652,,H
,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,108,Sus scrofa,Autocuration,,9823.0,2800,,,,,,B,1,BAO_0000019,773,8,CHEMBL857072,,H
,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,108,Sus scrofa,Autocuration,,9823.0,2801,,,,,,B,1,BAO_0000357,5033,8,CHEMBL617653,,H
,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12687,,Autocuration,,,2802,,,,,,B,1,BAO_0000019,12861,8,CHEMBL617654,,H
,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,12689,,Autocuration,,,2803,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617655,,H
,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,12689,,Expert,,,2804,,,,,,B,1,BAO_0000357,14970,8,CHEMBL617656,,H
,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,12689,,Autocuration,,,2805,,,,,,B,1,BAO_0000357,14970,8,CHEMBL617657,,H
,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,12689,,Autocuration,,,2806,,,,,,B,1,BAO_0000357,14970,8,CHEMBL617658,,H
,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,12689,Rattus norvegicus,Expert,,10116.0,2807,,,,,,B,1,BAO_0000357,14178,9,CHEMBL617659,,D
,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,12689,Rattus norvegicus,Expert,,10116.0,2808,,,,,,B,1,BAO_0000357,14178,9,CHEMBL617838,,D
,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,12689,Rattus norvegicus,Expert,,10116.0,2809,,,,,,B,1,BAO_0000249,14229,9,CHEMBL617839,Brain membranes,D
,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,12689,,Autocuration,,,2810,,,,,,B,1,BAO_0000357,16532,8,CHEMBL617840,,H
,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,12689,,Autocuration,,,2811,,,,,,B,1,BAO_0000019,14826,8,CHEMBL617841,,H
,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,12689,,Autocuration,,,2812,,,,,,B,1,BAO_0000019,17211,8,CHEMBL875915,,H
,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,12689,,Expert,,,2813,In vitro,,,,,B,1,BAO_0000219,17211,8,CHEMBL617842,,H
,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,723.0,12689,,Expert,,,2814,,NIH3T3,,,,B,1,BAO_0000219,13246,8,CHEMBL617843,,H
,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,12689,,Expert,,,2815,,,,,,B,1,BAO_0000357,13246,8,CHEMBL617844,,H
,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,12689,,Expert,,,2816,,,,,,B,1,BAO_0000357,12457,8,CHEMBL617845,,H
,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,723.0,12689,,Expert,,,2817,,NIH3T3,,,,B,1,BAO_0000219,12457,8,CHEMBL617846,,H
,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,12689,,Autocuration,,,2818,,,,,,B,1,BAO_0000357,4707,8,CHEMBL617847,,H
,,Binding affinity against 5-hydroxytryptamine 2C receptor,,12689,,Expert,,,2819,,,,,,B,1,BAO_0000357,13297,8,CHEMBL617848,,H
,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,12689,,Autocuration,,,2820,,,,,,B,1,BAO_0000357,16633,8,CHEMBL617849,,H
,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,12689,,Expert,,,2821,,,,,,B,1,BAO_0000357,16133,8,CHEMBL621507,,H
,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,12689,,Expert,,,2822,,,,,,B,1,BAO_0000357,16326,8,CHEMBL621508,,H
,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,12689,,Autocuration,,,2823,,,,,,B,1,BAO_0000019,14423,8,CHEMBL621509,,H
,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,12689,,Autocuration,,,2824,,,,,,B,1,BAO_0000019,15412,8,CHEMBL621510,,H
,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,12689,,Autocuration,,,2825,,,,,,B,1,BAO_0000019,15412,8,CHEMBL621511,,H
,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,625.0,12689,,Expert,,,2826,,A9,,,,B,1,BAO_0000219,15558,8,CHEMBL621512,,H
,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,12689,,Autocuration,,,2827,,,,,,B,1,BAO_0000357,16633,8,CHEMBL621513,,H
,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,12689,,Expert,,,2828,,,,,,B,1,BAO_0000357,6013,8,CHEMBL621514,,H
,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,12689,,Expert,,,2829,In vitro,,,,,B,1,BAO_0000219,17175,8,CHEMBL621515,,H
,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,12689,,Autocuration,,,2830,,,,,,B,1,BAO_0000219,12469,8,CHEMBL621516,,H
,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,12689,,Autocuration,5383.0,,2831,,,,,Caudate-putamen,B,1,BAO_0000019,3682,8,CHEMBL621517,,H
,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,12689,,Autocuration,,,2832,,,,,,B,1,BAO_0000357,4932,8,CHEMBL621518,,H
,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,12689,,Autocuration,,,2833,,,,,,B,1,BAO_0000019,4932,8,CHEMBL621519,,H
,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,12689,,Autocuration,,,2834,,,,,,B,1,BAO_0000357,3935,8,CHEMBL621520,,H
,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,12689,,Autocuration,,,2835,,,,,,B,1,BAO_0000357,15818,8,CHEMBL621521,,H
,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,12689,,Autocuration,,,2836,,,,,,B,1,BAO_0000357,15818,8,CHEMBL621522,,H
,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,12689,,Expert,,,2837,,,,,,B,1,BAO_0000219,14749,8,CHEMBL621523,,H
,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,12689,,Autocuration,,,2838,,,,,,B,1,BAO_0000357,15740,8,CHEMBL621524,,H
,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,12689,Rattus norvegicus,Expert,,10116.0,2839,,,,,,B,1,BAO_0000357,17133,9,CHEMBL621525,,D
,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,12689,,Autocuration,,,2840,,,,,,B,1,BAO_0000357,16532,8,CHEMBL872921,,H
,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,12689,,Autocuration,,,2841,,,,,,B,1,BAO_0000357,12369,8,CHEMBL621526,,H
,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,12689,,Expert,,,2842,,,,,,B,1,BAO_0000219,12369,8,CHEMBL621527,,H
,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,12689,Rattus norvegicus,Expert,,10116.0,2843,,,,,,B,1,BAO_0000019,2309,9,CHEMBL617865,,D
,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,12689,,Autocuration,,,2844,,,,,,B,1,BAO_0000357,12953,8,CHEMBL617866,,H
,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,12689,,Autocuration,,,2845,,,,,,B,1,BAO_0000019,12953,8,CHEMBL617867,,H
,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,12689,,Autocuration,,,2846,,,,,,B,1,BAO_0000357,12953,8,CHEMBL617487,,H
,,Binding affinity for 5-hydroxytryptamine 2C receptor,,12689,,Expert,,,2847,,,,,,B,1,BAO_0000357,12953,8,CHEMBL617488,,H
,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,12689,,Autocuration,,,2848,,,,,,B,1,BAO_0000357,17133,8,CHEMBL617489,,H
,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,12689,,Autocuration,,,2849,,,,,,B,1,BAO_0000019,17211,8,CHEMBL617490,,H
,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,12689,,Autocuration,,,2850,,,,,,B,1,BAO_0000019,17211,8,CHEMBL617491,,H
,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,12689,,Autocuration,,,2851,,,,,,B,1,BAO_0000019,14025,8,CHEMBL617492,,H
,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,12689,,Autocuration,,,2852,,,,,,B,1,BAO_0000019,14998,8,CHEMBL617493,,H
,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,12689,,Autocuration,,,2853,,,,,,B,1,BAO_0000357,4342,8,CHEMBL617494,,H
,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,12689,Rattus norvegicus,Expert,,10116.0,2854,,,,,,B,1,BAO_0000019,13735,9,CHEMBL617495,,D
,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,12689,,Autocuration,,,2855,,,,,,B,1,BAO_0000357,13181,8,CHEMBL617496,,H
,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,485.0,12689,,Autocuration,,,2856,,CHO-K1,,,,B,1,BAO_0000219,1883,8,CHEMBL617497,,H
,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,12689,,Autocuration,,,2857,,,,,,B,1,BAO_0000357,15194,8,CHEMBL617498,,H
,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,12689,,Autocuration,,,2858,,,,,,B,1,BAO_0000357,15194,8,CHEMBL617499,,H
,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,12689,,Autocuration,,,2859,,,,,,F,1,BAO_0000019,14579,8,CHEMBL617500,,H
,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,2860,,,,,,B,1,BAO_0000357,4639,8,CHEMBL617501,,H
,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,108,,Expert,,,2861,,,,,,B,1,BAO_0000357,4820,8,CHEMBL617502,,H
,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,227,,Autocuration,,,2862,,,,,,B,1,BAO_0000357,14442,8,CHEMBL617503,,H
,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,227,,Autocuration,,,2863,,,,,,B,1,BAO_0000357,14755,8,CHEMBL617504,,H
,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,227,,Autocuration,,,2864,,,,,,B,1,BAO_0000357,14744,8,CHEMBL617406,,H
,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,227,Homo sapiens,Expert,,9606.0,2865,,,,,,B,1,BAO_0000019,6857,9,CHEMBL617407,,D
,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,227,,Autocuration,,,2866,,,,,,B,1,BAO_0000357,16209,8,CHEMBL617408,,H
,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,227,,Autocuration,,,2867,,,,,,B,1,BAO_0000357,15363,8,CHEMBL617409,,H
,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,227,,Autocuration,,,2868,,,,,,B,1,BAO_0000357,15363,8,CHEMBL617410,,H
,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,227,,Autocuration,,,2869,,,,,,B,1,BAO_0000357,15363,8,CHEMBL617411,,H
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,227,,Autocuration,,,2870,,,,,,B,1,BAO_0000019,17085,8,CHEMBL617412,,H
,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,227,Homo sapiens,Expert,,9606.0,2871,,,,,,B,1,BAO_0000357,17200,9,CHEMBL617774,,D
,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,722.0,227,Homo sapiens,Expert,,9606.0,2872,,HEK293,,,,B,1,BAO_0000219,15851,9,CHEMBL617775,,D
,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,722.0,227,Homo sapiens,Expert,,9606.0,2873,,HEK293,,,,B,1,BAO_0000219,15851,9,CHEMBL617776,,D
,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,227,Homo sapiens,Expert,,9606.0,2874,,CHO,,,,F,1,BAO_0000219,6857,9,CHEMBL617777,,D
,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,227,Homo sapiens,Expert,,9606.0,2875,,CHO,,,,F,1,BAO_0000219,6857,9,CHEMBL617778,,D
,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",722.0,227,,Autocuration,,,2876,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL617779,,H
,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,722.0,227,,Expert,,,2877,,HEK293,,,,B,1,BAO_0000219,15851,8,CHEMBL617780,,H
,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",722.0,227,,Autocuration,,,2878,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL617781,,H
,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,722.0,227,Homo sapiens,Expert,,9606.0,2879,,HEK293,,,,B,1,BAO_0000219,14157,9,CHEMBL617782,,D
,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,722.0,227,Homo sapiens,Expert,,9606.0,2880,,HEK293,,,,B,1,BAO_0000219,4540,9,CHEMBL617783,,D
,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,227,,Autocuration,,,2881,,,,,,B,1,BAO_0000357,6166,8,CHEMBL617784,,H
,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,722.0,227,,Autocuration,,,2882,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL617785,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,722.0,227,,Expert,,,2883,,HEK293,,,,B,1,BAO_0000219,14391,8,CHEMBL857984,,H
,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,722.0,227,,Expert,,,2884,,HEK293,,,,B,1,BAO_0000219,3832,8,CHEMBL617786,,H
,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,722.0,227,,Expert,,,2885,,HEK293,,,,B,1,BAO_0000219,3833,8,CHEMBL617787,,H
,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,722.0,227,Homo sapiens,Expert,,9606.0,2886,,HEK293,,,,B,1,BAO_0000219,15851,9,CHEMBL617788,,D
,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,722.0,227,Homo sapiens,Expert,,9606.0,2887,,HEK293,,,,B,1,BAO_0000219,15851,9,CHEMBL617789,,D
,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,722.0,227,,Autocuration,,,2888,,HEK293,,,,B,1,BAO_0000219,4199,8,CHEMBL617790,,H
,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,485.0,227,,Expert,,,2889,,CHO-K1,,,,B,1,BAO_0000219,1883,8,CHEMBL617791,,H
,,Binding affinity against 5-hydroxytryptamine 2B receptor,,227,,Expert,,,2890,,,,,,B,1,BAO_0000357,4321,8,CHEMBL617608,,H
,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,722.0,227,,Autocuration,,,2891,,HEK293,,,,B,1,BAO_0000219,15146,8,CHEMBL617609,,H
,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,722.0,227,,Autocuration,,,2892,,HEK293,,,,B,1,BAO_0000219,5213,8,CHEMBL617610,,H
,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,722.0,227,,Autocuration,,,2893,,HEK293,,,,B,1,BAO_0000219,14818,8,CHEMBL617611,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",722.0,227,,Autocuration,,,2894,,HEK293,,,,B,1,BAO_0000219,4829,8,CHEMBL617612,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",722.0,227,,Autocuration,,,2895,,HEK293,,,,B,1,BAO_0000219,4829,8,CHEMBL617613,,H
,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,227,Oryctolagus cuniculus,Autocuration,,9986.0,2896,,,,,,B,1,BAO_0000019,14025,8,CHEMBL617614,,H
,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,12688,,Expert,945.0,,2897,,,,,Stomach,B,1,BAO_0000019,13463,8,CHEMBL617615,,H
,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,12688,,Expert,945.0,,2898,,,,,Stomach,B,1,BAO_0000357,7259,8,CHEMBL858114,,H
,,Affinity against serotonergic receptor in the isolated rat stomach fundus,,12688,,Autocuration,945.0,,2899,,,,,Stomach,B,1,BAO_0000357,7259,8,CHEMBL617616,,H
,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,12688,Rattus norvegicus,Expert,945.0,10116.0,2900,,,,,Stomach,F,1,BAO_0000019,7185,9,CHEMBL617617,,D
,,Antagonistic against 5-hydroxytryptamine 2B receptor,,12688,Rattus norvegicus,Expert,,10116.0,2901,,,,,,F,1,BAO_0000019,7185,9,CHEMBL875914,,D
,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,12688,,Autocuration,945.0,,2902,,,,,Stomach,F,1,BAO_0000019,13267,8,CHEMBL617618,,H
,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,12688,Rattus norvegicus,Expert,945.0,10116.0,2903,,,,,Stomach,B,1,BAO_0000357,13735,9,CHEMBL617619,,D
,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,12688,,Autocuration,,,2904,,,,,,F,1,BAO_0000019,15738,8,CHEMBL617620,,H
,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,12688,,Autocuration,,,2905,,,,,,F,1,BAO_0000019,15738,8,CHEMBL617621,,H
,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,12688,,Autocuration,,,2906,,,,,,F,1,BAO_0000019,15738,8,CHEMBL617622,,H
,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12688,Rattus norvegicus,Expert,945.0,10116.0,2907,,,,,Stomach,B,1,BAO_0000357,12936,9,CHEMBL617623,,D
,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12688,Rattus norvegicus,Expert,945.0,10116.0,2908,,,,,Stomach,B,1,BAO_0000357,12936,9,CHEMBL617624,,D
,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12688,Rattus norvegicus,Expert,945.0,10116.0,2909,,,,,Stomach,B,1,BAO_0000357,12936,9,CHEMBL617625,,D
,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12688,Rattus norvegicus,Expert,945.0,10116.0,2910,,,,,Stomach,B,1,BAO_0000357,12936,9,CHEMBL617626,,D
,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,12688,,Autocuration,945.0,,2911,,,,,Stomach,F,1,BAO_0000019,16404,8,CHEMBL617627,,H
,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,12688,,Expert,945.0,,2912,,,,,Stomach,F,1,BAO_0000019,16404,8,CHEMBL617628,,H
,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,12688,,Autocuration,945.0,,2913,,,,,Stomach,F,1,BAO_0000019,16404,8,CHEMBL617629,,H
,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,12688,,Autocuration,945.0,,2914,,,,,Stomach,F,1,BAO_0000019,16404,8,CHEMBL858115,,H
,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,12688,Rattus norvegicus,Expert,945.0,10116.0,2915,,,,,Stomach,F,1,BAO_0000019,16404,9,CHEMBL617630,,D
,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,12688,,Autocuration,1515.0,,2916,,,,,Thoracic aorta,F,1,BAO_0000019,16404,8,CHEMBL617631,,H
,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,12688,,Autocuration,,,2917,,,,,,B,1,BAO_0000357,7483,8,CHEMBL617632,,H
,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,12688,,Expert,,,2918,,,,,,B,1,BAO_0000357,7483,8,CHEMBL617633,,H
,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,12688,,Autocuration,,,2919,,,,,,B,1,BAO_0000357,7483,8,CHEMBL617634,,H
,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,12688,,Autocuration,,,2920,,,,,,B,1,BAO_0000357,7483,8,CHEMBL617635,,H
,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,12688,Rattus norvegicus,Autocuration,945.0,10116.0,2922,,,,,Stomach,F,1,BAO_0000019,16404,9,CHEMBL617637,,D
,,Binding affinity against 5-hydroxytryptamine 1A receptor,,227,,Autocuration,,,2923,,,,,,B,1,BAO_0000357,6347,8,CHEMBL617638,,H
,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,227,,Autocuration,,,2924,,,,,,B,1,BAO_0000357,4373,8,CHEMBL617639,,H
,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,227,,Autocuration,,,2925,,,,,,B,1,BAO_0000357,4373,8,CHEMBL617640,,H
,,Evaluated for the binding affinity to 5-HT 2B receptor,,227,,Autocuration,,,2926,,,,,,B,1,BAO_0000357,4687,8,CHEMBL617641,,H
,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,227,,Autocuration,,,2927,,,,,,B,1,BAO_0000357,16946,8,CHEMBL617642,,H
,,Binding affinities against 5-hydroxytryptamine 2B receptor,,227,,Autocuration,,,2928,,,,,,B,1,BAO_0000357,16633,8,CHEMBL617643,,H
,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,227,,Autocuration,,,2929,,,,,,B,1,BAO_0000357,16633,8,CHEMBL617644,,H
,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,227,,Autocuration,,,2930,,,,,,B,1,BAO_0000357,16633,8,CHEMBL617645,,H
,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,108,,Expert,,,2931,,,,,,B,1,BAO_0000357,15026,8,CHEMBL617646,,H
,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,108,Bos taurus,Autocuration,,9913.0,2932,,,,,,B,1,BAO_0000357,15738,8,CHEMBL617647,,H
,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,108,Bos taurus,Autocuration,,9913.0,2933,,,,,,B,1,BAO_0000357,15738,8,CHEMBL617648,,H
,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,108,Bos taurus,Autocuration,,9913.0,2934,,,,,,B,1,BAO_0000357,15738,8,CHEMBL617875,,H
,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,108,Bos taurus,Autocuration,,9913.0,2935,,,,,,B,1,BAO_0000357,15738,8,CHEMBL617876,,H
,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,108,Bos taurus,Expert,,9913.0,2936,,,,,,B,1,BAO_0000357,16404,8,CHEMBL617877,,H
,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,108,Bos taurus,Expert,,9913.0,2937,,,,,,B,1,BAO_0000357,15026,8,CHEMBL617878,,H
,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,108,Bos taurus,Autocuration,,9913.0,2938,,,,,,B,1,BAO_0000357,15738,8,CHEMBL617879,,H
,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,108,Cavia porcellus,Autocuration,,10141.0,2939,,,,,,B,1,BAO_0000019,16312,8,CHEMBL617880,,H
,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,2940,,,,,Striatum,B,1,BAO_0000357,5486,9,CHEMBL617881,,D
,,Binding affinity against 5-HT1A receptor,,51,,Autocuration,,,2941,,,,,,B,1,BAO_0000357,5254,8,CHEMBL857073,,H
,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,449.0,108,,Expert,,,2942,,CHO,,,,F,1,BAO_0000219,3857,8,CHEMBL617882,,H
,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,449.0,108,Homo sapiens,Expert,,9606.0,2943,,CHO,,,,F,1,BAO_0000219,6857,9,CHEMBL617883,,D
,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,108,,Autocuration,,,2944,,,,,,F,1,BAO_0000219,4176,8,CHEMBL617884,,H
,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,449.0,108,,Autocuration,,,2945,,CHO,,,,B,1,BAO_0000219,6347,8,CHEMBL617885,,H
,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",449.0,108,,Autocuration,,,2946,,CHO,,,,B,1,BAO_0000219,6347,8,CHEMBL617886,,H
,,Inhibition of human 5-hydroxytryptamine 2C receptor,,108,Homo sapiens,Expert,,9606.0,2947,,,,,,B,1,BAO_0000357,16146,9,CHEMBL617887,,D
,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,108,,Autocuration,,,2948,,,,,,B,1,BAO_0000357,3805,8,CHEMBL617888,,H
,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,108,,Autocuration,,,2949,,,,,,B,1,BAO_0000019,3857,8,CHEMBL617889,,H
,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,2950,,,,,,B,1,BAO_0000357,5635,8,CHEMBL617890,,H
,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,108,,Autocuration,,,2951,,,,,,B,1,BAO_0000357,5635,8,CHEMBL617891,,H
,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,108,,Autocuration,,,2952,,,,,,B,1,BAO_0000357,5635,8,CHEMBL617892,,H
,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,449.0,108,,Expert,,,2953,,CHO,,,,B,1,BAO_0000219,4012,8,CHEMBL617893,,H
,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,449.0,108,,Expert,,,2954,,CHO,,,,B,1,BAO_0000219,6366,8,CHEMBL617894,,H
,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,449.0,108,,Expert,,,2955,,CHO,,,,B,1,BAO_0000219,15949,8,CHEMBL617895,,H
,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,449.0,108,,Autocuration,,,2956,,CHO,,,,B,1,BAO_0000219,17211,8,CHEMBL617896,,H
,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,108,Homo sapiens,Expert,,9606.0,2957,,,,,,B,1,BAO_0000357,6491,9,CHEMBL617897,,D
,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,108,,Autocuration,,,2958,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617898,,H
,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,108,,Autocuration,,,2959,,,,,,F,1,BAO_0000019,13481,8,CHEMBL617899,,H
,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,449.0,108,Rattus norvegicus,Expert,,10116.0,2960,,CHO,,,,B,1,BAO_0000219,6347,8,CHEMBL617900,,H
,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,108,,Autocuration,,,2961,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617901,,H
,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,108,,Autocuration,,,2962,,,,,,F,1,BAO_0000019,14093,8,CHEMBL617902,,H
,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,108,,Autocuration,,,2963,,,,,,F,1,BAO_0000019,13481,8,CHEMBL617903,,H
,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,108,,Autocuration,,,2964,,,,,,B,1,BAO_0000357,14442,8,CHEMBL617904,,H
,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,108,,Autocuration,,,2965,,,,,,B,1,BAO_0000357,14442,8,CHEMBL617905,,H
,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,108,,Autocuration,,,2966,,,,,,B,1,BAO_0000357,14442,8,CHEMBL617906,,H
,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,108,,Autocuration,,,2967,,,,,,B,1,BAO_0000357,14755,8,CHEMBL617907,,H
,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,108,,Autocuration,,,2968,,,,,,B,1,BAO_0000357,14744,8,CHEMBL617908,,H
,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,449.0,108,,Expert,,,2969,,CHO,,,,B,1,BAO_0000219,16659,8,CHEMBL620617,,H
,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,108,Homo sapiens,Expert,,9606.0,2970,,,,,,B,1,BAO_0000019,6857,9,CHEMBL620618,,D
,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,108,,Expert,,,2971,,,,,,B,1,BAO_0000357,5635,8,CHEMBL620619,,H
,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,108,Homo sapiens,Expert,,9606.0,2972,,,,,,B,1,BAO_0000357,4234,9,CHEMBL620620,,D
,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,108,,Autocuration,,,2973,,,,,,B,1,BAO_0000357,16209,8,CHEMBL620621,,H
,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,104698,Rattus norvegicus,Autocuration,,10116.0,2974,,,,,,B,1,BAO_0000249,5778,7,CHEMBL872920,Membranes,D
,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,104698,,Autocuration,,,2975,,,,,,B,1,BAO_0000223,5094,6,CHEMBL620622,,H
,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,104698,Rattus norvegicus,Autocuration,,10116.0,2976,,,,,,B,1,BAO_0000019,809,7,CHEMBL620623,,D
,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,104698,,Autocuration,,,2977,,,,,,B,1,BAO_0000019,1578,6,CHEMBL620624,,H
,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,104698,,Autocuration,,,2978,,,,,,B,1,BAO_0000019,809,6,CHEMBL620625,,H
,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,104698,,Autocuration,,,2979,,,,,,B,1,BAO_0000219,12469,6,CHEMBL620626,,H
,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,104698,,Autocuration,,,2980,,,,,,B,1,BAO_0000019,14290,6,CHEMBL621307,,H
,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,104698,,Autocuration,,,2981,,,,,,B,1,BAO_0000019,14290,6,CHEMBL621308,,H
,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,104698,,Autocuration,,,2982,,,,,,B,1,BAO_0000223,10609,6,CHEMBL621309,,H
,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,104698,,Autocuration,,,2983,,,,,,B,1,BAO_0000223,10609,6,CHEMBL621310,,H
,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,104698,,Autocuration,,,2984,,,,,,B,1,BAO_0000223,10609,6,CHEMBL621311,,H
,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,104698,,Autocuration,,,2985,,,,,,B,1,BAO_0000249,15253,6,CHEMBL621502,,H
,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,104698,,Autocuration,,,2986,,,,,,B,1,BAO_0000249,15253,6,CHEMBL621503,,H
,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,104698,,Autocuration,,,2987,,,,,,B,1,BAO_0000249,11683,6,CHEMBL621504,Membranes,H
,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,104698,,Autocuration,,,2988,,,,,,B,1,BAO_0000223,12092,6,CHEMBL621505,,H
,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,104698,,Autocuration,,,2989,,,,,,B,1,BAO_0000019,1946,6,CHEMBL621506,,H
,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,104698,,Autocuration,,,2990,,,,,,B,1,BAO_0000223,11623,6,CHEMBL619781,,H
,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,104698,,Autocuration,,,2991,,,,,,B,1,BAO_0000223,11623,6,CHEMBL619782,,H
,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,104698,,Autocuration,,,2992,,,,,,B,1,BAO_0000019,14788,6,CHEMBL619783,,H
,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,2993,,,,,,B,1,BAO_0000019,5432,7,CHEMBL619784,,D
,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,104698,,Autocuration,,,2994,,,,,,B,1,BAO_0000249,14826,6,CHEMBL619785,,H
,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,104698,,Autocuration,,,2995,,,,,,B,1,BAO_0000223,2222,6,CHEMBL619786,,H
,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,104698,,Autocuration,,,2996,,,,,,B,1,BAO_0000019,11963,6,CHEMBL619787,,H
,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,104698,,Autocuration,,,2997,,,,,,B,1,BAO_0000019,14145,6,CHEMBL872925,,H
,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,104698,,Autocuration,,,2998,,,,,,B,1,BAO_0000019,17819,6,CHEMBL619788,,H
,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,104698,,Autocuration,,,2999,,,,,,B,1,BAO_0000249,10394,6,CHEMBL619789,,H
,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,104698,,Autocuration,,,3000,,,,,,B,1,BAO_0000249,10394,6,CHEMBL619790,,H
,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,104698,,Autocuration,,,3001,,,,,,B,1,BAO_0000019,15034,6,CHEMBL619791,,H
,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,104698,,Autocuration,,,3002,,,,,,B,1,BAO_0000019,691,6,CHEMBL619792,,H
,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,104698,,Autocuration,,,3003,,,,,,B,1,BAO_0000249,12092,6,CHEMBL619793,Membranes,H
,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3004,,,,,,B,1,BAO_0000223,11752,7,CHEMBL619794,,D
,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,104698,,Autocuration,955.0,,3005,,,,,Brain,B,1,BAO_0000221,11752,6,CHEMBL619795,,H
,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,104698,,Autocuration,,,3006,,,,,,B,1,BAO_0000019,301,6,CHEMBL619796,,H
,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,104698,,Autocuration,,,3007,,,,,,B,1,BAO_0000223,16532,6,CHEMBL620448,,H
,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,104698,,Autocuration,,,3008,,,,,,B,1,BAO_0000223,16532,6,CHEMBL620449,,H
,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,104698,,Autocuration,,,3009,,,,,,B,1,BAO_0000223,12092,6,CHEMBL620450,,H
,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,104698,,Autocuration,,,3010,,,,,,B,1,BAO_0000223,11684,6,CHEMBL620451,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,104698,,Autocuration,,,3011,,,,,,B,1,BAO_0000223,11684,6,CHEMBL620631,,H
,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,104698,,Autocuration,,,3012,,,,,,B,1,BAO_0000019,12953,6,CHEMBL620632,,H
,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,104698,,Autocuration,,,3013,,,,,,B,1,BAO_0000019,12953,6,CHEMBL620633,,H
,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,104698,,Autocuration,,,3014,,,,,,B,1,BAO_0000223,12953,6,CHEMBL620634,,H
,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,104698,,Autocuration,,,3015,,,,,,B,1,BAO_0000019,12861,6,CHEMBL620635,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3016,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620636,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,104698,,Autocuration,,,3017,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620637,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3018,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620638,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3019,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620639,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3020,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620640,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,104698,,Autocuration,,,3021,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620641,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3022,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620642,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3023,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620643,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3024,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620644,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3025,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620645,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,104698,,Autocuration,,,3026,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620646,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3027,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620647,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3028,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620648,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3029,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620649,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3030,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620650,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,104698,,Autocuration,,,3031,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620651,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,104698,,Autocuration,,,3032,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL872875,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,104698,,Autocuration,,,3033,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL620652,,H
,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,104698,,Autocuration,,,3034,,,,,,F,1,BAO_0000019,10609,6,CHEMBL620653,,H
,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,104698,,Autocuration,,,3035,,,,,,B,1,BAO_0000019,12861,6,CHEMBL857076,,H
,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3036,,,,,,B,1,BAO_0000019,12861,7,CHEMBL620654,,D
,,Binding activity radioligand.,,104698,,Autocuration,,,3037,,,,,,B,1,BAO_0000223,12861,6,CHEMBL620655,,H
,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,104698,,Autocuration,,,3038,,,,,,B,1,BAO_0000249,10728,6,CHEMBL620656,Brain membranes,H
,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,104698,,Autocuration,,,3039,,,,,,B,1,BAO_0000249,10728,6,CHEMBL620657,Brain membranes,H
,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,108,,Autocuration,,,3040,,,,,,B,1,BAO_0000357,5163,8,CHEMBL620658,,H
,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,108,,Autocuration,,,3041,,,,,,B,1,BAO_0000357,5163,8,CHEMBL620659,,H
,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,108,,Autocuration,,,3042,,,,,,B,1,BAO_0000357,6011,8,CHEMBL620660,,H
,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,3043,,,,,,B,1,BAO_0000357,5014,8,CHEMBL620661,,H
,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,3044,,,,,,B,1,BAO_0000357,5635,8,CHEMBL620662,,H
,,Affinity for 5-hydroxytryptamine 2C receptor,,108,,Expert,,,3045,,,,,,B,1,BAO_0000357,5163,8,CHEMBL620663,,H
,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,108,,Autocuration,,,3046,,,,,,B,1,BAO_0000357,6841,8,CHEMBL620664,,H
,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,108,,Expert,,,3047,,,,,,B,1,BAO_0000357,6119,8,CHEMBL620665,,H
,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,108,,Autocuration,,,3048,,,,,,B,1,BAO_0000357,4373,8,CHEMBL620666,,H
,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,108,,Autocuration,,,3049,,,,,,B,1,BAO_0000357,1633,8,CHEMBL620667,,H
,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,108,,Expert,,,3050,,,,,,B,1,BAO_0000357,1633,8,CHEMBL620668,,H
,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,108,,Autocuration,,,3051,,,,,,B,1,BAO_0000357,4373,8,CHEMBL620669,,H
,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,108,,Expert,,,3052,,,,,,B,1,BAO_0000357,6576,8,CHEMBL620670,,H
,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,3053,,,,,,B,1,BAO_0000357,4687,8,CHEMBL620671,,H
,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,108,,Autocuration,,,3054,,,,,,B,1,BAO_0000357,12146,8,CHEMBL620672,,H
,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,108,,Autocuration,,,3055,,,,,,B,1,BAO_0000357,12146,8,CHEMBL620673,,H
,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,3056,,,,,,B,1,BAO_0000357,16946,8,CHEMBL620674,,H
,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,3057,,,,,,B,1,BAO_0000357,14159,8,CHEMBL620675,,H
,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,108,,Autocuration,,,3058,,,,,,B,1,BAO_0000357,16700,8,CHEMBL620676,,H
,,Affinity against 5-hydroxytryptamine 2C receptor,,108,,Autocuration,,,3059,,,,,,B,1,BAO_0000357,3269,8,CHEMBL621382,,H
,,Binding affinity against 5-hydroxytryptamine 2C receptor,,108,Homo sapiens,Expert,,9606.0,3060,,,,,,B,1,BAO_0000357,1274,9,CHEMBL621383,,D
,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,108,,Autocuration,,,3061,,,,,,B,1,BAO_0000357,1317,8,CHEMBL621384,,H
,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,144,Bos taurus,Autocuration,,9913.0,3062,,,,,,B,1,BAO_0000357,5834,8,CHEMBL621385,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,144,Bos taurus,Autocuration,,9913.0,3063,,,,,,B,1,BAO_0000357,11147,8,CHEMBL617989,,H
,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,104714,Cavia porcellus,Expert,,10141.0,3064,,,,,,F,1,BAO_0000019,14145,4,CHEMBL617990,,H
,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3065,,,,,Ileum,B,1,BAO_0000221,10561,4,CHEMBL875085,,H
,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,104714,Cavia porcellus,Autocuration,,10141.0,3066,,,,,,F,1,BAO_0000019,15847,4,CHEMBL617991,,H
,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,104714,Cavia porcellus,Autocuration,,10141.0,3067,,,,,,F,1,BAO_0000019,15847,4,CHEMBL617992,,H
,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3068,,,,,Ileum,B,1,BAO_0000221,10561,4,CHEMBL617993,,H
,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3069,,,,,Ileum,B,1,BAO_0000221,11454,4,CHEMBL617994,,H
,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3070,,,,,,F,1,BAO_0000019,4639,4,CHEMBL617995,,H
,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3071,,,,,,F,1,BAO_0000019,4639,4,CHEMBL617996,,H
,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3072,,,,,,F,1,BAO_0000019,4639,4,CHEMBL617997,,H
,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,104714,Cavia porcellus,Autocuration,,10141.0,3073,,,,,,F,1,BAO_0000019,4639,4,CHEMBL617998,,H
,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3074,,,,,,F,1,BAO_0000019,4639,4,CHEMBL617999,,H
,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3075,,,,,,F,1,BAO_0000019,4639,4,CHEMBL618000,,H
,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3076,,,,,Ileum,F,1,BAO_0000221,15253,4,CHEMBL617815,,H
,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3077,,,,,Ileum,F,1,BAO_0000221,15253,4,CHEMBL617816,,H
,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3078,,,,,Ileum,F,1,BAO_0000221,11963,4,CHEMBL617817,,H
,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3079,,,,,Ileum,B,1,BAO_0000221,1946,4,CHEMBL617818,,H
,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3080,,,,,Ileum,B,1,BAO_0000221,1946,4,CHEMBL617819,,H
,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,104714,Cavia porcellus,Autocuration,,10141.0,3081,,,,,,B,1,BAO_0000223,12045,4,CHEMBL617820,,H
,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3082,,,,,Ileum,B,1,BAO_0000221,1559,4,CHEMBL617821,,H
,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3083,,,,,Ileum,F,1,BAO_0000221,273,4,CHEMBL617822,,H
,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3084,,,,,Ileum,F,1,BAO_0000221,273,4,CHEMBL617823,,H
,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3085,,,,,Ileum,F,1,BAO_0000221,188,4,CHEMBL617824,,H
,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3086,,,,,Ileum,F,1,BAO_0000221,12919,4,CHEMBL617825,,H
,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3087,,,,,Ileum,F,1,BAO_0000221,12918,4,CHEMBL617826,,H
,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3088,,,,,Ileum,B,1,BAO_0000221,1559,4,CHEMBL617827,,H
,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3089,,,,,Ileum,F,1,BAO_0000221,273,4,CHEMBL617828,,H
,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3090,,,,,Ileum,B,1,BAO_0000221,1559,4,CHEMBL617829,,H
,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3091,,,,,Ileum,B,1,BAO_0000221,1559,4,CHEMBL617830,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3092,,,,,Ileum,B,1,BAO_0000221,1559,4,CHEMBL617831,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,104714,Cavia porcellus,Autocuration,2116.0,10141.0,3093,,,,,Ileum,B,1,BAO_0000221,14424,4,CHEMBL617832,,H
,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,22226,Cavia porcellus,Autocuration,,10141.0,3094,,,,,,B,1,BAO_0000019,13181,0,CHEMBL617833,,U
,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,51,,Autocuration,,,3095,,,,,,B,1,BAO_0000357,5486,8,CHEMBL617834,,H
,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,104714,Homo sapiens,Expert,,9606.0,3096,,,,,,B,1,BAO_0000223,6491,5,CHEMBL617835,,D
,,Binding affinity towards 5-HT3 receptor,,104714,,Autocuration,,,3097,,,,,,B,1,BAO_0000223,6013,4,CHEMBL617836,,H
,,Binding activity radioligand.,,104714,,Autocuration,,,3098,,,,,,B,1,BAO_0000223,12861,4,CHEMBL617837,,H
,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,104714,,Autocuration,,,3099,,,,,,B,1,BAO_0000019,12861,4,CHEMBL620392,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,104714,,Autocuration,,,3100,,,,,,B,1,BAO_0000223,5104,4,CHEMBL620393,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,104714,,Autocuration,,,3101,,,,,,B,1,BAO_0000223,5105,4,CHEMBL620394,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,104714,,Autocuration,,,3102,,,,,,B,1,BAO_0000223,5104,4,CHEMBL620395,,H
,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,22226,,Autocuration,,,3103,,,,,,B,1,BAO_0000019,3935,0,CHEMBL620396,,U
,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,433.0,105030,,Expert,,,3104,,NG108-15,,,,B,1,BAO_0000219,13657,4,CHEMBL620582,,H
,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,105030,,Autocuration,,,3105,In vivo,,,,,B,1,BAO_0000218,10369,4,CHEMBL620583,,H
,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,105030,,Autocuration,,,3106,,,,,,B,1,BAO_0000019,10369,4,CHEMBL620584,,H
,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,105030,,Autocuration,,,3107,,,,,,B,1,BAO_0000224,12918,4,CHEMBL620585,,H
,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,105030,,Autocuration,,,3108,,,,,,B,1,BAO_0000224,12918,4,CHEMBL620586,,H
,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,105030,,Autocuration,,,3109,,,,,,B,1,BAO_0000019,10369,4,CHEMBL620587,,H
,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,105030,,Autocuration,,,3110,,,,,,B,1,BAO_0000019,773,4,CHEMBL620588,,H
,,5-hydroxytryptamine 3 receptor agonism in mouse,,105030,,Autocuration,,,3111,,,,,,F,1,BAO_0000218,12918,4,CHEMBL620589,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,105030,,Autocuration,,,3112,,,,,,B,1,BAO_0000219,10561,4,CHEMBL620590,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,105030,,Autocuration,,,3113,,,,,,B,1,BAO_0000019,12827,4,CHEMBL617956,,H
,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,105030,,Autocuration,,,3114,,,,,,B,1,BAO_0000019,12827,4,CHEMBL617957,,H
,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,105030,,Autocuration,,,3115,,,,,,B,1,BAO_0000224,12918,4,CHEMBL617958,,H
,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,105030,,Autocuration,,,3116,,,,,,B,1,BAO_0000219,273,4,CHEMBL617959,,H
,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,105030,,Autocuration,,,3117,,,,,,B,1,BAO_0000219,273,4,CHEMBL617960,,H
,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,105030,,Autocuration,,,3118,,,,,,B,1,BAO_0000224,10561,4,CHEMBL617961,,H
,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,105030,,Autocuration,,,3119,In vitro,,,,,B,1,BAO_0000219,5033,4,CHEMBL617962,,H
,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,339.0,105030,,Autocuration,,,3120,,N1E-115,,,,B,1,BAO_0000219,16429,4,CHEMBL617963,,H
,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,11765,,Autocuration,,,3121,,,,,,B,1,BAO_0000019,10322,8,CHEMBL617964,,H
,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,11765,,Autocuration,,,3122,,,,,,B,1,BAO_0000219,14331,8,CHEMBL617965,,H
,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,10630,Mus musculus,Autocuration,,10090.0,3123,,,,,,B,1,BAO_0000357,13462,9,CHEMBL617966,,D
,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,17106,,Autocuration,,,3124,,,,,,B,1,BAO_0000019,12861,8,CHEMBL857074,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,144,Sus scrofa,Autocuration,,9823.0,3125,,,,,,B,1,BAO_0000357,15086,8,CHEMBL617967,,H
,,Binding activity radioligand.,,144,Sus scrofa,Autocuration,,9823.0,3126,,,,,,B,1,BAO_0000357,12861,8,CHEMBL617968,,H
,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,104714,Oryctolagus cuniculus,Autocuration,,9986.0,3127,,,,,,B,1,BAO_0000223,10561,4,CHEMBL617969,,H
,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,104714,Oryctolagus cuniculus,Autocuration,,9986.0,3128,,,,,,B,1,BAO_0000223,10561,4,CHEMBL617970,,H
,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,104714,Oryctolagus cuniculus,Autocuration,,9986.0,3129,,,,,,B,1,BAO_0000223,10561,4,CHEMBL617971,,H
,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,104714,Oryctolagus cuniculus,Autocuration,,9986.0,3130,,,,,,B,1,BAO_0000019,10561,4,CHEMBL617972,,H
,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,104714,Oryctolagus cuniculus,Autocuration,,9986.0,3131,,,,,,F,1,BAO_0000019,273,4,CHEMBL617973,,H
,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,104714,Oryctolagus cuniculus,Autocuration,,9986.0,3132,,,,,,F,1,BAO_0000019,273,4,CHEMBL617974,,H
,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,104714,Oryctolagus cuniculus,Autocuration,2116.0,9986.0,3133,,,,,Ileum,F,1,BAO_0000221,273,4,CHEMBL617975,,H
,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,104714,Oryctolagus cuniculus,Autocuration,,9986.0,3134,,,,,,F,1,BAO_0000019,273,4,CHEMBL617976,,H
,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,104714,Oryctolagus cuniculus,Autocuration,,9986.0,3135,,,,,,F,1,BAO_0000019,273,4,CHEMBL617977,,H
,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,104714,Oryctolagus cuniculus,Autocuration,,9986.0,3136,,,,,,F,1,BAO_0000019,273,4,CHEMBL617978,,H
,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,104714,Oryctolagus cuniculus,Autocuration,,9986.0,3137,,,,,,F,1,BAO_0000019,273,4,CHEMBL617979,,H
,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,449.0,104714,Oryctolagus cuniculus,Autocuration,,9986.0,3138,,CHO,,,,B,1,BAO_0000219,13047,4,CHEMBL617980,,H
,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3139,,,,,,B,1,BAO_0000019,1650,7,CHEMBL617981,,D
,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,12020,,Autocuration,,,3140,,,,,,B,1,BAO_0000019,16288,8,CHEMBL617982,,H
,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,12020,,Autocuration,,,3141,,,,,,B,1,BAO_0000357,16288,8,CHEMBL617983,,H
,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,104698,Rattus norvegicus,Autocuration,,10116.0,3142,,,,,,B,1,BAO_0000019,10254,7,CHEMBL617984,,D
,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,104698,,Autocuration,,,3143,,,,,,B,1,BAO_0000019,14532,6,CHEMBL617985,,H
,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,104698,,Autocuration,948.0,,3144,In vivo,,,,Heart,F,1,BAO_0000218,13392,6,CHEMBL617986,,H
,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,104698,,Autocuration,948.0,,3145,,,,,Heart,F,1,BAO_0000019,13392,6,CHEMBL617987,,H
,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,104698,,Autocuration,948.0,,3146,,,,,Heart,F,1,BAO_0000019,13392,6,CHEMBL617988,,H
,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,104698,,Autocuration,948.0,,3147,,,,,Heart,F,1,BAO_0000019,13392,6,CHEMBL617792,,H
,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,104698,,Autocuration,948.0,,3148,,,,,Heart,F,1,BAO_0000019,13392,6,CHEMBL617793,,H
,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,104698,,Autocuration,,,3149,,,,,,F,1,BAO_0000019,13392,6,CHEMBL617794,,H
,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,104698,,Autocuration,,,3150,,,,,,F,1,BAO_0000019,13392,6,CHEMBL617795,,H
,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,104698,,Autocuration,,,3151,,,,,,F,1,BAO_0000019,13392,6,CHEMBL617796,,H
,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,104698,,Autocuration,,,3152,,,,,,F,1,BAO_0000019,13392,6,CHEMBL617797,,H
,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,104698,Rattus norvegicus,Autocuration,,10116.0,3153,In vivo,,,,,F,1,BAO_0000218,1089,7,CHEMBL617798,,D
,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,104698,,Autocuration,,,3154,In vivo,,,,,F,1,BAO_0000218,1089,6,CHEMBL617799,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698,Rattus norvegicus,Autocuration,,10116.0,3155,In vivo,,,,,F,1,BAO_0000218,11454,7,CHEMBL617800,,D
,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,104698,Rattus norvegicus,Autocuration,,10116.0,3156,,,,,,F,1,BAO_0000019,11454,7,CHEMBL617801,,D
,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,104698,Rattus norvegicus,Autocuration,,10116.0,3157,In vivo,,,,,F,1,BAO_0000218,12205,7,CHEMBL617802,,D
,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,104698,Rattus norvegicus,Autocuration,,10116.0,3158,,,,,,F,1,BAO_0000019,1089,7,CHEMBL617803,,D
,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,104698,,Autocuration,,,3159,,,,,,B,1,BAO_0000019,5094,6,CHEMBL617804,,H
,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3160,,,,,,B,1,BAO_0000019,2622,7,CHEMBL617805,,D
,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,104698,,Autocuration,,,3161,,,,,,B,1,BAO_0000223,245,6,CHEMBL617806,,H
,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,104698,,Autocuration,,,3162,,,,,,B,1,BAO_0000019,14788,6,CHEMBL617807,,H
,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,104698,,Autocuration,,,3163,,,,,,B,1,BAO_0000019,14788,6,CHEMBL617808,,H
,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,104698,,Autocuration,,,3164,,,,,,B,1,BAO_0000249,3020,6,CHEMBL617809,,H
,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,104698,,Autocuration,,,3165,,,,,,B,1,BAO_0000019,1742,6,CHEMBL617810,,H
,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,104698,,Autocuration,955.0,,3166,,,,,Brain,B,1,BAO_0000249,17394,6,CHEMBL617811,,H
,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,104698,,Autocuration,955.0,,3167,,,,,Brain,B,1,BAO_0000221,17394,6,CHEMBL617812,,H
,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,104698,,Autocuration,,,3168,,,,,,B,1,BAO_0000249,17394,6,CHEMBL617813,,H
,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,104698,,Autocuration,,,3169,,,,,,B,1,BAO_0000249,14286,6,CHEMBL617814,,H
,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,104698,,Autocuration,,,3170,,,,,,B,1,BAO_0000019,14178,6,CHEMBL617698,,H
,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,104698,Rattus norvegicus,Autocuration,,10116.0,3171,,,,,,B,1,BAO_0000019,14178,7,CHEMBL617699,,D
,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,104698,Rattus norvegicus,Autocuration,,10116.0,3172,,,,,,B,1,BAO_0000019,14178,7,CHEMBL617700,,D
,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3173,,,,,,B,1,BAO_0000223,14178,7,CHEMBL617701,,D
,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,104698,,Autocuration,,,3174,,,,,,B,1,BAO_0000019,15034,6,CHEMBL617702,,H
,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,104698,,Autocuration,,,3175,,,,,,B,1,BAO_0000249,1089,6,CHEMBL617703,Membranes,H
,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3176,,,,,,B,1,BAO_0000019,1089,7,CHEMBL617704,,D
,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,104698,,Autocuration,,,3177,,,,,,B,1,BAO_0000223,16532,6,CHEMBL617705,,H
,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3178,,,,,,B,1,BAO_0000223,12801,7,CHEMBL617706,,D
,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),433.0,104698,,Autocuration,,,3179,,NG108-15,,,,B,1,BAO_0000219,15194,6,CHEMBL617707,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,433.0,104698,,Autocuration,,,3180,,NG108-15,,,,B,1,BAO_0000219,15194,6,CHEMBL617708,,H
,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,104698,,Autocuration,,,3181,,,,,,B,1,BAO_0000019,15194,6,CHEMBL617709,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,104698,,Autocuration,,,3182,,,,,,B,1,BAO_0000019,15194,6,CHEMBL617710,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,104698,,Autocuration,,,3183,,,,,,B,1,BAO_0000019,15194,6,CHEMBL882925,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,104698,,Autocuration,,,3184,,,,,,B,1,BAO_0000019,15194,6,CHEMBL617711,,H
,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,104698,,Autocuration,,,3185,,,,,,F,1,BAO_0000019,10610,6,CHEMBL617712,,H
,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,104698,Rattus norvegicus,Autocuration,,10116.0,3186,,,,,,F,1,BAO_0000019,10355,7,CHEMBL617713,,D
,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,104698,,Autocuration,,,3187,,,,,,F,1,BAO_0000019,691,6,CHEMBL617714,,H
,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,104698,,Autocuration,,,3188,,,,,,F,1,BAO_0000218,10611,6,CHEMBL617715,,H
,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,104698,,Autocuration,,,3189,In vivo,,,,,F,1,BAO_0000218,12801,6,CHEMBL617716,,H
,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,104698,,Autocuration,,,3190,,,,,,F,1,BAO_0000218,10609,6,CHEMBL617717,,H
,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3191,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617718,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3192,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617719,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,104698,,Autocuration,,,3193,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617720,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,104698,Rattus norvegicus,Autocuration,,10116.0,3194,In vivo,,,,,F,1,BAO_0000218,11454,7,CHEMBL617721,,D
,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3195,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617722,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,104698,,Autocuration,,,3196,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617723,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3197,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617724,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3198,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617725,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3199,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617726,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3200,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617727,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3201,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617728,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3202,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617729,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3203,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617730,,H
,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3204,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617731,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3205,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617732,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3206,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617733,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3207,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617734,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,104698,,Autocuration,,,3208,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL872874,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,104698,,Autocuration,,,3209,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617735,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,104698,,Autocuration,,,3210,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617736,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,104698,,Autocuration,,,3211,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617737,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,104698,,Autocuration,,,3212,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617738,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3213,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617739,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3214,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617740,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3215,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617741,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3216,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617742,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3217,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617743,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3218,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617744,,H
,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,104698,,Autocuration,,,3219,In vivo,,,,,F,1,BAO_0000218,11454,6,CHEMBL617745,,H
,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,104698,,Autocuration,,,3220,,,,,,F,1,BAO_0000218,670,6,CHEMBL617746,,H
,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,104698,,Autocuration,,,3221,,,,,,F,1,BAO_0000218,670,6,CHEMBL617747,,H
,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,104698,,Autocuration,,,3222,In vivo,,,,,F,1,BAO_0000218,10321,6,CHEMBL617748,,H
,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,104698,,Autocuration,,,3223,In vivo,,,,,F,1,BAO_0000218,10321,6,CHEMBL618909,,H
,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,104698,,Autocuration,,,3224,In vivo,,,,,F,1,BAO_0000218,10321,6,CHEMBL618910,,H
,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,104698,,Autocuration,,,3225,In vivo,,,,,F,1,BAO_0000218,10321,6,CHEMBL618911,,H
,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,104698,,Autocuration,,,3226,In vivo,,,,,F,1,BAO_0000218,10321,6,CHEMBL618912,,H
,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,104698,,Autocuration,,,3227,In vivo,,,,,F,1,BAO_0000218,10322,6,CHEMBL618913,,H
,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,104698,,Autocuration,,,3228,,,,,,F,1,BAO_0000019,15412,6,CHEMBL618914,,H
,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,104698,,Autocuration,,,3229,,,,,,F,1,BAO_0000019,15412,6,CHEMBL618915,,H
,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3230,,,,,,B,1,BAO_0000223,15412,7,CHEMBL618916,,D
,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,104698,,Autocuration,,,3231,,,,,,F,1,BAO_0000019,15412,6,CHEMBL618917,,H
,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,104698,,Intermediate,10000000.0,,3232,,,,,Hippocampus,B,1,BAO_0000221,15412,7,CHEMBL618918,,D
,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,104698,Rattus norvegicus,Autocuration,,10116.0,3233,,,,,,B,1,BAO_0000019,15412,7,CHEMBL618919,,D
,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3234,,,,,,B,1,BAO_0000019,17394,7,CHEMBL618920,,D
,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,104698,,Autocuration,,,3235,,,,,,B,1,BAO_0000223,12457,6,CHEMBL618921,,H
,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,104698,,Autocuration,,,3236,,,,,,B,1,BAO_0000019,12457,6,CHEMBL618922,,H
,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,104698,,Autocuration,,,3237,,,,,,B,1,BAO_0000019,12205,6,CHEMBL618923,,H
,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,104698,,Autocuration,,,3238,,,,,,B,1,BAO_0000019,14532,6,CHEMBL618924,,H
,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,104698,,Autocuration,,,3239,,,,,,B,1,BAO_0000019,1122,6,CHEMBL618925,,H
,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,104698,,Autocuration,,,3240,,,,,,B,1,BAO_0000019,5094,6,CHEMBL618926,,H
,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3241,,,,,Ileum,F,1,BAO_0000221,809,9,CHEMBL618927,,D
,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3242,,,,,Ileum,F,1,BAO_0000221,809,9,CHEMBL618928,,D
,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3243,,,,,Ileum,F,1,BAO_0000221,14290,9,CHEMBL618929,,D
,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3244,,,,,Ileum,F,1,BAO_0000221,14290,9,CHEMBL618930,,D
,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3245,,,,,Ileum,F,1,BAO_0000221,14290,9,CHEMBL618931,,D
,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3246,,,,,Ileum,F,1,BAO_0000221,14290,9,CHEMBL619594,,D
,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3247,,,,,Ileum,F,1,BAO_0000221,14290,9,CHEMBL619595,,D
,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3248,,,,,Ileum,F,1,BAO_0000221,13961,9,CHEMBL619596,,D
,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3249,,,,,Ileum,F,1,BAO_0000221,13961,9,CHEMBL619755,,D
,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3250,,,,,Ileum,F,1,BAO_0000221,809,9,CHEMBL619756,,D
,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3251,,,,,Ileum,F,1,BAO_0000221,809,9,CHEMBL619757,,D
,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3252,,,,,Ileum,F,1,BAO_0000221,809,9,CHEMBL619758,,D
,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3253,,,,,Ileum,F,1,BAO_0000221,14290,9,CHEMBL619759,,D
,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3254,,,,,Ileum,F,1,BAO_0000221,14290,9,CHEMBL619760,,D
,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3255,,,,,Ileum,F,1,BAO_0000221,14290,9,CHEMBL619761,,D
,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3256,,,,,Ileum,F,1,BAO_0000221,14290,9,CHEMBL619762,,D
,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3257,,,,,Ileum,F,1,BAO_0000221,14290,9,CHEMBL619763,,D
,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3258,,,,,Ileum,F,1,BAO_0000221,14290,9,CHEMBL617868,,D
,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,20033,Cavia porcellus,Intermediate,,10141.0,3259,,,,,,B,1,BAO_0000357,15034,9,CHEMBL617869,,D
,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,3260,,,,,Striatum,B,1,BAO_0000249,5094,9,CHEMBL882926,,D
,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,3261,,,,,Striatum,B,1,BAO_0000249,5094,9,CHEMBL617870,,D
,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,3262,,,,,Striatum,B,1,BAO_0000357,5399,9,CHEMBL617871,,D
,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,3263,,,,,Striatum,B,1,BAO_0000357,17394,9,CHEMBL617872,,D
,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,3264,,,,,Striatum,B,1,BAO_0000357,17394,9,CHEMBL617873,,D
,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,3265,,,,,Striatum,B,1,BAO_0000357,17394,9,CHEMBL617874,,D
,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3266,,,,,Ileum,F,1,BAO_0000221,13961,9,CHEMBL619067,,D
,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3267,,,,,Ileum,F,1,BAO_0000221,13961,9,CHEMBL619068,,D
,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3268,,,,,Ileum,F,1,BAO_0000221,13961,9,CHEMBL619069,,D
,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,20033,Cavia porcellus,Intermediate,,10141.0,3269,,,,,,B,1,BAO_0000357,16946,9,CHEMBL619070,,D
,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,20033,Cavia porcellus,Intermediate,,10141.0,3270,,,,,,B,1,BAO_0000357,16946,9,CHEMBL619071,,D
,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,20033,Cavia porcellus,Intermediate,,10141.0,3271,,,,,,F,1,BAO_0000019,15034,9,CHEMBL619072,,D
,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,20033,Cavia porcellus,Intermediate,,10141.0,3272,,,,,,F,1,BAO_0000019,15034,9,CHEMBL619073,,D
,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,20033,Cavia porcellus,Intermediate,,10141.0,3273,,,,,,F,1,BAO_0000019,12918,9,CHEMBL619074,,D
,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,20033,Cavia porcellus,Intermediate,,10141.0,3274,,,,,,B,1,BAO_0000357,16946,9,CHEMBL619075,,D
,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,3275,,,,,Striatum,B,1,BAO_0000357,17394,9,CHEMBL619076,,D
,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,3276,,,,,Striatum,B,1,BAO_0000357,15034,9,CHEMBL619077,,D
,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,3277,,,,,Striatum,B,1,BAO_0000249,5094,9,CHEMBL619078,,D
,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,3278,,,,,Striatum,B,1,BAO_0000249,5094,9,CHEMBL619079,,D
,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3279,,,,,Ileum,B,1,BAO_0000221,17358,9,CHEMBL619080,,D
,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,20033,Cavia porcellus,Expert,,10141.0,3280,,,,,,B,1,BAO_0000357,12953,9,CHEMBL619081,,D
,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,20033,Cavia porcellus,Intermediate,,10141.0,3281,,,,,,B,1,BAO_0000357,12953,9,CHEMBL619082,,D
,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,20033,Cavia porcellus,Intermediate,,10141.0,3282,,,,,,B,1,BAO_0000357,12953,9,CHEMBL619083,,D
,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,20033,Cavia porcellus,Intermediate,,10141.0,3283,,,,,,B,1,BAO_0000357,12953,9,CHEMBL619084,,D
,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3284,,,,,Ileum,F,1,BAO_0000221,273,9,CHEMBL859397,,D
,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3285,,,,,Ileum,F,1,BAO_0000221,12918,9,CHEMBL619085,,D
,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3286,,,,,Ileum,F,1,BAO_0000221,12919,9,CHEMBL619086,,D
,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3287,,,,,Ileum,F,1,BAO_0000221,273,9,CHEMBL619087,,D
,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3288,,,,,Ileum,F,1,BAO_0000221,273,9,CHEMBL619088,,D
,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,20033,Cavia porcellus,Intermediate,,10141.0,3289,,,,,,B,1,BAO_0000357,13181,9,CHEMBL619089,,D
,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,168,Cavia porcellus,Autocuration,,10141.0,3290,,,,,,B,1,BAO_0000357,13181,8,CHEMBL619090,,H
,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,20033,Cavia porcellus,Intermediate,,10141.0,3291,,,,,,F,1,BAO_0000019,15034,9,CHEMBL619091,,D
,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,20033,Cavia porcellus,Intermediate,,10141.0,3292,,,,,,B,1,BAO_0000357,5033,9,CHEMBL619092,,D
,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,20033,Cavia porcellus,Intermediate,,10141.0,3293,,,,,,B,1,BAO_0000019,1980,9,CHEMBL619093,,D
,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,722.0,168,Cavia porcellus,Autocuration,,10141.0,3294,,HEK293,,,,B,1,BAO_0000219,13181,8,CHEMBL619094,,H
,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,20033,Cavia porcellus,Intermediate,,10141.0,3295,,,,,,B,1,BAO_0000019,14287,9,CHEMBL619095,,D
,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,20033,Cavia porcellus,Intermediate,,10141.0,3296,,,,,,B,1,BAO_0000357,1317,9,CHEMBL857988,,D
,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,20033,Cavia porcellus,Intermediate,,10141.0,3297,,,,,,B,1,BAO_0000357,15316,9,CHEMBL619096,,D
,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,20033,Cavia porcellus,Intermediate,2435.0,10141.0,3298,,,,,Striatum,B,1,BAO_0000357,16429,9,CHEMBL619097,,D
,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,20033,Cavia porcellus,Intermediate,10000000.0,10141.0,3299,,,,,Hippocampus,B,1,BAO_0000221,14818,9,CHEMBL619098,,D
,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,20033,Cavia porcellus,Intermediate,,10141.0,3300,,,,,,B,1,BAO_0000357,15194,9,CHEMBL619751,,D
,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,20033,Cavia porcellus,Intermediate,,10141.0,3301,,,,,,B,1,BAO_0000357,15194,9,CHEMBL619752,,D
,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3302,,,,,Ileum,F,1,BAO_0000221,13961,9,CHEMBL875096,,D
,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,108,,Autocuration,,,3303,,,,,,B,1,BAO_0000357,5486,8,CHEMBL619004,,H
,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,168,,Autocuration,,,3304,,,,,,B,1,BAO_0000357,16209,8,CHEMBL619005,,H
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,168,,Autocuration,,,3305,,,,,,B,1,BAO_0000019,17085,8,CHEMBL619006,,H
,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,308.0,168,,Autocuration,,,3306,,HeLa,,,,B,1,BAO_0000219,4199,8,CHEMBL619007,,H
,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,168,,Autocuration,,,3307,,,,,,B,1,BAO_0000357,15146,8,CHEMBL619008,,H
,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,168,,Autocuration,,,3308,,,,,,B,1,BAO_0000357,5213,8,CHEMBL619009,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",308.0,168,,Autocuration,,,3309,,HeLa,,,,B,1,BAO_0000219,4829,8,CHEMBL619010,,H
,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,10622,,Autocuration,,,3310,,,,,,B,1,BAO_0000357,17358,8,CHEMBL619011,,H
,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,10622,,Autocuration,,,3311,,,,,,B,1,BAO_0000357,17358,8,CHEMBL619012,,H
,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,10622,,Autocuration,,,3312,,,,,,B,1,BAO_0000219,16946,8,CHEMBL619013,,H
,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,10622,,Autocuration,,,3313,,,,,,B,1,BAO_0000357,17358,8,CHEMBL619014,,H
,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,11249,,Autocuration,2081.0,,3314,,,,,Cardiac atrium,F,1,BAO_0000019,268,8,CHEMBL857503,,H
,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,11249,,Autocuration,2081.0,,3315,,,,,Cardiac atrium,F,1,BAO_0000019,268,8,CHEMBL619015,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,11249,,Autocuration,,,3316,,,,,,B,1,BAO_0000357,15086,8,CHEMBL619016,,H
,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,11249,,Autocuration,10000000.0,,3317,,,,,Hippocampus,B,1,BAO_0000221,14875,8,CHEMBL619017,,H
,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,168,Sus scrofa,Autocuration,10000000.0,9823.0,3318,,,,,Hippocampus,B,1,BAO_0000221,13267,8,CHEMBL619018,,H
,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,168,Oryctolagus cuniculus,Autocuration,,9986.0,3319,,,,,,B,1,BAO_0000019,13047,8,CHEMBL619019,,H
,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,10623,Rattus norvegicus,Expert,,10116.0,3320,,,,,,B,1,BAO_0000357,1650,9,CHEMBL619020,,D
,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,10623,,Autocuration,,,3321,,,,,,F,1,BAO_0000019,567,8,CHEMBL619021,,H
,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,10623,,Autocuration,,,3322,,,,,,B,1,BAO_0000357,17358,8,CHEMBL619022,,H
,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,10623,,Autocuration,,,3323,,,,,,B,1,BAO_0000357,188,8,CHEMBL619023,,H
,,lntrinsic activity relative to 5-HT receptor,,10623,,Autocuration,,,3324,,,,,,F,1,BAO_0000019,670,8,CHEMBL619024,,H
,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,10623,,Autocuration,,,3325,,,,,,F,1,BAO_0000019,204,8,CHEMBL619025,,H
,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,10623,,Expert,,,3326,,,,,,F,1,BAO_0000019,1946,8,CHEMBL619026,,H
,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,10623,,Autocuration,,,3327,,,,,,F,1,BAO_0000019,6398,8,CHEMBL619027,,H
,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,10623,,Autocuration,,,3328,,,,,,F,1,BAO_0000019,6398,8,CHEMBL619028,,H
,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,10623,,Autocuration,,,3329,,,,,,F,1,BAO_0000019,17358,8,CHEMBL619029,,H
,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,10623,,Autocuration,,,3330,,,,,,F,1,BAO_0000019,6398,8,CHEMBL619030,,H
,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,10623,,Expert,,,3331,,,,,,B,1,BAO_0000357,11752,8,CHEMBL619031,,H
,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,10623,,Autocuration,,,3332,,,,,,F,1,BAO_0000019,809,8,CHEMBL619032,,H
,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,10623,Rattus norvegicus,Expert,,10116.0,3333,,,,,,B,1,BAO_0000357,14178,9,CHEMBL619033,,D
,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,10623,,Autocuration,,,3334,,,,,,B,1,BAO_0000357,567,8,CHEMBL619034,,H
,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,10623,,Autocuration,,,3335,,,,,,B,1,BAO_0000357,1946,8,CHEMBL619035,,H
,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,10623,,Autocuration,,,3336,,,,,,B,1,BAO_0000357,1946,8,CHEMBL619036,,H
,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,10623,Rattus norvegicus,Expert,,10116.0,3337,,,,,,B,1,BAO_0000019,13961,9,CHEMBL619037,,D
,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,10623,,Autocuration,2435.0,,3338,,,,,Striatum,B,1,BAO_0000249,6238,8,CHEMBL619038,,H
,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,10623,,Autocuration,,,3339,,,,,,B,1,BAO_0000249,14290,8,CHEMBL619039,,H
,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,10623,,Expert,,,3340,,,,,,B,1,BAO_0000249,14290,8,CHEMBL619040,,H
,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,10623,Rattus norvegicus,Expert,2435.0,10116.0,3341,,,,,Striatum,B,1,BAO_0000019,809,9,CHEMBL619041,,D
,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,10623,,Autocuration,2435.0,,3342,,,,,Striatum,B,1,BAO_0000019,1578,8,CHEMBL619042,,H
,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,10623,,Expert,2435.0,,3343,,,,,Striatum,B,1,BAO_0000249,16709,8,CHEMBL619043,,H
,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,10623,,Expert,2435.0,,3344,,,,,Striatum,B,1,BAO_0000019,1946,8,CHEMBL619044,,H
,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,10623,,Expert,2435.0,,3345,,,,,Striatum,B,1,BAO_0000249,15253,8,CHEMBL619045,,H
,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,10623,,Expert,2435.0,,3346,,,,,Striatum,B,1,BAO_0000249,4535,8,CHEMBL619046,,H
,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,10623,,Expert,,,3347,,,,,,B,1,BAO_0000249,13961,8,CHEMBL619047,,H
,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,10623,,Autocuration,955.0,,3348,,,,,Brain,F,1,BAO_0000221,17358,8,CHEMBL619048,,H
,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,10623,,Autocuration,,,3349,,,,,,F,1,BAO_0000019,15847,8,CHEMBL859398,,H
,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,10623,,Autocuration,,,3350,,,,,,F,1,BAO_0000019,15847,8,CHEMBL619049,,H
,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,10623,,Autocuration,,,3351,,,,,,F,1,BAO_0000019,670,8,CHEMBL857886,,H
,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,10623,,Autocuration,,,3352,,,,,,F,1,BAO_0000019,670,8,CHEMBL619050,,H
,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,10623,,Autocuration,,,3353,,,,,,F,1,BAO_0000019,1317,8,CHEMBL620591,,H
,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,10623,Rattus norvegicus,Expert,,10116.0,3354,,,,,,B,1,BAO_0000357,12936,9,CHEMBL620592,,D
,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,10623,,Expert,2435.0,,3355,,,,,Striatum,B,1,BAO_0000249,4535,8,CHEMBL620593,,H
,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,10623,Rattus norvegicus,Expert,,10116.0,3356,,,,,,F,1,BAO_0000019,14424,9,CHEMBL620594,,D
,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,10623,,Expert,,,3357,,,,,,F,1,BAO_0000019,14424,8,CHEMBL875079,,H
,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,10623,,Expert,,,3358,,,,,,F,1,BAO_0000019,14424,8,CHEMBL620595,,H
,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,10623,Rattus norvegicus,Expert,,10116.0,3359,,,,,,F,1,BAO_0000019,14424,9,CHEMBL620596,,D
,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,10623,,Autocuration,,,3360,,,,,,F,1,BAO_0000019,14424,8,CHEMBL620597,,H
,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,10623,,Expert,,,3361,,,,,,F,1,BAO_0000019,14424,8,CHEMBL620598,,H
,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,10623,,Expert,,,3362,,,,,,F,1,BAO_0000218,14424,8,CHEMBL620599,,H
,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,10623,,Autocuration,,,3363,,,,,,F,1,BAO_0000019,14424,8,CHEMBL620600,,H
,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,168,Rattus norvegicus,Autocuration,,10116.0,3364,,,,,,F,1,BAO_0000019,1980,8,CHEMBL620601,,H
,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,168,,Autocuration,,,3365,,,,,,F,1,BAO_0000019,4639,8,CHEMBL620602,,H
,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,168,,Autocuration,,,3366,,,,,,B,1,BAO_0000357,17358,8,CHEMBL620603,,H
,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,168,,Autocuration,,,3367,,,,,,B,1,BAO_0000357,17358,8,CHEMBL620604,,H
,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,168,,Autocuration,,,3368,,,,,,B,1,BAO_0000357,17358,8,CHEMBL620605,,H
,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,168,,Autocuration,,,3369,,,,,,B,1,BAO_0000357,1558,8,CHEMBL620606,,H
,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,168,,Autocuration,,,3370,,,,,,F,1,BAO_0000019,17358,8,CHEMBL620607,,H
,,In vitro binding affinity towards 5-HT4 receptor was determined,,168,,Autocuration,,,3371,,,,,,B,1,BAO_0000357,16117,8,CHEMBL620608,,H
,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,168,,Autocuration,,,3372,,,,,,F,1,BAO_0000019,17358,8,CHEMBL620609,,H
,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,168,,Autocuration,,,3373,,,,,,F,1,BAO_0000019,17358,8,CHEMBL620610,,H
,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,168,,Autocuration,,,3374,,,,,,B,1,BAO_0000357,17358,8,CHEMBL620611,,H
,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,168,,Autocuration,,,3375,,,,,,B,1,BAO_0000357,17358,8,CHEMBL620612,,H
,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,168,,Autocuration,,,3376,,,,,,B,1,BAO_0000357,17358,8,CHEMBL620613,,H
,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,168,,Autocuration,,,3377,,,,,,B,1,BAO_0000357,17358,8,CHEMBL620614,,H
,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,168,,Expert,,,3378,,,,,,B,1,BAO_0000357,1274,8,CHEMBL620615,,H
,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,104698,,Autocuration,,,3379,,,,,,B,1,BAO_0000249,10728,6,CHEMBL857075,Brain membranes,H
,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,104698,,Autocuration,,,3380,,,,,,B,1,BAO_0000249,11695,6,CHEMBL620616,Brain membranes,H
,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,104698,,Autocuration,,,3381,,,,,,B,1,BAO_0000249,11695,6,CHEMBL619411,Brain membranes,H
,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,104698,,Autocuration,,,3382,,,,,,B,1,BAO_0000019,12490,6,CHEMBL619412,,H
,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3383,,,,,,B,1,BAO_0000019,11828,7,CHEMBL619413,,D
,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,104698,,Autocuration,10000000.0,,3384,,,,,Hippocampus,B,1,BAO_0000221,12253,6,CHEMBL619414,,H
,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,104698,,Autocuration,,,3385,,,,,,B,1,BAO_0000019,10561,6,CHEMBL619415,,H
,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,104698,,Autocuration,,,3386,,,,,,B,1,BAO_0000019,10561,6,CHEMBL619416,,H
,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,104698,,Autocuration,,,3387,,,,,,F,1,BAO_0000019,14432,6,CHEMBL619417,,H
,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3388,,,,,,B,1,BAO_0000223,12936,7,CHEMBL619418,,D
,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3389,,,,,,B,1,BAO_0000223,1274,7,CHEMBL619419,,D
,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,104698,,Autocuration,,,3390,,,,,,B,1,BAO_0000019,1980,6,CHEMBL619420,,H
,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,104698,,Autocuration,,,3391,,,,,,B,1,BAO_0000249,670,6,CHEMBL619421,,H
,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,104698,Rattus norvegicus,Autocuration,,10116.0,3392,,,,,,B,1,BAO_0000019,968,7,CHEMBL619422,,D
,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,104698,,Autocuration,,,3393,,,,,,B,1,BAO_0000019,14287,6,CHEMBL619423,,H
,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,104698,,Autocuration,,,3394,,,,,,B,1,BAO_0000019,567,6,CHEMBL875080,,H
,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,104698,,Autocuration,,,3395,,,,,,B,1,BAO_0000019,13267,6,CHEMBL619424,,H
,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,104698,,Autocuration,,,3396,,,,,,B,1,BAO_0000249,14826,6,CHEMBL619425,,H
,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,104698,,Autocuration,,,3397,,,,,,B,1,BAO_0000223,15194,6,CHEMBL619426,,H
,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,104698,,Autocuration,,,3398,,,,,,B,1,BAO_0000223,15194,6,CHEMBL619427,,H
,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,104698,Rattus norvegicus,Autocuration,,10116.0,3399,,,,,,B,1,BAO_0000223,10394,7,CHEMBL619645,,D
,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,10576,,Expert,,,3400,,,,,,B,1,BAO_0000249,13657,9,CHEMBL619646,,D
,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,12020,,Autocuration,955.0,,3401,,,,,Brain,F,1,BAO_0000221,1879,8,CHEMBL619647,,H
,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,12020,,Autocuration,,,3402,,,,,,F,1,BAO_0000019,1879,8,CHEMBL619648,,H
,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,12020,,Autocuration,,,3403,,,,,,F,1,BAO_0000019,1879,8,CHEMBL619165,,H
,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,12020,,Autocuration,,,3404,In vivo,,,,,F,1,BAO_0000218,204,8,CHEMBL620719,,H
,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,12020,,Autocuration,,,3405,,,,,,B,1,BAO_0000019,1879,8,CHEMBL872924,,H
,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,12020,,Autocuration,,,3406,,,,,,B,1,BAO_0000357,1879,8,CHEMBL620720,,H
,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,12020,,Autocuration,,,3407,,,,,,B,1,BAO_0000019,1879,8,CHEMBL620721,,H
,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,12020,,Autocuration,,,3408,,,,,,B,1,BAO_0000019,1879,8,CHEMBL620722,,H
,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,104698,,Autocuration,,,3409,,,,,,B,1,BAO_0000019,10641,6,CHEMBL620723,,H
,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,12020,,Autocuration,,,3410,,,,,,B,1,BAO_0000019,773,8,CHEMBL620724,,H
,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,104698,,Autocuration,,,3411,,,,,,B,1,BAO_0000249,11952,6,CHEMBL620725,,H
,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,12020,Rattus norvegicus,Autocuration,,10116.0,3412,,,,,,F,1,BAO_0000019,14145,9,CHEMBL620726,,D
,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,144,,Expert,,,3413,,,,,,B,1,BAO_0000357,17066,8,CHEMBL620727,,H
,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,104714,,Autocuration,,,3414,,,,,,B,1,BAO_0000223,6398,4,CHEMBL620728,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,22226,,Autocuration,,,3415,,,,,,B,1,BAO_0000019,10321,0,CHEMBL620729,,U
,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,104714,,Autocuration,,,3416,,,,,,F,1,BAO_0000019,511,4,CHEMBL858288,,H
,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,104714,,Autocuration,,,3417,,,,,,B,1,BAO_0000223,4639,4,CHEMBL620730,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104714,,Autocuration,,,3418,,,,,,B,1,BAO_0000223,4639,4,CHEMBL620731,,H
,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3419,,,,,,F,1,BAO_0000019,4639,4,CHEMBL620732,,H
,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3420,,,,,,F,1,BAO_0000019,4639,4,CHEMBL618042,,H
,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3421,,,,,,F,1,BAO_0000019,4639,4,CHEMBL618043,,H
,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,104714,,Autocuration,,,3422,,,,,,B,1,BAO_0000223,1558,4,CHEMBL618044,,H
,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,104714,,Autocuration,,,3423,,,,,,F,1,BAO_0000019,268,4,CHEMBL618045,,H
,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,104714,,Autocuration,,,3424,,,,,,B,1,BAO_0000223,2474,4,CHEMBL618046,,H
,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,104714,,Autocuration,,,3425,,,,,,F,1,BAO_0000019,5067,4,CHEMBL618047,,H
,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,104714,,Autocuration,,,3426,,,,,,F,1,BAO_0000019,5067,4,CHEMBL875084,,H
,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,104714,,Autocuration,,,3427,,,,,,F,1,BAO_0000019,5067,4,CHEMBL618048,,H
,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,104714,,Autocuration,,,3428,,,,,,B,1,BAO_0000223,5067,4,CHEMBL618049,,H
,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,104714,,Autocuration,,,3429,,,,,,F,1,BAO_0000019,5067,4,CHEMBL619764,,H
,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,104714,,Autocuration,,,3430,,,,,,F,1,BAO_0000019,5067,4,CHEMBL619765,,H
,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,104714,,Autocuration,,,3431,,,,,,F,1,BAO_0000019,5067,4,CHEMBL619766,,H
,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,104714,,Autocuration,,,3432,,,,,,B,1,BAO_0000223,5067,4,CHEMBL619767,,H
,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,104714,,Autocuration,,,3433,,,,,,B,1,BAO_0000223,5067,4,CHEMBL619768,,H
,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,104714,,Autocuration,,,3434,,,,,,F,1,BAO_0000019,5067,4,CHEMBL619769,,H
,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,104714,,Autocuration,,,3435,,,,,,B,1,BAO_0000223,5067,4,CHEMBL619770,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104714,,Autocuration,,,3436,,,,,,B,1,BAO_0000223,5067,4,CHEMBL619771,,H
,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,104714,,Autocuration,,,3437,,,,,,B,1,BAO_0000219,14331,4,CHEMBL619772,,H
,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,104714,,Autocuration,,,3438,,,,,,B,1,BAO_0000223,5067,4,CHEMBL619773,,H
,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,433.0,104714,,Autocuration,,,3439,,NG108-15,,,,B,1,BAO_0000219,6179,4,CHEMBL619774,,H
,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,104714,,Autocuration,,,3440,,,,,,B,1,BAO_0000019,4265,4,CHEMBL875083,,H
,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,433.0,104714,,Autocuration,,,3441,,NG108-15,,,,B,1,BAO_0000219,4265,4,CHEMBL620718,,H
,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,104714,,Autocuration,,,3442,,,,,,B,1,BAO_0000223,17358,4,CHEMBL618127,,H
,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,104714,,Autocuration,,,3443,,,,,,B,1,BAO_0000223,17358,4,CHEMBL618128,,H
,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,104714,,Autocuration,,,3444,In vitro,,,,,B,1,BAO_0000219,13628,4,CHEMBL618129,,H
,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,104714,,Autocuration,,,3445,,,,,,B,1,BAO_0000223,4612,4,CHEMBL618130,,H
,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,104714,,Autocuration,,,3446,,,,,,F,1,BAO_0000019,17358,4,CHEMBL618131,,H
,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3447,,,,,,F,1,BAO_0000019,4639,4,CHEMBL618132,,H
,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3448,,,,,,F,1,BAO_0000019,4639,4,CHEMBL618133,,H
,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,104714,Cavia porcellus,Autocuration,,10141.0,3449,,,,,,F,1,BAO_0000019,4639,4,CHEMBL618134,,H
,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3450,,,,,,F,1,BAO_0000019,4639,4,CHEMBL618135,,H
,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,104714,,Autocuration,,,3451,,,,,,B,1,BAO_0000223,511,4,CHEMBL618136,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104714,,Autocuration,,,3452,,,,,,B,1,BAO_0000223,1479,4,CHEMBL618137,,H
,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,104714,,Autocuration,,,3453,,,,,,B,1,BAO_0000223,1317,4,CHEMBL618138,,H
,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,104714,,Autocuration,,,3454,,,,,,B,1,BAO_0000223,12146,4,CHEMBL618139,,H
,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,104714,,Autocuration,,,3455,,,,,,B,1,BAO_0000223,12146,4,CHEMBL618140,,H
,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,104714,,Autocuration,,,3456,,,,,,B,1,BAO_0000223,13969,4,CHEMBL618141,,H
,,Binding affinity for 5-hydroxytryptamine 2C receptor,,108,,Expert,,,3457,,,,,,B,1,BAO_0000357,13392,8,CHEMBL873478,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104698,,Autocuration,,,3458,,,,,,B,1,BAO_0000223,13392,6,CHEMBL618142,,H
,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,144,,Autocuration,,,3459,,,,,,B,1,BAO_0000357,14159,8,CHEMBL618143,,H
,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,144,,Autocuration,,,3460,,,,,,B,1,BAO_0000357,1558,8,CHEMBL618144,,H
,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,144,,Autocuration,,,3461,,,,,,B,1,BAO_0000357,16655,8,CHEMBL618145,,H
,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,104714,,Autocuration,,,3462,,,,,,B,1,BAO_0000223,13020,4,CHEMBL618146,,H
,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,104714,,Autocuration,,,3463,,,,,,B,1,BAO_0000223,13021,4,CHEMBL618147,,H
,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,104714,,Autocuration,,,3464,,,,,,B,1,BAO_0000223,13020,4,CHEMBL618148,,H
,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,144,,Autocuration,,,3465,,,,,,B,1,BAO_0000019,10321,8,CHEMBL618149,,H
,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,144,,Autocuration,,,3466,,,,,,B,1,BAO_0000357,15818,8,CHEMBL872927,,H
,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,144,,Autocuration,,,3467,,,,,,B,1,BAO_0000357,15818,8,CHEMBL618150,,H
,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,144,,Autocuration,,,3468,,,,,,B,1,BAO_0000357,17358,8,CHEMBL618151,,H
,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,144,,Autocuration,,,3469,,,,,,B,1,BAO_0000357,2222,8,CHEMBL875094,,H
,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,144,,Autocuration,,,3470,,,,,,B,1,BAO_0000019,10322,8,CHEMBL618152,,H
,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,144,,Autocuration,,,3471,,,,,,B,1,BAO_0000357,16117,8,CHEMBL618153,,H
,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,144,,Autocuration,,,3472,,,,,,B,1,BAO_0000357,17200,8,CHEMBL618888,,H
,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,144,,Autocuration,,,3473,,,,,,F,1,BAO_0000019,17358,8,CHEMBL618889,,H
,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,144,,Autocuration,,,3474,,,,,,B,1,BAO_0000357,16700,8,CHEMBL618890,,H
,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,144,,Autocuration,,,3475,,,,,,B,1,BAO_0000019,1980,8,CHEMBL618891,,H
,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,144,,Autocuration,,,3476,,,,,,B,1,BAO_0000019,1980,8,CHEMBL619054,,H
,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,104714,,Autocuration,,,3477,,,,,,B,1,BAO_0000223,12409,4,CHEMBL619055,,H
,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,144,,Autocuration,,,3478,,,,,,B,1,BAO_0000357,4365,8,CHEMBL619056,,H
,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,144,,Autocuration,,,3479,,,,,,F,1,BAO_0000019,4365,8,CHEMBL619057,,H
,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,144,,Autocuration,,,3480,,,,,,B,1,BAO_0000357,4365,8,CHEMBL619058,,H
,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,12020,Rattus norvegicus,Expert,,10116.0,3481,,Oocytes,,,,F,1,BAO_0000219,6769,9,CHEMBL619059,,D
,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,12020,Rattus norvegicus,Expert,,10116.0,3482,,Oocytes,,,,F,1,BAO_0000219,6769,9,CHEMBL619060,,D
,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,12020,Rattus norvegicus,Expert,,10116.0,3483,,Oocytes,,,,F,1,BAO_0000219,6769,9,CHEMBL875095,,D
,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3484,,,,,Ileum,F,1,BAO_0000221,809,9,CHEMBL619061,,D
,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3485,,,,,Ileum,F,1,BAO_0000221,809,9,CHEMBL619062,,D
,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,20033,Cavia porcellus,Intermediate,,10141.0,3486,,,,,,F,1,BAO_0000019,14290,9,CHEMBL619063,,D
,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3487,,,,,Ileum,B,1,BAO_0000221,17358,9,CHEMBL619064,,D
,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,20033,Cavia porcellus,Intermediate,,10141.0,3488,,,,,,B,1,BAO_0000357,17358,9,CHEMBL619065,,D
,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,20033,Cavia porcellus,Intermediate,2116.0,10141.0,3489,,,,,Ileum,B,1,BAO_0000221,17358,9,CHEMBL619066,,D
,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,10209,,Autocuration,2116.0,,3490,,,,,Ileum,B,1,BAO_0000221,17386,8,CHEMBL619775,,H
,,Affinity against 5-hydroxytryptamine 7 receptor,,10209,,Autocuration,,,3491,,,,,,B,1,BAO_0000357,3269,8,CHEMBL619776,,H
,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,104841,Cavia porcellus,Autocuration,,10141.0,3492,,,,,,B,1,BAO_0000224,7721,4,CHEMBL619777,,H
,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,104841,Cavia porcellus,Autocuration,,10141.0,3493,,,,,,B,1,BAO_0000224,7721,4,CHEMBL619778,,H
,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,104841,Cavia porcellus,Autocuration,2116.0,10141.0,3494,,,,,Ileum,B,1,BAO_0000221,9117,4,CHEMBL619779,,H
,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,104841,Cavia porcellus,Autocuration,,10141.0,3495,,,,,,B,1,BAO_0000224,7721,4,CHEMBL619780,,H
,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,104841,Cavia porcellus,Autocuration,,10141.0,3496,,,,,,B,1,BAO_0000224,7721,4,CHEMBL619166,,H
,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,104841,Cavia porcellus,Autocuration,,10141.0,3497,,,,,,F,1,BAO_0000019,15796,4,CHEMBL619167,,H
,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,104841,Cavia porcellus,Autocuration,,10141.0,3498,,,,,,F,1,BAO_0000019,15796,4,CHEMBL619168,,H
,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,168,Homo sapiens,Expert,2081.0,9606.0,3499,,,,,Cardiac atrium,B,1,BAO_0000219,15650,9,CHEMBL619169,,D
,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,168,Homo sapiens,Expert,2081.0,9606.0,3500,,,,,Cardiac atrium,B,1,BAO_0000219,15650,9,CHEMBL619170,,D
,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,104841,Homo sapiens,Autocuration,,9606.0,3501,,,,,,F,1,BAO_0000019,6866,5,CHEMBL619171,,D
,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,168,Homo sapiens,Expert,2081.0,9606.0,3502,,,,,Cardiac atrium,F,1,BAO_0000219,15650,9,CHEMBL619172,,D
,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,22226,Mus musculus,Autocuration,,10090.0,3503,,,,,,B,1,BAO_0000019,10063,0,CHEMBL619173,,U
,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,22226,Mus musculus,Autocuration,,10090.0,3504,,,,,,B,1,BAO_0000019,12665,0,CHEMBL619174,,U
,,5-hydroxytryptamine receptor binding affinity was determined in rats,,104705,,Autocuration,,,3505,,,,,,B,1,BAO_0000019,7504,4,CHEMBL619175,,H
,,Binding affinity at rat 5-hydroxytryptamine receptor.,,104705,,Autocuration,,,3506,,,,,,B,1,BAO_0000224,7504,4,CHEMBL619176,,H
,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,104705,,Autocuration,,,3507,,,,,,B,1,BAO_0000019,7038,4,CHEMBL619177,,H
,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,104705,,Autocuration,,,3508,,,,,,B,1,BAO_0000224,7626,4,CHEMBL619178,,H
,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,104705,,Autocuration,,,3509,,,,,,B,1,BAO_0000224,7626,4,CHEMBL619179,,H
,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,104705,,Autocuration,945.0,,3510,,,,,Stomach,F,1,BAO_0000019,7185,4,CHEMBL619180,,H
,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,104705,,Autocuration,945.0,,3511,,,,,Stomach,F,1,BAO_0000019,7185,4,CHEMBL619181,,H
,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,104705,,Autocuration,,,3512,,,,,,F,1,BAO_0000019,7185,4,CHEMBL619182,,H
,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,104705,,Autocuration,,,3513,,,,,,B,1,BAO_0000224,6960,4,CHEMBL619183,,H
,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,104705,,Autocuration,,,3514,,,,,,B,1,BAO_0000224,6960,4,CHEMBL619184,,H
,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,10576,,Autocuration,10000000.0,,3515,,,,,Hippocampus,B,1,BAO_0000221,12416,8,CHEMBL619185,,H
,,Binding affinity for rat 5-hydroxytryptamine transporter.,,12198,,Expert,,,3516,,,,,,B,1,BAO_0000357,15753,8,CHEMBL619186,,H
,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,104705,,Autocuration,,,3517,,,,,,B,1,BAO_0000019,8062,4,CHEMBL619187,,H
,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,104705,Rattus norvegicus,Autocuration,,10116.0,3518,,,,,,B,1,BAO_0000019,9036,5,CHEMBL619188,,D
,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,104705,Rattus norvegicus,Autocuration,,10116.0,3519,,,,,,B,1,BAO_0000224,15067,5,CHEMBL619189,,D
,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,12198,Rattus norvegicus,Expert,955.0,10116.0,3520,,,,,Brain,F,1,BAO_0000019,15753,9,CHEMBL619190,,D
,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,12198,Rattus norvegicus,Expert,2037.0,10116.0,3521,,,,,Cerebellum,F,1,BAO_0000221,15753,9,CHEMBL619191,,D
,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,104705,Rattus norvegicus,Autocuration,,10116.0,3522,,,,,,B,1,BAO_0000019,15295,5,CHEMBL619192,,D
,,Percent binding affinity against 5-hydroxytryptamine receptor,,104705,Rattus norvegicus,Autocuration,,10116.0,3523,,,,,,B,1,BAO_0000224,6347,5,CHEMBL619193,,D
,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,22226,,Autocuration,,,3524,,,,,,B,1,BAO_0000019,6763,0,CHEMBL619194,,U
,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,104705,Rattus norvegicus,Autocuration,,10116.0,3525,,,,,,B,1,BAO_0000224,12092,5,CHEMBL619195,,D
,,Affinity against 5-hydroxytryptamine receptor was determined,,104705,Rattus norvegicus,Autocuration,,10116.0,3526,,,,,,B,1,BAO_0000224,1579,5,CHEMBL619196,,D
,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,104705,Rattus norvegicus,Autocuration,945.0,10116.0,3527,,,,,Stomach,B,1,BAO_0000019,1579,5,CHEMBL619197,,D
,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,121,Homo sapiens,Expert,,9606.0,3528,In vitro,,,,,B,1,BAO_0000219,5963,9,CHEMBL619198,,D
,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,121,Homo sapiens,Expert,,9606.0,3529,In vitro,,,,,B,1,BAO_0000219,5963,9,CHEMBL875081,,D
,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,18065,,Autocuration,,,3530,,,,,,B,1,BAO_0000357,5030,8,CHEMBL884712,,H
,,Inhibition of 5-hydroxytryptamine reuptake,,121,,Expert,,,3531,,,,,,B,1,BAO_0000357,15796,8,CHEMBL884710,,H
,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,18065,,Autocuration,,,3532,,,,,,F,1,BAO_0000019,15413,8,CHEMBL619199,,H
,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,18065,,Autocuration,,,3533,,,,,,F,1,BAO_0000019,15413,8,CHEMBL619200,,H
,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,18065,,Autocuration,,,3534,,,,,,F,1,BAO_0000019,15413,8,CHEMBL619201,,H
,,Tested for 5-hydroxytryptamine receptor uptake,,18065,,Autocuration,,,3535,,,,,,F,1,BAO_0000019,12409,8,CHEMBL619202,,H
,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,449.0,51,Homo sapiens,Expert,,9606.0,3536,,CHO,,,,B,1,BAO_0000219,16909,9,CHEMBL619203,,D
,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,51,Homo sapiens,Expert,,9606.0,3537,,,,,,F,1,BAO_0000019,16909,9,CHEMBL619204,,D
,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,10576,Homo sapiens,Autocuration,,9606.0,3538,,,,,,B,1,BAO_0000249,15629,8,CHEMBL619205,,H
,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,10576,,Autocuration,,,3539,,,,,,B,1,BAO_0000357,15629,8,CHEMBL619206,,H
,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,10576,,Expert,,,3540,,,,,,B,1,BAO_0000249,15629,8,CHEMBL619207,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,10825,,Autocuration,2435.0,,3541,,,,,Striatum,F,1,BAO_0000019,10034,8,CHEMBL619208,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,10825,,Autocuration,2435.0,,3542,,,,,Striatum,F,1,BAO_0000019,10034,8,CHEMBL619209,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,10825,,Autocuration,2435.0,,3543,,,,,Striatum,F,1,BAO_0000019,10034,8,CHEMBL619210,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,10825,,Autocuration,2435.0,,3544,,,,,Striatum,F,1,BAO_0000019,10034,8,CHEMBL619211,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,10825,,Autocuration,2435.0,,3545,,,,,Striatum,F,1,BAO_0000019,10034,8,CHEMBL619212,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,10825,,Autocuration,2435.0,,3546,,,,,Striatum,F,1,BAO_0000019,10034,8,CHEMBL620681,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,10825,,Autocuration,2435.0,,3547,,,,,Striatum,F,1,BAO_0000019,10034,8,CHEMBL620682,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,10825,,Autocuration,2435.0,,3548,,,,,Striatum,F,1,BAO_0000019,10034,8,CHEMBL620683,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,10825,,Autocuration,2435.0,,3549,,,,,Striatum,F,1,BAO_0000019,10034,8,CHEMBL620684,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,10825,,Autocuration,2435.0,,3550,,,,,Striatum,F,1,BAO_0000019,10034,8,CHEMBL620685,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,10825,,Autocuration,2435.0,,3551,,,,,Striatum,F,1,BAO_0000019,10034,8,CHEMBL620686,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,10825,,Autocuration,349.0,,3552,,,,,Limbic system,F,1,BAO_0000019,10034,8,CHEMBL620687,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,10825,,Autocuration,349.0,,3553,,,,,Limbic system,F,1,BAO_0000019,10034,8,CHEMBL620688,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,10825,,Autocuration,349.0,,3554,,,,,Limbic system,F,1,BAO_0000019,10034,8,CHEMBL620689,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,10825,,Autocuration,349.0,,3555,,,,,Limbic system,F,1,BAO_0000019,10034,8,CHEMBL620690,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,10825,,Autocuration,349.0,,3556,,,,,Limbic system,F,1,BAO_0000019,10034,8,CHEMBL620691,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,10825,,Autocuration,349.0,,3557,,,,,Limbic system,F,1,BAO_0000019,10034,8,CHEMBL620692,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,10825,,Autocuration,349.0,,3558,,,,,Limbic system,F,1,BAO_0000019,10034,8,CHEMBL620693,,H
,,Binding affinity against 5-hydroxytryptamine 4 receptor,,168,,Expert,,,3559,,,,,,B,1,BAO_0000357,1274,8,CHEMBL620694,,H
,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,168,,Autocuration,,,3560,,,,,,F,1,BAO_0000019,17358,8,CHEMBL857986,,H
,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,168,,Autocuration,,,3561,,,,,,B,1,BAO_0000357,14532,8,CHEMBL620695,,H
,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,168,,Expert,,,3562,,,,,,B,1,BAO_0000357,16989,8,CHEMBL620696,,H
,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,168,,Autocuration,,,3563,,,,,,B,1,BAO_0000357,17200,8,CHEMBL620697,,H
,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,168,,Autocuration,,,3564,,,,,,B,1,BAO_0000357,15779,8,CHEMBL620698,,H
,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,168,,Autocuration,,,3565,,,,,,B,1,BAO_0000357,15779,8,CHEMBL620699,,H
,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,168,,Autocuration,,,3566,,,,,,B,1,BAO_0000357,15779,8,CHEMBL620700,,H
,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,643.0,168,,Autocuration,,,3567,,COS-7,,,,B,1,BAO_0000219,15650,8,CHEMBL620701,,H
,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,643.0,168,,Autocuration,,,3568,,COS-7,,,,B,1,BAO_0000219,15650,8,CHEMBL875082,,H
,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,643.0,168,,Autocuration,,,3569,,COS-7,,,,B,1,BAO_0000219,15650,8,CHEMBL620702,,H
,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,643.0,168,,Autocuration,,,3570,,COS-7,,,,B,1,BAO_0000219,15650,8,CHEMBL620703,,H
,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,673.0,168,,Autocuration,,,3571,,C6,,,,B,1,BAO_0000219,17046,8,CHEMBL620704,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,673.0,168,,Expert,,,3572,,C6,,,,B,1,BAO_0000219,17046,8,CHEMBL620705,,H
,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,673.0,168,,Expert,,,3573,,C6,,,,B,1,BAO_0000219,15650,8,CHEMBL620706,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,673.0,168,,Expert,,,3574,,C6,,,,B,1,BAO_0000219,17046,8,CHEMBL620707,,H
,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,10624,,Expert,,,3575,,,,,,B,1,BAO_0000357,17066,8,CHEMBL620708,,H
,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,105,,Autocuration,,,3576,,,,,,B,1,BAO_0000357,17200,8,CHEMBL620709,,H
,,Binding affinity against 5-hydroxytryptamine 5A receptor,,10624,Homo sapiens,Expert,,9606.0,3577,,,,,,B,1,BAO_0000357,16146,9,CHEMBL620710,,D
,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,449.0,10624,,Autocuration,,,3578,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL620711,,H
,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,10624,Homo sapiens,Expert,,9606.0,3579,,,,,,B,1,BAO_0000357,6491,9,CHEMBL620712,,D
,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,10624,Homo sapiens,Expert,,9606.0,3580,,,,,,B,1,BAO_0000357,17066,9,CHEMBL620713,,D
,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,10624,Homo sapiens,Expert,,9606.0,3581,,,,,,B,1,BAO_0000357,17066,9,CHEMBL620714,,D
,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,10624,Homo sapiens,Expert,,9606.0,3582,,,,,,B,1,BAO_0000357,4234,9,CHEMBL620715,,D
,,Binding affinity towards 5-HT5A receptor,,10624,,Autocuration,,,3583,,,,,,B,1,BAO_0000357,6013,8,CHEMBL620716,,H
,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,10624,,Expert,,,3584,,,,,,B,1,BAO_0000357,17175,8,CHEMBL620717,,H
,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,10624,,Autocuration,,,3585,,,,,,B,1,BAO_0000357,15818,8,CHEMBL618072,,H
,,Binding affinity towards cloned human 5-HT5A receptor was determined,,10624,,Autocuration,,,3586,,,,,,B,1,BAO_0000357,6166,8,CHEMBL857987,,H
,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,10624,,Autocuration,,,3587,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL618073,,H
,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,722.0,10624,,Autocuration,,,3588,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL618074,,H
,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),722.0,10624,,Autocuration,,,3589,,HEK293,,,,B,1,BAO_0000219,5213,8,CHEMBL618075,,H
,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,10625,Mus musculus,Expert,,10090.0,3590,,,,,,B,1,BAO_0000357,17066,9,CHEMBL618076,,D
,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,10625,Mus musculus,Expert,,10090.0,3591,,,,,,B,1,BAO_0000357,17066,9,CHEMBL618077,,D
,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,10625,Mus musculus,Expert,,10090.0,3592,,,,,,B,1,BAO_0000357,17066,9,CHEMBL618078,,D
,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,10625,Mus musculus,Expert,,10090.0,3593,,,,,,B,1,BAO_0000357,17066,9,CHEMBL881821,,D
,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,10625,Mus musculus,Expert,,10090.0,3594,,,,,,B,1,BAO_0000357,17066,9,CHEMBL618079,,D
,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,10625,,Expert,,,3595,,,,,,B,1,BAO_0000357,17175,8,CHEMBL618080,,H
,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,722.0,10576,,Autocuration,,,3596,,HEK293,,,,B,1,BAO_0000219,16190,8,CHEMBL618081,,H
,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,722.0,10626,,Autocuration,,,3597,,HEK293,,,,B,1,BAO_0000219,16190,8,CHEMBL618082,,H
,,Binding affinity towards 5-HT5a receptor,,10624,,Expert,,,3598,,,,,,B,1,BAO_0000357,4820,8,CHEMBL618083,,H
,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,10624,Homo sapiens,Expert,,9606.0,3599,,,,,,B,1,BAO_0000357,17066,9,CHEMBL618084,,D
,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,10624,,Expert,,,3600,,,,,,B,1,BAO_0000357,17066,8,CHEMBL618085,,H
,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,10624,,Expert,,,3601,,,,,,B,1,BAO_0000357,17175,8,CHEMBL618086,,H
,,Binding affinities against 5-hydroxytryptamine 5A receptor,,10624,,Autocuration,,,3602,,,,,,B,1,BAO_0000357,16633,8,CHEMBL875092,,H
,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,10624,,Autocuration,,,3603,,,,,,B,1,BAO_0000357,16633,8,CHEMBL618087,,H
,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,10624,,Autocuration,,,3604,,,,,,B,1,BAO_0000357,16700,8,CHEMBL872926,,H
,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,104714,Cavia porcellus,Autocuration,,10141.0,3605,,,,,,F,1,BAO_0000019,4639,4,CHEMBL618088,,H
,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,104714,,Autocuration,,,3606,,,,,,B,1,BAO_0000223,5486,4,CHEMBL618089,,H
,,Inhibition of human 5-hydroxytryptamine 6 receptor,,10627,Homo sapiens,Expert,,9606.0,3607,,,,,,B,1,BAO_0000357,16146,9,CHEMBL618090,,D
,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,10627,Homo sapiens,Expert,,9606.0,3608,,,,,,B,1,BAO_0000357,17273,9,CHEMBL618091,,D
,,Inhibition against human 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3609,,,,,,B,1,BAO_0000357,17687,8,CHEMBL618092,,H
,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,10627,Homo sapiens,Expert,,9606.0,3610,,,,,,B,1,BAO_0000357,6491,9,CHEMBL618093,,D
,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,308.0,10627,,Expert,,,3611,,HeLa,,,,B,1,BAO_0000219,16190,8,CHEMBL618094,,H
,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,10627,Homo sapiens,Expert,,9606.0,3612,,,,,,B,1,BAO_0000357,17066,9,CHEMBL618095,,D
,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,Homo sapiens,Expert,,9606.0,3613,,,,,,B,1,BAO_0000357,17066,9,CHEMBL875093,,D
,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,10627,Homo sapiens,Expert,,9606.0,3614,,,,,,B,1,BAO_0000357,17066,9,CHEMBL618096,,D
,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,10627,Homo sapiens,Expert,,9606.0,3615,,,,,,B,1,BAO_0000357,17066,9,CHEMBL618118,,D
,,Binding affinity against 5-hydroxytryptamine 6 receptor,,10627,Homo sapiens,Expert,,9606.0,3616,,,,,,B,1,BAO_0000357,3555,9,CHEMBL618119,,D
,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,Expert,,,3617,,,,,,B,1,BAO_0000357,5808,8,CHEMBL618120,,H
,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3618,,,,,,B,1,BAO_0000357,6013,8,CHEMBL618121,,H
,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",722.0,10627,,Expert,,,3619,,HEK293,,,,B,1,BAO_0000219,15818,8,CHEMBL618122,,H
,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,10627,,Autocuration,,,3620,,,,,,B,1,BAO_0000357,16209,8,CHEMBL618123,,H
,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,722.0,10627,,Expert,,,3621,,HEK293,,,,B,1,BAO_0000219,3935,8,CHEMBL618124,,H
,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3622,,,,,,B,1,BAO_0000357,15818,8,CHEMBL618125,,H
,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,722.0,10627,Homo sapiens,Expert,,9606.0,3623,,HEK293,,,,B,1,BAO_0000219,3805,9,CHEMBL618126,,D
,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,10627,,Expert,,,3624,,,,,,B,1,BAO_0000019,16441,8,CHEMBL618236,,H
,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,10627,,Expert,,,3625,,,,,,B,1,BAO_0000019,16441,8,CHEMBL618237,,H
,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,643.0,10627,,Expert,,,3626,,COS-7,,,,B,1,BAO_0000219,6786,8,CHEMBL618238,,H
,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,10627,Homo sapiens,Expert,,9606.0,3627,,,,,,B,1,BAO_0000357,4234,9,CHEMBL618239,,D
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3628,,,,,,B,1,BAO_0000019,17085,8,CHEMBL618240,,H
,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,10627,,Autocuration,,,3629,,,,,,B,1,BAO_0000357,17200,8,CHEMBL618241,,H
,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,722.0,10627,,Autocuration,,,3630,,HEK293,,,,B,1,BAO_0000219,17451,8,CHEMBL859399,,H
,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,10627,,Autocuration,,,3631,,,,,,F,1,BAO_0000019,3935,8,CHEMBL618242,,H
,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3632,,,,,,B,1,BAO_0000357,5033,8,CHEMBL857991,,H
,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,10627,,Expert,,,3633,,,,,,B,1,BAO_0000357,4540,8,CHEMBL619951,,H
,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,308.0,10627,Homo sapiens,Expert,,9606.0,3634,,HeLa,,,,B,1,BAO_0000219,4540,9,CHEMBL619952,,D
,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,308.0,10627,Homo sapiens,Expert,,9606.0,3635,,HeLa,,,,B,1,BAO_0000219,4540,9,CHEMBL619953,,D
,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,308.0,10627,,Autocuration,,,3636,,HeLa,,,,B,1,BAO_0000219,17296,8,CHEMBL619954,,H
,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,308.0,10627,,Autocuration,,,3637,,HeLa,,,,B,1,BAO_0000219,17296,8,CHEMBL619955,,H
,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,308.0,10627,,Autocuration,,,3638,,HeLa,,,,B,1,BAO_0000219,17296,8,CHEMBL619956,,H
,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,449.0,10627,,Autocuration,,,3639,,CHO,,,,B,1,BAO_0000219,15779,8,CHEMBL619957,,H
,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,10627,,Autocuration,,,3640,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL619958,,H
,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,722.0,10627,,Autocuration,,,3641,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL620627,,H
,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,722.0,10627,,Autocuration,,,3642,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL620628,,H
,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,308.0,10627,,Autocuration,,,3643,,HeLa,,,,B,1,BAO_0000219,15779,8,CHEMBL620629,,H
,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3644,,,,,,B,1,BAO_0000357,6166,8,CHEMBL620630,,H
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,308.0,10627,,Autocuration,,,3645,,HeLa,,,,B,1,BAO_0000219,17451,8,CHEMBL620782,,H
,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3646,,,,,,B,1,BAO_0000357,15316,8,CHEMBL620783,,H
,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,10627,,Expert,,,3647,,,,,,B,1,BAO_0000357,4199,8,CHEMBL620784,,H
,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,308.0,10627,,Expert,,,3648,,HeLa,,,,B,1,BAO_0000219,15146,8,CHEMBL620785,,H
,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,10627,,Autocuration,,,3649,,,,,,B,1,BAO_0000357,5213,8,CHEMBL857992,,H
,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,10627,,Autocuration,,,3650,,,,,,B,1,BAO_0000219,16429,8,CHEMBL620786,,H
,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,308.0,10627,,Autocuration,,,3651,,HeLa,,,,B,1,BAO_0000219,14818,8,CHEMBL620787,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",308.0,10627,,Autocuration,,,3652,,HeLa,,,,B,1,BAO_0000219,4829,8,CHEMBL620788,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",308.0,10627,,Autocuration,,,3653,,HeLa,,,,B,1,BAO_0000219,4829,8,CHEMBL620789,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",308.0,10627,,Autocuration,,,3654,,HeLa,,,,B,1,BAO_0000219,4829,8,CHEMBL620790,,H
,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,449.0,10628,,Autocuration,,,3655,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL620791,,H
,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,10628,,Autocuration,,,3656,,,,,,B,1,BAO_0000019,14423,8,CHEMBL620792,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,10628,,Autocuration,,,3657,,,,,,B,1,BAO_0000357,15086,8,CHEMBL620793,,H
,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,10628,,Autocuration,,,3658,,,,,,B,1,BAO_0000357,4342,8,CHEMBL620794,,H
,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,308.0,10627,Homo sapiens,Autocuration,,9606.0,3659,,HeLa,,,,B,1,BAO_0000219,16190,9,CHEMBL620795,,D
,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,Expert,,,3660,,,,,,B,1,BAO_0000357,4820,8,CHEMBL620796,,H
,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,10627,,Autocuration,,,3661,,,,,,B,1,BAO_0000357,4639,8,CHEMBL620797,,H
,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,10627,Homo sapiens,Expert,,9606.0,3662,,,,,,F,1,BAO_0000019,17066,9,CHEMBL620798,,D
,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,10627,,Autocuration,,,3663,,,,,,B,1,BAO_0000357,6011,8,CHEMBL620799,,H
,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,Expert,,,3664,,,,,,B,1,BAO_0000357,17066,8,CHEMBL620800,,H
,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,10627,,Autocuration,,,3665,,,,,,B,1,BAO_0000357,17515,8,CHEMBL620801,,H
,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3666,,,,,,B,1,BAO_0000357,5014,8,CHEMBL875100,,H
,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,10627,,Autocuration,,,3667,,,,,,B,1,BAO_0000357,4373,8,CHEMBL620802,,H
,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,10627,,Expert,,,3668,,,,,,F,1,BAO_0000019,17066,8,CHEMBL620803,,H
,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,10627,,Expert,,,3669,,,,,,F,1,BAO_0000019,17066,8,CHEMBL620804,,H
,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,10627,,Autocuration,,,3670,,,,,,B,1,BAO_0000357,4373,8,CHEMBL620805,,H
,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3671,,,,,,B,1,BAO_0000357,4687,8,CHEMBL620806,,H
,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,10627,,Autocuration,,,3672,,,,,,B,1,BAO_0000357,16946,8,CHEMBL620807,,H
,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,10627,,Autocuration,,,3673,,,,,,B,1,BAO_0000357,16946,8,CHEMBL620808,,H
,,Binding affinities against 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3674,,,,,,B,1,BAO_0000357,16633,8,CHEMBL620809,,H
,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3675,,,,,,B,1,BAO_0000357,16633,8,CHEMBL620810,,H
,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,10627,Homo sapiens,Expert,,9606.0,3676,,,,,,B,1,BAO_0000357,17066,9,CHEMBL620811,,D
,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,10627,,Autocuration,,,3677,,,,,,B,1,BAO_0000357,16700,8,CHEMBL620812,,H
,,Affinity against 5-hydroxytryptamine 6 receptor,,10627,,Autocuration,,,3678,,,,,,B,1,BAO_0000357,3269,8,CHEMBL620813,,H
,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,10627,,Autocuration,,,3679,,,,,,B,1,BAO_0000357,5486,8,CHEMBL620814,,H
,,Inhibition of human 5-hydroxytryptamine 7 receptor,,10209,Homo sapiens,Expert,,9606.0,3680,,,,,,B,1,BAO_0000357,16146,9,CHEMBL620815,,D
,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,722.0,10209,,Autocuration,,,3681,,HEK293,,,,B,1,BAO_0000219,5014,8,CHEMBL620816,,H
,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,10209,,Autocuration,,,3682,,,,,,B,1,BAO_0000357,15463,8,CHEMBL620817,,H
,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,10209,,Autocuration,,,3683,,,,,,B,1,BAO_0000357,3805,8,CHEMBL620818,,H
,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,722.0,10209,,Expert,,,3684,,HEK293,,,,B,1,BAO_0000219,5014,8,CHEMBL620819,,H
,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,10209,Homo sapiens,Expert,,9606.0,3685,,,,,,B,1,BAO_0000357,6491,9,CHEMBL620820,,D
,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,449.0,10209,,Autocuration,,,3686,,CHO,,,,B,1,BAO_0000219,16190,8,CHEMBL620821,,H
,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,10209,Homo sapiens,Expert,,9606.0,3687,,,,,,B,1,BAO_0000357,17066,9,CHEMBL620822,,D
,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,10209,Homo sapiens,Expert,,9606.0,3688,,,,,,B,1,BAO_0000357,17066,9,CHEMBL620823,,D
,,Binding affinity against 5-hydroxytryptamine 7 receptor,,10209,Homo sapiens,Expert,,9606.0,3689,,,,,,B,1,BAO_0000357,3555,9,CHEMBL620824,,D
,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,449.0,10209,,Expert,,,3690,,CHO,,,,B,1,BAO_0000219,6588,8,CHEMBL620825,,H
,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,10209,,Autocuration,,,3691,,,,,,B,1,BAO_0000357,15463,8,CHEMBL872930,,H
,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,10209,,Autocuration,,,3692,,,,,,B,1,BAO_0000357,6013,8,CHEMBL620826,,H
,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,10209,,Autocuration,,,3693,,,,,,B,1,BAO_0000357,16209,8,CHEMBL620827,,H
,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,10209,,Autocuration,,,3694,,,,,,B,1,BAO_0000357,3935,8,CHEMBL620828,,H
,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,10209,,Autocuration,,,3695,,,,,,B,1,BAO_0000357,15818,8,CHEMBL620829,,H
,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,722.0,10209,,Expert,,,3696,,HEK293,,,,B,1,BAO_0000219,5014,8,CHEMBL620830,,H
,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,10209,,Expert,,,3697,,,,,,B,1,BAO_0000019,16441,8,CHEMBL620831,,H
,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,10209,,Expert,,,3698,,,,,,B,1,BAO_0000019,16441,8,CHEMBL620832,,H
,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,10209,Homo sapiens,Expert,,9606.0,3699,,,,,,B,1,BAO_0000357,4234,9,CHEMBL621548,,D
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,10209,,Autocuration,,,3700,,,,,,B,1,BAO_0000019,17085,8,CHEMBL621549,,H
,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,10209,,Autocuration,,,3701,,,,,,B,1,BAO_0000357,17200,8,CHEMBL621550,,H
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,449.0,10209,,Autocuration,,,3702,,CHO,,,,B,1,BAO_0000219,17451,8,CHEMBL621551,,H
,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,10209,,Autocuration,,,3703,,,,,,B,1,BAO_0000019,17085,8,CHEMBL621552,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,10209,,Autocuration,,,3704,,,,,,B,1,BAO_0000357,5104,8,CHEMBL857077,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,10209,,Autocuration,,,3705,,,,,,B,1,BAO_0000357,5104,8,CHEMBL618158,,H
,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,643.0,10209,Homo sapiens,Expert,,9606.0,3706,,COS-7,,,,B,1,BAO_0000219,5033,9,CHEMBL618159,,D
,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,643.0,10209,,Autocuration,,,3707,,COS-7,,,,B,1,BAO_0000219,5486,8,CHEMBL875101,,H
,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,722.0,10209,Homo sapiens,Expert,,9606.0,3708,,HEK293,,,,B,1,BAO_0000219,4540,9,CHEMBL618160,,D
,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,10209,,Expert,,,3709,,,,,,B,1,BAO_0000357,6166,8,CHEMBL618161,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,722.0,10209,,Expert,,,3710,,HEK293,,,,B,1,BAO_0000219,17342,8,CHEMBL618162,,H
,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,10209,,Expert,,,3711,,,,,,B,1,BAO_0000357,17342,8,CHEMBL618163,,H
,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,10209,,Autocuration,,,3712,,,,,,B,1,BAO_0000357,17296,8,CHEMBL618164,,H
,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,10209,,Expert,,,3713,,,,,,B,1,BAO_0000219,16429,8,CHEMBL618165,,H
,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,722.0,10209,,Autocuration,,,3714,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL618166,,H
,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,722.0,10209,,Autocuration,,,3715,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL857989,,H
,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,722.0,10209,,Autocuration,,,3716,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL619888,,H
,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,722.0,10209,,Autocuration,,,3717,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL619889,,H
,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,722.0,10209,,Autocuration,,,3718,,HEK293,,,,B,1,BAO_0000219,15779,8,CHEMBL619890,,H
,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,449.0,10209,,Autocuration,,,3719,,CHO,,,,B,1,BAO_0000219,17451,8,CHEMBL619891,,H
,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),722.0,10209,,Autocuration,,,3720,,HEK293,,,,B,1,BAO_0000219,4199,8,CHEMBL619892,,H
,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,722.0,10209,,Expert,,,3721,,HEK293,,,,B,1,BAO_0000219,4199,9,CHEMBL619893,,D
,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),722.0,10209,,Autocuration,,,3722,,HEK293,,,,B,1,BAO_0000219,4199,8,CHEMBL619894,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,722.0,10209,,Intermediate,,,3723,,HEK293,,,,B,1,BAO_0000219,3680,9,CHEMBL619895,,D
,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,10209,,Intermediate,,,3724,,,,,,B,1,BAO_0000357,3680,9,CHEMBL619896,,D
,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,643.0,10209,,Autocuration,,,3725,,COS-7,,,,B,1,BAO_0000219,15316,8,CHEMBL619897,,H
,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,722.0,10209,,Autocuration,,,3726,,HEK293,,,,B,1,BAO_0000219,15146,8,CHEMBL619898,,H
,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,722.0,10209,,Expert,,,3727,,HEK293,,,,B,1,BAO_0000219,5213,8,CHEMBL619899,,H
,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),722.0,10209,,Autocuration,,,3728,,HEK293,,,,B,1,BAO_0000219,5213,8,CHEMBL619900,,H
,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,722.0,10209,Homo sapiens,Expert,,9606.0,3729,,HEK293,,,,B,1,BAO_0000219,14818,9,CHEMBL619901,,D
,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,722.0,10209,,Autocuration,,,3730,,HEK293,,,,B,1,BAO_0000219,14818,8,CHEMBL620580,,H
,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,722.0,10209,,Autocuration,,,3731,,HEK293,,,,B,1,BAO_0000219,14818,8,CHEMBL620581,,H
,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",722.0,10209,,Autocuration,,,3732,,HEK293,,,,B,1,BAO_0000219,4829,8,CHEMBL620733,,H
,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,10209,Homo sapiens,Autocuration,,9606.0,3733,,,,,,B,1,BAO_0000357,17200,9,CHEMBL620734,,D
,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,10022,Mus musculus,Expert,,10090.0,3734,,,,,,B,1,BAO_0000357,17066,9,CHEMBL620735,,D
,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,10209,Oryctolagus cuniculus,Autocuration,,9986.0,3735,,,,,,B,1,BAO_0000019,14025,8,CHEMBL620736,,H
,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,449.0,11923,,Autocuration,,,3736,,CHO,,,,B,1,BAO_0000219,15250,8,CHEMBL620737,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,449.0,11923,,Autocuration,,,3737,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620738,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,449.0,11923,,Autocuration,,,3738,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620739,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,449.0,11923,,Autocuration,,,3739,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620740,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,449.0,11923,,Autocuration,,,3740,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620741,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,449.0,11923,,Autocuration,,,3741,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620742,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,449.0,11923,,Autocuration,,,3742,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620743,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,449.0,11923,,Autocuration,,,3743,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620744,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,449.0,11923,,Autocuration,,,3744,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620745,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,449.0,11923,,Autocuration,,,3745,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620746,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,449.0,11923,,Autocuration,,,3746,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620747,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,449.0,11923,,Autocuration,,,3747,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620748,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,449.0,11923,,Autocuration,,,3748,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620749,,H
,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,11923,,Expert,,,3749,,,,,,B,1,BAO_0000357,17066,8,CHEMBL620750,,H
,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,11923,Rattus norvegicus,Expert,,10116.0,3750,,,,,,B,1,BAO_0000357,17066,9,CHEMBL620751,,D
,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,11923,,Expert,,,3751,,,,,,B,1,BAO_0000357,17386,8,CHEMBL620752,,H
,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,11923,,Autocuration,,,3752,,,,,,B,1,BAO_0000019,14423,8,CHEMBL872929,,H
,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,11923,Rattus norvegicus,Expert,,10116.0,3753,,,,,,B,1,BAO_0000357,15874,9,CHEMBL620753,,D
,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,11923,Rattus norvegicus,Expert,,10116.0,3754,,,,,,B,1,BAO_0000357,15874,9,CHEMBL620754,,D
,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,449.0,11923,Rattus norvegicus,Expert,,10116.0,3755,,CHO,,,,B,1,BAO_0000219,16372,9,CHEMBL620755,,D
,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,11923,,Autocuration,,,3756,,,,,,B,1,BAO_0000357,4622,8,CHEMBL620756,,H
,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,11923,,Autocuration,,,3757,,,,,,B,1,BAO_0000357,15086,8,CHEMBL620757,,H
,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",449.0,11923,,Autocuration,,,3758,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620758,,H
,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",449.0,11923,,Autocuration,,,3759,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620759,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,449.0,11923,,Autocuration,,,3760,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620760,,H
,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,449.0,11923,,Autocuration,,,3761,,CHO,,,,B,1,BAO_0000219,16372,8,CHEMBL620761,,H
,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,11923,,Autocuration,2116.0,,3762,,,,,Ileum,F,1,BAO_0000221,17386,8,CHEMBL620762,,H
,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,11923,,Autocuration,2116.0,,3763,,,,,Ileum,F,1,BAO_0000221,17386,8,CHEMBL620763,,H
,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,11923,,Autocuration,2116.0,,3764,,,,,Ileum,F,1,BAO_0000221,17386,8,CHEMBL620764,,H
,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,11923,Rattus norvegicus,Expert,,10116.0,3765,,,,,,B,1,BAO_0000249,5831,9,CHEMBL857990,Membranes,D
,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,11923,,Autocuration,,,3766,,,,,,B,1,BAO_0000357,4342,8,CHEMBL620765,,H
,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,11923,,Expert,,,3767,,,,,,B,1,BAO_0000357,17319,8,CHEMBL620766,,H
,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,11923,,Expert,1898.0,,3768,,,,,Hypothalamus,B,1,BAO_0000019,17342,8,CHEMBL620767,,H
,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,11923,,Autocuration,,,3769,,,,,,B,1,BAO_0000357,17342,8,CHEMBL620768,,H
,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,11923,,Expert,1898.0,,3770,,,,,Hypothalamus,B,1,BAO_0000249,3680,8,CHEMBL619051,,H
,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,11923,,Expert,,,3771,,,,,,B,1,BAO_0000357,3680,8,CHEMBL619052,,H
,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,722.0,11923,Rattus norvegicus,Expert,,10116.0,3772,,HEK293,,,,F,1,BAO_0000219,17319,9,CHEMBL619053,,D
,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,722.0,11923,Rattus norvegicus,Expert,,10116.0,3773,,HEK293,,,,F,1,BAO_0000219,17319,9,CHEMBL619703,,D
,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,722.0,11923,Rattus norvegicus,Autocuration,,10116.0,3774,,HEK293,,,,F,1,BAO_0000219,17319,9,CHEMBL619704,,D
,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,10209,,Expert,,,3775,,,,,,B,1,BAO_0000357,4820,8,CHEMBL619851,,H
,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,10209,,Autocuration,,,3776,,,,,,B,1,BAO_0000357,4639,8,CHEMBL619852,,H
,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,10209,,Autocuration,,,3777,,,,,,B,1,BAO_0000357,6011,8,CHEMBL619853,,H
,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,10209,Homo sapiens,Expert,,9606.0,3778,,,,,,B,1,BAO_0000357,17066,9,CHEMBL619854,,D
,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,10209,,Expert,,,3779,,,,,,B,1,BAO_0000357,17066,8,CHEMBL619855,,H
,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,10209,,Autocuration,,,3780,,,,,,B,1,BAO_0000357,17515,8,CHEMBL619856,,H
,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,10209,,Autocuration,,,3781,,,,,,B,1,BAO_0000357,4373,8,CHEMBL619857,,H
,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,10209,,Expert,,,3782,,,,,,F,1,BAO_0000019,17066,8,CHEMBL619858,,H
,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,10209,,Autocuration,,,3783,,,,,,B,1,BAO_0000357,4373,8,CHEMBL619859,,H
,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,10209,,Autocuration,,,3784,,,,,,B,1,BAO_0000357,4373,8,CHEMBL619860,,H
,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,10209,,Autocuration,,,3785,,,,,,B,1,BAO_0000357,4687,8,CHEMBL619861,,H
,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,10209,,Expert,,,3786,,,,,,B,1,BAO_0000357,17342,8,CHEMBL619862,,H
,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,10209,,Autocuration,,,3787,,,,,,B,1,BAO_0000357,16946,8,CHEMBL619863,,H
,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,10209,,Autocuration,,,3788,,,,,,B,1,BAO_0000357,16946,8,CHEMBL619864,,H
,,Binding affinities against 5-hydroxytryptamine 7 receptor,,10209,,Autocuration,,,3789,,,,,,B,1,BAO_0000357,16633,8,CHEMBL872928,,H
,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,10209,,Autocuration,,,3790,,,,,,B,1,BAO_0000357,16633,8,CHEMBL619865,,H
,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,10209,,Expert,,,3791,,,,,,B,1,BAO_0000357,17066,8,CHEMBL619866,,H
,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,10209,,Autocuration,,,3792,,,,,,B,1,BAO_0000357,16700,8,CHEMBL619867,,H
,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,10209,,Autocuration,2116.0,,3793,,,,,Ileum,B,1,BAO_0000221,17386,8,CHEMBL619868,,H
,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,55,,Autocuration,,,3794,,,,,,F,1,BAO_0000019,14080,8,CHEMBL619869,,H
,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,55,Homo sapiens,Expert,,9606.0,3795,,,,,,F,1,BAO_0000019,14080,9,CHEMBL619870,,D
,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,55,,Autocuration,,,3796,,,,,,B,1,BAO_0000357,409,8,CHEMBL619871,,H
,,In vitro inhibition of human recombinant lipoxygenase enzyme,,55,,Autocuration,,,3797,,,,,,B,1,BAO_0000357,409,8,CHEMBL619872,,H
,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,55,,Autocuration,,,3798,,,,,,B,1,BAO_0000357,409,8,CHEMBL619873,,H
,,Inhibition of 5-lipoxygenase in human whole blood.,,55,,Expert,178.0,,3799,,,,,Blood,B,1,BAO_0000357,11090,8,CHEMBL619874,,H
,,Inhibition of 5-lipoxygenase in human whole blood.,,55,,Expert,178.0,,3800,,,,,Blood,B,1,BAO_0000357,11090,8,CHEMBL619875,,H
,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,55,,Autocuration,,,3801,,,,,,B,1,BAO_0000357,948,8,CHEMBL619876,,H
,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,55,,Autocuration,,,3802,,,,,,B,1,BAO_0000357,948,8,CHEMBL619877,,H
,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,55,,Expert,,,3803,,,,,,F,1,BAO_0000219,13622,8,CHEMBL619878,,H
,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,55,,Autocuration,178.0,,3804,,,,,Blood,F,1,BAO_0000019,13622,8,CHEMBL619879,,H
,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,55,,Autocuration,,,3805,,,,,,B,1,BAO_0000357,9637,8,CHEMBL619880,,H
,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,55,,Autocuration,,,3806,,,,,,B,1,BAO_0000357,11320,8,CHEMBL619881,,H
,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,55,,Expert,,,3807,,,,,,B,1,BAO_0000357,11320,8,CHEMBL619882,,H
,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,55,,Autocuration,,,3808,,,,,,B,1,BAO_0000357,6838,8,CHEMBL619883,,H
,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,55,Homo sapiens,Expert,178.0,9606.0,3809,,,,,Blood,B,1,BAO_0000357,17667,9,CHEMBL619884,,D
,,In vitro potency against human 5-Lipoxygenase,,55,,Autocuration,,,3810,,,,,,B,1,BAO_0000357,12703,8,CHEMBL619885,,H
,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,55,Homo sapiens,Expert,,9606.0,3811,,,,,,F,1,BAO_0000019,14312,9,CHEMBL619886,,D
,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,55,,Autocuration,178.0,,3812,,,,,Blood,F,1,BAO_0000019,14312,8,CHEMBL619887,,H
,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,55,,Autocuration,,,3813,,,,,,F,1,BAO_0000019,5364,8,CHEMBL875097,,H
,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,55,,Autocuration,,,3814,,,,,,B,1,BAO_0000219,951,8,CHEMBL618001,,H
,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,55,,Autocuration,,,3815,,,,,,B,1,BAO_0000219,951,8,CHEMBL618002,,H
,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,55,,Autocuration,,,3816,,,,,,B,1,BAO_0000219,951,8,CHEMBL618003,,H
,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,55,,Autocuration,,,3817,,,,,,B,1,BAO_0000219,951,8,CHEMBL618004,,H
,,Inhibition of human 5-lipoxygenase in human cells,,55,,Autocuration,,,3818,,,,,,B,1,BAO_0000219,12365,8,CHEMBL618005,,H
,,Inhibition of human neutrophil 5-lipoxygenase,,55,,Expert,,,3819,,,,,,B,1,BAO_0000357,10603,8,CHEMBL618006,,H
,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,55,,Autocuration,,,3820,,,,,,B,1,BAO_0000019,10501,8,CHEMBL875086,,H
,,Inhibition of 5-lipoxygenase from human whole blood,,55,,Expert,178.0,,3821,,,,,Blood,B,1,BAO_0000357,12281,8,CHEMBL618007,,H
,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,55,,Autocuration,,,3822,,,,,,B,1,BAO_0000357,2567,8,CHEMBL618008,,H
,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,55,,Autocuration,,,3823,,,,,,B,1,BAO_0000219,2567,8,CHEMBL618009,,H
,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,55,,Expert,,,3824,,,,,,B,1,BAO_0000357,10193,8,CHEMBL618010,,H
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,55,,Autocuration,,,3825,,,,,,B,1,BAO_0000357,10193,8,CHEMBL618011,,H
,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,55,,Expert,,,3826,,,,,,B,1,BAO_0000357,13623,8,CHEMBL618012,,H
,,Tested against 5-lipoxygenase,,55,,Autocuration,,,3827,,,,,,B,1,BAO_0000357,12780,8,CHEMBL882927,,H
,,Tested for activity against 5-Lipoxygenase (5-LO),,55,,Autocuration,,,3828,,,,,,B,1,BAO_0000357,12780,8,CHEMBL618013,,H
,,Tested for activity against 5-lipoxygenase,,55,,Autocuration,,,3829,,,,,,B,1,BAO_0000357,12780,8,CHEMBL618014,,H
,,Tested for inhibition of 5-HPETE production by human 5-LO,,55,,Autocuration,,,3830,,,,,,B,1,BAO_0000357,11966,8,CHEMBL618015,,H
,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,55,,Autocuration,,,3831,,,,,,F,1,BAO_0000019,5364,8,CHEMBL618016,,H
,,Inhibition of Human 5-lipoxygenase,,55,,Expert,,,3832,,,,,,B,1,BAO_0000357,13165,8,CHEMBL618017,,H
,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,55,,Autocuration,,,3833,,,,,,B,1,BAO_0000019,5364,8,CHEMBL618018,,H
,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,55,,Autocuration,,,3834,,,,,,B,1,BAO_0000219,11311,8,CHEMBL875087,,H
,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,55,,Autocuration,,,3835,,,,,,B,1,BAO_0000219,11311,8,CHEMBL618019,,H
,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,55,,Autocuration,,,3836,,,,,,B,1,BAO_0000019,14863,8,CHEMBL618020,,H
,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,55,,Autocuration,,,3837,,,,,,B,1,BAO_0000019,14863,8,CHEMBL618021,,H
,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,55,,Autocuration,178.0,,3838,,,,,Blood,B,1,BAO_0000357,11087,8,CHEMBL618022,,H
,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,55,,Autocuration,,,3839,,,,,,B,1,BAO_0000357,455,8,CHEMBL618023,,H
,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,55,,Autocuration,,,3840,,,,,,B,1,BAO_0000357,13183,8,CHEMBL618024,,H
,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,55,,Expert,,,3841,,,,,,B,1,BAO_0000019,10319,8,CHEMBL873950,,H
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,55,,Autocuration,,,3842,,,,,,B,1,BAO_0000357,10193,8,CHEMBL618025,,H
,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,55,,Autocuration,,,3843,,,,,,B,1,BAO_0000219,951,8,CHEMBL618026,,H
,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,55,,Autocuration,,,3844,,,,,,B,1,BAO_0000219,951,8,CHEMBL618027,,H
,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,55,,Autocuration,,,3845,,,,,,B,1,BAO_0000219,951,8,CHEMBL618028,,H
,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,55,,Autocuration,,,3846,,,,,,B,1,BAO_0000219,951,8,CHEMBL618029,,H
,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,55,,Expert,,,3847,,,,,,B,1,BAO_0000357,9859,8,CHEMBL618030,,H
,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,55,,Expert,,,3848,,,,,,B,1,BAO_0000357,9859,8,CHEMBL618031,,H
,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,55,,Autocuration,,,3849,,,,,,B,1,BAO_0000357,9859,8,CHEMBL618032,,H
,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,55,,Autocuration,,,3850,,,,,,B,1,BAO_0000357,2567,8,CHEMBL618033,,H
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,55,,Autocuration,,,3851,,,,,,B,1,BAO_0000357,10193,8,CHEMBL618034,,H
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,55,,Autocuration,,,3852,,,,,,B,1,BAO_0000357,10193,8,CHEMBL875088,,H
,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,55,,Autocuration,,,3853,,,,,,B,1,BAO_0000019,949,8,CHEMBL618035,,H
,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,55,,Autocuration,,,3854,,,,,,B,1,BAO_0000019,949,8,CHEMBL618036,,H
,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,55,,Expert,,,3855,,,,,,B,1,BAO_0000357,10603,8,CHEMBL618037,,H
,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,55,,Expert,,,3856,,,,,,B,1,BAO_0000357,10603,8,CHEMBL618038,,H
,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,55,,Autocuration,,,3857,,,,,,F,1,BAO_0000019,10603,8,CHEMBL618761,,H
,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,55,,Expert,,,3858,,,,,,B,1,BAO_0000357,10603,8,CHEMBL618762,,H
,,Inhibition of lipoxygenase at the concentration of 1 uM,,55,,Expert,,,3859,,,,,,B,1,BAO_0000357,10603,8,CHEMBL618763,,H
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,55,,Autocuration,,,3860,,,,,,B,1,BAO_0000357,10193,8,CHEMBL618764,,H
,,Inhibition of 5-Lipoxygenase (5-LOX),,55,Homo sapiens,Expert,,9606.0,3861,,,,,,B,1,BAO_0000357,14580,9,CHEMBL618765,,D
,,Inhibition of 5-lipoxygenase in mouse macrophages.,,17087,,Expert,,,3862,,,,,,B,1,BAO_0000357,11090,8,CHEMBL618766,,H
,,Inhibition of 5-lipoxygenase in mouse macrophages.,,17087,,Expert,,,3863,,,,,,B,1,BAO_0000357,11090,8,CHEMBL618767,,H
,,Inhibitory activity against lipoxygenase-2 in mice,,17087,,Autocuration,,,3864,,,,,,B,1,BAO_0000357,6339,8,CHEMBL619380,,H
,,Inhibitory activity against murine lipoxygenase-2.,,17087,,Expert,,,3865,,,,,,B,1,BAO_0000357,6339,8,CHEMBL619381,,H
,,Inhibition of 5-lipoxygenase from mouse macrophage,,17087,Mus musculus,Expert,,10090.0,3866,,,,,,B,1,BAO_0000357,12281,9,CHEMBL619382,,D
,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,17087,,Autocuration,,,3867,,,,,,B,1,BAO_0000357,11311,8,CHEMBL619383,,H
,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,55,Sus scrofa,Autocuration,,9823.0,3868,,,,,,B,1,BAO_0000019,11089,8,CHEMBL619384,,H
,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,55,Sus scrofa,Autocuration,,9823.0,3869,,,,,,B,1,BAO_0000019,10091,8,CHEMBL619385,,H
,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,55,Oryctolagus cuniculus,Autocuration,,9986.0,3870,,,,,,B,1,BAO_0000019,14352,8,CHEMBL882928,,H
,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,12166,Rattus norvegicus,Expert,,10116.0,3871,,,,,,B,1,BAO_0000019,13329,9,CHEMBL619386,,D
,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,12166,,Autocuration,,,3872,,,,,,B,1,BAO_0000019,13329,8,CHEMBL619387,,H
,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,12166,,Autocuration,,,3873,,,,,,B,1,BAO_0000019,13329,8,CHEMBL619388,,H
,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,12166,,Autocuration,,,3874,,,,,,B,1,BAO_0000019,13329,8,CHEMBL619389,,H
,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,12166,,Expert,,,3875,,,,,,B,1,BAO_0000019,13329,8,CHEMBL619390,,H
,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,12166,,Expert,,,3876,,,,,,B,1,BAO_0000019,13329,8,CHEMBL619391,,H
,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,12166,,Autocuration,,,3877,,,,,,B,1,BAO_0000019,13329,8,CHEMBL619392,,H
,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,12166,,Autocuration,,,3878,,,,,,B,1,BAO_0000019,11311,8,CHEMBL619393,,H
,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,12166,,Autocuration,,,3879,,,,,,B,1,BAO_0000019,11311,8,CHEMBL619394,,H
,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",702.0,12166,,Autocuration,,,3880,,RBL-1,,,,B,1,BAO_0000219,105,8,CHEMBL619395,,H
,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",702.0,12166,,Autocuration,,,3881,,RBL-1,,,,B,1,BAO_0000219,105,8,CHEMBL619396,,H
,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,12166,,Autocuration,,,3882,,,,,,B,1,BAO_0000357,9138,8,CHEMBL619397,,H
,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,12166,,Autocuration,,,3883,,,,,,B,1,BAO_0000357,9138,8,CHEMBL619398,,H
,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,12166,,Autocuration,,,3884,,,,,,B,1,BAO_0000357,9138,8,CHEMBL619399,,H
,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,12166,,Autocuration,,,3885,,,,,,B,1,BAO_0000357,14427,8,CHEMBL619400,,H
,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,12166,,Autocuration,,,3886,,,,,,B,1,BAO_0000019,13329,8,CHEMBL619401,,H
,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,12166,,Autocuration,,,3887,,,,,,B,1,BAO_0000019,13329,8,CHEMBL619402,,H
,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,663.0,12166,Rattus norvegicus,Expert,,10116.0,3888,,RBL-2H3,,,,B,1,BAO_0000219,14427,9,CHEMBL619403,,D
,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,12166,,Autocuration,,,3889,,,,,,B,1,BAO_0000357,14427,8,CHEMBL619404,,H
,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,12166,,Autocuration,,,3890,,,,,,B,1,BAO_0000357,14427,8,CHEMBL619405,,H
,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,702.0,12166,,Expert,,,3891,,RBL-1,,,,B,1,BAO_0000219,10293,8,CHEMBL619406,,H
,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,702.0,12166,Rattus norvegicus,Expert,,10116.0,3892,,RBL-1,,,,B,1,BAO_0000219,338,9,CHEMBL619407,,D
,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,12166,,Autocuration,,,3893,,,,,,B,1,BAO_0000357,303,8,CHEMBL619408,,H
,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,702.0,12166,,Autocuration,,,3894,,RBL-1,,,,B,1,BAO_0000219,303,8,CHEMBL619409,,H
,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,702.0,12166,,Expert,,,3895,,RBL-1,,,,B,1,BAO_0000219,9247,8,CHEMBL619410,,H
,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,702.0,12166,,Autocuration,,,3896,,RBL-1,,,,B,1,BAO_0000219,9247,8,CHEMBL619753,,H
,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,702.0,12166,,Autocuration,,,3897,,RBL-1,,,,B,1,BAO_0000219,137,8,CHEMBL619754,,H
,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,12166,,Expert,,,3898,,,,,,B,1,BAO_0000357,11481,8,CHEMBL619903,,H
,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,12166,,Expert,,,3899,,,,,,B,1,BAO_0000357,11481,8,CHEMBL619904,,H
,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,12166,,Expert,,,3900,,,,,,B,1,BAO_0000357,9029,8,CHEMBL619905,,H
,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,12166,,Autocuration,,,3901,,,,,,B,1,BAO_0000019,1701,8,CHEMBL619906,,H
,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,12166,,Autocuration,,,3902,,,,,,B,1,BAO_0000019,1701,8,CHEMBL619907,,H
,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,12166,,Autocuration,,,3903,,,,,,B,1,BAO_0000019,1701,8,CHEMBL619908,,H
,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,12166,,Autocuration,,,3904,,,,,,B,1,BAO_0000019,1701,8,CHEMBL619909,,H
,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,702.0,12166,,Expert,,,3905,,RBL-1,,,,F,1,BAO_0000219,13358,8,CHEMBL619910,,H
,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,702.0,12166,,Expert,,,3906,,RBL-1,,,,B,1,BAO_0000219,1175,8,CHEMBL882929,,H
,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,702.0,12166,,Expert,,,3907,,RBL-1,,,,B,1,BAO_0000219,8797,8,CHEMBL619911,,H
,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,12166,,Autocuration,,,3908,,,,,,B,1,BAO_0000019,8797,8,CHEMBL619912,,H
,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,12166,Rattus norvegicus,Expert,,10116.0,3909,,,,,,B,1,BAO_0000357,577,9,CHEMBL619913,,D
,,In vitro inhibitory activity against RBL-1 5-LO,702.0,12166,,Expert,,,3910,,RBL-1,,,,B,1,BAO_0000219,9295,8,CHEMBL619914,,H
,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),702.0,12166,,Autocuration,,,3911,,RBL-1,,,,B,1,BAO_0000219,9295,8,CHEMBL619915,,H
,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),702.0,12166,,Autocuration,,,3912,,RBL-1,,,,B,1,BAO_0000219,9295,8,CHEMBL619916,,H
,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,12166,,Autocuration,,,3913,,,,,,B,1,BAO_0000218,9295,8,CHEMBL619917,,H
,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,12166,,Autocuration,,,3914,,,,,,B,1,BAO_0000357,9295,8,CHEMBL619918,,H
,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,12166,,Autocuration,,,3915,,,,,,B,1,BAO_0000218,216,8,CHEMBL619919,,H
,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,702.0,12166,,Autocuration,,,3916,,RBL-1,,,,B,1,BAO_0000219,11090,8,CHEMBL883710,,H
,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,12166,,Autocuration,178.0,,3917,,,,,Blood,B,1,BAO_0000019,11090,8,CHEMBL619920,,H
,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,12166,,Expert,,,3918,,,,,,B,1,BAO_0000357,10091,8,CHEMBL619921,,H
,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,12166,,Autocuration,,,3919,,,,,,F,1,BAO_0000019,10274,8,CHEMBL619922,,H
,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,12166,,Autocuration,,,3920,,,,,,F,1,BAO_0000219,13622,8,CHEMBL619923,,H
,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,702.0,12166,,Expert,,,3921,,RBL-1,,,,B,1,BAO_0000219,12118,8,CHEMBL619924,,H
,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,12166,,Expert,,,3922,,,,,,B,1,BAO_0000357,12576,8,CHEMBL619925,,H
,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,702.0,12166,,Expert,,,3923,,RBL-1,,,,B,1,BAO_0000219,9546,8,CHEMBL619926,,H
,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,702.0,12166,,Autocuration,,,3924,,RBL-1,,,,B,1,BAO_0000219,9521,8,CHEMBL619927,,H
,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,702.0,12166,,Expert,,,3925,,RBL-1,,,,B,1,BAO_0000219,10626,8,CHEMBL619928,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase,702.0,12166,,Autocuration,,,3926,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619929,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,702.0,12166,,Autocuration,,,3927,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL875089,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,702.0,12166,,Autocuration,,,3928,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619930,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,702.0,12166,,Autocuration,,,3929,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619931,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,702.0,12166,,Autocuration,,,3930,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619932,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,702.0,12166,,Autocuration,,,3931,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619933,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,702.0,12166,,Autocuration,,,3932,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619934,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,702.0,12166,,Autocuration,,,3933,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619935,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,702.0,12166,,Autocuration,,,3934,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619936,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,702.0,12166,,Autocuration,,,3935,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619937,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,702.0,12166,,Autocuration,,,3936,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619938,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,702.0,12166,,Autocuration,,,3937,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619939,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,702.0,12166,,Autocuration,,,3938,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619940,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,702.0,12166,,Autocuration,,,3939,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL875090,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,702.0,12166,,Autocuration,,,3940,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619941,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,702.0,12166,,Autocuration,,,3941,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619942,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,702.0,12166,,Autocuration,,,3942,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL883711,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,702.0,12166,,Autocuration,,,3943,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619943,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,702.0,12166,,Autocuration,,,3944,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619944,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,702.0,12166,,Autocuration,,,3945,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619945,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,702.0,12166,,Autocuration,,,3946,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619946,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,702.0,12166,,Autocuration,,,3947,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619947,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,702.0,12166,,Autocuration,,,3948,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619948,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,702.0,12166,,Autocuration,,,3949,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL619949,,H
,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,12166,,Expert,,,3950,,,,,,B,1,BAO_0000019,9401,8,CHEMBL619950,,H
,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,12166,,Autocuration,,,3951,,,,,,B,1,BAO_0000019,10325,8,CHEMBL618050,,H
,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,663.0,12166,,Expert,,,3952,,RBL-2H3,,,,F,1,BAO_0000219,1556,8,CHEMBL875091,,H
,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,663.0,12166,,Expert,,,3953,,RBL-2H3,,,,F,1,BAO_0000219,1556,8,CHEMBL618051,,H
,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,702.0,12166,Rattus norvegicus,Expert,,10116.0,3954,,RBL-1,,,,B,1,BAO_0000219,961,9,CHEMBL618052,,D
,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,12166,,Autocuration,,,3955,,,,,,B,1,BAO_0000019,6838,8,CHEMBL618053,,H
,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,12166,,Expert,,,3956,,,,,,B,1,BAO_0000019,10325,8,CHEMBL618054,,H
,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,702.0,12166,Rattus norvegicus,Expert,,10116.0,3957,,RBL-1,,,,B,1,BAO_0000219,9209,9,CHEMBL618055,,D
,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,702.0,12166,,Expert,,,3958,,RBL-1,,,,B,1,BAO_0000219,11520,8,CHEMBL618056,,H
,,In vitro inhibitory activity against 5-lipoxygenase was determined,,12166,,Autocuration,,,3959,,,,,,B,1,BAO_0000357,137,8,CHEMBL618057,,H
,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,702.0,12166,,Autocuration,,,3960,,RBL-1,,,,B,1,BAO_0000219,4717,8,CHEMBL618058,,H
,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,702.0,12166,,Expert,,,3961,,RBL-1,,,,B,1,BAO_0000219,10636,8,CHEMBL618059,,H
,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,12166,Rattus norvegicus,Expert,,10116.0,3962,,,,,,F,1,BAO_0000019,14312,9,CHEMBL618060,,D
,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,702.0,12166,,Autocuration,,,3963,,RBL-1,,,,B,1,BAO_0000219,1203,8,CHEMBL618061,,H
,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,12166,,Autocuration,,,3964,,,,,,B,1,BAO_0000019,1203,8,CHEMBL618062,,H
,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,702.0,12166,,Expert,,,3965,,RBL-1,,,,B,1,BAO_0000219,13622,8,CHEMBL618063,,H
,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,12166,,Autocuration,,,3966,,,,,,B,1,BAO_0000357,9793,8,CHEMBL618064,,H
,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,702.0,12166,Rattus norvegicus,Expert,,10116.0,3967,,RBL-1,,,,B,1,BAO_0000219,1143,9,CHEMBL618065,,D
,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,702.0,12166,Rattus norvegicus,Expert,,10116.0,3968,,RBL-1,,,,B,1,BAO_0000219,11854,9,CHEMBL618066,,D
,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),702.0,12166,,Autocuration,,,3969,,RBL-1,,,,B,1,BAO_0000219,3595,8,CHEMBL618067,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),702.0,12166,,Autocuration,,,3970,,RBL-1,,,,B,1,BAO_0000219,3595,8,CHEMBL618068,,H
,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,702.0,12166,Rattus norvegicus,Expert,,10116.0,3971,,RBL-1,,,,B,1,BAO_0000219,10501,9,CHEMBL618069,,D
,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,12166,,Expert,,,3972,,RBL-1,,,,B,1,BAO_0000219,12526,8,CHEMBL618070,,H
,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,10825,,Autocuration,349.0,,3973,,,,,Limbic system,F,1,BAO_0000019,10034,8,CHEMBL618071,,H
,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,10825,,Autocuration,349.0,,3974,,,,,Limbic system,F,1,BAO_0000019,10034,8,CHEMBL619247,,H
,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,10825,,Autocuration,,,3975,,,,,,F,1,BAO_0000019,10034,8,CHEMBL619248,,H
,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10576,,Autocuration,10000000.0,,3976,,,,,Hippocampus,B,1,BAO_0000221,10046,8,CHEMBL619249,,H
,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10576,,Autocuration,10000000.0,,3977,,,,,Hippocampus,B,1,BAO_0000221,10046,8,CHEMBL619250,,H
,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,10577,,Autocuration,,,3978,,,,,,B,1,BAO_0000019,10046,8,CHEMBL619251,,H
,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3979,,,,,Blood,F,1,BAO_0000019,12079,8,CHEMBL619252,,H
,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,55,,Autocuration,178.0,,3980,,,,,Blood,F,1,BAO_0000019,12079,8,CHEMBL619253,,H
,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,12166,,Autocuration,,,3981,,,,,,B,1,BAO_0000219,11311,8,CHEMBL619254,,H
,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,17140,,Expert,,,3982,,,,,,B,1,BAO_0000219,12338,8,CHEMBL619255,,H
,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,17140,,Expert,,,3983,,,,,,B,1,BAO_0000219,12143,8,CHEMBL619256,,H
,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,17140,,Autocuration,,,3984,,,,,,B,1,BAO_0000219,12143,8,CHEMBL875418,,H
,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,17140,,Expert,,,3985,,,,,,B,1,BAO_0000219,12143,8,CHEMBL619257,,H
,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,17140,,Autocuration,,,3986,,,,,,B,1,BAO_0000219,12143,8,CHEMBL619258,,H
,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,17140,,Expert,,,3987,,,,,,B,1,BAO_0000357,12365,8,CHEMBL619259,,H
,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,17140,,Expert,,,3988,,,,,,B,1,BAO_0000357,13500,8,CHEMBL619260,,H
,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3989,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619261,,H
,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3990,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619263,,H
,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3991,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619264,,H
,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3992,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619265,,H
,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3993,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619266,,H
,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3994,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619902,,H
,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3995,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620058,,H
,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3996,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620059,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3997,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620060,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3998,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620061,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,3999,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620062,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4000,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620063,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4001,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620064,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4002,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620065,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4003,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620066,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4004,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620067,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4005,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620068,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4006,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620069,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4007,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620070,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4008,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620071,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4009,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620072,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4010,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620036,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4011,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL857702,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4012,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620037,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4013,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620038,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4014,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620039,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4015,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620040,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4016,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620041,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4017,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620042,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4018,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620043,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4019,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620044,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4020,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620045,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4021,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620046,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4022,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620047,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4023,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620048,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4024,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL857703,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4025,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620049,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4026,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620050,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4027,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL620051,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4028,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619213,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4029,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619214,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4030,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619804,,H
,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4031,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619805,,H
,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4032,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619806,,H
,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4033,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619807,,H
,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,55,Canis lupus familiaris,Autocuration,178.0,9615.0,4034,In vivo,,,,Blood,F,1,BAO_0000218,12832,8,CHEMBL619808,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,55,Canis lupus familiaris,Autocuration,,9615.0,4035,,,,,,B,1,BAO_0000218,3595,8,CHEMBL619809,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,55,Canis lupus familiaris,Autocuration,,9615.0,4036,,,,,,B,1,BAO_0000218,3595,8,CHEMBL619810,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,55,Canis lupus familiaris,Autocuration,,9615.0,4037,,,,,,B,1,BAO_0000218,3595,8,CHEMBL619811,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,55,Canis lupus familiaris,Autocuration,,9615.0,4038,,,,,,B,1,BAO_0000218,3595,8,CHEMBL620769,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,55,Canis lupus familiaris,Autocuration,,9615.0,4039,,,,,,B,1,BAO_0000218,3595,8,CHEMBL620770,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,55,Canis lupus familiaris,Autocuration,,9615.0,4040,,,,,,B,1,BAO_0000218,3595,8,CHEMBL620771,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,55,Canis lupus familiaris,Autocuration,,9615.0,4041,,,,,,B,1,BAO_0000218,3595,8,CHEMBL620772,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,55,Canis lupus familiaris,Autocuration,,9615.0,4042,,,,,,B,1,BAO_0000218,3595,8,CHEMBL620773,,H
,,Ability to inhibit 5-lipoxygenase in guinea pig,,55,Cavia porcellus,Autocuration,,10141.0,4043,,,,,,B,1,BAO_0000357,9203,8,CHEMBL620774,,H
,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,55,Cavia porcellus,Expert,,10141.0,4044,,,,,,B,1,BAO_0000357,82,8,CHEMBL620775,,H
,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,55,Cavia porcellus,Autocuration,,10141.0,4045,,,,,,B,1,BAO_0000357,11090,8,CHEMBL620776,,H
,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,55,Cavia porcellus,Autocuration,178.0,10141.0,4046,,,,,Blood,B,1,BAO_0000218,12832,8,CHEMBL620777,,H
,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,55,Cavia porcellus,Autocuration,,10141.0,4047,,,,,,B,1,BAO_0000357,1065,8,CHEMBL620778,,H
,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,55,Cavia porcellus,Autocuration,,10141.0,4048,,,,,,B,1,BAO_0000357,1065,8,CHEMBL620779,,H
,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,55,Cavia porcellus,Expert,,10141.0,4049,,,,,,B,1,BAO_0000019,12832,8,CHEMBL621500,,H
,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,55,Cavia porcellus,Expert,,10141.0,4050,,,,,,B,1,BAO_0000019,12832,8,CHEMBL621501,,H
,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,55,Cavia porcellus,Autocuration,,10141.0,4051,,,,,,B,1,BAO_0000019,12832,8,CHEMBL618098,,H
,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,55,Cavia porcellus,Autocuration,,10141.0,4052,,,,,,B,1,BAO_0000019,10504,8,CHEMBL618099,,H
,,Inhibitory activity against 5-lipoxygenase,,55,Cavia porcellus,Autocuration,,10141.0,4053,,,,,,B,1,BAO_0000357,7788,8,CHEMBL618100,,H
,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,55,Cavia porcellus,Autocuration,,10141.0,4054,,,,,,B,1,BAO_0000357,10001,8,CHEMBL618101,,H
,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,55,Cavia porcellus,Autocuration,,10141.0,4055,,,,,,B,1,BAO_0000357,10193,8,CHEMBL618102,,H
,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,55,Cavia porcellus,Autocuration,,10141.0,4056,,,,,,B,1,BAO_0000357,13243,8,CHEMBL618103,,H
,,Inhibitory activity uM,,55,Cavia porcellus,Autocuration,,10141.0,4057,,,,,,B,1,BAO_0000357,13243,8,CHEMBL618104,,H
,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,55,Cavia porcellus,Autocuration,,10141.0,4058,,,,,,B,1,BAO_0000219,969,8,CHEMBL883712,,H
,,Inhibitory activity against 5-lipoxygenase at 10 uM,,55,Cavia porcellus,Autocuration,,10141.0,4059,,,,,,B,1,BAO_0000357,10001,8,CHEMBL618105,,H
,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,55,Cavia porcellus,Autocuration,,10141.0,4060,,,,,,B,1,BAO_0000357,7788,8,CHEMBL618106,,H
,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,55,Cavia porcellus,Autocuration,,10141.0,4061,,,,,,B,1,BAO_0000357,10001,8,CHEMBL618107,,H
,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,55,Cavia porcellus,Autocuration,,10141.0,4062,,,,,,B,1,BAO_0000357,10193,8,CHEMBL618108,,H
,,Inhibitory activity uM,,55,Cavia porcellus,Autocuration,,10141.0,4063,,,,,,B,1,BAO_0000357,13243,8,CHEMBL618109,,H
,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,55,Cavia porcellus,Autocuration,,10141.0,4064,,,,,,B,1,BAO_0000357,13243,8,CHEMBL618110,,H
,,Inhibitory activity uM,,55,Cavia porcellus,Expert,,10141.0,4065,,,,,,B,1,BAO_0000357,13243,8,CHEMBL618111,,H
,,Inhibitory activity uM,,55,Cavia porcellus,Autocuration,,10141.0,4066,,,,,,F,1,BAO_0000019,13243,8,CHEMBL618112,,H
,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,55,Cavia porcellus,Autocuration,,10141.0,4067,,,,,,B,1,BAO_0000019,10504,8,CHEMBL618113,,H
,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,55,Cavia porcellus,Autocuration,,10141.0,4068,,,,,,B,1,BAO_0000357,7788,8,CHEMBL618114,,H
,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,55,Cavia porcellus,Expert,2116.0,10141.0,4069,,,,,Ileum,F,1,BAO_0000221,10546,8,CHEMBL620871,,H
,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,55,,Autocuration,,,4070,,,,,,B,1,BAO_0000357,13183,8,CHEMBL620872,,H
,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,55,,Autocuration,,,4071,,,,,,B,1,BAO_0000357,13183,8,CHEMBL620873,,H
,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,55,,Autocuration,,,4072,,,,,,B,1,BAO_0000357,2578,8,CHEMBL620874,,H
,,In vitro inhibition of human 5-Lipoxygenase.,,55,,Expert,,,4073,,,,,,B,1,BAO_0000357,12780,8,CHEMBL620875,,H
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4074,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620876,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4075,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620877,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4076,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL857854,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4077,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620878,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4078,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620879,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4079,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620880,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4080,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620881,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4081,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620882,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4082,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620883,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4083,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620884,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4084,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620885,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4085,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620886,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4086,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620887,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4087,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618039,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4088,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618040,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4089,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618041,Microsomes,U
,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4090,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618216,Microsomes,U
,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4091,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618217,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4092,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618218,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4093,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618219,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4094,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618220,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4095,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618221,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4096,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618222,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4097,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618223,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4098,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618224,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4099,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618225,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4100,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618226,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4101,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618227,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4102,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618228,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4103,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618229,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4104,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618230,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4105,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618231,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4106,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618232,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4107,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618233,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4108,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618234,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4109,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618235,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4110,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618115,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4111,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618116,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4112,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL618117,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4113,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619968,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4114,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619969,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4115,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619970,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4116,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619971,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4117,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619972,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4118,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619973,Microsomes,U
,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4119,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619974,Microsomes,U
,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4120,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619975,Microsomes,U
,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,22226,Rattus norvegicus,Autocuration,,10116.0,4121,,,,,,B,1,BAO_0000251,7411,0,CHEMBL619976,Microsomes,U
,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4122,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619977,Microsomes,U
,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4123,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619978,Microsomes,U
,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4124,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619979,Microsomes,U
,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4125,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619980,Microsomes,U
,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4126,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619981,Microsomes,U
,,In vitro inhibition of 7226/S myeloma cancer cell line,741.0,80433,Homo sapiens,Intermediate,,9606.0,4127,,RPMI-8226,,,,F,1,BAO_0000219,10797,1,CHEMBL619982,,N
,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),993.0,80698,Homo sapiens,Intermediate,,9606.0,4128,,BEL-7404 tumor cell line,,,,F,1,BAO_0000219,6881,1,CHEMBL619983,,N
,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,391.0,80640,Homo sapiens,Intermediate,,9606.0,4129,,786-0,,,,F,1,BAO_0000219,3838,1,CHEMBL620031,,N
,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,391.0,80640,Homo sapiens,Intermediate,,9606.0,4130,,786-0,,,,F,1,BAO_0000219,3838,1,CHEMBL620032,,N
,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,505.0,81264,Cricetulus griseus,Expert,,10029.0,4131,,V79,,,,F,1,BAO_0000219,12981,1,CHEMBL620033,,N
,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,505.0,81264,Cricetulus griseus,Expert,,10029.0,4132,,V79,,,,F,1,BAO_0000219,12981,1,CHEMBL620034,,N
,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,1119.0,80635,Rattus norvegicus,Intermediate,,10116.0,4133,,7800C1 cell line,,,,F,1,BAO_0000219,7653,1,CHEMBL620035,,N
,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,1119.0,80635,Rattus norvegicus,Intermediate,,10116.0,4134,,7800C1 cell line,,,,F,1,BAO_0000219,7653,1,CHEMBL618318,,N
,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,1119.0,80635,Rattus norvegicus,Intermediate,,10116.0,4135,,7800C1 cell line,,,,F,1,BAO_0000219,7653,1,CHEMBL618319,,N
,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,1119.0,80635,Rattus norvegicus,Intermediate,,10116.0,4136,,7800C1 cell line,,,,F,1,BAO_0000219,7653,1,CHEMBL618320,,N
,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,1119.0,80635,Rattus norvegicus,Intermediate,,10116.0,4137,,7800C1 cell line,,,,F,1,BAO_0000219,7653,1,CHEMBL618321,,N
,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,1119.0,80635,Rattus norvegicus,Intermediate,,10116.0,4138,,7800C1 cell line,,,,F,1,BAO_0000219,7653,1,CHEMBL883118,,N
,,In vitro antitumor activity against renal 786-0 tumor cell lines,391.0,80640,Homo sapiens,Intermediate,,9606.0,4139,,786-0,,,,F,1,BAO_0000219,17229,1,CHEMBL883795,,N
,,Cytotoxic activity against 786-0 Renal cancer cell line,391.0,80640,Homo sapiens,Intermediate,,9606.0,4140,,786-0,,,,F,1,BAO_0000219,12858,1,CHEMBL618322,,N
,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,391.0,80640,Homo sapiens,Intermediate,,9606.0,4141,,786-0,,,,F,1,BAO_0000219,16325,1,CHEMBL618323,,N
,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,391.0,80640,Homo sapiens,Intermediate,,9606.0,4142,,786-0,,,,F,1,BAO_0000219,16325,1,CHEMBL618324,,N
,,In vitro antitumor activity against human renal 786-0 cell line,391.0,80640,Homo sapiens,Intermediate,,9606.0,4143,,786-0,,,,F,1,BAO_0000219,5858,1,CHEMBL618325,,N
,,Inhibition of Renal cancer in 786-0 cancer cell lines,391.0,80640,Homo sapiens,Intermediate,,9606.0,4144,,786-0,,,,F,1,BAO_0000219,16325,1,CHEMBL875416,,N
,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,391.0,80640,Homo sapiens,Intermediate,,9606.0,4145,,786-0,,,,F,1,BAO_0000219,14696,1,CHEMBL618326,,N
,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,391.0,80640,Homo sapiens,Intermediate,,9606.0,4146,,786-0,,,,F,1,BAO_0000219,3786,1,CHEMBL618327,,N
,,inhibition of the growth of renal cancer(786-0) cell line,391.0,80640,Homo sapiens,Intermediate,,9606.0,4147,,786-0,,,,F,1,BAO_0000219,14696,1,CHEMBL619215,,N
,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),391.0,80640,Homo sapiens,Intermediate,,9606.0,4148,,786-0,,,,F,1,BAO_0000219,14769,1,CHEMBL619216,,N
,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,391.0,80640,Homo sapiens,Intermediate,,9606.0,4149,,786-0,,,,F,1,BAO_0000219,15354,1,CHEMBL619217,,N
,,The IC50 value was measured on 786-0 cell line in ovarian tumor,391.0,80640,Homo sapiens,Intermediate,,9606.0,4150,,786-0,,,,F,1,BAO_0000219,14255,1,CHEMBL619218,,N
,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,391.0,80640,Homo sapiens,Intermediate,,9606.0,4151,,786-0,,,,F,1,BAO_0000219,14255,1,CHEMBL619219,,N
,,The IC50 value was measured on 786-0 cell line in renal tumor type.,391.0,80640,Homo sapiens,Intermediate,,9606.0,4152,,786-0,,,,F,1,BAO_0000219,14255,1,CHEMBL619220,,N
,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,391.0,80640,Homo sapiens,Intermediate,,9606.0,4153,,786-0,,,,F,1,BAO_0000219,14696,1,CHEMBL619221,,N
,,Tested for cytotoxic activity against renal cancer 786-0 cell line,391.0,80640,Homo sapiens,Intermediate,,9606.0,4154,,786-0,,,,F,1,BAO_0000219,12016,1,CHEMBL619222,,N
,,Compound was tested for growth inhibitory activity against 786-0 cell line,391.0,80640,Homo sapiens,Intermediate,,9606.0,4155,,786-0,,,,F,1,BAO_0000219,2597,1,CHEMBL857454,,N
,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,702.0,12166,,Autocuration,,,4156,,RBL-1,,,,B,1,BAO_0000219,12526,8,CHEMBL619223,,H
,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,702.0,12166,,Autocuration,,,4157,,RBL-1,,,,B,1,BAO_0000219,12526,8,CHEMBL619224,,H
,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,12166,,Autocuration,,,4158,,,,,,B,1,BAO_0000019,14799,8,CHEMBL619225,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),702.0,12166,,Expert,,,4159,,RBL-1,,,,B,1,BAO_0000219,3595,8,CHEMBL619226,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),702.0,12166,,Expert,,,4160,,RBL-1,,,,B,1,BAO_0000219,3595,8,CHEMBL619227,,H
,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,12166,,Autocuration,,,4161,,,,,,B,1,BAO_0000357,12767,8,CHEMBL619228,,H
,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,12166,,Autocuration,,,4162,,,,,,B,1,BAO_0000219,10997,8,CHEMBL619229,,H
,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,702.0,12166,,Autocuration,,,4163,,RBL-1,,,,B,1,BAO_0000219,11388,8,CHEMBL619230,,H
,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,12166,,Autocuration,,,4164,,,,,,B,1,BAO_0000357,167,8,CHEMBL619231,,H
,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,12166,,Autocuration,,,4165,,,,,,B,1,BAO_0000357,167,8,CHEMBL619232,,H
,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,12166,,Expert,,,4166,,,,,,B,1,BAO_0000357,13744,8,CHEMBL619233,,H
,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,12166,,Autocuration,,,4167,,,,,,B,1,BAO_0000357,1630,8,CHEMBL619234,,H
,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,12166,,Autocuration,,,4168,,,,,,B,1,BAO_0000357,1630,8,CHEMBL619235,,H
,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,12166,Rattus norvegicus,Expert,,10116.0,4169,,,,,,B,1,BAO_0000019,969,9,CHEMBL619236,,D
,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,702.0,12166,,Autocuration,,,4170,,RBL-1,,,,B,1,BAO_0000219,13621,8,CHEMBL619237,,H
,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,12166,,Autocuration,,,4171,,,,,,B,1,BAO_0000357,10089,8,CHEMBL619238,,H
,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,12166,,Expert,,,4172,,,,,,B,1,BAO_0000357,10193,8,CHEMBL619239,,H
,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,12166,,Autocuration,,,4173,,,,,,B,1,BAO_0000357,11966,8,CHEMBL619240,,H
,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,12166,,Autocuration,,,4174,,,,,,B,1,BAO_0000019,12251,8,CHEMBL875417,,H
,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),702.0,12166,,Autocuration,,,4175,,RBL-1,,,,B,1,BAO_0000219,211,8,CHEMBL619241,,H
,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,12166,,Expert,,,4176,,,,,,F,1,BAO_0000019,12251,8,CHEMBL619242,,H
,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,702.0,12166,,Autocuration,,,4177,,RBL-1,,,,B,1,BAO_0000219,12495,8,CHEMBL883796,,H
,,Tested for its inhibitory activity against 5-lipoxygenase,,12166,,Autocuration,,,4178,,,,,,B,1,BAO_0000357,414,8,CHEMBL619243,,H
,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,12166,,Autocuration,,,4179,,,,,,B,1,BAO_0000357,414,8,CHEMBL619244,,H
,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,12166,,Expert,,,4180,,,,,,B,1,BAO_0000019,10325,8,CHEMBL619245,,H
,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,12166,,Expert,,,4181,,,,,,B,1,BAO_0000019,11966,8,CHEMBL619246,,H
,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,702.0,12166,,Expert,,,4182,,RBL-1,,,,B,1,BAO_0000219,165,8,CHEMBL619984,,H
,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,702.0,12166,,Autocuration,,,4183,,RBL-1,,,,B,1,BAO_0000219,165,8,CHEMBL619985,,H
,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,702.0,12166,,Autocuration,,,4184,,RBL-1,,,,B,1,BAO_0000219,165,8,CHEMBL619986,,H
,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,702.0,12166,,Expert,,,4185,,RBL-1,,,,B,1,BAO_0000219,165,8,CHEMBL619987,,H
,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,12166,,Autocuration,,,4186,,,,,,B,1,BAO_0000218,11311,8,CHEMBL619988,,H
,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,702.0,12166,,Autocuration,,,4187,,RBL-1,,,,B,1,BAO_0000219,11311,8,CHEMBL619989,,H
,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,702.0,12166,,Autocuration,,,4188,,RBL-1,,,,B,1,BAO_0000219,11311,8,CHEMBL619990,,H
,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,12166,,Autocuration,,,4189,,,,,,B,1,BAO_0000219,11311,8,CHEMBL619991,,H
,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,12166,,Autocuration,,,4190,,,,,,B,1,BAO_0000219,11311,8,CHEMBL619992,,H
,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,12166,,Autocuration,,,4191,In vivo,,,,,B,1,BAO_0000218,11311,8,CHEMBL619993,,H
,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,663.0,12166,,Autocuration,,,4192,,RBL-2H3,,,,F,1,BAO_0000219,11311,8,CHEMBL619994,,H
,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,663.0,12166,,Autocuration,,,4193,,RBL-2H3,,,,F,1,BAO_0000219,11311,8,CHEMBL619995,,H
,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,12166,,Autocuration,,,4194,,,,,,B,1,BAO_0000019,11311,8,CHEMBL619996,,H
,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,12166,,Autocuration,,,4195,,,,,,B,1,BAO_0000019,11732,8,CHEMBL619997,,H
,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,12166,,Expert,,,4196,,,,,,B,1,BAO_0000019,11732,8,CHEMBL619998,,H
,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,12166,,Expert,,,4197,,,,,,B,1,BAO_0000019,11087,8,CHEMBL619999,,H
,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,12166,,Autocuration,,,4198,,,,,,B,1,BAO_0000019,11087,8,CHEMBL620000,,H
,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,702.0,12166,,Autocuration,,,4199,,RBL-1,,,,B,1,BAO_0000219,11087,8,CHEMBL620001,,H
,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,12166,Rattus norvegicus,Expert,,10116.0,4200,,,,,,B,1,BAO_0000357,11087,9,CHEMBL620002,,D
,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,702.0,12166,,Autocuration,,,4201,,RBL-1,,,,B,1,BAO_0000219,496,8,CHEMBL620003,,H
,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,702.0,12166,,Expert,,,4202,,RBL-1,,,,F,1,BAO_0000219,13986,8,CHEMBL620004,,H
,,Compound was evaluated for the inhibition of 5-lipoxygenase,,12166,,Autocuration,,,4203,,,,,,B,1,BAO_0000357,11520,8,CHEMBL874063,,H
,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,702.0,12166,,Autocuration,,,4204,,RBL-1,,,,B,1,BAO_0000219,10293,8,CHEMBL620005,,H
,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,702.0,12166,,Autocuration,,,4205,,RBL-1,,,,B,1,BAO_0000219,303,8,CHEMBL620006,,H
,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,702.0,12166,,Autocuration,,,4206,,RBL-1,,,,B,1,BAO_0000219,303,8,CHEMBL620007,,H
,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,702.0,12166,,Autocuration,,,4207,,RBL-1,,,,B,1,BAO_0000219,9247,8,CHEMBL620008,,H
,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,702.0,12166,Rattus norvegicus,Expert,,10116.0,4208,,RBL-1,,,,B,1,BAO_0000219,9247,9,CHEMBL620009,,D
,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,702.0,12166,,Autocuration,,,4209,,RBL-1,,,,B,1,BAO_0000219,9247,8,CHEMBL620010,,H
,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,702.0,12166,,Autocuration,,,4210,,RBL-1,,,,B,1,BAO_0000219,9247,8,CHEMBL620011,,H
,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,702.0,12166,,Autocuration,,,4211,,RBL-1,,,,B,1,BAO_0000219,9247,8,CHEMBL620677,,H
,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,702.0,12166,,Autocuration,,,4212,,RBL-1,,,,B,1,BAO_0000219,9247,8,CHEMBL620678,,H
,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,702.0,12166,,Autocuration,,,4213,,RBL-1,,,,B,1,BAO_0000219,9247,8,CHEMBL620679,,H
,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,702.0,12166,,Autocuration,,,4214,,RBL-1,,,,B,1,BAO_0000219,9247,8,CHEMBL620680,,H
,,Inhibitory activity against 5-lipoxygenase at 10 uM,,12166,Rattus norvegicus,Expert,,10116.0,4215,,,,,,B,1,BAO_0000357,11481,9,CHEMBL620838,,D
,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,12166,,Autocuration,,,4216,,,,,,B,1,BAO_0000357,105,8,CHEMBL620839,,H
,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,12166,,Expert,,,4217,,,,,,B,1,BAO_0000357,9029,8,CHEMBL620840,,H
,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,702.0,12166,,Expert,,,4218,,RBL-1,,,,B,1,BAO_0000219,1175,8,CHEMBL620841,,H
,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,702.0,12166,,Autocuration,,,4219,,RBL-1,,,,B,1,BAO_0000219,12118,8,CHEMBL620842,,H
,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,702.0,12166,,Autocuration,,,4220,,RBL-1,,,,B,1,BAO_0000219,12118,8,CHEMBL620843,,H
,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,702.0,12166,,Autocuration,,,4221,,RBL-1,,,,B,1,BAO_0000219,12118,8,CHEMBL620844,,H
,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,702.0,12166,,Autocuration,,,4222,,RBL-1,,,,B,1,BAO_0000219,9225,8,CHEMBL620845,,H
,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,12166,,Autocuration,,,4223,,,,,,B,1,BAO_0000019,9401,8,CHEMBL620846,,H
,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,12166,,Autocuration,,,4224,,,,,,B,1,BAO_0000357,137,8,CHEMBL873951,,H
,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,12166,,Autocuration,,,4225,,,,,,B,1,BAO_0000357,137,8,CHEMBL620847,,H
,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,702.0,12166,,Autocuration,,,4226,,RBL-1,,,,B,1,BAO_0000219,4717,8,CHEMBL620848,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,702.0,12166,,Autocuration,,,4227,,RBL-1,,,,B,1,BAO_0000219,3595,8,CHEMBL620849,,H
,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,702.0,12166,,Autocuration,,,4228,,RBL-1,,,,B,1,BAO_0000219,10501,8,CHEMBL620850,,H
,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,702.0,12166,,Autocuration,,,4229,,RBL-1,,,,B,1,BAO_0000219,10501,8,CHEMBL620851,,H
,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,702.0,12166,,Autocuration,,,4230,,RBL-1,,,,B,1,BAO_0000219,10501,8,CHEMBL620852,,H
,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,12166,,Autocuration,,,4231,,RBL-1,,,,B,1,BAO_0000219,12526,8,CHEMBL875098,,H
,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,702.0,12166,Rattus norvegicus,Expert,,10116.0,4232,,RBL-1,,,,B,1,BAO_0000219,14799,9,CHEMBL620853,,D
,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,12166,,Autocuration,,,4233,,,,,,B,1,BAO_0000019,14799,8,CHEMBL620854,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,702.0,12166,,Autocuration,,,4234,,RBL-1,,,,B,1,BAO_0000219,3595,8,CHEMBL620855,,H
,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,702.0,12166,,Expert,,,4235,,RBL-1,,,,B,1,BAO_0000219,3595,8,CHEMBL839884,,H
,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,12166,,Autocuration,,,4236,,RBL-1,,,,B,1,BAO_0000219,12526,8,CHEMBL620856,,H
,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,12166,,Autocuration,,,4237,,RBL-1,,,,B,1,BAO_0000219,12526,8,CHEMBL620857,,H
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,12166,,Autocuration,,,4238,,,,,,B,1,BAO_0000019,10193,8,CHEMBL620858,,H
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,12166,,Autocuration,,,4239,,,,,,B,1,BAO_0000019,10193,8,CHEMBL620859,,H
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,12166,,Autocuration,,,4240,,,,,,B,1,BAO_0000019,10193,8,CHEMBL620860,,H
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,12166,,Autocuration,,,4241,,,,,,B,1,BAO_0000019,10193,8,CHEMBL620861,,H
,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,12166,,Expert,,,4242,,,,,,B,1,BAO_0000357,9138,8,CHEMBL620862,,H
,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,12166,,Autocuration,,,4243,,,,,,B,1,BAO_0000357,9138,8,CHEMBL620863,,H
,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,12166,,Autocuration,,,4244,,,,,,B,1,BAO_0000019,11966,8,CHEMBL620864,,H
,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,702.0,12166,,Autocuration,,,4245,,RBL-1,,,,B,1,BAO_0000219,165,8,CHEMBL620865,,H
,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,702.0,12166,,Autocuration,,,4246,,RBL-1,,,,B,1,BAO_0000219,165,8,CHEMBL620866,,H
,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,663.0,12166,,Autocuration,,,4247,,RBL-2H3,,,,B,1,BAO_0000219,11311,8,CHEMBL620867,,H
,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,663.0,12166,,Autocuration,,,4248,,RBL-2H3,,,,B,1,BAO_0000219,11311,8,CHEMBL620868,,H
,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,663.0,12166,,Autocuration,,,4249,,RBL-2H3,,,,F,1,BAO_0000219,11311,8,CHEMBL620869,,H
,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,12166,,Autocuration,,,4250,,,,,,F,1,BAO_0000019,11311,8,CHEMBL873952,,H
,,The compound was tested for inhibition of isolated 5-lipoxygenase,,12166,,Autocuration,,,4251,,,,,,B,1,BAO_0000357,11311,8,CHEMBL875099,,H
,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,663.0,12166,,Autocuration,,,4252,,RBL-2H3,,,,F,1,BAO_0000219,11311,8,CHEMBL620870,,H
,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,12166,,Autocuration,,,4253,,,,,,B,1,BAO_0000019,11087,8,CHEMBL618261,,H
,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,12166,,Autocuration,,,4254,,,,,,B,1,BAO_0000019,11087,8,CHEMBL618262,,H
,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,12166,,Autocuration,,,4255,,,,,,B,1,BAO_0000019,11087,8,CHEMBL619428,,H
,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,12166,,Autocuration,,,4256,,,,,,B,1,BAO_0000019,11087,8,CHEMBL619429,,H
,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,12166,,Autocuration,,,4257,,,,,,B,1,BAO_0000019,11087,8,CHEMBL619430,,H
,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,702.0,12166,,Autocuration,,,4258,,RBL-1,,,,B,1,BAO_0000219,496,8,CHEMBL620017,,H
,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,702.0,12166,,Autocuration,,,4259,,RBL-1,,,,B,1,BAO_0000219,496,8,CHEMBL620018,,H
,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,702.0,12166,,Autocuration,,,4260,,RBL-1,,,,F,1,BAO_0000219,13986,8,CHEMBL620019,,H
,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,702.0,12166,,Autocuration,,,4261,,RBL-1,,,,F,1,BAO_0000219,13986,8,CHEMBL620020,,H
,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,702.0,12166,,Autocuration,,,4262,,RBL-1,,,,F,1,BAO_0000219,13986,8,CHEMBL620021,,H
,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,702.0,12166,,Autocuration,,,4263,,RBL-1,,,,F,1,BAO_0000219,13986,8,CHEMBL620022,,H
,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,702.0,12166,,Autocuration,,,4264,,RBL-1,,,,F,1,BAO_0000219,13986,8,CHEMBL620023,,H
,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,702.0,12166,,Autocuration,,,4265,,RBL-1,,,,F,1,BAO_0000219,13986,8,CHEMBL620024,,H
,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,702.0,12166,,Autocuration,,,4266,,RBL-1,,,,F,1,BAO_0000219,13986,8,CHEMBL620025,,H
,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,702.0,12166,,Autocuration,,,4267,,RBL-1,,,,F,1,BAO_0000219,13986,8,CHEMBL620026,,H
,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,702.0,12166,,Autocuration,,,4268,,RBL-1,,,,F,1,BAO_0000219,13986,8,CHEMBL620027,,H
,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,12166,Rattus norvegicus,Expert,,10116.0,4269,,,,,,F,1,BAO_0000019,13986,9,CHEMBL620028,,D
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,12166,,Autocuration,,,4270,,,,,,B,1,BAO_0000357,10193,8,CHEMBL620029,,H
,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,12166,,Autocuration,,,4271,,,,,,B,1,BAO_0000357,9295,8,CHEMBL620030,,H
,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,702.0,12166,,Autocuration,,,4272,,RBL-1,,,,B,1,BAO_0000219,4717,8,CHEMBL875415,,H
,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,702.0,12166,,Autocuration,,,4273,,RBL-1,,,,B,1,BAO_0000219,4717,8,CHEMBL618256,,H
,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,702.0,12166,,Autocuration,,,4274,,RBL-1,,,,B,1,BAO_0000219,11854,8,CHEMBL618257,,H
,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,702.0,12166,,Autocuration,,,4275,,RBL-1,,,,B,1,BAO_0000219,11854,8,CHEMBL618258,,H
,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,702.0,12166,,Autocuration,,,4276,,RBL-1,,,,B,1,BAO_0000219,11854,8,CHEMBL618259,,H
,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,12166,,Autocuration,,,4277,,,,,,B,1,BAO_0000019,10193,8,CHEMBL618260,,H
,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,702.0,12166,,Autocuration,,,4278,,RBL-1,,,,B,1,BAO_0000219,9295,8,CHEMBL618215,,H
,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,702.0,12166,,Autocuration,,,4279,,RBL-1,,,,B,1,BAO_0000219,9295,8,CHEMBL618390,,H
,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,702.0,12166,,Autocuration,,,4280,,RBL-1,,,,B,1,BAO_0000219,9295,8,CHEMBL618391,,H
,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,702.0,12166,,Autocuration,,,4281,,RBL-1,,,,B,1,BAO_0000219,9295,8,CHEMBL618392,,H
,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,702.0,12166,,Autocuration,,,4282,,RBL-1,,,,B,1,BAO_0000219,165,8,CHEMBL618393,,H
,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,12166,,Autocuration,,,4283,,,,,,B,1,BAO_0000219,11311,8,CHEMBL618394,,H
,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),702.0,12166,Homo sapiens,Expert,,9606.0,4284,,RBL-1,,,,B,1,BAO_0000219,10489,8,CHEMBL618395,,H
,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),702.0,12166,Rattus norvegicus,Expert,,10116.0,4285,,RBL-1,,,,B,1,BAO_0000219,10489,9,CHEMBL618396,,D
,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),702.0,12166,Rattus norvegicus,Expert,,10116.0,4286,,RBL-1,,,,B,1,BAO_0000219,10489,9,CHEMBL858253,,D
,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,12166,Rattus norvegicus,Autocuration,,10116.0,4287,,,,,,B,1,BAO_0000019,14799,9,CHEMBL618397,,D
,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,12054,Glycine max,Autocuration,,3847.0,4288,,,,,,B,1,BAO_0000357,9295,8,CHEMBL618398,,H
,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,22226,,Autocuration,,,4289,,,,,,B,1,BAO_0000019,16811,0,CHEMBL618399,,U
,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,55,,Expert,,,4290,,,,,,B,1,BAO_0000357,168,8,CHEMBL618400,,H
,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,55,,Autocuration,,,4291,,,,,,B,1,BAO_0000357,6309,8,CHEMBL618401,,H
,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,55,,Autocuration,,,4292,,,,,,B,1,BAO_0000357,6309,8,CHEMBL618402,,H
,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,702.0,55,,Autocuration,,,4293,,RBL-1,,,,B,1,BAO_0000219,3092,8,CHEMBL876400,,H
,,Inhibitory activity against 5-lipoxygenase.,,55,,Expert,,,4294,,,,,,B,1,BAO_0000357,168,8,CHEMBL618403,,H
,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,55,,Autocuration,,,4295,,,,,,B,1,BAO_0000357,168,8,CHEMBL618404,,H
,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,55,,Autocuration,,,4296,,,,,,B,1,BAO_0000357,168,8,CHEMBL618405,,H
,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,55,,Autocuration,,,4297,,,,,,B,1,BAO_0000357,168,8,CHEMBL618406,,H
,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,55,,Expert,,,4298,,,,,,F,1,BAO_0000019,12338,8,CHEMBL618407,,H
,,Tested for the inhibitory activity against 5-lipoxygenase,,55,,Autocuration,,,4299,,,,,,B,1,BAO_0000357,4501,8,CHEMBL618408,,H
,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,55,,Autocuration,,,4300,,,,,,B,1,BAO_0000357,1132,8,CHEMBL618409,,H
,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,55,,Autocuration,,,4301,,,,,,B,1,BAO_0000357,2117,8,CHEMBL618410,,H
,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,55,,Autocuration,,,4302,,,,,,B,1,BAO_0000357,168,8,CHEMBL618411,,H
,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,55,,Autocuration,,,4303,,,,,,B,1,BAO_0000357,168,8,CHEMBL618412,,H
,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,702.0,12166,,Autocuration,,,4304,,RBL-1,,,,B,1,BAO_0000219,13575,8,CHEMBL618413,,H
,,,,12166,,Autocuration,,,4305,,,,,,B,1,BAO_0000357,11089,8,CHEMBL618414,,H
,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,10102,,Autocuration,,,4306,,,,,,B,1,BAO_0000357,216,8,CHEMBL618415,,H
,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,10102,,Autocuration,,,4307,,,,,,B,1,BAO_0000019,13165,8,CHEMBL618416,,H
,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,10102,,Autocuration,,,4308,,,,,,B,1,BAO_0000357,3278,8,CHEMBL876401,,H
,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,10102,,Expert,,,4309,,,,,,B,1,BAO_0000357,3278,8,CHEMBL618417,,H
,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,10102,,Autocuration,,,4310,,,,,,B,1,BAO_0000357,11966,8,CHEMBL618418,,H
,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,10102,,Autocuration,,,4311,,,,,,B,1,BAO_0000357,175,8,CHEMBL618419,,H
,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,10102,,Autocuration,,,4312,,,,,,B,1,BAO_0000357,175,8,CHEMBL618420,,H
,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,10102,,Autocuration,,,4313,,,,,,B,1,BAO_0000357,13449,8,CHEMBL618421,,H
,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,11238,,Autocuration,,,4314,,,,,,B,1,BAO_0000019,12014,8,CHEMBL618422,,H
,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,11238,,Autocuration,,,4315,,,,,,B,1,BAO_0000019,12014,8,CHEMBL618423,,H
,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,11238,,Autocuration,,,4316,,,,,,B,1,BAO_0000019,12014,8,CHEMBL618424,,H
,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,100284,,Intermediate,,,4317,,,,,,B,1,BAO_0000220,99,2,CHEMBL618425,,S
,,The dark toxicity against 543 human galactophore carcinoma cells,,22226,Homo sapiens,Autocuration,,9606.0,4318,,,,,,F,1,BAO_0000019,4349,0,CHEMBL618426,,U
,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,390.0,80623,Homo sapiens,Expert,,9606.0,4319,,Panel (56 tumour cell lines),,,,F,1,BAO_0000219,4071,1,CHEMBL618427,,N
,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,345.0,80008,Homo sapiens,Expert,,9606.0,4320,,5637,,,,F,1,BAO_0000219,17589,1,CHEMBL618428,,N
,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,345.0,80008,Homo sapiens,Intermediate,,9606.0,4321,,5637,,,,F,1,BAO_0000219,15002,1,CHEMBL618429,,N
,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",345.0,80008,Homo sapiens,Intermediate,,9606.0,4322,,5637,,,,F,1,BAO_0000219,13958,1,CHEMBL618430,,N
,,Growth inhibition against human 5637 cell lines,345.0,80008,Homo sapiens,Expert,,9606.0,4323,,5637,,,,F,1,BAO_0000219,17589,1,CHEMBL618431,,N
,,Antitumor activity against human bladder carcinoma 5637 cells.,345.0,80008,Homo sapiens,Expert,,9606.0,4324,,5637,,,,F,1,BAO_0000219,16748,1,CHEMBL883799,,N
,,Antitumor activity against human bladder carcinoma 5637 cells,345.0,80008,Homo sapiens,Intermediate,,9606.0,4325,,5637,,,,F,1,BAO_0000219,16747,1,CHEMBL618432,,N
,,Antitumor activity against human bladder carcinoma 5637 cells,345.0,80008,Homo sapiens,Intermediate,,9606.0,4326,,5637,,,,F,1,BAO_0000219,16747,1,CHEMBL618433,,N
,,In vitro inhibition of bovine trypsin(Trp).,,10443,Bos taurus,Expert,,9913.0,4327,,,,,,B,1,BAO_0000357,15285,9,CHEMBL618434,,D
,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,407.0,240,Cercopithecidae,Expert,,9527.0,4328,,CV-1,,,,B,1,BAO_0000219,3726,8,CHEMBL618435,,H
,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,10577,,Autocuration,,,4329,,,,,,B,1,BAO_0000357,5033,8,CHEMBL876402,,H
,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,104698,,Autocuration,,,4330,,,,,,F,1,BAO_0000019,11756,6,CHEMBL618436,,H
,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,22226,,Autocuration,,,4331,In vivo,,,,,F,1,BAO_0000218,11953,0,CHEMBL618437,,U
,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,20033,Cavia porcellus,Intermediate,,10141.0,4332,,,,,,B,1,BAO_0000357,5033,9,CHEMBL618438,,D
,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,17045,Rattus norvegicus,Expert,,10116.0,4333,,,,,,A,1,BAO_0000251,11347,8,CHEMBL883800,Microsomes,H
,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,17045,Rattus norvegicus,Expert,,10116.0,4334,,,,,,A,1,BAO_0000251,11347,8,CHEMBL618439,Microsomes,H
,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,22226,,Intermediate,,,4335,,,,,,F,1,BAO_0000019,1229,0,CHEMBL618440,,U
,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,22226,,Intermediate,,,4336,,,,,,F,1,BAO_0000019,1229,0,CHEMBL618441,,U
,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,11938,Trypanosoma brucei,Expert,,5691.0,4337,,,,,,B,1,BAO_0000019,17588,8,CHEMBL618442,,H
,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,11938,Trypanosoma brucei,Autocuration,,5691.0,4338,,,,,,B,1,BAO_0000019,17588,8,CHEMBL618443,,H
,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,11938,Ovis aries,Expert,,9940.0,4339,,,,,,B,1,BAO_0000019,17588,8,CHEMBL619158,,H
,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,11938,Ovis aries,Autocuration,,9940.0,4340,,,,,,B,1,BAO_0000019,17588,8,CHEMBL620974,,H
,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,11938,,Autocuration,,,4341,,,,,,B,1,BAO_0000357,16485,8,CHEMBL620975,,H
,,Average inhibitory concentration against 60 human cell lines was reported,,22226,Homo sapiens,Intermediate,,9606.0,4342,,,,,,F,1,BAO_0000019,4337,0,CHEMBL620976,,U
,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,22226,Homo sapiens,Expert,,9606.0,4343,,,,,,F,1,BAO_0000019,4112,0,CHEMBL620977,,U
,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,542.0,80315,Homo sapiens,Intermediate,,9606.0,4344,,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,BAO_0000219,16160,1,CHEMBL620978,,N
,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,542.0,80315,Homo sapiens,Intermediate,,9606.0,4345,,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,BAO_0000219,16160,1,CHEMBL620979,,N
,,In vitro mean growth inhibitory activity against 60-cell panel,542.0,80315,,Expert,,,4346,,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,BAO_0000219,17376,1,CHEMBL620980,,N
,,In vitro mean growth lethal concentration against 60-cell panel,542.0,80315,,Expert,,,4347,,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,BAO_0000219,17376,1,CHEMBL620981,,N
,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,542.0,80315,,Expert,,,4348,,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,BAO_0000219,17376,1,CHEMBL620982,,N
,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,542.0,80315,,Expert,,,4349,,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,BAO_0000219,17376,1,CHEMBL620983,,N
,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,104775,,Autocuration,,,4350,,,,,,F,1,BAO_0000019,3241,4,CHEMBL620984,,H
,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,104775,,Autocuration,,,4351,,,,,,F,1,BAO_0000019,3241,4,CHEMBL620985,,H
,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,275,,Expert,,,4352,,,,,,B,1,BAO_0000357,3725,8,CHEMBL620986,,H
,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,50425,Plasmodium falciparum,Expert,,5833.0,4353,,,,,,F,1,BAO_0000218,10805,1,CHEMBL620987,,N
,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,50425,Plasmodium falciparum,Expert,,5833.0,4354,,,,,,F,1,BAO_0000218,10805,1,CHEMBL620988,,N
,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,50425,Plasmodium falciparum,Expert,,5833.0,4355,,,,,,F,1,BAO_0000218,10805,1,CHEMBL620989,,N
,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,50425,Plasmodium falciparum,Expert,,5833.0,4356,,,,,,F,1,BAO_0000218,10805,1,CHEMBL620990,,N
,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,50425,Plasmodium falciparum,Intermediate,,5833.0,4357,,,,,,F,1,BAO_0000218,10805,1,CHEMBL620991,,N
,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,850.0,80628,Mus musculus,Intermediate,,10090.0,4358,,6C3HED,,,,F,1,BAO_0000218,10144,1,CHEMBL620992,,N
,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,850.0,80628,Mus musculus,Intermediate,,10090.0,4359,,6C3HED,,,,F,1,BAO_0000218,10144,1,CHEMBL620993,,N
,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,850.0,80628,Mus musculus,Intermediate,,10090.0,4360,,6C3HED,,,,F,1,BAO_0000218,10144,1,CHEMBL620994,,N
,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,850.0,80628,Mus musculus,Intermediate,,10090.0,4361,,6C3HED,,,,F,1,BAO_0000218,10144,1,CHEMBL620995,,N
,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,850.0,80628,Mus musculus,Intermediate,,10090.0,4362,,6C3HED,,,,F,1,BAO_0000218,10144,1,CHEMBL620996,,N
,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,850.0,80628,Mus musculus,Intermediate,,10090.0,4363,,6C3HED,,,,F,1,BAO_0000218,10144,1,CHEMBL875581,,N
,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,22224,Mus musculus,Autocuration,,10090.0,4364,In vivo,,,,,F,1,BAO_0000218,10685,0,CHEMBL620997,,U
,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,22224,Mus musculus,Autocuration,,10090.0,4365,In vivo,,,,,F,1,BAO_0000218,10685,0,CHEMBL620998,,U
,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,22224,Mus musculus,Autocuration,,10090.0,4366,In vivo,,,,,F,1,BAO_0000218,10685,0,CHEMBL620999,,U
,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,22224,Mus musculus,Autocuration,,10090.0,4367,In vivo,,,,,F,1,BAO_0000218,10685,0,CHEMBL621000,,U
,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,22224,Mus musculus,Autocuration,,10090.0,4368,In vivo,,,,,F,1,BAO_0000218,10685,0,CHEMBL621001,,U
,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,22224,Mus musculus,Autocuration,,10090.0,4369,In vivo,,,,,F,1,BAO_0000218,10685,0,CHEMBL621002,,U
,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,22224,Mus musculus,Autocuration,,10090.0,4370,In vivo,,,,,F,1,BAO_0000218,10685,0,CHEMBL621003,,U
,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,22224,Mus musculus,Autocuration,,10090.0,4371,In vivo,,,,,F,1,BAO_0000218,10685,0,CHEMBL621004,,U
,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,22224,Mus musculus,Autocuration,,10090.0,4372,In vivo,,,,,F,1,BAO_0000218,10685,0,CHEMBL621005,,U
,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,22224,Mus musculus,Autocuration,,10090.0,4373,In vivo,,,,,F,1,BAO_0000218,10685,0,CHEMBL621006,,U
,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,22224,Mus musculus,Autocuration,,10090.0,4374,In vivo,,,,,F,1,BAO_0000218,10685,0,CHEMBL621007,,U
,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,22224,Mus musculus,Autocuration,,10090.0,4375,,,,,,F,1,BAO_0000218,10144,0,CHEMBL621008,,U
,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,22224,Mus musculus,Autocuration,,10090.0,4376,,,,,,F,1,BAO_0000218,10144,0,CHEMBL621009,,U
,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,22224,Mus musculus,Autocuration,,10090.0,4377,,,,,,F,1,BAO_0000218,10144,0,CHEMBL857705,,U
,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,22224,Mus musculus,Autocuration,,10090.0,4378,,,,,,F,1,BAO_0000218,10144,0,CHEMBL619828,,U
,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,22224,Mus musculus,Autocuration,,10090.0,4379,,,,,,F,1,BAO_0000218,10685,0,CHEMBL619829,,U
,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,22224,Mus musculus,Autocuration,,10090.0,4380,,,,,,F,1,BAO_0000218,10685,0,CHEMBL619830,,U
,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,22224,Mus musculus,Autocuration,,10090.0,4381,,,,,,F,1,BAO_0000218,10685,0,CHEMBL619831,,U
,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,22224,Mus musculus,Autocuration,,10090.0,4382,,,,,,F,1,BAO_0000218,10685,0,CHEMBL619832,,U
,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,22224,Mus musculus,Autocuration,,10090.0,4383,,,,,,A,1,BAO_0000218,10685,0,CHEMBL619833,,U
,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,22224,Mus musculus,Autocuration,,10090.0,4384,,,,,,A,1,BAO_0000218,10685,0,CHEMBL619834,,U
,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,22224,Mus musculus,Autocuration,,10090.0,4385,,,,,,A,1,BAO_0000218,10685,0,CHEMBL619835,,U
,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,22224,Mus musculus,Autocuration,,10090.0,4386,,,,,,A,1,BAO_0000218,10685,0,CHEMBL619836,,U
,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",850.0,80628,Mus musculus,Intermediate,,10090.0,4387,,6C3HED,,,,F,1,BAO_0000218,8831,1,CHEMBL619837,,N
,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,22224,,Autocuration,,,4388,In vivo,,,,,F,1,BAO_0000218,11704,0,CHEMBL619838,,U
,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,50594,Mus musculus,Intermediate,,10090.0,4389,,,,,,A,1,BAO_0000218,11704,1,CHEMBL619839,,N
,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,850.0,80628,Mus musculus,Intermediate,,10090.0,4390,In vivo,6C3HED,,,,F,1,BAO_0000218,10685,1,CHEMBL619840,,N
,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,850.0,80628,Mus musculus,Intermediate,,10090.0,4391,In vivo,6C3HED,,,,F,1,BAO_0000218,10685,1,CHEMBL619841,,N
,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),850.0,80628,Mus musculus,Expert,,10090.0,4392,,6C3HED,,,,F,1,BAO_0000218,11368,1,CHEMBL857704,,N
,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),850.0,80628,Mus musculus,Intermediate,,10090.0,4393,,6C3HED,,,,F,1,BAO_0000218,11368,1,CHEMBL619842,,N
,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),850.0,80628,Mus musculus,Expert,,10090.0,4394,,6C3HED,,,,F,1,BAO_0000218,11368,1,CHEMBL619843,,N
,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,22226,Staphylococcus aureus,Autocuration,,1280.0,4395,,,,,,B,1,BAO_0000019,17763,0,CHEMBL619844,,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4396,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL857855,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4397,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619845,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4398,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619846,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4399,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619847,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4400,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL619848,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4401,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620893,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4402,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620894,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4403,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620895,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4404,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620896,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4405,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620897,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4406,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620898,Microsomes,U
,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,22226,Rattus norvegicus,Autocuration,2107.0,10116.0,4407,,,,,Liver,B,1,BAO_0000251,7411,0,CHEMBL620899,Microsomes,U
,,The apparent total plasma clearance in monkey,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,4408,In vivo,,,,Plasma,A,1,BAO_0000218,347,0,CHEMBL620900,,U
,,Compound was evaluated for Hepatic clearance in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4409,In vivo,,,,,A,1,BAO_0000218,3341,0,CHEMBL620901,,U
,,Lower clearance in monkey (i.v.) at 0.5 mpk,,22224,Cercopithecidae,Autocuration,,9527.0,4410,In vivo,,,,,A,1,BAO_0000218,17853,0,CHEMBL620902,,U
,,Plasma clearance in rhesus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4411,In vivo,,,,,A,1,BAO_0000218,4514,0,CHEMBL620903,,U
,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,4412,In vivo,,,,,A,1,BAO_0000218,6062,0,CHEMBL620904,,U
,,Plasma clearance of compound was determined in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4413,In vivo,,,,,A,1,BAO_0000218,6821,0,CHEMBL620905,,U
,,Plasma clearance was calculated in rhesus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4414,In vivo,,,,,A,1,BAO_0000218,6057,0,CHEMBL620906,,U
,,Plasma clearance in rhesus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4415,In vivo,,,,,A,1,BAO_0000218,5145,0,CHEMBL875420,,U
,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,22224,Cercopithecidae,Autocuration,,9527.0,4416,In vivo,,,,,A,1,BAO_0000218,6641,0,CHEMBL620907,,U
,,Plasma clearance was evaluated in rhesus,,22224,Cercopithecidae,Autocuration,,9527.0,4417,In vivo,,,,,A,1,BAO_0000218,5472,0,CHEMBL620908,,U
,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,22224,Cercopithecidae,Autocuration,,9527.0,4418,In vivo,,,,,A,1,BAO_0000218,4257,0,CHEMBL620909,,U
,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,22224,Cercopithecidae,Autocuration,,9527.0,4419,In vivo,,,,,A,1,BAO_0000218,5546,0,CHEMBL620910,,U
,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,22224,Cercopithecidae,Autocuration,,9527.0,4420,In vivo,,,,,A,1,BAO_0000218,5334,0,CHEMBL620911,,U
,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,22224,Cercopithecidae,Autocuration,,9527.0,4421,In vivo,,,,,A,1,BAO_0000218,5334,0,CHEMBL620912,,U
,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,4422,In vivo,,,,,A,1,BAO_0000218,17509,0,CHEMBL620913,,U
,,Cmax in monkey after administration of 1 mg/kg iv,,22224,Cercopithecidae,Autocuration,,9527.0,4423,In vivo,,,,,A,1,BAO_0000218,6535,0,CHEMBL620914,,U
,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,22224,Cercopithecidae,Autocuration,,9527.0,4424,In vivo,,,,,A,1,BAO_0000218,5668,0,CHEMBL620915,,U
,,Cmax in cynomolgus monkey by iv administration,,22224,Cercopithecidae,Autocuration,,9527.0,4425,In vivo,,,,,A,1,BAO_0000218,5922,0,CHEMBL620916,,U
,,Cmax in cynomolgus monkey by po administration,,22224,Cercopithecidae,Autocuration,,9527.0,4426,In vivo,,,,,A,1,BAO_0000218,5922,0,CHEMBL620917,,U
,,Cmax value evaluated in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4427,In vivo,,,,,A,1,BAO_0000218,6078,0,CHEMBL620918,,U
,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4428,In vivo,,,,,A,1,BAO_0000218,2661,0,CHEMBL620919,,U
,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,4429,In vivo,,,,Plasma,A,1,BAO_0000218,3249,0,CHEMBL620920,,U
,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,4430,In vivo,,,,Plasma,A,1,BAO_0000218,3249,0,CHEMBL620921,,U
,,Maximal plasma concentration in squirrel monkeys,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,4431,In vivo,,,,Plasma,A,1,BAO_0000218,5553,0,CHEMBL620922,,U
,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,22224,Cercopithecidae,Autocuration,,9527.0,4432,In vivo,,,,,A,1,BAO_0000218,1916,0,CHEMBL620923,,U
,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,4433,In vivo,,,,Plasma,A,1,BAO_0000218,6227,0,CHEMBL620924,,U
,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,22224,Cercopithecidae,Autocuration,,9527.0,4434,In vivo,,,,,A,1,BAO_0000218,4809,0,CHEMBL620925,,U
,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,22224,Cercopithecidae,Autocuration,,9527.0,4435,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL620926,,U
,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,22224,Cercopithecidae,Autocuration,,9527.0,4436,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL620927,,U
,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,22224,Cercopithecidae,Autocuration,,9527.0,4437,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL620928,,U
,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,4438,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL620929,,U
,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,4439,In vivo,,,,Plasma,A,1,BAO_0000218,6221,0,CHEMBL620930,,U
,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,22224,Cercopithecidae,Autocuration,,9527.0,4440,,,,,,A,1,BAO_0000218,167,0,CHEMBL620931,,U
,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,22224,Cercopithecidae,Autocuration,,9527.0,4441,,,,,,A,1,BAO_0000218,167,0,CHEMBL620932,,U
,,Absolute bioavailability was evaluated in monkey,,22224,monkey,Autocuration,,9443.0,4442,In vivo,,,,,A,1,BAO_0000218,4257,0,CHEMBL620933,,U
,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,22224,monkey,Autocuration,,9443.0,4443,In vivo,,,,,A,1,BAO_0000218,6221,0,CHEMBL620934,,U
,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,22224,monkey,Autocuration,,9443.0,4444,In vivo,,,,,A,1,BAO_0000218,17667,0,CHEMBL620935,,U
,,Bioavailability of compound was determined in rhesus monkey,,22224,Macaca mulatta,Autocuration,,9544.0,4445,In vivo,,,,,A,1,BAO_0000218,17267,0,CHEMBL620936,,U
,,Bioavailability determined after oral administration in marmoset,,22224,marmosets,Autocuration,,38020.0,4446,In vivo,,,,,A,1,BAO_0000218,4256,0,CHEMBL620937,,U
,,Oral bioavailability in cynomolgus monkey,,22224,Macaca fascicularis,Autocuration,,9541.0,4447,In vivo,,,,,A,1,BAO_0000218,4256,0,CHEMBL620938,,U
,,Bioavailability in monkey (p.o.) at 2.0 mpk,,22224,monkey,Autocuration,,9443.0,4448,In vivo,,,,,A,1,BAO_0000218,17853,0,CHEMBL620939,,U
,,Bioavailability was evaluated after oral administration in monkey,,22224,monkey,Autocuration,,9443.0,4449,In vivo,,,,,A,1,BAO_0000218,16365,0,CHEMBL620940,,U
,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,22224,Macaca fascicularis,Autocuration,,9541.0,4450,In vivo,,,,,A,1,BAO_0000218,1916,0,CHEMBL620941,,U
,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,22224,Macaca mulatta,Autocuration,,9544.0,4451,In vivo,,,,,A,1,BAO_0000218,5334,0,CHEMBL620942,,U
,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,22224,Macaca mulatta,Autocuration,,9544.0,4452,In vivo,,,,,A,1,BAO_0000218,5334,0,CHEMBL620943,,U
,,Bioavailability of the compound was determined in monkey,,22224,monkey,Autocuration,,9443.0,4453,In vivo,,,,,A,1,BAO_0000218,17592,0,CHEMBL620944,,U
,,Bioavailability in squirrel monkey (dose 5 mg/kg),,22224,Saimiri sciureus,Autocuration,,9521.0,4454,In vivo,,,,,A,1,BAO_0000218,1399,0,CHEMBL620945,,U
,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,22224,monkey,Autocuration,,9443.0,4455,In vivo,,,,,A,1,BAO_0000218,4809,0,CHEMBL620946,,U
,,Oral bioavailability in monkey,,22224,monkey,Autocuration,,9443.0,4456,In vivo,,,,,A,1,BAO_0000218,3341,0,CHEMBL620947,,U
,,Compound was tested for bioavailability in squirrel monkey,,22224,Saimiri sciureus,Autocuration,,9521.0,4457,In vivo,,,,,A,1,BAO_0000218,64,0,CHEMBL620948,,U
,,Oral bioavailability in Rhesus monkey,,22224,Macaca mulatta,Autocuration,,9544.0,4458,In vivo,,,,,A,1,BAO_0000218,5005,0,CHEMBL620949,,U
,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,22224,Macaca mulatta,Autocuration,,9544.0,4459,In vivo,,,,,A,1,BAO_0000218,5005,0,CHEMBL620950,,U
,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,22224,Macaca fascicularis,Autocuration,,9541.0,4460,In vivo,,,,,A,1,BAO_0000218,5237,0,CHEMBL620951,,U
,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,22224,Macaca fascicularis,Autocuration,,9541.0,4461,In vivo,,,,,A,1,BAO_0000218,5237,0,CHEMBL620952,,U
,,Oral bioavailability in monkey (dose 5 mg/kg),,22224,monkey,Autocuration,,9443.0,4462,In vivo,,,,,A,1,BAO_0000218,5302,0,CHEMBL875421,,U
,,Oral bioavailability of compound at 5 mg/kg in monkey,,22224,monkey,Autocuration,,9443.0,4463,In vivo,,,,,A,1,BAO_0000218,17667,0,CHEMBL620953,,U
,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,4464,In vivo,,,,,A,1,BAO_0000218,6161,1,CHEMBL873491,,N
,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,4465,In vivo,,,,,A,1,BAO_0000218,6161,1,CHEMBL620954,,N
,,Plasma half life determined,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,4466,,,,,Plasma,A,1,BAO_0000218,3854,1,CHEMBL620955,,N
,,Plasma half life in dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,4467,,,,,Plasma,A,1,BAO_0000218,993,1,CHEMBL618097,,N
,,Plasma half-life in Beagle dogs,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,4468,,,,,Plasma,A,1,BAO_0000218,4514,1,CHEMBL618268,,N
,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,4469,In vivo,,,,Plasma,A,1,BAO_0000218,5334,1,CHEMBL618269,,N
,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,4470,In vivo,,,,Plasma,A,1,BAO_0000218,5334,1,CHEMBL618270,,N
,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,4471,In vivo,,,,,A,1,BAO_0000218,1466,1,CHEMBL618271,,N
,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,4472,In vivo,,,,,A,1,BAO_0000218,1466,1,CHEMBL873493,,N
,,Tested for the half life period in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,4473,,,,,,A,1,BAO_0000218,5313,1,CHEMBL621031,,N
,,Tested for the half life period in dog at dosage of 10 mpk,,50588,Canis lupus familiaris,Intermediate,,9615.0,4474,In vivo,,,,,A,1,BAO_0000218,5313,1,CHEMBL621032,,N
,,The compound was tested for half life in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,4475,,,,,,A,1,BAO_0000218,3880,1,CHEMBL621033,,N
,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,4476,,,,,Plasma,A,1,BAO_0000218,3639,1,CHEMBL621034,,N
,,The half life was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,4477,,,,,,A,1,BAO_0000218,3880,1,CHEMBL621035,,N
,,The plasma half-life in dogs,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,4478,,,,,Plasma,A,1,BAO_0000218,3918,1,CHEMBL621036,,N
,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,4479,,,,,Plasma,A,1,BAO_0000218,16452,1,CHEMBL621037,,N
,,Half life in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,4480,,,,,,A,1,BAO_0000218,17796,1,CHEMBL619812,,N
,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,50588,Canis lupus familiaris,Intermediate,,9615.0,4481,In vivo,,,,,A,1,BAO_0000218,5983,1,CHEMBL619813,,N
,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,4482,In vivo,,,,,A,1,BAO_0000218,1466,1,CHEMBL873335,,N
,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,4483,In vivo,,,,,A,1,BAO_0000218,16456,1,CHEMBL619814,,N
,,Cmax in ferrets after 30 mg/kg oral dose,,50506,Mustela putorius furo,Expert,,9669.0,4484,In vivo,,,,,A,1,BAO_0000218,6113,1,CHEMBL619815,,N
,,Emesis in ferrets at 30 mg/kg oral dose,,50506,Mustela putorius furo,Expert,,9669.0,4485,In vivo,,,,,F,1,BAO_0000218,6113,1,CHEMBL619816,,N
,,Bioavailability in cynomolgus monkey,,22224,Macaca fascicularis,Autocuration,,9541.0,4486,In vivo,,,,,A,1,BAO_0000218,17796,0,CHEMBL619817,,U
,,Volume of distribution in cynomolgus,,100710,Macaca fascicularis,Intermediate,,9541.0,4487,In vivo,,,,,A,1,BAO_0000218,17796,1,CHEMBL619818,,N
,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,22224,Cavia porcellus,Autocuration,1969.0,10141.0,4488,,,,,Plasma,A,1,BAO_0000218,5308,0,CHEMBL619819,,U
,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,22224,Cavia porcellus,Autocuration,,10141.0,4489,,,,,,A,1,BAO_0000218,4877,0,CHEMBL619820,,U
,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,22224,Cavia porcellus,Autocuration,,10141.0,4490,,,,,,A,1,BAO_0000218,4876,0,CHEMBL875419,,U
,,AUC in guinea pig after 3mg/kg oral dose,,22224,Cavia porcellus,Autocuration,1969.0,10141.0,4491,In vivo,,,,Plasma,A,1,BAO_0000218,4878,0,CHEMBL619821,,U
,,Bioavailability in guinea pig was tested,,22224,Cavia porcellus,Autocuration,,10141.0,4492,In vivo,,,,,A,1,BAO_0000218,5308,0,CHEMBL619822,,U
,,Tested for oral bioavailability in guinea pig at 5 mg/kg,,22224,Cavia porcellus,Autocuration,,10141.0,4493,In vivo,,,,,A,1,BAO_0000218,4877,0,CHEMBL619823,,U
,,Tested for the oral bioavailability of the compound,,22224,Cavia porcellus,Autocuration,,10141.0,4494,In vivo,,,,,A,1,BAO_0000218,4876,0,CHEMBL619824,,U
,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,22224,Cavia porcellus,Autocuration,,10141.0,4495,In vivo,,,,,A,1,BAO_0000218,4876,0,CHEMBL619825,,U
,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,22224,Cavia porcellus,Autocuration,,10141.0,4496,In vivo,,,,,A,1,BAO_0000218,5308,0,CHEMBL619826,,U
,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,22224,Cavia porcellus,Autocuration,2048.0,10141.0,4497,In vivo,,,,Lung,A,1,BAO_0000218,4877,0,CHEMBL619827,,U
,,Cmax in guinea pig after 3mg/kg oral dose,,22224,Cavia porcellus,Autocuration,,10141.0,4498,In vivo,,,,,A,1,BAO_0000218,4878,0,CHEMBL618167,,U
,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,22224,Cavia porcellus,Autocuration,178.0,10141.0,4499,,,,,Blood,A,1,BAO_0000019,5689,0,CHEMBL618168,,U
,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,22224,Cavia porcellus,Autocuration,955.0,10141.0,4500,,,,,Brain,A,1,BAO_0000019,5689,0,CHEMBL618169,,U
,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,22224,Cavia porcellus,Autocuration,,10141.0,4501,,,,,,A,1,BAO_0000019,5689,0,CHEMBL618170,,U
,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,22224,Cavia porcellus,Autocuration,160.0,10141.0,4502,,,,,Intestine,A,1,BAO_0000019,5689,0,CHEMBL618171,,U
,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,22224,Cavia porcellus,Autocuration,2113.0,10141.0,4503,,,,,Kidney,A,1,BAO_0000019,5689,0,CHEMBL618172,,U
,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,22224,Cavia porcellus,Autocuration,2107.0,10141.0,4504,,,,,Liver,A,1,BAO_0000019,5689,0,CHEMBL618173,,U
,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,22224,Cavia porcellus,Autocuration,,10141.0,4505,,,,,,A,1,BAO_0000019,5689,0,CHEMBL618174,,U
,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,22224,Cavia porcellus,Autocuration,2106.0,10141.0,4506,,,,,Spleen,A,1,BAO_0000019,5689,0,CHEMBL875408,,U
,,Elimination T1/2 in Guinea pig (PO dose),,22224,Cavia porcellus,Autocuration,,10141.0,4507,In vivo,,,,,A,1,BAO_0000218,14465,0,CHEMBL839827,,U
,,Partition coefficient was measured as -log (counts per min ),,22224,Cavia porcellus,Autocuration,,10141.0,4508,,,,,,A,1,BAO_0000019,5689,0,CHEMBL618175,,U
,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,22224,Cavia porcellus,Autocuration,,10141.0,4509,In vivo,,,,,A,1,BAO_0000218,611,0,CHEMBL618176,,U
,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,22224,Cavia porcellus,Autocuration,,10141.0,4510,In vivo,,,,,A,1,BAO_0000218,611,0,CHEMBL618177,,U
,,Elimination T1/2 in Guinea pig (PO dose),,22224,Cavia porcellus,Autocuration,,10141.0,4511,In vivo,,,,,A,1,BAO_0000218,14465,0,CHEMBL618178,,U
,,"Tested for the half life period of the compound, intravenously",,22224,Cavia porcellus,Autocuration,,10141.0,4512,In vivo,,,,,A,1,BAO_0000218,4876,0,CHEMBL618179,,U
,,Half-life was measured,,22224,Cavia porcellus,Autocuration,,10141.0,4513,,,,,,A,1,BAO_0000019,5689,0,CHEMBL873489,,U
,,The time required for onset of inotropy after addition of a single dose of delta F75,,22224,Cavia porcellus,Autocuration,,10141.0,4514,,,,,,A,1,BAO_0000019,7515,0,CHEMBL618180,,U
,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,22224,Cavia porcellus,Autocuration,,10141.0,4515,In vivo,,,,,A,1,BAO_0000218,17667,0,CHEMBL618181,,U
,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,22224,Cavia porcellus,Autocuration,,10141.0,4516,In vivo,,,,,A,1,BAO_0000218,17667,0,CHEMBL618182,,U
,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,22224,Cricetulus griseus,Autocuration,,10029.0,4517,In vivo,,,,,A,1,BAO_0000218,4727,0,CHEMBL618183,,U
,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,,10090.0,4518,In vivo,,,,,A,1,BAO_0000218,10107,1,CHEMBL618184,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594,Mus musculus,Intermediate,,10090.0,4519,In vivo,,,,,A,1,BAO_0000218,10107,1,CHEMBL618185,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,,10090.0,4520,In vivo,,,,,A,1,BAO_0000218,10107,1,CHEMBL618186,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,,10090.0,4521,In vivo,,,,,A,1,BAO_0000218,10107,1,CHEMBL618187,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,50594,Mus musculus,Intermediate,,10090.0,4522,In vivo,,,,,A,1,BAO_0000218,10107,1,CHEMBL618188,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,,10090.0,4523,In vivo,,,,,A,1,BAO_0000218,10107,1,CHEMBL875409,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,,10090.0,4524,In vivo,,,,,A,1,BAO_0000218,10107,1,CHEMBL618189,,N
,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,50594,Mus musculus,Intermediate,178.0,10090.0,4525,In vivo,,,,Blood,A,1,BAO_0000218,3655,1,CHEMBL618190,,N
,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,50594,Mus musculus,Intermediate,178.0,10090.0,4526,In vivo,,,,Blood,A,1,BAO_0000218,3655,1,CHEMBL618191,,N
,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,50594,Mus musculus,Intermediate,178.0,10090.0,4527,In vivo,,,,Blood,A,1,BAO_0000218,3655,1,CHEMBL618192,,N
,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,50594,Mus musculus,Intermediate,10000001.0,10090.0,4528,In vivo,,,,Bone,A,1,BAO_0000218,3655,1,CHEMBL618193,,N
,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,50594,Mus musculus,Intermediate,10000001.0,10090.0,4529,In vivo,,,,Bone,A,1,BAO_0000218,3655,1,CHEMBL618194,,N
,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,50594,Mus musculus,Intermediate,10000001.0,10090.0,4530,In vivo,,,,Bone,A,1,BAO_0000218,3655,1,CHEMBL618195,,N
,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,50594,Mus musculus,Intermediate,955.0,10090.0,4531,In vivo,,,,Brain,A,1,BAO_0000218,3655,1,CHEMBL618196,,N
,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,50594,Mus musculus,Intermediate,955.0,10090.0,4532,In vivo,,,,Brain,A,1,BAO_0000218,3655,1,CHEMBL618197,,N
,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,50594,Mus musculus,Intermediate,955.0,10090.0,4533,In vivo,,,,Brain,A,1,BAO_0000218,3655,1,CHEMBL618198,,N
,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,50594,Mus musculus,Intermediate,948.0,10090.0,4534,In vivo,,,,Heart,A,1,BAO_0000218,3655,1,CHEMBL618199,,N
,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,50594,Mus musculus,Intermediate,948.0,10090.0,4535,In vivo,,,,Heart,A,1,BAO_0000218,3655,1,CHEMBL618200,,N
,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,50594,Mus musculus,Intermediate,948.0,10090.0,4536,In vivo,,,,Heart,A,1,BAO_0000218,3655,1,CHEMBL618201,,N
,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,50594,Mus musculus,Intermediate,160.0,10090.0,4537,In vivo,,,,Intestine,A,1,BAO_0000218,3655,1,CHEMBL618202,,N
,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,50594,Mus musculus,Intermediate,160.0,10090.0,4538,In vivo,,,,Intestine,A,1,BAO_0000218,3655,1,CHEMBL618203,,N
,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,50594,Mus musculus,Intermediate,160.0,10090.0,4539,In vivo,,,,Intestine,A,1,BAO_0000218,3655,1,CHEMBL618204,,N
,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,50594,Mus musculus,Intermediate,2113.0,10090.0,4540,In vivo,,,,Kidney,A,1,BAO_0000218,3655,1,CHEMBL618205,,N
,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,50594,Mus musculus,Intermediate,2113.0,10090.0,4541,In vivo,,,,Kidney,A,1,BAO_0000218,3655,1,CHEMBL618206,,N
,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,50594,Mus musculus,Intermediate,2113.0,10090.0,4542,In vivo,,,,Kidney,A,1,BAO_0000218,3655,1,CHEMBL618207,,N
,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,50594,Mus musculus,Intermediate,2107.0,10090.0,4543,In vivo,,,,Liver,A,1,BAO_0000218,3655,1,CHEMBL618208,,N
,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,50594,Mus musculus,Intermediate,2107.0,10090.0,4544,In vivo,,,,Liver,A,1,BAO_0000218,3655,1,CHEMBL618932,,N
,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,50594,Mus musculus,Intermediate,2107.0,10090.0,4545,In vivo,,,,Liver,A,1,BAO_0000218,3655,1,CHEMBL618933,,N
,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,50594,Mus musculus,Intermediate,2048.0,10090.0,4546,In vivo,,,,Lung,A,1,BAO_0000218,3655,1,CHEMBL618934,,N
,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,50594,Mus musculus,Intermediate,2048.0,10090.0,4547,In vivo,,,,Lung,A,1,BAO_0000218,3655,1,CHEMBL618935,,N
,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,50594,Mus musculus,Intermediate,2048.0,10090.0,4548,In vivo,,,,Lung,A,1,BAO_0000218,3655,1,CHEMBL618936,,N
,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,50594,Mus musculus,Intermediate,2385.0,10090.0,4549,In vivo,,,,Muscle tissue,A,1,BAO_0000218,3655,1,CHEMBL618937,,N
,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,50594,Mus musculus,Intermediate,2385.0,10090.0,4550,In vivo,,,,Muscle tissue,A,1,BAO_0000218,3655,1,CHEMBL618938,,N
,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,50594,Mus musculus,Intermediate,2385.0,10090.0,4551,In vivo,,,,Muscle tissue,A,1,BAO_0000218,3655,1,CHEMBL619104,,N
,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,50594,Mus musculus,Intermediate,2106.0,10090.0,4552,In vivo,,,,Spleen,A,1,BAO_0000218,3655,1,CHEMBL619105,,N
,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,50594,Mus musculus,Intermediate,2106.0,10090.0,4553,In vivo,,,,Spleen,A,1,BAO_0000218,3655,1,CHEMBL619106,,N
,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,50594,Mus musculus,Intermediate,2106.0,10090.0,4554,In vivo,,,,Spleen,A,1,BAO_0000218,3655,1,CHEMBL619107,,N
,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,50594,Mus musculus,Intermediate,945.0,10090.0,4555,In vivo,,,,Stomach,A,1,BAO_0000218,3655,1,CHEMBL875410,,N
,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,50594,Mus musculus,Intermediate,945.0,10090.0,4556,In vivo,,,,Stomach,A,1,BAO_0000218,3655,1,CHEMBL619108,,N
,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,50594,Mus musculus,Intermediate,945.0,10090.0,4557,In vivo,,,,Stomach,A,1,BAO_0000218,3655,1,CHEMBL619109,,N
,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,50594,Mus musculus,Intermediate,,10090.0,4558,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL619110,,N
,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,50594,Mus musculus,Intermediate,,10090.0,4559,In vivo,,,,,F,1,BAO_0000218,16597,1,CHEMBL619111,,N
,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,50594,Mus musculus,Intermediate,,10090.0,4560,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL619112,,N
,,MRT value at a dose of 10 mg/kg peroral administration in mice.,,50594,Mus musculus,Intermediate,,10090.0,4561,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL619113,,N
,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4562,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL619114,,N
,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4563,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL619115,,N
,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,478.0,81034,Homo sapiens,Intermediate,,9606.0,4564,,A2780,,,,F,1,BAO_0000219,3830,1,CHEMBL619116,,N
,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,478.0,81034,Homo sapiens,Intermediate,,9606.0,4565,,A2780,,,,F,1,BAO_0000219,3829,1,CHEMBL619117,,N
,,Compound was evaluated for cytotoxicity against A2780 cell lines.,478.0,81034,Homo sapiens,Intermediate,,9606.0,4566,,A2780,,,,F,1,BAO_0000219,2040,1,CHEMBL619118,,N
,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,478.0,81034,Homo sapiens,Intermediate,,9606.0,4567,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619119,,N
,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,478.0,81034,Homo sapiens,Intermediate,,9606.0,4568,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619120,,N
,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,478.0,81034,Homo sapiens,Intermediate,,9606.0,4569,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619121,,N
,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,478.0,81034,Homo sapiens,Intermediate,,9606.0,4570,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619122,,N
,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,478.0,81034,Homo sapiens,Intermediate,,9606.0,4571,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619123,,N
,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,478.0,81034,Homo sapiens,Intermediate,,9606.0,4572,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619124,,N
,,Compound was evaluated for cytotoxicity against A2780 cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,4573,,A2780,,,,F,1,BAO_0000219,2859,1,CHEMBL619125,,N
,,In vitro inhibitory activity against human tumor cell line A2780,478.0,81034,Homo sapiens,Intermediate,,9606.0,4574,,A2780,,,,F,1,BAO_0000219,5618,1,CHEMBL875411,,N
,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,478.0,81034,Homo sapiens,Intermediate,,9606.0,4575,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619126,,N
,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,478.0,81034,Homo sapiens,Intermediate,,9606.0,4576,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619127,,N
,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,478.0,81034,Homo sapiens,Intermediate,,9606.0,4577,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619128,,N
,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,478.0,81034,Homo sapiens,Intermediate,,9606.0,4578,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619129,,N
,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,478.0,81034,Homo sapiens,Intermediate,,9606.0,4579,,A2780,,,,F,1,BAO_0000219,2113,1,CHEMBL619130,,N
,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,478.0,81034,Homo sapiens,Intermediate,,9606.0,4580,,A2780,,,,F,1,BAO_0000219,2113,1,CHEMBL619131,,N
,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,478.0,81034,Homo sapiens,Intermediate,,9606.0,4581,,A2780,,,,F,1,BAO_0000219,16745,1,CHEMBL619132,,N
,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,478.0,81034,Homo sapiens,Expert,,9606.0,4582,,A2780,,,,F,1,BAO_0000218,16597,1,CHEMBL619133,,N
,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,478.0,81034,Homo sapiens,Intermediate,,9606.0,4583,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619134,,N
,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,478.0,81034,Homo sapiens,Intermediate,,9606.0,4584,,A2780,,,,F,1,BAO_0000219,15684,1,CHEMBL619135,,N
,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,478.0,81034,Homo sapiens,Intermediate,,9606.0,4585,,A2780,,,,F,1,BAO_0000219,2040,1,CHEMBL619136,,N
,,Relative resistance factor in A2780 cisplatin-resistant line,478.0,81034,Homo sapiens,Intermediate,,9606.0,4586,,A2780,,,,F,1,BAO_0000219,2040,1,CHEMBL619137,,N
,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,478.0,81034,Homo sapiens,Intermediate,,9606.0,4587,,A2780,,,,F,1,BAO_0000219,16165,1,CHEMBL883713,,N
,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,478.0,81034,Homo sapiens,Intermediate,,9606.0,4588,,A2780,,,,F,1,BAO_0000219,16165,1,CHEMBL875412,,N
,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,478.0,81034,Homo sapiens,Expert,,9606.0,4589,,A2780,,,,F,1,BAO_0000218,16597,1,CHEMBL619138,,N
,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,478.0,81034,Homo sapiens,Expert,,9606.0,4590,,A2780,,,,F,1,BAO_0000218,16597,1,CHEMBL619262,,N
,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,478.0,81034,Homo sapiens,Intermediate,,9606.0,4591,,A2780,,,,F,1,BAO_0000219,3992,1,CHEMBL619139,,N
,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,478.0,81034,Homo sapiens,Intermediate,,9606.0,4592,,A2780,,,,F,1,BAO_0000219,10553,1,CHEMBL619140,,N
,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,478.0,81034,Homo sapiens,Intermediate,,9606.0,4593,,A2780,,,,F,1,BAO_0000219,15608,1,CHEMBL619141,,N
,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,478.0,81034,Homo sapiens,Intermediate,,9606.0,4594,,A2780,,,,F,1,BAO_0000219,15608,1,CHEMBL619142,,N
,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,478.0,81034,Homo sapiens,Intermediate,,9606.0,4595,,A2780,,,,F,1,BAO_0000219,15608,1,CHEMBL619143,,N
,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,478.0,81034,Homo sapiens,Intermediate,,9606.0,4596,,A2780,,,,F,1,BAO_0000219,15608,1,CHEMBL619144,,N
,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,478.0,81034,Homo sapiens,Intermediate,,9606.0,4597,,A2780,,,,F,1,BAO_0000219,15608,1,CHEMBL619145,,N
,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,478.0,81034,Homo sapiens,Intermediate,,9606.0,4598,,A2780,,,,F,1,BAO_0000219,15608,1,CHEMBL619146,,N
,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,478.0,81034,Homo sapiens,Intermediate,,9606.0,4599,,A2780,,,,F,1,BAO_0000219,15569,1,CHEMBL619147,,N
,,Antiproliferative effect of compound on A2780/DX cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,4600,,A2780,,,,F,1,BAO_0000219,17420,1,CHEMBL619148,,N
,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,478.0,81034,Homo sapiens,Intermediate,,9606.0,4601,,A2780,,,,F,1,BAO_0000219,17420,1,CHEMBL619149,,N
,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),478.0,81034,Homo sapiens,Intermediate,,9606.0,4602,,A2780,,,,F,1,BAO_0000219,15099,1,CHEMBL619150,,N
,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),478.0,81034,Homo sapiens,Intermediate,,9606.0,4603,,A2780,,,,F,1,BAO_0000219,15099,1,CHEMBL619151,,N
,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,478.0,81034,Homo sapiens,Intermediate,,9606.0,4604,,A2780,,,,F,1,BAO_0000219,17672,1,CHEMBL883794,,N
,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,478.0,81034,Homo sapiens,Intermediate,,9606.0,4605,,A2780,,,,F,1,BAO_0000219,17672,1,CHEMBL619152,,N
,,In vitro cytotoxicity against A2780ADR cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,4606,,A2780,,,,F,1,BAO_0000219,17270,1,CHEMBL619153,,N
,,In vitro cytotoxicity against A2780CIS cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,4607,,A2780,,,,F,1,BAO_0000219,17270,1,CHEMBL619154,,N
,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,478.0,81034,Homo sapiens,Intermediate,,9606.0,4608,,A2780,,,,F,1,BAO_0000219,5574,1,CHEMBL619155,,N
,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,478.0,81034,Homo sapiens,Intermediate,,9606.0,4609,,A2780,,,,F,1,BAO_0000219,2113,1,CHEMBL619156,,N
,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,81034,Homo sapiens,Intermediate,,9606.0,4610,,A2780,,,,F,1,BAO_0000219,16913,1,CHEMBL619157,,N
,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,81034,Homo sapiens,Intermediate,,9606.0,4611,,A2780,,,,F,1,BAO_0000219,16913,1,CHEMBL619797,,N
,,Oral bioavailability of compound in rhesus macaques,,22224,Macaca mulatta,Autocuration,,9544.0,4612,In vivo,,,,,A,1,BAO_0000218,17839,0,CHEMBL619798,,U
,,Oral bioavailability in monkey,,22224,monkey,Autocuration,,9443.0,4613,In vivo,,,,,A,1,BAO_0000218,6821,0,CHEMBL619799,,U
,,Oral bioavailability evaluated in monkey,,22224,monkey,Autocuration,,9443.0,4614,In vivo,,,,,A,1,BAO_0000218,6078,0,CHEMBL619800,,U
,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,22224,monkey,Autocuration,,9443.0,4615,In vivo,,,,,A,1,BAO_0000218,6535,0,CHEMBL619801,,U
,,Oral bioavailability in Rhesus monkey,,22224,Macaca mulatta,Autocuration,,9544.0,4616,In vivo,,,,,A,1,BAO_0000218,4449,0,CHEMBL619802,,U
,,Oral bioavailability was calculated in rhesus monkey,,22224,Macaca mulatta,Autocuration,,9544.0,4617,In vivo,,,,,A,1,BAO_0000218,6057,0,CHEMBL619803,,U
,,Oral bioavailability in cynomolgus monkey,,22224,Macaca fascicularis,Autocuration,,9541.0,4618,In vivo,,,,,A,1,BAO_0000218,5922,0,CHEMBL619965,,U
,,Oral bioavailability in monkey,,22224,monkey,Autocuration,,9443.0,4619,In vivo,,,,,A,1,BAO_0000218,5940,0,CHEMBL619966,,U
,,Oral bioavailability in monkey,,22224,monkey,Autocuration,,9443.0,4620,In vivo,,,,,A,1,BAO_0000218,6265,0,CHEMBL619967,,U
,,Oral bioavailability in monkey (dose 1 mg/kg),,22224,monkey,Autocuration,,9443.0,4621,In vivo,,,,,A,1,BAO_0000218,6265,0,CHEMBL620073,,U
,,Oral bioavailability in monkey (dose 5 mg/kg),,22224,monkey,Autocuration,,9443.0,4622,In vivo,,,,,A,1,BAO_0000218,6265,0,CHEMBL620074,,U
,,Oral bioavailability in monkey,,22224,monkey,Autocuration,,9443.0,4623,In vivo,,,,,A,1,BAO_0000218,5940,0,CHEMBL620075,,U
,,Oral bioavailability in monkey,,22224,monkey,Autocuration,,9443.0,4624,In vivo,,,,,A,1,BAO_0000218,5940,0,CHEMBL620076,,U
,,Oral bioavailability in rhesus monkey,,22224,Macaca mulatta,Autocuration,,9544.0,4625,In vivo,,,,,A,1,BAO_0000218,4514,0,CHEMBL620077,,U
,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,22224,Macaca mulatta,Autocuration,,9544.0,4626,In vivo,,,,,A,1,BAO_0000218,5546,0,CHEMBL620078,,U
,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,22224,Saimiri sciureus,Autocuration,,9521.0,4627,In vivo,,,,,A,1,BAO_0000218,5553,0,CHEMBL620079,,U
,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,22224,monkey,Autocuration,,9443.0,4628,In vivo,,,,,A,1,BAO_0000218,6641,0,CHEMBL620080,,U
,,Oral bioavailability in Rhesus monkey,,22224,Macaca mulatta,Autocuration,,9544.0,4629,In vivo,,,,,A,1,BAO_0000218,5472,0,CHEMBL620081,,U
,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,22224,Macaca mulatta,Autocuration,,9544.0,4630,In vivo,,,,,A,1,BAO_0000218,5668,0,CHEMBL620082,,U
,,Oral bioavailability in monkey at 10 mg/kg of the compound,,22224,monkey,Autocuration,,9443.0,4631,In vivo,,,,,A,1,BAO_0000218,5711,0,CHEMBL620083,,U
,,Bioavailability in Rhesus monkey,,22224,Macaca mulatta,Autocuration,,9544.0,4632,In vivo,,,,,A,1,BAO_0000218,5145,0,CHEMBL620084,,U
,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,,9527.0,4633,,,,,,A,1,BAO_0000218,3443,0,CHEMBL620085,,U
,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,,9527.0,4634,,,,,,A,1,BAO_0000218,3443,0,CHEMBL874595,,U
,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,4635,In vivo,,,,,A,1,BAO_0000218,3249,0,CHEMBL873352,,U
,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,4636,In vivo,,,,,A,1,BAO_0000218,3249,0,CHEMBL620086,,U
,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,4637,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL620087,,U
,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,22224,Cercopithecidae,Autocuration,,9527.0,4638,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL620088,,U
,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,22224,Cercopithecidae,Autocuration,,9527.0,4639,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL620089,,U
,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,22224,Cercopithecidae,Autocuration,,9527.0,4640,In vivo,,,,,A,1,BAO_0000218,4809,0,CHEMBL620090,,U
,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,22224,Cercopithecidae,Autocuration,,9527.0,4641,In vivo,,,,,A,1,BAO_0000218,4809,0,CHEMBL620091,,U
,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,22224,Cercopithecidae,Autocuration,,9527.0,4642,,,,,,A,1,BAO_0000251,14294,0,CHEMBL620092,Microsomes,U
,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,22224,Cercopithecidae,Autocuration,,9527.0,4643,,,,,,A,1,BAO_0000251,14294,0,CHEMBL620093,Microsomes,U
,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,22224,Cercopithecidae,Autocuration,,9527.0,4644,,,,,,A,1,BAO_0000251,14294,0,CHEMBL620094,Microsomes,U
,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,22224,Cercopithecidae,Autocuration,,9527.0,4645,,,,,,A,1,BAO_0000251,14294,0,CHEMBL620095,Microsomes,U
,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,,9527.0,4646,In vivo,,,,,A,1,BAO_0000218,3443,0,CHEMBL620096,,U
,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,,9527.0,4647,In vivo,,,,,A,1,BAO_0000218,3443,0,CHEMBL620097,,U
,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,22224,Cercopithecidae,Autocuration,,9527.0,4648,,,,,,A,1,BAO_0000019,11271,0,CHEMBL620098,,U
,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,,9527.0,4649,,,,,,A,1,BAO_0000218,3443,0,CHEMBL620099,,U
,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,,9527.0,4650,,,,,,A,1,BAO_0000218,3443,0,CHEMBL620100,,U
,,Elimination Half-life of compound was determined in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4651,,,,,,A,1,BAO_0000019,6821,0,CHEMBL620101,,U
,,Half life of compound was determined in rhesus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4652,,,,,,A,1,BAO_0000019,17267,0,CHEMBL620102,,U
,,Half life in monkey plasma,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,4653,,,,,Plasma,A,1,BAO_0000366,5819,0,CHEMBL620103,,U
,,Half life in monkey plasma; Not detected,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,4654,,,,,Plasma,A,1,BAO_0000366,5819,0,CHEMBL620104,,U
,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,22224,Cercopithecidae,Autocuration,,9527.0,4655,In vivo,,,,,A,1,BAO_0000218,1916,0,CHEMBL874596,,U
,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,4656,In vivo,,,,,A,1,BAO_0000218,17509,0,CHEMBL873490,,U
,,Terminal half life of the compound.,,22224,Cercopithecidae,Autocuration,,9527.0,4657,,,,,,A,1,BAO_0000019,1399,0,CHEMBL620105,,U
,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,22224,Cercopithecidae,Autocuration,,9527.0,4658,In vivo,,,,,A,1,BAO_0000218,1916,0,CHEMBL620780,,U
,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,22224,Cercopithecidae,Autocuration,,9527.0,4659,In vivo,,,,,A,1,BAO_0000218,4809,0,CHEMBL620781,,U
,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,22224,Cercopithecidae,Autocuration,,9527.0,4660,,,,,,A,1,BAO_0000218,5546,0,CHEMBL620956,,U
,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,1088.0,9527.0,4661,,,,,Urine,A,1,BAO_0000218,3443,0,CHEMBL620957,,U
,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,1088.0,9527.0,4662,,,,,Urine,A,1,BAO_0000218,3443,0,CHEMBL620958,,U
,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,22224,Cercopithecidae,Autocuration,,9527.0,4663,In vivo,,,,,A,1,BAO_0000218,4257,0,CHEMBL620959,,U
,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,22224,Cercopithecidae,Autocuration,,9527.0,4664,In vivo,,,,,A,1,BAO_0000218,6221,0,CHEMBL620960,,U
,,Volume of distribution was evaluated in rhesus,,22224,Cercopithecidae,Autocuration,,9527.0,4665,In vivo,,,,,A,1,BAO_0000218,5472,0,CHEMBL620961,,U
,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,22224,Cricetulus griseus,Autocuration,,10029.0,4666,In vivo,,,,,A,1,BAO_0000218,4727,0,CHEMBL620962,,U
,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,22224,Cricetulus griseus,Autocuration,,10029.0,4667,In vivo,,,,,A,1,BAO_0000218,4727,0,CHEMBL620963,,U
,,Bioavailability in hamster was determined,,22224,Cricetulus griseus,Autocuration,,10029.0,4668,In vivo,,,,,A,1,BAO_0000218,4727,0,CHEMBL620964,,U
,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,22224,Cricetulus griseus,Autocuration,,10029.0,4669,In vivo,,,,,A,1,BAO_0000218,4727,0,CHEMBL620965,,U
,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,22224,Cricetulus griseus,Autocuration,,10029.0,4670,In vivo,,,,,A,1,BAO_0000218,4727,0,CHEMBL620966,,U
,,Half life of compound was determined in hamster blood,,22224,Cricetulus griseus,Autocuration,178.0,10029.0,4671,,,,,Blood,A,1,BAO_0000221,4727,0,CHEMBL620967,,U
,,Michaelis-Menten constant of the compound.,,22224,Sus scrofa,Autocuration,,9823.0,4672,,,,,,A,1,BAO_0000019,1452,0,CHEMBL620968,,U
,,Vmax value was measured at 0 uM concentration of silyl ether.,,22224,Sus scrofa,Autocuration,,9823.0,4673,,,,,,A,1,BAO_0000019,1452,0,CHEMBL874597,,U
,,Vmax value was measured at 10 uM concentration of silyl ether.,,22224,Sus scrofa,Autocuration,,9823.0,4674,,,,,,A,1,BAO_0000019,1452,0,CHEMBL620969,,U
,,Vmax value was measured at 5 uM concentration of silyl ether.,,22224,Sus scrofa,Autocuration,,9823.0,4675,,,,,,A,1,BAO_0000019,1452,0,CHEMBL620970,,U
,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,235,Homo sapiens,Expert,,9606.0,4676,,,,,,B,1,BAO_0000357,11706,9,CHEMBL620971,,D
,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,22224,Homo sapiens,Autocuration,,9606.0,4677,,,,,,A,1,BAO_0000218,1916,0,CHEMBL620972,,U
,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,22224,Homo sapiens,Autocuration,,9606.0,4678,,,,,,A,1,BAO_0000019,17791,0,CHEMBL620973,,U
,,Active metabolite of ifosfamide determined in humans; A-Active,,22224,Homo sapiens,Autocuration,,9606.0,4679,,,,,,A,1,BAO_0000019,7766,0,CHEMBL618243,,U
,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,22224,Homo sapiens,Autocuration,,9606.0,4680,,,,,,A,1,BAO_0000019,6567,0,CHEMBL618244,,U
,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,22224,Homo sapiens,Autocuration,,9606.0,4681,,,,,,A,1,BAO_0000019,6567,0,CHEMBL618245,,U
,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,22224,Homo sapiens,Autocuration,,9606.0,4682,,,,,,A,1,BAO_0000019,6567,0,CHEMBL618246,,U
,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,22224,Homo sapiens,Autocuration,,9606.0,4683,,,,,,A,1,BAO_0000019,6567,0,CHEMBL618247,,U
,,Compound was evaluated for oral bioavailability in human,,22224,Homo sapiens,Autocuration,,9606.0,4684,,,,,,A,1,BAO_0000218,17791,0,CHEMBL618248,,U
,,Metabolite of ifosfamide determined in urine; NF-Not found,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4685,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL618249,,U
,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,22224,Homo sapiens,Autocuration,,9606.0,4686,,,,,,A,1,BAO_0000019,6852,0,CHEMBL618250,,U
,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,22224,Homo sapiens,Autocuration,,9606.0,4687,,,,,,A,1,BAO_0000019,6852,0,CHEMBL874598,,U
,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,22224,Homo sapiens,Autocuration,,9606.0,4688,,,,,,A,1,BAO_0000019,6852,0,CHEMBL618251,,U
,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,22224,Homo sapiens,Autocuration,,9606.0,4689,,,,,,A,1,BAO_0000019,6852,0,CHEMBL618252,,U
,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,22224,Homo sapiens,Autocuration,,9606.0,4690,,,,,,A,1,BAO_0000019,6852,0,CHEMBL618253,,U
,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,22224,Homo sapiens,Autocuration,,9606.0,4691,,,,,,A,1,BAO_0000019,6852,0,CHEMBL618254,,U
,,Percent of compound in healthy individuals (Group D),,22224,Homo sapiens,Autocuration,,9606.0,4692,,,,,,A,1,BAO_0000019,6852,0,CHEMBL618255,,U
,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,4693,,,,,Liver,A,1,BAO_0000251,4397,0,CHEMBL618983,Microsomes,U
,,Binding towards human plasma protein at 10 uM,,22224,Homo sapiens,Autocuration,,9606.0,4694,,,,,,A,1,BAO_0000019,17409,0,CHEMBL618984,,U
,,Binding towards human plasma protein at 100 uM,,22224,Homo sapiens,Autocuration,,9606.0,4695,,,,,,A,1,BAO_0000019,17409,0,CHEMBL618985,,U
,,Human plasma protein binding activity was determined,,22224,Homo sapiens,Autocuration,,9606.0,4696,,,,,,A,1,BAO_0000019,17176,0,CHEMBL618986,,U
,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,22224,Homo sapiens,Autocuration,,9606.0,4697,,,,,,A,1,BAO_0000019,15444,0,CHEMBL618987,,U
,,Percent binding of compound towards human plasma protein was determined,,22224,Homo sapiens,Autocuration,,9606.0,4698,,,,,,A,1,BAO_0000019,17267,0,CHEMBL618988,,U
,,Plasma clearance in human liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,4699,In vitro,,,,Liver,A,1,BAO_0000251,5944,0,CHEMBL618989,Microsomes,U
,,In vitro intrinsic clearance in human liver microsome,,22224,Homo sapiens,Autocuration,2107.0,9606.0,4700,In vitro,,,,Liver,A,1,BAO_0000251,5668,0,CHEMBL618990,Microsomes,U
,,In vitro intrinsic clearance in human liver microsome,,22224,Homo sapiens,Autocuration,2107.0,9606.0,4701,In vitro,,,,Liver,A,1,BAO_0000251,5669,0,CHEMBL618991,Microsomes,U
,,In vitro microsome metabolism clearance in human was determined,,22224,Homo sapiens,Autocuration,,9606.0,4702,In vitro,,,,,A,1,BAO_0000251,5041,0,CHEMBL876725,Microsomes,U
,,In vitro microsome metabolism clearance in human was determined; High,,22224,Homo sapiens,Autocuration,,9606.0,4703,In vitro,,,,,A,1,BAO_0000251,5041,0,CHEMBL618992,Microsomes,U
,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,22224,Homo sapiens,Autocuration,,9606.0,4704,In vitro,,,,,A,1,BAO_0000251,5041,0,CHEMBL618993,Microsomes,U
,,Pharmacokinetic property (clearance) in human liver microsome,,22224,Homo sapiens,Autocuration,2107.0,9606.0,4705,In vitro,,,,Liver,A,1,BAO_0000251,5676,0,CHEMBL618994,Microsomes,U
,,Plasma clearance in human liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,4706,In vitro,,,,Liver,A,1,BAO_0000251,5944,0,CHEMBL618995,Microsomes,U
,,In vitro clearance in human liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,4707,In vitro,,,,Liver,A,1,BAO_0000251,17538,0,CHEMBL618996,Microsomes,U
,,Intrinsic clearance in human liver microsomes was determined,,22224,Homo sapiens,Autocuration,2107.0,9606.0,4708,In vitro,,,,Liver,A,1,BAO_0000251,6331,0,CHEMBL618997,Microsomes,U
,,Intrinsic clearance in human liver microsomes was determined,,22224,Homo sapiens,Autocuration,2107.0,9606.0,4709,In vitro,,,,Liver,A,1,BAO_0000251,5948,0,CHEMBL618998,Microsomes,U
,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,22224,Homo sapiens,Autocuration,,9606.0,4710,In vivo,,,,,A,1,BAO_0000218,5965,0,CHEMBL618999,,U
,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,22224,Homo sapiens,Autocuration,,9606.0,4711,In vivo,,,,,A,1,BAO_0000218,1916,0,CHEMBL620223,,U
,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,22224,Homo sapiens,Autocuration,,9606.0,4712,,,,,,A,1,BAO_0000218,5965,0,CHEMBL620224,,U
,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,22224,Homo sapiens,Autocuration,,9606.0,4713,,,,,,A,1,BAO_0000019,1299,0,CHEMBL620225,,U
,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,22224,Homo sapiens,Autocuration,,9606.0,4714,,,,,,A,1,BAO_0000019,1299,0,CHEMBL620226,,U
,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4715,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL620227,,U
,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4716,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL876726,,U
,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4717,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL620228,,U
,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4718,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL620229,,U
,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4719,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL620230,,N
,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4720,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL620231,,N
,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4721,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL620232,,N
,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4722,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL620233,,N
,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,50594,Mus musculus,Intermediate,,10090.0,4723,,,,,,A,1,BAO_0000218,14294,1,CHEMBL620234,,N
,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,50594,Mus musculus,Intermediate,,10090.0,4724,,,,,,A,1,BAO_0000218,14294,1,CHEMBL620235,,N
,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,50594,Mus musculus,Intermediate,,10090.0,4725,,,,,,A,1,BAO_0000218,14294,1,CHEMBL620236,,N
,,In vitro metabolic potential in mouse liver microsomes,,50594,Mus musculus,Intermediate,2107.0,10090.0,4726,,,,,Liver,A,1,BAO_0000218,6251,1,CHEMBL620237,,N
,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,50594,Mus musculus,Intermediate,,10090.0,4727,,,,,,A,1,BAO_0000218,17582,1,CHEMBL620238,,N
,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,50594,Mus musculus,Intermediate,2369.0,10090.0,4728,,,,,Adrenal gland,A,1,BAO_0000218,17811,1,CHEMBL620239,,N
,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,50594,Mus musculus,Intermediate,955.0,10090.0,4729,,,,,Brain,A,1,BAO_0000218,17811,1,CHEMBL620240,,N
,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,50594,Mus musculus,Intermediate,955.0,10090.0,4730,,,,,Brain,A,1,BAO_0000218,17811,1,CHEMBL620241,,N
,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,50594,Mus musculus,Intermediate,,10090.0,4731,,,,,,A,1,BAO_0000218,17811,1,CHEMBL876727,,N
,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,50594,Mus musculus,Intermediate,2113.0,10090.0,4732,,,,,Kidney,A,1,BAO_0000218,17811,1,CHEMBL620242,,N
,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,50594,Mus musculus,Intermediate,,10090.0,4733,,,,,,A,1,BAO_0000218,17811,1,CHEMBL620243,,N
,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,4734,,,,,,A,1,BAO_0000218,5288,1,CHEMBL620244,,N
,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,50594,Mus musculus,Intermediate,1977.0,10090.0,4735,,,,,Serum,A,1,BAO_0000218,2717,1,CHEMBL620245,,N
,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,50594,Mus musculus,Intermediate,1977.0,10090.0,4736,,,,,Serum,A,1,BAO_0000218,2717,1,CHEMBL620246,,N
,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,50594,Mus musculus,Intermediate,1977.0,10090.0,4737,,,,,Serum,A,1,BAO_0000218,2717,1,CHEMBL620247,,N
,,Half life of compound was determined in plasma of mice at 24 mg/Kg,,50594,Mus musculus,Intermediate,1969.0,10090.0,4738,In vivo,,,,Plasma,A,1,BAO_0000218,17753,1,CHEMBL620248,,N
,,Half life of compound was determined in plasma of mice at 40 mg/Kg,,50594,Mus musculus,Intermediate,1969.0,10090.0,4739,In vivo,,,,Plasma,A,1,BAO_0000218,17753,1,CHEMBL873497,,N
,,Half life of compound was determined in plasma of mice at 5 mg/Kg,,50594,Mus musculus,Intermediate,1969.0,10090.0,4740,In vivo,,,,Plasma,A,1,BAO_0000218,17753,1,CHEMBL620249,,N
,,Half life after intraperitoneal administration in mice at 18 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4741,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL620250,,N
,,Half life after intraperitoneal administration in mice at 23 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4742,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL620251,,N
,,Half life after intraperitoneal administration in mice at 25 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4743,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL620252,,N
,,Half life after intraperitoneal administration in mice at 26 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4744,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL620253,,N
,,Half life after intravenous administration in mice at 23 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4745,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL620254,,N
,,Half life after intravenous administration in mice at 24 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4746,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL620255,,N
,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,50594,Mus musculus,Intermediate,,10090.0,4747,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL620256,,N
,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,50594,Mus musculus,Intermediate,,10090.0,4748,In vivo,,,,,A,1,BAO_0000218,2675,1,CHEMBL876728,,N
,,Maximum time required to reach Cp max was evaluated in mice after oral administration,,50594,Mus musculus,Intermediate,,10090.0,4749,In vivo,,,,,A,1,BAO_0000218,2675,1,CHEMBL620257,,N
,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,50594,Mus musculus,Intermediate,,10090.0,4750,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL620258,,N
,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,50594,Mus musculus,Intermediate,,10090.0,4751,In vivo,,,,,A,1,BAO_0000218,4890,1,CHEMBL620259,,N
,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,4752,In vivo,,,,,A,1,BAO_0000218,429,1,CHEMBL620260,,N
,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,50594,Mus musculus,Intermediate,178.0,10090.0,4753,In vivo,,,,Blood,A,1,BAO_0000218,17837,1,CHEMBL620261,,N
,,Half life at a dose of 10 mg/kg intravenous administration in mice.,,50594,Mus musculus,Intermediate,,10090.0,4754,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL620262,,N
,,Half life at a dose of 10 mg/kg peroral administration in mice.,,50594,Mus musculus,Intermediate,,10090.0,4755,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL620263,,N
,,Half life in ob/ob mice,,50594,Mus musculus,Intermediate,,10090.0,4756,,,,,,A,1,BAO_0000218,6619,1,CHEMBL620264,,N
,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,4757,In vivo,,,,,A,1,BAO_0000218,4066,1,CHEMBL620265,,N
,,Half-life was measured in mouse,,50594,Mus musculus,Intermediate,,10090.0,4758,,,,,,A,1,BAO_0000218,4239,1,CHEMBL620266,,N
,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,4759,In vivo,,,,,A,1,BAO_0000218,5969,1,CHEMBL620267,,N
,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,50594,Mus musculus,Intermediate,,10090.0,4760,,,,,,A,1,BAO_0000218,8999,1,CHEMBL619364,,N
,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,50594,Mus musculus,Intermediate,,10090.0,4761,,,,,,A,1,BAO_0000218,8999,1,CHEMBL619365,,N
,,T2 in brain of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,955.0,10090.0,4762,,,,,Brain,A,1,BAO_0000218,17641,1,CHEMBL619366,,N
,,T2 in kidney of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2113.0,10090.0,4763,,,,,Kidney,A,1,BAO_0000218,17641,1,CHEMBL619367,,N
,,T2 in liver of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2107.0,10090.0,4764,,,,,Liver,A,1,BAO_0000218,17641,1,CHEMBL619368,,N
,,T2 in lungs of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2048.0,10090.0,4765,,,,,Lung,A,1,BAO_0000218,17641,1,CHEMBL619369,,N
,,T2 in spleen of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2106.0,10090.0,4766,,,,,Spleen,A,1,BAO_0000218,17641,1,CHEMBL876729,,N
,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,50594,Mus musculus,Intermediate,,10090.0,4767,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL619370,,N
,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,50594,Mus musculus,Intermediate,,10090.0,4768,In vivo,,,,,A,1,BAO_0000218,4890,1,CHEMBL619371,,N
,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,4769,In vivo,,,,,A,1,BAO_0000218,429,1,CHEMBL619372,,N
,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,50594,Mus musculus,Intermediate,,10090.0,4770,In vivo,,,,,A,1,BAO_0000218,429,1,CHEMBL620012,,N
,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,4771,In vivo,,,,,A,1,BAO_0000218,5969,1,CHEMBL620013,,N
,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,81034,Homo sapiens,Intermediate,,9606.0,4772,,A2780,,,,F,1,BAO_0000219,16913,1,CHEMBL620014,,N
,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,81034,Homo sapiens,Intermediate,,9606.0,4773,,A2780,,,,F,1,BAO_0000219,16913,1,CHEMBL620015,,N
,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,81034,Homo sapiens,Intermediate,,9606.0,4774,,A2780,,,,F,1,BAO_0000219,16913,1,CHEMBL621010,,N
,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,81034,Homo sapiens,Intermediate,,9606.0,4775,,A2780,,,,F,1,BAO_0000219,16913,1,CHEMBL621011,,N
,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,81034,Homo sapiens,Intermediate,,9606.0,4776,,A2780,,,,F,1,BAO_0000219,16913,1,CHEMBL621012,,N
,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,81034,Homo sapiens,Intermediate,,9606.0,4777,,A2780,,,,F,1,BAO_0000219,16913,1,CHEMBL621013,,N
,,In vitro cytotoxicity against A2780TAX cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,4778,,A2780,,,,F,1,BAO_0000219,17270,1,CHEMBL621014,,N
,,In vitro inhibitory activity against human tumor cell line A2780cis,481.0,80017,Homo sapiens,Intermediate,,9606.0,4779,,A2780cisR,,,,F,1,BAO_0000219,5618,1,CHEMBL618154,,N
,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,478.0,81034,Homo sapiens,Expert,,9606.0,4780,,A2780,,,,F,1,BAO_0000219,17777,1,CHEMBL618155,,N
,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,481.0,80017,Homo sapiens,Intermediate,,9606.0,4781,,A2780cisR,,,,F,1,BAO_0000219,16112,1,CHEMBL618156,,N
,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),481.0,80017,Homo sapiens,Intermediate,,9606.0,4782,,A2780cisR,,,,F,1,BAO_0000219,15748,1,CHEMBL618157,,N
,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,478.0,81034,Homo sapiens,Intermediate,,9606.0,4783,,A2780,,,,F,1,BAO_0000219,6633,1,CHEMBL618328,,N
,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,478.0,81034,Homo sapiens,Intermediate,,9606.0,4784,,A2780,,,,F,1,BAO_0000219,16930,1,CHEMBL618329,,N
,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,4785,,A2780,,,,F,1,BAO_0000219,17496,1,CHEMBL618330,,N
,,In vitro antitumor activity against A2780cisR cell line.,478.0,81034,Homo sapiens,Expert,,9606.0,4786,,A2780,,,,F,1,BAO_0000219,12989,1,CHEMBL618331,,N
,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),478.0,81034,Homo sapiens,Intermediate,,9606.0,4787,,A2780,,,,F,1,BAO_0000219,4840,1,CHEMBL618332,,N
,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,478.0,81034,Homo sapiens,Expert,,9606.0,4788,,A2780,,,,F,1,BAO_0000219,12989,1,CHEMBL618333,,N
,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,481.0,80017,Homo sapiens,Intermediate,,9606.0,4789,,A2780cisR,,,,F,1,BAO_0000219,16745,1,CHEMBL618334,,N
,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,478.0,81034,Homo sapiens,Expert,,9606.0,4790,,A2780,,,,F,1,BAO_0000219,16597,1,CHEMBL618335,,N
,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,11736,Rattus norvegicus,Expert,,10116.0,4791,,,,,,B,1,BAO_0000019,16547,9,CHEMBL618336,,D
,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,11736,,Expert,,,4792,,,,,,F,1,BAO_0000019,16547,8,CHEMBL618337,,H
,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,11736,Rattus norvegicus,Expert,,10116.0,4793,,,,,,F,1,BAO_0000019,16547,9,CHEMBL618338,,D
,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,722.0,278,Homo sapiens,Expert,,9606.0,4794,,HEK293,,,,F,1,BAO_0000219,15856,9,CHEMBL618339,,D
,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,722.0,278,Homo sapiens,Expert,,9606.0,4795,,HEK293,,,,F,1,BAO_0000219,15856,9,CHEMBL618340,,D
,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,11831,Mus musculus,Expert,,10090.0,4796,,,,,,B,1,BAO_0000019,16547,9,CHEMBL618341,,D
,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,11831,,Expert,,,4797,,,,,,F,1,BAO_0000019,16547,8,CHEMBL618342,,H
,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,11831,Mus musculus,Expert,,10090.0,4798,,,,,,F,1,BAO_0000019,16547,9,CHEMBL618343,,D
,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,280,,Expert,,,4799,,,,,,B,1,BAO_0000357,17402,8,CHEMBL621038,,H
,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),574.0,22226,Homo sapiens,Autocuration,,9606.0,4800,,T-cells,,,,F,1,BAO_0000219,11746,0,CHEMBL621039,,U
,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,574.0,22226,Homo sapiens,Autocuration,,9606.0,4801,,T-cells,,,,F,1,BAO_0000219,11746,0,CHEMBL621040,,U
,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,455.0,80018,Homo sapiens,Intermediate,,9606.0,4802,,A-375,,,,F,1,BAO_0000219,5455,1,CHEMBL621041,,N
,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,455.0,80018,Homo sapiens,Intermediate,,9606.0,4803,,A-375,,,,F,1,BAO_0000219,2068,1,CHEMBL621042,,N
,,In vitro antitumor activity against A375cell line extracted form melanoma,455.0,80018,Homo sapiens,Intermediate,,9606.0,4804,,A-375,,,,F,1,BAO_0000219,2683,1,CHEMBL621043,,N
,,Inhibition of cell growth in (A375) melan cell line,455.0,80018,Homo sapiens,Expert,,9606.0,4805,,A-375,,,,F,1,BAO_0000219,15313,1,CHEMBL621044,,N
,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,455.0,80018,Homo sapiens,Intermediate,,9606.0,4806,,A-375,,,,F,1,BAO_0000219,13739,1,CHEMBL621045,,N
,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,455.0,80018,Homo sapiens,Intermediate,,9606.0,4807,,A-375,,,,F,1,BAO_0000219,13739,1,CHEMBL621046,,N
,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,455.0,80018,Homo sapiens,Intermediate,,9606.0,4808,,A-375,,,,F,1,BAO_0000219,14750,1,CHEMBL621047,,N
,,Antiproliferative activity measured against A427 human lung carcinoma,797.0,80019,Homo sapiens,Intermediate,,9606.0,4809,,A-427,,,,F,1,BAO_0000219,14777,1,CHEMBL621048,,N
,,Antiproliferative activity measured against A427 human lung carcinoma,797.0,80019,Homo sapiens,Intermediate,,9606.0,4810,,A-427,,,,F,1,BAO_0000219,14777,1,CHEMBL883798,,N
,,Cytotoxicity against lung carcinoma A427 tumor cell lines,797.0,80019,Homo sapiens,Intermediate,,9606.0,4811,,A-427,,,,F,1,BAO_0000219,17672,1,CHEMBL621049,,N
,,Inhibition of large cell lung carcinoma (A427),797.0,80019,Homo sapiens,Intermediate,,9606.0,4812,,A-427,,,,F,1,BAO_0000219,14368,1,CHEMBL621050,,N
,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,797.0,80019,Homo sapiens,Intermediate,,9606.0,4813,,A-427,,,,F,1,BAO_0000219,14368,1,CHEMBL621051,,N
,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,797.0,80019,Homo sapiens,Intermediate,,9606.0,4814,,A-427,,,,F,1,BAO_0000219,13866,1,CHEMBL621052,,N
,,Inhibitory concentration in human lung carcinoma A427 cell line,797.0,80019,Homo sapiens,Intermediate,,9606.0,4815,,A-427,,,,F,1,BAO_0000219,2545,1,CHEMBL621053,,N
,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,797.0,80019,Homo sapiens,Intermediate,,9606.0,4816,,A-427,,,,F,1,BAO_0000219,2545,1,CHEMBL621054,,N
,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,4817,In vivo,,,,,A,1,BAO_0000218,6062,0,CHEMBL621055,,U
,,Tested for volume of distribution upon iv administration to african green monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4818,In vivo,,,,,A,1,BAO_0000218,4578,0,CHEMBL876398,,U
,,Volume of distribution in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4819,In vivo,,,,,A,1,BAO_0000218,17592,0,CHEMBL621056,,U
,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,22224,Macaca mulatta,Autocuration,,9544.0,4820,In vivo,,,,,A,1,BAO_0000218,5005,0,CHEMBL621057,,U
,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,22224,Macaca mulatta,Autocuration,,9544.0,4821,In vivo,,,,,A,1,BAO_0000218,5005,0,CHEMBL621058,,U
,,Pharmacokinetic property(Vdss) in cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4822,In vivo,,,,,A,1,BAO_0000218,5922,0,CHEMBL621059,,U
,,The distribution volume after intravenous administration in cynomolgus monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,4823,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL621060,,U
,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,22224,Cercopithecidae,Autocuration,,9527.0,4824,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL621061,,U
,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,22224,Cercopithecidae,Autocuration,,9527.0,4825,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL621062,,U
,,Volume displacement was calculated in rhesus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4826,In vivo,,,,,A,1,BAO_0000218,6057,0,CHEMBL621063,,U
,,Volume of distribution in steady state was determined in rhesus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4827,In vivo,,,,,A,1,BAO_0000218,5145,0,CHEMBL621064,,U
,,Volume of distribution of compound was determined in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4828,In vivo,,,,,A,1,BAO_0000218,6821,0,CHEMBL621065,,U
,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,22224,Cercopithecidae,Autocuration,,9527.0,4829,In vivo,,,,,A,1,BAO_0000218,5334,0,CHEMBL621066,,U
,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,22224,Cercopithecidae,Autocuration,,9527.0,4830,In vivo,,,,,A,1,BAO_0000218,5334,0,CHEMBL621067,,U
,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,22224,Cercopithecidae,Autocuration,,9527.0,4831,In vivo,,,,,A,1,BAO_0000218,6641,0,CHEMBL621068,,U
,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4832,In vivo,,,,,A,1,BAO_0000218,2661,0,CHEMBL876399,,U
,,Volume distribution in monkey after administration of 1 mg/kg iv,,22224,Cercopithecidae,Autocuration,,9527.0,4833,In vivo,,,,,A,1,BAO_0000218,6535,0,CHEMBL621069,,U
,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,22224,Cercopithecidae,Autocuration,,9527.0,4834,In vivo,,,,,A,1,BAO_0000218,4809,0,CHEMBL621070,,U
,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,4835,In vivo,,,,,A,1,BAO_0000218,6062,0,CHEMBL621071,,U
,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,,9527.0,4836,In vivo,,,,,A,1,BAO_0000218,3443,0,CHEMBL621072,,U
,,Oral systemic bioavailability upon iv administration to african green monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4837,In vivo,,,,,A,1,BAO_0000218,4578,0,CHEMBL618209,,U
,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,22224,Cercopithecidae,Autocuration,,9527.0,4838,In vivo,,,,,A,1,BAO_0000218,4809,0,CHEMBL618210,,U
,,Baboon plasma free fraction. ,,22224,Cercopithecidae,Autocuration,,9527.0,4839,,,,,,A,1,BAO_0000019,11271,0,CHEMBL618211,,U
,,Area under the curve was calculated in rhesus monkey after iv administration,,22224,Cercopithecidae,Autocuration,,9527.0,4840,,,,,,A,1,BAO_0000218,6057,0,CHEMBL618212,,U
,,Area under the curve was calculated in rhesus monkey after peroral administration,,22224,Cercopithecidae,Autocuration,,9527.0,4841,,,,,,A,1,BAO_0000019,6057,0,CHEMBL618213,,U
,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,22224,Cercopithecidae,Autocuration,,9527.0,4842,,,,,,A,1,BAO_0000019,17853,0,CHEMBL618214,,U
,,Half life period in monkey after 5 mg/kg dose,,22224,Cercopithecidae,Autocuration,,9527.0,4843,In vivo,,,,,A,1,BAO_0000218,5302,0,CHEMBL873492,,U
,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,22224,Cercopithecidae,Autocuration,,9527.0,4844,In vivo,,,,,A,1,BAO_0000218,4257,0,CHEMBL618272,,U
,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,22224,Cercopithecidae,Autocuration,,9527.0,4845,In vivo,,,,,A,1,BAO_0000218,4257,0,CHEMBL618273,,U
,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,4846,In vivo,,,,Plasma,A,1,BAO_0000218,13501,0,CHEMBL618274,,U
,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,4847,In vivo,,,,,A,1,BAO_0000218,5394,0,CHEMBL618275,,U
,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4848,In vivo,,,,,A,1,BAO_0000218,2661,0,CHEMBL618276,,U
,,Compound was evaluated for terminal half life in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4849,,,,,,A,1,BAO_0000019,3341,0,CHEMBL618277,,U
,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4850,In vivo,,,,,A,1,BAO_0000218,3045,0,CHEMBL618278,,U
,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,22224,Macaca mulatta,Autocuration,1969.0,9544.0,4851,In vivo,,,,Plasma,A,1,BAO_0000218,5005,0,CHEMBL618279,,U
,,Half life of compound was determined in squirrel monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4852,,,,,,A,1,BAO_0000019,4847,0,CHEMBL618280,,U
,,Half life after iv administration in cynomolgus monkey,,22224,Macaca fascicularis,Autocuration,,9541.0,4853,In vivo,,,,,A,1,BAO_0000218,4256,0,CHEMBL618281,,U
,,Half life in monkey plasma after administration of 1 mg/kg iv,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,4854,In vivo,,,,Plasma,A,1,BAO_0000218,6535,0,CHEMBL618282,,U
,,Half life was calculated in rhesus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4855,,,,,,A,1,BAO_0000019,6057,0,CHEMBL618283,,U
,,Half life in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4856,,,,,,A,1,BAO_0000019,17592,0,CHEMBL618284,,U
,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,22224,Cercopithecidae,Autocuration,,9527.0,4857,In vivo,,,,,A,1,BAO_0000218,6641,0,CHEMBL618285,,U
,,Half life was evaluated in rhesus,,22224,Cercopithecidae,Autocuration,,9527.0,4858,,,,,,A,1,BAO_0000019,5472,0,CHEMBL618286,,U
,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,22224,Cercopithecidae,Autocuration,,9527.0,4859,In vivo,,,,,A,1,BAO_0000218,6221,0,CHEMBL618287,,U
,,Half life period was determine after peroral administration at 10 mpk in Rhesus,,22224,Cercopithecidae,Autocuration,,9527.0,4860,In vivo,,,,,A,1,BAO_0000218,5668,0,CHEMBL618288,,U
,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,22224,Cercopithecidae,Autocuration,,9527.0,4861,In vivo,,,,,A,1,BAO_0000218,4809,0,CHEMBL876393,,U
,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,22224,Cercopithecidae,Autocuration,,9527.0,4862,In vivo,,,,,A,1,BAO_0000218,5546,0,CHEMBL618289,,U
,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,4863,In vivo,,,,,A,1,BAO_0000218,5553,0,CHEMBL618290,,U
,,Half-life was calculated in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4864,,,,,,A,1,BAO_0000019,6078,0,CHEMBL618291,,U
,,Half-life in Squirrel monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4865,,,,,,A,1,BAO_0000019,5147,0,CHEMBL618292,,U
,,Half-life in rhesus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,4866,,,,,,A,1,BAO_0000019,5145,0,CHEMBL618293,,U
,,Half-life was measured in monkey after an iv dose of 1 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,4867,In vivo,,,,,A,1,BAO_0000218,6062,0,CHEMBL618294,,U
,,Half-life period after intravenous administration in cynomolgus monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,4868,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL618295,,U
,,Half-life period after oral administration in cynomolgus monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,4869,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL618296,,U
,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,22224,Cercopithecidae,Autocuration,,9527.0,4870,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL618297,,U
,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4871,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL618298,,U
,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4872,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL618299,,U
,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4873,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL618300,,U
,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4874,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL618301,,U
,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4875,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL618302,,U
,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4876,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL876394,,U
,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4877,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL618303,,U
,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4878,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL618304,,U
,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,22224,Homo sapiens,Autocuration,,9606.0,4879,In vivo,,,,,A,1,BAO_0000218,1916,0,CHEMBL618305,,U
,,Oral bioavailability in human,,22224,Homo sapiens,Autocuration,,9606.0,4880,In vivo,,,,,A,1,BAO_0000218,16643,0,CHEMBL618306,,U
,,Compound was tested for human plasma protein binding,,22224,Homo sapiens,Autocuration,,9606.0,4881,,,,,,A,1,BAO_0000019,17248,0,CHEMBL618307,,U
,,Compound was tested for human plasma protein binding; Not determined,,22224,Homo sapiens,Autocuration,,9606.0,4882,,,,,,A,1,BAO_0000019,17248,0,CHEMBL618308,,U
,,Protein binding activity of compound in human plasma; % Free,,22224,Homo sapiens,Autocuration,,9606.0,4883,,,,,,A,1,BAO_0000019,6241,0,CHEMBL618309,,U
,,Unbound fraction (plasma),,22224,Homo sapiens,Autocuration,,9606.0,4884,,,,,,A,1,BAO_0000019,17716,0,CHEMBL618310,,U
,,Half life for the hydrolysis of compound in human blood serum,,22224,Homo sapiens,Autocuration,1969.0,9606.0,4885,,,,,Plasma,A,1,BAO_0000366,17605,0,CHEMBL873353,,U
,,Half life period in human plasma using phosphate buffer (0.08 M),,22224,Homo sapiens,Autocuration,1969.0,9606.0,4886,,,,,Plasma,A,1,BAO_0000366,17625,0,CHEMBL618311,,U
,,Half life period in human plasma using phosphate buffer (0.1 M),,22224,Homo sapiens,Autocuration,1969.0,9606.0,4887,,,,,Plasma,A,1,BAO_0000366,17625,0,CHEMBL618312,,U
,,Half-life in human plasma was determined,,22224,Homo sapiens,Autocuration,1969.0,9606.0,4888,,,,,Plasma,A,1,BAO_0000366,17747,0,CHEMBL618313,,U
,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,22224,Homo sapiens,Autocuration,,9606.0,4889,,,,,,A,1,BAO_0000019,15613,0,CHEMBL618314,,U
,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,22224,Homo sapiens,Autocuration,,9606.0,4890,,,,,,A,1,BAO_0000019,354,0,CHEMBL618315,,U
,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,22224,Homo sapiens,Autocuration,,9606.0,4891,,,,,,A,1,BAO_0000019,3741,0,CHEMBL618316,,U
,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,22224,Homo sapiens,Autocuration,,9606.0,4892,,,,,,A,1,BAO_0000019,3741,0,CHEMBL618317,,U
,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,22224,Homo sapiens,Autocuration,,9606.0,4893,,,,,,A,1,BAO_0000019,3741,0,CHEMBL620138,,U
,,Partition coefficient (logP),,22224,Homo sapiens,Autocuration,,9606.0,4894,,,,,,A,1,BAO_0000019,17599,0,CHEMBL858280,,U
,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,22224,Homo sapiens,Autocuration,,9606.0,4895,,,,,,A,1,BAO_0000019,5486,0,CHEMBL620139,,U
,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,22224,Homo sapiens,Autocuration,,9606.0,4896,,,,,,A,1,BAO_0000251,5600,0,CHEMBL620140,Microsomes,U
,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,22224,Homo sapiens,Autocuration,,9606.0,4897,,,,,,A,1,BAO_0000019,14294,0,CHEMBL620141,,U
,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,22224,Homo sapiens,Autocuration,,9606.0,4898,,,,,,A,1,BAO_0000019,14294,0,CHEMBL620142,,U
,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,22224,Homo sapiens,Autocuration,,9606.0,4899,,,,,,A,1,BAO_0000019,14294,0,CHEMBL620143,,U
,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,22224,Homo sapiens,Autocuration,,9606.0,4900,,,,,,A,1,BAO_0000251,14294,0,CHEMBL620144,Microsomes,U
,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,22224,Homo sapiens,Autocuration,,9606.0,4901,,,,,,A,1,BAO_0000251,14294,0,CHEMBL620145,Microsomes,U
,,Metabolism of compound in human microsomes; Trace,,22224,Homo sapiens,Autocuration,,9606.0,4902,,,,,,A,1,BAO_0000251,14294,0,CHEMBL620146,Microsomes,U
,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,4903,,,,,Liver,A,1,BAO_0000251,6260,0,CHEMBL620147,Microsomes,U
,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,22224,Homo sapiens,Autocuration,,9606.0,4904,,,,,,A,1,BAO_0000251,6187,0,CHEMBL620148,Microsomes,U
,,In vitro metabolic potential in human liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,4905,,,,,Liver,A,1,BAO_0000251,6251,0,CHEMBL620149,Microsomes,U
,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,22224,Homo sapiens,Autocuration,,9606.0,4906,,,,,,A,1,BAO_0000019,3246,0,CHEMBL876412,,U
,,Tested for human plasma protein binding of the compound; Not tested,,22224,Homo sapiens,Autocuration,,9606.0,4907,,,,,,A,1,BAO_0000019,17313,0,CHEMBL619352,,U
,,Compound was tested for percent protein binding (PB) in human,,22224,Homo sapiens,Autocuration,,9606.0,4908,,,,,,A,1,BAO_0000019,6227,0,CHEMBL619353,,U
,,Protein binding in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,4909,,,,,Plasma,A,1,BAO_0000019,5530,0,CHEMBL619354,,U
,,Permeability coefficient (B to A) in Caco-2 cell,,22224,Homo sapiens,Autocuration,,9606.0,4910,,,,,,A,1,BAO_0000019,6108,0,CHEMBL619355,,U
,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,22224,Homo sapiens,Autocuration,,9606.0,4911,,,,,,A,1,BAO_0000019,6108,0,CHEMBL619356,,U
,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,22224,Homo sapiens,Autocuration,,9606.0,4912,,,,,,A,1,BAO_0000019,2774,0,CHEMBL619357,,U
,,In vitro rate of absorption observed as Caco-2 permeability in humans,,22224,Homo sapiens,Autocuration,,9606.0,4913,,,,,,A,1,BAO_0000019,16643,0,CHEMBL619358,,U
,,Cellular permeability of compound was determined in Caco-2 cells; High,495.0,22224,Homo sapiens,Autocuration,,9606.0,4914,,Caco-2,,,,A,1,BAO_0000219,17582,0,CHEMBL619359,,U
,,Permeability in Caco-2 cells of compound,495.0,22224,Homo sapiens,Autocuration,,9606.0,4915,,Caco-2,,,,A,1,BAO_0000219,6838,0,CHEMBL619360,,U
,,Permeability coefficient (A to B) in Caco-2 cell,,22224,Homo sapiens,Autocuration,,9606.0,4916,,,,,,A,1,BAO_0000019,6108,0,CHEMBL619361,,U
,,Permeability coefficient (B to A) in Caco-2 cell,,22224,Homo sapiens,Autocuration,,9606.0,4917,,,,,,A,1,BAO_0000019,6108,0,CHEMBL619362,,U
,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,22224,Homo sapiens,Autocuration,,9606.0,4918,,,,,,A,1,BAO_0000019,6108,0,CHEMBL619363,,U
,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,22224,Homo sapiens,Autocuration,,9606.0,4919,,,,,,A,1,BAO_0000019,2146,0,CHEMBL618942,,U
,,Compound was tested for protein binding in human plasma,,22224,Homo sapiens,Autocuration,,9606.0,4920,,,,,,A,1,BAO_0000019,4514,0,CHEMBL618943,,U
,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,22224,Homo sapiens,Autocuration,,9606.0,4921,,,,,,A,1,BAO_0000019,6108,0,CHEMBL618944,,U
,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,22224,Homo sapiens,Autocuration,1088.0,9606.0,4922,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL618945,,U
,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,4923,In vivo,,,,,A,1,BAO_0000218,5969,1,CHEMBL618946,,N
,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,50594,Mus musculus,Intermediate,,10090.0,4924,In vivo,,,,,A,1,BAO_0000218,3277,1,CHEMBL876413,,N
,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,50594,Mus musculus,Intermediate,,10090.0,4925,In vivo,,,,,A,1,BAO_0000218,3802,1,CHEMBL618947,,N
,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,50594,Mus musculus,Intermediate,1969.0,10090.0,4926,In vivo,,,,Plasma,A,1,BAO_0000218,2862,1,CHEMBL618948,,N
,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,50594,Mus musculus,Intermediate,1969.0,10090.0,4927,In vivo,,,,Plasma,A,1,BAO_0000218,6348,1,CHEMBL618949,,N
,,Tmax after intraperitoneal administration in mice at 23 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4928,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL618950,,N
,,Tmax after oral administration at 30 mg/kg in ICR mouse,,50594,Mus musculus,Intermediate,,10090.0,4929,In vivo,,,,,A,1,BAO_0000218,5781,1,CHEMBL618951,,N
,,Tmax after peroral administration in mice at 2.4 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4930,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL618952,,N
,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,4931,In vivo,,,,,A,1,BAO_0000218,4066,1,CHEMBL618953,,N
,,Tmax in brain of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,955.0,10090.0,4932,In vivo,,,,Brain,A,1,BAO_0000218,17641,1,CHEMBL618954,,N
,,Tmax in kidney of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2113.0,10090.0,4933,In vivo,,,,Kidney,A,1,BAO_0000218,17641,1,CHEMBL618955,,N
,,Tmax in liver of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2107.0,10090.0,4934,In vivo,,,,Liver,A,1,BAO_0000218,17641,1,CHEMBL618956,,N
,,Tmax in lungs of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2048.0,10090.0,4935,In vivo,,,,Lung,A,1,BAO_0000218,17641,1,CHEMBL618957,,N
,,Tmax in mice at 18 uM/kg i.p. administration,,50594,Mus musculus,Intermediate,,10090.0,4936,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL618958,,N
,,Tmax in mice at 23 uM/kg i.v. administration,,50594,Mus musculus,Intermediate,,10090.0,4937,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL618959,,N
,,Tmax in mice at 25 uM/kg i.p. administration,,50594,Mus musculus,Intermediate,,10090.0,4938,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL618960,,N
,,Tmax in mice at 26 uM/kg i.p. administration,,50594,Mus musculus,Intermediate,,10090.0,4939,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL876723,,N
,,Tmax in spleen of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2106.0,10090.0,4940,In vivo,,,,Spleen,A,1,BAO_0000218,17641,1,CHEMBL618961,,N
,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,50594,Mus musculus,Intermediate,,10090.0,4941,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL618962,,N
,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,50594,Mus musculus,Intermediate,,10090.0,4942,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL618963,,N
,,Tmax value in IRC mice,,50594,Mus musculus,Intermediate,,10090.0,4943,,,,,,A,1,BAO_0000218,5951,1,CHEMBL618964,,N
,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,50594,Mus musculus,Intermediate,,10090.0,4944,In vivo,,,,,A,1,BAO_0000218,5506,1,CHEMBL618965,,N
,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,50594,Mus musculus,Intermediate,,10090.0,4945,In vivo,,,,,A,1,BAO_0000218,5506,1,CHEMBL618966,,N
,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,50594,Mus musculus,Intermediate,1088.0,10090.0,4946,,,,,Urine,A,1,BAO_0000218,429,1,CHEMBL618967,,N
,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,50594,Mus musculus,Intermediate,1088.0,10090.0,4947,,,,,Urine,A,1,BAO_0000218,429,1,CHEMBL618968,,N
,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,50594,Mus musculus,Intermediate,1088.0,10090.0,4948,,,,,Urine,A,1,BAO_0000218,4066,1,CHEMBL618969,,N
,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,4949,,,,,,A,1,BAO_0000218,17734,1,CHEMBL618970,,N
,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,4950,,,,,,A,1,BAO_0000218,17734,1,CHEMBL618971,,N
,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,4951,In vivo,,,,,A,1,BAO_0000218,6062,1,CHEMBL618972,,N
,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,4952,In vivo,,,,,A,1,BAO_0000218,5969,1,CHEMBL618973,,N
,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,4953,In vivo,,,,,A,1,BAO_0000218,5969,1,CHEMBL618974,,N
,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,50594,Mus musculus,Intermediate,,10090.0,4954,In vivo,,,,,A,1,BAO_0000218,5969,1,CHEMBL618975,,N
,,Vd in mice,,50594,Mus musculus,Intermediate,,10090.0,4955,In vivo,,,,,A,1,BAO_0000218,5980,1,CHEMBL618976,,N
,,Volume of distribution in mouse,,50594,Mus musculus,Intermediate,,10090.0,4956,In vivo,,,,,A,1,BAO_0000218,17592,1,CHEMBL618977,,N
,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,50594,Mus musculus,Intermediate,,10090.0,4957,In vivo,,,,,A,1,BAO_0000218,6348,1,CHEMBL876724,,N
,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,4958,In vivo,,,,,A,1,BAO_0000218,17753,1,CHEMBL618978,,N
,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,4959,In vivo,,,,,A,1,BAO_0000218,17753,1,CHEMBL618979,,N
,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,4960,In vivo,,,,,A,1,BAO_0000218,17753,1,CHEMBL618980,,N
,,Pharmacokinetic property (vdss) was measured in mouse,,50594,Mus musculus,Intermediate,,10090.0,4961,In vivo,,,,,A,1,BAO_0000218,4239,1,CHEMBL618981,,N
,,Value distribution upon iv administration in mouse,,50594,Mus musculus,Intermediate,,10090.0,4962,In vivo,,,,,A,1,BAO_0000218,2862,1,CHEMBL618982,,N
,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,4963,In vivo,,,,,A,1,BAO_0000218,17734,1,CHEMBL620150,,N
,,Volume of distribution was evaluated in mice after intravenous administration,,50594,Mus musculus,Intermediate,,10090.0,4964,In vivo,,,,,A,1,BAO_0000218,2675,1,CHEMBL620151,,N
,,Volume of distribution was evaluated in mice after oral administration,,50594,Mus musculus,Intermediate,,10090.0,4965,In vivo,,,,,A,1,BAO_0000218,2675,1,CHEMBL620152,,N
,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,4966,In vivo,,,,,A,1,BAO_0000218,17837,1,CHEMBL620153,,N
,,Steady state volume of distribution was determined in mice,,50594,Mus musculus,Intermediate,,10090.0,4967,In vivo,,,,,A,1,BAO_0000218,5727,1,CHEMBL876395,,N
,,Volume distribution (steady state) of compound was determined in mouse,,50594,Mus musculus,Intermediate,,10090.0,4968,In vivo,,,,,A,1,BAO_0000218,17852,1,CHEMBL620154,,N
,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,4969,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL620155,,N
,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,50594,Mus musculus,Intermediate,,10090.0,4970,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL620156,,N
,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,4971,In vivo,,,,,A,1,BAO_0000218,6062,1,CHEMBL620157,,N
,,Biodistribution of compound (oxidized form) in in kidney tissue,,50594,Mus musculus,Intermediate,2113.0,10090.0,4972,In vivo,,,,Kidney,A,1,BAO_0000218,16438,1,CHEMBL620158,,N
,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,50594,Mus musculus,Intermediate,178.0,10090.0,4973,In vivo,,,,Blood,A,1,BAO_0000218,16438,1,CHEMBL620159,,N
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,50594,Mus musculus,Intermediate,178.0,10090.0,4974,In vivo,,,,Blood,A,1,BAO_0000218,16438,1,CHEMBL620160,,N
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,178.0,10090.0,4975,In vivo,,,,Blood,A,1,BAO_0000218,16438,1,CHEMBL620161,,N
,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,797.0,80019,Homo sapiens,Intermediate,,9606.0,4976,,A-427,,,,F,1,BAO_0000219,10708,1,CHEMBL620162,,N
,,Inhibition of A431 human squamous cell carcinoma cell proliferation,500.0,80852,Homo sapiens,Expert,,9606.0,4977,,A-431,,,,F,1,BAO_0000219,16597,1,CHEMBL620163,,N
,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,500.0,80852,Homo sapiens,Expert,,9606.0,4978,,A-431,,,,F,1,BAO_0000219,16062,1,CHEMBL620833,,N
,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,500.0,80852,Homo sapiens,Expert,,9606.0,4979,,A-431,,,,F,1,BAO_0000219,16062,1,CHEMBL876396,,N
,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,500.0,80852,Homo sapiens,Expert,,9606.0,4980,,A-431,,,,F,1,BAO_0000219,16958,1,CHEMBL620834,,N
,,Inhibition of A431 human carcinoma cell proliferation,500.0,80852,Homo sapiens,Expert,,9606.0,4981,,A-431,,,,F,1,BAO_0000219,6700,1,CHEMBL620835,,N
,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,500.0,80852,Homo sapiens,Expert,,9606.0,4982,,A-431,,,,F,1,BAO_0000219,17226,1,CHEMBL620836,,N
,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,500.0,80852,Homo sapiens,Intermediate,,9606.0,4983,,A-431,,,,F,1,BAO_0000219,6828,1,CHEMBL620837,,N
,,In vitro cytotoxicity against epidermoid carcinoma cell line,500.0,80852,Homo sapiens,Intermediate,,9606.0,4984,,A-431,,,,F,1,BAO_0000219,12314,1,CHEMBL621017,,N
,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",500.0,9,Homo sapiens,Expert,,9606.0,4985,,A-431,,,,F,1,BAO_0000218,13412,9,CHEMBL621018,,D
,,Antiproliferative activity of compound was measured on human tumor cell line A431.,500.0,80852,Homo sapiens,Intermediate,,9606.0,4986,,A-431,,,,F,1,BAO_0000219,13299,1,CHEMBL621019,,N
,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,500.0,80852,Homo sapiens,Intermediate,,9606.0,4987,,A-431,,,,F,1,BAO_0000219,17420,1,CHEMBL621020,,N
,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,500.0,80852,Homo sapiens,Intermediate,,9606.0,4988,,A-431,,,,F,1,BAO_0000219,13678,1,CHEMBL621021,,N
,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,500.0,9,,Expert,,,4989,,A-431,,,,F,1,BAO_0000219,14171,8,CHEMBL621022,,H
,,Tested for antiproliferative activity against human A431 cells,500.0,80852,Homo sapiens,Expert,,9606.0,4990,,A-431,,,,F,1,BAO_0000219,6333,1,CHEMBL621023,,N
,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,500.0,9,Homo sapiens,Expert,,9606.0,4991,,A-431,,,,F,1,BAO_0000219,2356,9,CHEMBL621024,,D
,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,500.0,80852,Homo sapiens,Expert,,9606.0,4992,,A-431,,,,F,1,BAO_0000219,15578,1,CHEMBL621025,,N
,,Inhibition of A431 cell proliferation,500.0,80852,Homo sapiens,Expert,,9606.0,4993,,A-431,,,,F,1,BAO_0000219,5126,1,CHEMBL621026,,N
,,Cytotoxic effect on A431 human epidermoid carcinoma cells,500.0,80852,Homo sapiens,Expert,,9606.0,4994,,A-431,,,,F,1,BAO_0000219,6844,1,CHEMBL621027,,N
,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),500.0,80852,Homo sapiens,Expert,,9606.0,4995,,A-431,,,,F,1,BAO_0000219,6844,1,CHEMBL876397,,N
,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,500.0,80852,Homo sapiens,Intermediate,,9606.0,4996,,A-431,,,,F,1,BAO_0000219,4925,1,CHEMBL883797,,N
,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,500.0,80852,Homo sapiens,Intermediate,,9606.0,4997,,A-431,,,,F,1,BAO_0000219,4925,1,CHEMBL621028,,N
,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,500.0,80852,Homo sapiens,Intermediate,,9606.0,4998,,A-431,,,,F,1,BAO_0000219,13978,1,CHEMBL621029,,N
,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,500.0,80852,Homo sapiens,Intermediate,,9606.0,4999,,A-431,,,,F,1,BAO_0000219,16786,1,CHEMBL621030,,N
,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,500.0,9,,Expert,,,5000,,A-431,,,,F,1,BAO_0000219,13412,8,CHEMBL621147,,H
,,In vivo antiproliferative activity against A431 cell line,500.0,80852,Homo sapiens,Intermediate,,9606.0,5001,,A-431,,,,F,1,BAO_0000218,17824,1,CHEMBL621148,,N
,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,500.0,9,Homo sapiens,Expert,,9606.0,5002,,A-431,,,,F,1,BAO_0000219,12751,9,CHEMBL621149,,D
,,Inhibition of A431 human epidermoid carcinoma cell proliferation,500.0,80852,Homo sapiens,Expert,,9606.0,5003,,A-431,,,,F,1,BAO_0000219,12380,1,CHEMBL621150,,N
,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,500.0,9,Homo sapiens,Expert,,9606.0,5004,,A-431,,,,F,1,BAO_0000219,4959,9,CHEMBL621151,,D
,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),500.0,80852,Homo sapiens,Intermediate,,9606.0,5005,,A-431,,,,F,1,BAO_0000219,6333,1,CHEMBL621152,,N
,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),500.0,80852,Homo sapiens,Intermediate,,9606.0,5006,,A-431,,,,F,1,BAO_0000219,6333,1,CHEMBL621153,,N
,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),500.0,80852,Homo sapiens,Intermediate,,9606.0,5007,,A-431,,,,F,1,BAO_0000219,6333,1,CHEMBL884000,,N
,,Inhibition of EGFR overexpressing A431 cell proliferation,,9,Homo sapiens,Expert,,9606.0,5008,,,,,,F,1,BAO_0000019,5296,9,CHEMBL621154,,D
,,Inhibition of A431 cell proliferation,500.0,80852,Homo sapiens,Expert,,9606.0,5009,,A-431,,,,F,1,BAO_0000219,12624,1,CHEMBL621155,,N
,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,500.0,9,Homo sapiens,Expert,,9606.0,5010,,A-431,,,,F,1,BAO_0000219,14926,9,CHEMBL621156,,D
,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",500.0,9,Homo sapiens,Expert,,9606.0,5011,,A-431,,,,F,1,BAO_0000219,14926,9,CHEMBL621157,,D
,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),500.0,9,,Expert,,,5012,,A-431,,,,F,1,BAO_0000219,14926,8,CHEMBL621158,,H
,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,500.0,80852,Homo sapiens,Intermediate,,9606.0,5013,,A-431,,,,F,1,BAO_0000219,15144,1,CHEMBL621159,,N
,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,500.0,80852,Homo sapiens,Intermediate,,9606.0,5014,,A-431,,,,F,1,BAO_0000219,15144,1,CHEMBL621160,,N
,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,500.0,80852,Homo sapiens,Intermediate,,9606.0,5015,,A-431,,,,F,1,BAO_0000219,5245,1,CHEMBL621161,,N
,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,500.0,80852,Homo sapiens,Intermediate,,9606.0,5016,,A-431,,,,F,1,BAO_0000219,5245,1,CHEMBL621162,,N
,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,500.0,80852,Homo sapiens,Intermediate,,9606.0,5017,,A-431,,,,F,1,BAO_0000219,5245,1,CHEMBL621163,,N
,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,500.0,80852,Homo sapiens,Intermediate,,9606.0,5018,,A-431,,,,F,1,BAO_0000219,5245,1,CHEMBL621164,,N
,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,500.0,80852,Homo sapiens,Intermediate,,9606.0,5019,,A-431,,,,F,1,BAO_0000219,5245,1,CHEMBL621165,,N
,,Half-life period in cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,5020,,,,,,A,1,BAO_0000019,5922,0,CHEMBL619159,,U
,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,22224,Cercopithecidae,Autocuration,1969.0,9527.0,5021,In vitro,,,,Plasma,A,1,BAO_0000366,1116,0,CHEMBL619160,,U
,,Longer half-life in monkey (i.v.) at 0.5 mpk,,22224,Cercopithecidae,Autocuration,,9527.0,5022,In vivo,,,,,A,1,BAO_0000218,17853,0,CHEMBL619161,,U
,,Plasma half life in monkey,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,5023,,,,,Plasma,A,1,BAO_0000366,993,0,CHEMBL619162,,U
,,Plasma half-life in rhesus monkey,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,5024,,,,,Plasma,A,1,BAO_0000366,4514,0,CHEMBL619163,,U
,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,22224,Cercopithecidae,Autocuration,1969.0,9527.0,5025,In vivo,,,,Plasma,A,1,BAO_0000218,5334,0,CHEMBL619164,,U
,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,22224,Cercopithecidae,Autocuration,1969.0,9527.0,5026,In vivo,,,,Plasma,A,1,BAO_0000218,5334,0,CHEMBL619320,,U
,,Tested for half life upon iv administration to african green monkey,,22224,Cercopithecidae,Autocuration,,9527.0,5027,In vivo,,,,,A,1,BAO_0000218,4578,0,CHEMBL619321,,U
,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,5028,In vivo,,,,,A,1,BAO_0000218,2661,0,CHEMBL873336,,U
,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,22224,Cercopithecidae,Autocuration,,9527.0,5029,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL619322,,U
,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,22224,Cercopithecidae,Autocuration,,9527.0,5030,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL619323,,U
,,The time for peak concentration value after oral administration in cynomolgus monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,5031,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL619324,,U
,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5032,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619325,,U
,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5033,,,,,,A,1,BAO_0000019,11271,0,CHEMBL876411,,U
,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5034,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619326,,U
,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5035,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619327,,U
,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5036,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619328,,U
,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5037,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619329,,U
,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5038,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619330,,U
,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5039,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619331,,U
,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5040,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619332,,U
,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5041,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619333,,U
,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5042,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619334,,U
,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5043,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619335,,U
,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5044,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619336,,U
,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5045,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619337,,U
,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5046,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619338,,U
,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,22224,Cercopithecidae,Autocuration,,9527.0,5047,,,,,,A,1,BAO_0000019,11271,0,CHEMBL619339,,U
,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,50597,Rattus norvegicus,Intermediate,,10116.0,5048,In vivo,,,,,A,1,BAO_0000218,5809,1,CHEMBL619340,,N
,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,50597,Rattus norvegicus,Intermediate,1969.0,10116.0,5049,In vivo,,,,Plasma,A,1,BAO_0000218,17720,1,CHEMBL873496,,N
,,AUC value in rat after IV administration at a dose of 10 mg/kg,,50597,Rattus norvegicus,Intermediate,1969.0,10116.0,5050,,,,,Plasma,A,1,BAO_0000218,3546,1,CHEMBL619341,,N
,,AUC value in rat after oral administration at a dose of 10 mg/kg,,50597,Rattus norvegicus,Intermediate,1969.0,10116.0,5051,,,,,Plasma,A,1,BAO_0000218,3546,1,CHEMBL619342,,N
,,Cmax value in rat after oral administration at a dose of 10 mg/kg,,50597,Rattus norvegicus,Intermediate,,10116.0,5052,In vivo,,,,,A,1,BAO_0000218,3546,1,CHEMBL619343,,N
,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,50597,Rattus norvegicus,Intermediate,,10116.0,5053,In vivo,,,,,A,1,BAO_0000218,3546,1,CHEMBL619344,,N
,,Tmax value in rat after oral administration at a dose of 10 mg/kg,,50597,Rattus norvegicus,Intermediate,,10116.0,5054,In vivo,,,,,A,1,BAO_0000218,3546,1,CHEMBL619345,,N
,,Vc value in rat after IV administration at a dose of 10 mg/kg,,50597,Rattus norvegicus,Intermediate,,10116.0,5055,,,,,,A,1,BAO_0000218,3546,1,CHEMBL619346,,N
,,Half life period in rat after IV administration at a dose of 10 mg/kg,,50597,Rattus norvegicus,Intermediate,,10116.0,5056,In vivo,,,,,A,1,BAO_0000218,3546,1,CHEMBL619347,,N
,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,22224,Papio hamadryas,Autocuration,,9557.0,5057,,,,,,A,1,BAO_0000019,10625,0,CHEMBL619348,,U
,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,22224,Papio hamadryas,Autocuration,,9557.0,5058,,,,,,A,1,BAO_0000019,10625,0,CHEMBL619349,,U
,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,22224,Papio hamadryas,Autocuration,,9557.0,5059,,,,,,A,1,BAO_0000019,10625,0,CHEMBL619350,,U
,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,22224,Papio hamadryas,Autocuration,,9557.0,5060,,,,,,A,1,BAO_0000019,10625,0,CHEMBL619351,,U
,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,22224,Papio hamadryas,Autocuration,,9557.0,5061,,,,,,A,1,BAO_0000019,10625,0,CHEMBL875953,,U
,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,22224,Papio hamadryas,Autocuration,,9557.0,5062,,,,,,A,1,BAO_0000019,10625,0,CHEMBL621716,,U
,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,22224,Papio hamadryas,Autocuration,,9557.0,5063,,,,,,A,1,BAO_0000019,10625,0,CHEMBL621717,,U
,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,22224,Papio hamadryas,Autocuration,,9557.0,5064,,,,,,A,1,BAO_0000019,10625,0,CHEMBL621718,,U
,,Area under curve after 1 mpk peroral administration to beagles,,22224,beagle,Autocuration,,9615.0,5065,,,,,,A,1,BAO_0000019,3510,0,CHEMBL621719,,U
,,Area under curve after 2 mpk peroral administration to beagles,,22224,beagle,Autocuration,,9615.0,5066,,,,,,A,1,BAO_0000019,3510,0,CHEMBL621720,,U
,,Cmax value after 1 mpk peroral administration to beagles,,22224,beagle,Autocuration,,9615.0,5067,In vivo,,,,,A,1,BAO_0000218,3510,0,CHEMBL621721,,U
,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,22224,Homo sapiens,Autocuration,1088.0,9606.0,5068,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL621722,,U
,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,22224,Homo sapiens,Autocuration,1088.0,9606.0,5069,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL621723,,U
,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,22224,Homo sapiens,Autocuration,1088.0,9606.0,5070,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL621724,,U
,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,22224,Homo sapiens,Autocuration,1088.0,9606.0,5071,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL623443,,U
,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,22224,Homo sapiens,Autocuration,1088.0,9606.0,5072,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL623444,,U
,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,22224,Homo sapiens,Autocuration,1088.0,9606.0,5073,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL623445,,U
,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,22224,Homo sapiens,Autocuration,1088.0,9606.0,5074,,,,,Urine,A,1,BAO_0000019,7766,0,CHEMBL623446,,U
,,Metabolic stability observed at 30 min after administration in human liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5075,,,,,Liver,A,1,BAO_0000251,16643,0,CHEMBL623447,Microsomes,U
,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,22224,Homo sapiens,Autocuration,,9606.0,5076,,,,,,A,1,BAO_0000019,6852,0,CHEMBL623448,,U
,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,22224,Homo sapiens,Autocuration,,9606.0,5077,,,,,,A,1,BAO_0000019,6852,0,CHEMBL623449,,U
,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,22224,Homo sapiens,Autocuration,,9606.0,5078,,,,,,A,1,BAO_0000019,6852,0,CHEMBL623450,,U
,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,22224,Homo sapiens,Autocuration,2107.0,9606.0,5079,,,,,Liver,A,1,BAO_0000251,6567,0,CHEMBL623451,Microsomes,U
,,Metabolic stability (% remaining at 30 mins) in human S9.,,22224,Homo sapiens,Autocuration,,9606.0,5080,,,,,,A,1,BAO_0000019,6570,0,CHEMBL623452,,U
,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,22224,Homo sapiens,Autocuration,,9606.0,5081,,,,,,A,1,BAO_0000019,6570,0,CHEMBL623453,,U
,,Percent parent compound remaining after 20 min incubation with human liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5082,,,,,Liver,A,1,BAO_0000251,5237,0,CHEMBL623454,Microsomes,U
,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5083,,,,,Liver,A,1,BAO_0000251,5237,0,CHEMBL623455,Microsomes,U
,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5084,,,,,Liver,A,1,BAO_0000251,5237,0,CHEMBL624371,Microsomes,U
,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,22224,Homo sapiens,Autocuration,,9606.0,5085,,,,,,A,1,BAO_0000218,5202,0,CHEMBL624372,,U
,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,22224,Homo sapiens,Autocuration,,9606.0,5086,,,,,,A,1,BAO_0000019,5481,0,CHEMBL624373,,U
,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,22224,Homo sapiens,Autocuration,,9606.0,5087,,,,,,A,1,BAO_0000019,5481,0,CHEMBL624374,,U
,,The percent remaining in human plasma after 30 min was determined,,22224,Homo sapiens,Autocuration,,9606.0,5088,,,,,,A,1,BAO_0000019,3956,0,CHEMBL624556,,U
,,Conversion rate of the prodrug in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5089,,,,,Plasma,A,1,BAO_0000366,5074,0,CHEMBL624557,,U
,,Conversion rate of the prodrug in human plasma; ND means no data,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5090,,,,,Plasma,A,1,BAO_0000366,5074,0,CHEMBL624558,,U
,,Half life of compound was determined in human blood,,22224,Homo sapiens,Autocuration,178.0,9606.0,5091,,,,,Blood,A,1,BAO_0000221,4727,0,CHEMBL624559,,U
,,Half life of compound was determined in man with once daily dosing,,22224,Homo sapiens,Autocuration,,9606.0,5092,,,,,,A,1,BAO_0000019,5965,0,CHEMBL624560,,U
,,Half life in human microsomes,,22224,Homo sapiens,Autocuration,,9606.0,5093,In vitro,,,,,A,1,BAO_0000251,5732,0,CHEMBL624561,Microsomes,U
,,Half life in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5094,,,,,Plasma,A,1,BAO_0000366,5819,0,CHEMBL624562,,U
,,Half life in human plasma; Not detected,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5095,,,,,Plasma,A,1,BAO_0000366,5819,0,CHEMBL624563,,U
,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,22224,Homo sapiens,Autocuration,,9606.0,5096,In vivo,,,,,A,1,BAO_0000218,1916,0,CHEMBL624564,,U
,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5097,In vitro,,,,Liver,A,1,BAO_0000251,6597,0,CHEMBL624565,Microsomes,U
,,Half-life in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5098,,,,,Plasma,A,1,BAO_0000366,5229,0,CHEMBL875152,,U
,,Half-life of the parent prodrug in plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5099,,,,,Plasma,A,1,BAO_0000366,5229,0,CHEMBL624566,,U
,,In vitro half life in human plasma was determined,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5100,In vitro,,,,Plasma,A,1,BAO_0000366,2192,0,CHEMBL873805,,U
,,The compound was tested In Vitro for half life in human liver microsomes.,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5101,In vitro,,,,Liver,A,1,BAO_0000251,3032,0,CHEMBL624567,Microsomes,U
,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,22224,Homo sapiens,Autocuration,,9606.0,5102,In vivo,,,,,A,1,BAO_0000218,1916,0,CHEMBL624568,,U
,,Observed volume of distribution,,22224,Homo sapiens,Autocuration,,9606.0,5103,In vivo,,,,,A,1,BAO_0000218,17716,0,CHEMBL624569,,U
,,Oral bioavailability in human,,22224,Homo sapiens,Autocuration,,9606.0,5104,In vivo,,,,,A,1,BAO_0000218,15778,0,CHEMBL624570,,U
,,Tested for human plasma protein binding of the compound,,22224,Homo sapiens,Autocuration,,9606.0,5105,,,,,,A,1,BAO_0000019,17313,0,CHEMBL624571,,U
,,"First order rate constant, k was determined in human plasma",,22224,Homo sapiens,Autocuration,,9606.0,5106,,,,,,A,1,BAO_0000019,4231,0,CHEMBL624572,,U
,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,22224,Homo sapiens,Autocuration,,9606.0,5107,,,,,,A,1,BAO_0000019,4755,0,CHEMBL624573,,U
,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,22224,Homo sapiens,Autocuration,,9606.0,5108,,,,,,A,1,BAO_0000019,4755,0,CHEMBL875153,,U
,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5109,,,,,Liver,A,1,BAO_0000251,16907,0,CHEMBL624574,Microsomes,U
,,The compound was tested for the plasma binding in human,,22224,Homo sapiens,Autocuration,,9606.0,5110,,,,,,A,1,BAO_0000019,10839,0,CHEMBL624575,,U
,,Plasma protein binding (human),,22224,Homo sapiens,Autocuration,,9606.0,5111,,,,,,A,1,BAO_0000019,10839,0,CHEMBL624576,,U
,,Compound was evaluated for half-life in human liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5112,In vitro,,,,Liver,A,1,BAO_0000251,3199,0,CHEMBL624577,Microsomes,U
,,Half life measured in vitro for its stability in human blood,,22224,Homo sapiens,Autocuration,178.0,9606.0,5113,In vitro,,,,Blood,A,1,BAO_0000221,1345,0,CHEMBL624578,,U
,,Half life in human serum,,22224,Homo sapiens,Autocuration,1977.0,9606.0,5114,,,,,Serum,A,1,BAO_0000019,4297,0,CHEMBL622796,,U
,,Half life in human serum; ND=not determined,,22224,Homo sapiens,Autocuration,1977.0,9606.0,5115,,,,,Serum,A,1,BAO_0000019,4297,0,CHEMBL622797,,U
,,Half life were determined in CEM-SS cell extract in decomposition step 1,,22224,Homo sapiens,Autocuration,,9606.0,5116,,,,,,A,1,BAO_0000019,4297,0,CHEMBL622798,,U
,,Half life were determined in CEM-SS cell extract in decomposition step 2,,22224,Homo sapiens,Autocuration,,9606.0,5117,,,,,,A,1,BAO_0000019,4297,0,CHEMBL622799,,U
,,Half life of the in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5118,,,,,Plasma,A,1,BAO_0000366,4231,0,CHEMBL622800,,U
,,Half life period in human hepatic S9 fraction was determined,,22224,Homo sapiens,Autocuration,,9606.0,5119,In vitro,,,,,A,1,BAO_0000220,5633,0,CHEMBL622801,S9,U
,,Half life period in human liver microsome was determined,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5120,In vitro,,,,Liver,A,1,BAO_0000251,5633,0,CHEMBL622802,Microsomes,U
,,Half life period was determined; 6-7,,22224,Homo sapiens,Autocuration,,9606.0,5121,,,,,,A,1,BAO_0000019,17791,0,CHEMBL622803,,U
,,Half life period was evaluated in human,,22224,Homo sapiens,Autocuration,,9606.0,5122,,,,,,A,1,BAO_0000019,17791,0,CHEMBL875154,,U
,,Half life time in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5123,,,,,Plasma,A,1,BAO_0000366,3160,0,CHEMBL622804,,U
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,955.0,10090.0,5124,In vivo,,,,Brain,A,1,BAO_0000218,16438,1,CHEMBL622805,,N
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,948.0,10090.0,5125,In vivo,,,,Heart,A,1,BAO_0000218,16438,1,CHEMBL622611,,N
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,948.0,10090.0,5126,In vivo,,,,Heart,A,1,BAO_0000218,16438,1,CHEMBL622612,,N
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,2113.0,10090.0,5127,In vivo,,,,Kidney,A,1,BAO_0000218,16438,1,CHEMBL875160,,N
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,50594,Mus musculus,Intermediate,2113.0,10090.0,5128,In vivo,,,,Kidney,A,1,BAO_0000218,16438,1,CHEMBL622613,,N
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,2113.0,10090.0,5129,In vivo,,,,Kidney,A,1,BAO_0000218,16438,1,CHEMBL622614,,N
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,2107.0,10090.0,5130,In vivo,,,,Liver,A,1,BAO_0000218,16438,1,CHEMBL622615,,N
,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,50594,Mus musculus,Intermediate,2107.0,10090.0,5131,In vivo,,,,Liver,A,1,BAO_0000218,16438,1,CHEMBL622616,,N
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,2107.0,10090.0,5132,In vivo,,,,Liver,A,1,BAO_0000218,16438,1,CHEMBL622617,,N
,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,50594,Mus musculus,Intermediate,2106.0,10090.0,5133,In vivo,,,,Spleen,A,1,BAO_0000218,16438,1,CHEMBL622618,,N
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,50594,Mus musculus,Intermediate,2106.0,10090.0,5134,In vivo,,,,Spleen,A,1,BAO_0000218,16438,1,CHEMBL622619,,N
,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,2106.0,10090.0,5135,In vivo,,,,Spleen,A,1,BAO_0000218,16438,1,CHEMBL622620,,N
,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,50594,Mus musculus,Intermediate,955.0,10090.0,5136,In vivo,,,,Brain,A,1,BAO_0000218,16438,1,CHEMBL622621,,N
,,Biodistribution of compound (oxidized form) in blood tissue,,50594,Mus musculus,Intermediate,178.0,10090.0,5137,In vivo,,,,Blood,A,1,BAO_0000218,16438,1,CHEMBL622622,,N
,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,178.0,10090.0,5138,In vivo,,,,Blood,A,1,BAO_0000218,16438,1,CHEMBL622623,,N
,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,50594,Mus musculus,Intermediate,178.0,10090.0,5139,In vivo,,,,Blood,A,1,BAO_0000218,16438,1,CHEMBL622624,,N
,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,50594,Mus musculus,Intermediate,178.0,10090.0,5140,In vivo,,,,Blood,A,1,BAO_0000218,16438,1,CHEMBL622625,,N
,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,178.0,10090.0,5141,In vivo,,,,Blood,A,1,BAO_0000218,16438,1,CHEMBL622626,,N
,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,50594,Mus musculus,Intermediate,178.0,10090.0,5142,In vivo,,,,Blood,A,1,BAO_0000218,16438,1,CHEMBL622627,,N
,,Biodistribution of compound (oxidized form) in brain tissue of mice,,50594,Mus musculus,Intermediate,955.0,10090.0,5143,In vivo,,,,Brain,A,1,BAO_0000218,16438,1,CHEMBL622628,,N
,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,955.0,10090.0,5144,In vivo,,,,Brain,A,1,BAO_0000218,16438,1,CHEMBL622629,,N
,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,50594,Mus musculus,Intermediate,955.0,10090.0,5145,In vivo,,,,Brain,A,1,BAO_0000218,16438,1,CHEMBL622630,,N
,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,955.0,10090.0,5146,In vivo,,,,Brain,A,1,BAO_0000218,16438,1,CHEMBL622631,,N
,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,50594,Mus musculus,Intermediate,955.0,10090.0,5147,In vivo,,,,Brain,A,1,BAO_0000218,16438,1,CHEMBL622632,,N
,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,50594,Mus musculus,Intermediate,955.0,10090.0,5148,In vivo,,,,Brain,A,1,BAO_0000218,16438,1,CHEMBL622633,,N
,,Biodistribution of compound (oxidized form) in heart tissue of mice,,50594,Mus musculus,Intermediate,948.0,10090.0,5149,In vivo,,,,Heart,A,1,BAO_0000218,16438,1,CHEMBL622634,,N
,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,948.0,10090.0,5150,In vivo,,,,Heart,A,1,BAO_0000218,16438,1,CHEMBL622635,,N
,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,948.0,10090.0,5151,In vivo,,,,Heart,A,1,BAO_0000218,16438,1,CHEMBL875161,,N
,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,50594,Mus musculus,Intermediate,948.0,10090.0,5152,In vivo,,,,Heart,A,1,BAO_0000218,16438,1,CHEMBL622636,,N
,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,948.0,10090.0,5153,In vivo,,,,Heart,A,1,BAO_0000218,16438,1,CHEMBL623335,,N
,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,50594,Mus musculus,Intermediate,948.0,10090.0,5154,In vivo,,,,Heart,A,1,BAO_0000218,16438,1,CHEMBL623336,,N
,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,2113.0,10090.0,5155,In vivo,,,,Kidney,A,1,BAO_0000218,16438,1,CHEMBL623337,,N
,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,50594,Mus musculus,Intermediate,2113.0,10090.0,5156,In vivo,,,,Kidney,A,1,BAO_0000218,16438,1,CHEMBL623338,,N
,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,50594,Mus musculus,Intermediate,2113.0,10090.0,5157,In vivo,,,,Kidney,A,1,BAO_0000218,16438,1,CHEMBL623339,,N
,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,2113.0,10090.0,5158,In vivo,,,,Kidney,A,1,BAO_0000218,16438,1,CHEMBL623524,,N
,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,50594,Mus musculus,Intermediate,2113.0,10090.0,5159,In vivo,,,,Kidney,A,1,BAO_0000218,16438,1,CHEMBL623525,,N
,,Biodistribution of compound (oxidized form) in liver tissue,,50594,Mus musculus,Intermediate,2107.0,10090.0,5160,In vivo,,,,Liver,A,1,BAO_0000218,16438,1,CHEMBL623526,,N
,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,50594,Mus musculus,Intermediate,2107.0,10090.0,5161,In vivo,,,,Liver,A,1,BAO_0000218,16438,1,CHEMBL623527,,N
,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,50594,Mus musculus,Intermediate,2107.0,10090.0,5162,In vivo,,,,Liver,A,1,BAO_0000218,16438,1,CHEMBL623528,,N
,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,500.0,80852,Homo sapiens,Intermediate,,9606.0,5163,,A-431,,,,F,1,BAO_0000219,5245,1,CHEMBL624615,,N
,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,500.0,80852,Homo sapiens,Intermediate,,9606.0,5164,,A-431,,,,F,1,BAO_0000219,5245,1,CHEMBL621672,,N
,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",500.0,80852,,Expert,,,5165,,A-431,,,,F,1,BAO_0000218,16289,1,CHEMBL621673,,N
,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",500.0,80852,,Expert,,,5166,,A-431,,,,F,1,BAO_0000218,16289,1,CHEMBL621674,,N
,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,500.0,9,Homo sapiens,Expert,,9606.0,5167,,A-431,,,,F,1,BAO_0000219,16093,9,CHEMBL884002,,D
,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",500.0,80852,Homo sapiens,Intermediate,,9606.0,5168,,A-431,,,,F,1,BAO_0000219,16825,1,CHEMBL621850,,N
,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,500.0,80852,Homo sapiens,Intermediate,,9606.0,5169,,A-431,,,,F,1,BAO_0000219,4848,1,CHEMBL621851,,N
,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,500.0,9,Homo sapiens,Expert,,9606.0,5170,,A-431,,,,F,1,BAO_0000219,14827,9,CHEMBL621852,,D
,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,500.0,9,Homo sapiens,Expert,,9606.0,5171,,A-431,,,,F,1,BAO_0000219,14827,9,CHEMBL621853,,D
,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",500.0,80852,,Expert,,,5172,,A-431,,,,F,1,BAO_0000218,16289,1,CHEMBL621854,,N
,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",500.0,80852,,Expert,,,5173,,A-431,,,,F,1,BAO_0000218,16289,1,CHEMBL621855,,N
,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",500.0,80852,,Expert,,,5174,,A-431,,,,F,1,BAO_0000218,16289,1,CHEMBL623724,,N
,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",500.0,80852,,Expert,,,5175,,A-431,,,,F,1,BAO_0000218,16289,1,CHEMBL623725,,N
,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",500.0,80852,,Expert,,,5176,,A-431,,,,F,1,BAO_0000218,16289,1,CHEMBL623726,,N
,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",500.0,9,Homo sapiens,Expert,,9606.0,5177,,A-431,,,,F,1,BAO_0000219,16289,9,CHEMBL623727,,D
,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,500.0,9,,Expert,,,5178,,A-431,,,,F,1,BAO_0000219,16289,8,CHEMBL623728,,H
,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",500.0,80852,,Expert,,,5179,,A-431,,,,F,1,BAO_0000218,16289,1,CHEMBL623729,,N
,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",500.0,80852,,Expert,,,5180,,A-431,,,,F,1,BAO_0000218,16289,1,CHEMBL623730,,N
,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",500.0,80852,,Expert,,,5181,,A-431,,,,F,1,BAO_0000218,16289,1,CHEMBL623731,,N
,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,80852,Mus musculus,Expert,,10090.0,5182,,A-431,,,,F,1,BAO_0000218,14555,1,CHEMBL623732,,N
,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,80852,Mus musculus,Expert,,10090.0,5183,,A-431,,,,F,1,BAO_0000218,14555,1,CHEMBL623733,,N
,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,80852,Mus musculus,Expert,,10090.0,5184,,A-431,,,,F,1,BAO_0000218,14555,1,CHEMBL623734,,N
,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,80852,Mus musculus,Expert,,10090.0,5185,,A-431,,,,F,1,BAO_0000218,14555,1,CHEMBL623735,,N
,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,500.0,80852,Homo sapiens,Expert,,9606.0,5186,,A-431,,,,F,1,BAO_0000219,1937,1,CHEMBL623736,,N
,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,500.0,80852,Homo sapiens,Intermediate,,9606.0,5187,,A-431,,,,F,1,BAO_0000219,13739,1,CHEMBL623737,,N
,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,500.0,80852,Homo sapiens,Intermediate,,9606.0,5188,,A-431,,,,F,1,BAO_0000219,3558,1,CHEMBL623738,,N
,,Dose giving a 50% decrease in the living cell number (A437 cells),500.0,80852,Homo sapiens,Intermediate,,9606.0,5189,,A-431,,,,F,1,BAO_0000219,3558,1,CHEMBL875168,,N
,,In vitro inhibitory concentration against proliferation of A459 cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,5190,,A549,,,,F,1,BAO_0000219,17686,1,CHEMBL623739,,N
,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,5191,,A549,,,,F,1,BAO_0000219,5305,1,CHEMBL623740,,N
,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,646.0,80682,Homo sapiens,Intermediate,,9606.0,5192,,A549,,,,F,1,BAO_0000219,3614,1,CHEMBL624424,,N
,,In vitro antitumor activity against renal A498 tumor cell lines,624.0,80021,Homo sapiens,Intermediate,,9606.0,5193,,A498,,,,F,1,BAO_0000219,17229,1,CHEMBL624425,,N
,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",624.0,80021,Homo sapiens,Intermediate,,9606.0,5194,,A498,,,,F,1,BAO_0000219,15935,1,CHEMBL624426,,N
,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",624.0,80021,Homo sapiens,Intermediate,,9606.0,5195,,A498,,,,F,1,BAO_0000219,15935,1,CHEMBL624427,,N
,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,624.0,80021,Homo sapiens,Intermediate,,9606.0,5196,,A498,,,,F,1,BAO_0000219,15560,1,CHEMBL624428,,N
,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5197,,A498,,,,F,1,BAO_0000219,13891,1,CHEMBL624429,,N
,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,624.0,80021,Homo sapiens,Intermediate,,9606.0,5198,,A498,,,,F,1,BAO_0000219,13891,1,CHEMBL624620,,N
,,Cytotoxicity on kidney carcinoma (A-498) cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5199,,A498,,,,F,1,BAO_0000219,13788,1,CHEMBL624621,,N
,,Compound was evaluated against Human cell line renal A498,624.0,80021,Homo sapiens,Intermediate,,9606.0,5200,,A498,,,,F,1,BAO_0000219,15403,1,CHEMBL624622,,N
,,Compound was tested for inhibition of A498 human renal cancer cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5201,,A498,,,,F,1,BAO_0000219,1009,1,CHEMBL624623,,N
,,Growth inhibitory activity against A498 human cancer cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5202,,A498,,,,F,1,BAO_0000219,1043,1,CHEMBL874365,,N
,,In vitro antitumor activity against human renal A498 cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5203,,A498,,,,F,1,BAO_0000219,5858,1,CHEMBL624624,,N
,,In vitro cytotoxic activity against renal (A498) cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5204,,A498,,,,F,1,BAO_0000219,5958,1,CHEMBL624625,,N
,,In vitro cytotoxic activity against human renal cancer (A498) cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5205,,A498,,,,F,1,BAO_0000219,5506,1,CHEMBL624626,,N
,,Tested for cytostatic activity against renal A498 cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5206,,A498,,,,F,1,BAO_0000219,12781,1,CHEMBL624627,,N
,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,624.0,80021,Homo sapiens,Intermediate,,9606.0,5207,,A498,,,,F,1,BAO_0000219,14399,1,CHEMBL883157,,N
,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,624.0,80021,Homo sapiens,Expert,,9606.0,5208,,A498,,,,F,1,BAO_0000219,5958,1,CHEMBL624628,,N
,,Cmax value after 2 mpk peroral administration to beagles,,22224,beagle,Autocuration,,9615.0,5209,In vivo,,,,,A,1,BAO_0000218,3510,0,CHEMBL624629,,U
beagle,,Bioavailability,,22224,Canis lupus familiaris,Autocuration,,9615.0,5210,In vivo,,,,,A,1,BAO_0000218,3510,0,CHEMBL623551,,U
beagle,,Bioavailability after 1 mpk peroral administration to beagles,,22224,Canis lupus familiaris,Autocuration,,9615.0,5211,In vivo,,,,,A,1,BAO_0000218,3510,0,CHEMBL623552,,U
beagle,,Bioavailability after 2 mpk peroral administration to beagles,,22224,Canis lupus familiaris,Autocuration,,9615.0,5212,In vivo,,,,,A,1,BAO_0000218,3510,0,CHEMBL623553,,U
,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,22224,Bos taurus,Autocuration,,9913.0,5213,,,,,,A,1,BAO_0000019,3085,0,CHEMBL623554,,U
,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,22224,Bos taurus,Autocuration,,9913.0,5214,,,,,,A,1,BAO_0000019,3085,0,CHEMBL623555,,U
,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,22224,Bos taurus,Autocuration,,9913.0,5215,,,,,,A,1,BAO_0000019,3085,0,CHEMBL623556,,U
,,Solubility against bovine alpha-chymotrypsin,,22224,Bos taurus,Autocuration,,9913.0,5216,,,,,,A,1,BAO_0000019,9372,0,CHEMBL623557,,U
,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,22224,Bos taurus,Autocuration,,9913.0,5217,,,,,,A,1,BAO_0000019,3085,0,CHEMBL623558,,U
,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,22224,Bos taurus,Autocuration,,9913.0,5218,,,,,,A,1,BAO_0000019,3085,0,CHEMBL623559,,U
,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,22224,Bos taurus,Autocuration,2106.0,9913.0,5219,,,,,Spleen,A,1,BAO_0000221,1469,0,CHEMBL623560,,U
,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,22224,Bos taurus,Autocuration,,9913.0,5220,,,,,,A,1,BAO_0000019,4297,0,CHEMBL623561,,U
,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,22224,Bos taurus,Autocuration,,9913.0,5221,,,,,,A,1,BAO_0000019,4297,0,CHEMBL623562,,U
,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,22224,Bos taurus,Autocuration,,9913.0,5222,,,,,,A,1,BAO_0000019,17585,0,CHEMBL623563,,U
,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,22224,Bos taurus,Autocuration,2106.0,9913.0,5223,,,,,Spleen,A,1,BAO_0000221,1336,0,CHEMBL623564,,U
,,Half life in presence of 2 mg/mL BSA at pH 8.8,,22224,Bos taurus,Autocuration,,9913.0,5224,,,,,,A,1,BAO_0000019,3085,0,CHEMBL873806,,U
,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,22224,Bos taurus,Autocuration,,9913.0,5225,,,,,,A,1,BAO_0000019,2857,0,CHEMBL623565,,U
,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,22224,Bos taurus,Autocuration,,9913.0,5226,,,,,,A,1,BAO_0000019,2857,0,CHEMBL623566,,U
,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,22224,Bos taurus,Autocuration,,9913.0,5227,,,,,,A,1,BAO_0000019,2857,0,CHEMBL623567,,U
,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,22224,Bos taurus,Autocuration,,9913.0,5228,,,,,,A,1,BAO_0000019,1540,0,CHEMBL623568,,U
,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5229,,,,,Plasma,A,1,BAO_0000218,6316,1,CHEMBL623569,,N
,,AUC after administration at 100 mg/kg/day in dogs,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5230,,,,,Plasma,A,1,BAO_0000218,17594,1,CHEMBL623570,,N
,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5231,,,,,Plasma,A,1,BAO_0000218,4953,1,CHEMBL624254,,N
,,AUC value after 15 mg/kg iv dose in Dogs,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5232,,,,,Plasma,A,1,BAO_0000218,16907,1,CHEMBL624255,,N
,,AUC value after 30 mg/kg po dose in Dogs,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5233,,,,,Plasma,A,1,BAO_0000218,16907,1,CHEMBL624256,,N
,,AUC value after administration of 4 mg/Kg oral dose in dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5234,,,,,Plasma,A,1,BAO_0000218,2959,1,CHEMBL624257,,N
,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5235,,,,,Plasma,A,1,BAO_0000218,17594,1,CHEMBL624258,,N
,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,50588,Canis lupus familiaris,Intermediate,,9615.0,5236,,,,,,A,1,BAO_0000218,5356,1,CHEMBL875277,,N
,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,50588,Canis lupus familiaris,Intermediate,,9615.0,5237,,,,,,A,1,BAO_0000218,16807,1,CHEMBL622667,,N
,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5238,,,,,,A,1,BAO_0000218,4527,1,CHEMBL622668,,N
,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5239,,,,,,A,1,BAO_0000218,4527,1,CHEMBL622669,,N
,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5240,,,,,,A,1,BAO_0000218,15660,1,CHEMBL622670,,N
,,Area under curve determined in dogs after oral administration of 10 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5241,,,,,,A,1,BAO_0000218,15660,1,CHEMBL622671,,N
,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5242,,,,,,A,1,BAO_0000218,5802,1,CHEMBL622672,,N
,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,50588,Canis lupus familiaris,Expert,,9615.0,5243,,,,,,A,1,BAO_0000218,3598,1,CHEMBL622673,,N
,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,50588,Canis lupus familiaris,Expert,,9615.0,5244,,,,,,A,1,BAO_0000218,3598,1,CHEMBL622674,,N
,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,5245,,,,,,A,1,BAO_0000218,5944,1,CHEMBL622675,,N
,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,5246,,,,,,A,1,BAO_0000218,5944,1,CHEMBL622676,,N
,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,5247,,,,,,A,1,BAO_0000218,5944,1,CHEMBL622677,,N
,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,5248,,,,,,A,1,BAO_0000218,5944,1,CHEMBL622678,,N
,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,50588,Canis lupus familiaris,Intermediate,,9615.0,5249,,,,,,A,1,BAO_0000218,4186,1,CHEMBL622679,,N
,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,5250,,,,,,A,1,BAO_0000218,5007,1,CHEMBL622680,,N
,,Area under curve was determine after peroral administration at 10 mpk in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5251,,,,,,A,1,BAO_0000218,5668,1,CHEMBL622681,,N
,,Area under curve was determine after peroral administration at 5 mpk in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5252,,,,,,A,1,BAO_0000218,5668,1,CHEMBL875278,,N
,,Area under curve was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5253,,,,,,A,1,BAO_0000218,5006,1,CHEMBL622682,,N
,,Area under curve in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5254,,,,,,A,1,BAO_0000218,5006,1,CHEMBL622683,,N
,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,5255,,,,,,A,1,BAO_0000218,3771,1,CHEMBL622684,,N
,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,50588,Canis lupus familiaris,Intermediate,,9615.0,5256,,,,,,A,1,BAO_0000218,3771,1,CHEMBL622685,,N
,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,5257,,,,,,A,1,BAO_0000218,3771,1,CHEMBL622686,,N
,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,5258,,,,,,A,1,BAO_0000218,1916,1,CHEMBL618344,,N
,,Area under curve value in dog at a dose of 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5259,,,,,,A,1,BAO_0000218,5302,1,CHEMBL875582,,N
,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5260,,,,,,A,1,BAO_0000218,5600,1,CHEMBL618345,,N
,,Area under curve was determined after 0.3 mg/kg po administration in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5261,,,,,,A,1,BAO_0000218,5600,1,CHEMBL618346,,N
,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5262,,,,,,A,1,BAO_0000218,17764,1,CHEMBL618347,,N
,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5263,,,,,,A,1,BAO_0000218,4368,1,CHEMBL618348,,N
,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,22224,Homo sapiens,Autocuration,,9606.0,5264,,,,,,A,1,BAO_0000019,5318,0,CHEMBL618349,,U
,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,22224,Homo sapiens,Autocuration,,9606.0,5265,,,,,,A,1,BAO_0000019,5318,0,CHEMBL618350,,U
,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,22224,Homo sapiens,Autocuration,,9606.0,5266,,,,,,A,1,BAO_0000019,5318,0,CHEMBL618351,,U
,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,22224,Homo sapiens,Autocuration,,9606.0,5267,,,,,,A,1,BAO_0000019,5318,0,CHEMBL618352,,U
,,Time taken to reduce 50% of the concentration of compound in blood plasma,,22224,Homo sapiens,Autocuration,178.0,9606.0,5268,,,,,Blood,A,1,BAO_0000221,14518,0,CHEMBL873494,,U
,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,22224,Homo sapiens,Autocuration,1969.0,9606.0,5269,,,,,Plasma,A,1,BAO_0000366,2209,0,CHEMBL618353,,U
,,Half life in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5270,,,,,Plasma,A,1,BAO_0000366,6787,0,CHEMBL618354,,U
,,Half life in human plasma was reported,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5271,,,,,Plasma,A,1,BAO_0000366,4898,0,CHEMBL875583,,U
,,Half life in human serum,,22224,Homo sapiens,Autocuration,1977.0,9606.0,5272,,,,,Serum,A,1,BAO_0000019,6072,0,CHEMBL618355,,U
,,Half life upon exposure to human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5273,,,,,Plasma,A,1,BAO_0000366,16907,0,CHEMBL618356,,U
,,t1/2 in human microsomes,,22224,Homo sapiens,Autocuration,,9606.0,5274,In vitro,,,,,A,1,BAO_0000251,5656,0,CHEMBL618357,Microsomes,U
,,Half life period in 80% human plasma at 37 degree Centigrade,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5275,,,,,Plasma,A,1,BAO_0000366,4755,0,CHEMBL618358,,U
,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,22224,Homo sapiens,Autocuration,14.0,9606.0,5276,,,,,Zone of skin,A,1,BAO_0000221,17503,0,CHEMBL618359,,U
,,Half-life measured in in vitro Cathepsin B assay in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5277,In vitro,,,,Plasma,A,1,BAO_0000366,12357,0,CHEMBL618360,,U
,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,22224,Homo sapiens,Autocuration,,9606.0,5278,,,,,,A,1,BAO_0000019,3076,0,CHEMBL618361,,U
,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5279,In vitro,,,,Liver,A,1,BAO_0000251,6410,0,CHEMBL618362,Microsomes,U
,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,22224,Homo sapiens,Autocuration,1969.0,9606.0,5280,,,,,Plasma,A,1,BAO_0000366,3741,0,CHEMBL618363,,U
,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,22224,Homo sapiens,Autocuration,1969.0,9606.0,5281,,,,,Plasma,A,1,BAO_0000366,3741,0,CHEMBL618364,,U
,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,22224,Homo sapiens,Autocuration,1969.0,9606.0,5282,,,,,Plasma,A,1,BAO_0000366,3741,0,CHEMBL875584,,U
,,Half-life in the CEM cell extracts,,22224,Homo sapiens,Autocuration,,9606.0,5283,,,,,,A,1,BAO_0000019,1540,0,CHEMBL618365,,U
,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5284,,,,,Plasma,A,1,BAO_0000366,2905,0,CHEMBL873495,,U
,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5285,,,,,Plasma,A,1,BAO_0000366,2905,0,CHEMBL618366,,U
,,Half-life was determined,,22224,Homo sapiens,Autocuration,,9606.0,5286,,,,,,A,1,BAO_0000019,5523,0,CHEMBL618367,,U
,,Half-life (human blood stability),,22224,Homo sapiens,Autocuration,178.0,9606.0,5287,,,,,Blood,A,1,BAO_0000221,1499,0,CHEMBL618368,,U
,,Half-life (human blood stability); no data,,22224,Homo sapiens,Autocuration,178.0,9606.0,5288,,,,,Blood,A,1,BAO_0000221,1499,0,CHEMBL618369,,U
,,Half-life in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5289,,,,,Plasma,A,1,BAO_0000366,17065,0,CHEMBL618370,,U
,,CYP3A4 metabolism half-life (t1/2),,22224,Homo sapiens,Autocuration,,9606.0,5290,,,,,,A,1,BAO_0000019,6861,0,CHEMBL618371,,U
,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,22224,Homo sapiens,Autocuration,178.0,9606.0,5291,,,,,Blood,A,1,BAO_0000221,1499,0,CHEMBL618372,,U
,,In vitro half life in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5292,In vitro,,,,Plasma,A,1,BAO_0000366,530,0,CHEMBL618373,,U
,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,22224,Homo sapiens,Autocuration,1969.0,9606.0,5293,In vitro,,,,Plasma,A,1,BAO_0000366,1116,0,CHEMBL618374,,U
,,In vitro hydrolysis in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5294,In vitro,,,,Plasma,A,1,BAO_0000366,6695,0,CHEMBL618375,,U
,,In vitro hydrolysis in human plasma; no data,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5295,In vitro,,,,Plasma,A,1,BAO_0000366,6695,0,CHEMBL618376,,U
,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5296,In vitro,,,,Liver,A,1,BAO_0000251,10,0,CHEMBL618377,Microsomes,U
,,Plasma half life in human,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5297,,,,,Plasma,A,1,BAO_0000366,993,0,CHEMBL618378,,U
,,Stability after incubation with human plasma (at 37 degree C),,22224,Homo sapiens,Autocuration,1969.0,9606.0,5298,,,,,Plasma,A,1,BAO_0000366,15429,0,CHEMBL618379,,U
,,T1/2 was evaluated in human plasma,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5299,,,,,Plasma,A,1,BAO_0000366,1675,0,CHEMBL618380,,U
,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,22224,Homo sapiens,Autocuration,1969.0,9606.0,5300,,,,,Plasma,A,1,BAO_0000366,2209,0,CHEMBL618381,,U
,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,22224,Homo sapiens,Autocuration,1969.0,9606.0,5301,,,,,Plasma,A,1,BAO_0000366,2209,0,CHEMBL618382,,U
,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,22224,Homo sapiens,Autocuration,,9606.0,5302,,,,,,A,1,BAO_0000019,5318,0,CHEMBL618383,,U
,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,22224,Homo sapiens,Autocuration,,9606.0,5303,In vitro,,,,,A,1,BAO_0000019,2412,0,CHEMBL618384,,U
,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,22224,Homo sapiens,Autocuration,,9606.0,5304,In vitro,,,,,A,1,BAO_0000019,2412,0,CHEMBL618385,,U
,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5305,,,,,Plasma,A,1,BAO_0000366,2906,0,CHEMBL619099,,U
,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,22224,Homo sapiens,Autocuration,1969.0,9606.0,5306,,,,,Plasma,A,1,BAO_0000366,2906,0,CHEMBL619100,,U
,,Time taken for 50% to be consumed by serum PON1 was determined,,22224,Homo sapiens,Autocuration,,9606.0,5307,,,,,,A,1,BAO_0000019,5495,0,CHEMBL619101,,U
,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,22224,Homo sapiens,Autocuration,,9606.0,5308,,,,,,A,1,BAO_0000019,5495,0,CHEMBL619102,,U
,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,22224,Homo sapiens,Autocuration,2107.0,9606.0,5309,,,,,Liver,A,1,BAO_0000251,4397,0,CHEMBL619103,Microsomes,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224,Mus sp.,Autocuration,,10095.0,5310,,,,,,A,1,BAO_0000218,2413,0,CHEMBL619268,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224,Mus sp.,Autocuration,,10095.0,5311,,,,,,A,1,BAO_0000218,2413,0,CHEMBL619269,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224,Mus sp.,Autocuration,,10095.0,5312,,,,,,A,1,BAO_0000218,2413,0,CHEMBL619270,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224,Mus sp.,Autocuration,,10095.0,5313,,,,,,A,1,BAO_0000218,2413,0,CHEMBL619271,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224,Mus sp.,Autocuration,,10095.0,5314,,,,,,A,1,BAO_0000218,2413,0,CHEMBL875585,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,22224,Mus sp.,Autocuration,,10095.0,5315,,,,,,A,1,BAO_0000218,2413,0,CHEMBL619272,,U
,,Compound tested for growth inhibition of renal cancer cell line 786-0,391.0,80640,Homo sapiens,Intermediate,,9606.0,5316,,786-0,,,,F,1,BAO_0000219,6058,1,CHEMBL619273,,N
,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,391.0,80640,Homo sapiens,Intermediate,,9606.0,5317,,786-0,,,,F,1,BAO_0000219,17708,1,CHEMBL619274,,N
,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,391.0,80640,Homo sapiens,Expert,,9606.0,5318,,786-0,,,,F,1,BAO_0000219,14017,1,CHEMBL619275,,N
,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",391.0,80640,Homo sapiens,Intermediate,,9606.0,5319,,786-0,,,,F,1,BAO_0000219,16818,1,CHEMBL619276,,N
,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",391.0,80640,Homo sapiens,Intermediate,,9606.0,5320,,786-0,,,,F,1,BAO_0000219,16818,1,CHEMBL619277,,N
,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",391.0,80640,Homo sapiens,Intermediate,,9606.0,5321,,786-0,,,,F,1,BAO_0000219,16818,1,CHEMBL619278,,N
,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,391.0,80640,Homo sapiens,Intermediate,,9606.0,5322,,786-0,,,,F,1,BAO_0000219,11970,1,CHEMBL619279,,N
,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,391.0,80640,Homo sapiens,Intermediate,,9606.0,5323,,786-0,,,,F,1,BAO_0000219,12400,1,CHEMBL858458,,N
,,Cytotoxic effect on renal cancer line 786-0,391.0,80640,Homo sapiens,Expert,,9606.0,5324,,786-0,,,,F,1,BAO_0000219,12888,1,CHEMBL619280,,N
,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,391.0,80640,Homo sapiens,Intermediate,,9606.0,5325,,786-0,,,,F,1,BAO_0000219,15300,1,CHEMBL619281,,N
,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),391.0,80640,Homo sapiens,Intermediate,,9606.0,5326,,786-0,,,,F,1,BAO_0000219,14769,1,CHEMBL619282,,N
,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",391.0,80640,Homo sapiens,Intermediate,,9606.0,5327,,786-0,,,,F,1,BAO_0000219,15895,1,CHEMBL619283,,N
,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,391.0,80640,Homo sapiens,Intermediate,,9606.0,5328,,786-0,,,,F,1,BAO_0000219,17376,1,CHEMBL619284,,N
,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,391.0,80640,Homo sapiens,Intermediate,,9606.0,5329,,786-0,,,,F,1,BAO_0000219,14882,1,CHEMBL619285,,N
,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),391.0,80640,Homo sapiens,Intermediate,,9606.0,5330,,786-0,,,,F,1,BAO_0000219,14882,1,CHEMBL619286,,N
,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,391.0,80640,Homo sapiens,Intermediate,,9606.0,5331,,786-0,,,,F,1,BAO_0000219,15176,1,CHEMBL619287,,N
,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,391.0,80640,Homo sapiens,Intermediate,,9606.0,5332,,786-0,,,,F,1,BAO_0000219,12696,1,CHEMBL857455,,N
,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),391.0,80640,Homo sapiens,Intermediate,,9606.0,5333,,786-0,,,,F,1,BAO_0000219,2496,1,CHEMBL883801,,N
,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,972.0,80641,Homo sapiens,Intermediate,,9606.0,5334,,791T cell line,,,,F,1,BAO_0000219,11831,1,CHEMBL619288,,N
,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),972.0,80641,Homo sapiens,Intermediate,,9606.0,5335,,791T cell line,,,,F,1,BAO_0000219,11831,1,CHEMBL619289,,N
,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,972.0,80641,Homo sapiens,Intermediate,,9606.0,5336,,791T cell line,,,,F,1,BAO_0000219,11831,1,CHEMBL619290,,N
,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),972.0,80641,Homo sapiens,Intermediate,,9606.0,5337,,791T cell line,,,,F,1,BAO_0000219,11831,1,CHEMBL619291,,N
,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),972.0,80641,Homo sapiens,Intermediate,,9606.0,5338,,791T cell line,,,,F,1,BAO_0000219,11831,1,CHEMBL619292,,N
,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,972.0,80641,Homo sapiens,Intermediate,,9606.0,5339,,791T cell line,,,,F,1,BAO_0000219,11831,1,CHEMBL619293,,N
,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),972.0,80641,Homo sapiens,Intermediate,,9606.0,5340,,791T cell line,,,,F,1,BAO_0000219,11831,1,CHEMBL619294,,N
,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),972.0,80641,Homo sapiens,Intermediate,,9606.0,5341,,791T cell line,,,,F,1,BAO_0000219,11831,1,CHEMBL619295,,N
,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),972.0,80641,Homo sapiens,Intermediate,,9606.0,5342,,791T cell line,,,,F,1,BAO_0000219,11831,1,CHEMBL619296,,N
,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,972.0,80641,Homo sapiens,Intermediate,,9606.0,5343,,791T cell line,,,,F,1,BAO_0000219,11831,1,CHEMBL619297,,N
,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,391.0,80640,Homo sapiens,Intermediate,,9606.0,5344,,786-0,,,,F,1,BAO_0000219,12782,1,CHEMBL619298,,N
,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,22226,,Intermediate,,,5345,,,,,,F,1,BAO_0000019,1229,0,CHEMBL619299,,U
,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,741.0,80433,Homo sapiens,Expert,,9606.0,5346,,RPMI-8226,,,,F,1,BAO_0000219,15313,1,CHEMBL619300,,N
,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,741.0,80433,Homo sapiens,Expert,,9606.0,5347,,RPMI-8226,,,,F,1,BAO_0000219,15313,1,CHEMBL619301,,N
,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,741.0,80433,Homo sapiens,Intermediate,,9606.0,5348,,RPMI-8226,,,,F,1,BAO_0000219,11544,1,CHEMBL619302,,N
,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,741.0,80433,Homo sapiens,Intermediate,,9606.0,5349,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL619303,,N
,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,741.0,80433,Homo sapiens,Intermediate,,9606.0,5350,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL619304,,N
,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5351,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL857706,,N
,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5352,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL619305,,N
,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5353,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL619306,,N
,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5354,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL619307,,N
,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5355,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL619308,,N
,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5356,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL619309,,N
,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5357,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL619310,,N
,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),624.0,80021,Homo sapiens,Intermediate,,9606.0,5358,,A498,,,,F,1,BAO_0000219,14769,1,CHEMBL619311,,N
,,Compound was tested for the growth inhibition of A498 renal tumor cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5359,,A498,,,,F,1,BAO_0000219,15354,1,CHEMBL619312,,N
,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),624.0,80021,Homo sapiens,Intermediate,,9606.0,5360,,A498,,,,F,1,BAO_0000219,17445,1,CHEMBL619313,,N
,,In vitro inhibitory concentration against renal cancer cell line A498,624.0,80021,Homo sapiens,Intermediate,,9606.0,5361,,A498,,,,F,1,BAO_0000219,4337,1,CHEMBL619314,,N
,,Cytotoxicity against A 498 tumor cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5362,,A498,,,,F,1,BAO_0000219,15277,1,CHEMBL619959,,N
,,In vitro antitumor activity against A498 human cancer cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5363,,A498,,,,F,1,BAO_0000219,4812,1,CHEMBL619960,,N
,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),624.0,80021,Homo sapiens,Intermediate,,9606.0,5364,,A498,,,,F,1,BAO_0000219,4812,1,CHEMBL619961,,N
,,Inhibitory dose required against A498 human tumor cell lines,624.0,80021,Homo sapiens,Intermediate,,9606.0,5365,,A498,,,,F,1,BAO_0000219,4995,1,CHEMBL619962,,N
,,Anticancer activity against one renal cancer (A498 cell line),624.0,80021,Homo sapiens,Intermediate,,9606.0,5366,,A498,,,,F,1,BAO_0000219,5847,1,CHEMBL875586,,N
,,In vitro cytotoxicity against melanoma A498 cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5367,,A498,,,,F,1,BAO_0000219,6557,1,CHEMBL619963,,N
,,Compound was tested for growth inhibitory activity against A498 cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5368,,A498,,,,F,1,BAO_0000219,2597,1,CHEMBL619964,,N
,,Compound tested for growth inhibition of renal cancer cell line A498,624.0,80021,Homo sapiens,Intermediate,,9606.0,5369,,A498,,,,F,1,BAO_0000219,6058,1,CHEMBL620108,,N
,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5370,,A498,,,,F,1,BAO_0000219,17708,1,CHEMBL620109,,N
,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,624.0,80021,Homo sapiens,Intermediate,,9606.0,5371,,A498,,,,F,1,BAO_0000219,15176,1,CHEMBL620110,,N
,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,624.0,80021,Homo sapiens,Intermediate,,9606.0,5372,,A498,,,,F,1,BAO_0000219,15300,1,CHEMBL620111,,N
,,Tested for cytotoxicity against A498 cell lines in renal cancer,624.0,80021,Homo sapiens,Intermediate,,9606.0,5373,,A498,,,,F,1,BAO_0000219,11970,1,CHEMBL620112,,N
,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,624.0,80021,Homo sapiens,Intermediate,,9606.0,5374,,A498,,,,F,1,BAO_0000219,12400,1,CHEMBL620113,,N
,,Cytotoxic effect on renal cancer lines A498,624.0,80021,Homo sapiens,Expert,,9606.0,5375,,A498,,,,F,1,BAO_0000219,12888,1,CHEMBL620114,,N
,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,624.0,80021,Homo sapiens,Intermediate,,9606.0,5376,,A498,,,,F,1,BAO_0000219,3030,1,CHEMBL620115,,N
,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),624.0,80021,Homo sapiens,Intermediate,,9606.0,5377,,A498,,,,F,1,BAO_0000219,14769,1,CHEMBL620116,,N
,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5378,,A498,,,,F,1,BAO_0000219,17376,1,CHEMBL620117,,N
,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,624.0,80021,Homo sapiens,Intermediate,,9606.0,5379,,A498,,,,F,1,BAO_0000219,16558,1,CHEMBL620118,,N
,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,624.0,80021,Homo sapiens,Intermediate,,9606.0,5380,,A498,,,,F,1,BAO_0000219,5194,1,CHEMBL620119,,N
,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,624.0,80021,Homo sapiens,Intermediate,,9606.0,5381,,A498,,,,F,1,BAO_0000219,10708,1,CHEMBL620120,,N
,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,5382,,A549,,,,F,1,BAO_0000219,16880,1,CHEMBL620121,,N
,,Antitumor activity against A549 human lung carcinoma cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5383,,A549,,,,F,1,BAO_0000219,10196,1,CHEMBL620122,,N
,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,646.0,80682,Homo sapiens,Intermediate,,9606.0,5384,,A549,,,,F,1,BAO_0000219,10196,1,CHEMBL620123,,N
,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,646.0,80682,Homo sapiens,Intermediate,,9606.0,5385,,A549,,,,F,1,BAO_0000219,10196,1,CHEMBL620124,,N
,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",646.0,80682,Homo sapiens,Intermediate,,9606.0,5386,,A549,,,,F,1,BAO_0000219,12083,1,CHEMBL620125,,N
,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,646.0,80682,Homo sapiens,Expert,,9606.0,5387,,A549,,,,F,1,BAO_0000219,16464,1,CHEMBL620126,,N
,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,646.0,80682,Homo sapiens,Intermediate,,9606.0,5388,,A549,,,,F,1,BAO_0000219,16464,1,CHEMBL883027,,N
,,In vitro cytotoxic activity against human lung A549 cell line,646.0,80682,Homo sapiens,Expert,,9606.0,5389,,A549,,,,F,1,BAO_0000219,16470,1,CHEMBL620127,,N
,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),646.0,80682,Homo sapiens,Intermediate,,9606.0,5390,,A549,,,,F,1,BAO_0000219,16470,1,CHEMBL620128,,N
,,In vitro cytotoxic activity against human lung A549 cell line),646.0,80682,Homo sapiens,Intermediate,,9606.0,5391,,A549,,,,F,1,BAO_0000219,16470,1,CHEMBL620129,,N
,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,646.0,80682,Homo sapiens,Intermediate,,9606.0,5392,,A549,,,,F,1,BAO_0000219,16470,1,CHEMBL620130,,N
,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,646.0,80682,Homo sapiens,Expert,,9606.0,5393,,A549,,,,F,1,BAO_0000219,16582,1,CHEMBL620131,,N
,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",646.0,80682,Homo sapiens,Intermediate,,9606.0,5394,,A549,,,,F,1,BAO_0000219,15935,1,CHEMBL620132,,N
,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",646.0,80682,Homo sapiens,Intermediate,,9606.0,5395,,A549,,,,F,1,BAO_0000219,15935,1,CHEMBL620133,,N
,,Inhibition of A549 human lung carcinoma cell proliferation,646.0,80682,Homo sapiens,Expert,,9606.0,5396,,A549,,,,F,1,BAO_0000219,16597,1,CHEMBL620134,,N
,,Inhibitory activity against A549 lung adenocarcinoma cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5397,,A549,,,,F,1,BAO_0000219,17376,1,CHEMBL620135,,N
,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5398,,A549,,,,F,1,BAO_0000219,16496,1,CHEMBL620136,,N
,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5399,,A549,,,,F,1,BAO_0000219,16152,1,CHEMBL620137,,N
,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5400,,A549,,,,F,1,BAO_0000219,16152,1,CHEMBL620268,,N
,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,646.0,80682,Homo sapiens,Intermediate,,9606.0,5401,,A549,,,,F,1,BAO_0000219,16464,1,CHEMBL620269,,N
,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5402,,A549,,,,F,1,BAO_0000219,2288,1,CHEMBL620270,,N
,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5403,,A549,,,,F,1,BAO_0000219,17350,1,CHEMBL620271,,N
,,Inhibition of A549 cancer cell proliferation,646.0,80682,Homo sapiens,Expert,,9606.0,5404,,A549,,,,F,1,BAO_0000219,4090,1,CHEMBL620272,,N
,,Inhibition of A549 cancer cell proliferation (Not tested),646.0,80682,Homo sapiens,Expert,,9606.0,5405,,A549,,,,F,1,BAO_0000219,4090,1,CHEMBL620273,,N
,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5406,,A549,,,,F,1,BAO_0000219,17350,1,CHEMBL620274,,N
,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,646.0,80682,Homo sapiens,Intermediate,,9606.0,5407,,A549,,,,F,1,BAO_0000219,4197,1,CHEMBL620275,,N
,,Antiproliferative potency determined as inhibitory concentration against A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,5408,,A549,,,,F,1,BAO_0000219,17072,1,CHEMBL620276,,N
,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,646.0,80682,Homo sapiens,Intermediate,,9606.0,5409,,A549,,,,F,1,BAO_0000219,17072,1,CHEMBL620277,,N
,,Cytotoxicity against Renal cell lines A549 was determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,5410,,A549,,,,F,1,BAO_0000219,5194,1,CHEMBL620278,,N
,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,50588,Canis lupus familiaris,Intermediate,,9615.0,5411,,,,,,A,1,BAO_0000218,4257,1,CHEMBL620279,,N
,,Area under curve was determined in dog after oral administration at 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5412,,,,,,A,1,BAO_0000218,6123,1,CHEMBL620280,,N
,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,50588,Canis lupus familiaris,Intermediate,,9615.0,5413,,,,,,A,1,BAO_0000218,1337,1,CHEMBL620281,,N
,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,50588,Canis lupus familiaris,Intermediate,,9615.0,5414,,,,,,A,1,BAO_0000218,1337,1,CHEMBL620282,,N
,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,50588,Canis lupus familiaris,Intermediate,,9615.0,5415,,,,,,A,1,BAO_0000218,8833,1,CHEMBL621134,,N
,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,50588,Canis lupus familiaris,Intermediate,,9615.0,5416,,,,,,A,1,BAO_0000218,8833,1,CHEMBL621135,,N
,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,50588,Canis lupus familiaris,Intermediate,,9615.0,5417,,,,,,A,1,BAO_0000218,8833,1,CHEMBL621136,,N
,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,50588,Canis lupus familiaris,Intermediate,,9615.0,5418,,,,,,A,1,BAO_0000218,8833,1,CHEMBL621137,,N
,,Area under plasma concentration time curve in dog upon oral administration,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5419,,,,,Plasma,A,1,BAO_0000218,17657,1,CHEMBL621138,,N
,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5420,,,,,Plasma,A,1,BAO_0000218,17650,1,CHEMBL875587,,N
,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,50588,Canis lupus familiaris,Intermediate,,9615.0,5421,,,,,,A,1,BAO_0000218,1977,1,CHEMBL621139,,N
,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,50588,Canis lupus familiaris,Intermediate,,9615.0,5422,,,,,,A,1,BAO_0000218,1977,1,CHEMBL621140,,N
,,Area under the curve for the compound was obtained when tested in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5423,,,,,,A,1,BAO_0000218,3132,1,CHEMBL621141,,N
,,Area under the curve at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5424,,,,,,A,1,BAO_0000218,5473,1,CHEMBL621142,,N
,,Area under the curve at a dose of 1 mg/kg (oral),,50588,Canis lupus familiaris,Intermediate,,9615.0,5425,,,,,,A,1,BAO_0000218,5474,1,CHEMBL621143,,N
,,Area under the curve at i.v. dose of 0.2 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5426,,,,,,A,1,BAO_0000218,5474,1,CHEMBL621144,,N
,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5427,,,,,,A,1,BAO_0000218,6062,1,CHEMBL621145,,N
,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5428,,,,,,A,1,BAO_0000218,4709,1,CHEMBL621146,,N
,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,50588,Canis lupus familiaris,Intermediate,,9615.0,5429,,,,,,A,1,BAO_0000218,2652,1,CHEMBL622567,,N
,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,50588,Canis lupus familiaris,Intermediate,,9615.0,5430,,,,,,A,1,BAO_0000218,2652,1,CHEMBL622568,,N
,,Compound was evaluated for area under the curve in dog blood.,,50588,Canis lupus familiaris,Intermediate,,9615.0,5431,,,,,,A,1,BAO_0000218,2877,1,CHEMBL622569,,N
,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5432,,,,,,A,1,BAO_0000218,5444,1,CHEMBL622570,,N
,,AUC in dog after oral dose (1 mg/kg),,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5433,,,,,Plasma,A,1,BAO_0000218,5130,1,CHEMBL622571,,N
,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5434,,,,,,A,1,BAO_0000218,6265,1,CHEMBL622572,,N
,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,50588,Canis lupus familiaris,Intermediate,,9615.0,5435,,,,,,A,1,BAO_0000218,4657,1,CHEMBL622573,,N
,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5436,,,,,,A,1,BAO_0000218,16367,1,CHEMBL622574,,N
,,Pharmacokinetic parameter AUC after oral administration to dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5437,,,,,,A,1,BAO_0000218,16367,1,CHEMBL622575,,N
,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,50588,Canis lupus familiaris,Intermediate,,9615.0,5438,,,,,,A,1,BAO_0000218,9579,1,CHEMBL622576,,N
,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,50588,Canis lupus familiaris,Intermediate,,9615.0,5439,,,,,,A,1,BAO_0000218,9579,1,CHEMBL622577,,N
,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,50588,Canis lupus familiaris,Intermediate,,9615.0,5440,,,,,,A,1,BAO_0000218,5983,1,CHEMBL622578,,N
,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5441,,,,,,A,1,BAO_0000218,6241,1,CHEMBL622579,,N
,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,50588,Canis lupus familiaris,Intermediate,,9615.0,5442,,,,,,A,1,BAO_0000218,5313,1,CHEMBL622580,,N
,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,50588,Canis lupus familiaris,Intermediate,,9615.0,5443,,,,,,A,1,BAO_0000218,5313,1,CHEMBL622581,,N
,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,50588,Canis lupus familiaris,Intermediate,,9615.0,5444,,,,,,A,1,BAO_0000218,6642,1,CHEMBL622582,,N
,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,50588,Canis lupus familiaris,Intermediate,,9615.0,5445,,,,,,A,1,BAO_0000218,6642,1,CHEMBL622583,,N
,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,50588,Canis lupus familiaris,Intermediate,,9615.0,5446,,,,,,A,1,BAO_0000218,6641,1,CHEMBL622584,,N
,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,50588,Canis lupus familiaris,Intermediate,,9615.0,5447,,,,,,A,1,BAO_0000218,6642,1,CHEMBL622585,,N
,,Compound was evaluated for oral bioavailability in dog; 90-100,,50588,Canis lupus familiaris,Intermediate,,9615.0,5448,,,,,,A,1,BAO_0000218,17791,1,CHEMBL622586,,N
,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,50588,Canis lupus familiaris,Intermediate,,9615.0,5449,,,,,,A,1,BAO_0000218,17655,1,CHEMBL623281,,N
,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5450,,,,,,A,1,BAO_0000218,17655,1,CHEMBL623282,,N
,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,50588,Canis lupus familiaris,Intermediate,,9615.0,5451,,,,,,A,1,BAO_0000218,6596,1,CHEMBL623283,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5452,,,,,,A,1,BAO_0000218,3880,1,CHEMBL623284,,N
,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5453,,,,,,A,1,BAO_0000218,16367,1,CHEMBL623285,,N
,,Plasma protein binding towards dog plasma at 10 uM,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5454,,,,,Plasma,A,1,BAO_0000218,17409,1,CHEMBL623463,,N
,,Plasma protein binding towards dog plasma at 100 uM,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5455,,,,,Plasma,A,1,BAO_0000218,17409,1,CHEMBL875952,,N
,,Bioavailability in dog (dose 4 mg/kg p.o.),,50588,Canis lupus familiaris,Intermediate,,9615.0,5456,In vivo,,,,,A,1,BAO_0000218,2959,1,CHEMBL621705,,N
,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5457,In vivo,,,,,A,1,BAO_0000218,13501,1,CHEMBL621706,,N
,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5458,In vivo,,,,,A,1,BAO_0000218,4527,1,CHEMBL621707,,N
,,Bioavailability in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5459,In vivo,,,,,A,1,BAO_0000218,15145,1,CHEMBL621708,,N
,,Bioavailability,,50588,Canis lupus familiaris,Intermediate,,9615.0,5460,In vivo,,,,,A,1,BAO_0000218,4219,1,CHEMBL621709,,N
,,Oral bioavailability in dog (dose 10 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,5461,In vivo,,,,,A,1,BAO_0000218,17538,1,CHEMBL621710,,N
,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5462,In vivo,,,,,A,1,BAO_0000218,17538,1,CHEMBL621711,,N
,,Bioavailability in dog (dose 10.0 mg/kg p.o.),,50588,Canis lupus familiaris,Intermediate,,9615.0,5463,In vivo,,,,,A,1,BAO_0000218,1466,1,CHEMBL621712,,N
,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5464,In vivo,,,,,A,1,BAO_0000218,17650,1,CHEMBL621713,,N
,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5465,In vivo,,,,,A,1,BAO_0000218,3132,1,CHEMBL621714,,N
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224,Mus sp.,Autocuration,,10095.0,5466,,,,,,A,1,BAO_0000218,2413,0,CHEMBL621715,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224,Mus sp.,Autocuration,2107.0,10095.0,5467,,,,,Liver,A,1,BAO_0000218,2413,0,CHEMBL623717,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,22224,Mus sp.,Autocuration,2107.0,10095.0,5468,,,,,Liver,A,1,BAO_0000218,2413,0,CHEMBL623718,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224,Mus sp.,Autocuration,2107.0,10095.0,5469,,,,,Liver,A,1,BAO_0000218,2413,0,CHEMBL623719,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224,Mus sp.,Autocuration,,10095.0,5470,,,,,,A,1,BAO_0000218,2413,0,CHEMBL623720,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224,Mus sp.,Autocuration,,10095.0,5471,,,,,,A,1,BAO_0000218,2413,0,CHEMBL623721,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224,Mus sp.,Autocuration,2385.0,10095.0,5472,,,,,Muscle tissue,A,1,BAO_0000218,2413,0,CHEMBL623722,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,22224,Mus sp.,Autocuration,2385.0,10095.0,5473,,,,,Muscle tissue,A,1,BAO_0000218,2413,0,CHEMBL623723,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224,Mus sp.,Autocuration,2385.0,10095.0,5474,,,,,Muscle tissue,A,1,BAO_0000218,2413,0,CHEMBL618543,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224,Mus sp.,Autocuration,2106.0,10095.0,5475,,,,,Spleen,A,1,BAO_0000218,2413,0,CHEMBL618544,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224,Mus sp.,Autocuration,2106.0,10095.0,5476,,,,,Spleen,A,1,BAO_0000218,2413,0,CHEMBL875155,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,22224,Mus sp.,Autocuration,,10095.0,5477,,,,,,A,1,BAO_0000218,2413,0,CHEMBL618545,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,22224,Mus sp.,Autocuration,,10095.0,5478,,,,,,A,1,BAO_0000218,2413,0,CHEMBL618546,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224,Mus sp.,Autocuration,,10095.0,5479,,,,,,A,1,BAO_0000218,2413,0,CHEMBL623529,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,22224,Mus sp.,Autocuration,,10095.0,5480,,,,,,A,1,BAO_0000218,2413,0,CHEMBL623530,,U
,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,22224,Mus sp.,Autocuration,,10095.0,5481,,,,,,A,1,BAO_0000218,2413,0,CHEMBL621764,,U
,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,22224,Cercopithecidae,Autocuration,,9527.0,5482,,,,,,A,1,BAO_0000019,17827,0,CHEMBL621765,,U
,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,22224,Cercopithecidae,Autocuration,2037.0,9527.0,5483,,,,,Cerebellum,A,1,BAO_0000019,17827,0,CHEMBL621766,,U
,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,22224,Cercopithecidae,Autocuration,1870.0,9527.0,5484,,,,,Frontal cortex,A,1,BAO_0000019,17827,0,CHEMBL621767,,U
,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,22224,Cercopithecidae,Autocuration,,9527.0,5485,,,,,,A,1,BAO_0000019,17827,0,CHEMBL621768,,U
,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,22224,Cercopithecidae,Autocuration,2435.0,9527.0,5486,,,,,Striatum,A,1,BAO_0000019,17827,0,CHEMBL621769,,U
,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,22224,Cercopithecidae,Autocuration,,9527.0,5487,,,,,,A,1,BAO_0000019,17827,0,CHEMBL621770,,U
,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,22224,Cercopithecidae,Autocuration,2037.0,9527.0,5488,,,,,Cerebellum,A,1,BAO_0000019,17827,0,CHEMBL621771,,U
,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,22224,Cercopithecidae,Autocuration,1870.0,9527.0,5489,,,,,Frontal cortex,A,1,BAO_0000019,17827,0,CHEMBL621772,,U
,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,22224,Cercopithecidae,Autocuration,,9527.0,5490,,,,,,A,1,BAO_0000019,17827,0,CHEMBL621773,,U
,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,22224,Cercopithecidae,Autocuration,2435.0,9527.0,5491,,,,,Striatum,A,1,BAO_0000019,17827,0,CHEMBL621774,,U
,,Compound was evaluated for oral bioavailability in rats,,22224,Cercopithecidae,Autocuration,,9527.0,5492,,,,,,A,1,BAO_0000218,17791,0,CHEMBL621775,,U
,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,5493,In vivo,,,,Plasma,A,1,BAO_0000218,17667,0,CHEMBL621776,,U
,,Half life period was evaluated in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,5494,,,,,,A,1,BAO_0000019,17791,0,CHEMBL621777,,U
,,Half-life in rhesus monkeys by intravenous administration of dose,,22224,Cercopithecidae,Autocuration,,9527.0,5495,In vivo,,,,,A,1,BAO_0000218,110,0,CHEMBL875162,,U
,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,50594,Mus musculus,Intermediate,1969.0,10090.0,5496,,,,,Plasma,A,1,BAO_0000218,5781,1,CHEMBL621778,,N
,,AUC after intraperitoneal administration of 100 mg/kg in mice,,50594,Mus musculus,Intermediate,1969.0,10090.0,5497,,,,,Plasma,A,1,BAO_0000218,17734,1,CHEMBL621779,,N
,,AUC value was determined after oral administration,,50594,Mus musculus,Intermediate,1969.0,10090.0,5498,,,,,Plasma,A,1,BAO_0000218,17718,1,CHEMBL622479,,N
,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,50594,Mus musculus,Intermediate,,10090.0,5499,,,,,,A,1,BAO_0000218,4573,1,CHEMBL622480,,N
,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,50594,Mus musculus,Intermediate,,10090.0,5500,,,,,,A,1,BAO_0000218,3277,1,CHEMBL622481,,N
,,Area under curve by ioral administration in mouse,,50594,Mus musculus,Intermediate,,10090.0,5501,,,,,,A,1,BAO_0000218,2862,1,CHEMBL622482,,N
,,Area under curve by iv administration in mouse,,50594,Mus musculus,Intermediate,,10090.0,5502,,,,,,A,1,BAO_0000218,2862,1,CHEMBL622483,,N
,,Area under curve at 0-8 hr in IRC mice after peroral administration,,50594,Mus musculus,Intermediate,,10090.0,5503,,,,,,A,1,BAO_0000218,5951,1,CHEMBL622484,,N
,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5504,,,,,,A,1,BAO_0000218,17729,1,CHEMBL622641,,N
,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5505,,,,,,A,1,BAO_0000218,17728,1,CHEMBL622642,,N
,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5506,,,,,,A,1,BAO_0000218,17728,1,CHEMBL622643,,N
,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5507,,,,,,A,1,BAO_0000218,17729,1,CHEMBL622644,,N
,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,741.0,80433,Homo sapiens,Intermediate,,9606.0,5508,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL622645,,N
,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,741.0,80433,Homo sapiens,Intermediate,,9606.0,5509,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL622646,,N
,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5510,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL621238,,N
,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5511,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL621239,,N
,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5512,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL621240,,N
,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5513,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL621241,,N
,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5514,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL621242,,N
,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5515,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL620350,,N
,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,741.0,80433,Homo sapiens,Intermediate,,9606.0,5516,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL620351,,N
,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,741.0,80433,Homo sapiens,Intermediate,,9606.0,5517,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL620352,,N
,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5518,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL620353,,N
,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5519,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL620354,,N
,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5520,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL620355,,N
,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5521,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL620356,,N
,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5522,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL620357,,N
,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),741.0,80433,Homo sapiens,Intermediate,,9606.0,5523,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL620358,,N
,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,741.0,80433,Homo sapiens,Expert,,9606.0,5524,,RPMI-8226,,,,F,1,BAO_0000219,9424,1,CHEMBL620359,,N
,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,741.0,80433,Homo sapiens,Intermediate,,9606.0,5525,,RPMI-8226,,,,F,1,BAO_0000219,11544,1,CHEMBL620360,,N
,,Cytotoxicity of compound against 8226/DOX1V cells,741.0,80433,Homo sapiens,Intermediate,,9606.0,5526,,RPMI-8226,,,,F,1,BAO_0000219,17378,1,CHEMBL620361,,N
,,Cytotoxicity of compound against 8226/S cells,741.0,80433,Homo sapiens,Intermediate,,9606.0,5527,,RPMI-8226,,,,F,1,BAO_0000219,17378,1,CHEMBL620362,,N
,,Inhibitory concentration against 8226 myeloma cancer cell line,741.0,80433,Homo sapiens,Intermediate,,9606.0,5528,,RPMI-8226,,,,F,1,BAO_0000219,17079,1,CHEMBL620363,,N
,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,741.0,80433,Homo sapiens,Intermediate,,9606.0,5529,,RPMI-8226,,,,F,1,BAO_0000219,17079,1,CHEMBL620364,,N
,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,854.0,80647,Homo sapiens,Intermediate,,9606.0,5530,,833K,,,,F,1,BAO_0000219,13466,1,CHEMBL620365,,N
,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',854.0,80647,Homo sapiens,Intermediate,,9606.0,5531,,833K,,,,F,1,BAO_0000219,13466,1,CHEMBL620366,,N
,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,854.0,80647,Homo sapiens,Expert,,9606.0,5532,,833K,,,,F,1,BAO_0000219,2392,1,CHEMBL620367,,N
,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,854.0,80647,Homo sapiens,Intermediate,,9606.0,5533,,833K,,,,F,1,BAO_0000219,2392,1,CHEMBL620368,,N
,,Inhibitory activity against caspase-1,,22226,,Autocuration,,,5534,,,,,,B,1,BAO_0000019,6608,0,CHEMBL620369,,U
,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,45,Enterococcus faecalis,Autocuration,,1351.0,5535,,,,,,B,1,BAO_0000357,10199,8,CHEMBL620370,,H
,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,705.0,80648,Homo sapiens,Intermediate,,9606.0,5536,,8701-BC,,,,F,1,BAO_0000219,17749,1,CHEMBL620371,,N
,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,705.0,80648,Homo sapiens,Intermediate,,9606.0,5537,,8701-BC,,,,F,1,BAO_0000219,17749,1,CHEMBL620372,,N
,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,22226,,Intermediate,,,5538,,,,,,F,1,BAO_0000019,1229,0,CHEMBL876492,,U
,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,22226,,Intermediate,,,5539,,,,,,F,1,BAO_0000019,1229,0,CHEMBL620373,,U
,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,22226,,Intermediate,,,5540,,,,,,F,1,BAO_0000019,1229,0,CHEMBL620374,,U
,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,22226,,Autocuration,,,5541,,,,,,B,1,BAO_0000019,6390,0,CHEMBL620375,,U
,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,22226,Streptococcus pyogenes,Autocuration,,1314.0,5542,,,,,,F,1,BAO_0000019,16219,0,CHEMBL857902,,U
,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,22226,Streptococcus pyogenes,Autocuration,,1314.0,5543,,,,,,F,1,BAO_0000019,16219,0,CHEMBL620376,,U
,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,11922,,Autocuration,,,5544,,,,,,B,1,BAO_0000357,17043,8,CHEMBL620377,,H
,,Tested for in vitro cytotoxic potency of compound in 9KB assay,324.0,81115,Homo sapiens,Intermediate,,9606.0,5545,,KB ,,,,F,1,BAO_0000219,6929,1,CHEMBL620378,,N
,,Tested for in vitro cytotoxic potency of compound in 9KB assay,324.0,81115,Homo sapiens,Intermediate,,9606.0,5546,,KB ,,,,A,1,BAO_0000219,6929,1,CHEMBL620379,,N
,,In vitro cytotoxicity of compound was tested against 9KB cells.,,22226,Homo sapiens,Autocuration,,9606.0,5547,,,,,,F,1,BAO_0000219,7083,0,CHEMBL620380,,U
,,Cytotoxic concentration against 9L cells was determined on day 3,392.0,80653,Rattus norvegicus,Intermediate,,10116.0,5548,,9L,,,,F,1,BAO_0000219,12446,1,CHEMBL884006,,N
,,Tested in vitro for anticancer activity against 9L cells,392.0,80653,Rattus norvegicus,Expert,,10116.0,5549,,9L,,,,F,1,BAO_0000219,15345,1,CHEMBL620381,,N
,,Tested in vitro for anticancer activity against 9L cells; Not determined,392.0,80653,Rattus norvegicus,Expert,,10116.0,5550,,9L,,,,F,1,BAO_0000219,15345,1,CHEMBL620382,,N
,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,646.0,80682,Homo sapiens,Intermediate,,9606.0,5551,,A549,,,,F,1,BAO_0000219,6301,1,CHEMBL620383,,N
,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,646.0,80682,Homo sapiens,Intermediate,,9606.0,5552,,A549,,,,F,1,BAO_0000219,4833,1,CHEMBL876493,,N
,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,646.0,80682,Homo sapiens,Intermediate,,9606.0,5553,,A549,,,,F,1,BAO_0000219,4833,1,CHEMBL620384,,N
,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,646.0,80682,Homo sapiens,Intermediate,,9606.0,5554,,A549,,,,F,1,BAO_0000219,4833,1,CHEMBL620385,,N
,,Cytotoxicity against human lung carcinoma A549 cell line,646.0,80682,Homo sapiens,Expert,,9606.0,5555,,A549,,,,F,1,BAO_0000219,13330,1,CHEMBL620386,,N
,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,646.0,25,Homo sapiens,Expert,,9606.0,5556,,A549,,,,F,1,BAO_0000219,17517,9,CHEMBL620387,,D
,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",646.0,25,Homo sapiens,Expert,,9606.0,5557,,A549,,,,F,1,BAO_0000219,17517,9,CHEMBL621404,,D
,,"In vitro growth inhibition of A549, lung carcinoma",646.0,80682,Homo sapiens,Intermediate,,9606.0,5558,,A549,,,,F,1,BAO_0000219,14425,1,CHEMBL621405,,N
,,"In vitro growth inhibition of A549, lung carcinoma.",646.0,80682,Homo sapiens,Intermediate,,9606.0,5559,,A549,,,,F,1,BAO_0000219,14425,1,CHEMBL621406,,N
,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,5560,,A549,,,,F,1,BAO_0000219,5228,1,CHEMBL621407,,N
,,Cytotoxic activity against human lung cancer A549 cell line was determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,5561,,A549,,,,F,1,BAO_0000219,5351,1,CHEMBL621408,,N
,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,646.0,80682,Homo sapiens,Expert,,9606.0,5562,,A549,,,,F,1,BAO_0000219,12198,1,CHEMBL885345,,N
,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5563,,A549,,,,F,1,BAO_0000219,13891,1,CHEMBL621409,,N
,,Cytotoxicity in A549 (human carcinoma) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,5564,,A549,,,,F,1,BAO_0000219,5677,1,CHEMBL876034,,N
,,Cytotoxicity on lung carcinoma (A-549) cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5565,,A549,,,,F,1,BAO_0000219,13788,1,CHEMBL621410,,N
,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,646.0,80682,Homo sapiens,Expert,,9606.0,5566,,A549,,,,F,1,BAO_0000219,13384,1,CHEMBL621411,,N
,,Effective dose of compound against replication of A549 cell line was evaluated,646.0,80682,Homo sapiens,Intermediate,,9606.0,5567,,A549,,,,F,1,BAO_0000219,6726,1,CHEMBL621412,,N
,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,646.0,80682,Homo sapiens,Expert,,9606.0,5568,,A549,,,,F,1,BAO_0000219,3455,1,CHEMBL621413,,N
,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),646.0,80682,Homo sapiens,Intermediate,,9606.0,5569,,A549,,,,F,1,BAO_0000219,5726,1,CHEMBL621414,,N
,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,646.0,80682,Homo sapiens,Intermediate,,9606.0,5570,,A549,,,,F,1,BAO_0000219,5726,1,CHEMBL621415,,N
,,The compound was evaluated for antiproliferative activity against A549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5571,,A549,,,,F,1,BAO_0000219,3936,1,CHEMBL621416,,N
,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,646.0,80682,Homo sapiens,Intermediate,,9606.0,5572,,A549,,,,F,1,BAO_0000219,14991,1,CHEMBL621417,,N
,,Concentration required for growth inhibition of human lung carcinoma cell line A549,646.0,80682,Homo sapiens,Intermediate,,9606.0,5573,,A549,,,,F,1,BAO_0000219,5243,1,CHEMBL621418,,N
,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5574,,A549,,,,F,1,BAO_0000219,12858,1,CHEMBL621419,,N
,,Growth inhibition against A549 cell line was evaluated,646.0,80682,Homo sapiens,Intermediate,,9606.0,5575,,A549,,,,F,1,BAO_0000219,6776,1,CHEMBL621420,,N
,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5576,,A549,,,,F,1,BAO_0000219,16558,1,CHEMBL875823,,N
,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,646.0,80682,Homo sapiens,Expert,,9606.0,5577,,A549,,,,F,1,BAO_0000219,4583,1,CHEMBL621421,,N
,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,646.0,80682,Homo sapiens,Intermediate,,9606.0,5578,,A549,,,,F,1,BAO_0000219,13514,1,CHEMBL621422,,N
,,Chemosensitivity against DT-diaphorase rich A549 cell lines,646.0,80682,Homo sapiens,Expert,,9606.0,5579,,A549,,,,F,1,BAO_0000219,15166,1,CHEMBL884014,,N
,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,646.0,80682,Homo sapiens,Intermediate,,9606.0,5580,,A549,,,,F,1,BAO_0000219,13873,1,CHEMBL621423,,N
,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,5581,,A549,,,,F,1,BAO_0000219,6447,1,CHEMBL621424,,N
,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,646.0,80682,Homo sapiens,Intermediate,,9606.0,5582,,A549,,,,F,1,BAO_0000219,2068,1,CHEMBL621425,,N
,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,646.0,80682,Homo sapiens,Expert,,9606.0,5583,,A549,,,,F,1,BAO_0000219,1863,1,CHEMBL621426,,N
,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,646.0,80682,Homo sapiens,Intermediate,,9606.0,5584,,A549,,,,F,1,BAO_0000219,13873,1,CHEMBL621427,,N
,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,646.0,80682,Homo sapiens,Intermediate,,9606.0,5585,,A549,,,,F,1,BAO_0000219,13873,1,CHEMBL621428,,N
,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,646.0,80682,Homo sapiens,Expert,,9606.0,5586,,A549,,,,F,1,BAO_0000219,13873,1,CHEMBL621429,,N
,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),646.0,80682,Homo sapiens,Intermediate,,9606.0,5587,,A549,,,,F,1,BAO_0000219,579,1,CHEMBL621430,,N
,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,646.0,80682,Homo sapiens,Intermediate,,9606.0,5588,,A549,,,,F,1,BAO_0000219,579,1,CHEMBL621431,,N
,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,646.0,80682,Homo sapiens,Intermediate,,9606.0,5589,,A549,,,,F,1,BAO_0000219,4584,1,CHEMBL621432,,N
,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,646.0,80682,Homo sapiens,Expert,,9606.0,5590,,A549,,,,F,1,BAO_0000219,5421,1,CHEMBL621433,,N
,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5591,,A549,,,,F,1,BAO_0000219,5421,1,CHEMBL875824,,N
,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,646.0,80682,Homo sapiens,Intermediate,,9606.0,5592,,A549,,,,F,1,BAO_0000219,5421,1,CHEMBL621434,,N
,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,646.0,80682,Homo sapiens,Intermediate,,9606.0,5593,,A549,,,,F,1,BAO_0000219,5421,1,CHEMBL621435,,N
,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,646.0,80682,Homo sapiens,Intermediate,,9606.0,5594,,A549,,,,F,1,BAO_0000219,14188,1,CHEMBL621436,,N
,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,646.0,80682,Homo sapiens,Intermediate,,9606.0,5595,,A549,,,,F,1,BAO_0000219,14188,1,CHEMBL621437,,N
,,Compound was tested for the growth inhibition of A549 lung tumor cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5596,,A549,,,,F,1,BAO_0000219,15354,1,CHEMBL621438,,N
,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,646.0,80682,Homo sapiens,Expert,,9606.0,5597,,A549,,,,F,1,BAO_0000219,14253,1,CHEMBL621439,,N
,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,646.0,80682,Homo sapiens,Intermediate,,9606.0,5598,,A549,,,,F,1,BAO_0000219,13873,1,CHEMBL621440,,N
,,Oral bioavailability in dog (conscious),,50588,Canis lupus familiaris,Intermediate,,9615.0,5599,In vivo,,,,,A,1,BAO_0000218,3043,1,CHEMBL621441,,N
,,Compound was evaluated for the oral bioavailability after oral administration in dog.,,50588,Canis lupus familiaris,Intermediate,,9615.0,5600,In vivo,,,,,A,1,BAO_0000218,3045,1,CHEMBL621442,,N
,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5601,In vivo,,,,,A,1,BAO_0000218,3022,1,CHEMBL621443,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5602,In vivo,,,,,A,1,BAO_0000218,4453,1,CHEMBL621444,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5603,In vivo,,,,,A,1,BAO_0000218,1696,1,CHEMBL625133,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5604,In vivo,,,,,A,1,BAO_0000218,5045,1,CHEMBL625134,,N
,,Oral bioavailability in dog (fasted),,50588,Canis lupus familiaris,Intermediate,,9615.0,5605,In vivo,,,,,A,1,BAO_0000218,5356,1,CHEMBL625135,,N
,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5606,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL625136,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5607,In vivo,,,,,A,1,BAO_0000218,6448,1,CHEMBL625137,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5608,In vivo,,,,,A,1,BAO_0000218,1475,1,CHEMBL625138,,N
,,Percent bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5609,In vivo,,,,,A,1,BAO_0000218,3788,1,CHEMBL625139,,N
,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5610,In vivo,,,,,A,1,BAO_0000218,3639,1,CHEMBL872264,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5611,In vivo,,,,,A,1,BAO_0000218,13397,1,CHEMBL625140,,N
,,The compound was evaluated for bioavailability in dogs; 34-44,,50588,Canis lupus familiaris,Intermediate,,9615.0,5612,In vivo,,,,,A,1,BAO_0000218,2137,1,CHEMBL624436,,N
,,Bioavailability in dog (dose 4 mg/kg p.o.),,50588,Canis lupus familiaris,Intermediate,,9615.0,5613,In vivo,,,,,A,1,BAO_0000218,2959,1,CHEMBL624437,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5614,In vivo,,,,,A,1,BAO_0000218,6448,1,CHEMBL872261,,N
,,8 hour trough Blood level in dog was measured after administration of compound,,50588,Canis lupus familiaris,Intermediate,,9615.0,5615,,,,,,A,1,BAO_0000218,6084,1,CHEMBL624438,,N
,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5616,In vivo,,,,Plasma,A,1,BAO_0000218,3639,1,CHEMBL624439,,N
,,C24 after oral administration at 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5617,,,,,,A,1,BAO_0000218,6316,1,CHEMBL624440,,N
,,Clearance after oral and iv dosing in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5618,,,,,,A,1,BAO_0000218,5238,1,CHEMBL624441,,N
,,Clearance of the drug was measured in the plasma of dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5619,,,,,Plasma,A,1,BAO_0000218,17796,1,CHEMBL624442,,N
,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,50588,Canis lupus familiaris,Intermediate,,9615.0,5620,,,,,,A,1,BAO_0000218,2652,1,CHEMBL624443,,N
,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5621,In vivo,,,,,A,1,BAO_0000218,5654,1,CHEMBL624444,,N
,,Clearance of compound was determined in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5622,In vivo,,,,,A,1,BAO_0000218,6621,1,CHEMBL624445,,N
,,Clearance on i.v. administration of 2 mg/kg was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5623,In vivo,,,,,A,1,BAO_0000218,6505,1,CHEMBL624446,,N
,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5624,In vivo,,,,,A,1,BAO_0000218,5802,1,CHEMBL624447,,N
,,Plasma clearance in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5625,In vivo,,,,,A,1,BAO_0000218,17267,1,CHEMBL624448,,N
,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5626,In vivo,,,,,A,1,BAO_0000218,4521,1,CHEMBL624449,,N
,,Plasma clearance in dog after administration of 0.25 mg/kg iv,,50588,Canis lupus familiaris,Intermediate,,9615.0,5627,In vivo,,,,,A,1,BAO_0000218,6535,1,CHEMBL624450,,N
,,Plasma clearance in dog after administration of 1 mg/kg iv,,50588,Canis lupus familiaris,Intermediate,,9615.0,5628,In vivo,,,,,A,1,BAO_0000218,6535,1,CHEMBL875942,,N
,,Plasma clearance in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5629,In vivo,,,,,A,1,BAO_0000218,6535,1,CHEMBL624451,,N
,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5630,In vivo,,,,,A,1,BAO_0000218,5542,1,CHEMBL624452,,N
,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,50588,Canis lupus familiaris,Intermediate,,9615.0,5631,In vivo,,,,,A,1,BAO_0000218,5199,1,CHEMBL624453,,N
,,Plasma clearance after 15 mg/kg iv dose in Dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5632,In vivo,,,,,A,1,BAO_0000218,16907,1,CHEMBL624454,,N
,,Plasma clearance after 30 mg/kg po dose in Dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5633,In vivo,,,,,A,1,BAO_0000218,16907,1,CHEMBL624455,,N
,,Plasma administration to dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5634,In vivo,,,,,A,1,BAO_0000218,16367,1,CHEMBL624456,,N
,,Plasma clearance was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5635,In vivo,,,,,A,1,BAO_0000218,5505,1,CHEMBL624457,,N
,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5636,In vivo,,,,,A,1,BAO_0000218,6215,1,CHEMBL624458,,N
,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5637,In vivo,,,,,A,1,BAO_0000218,1466,1,CHEMBL624459,,N
,,Intrinsic clearance in human liver microsomes,,102164,Homo sapiens,Intermediate,2107.0,9606.0,5638,In vitro,,,,Liver,A,1,BAO_0000251,5007,2,CHEMBL624460,Microsomes,S
,,Intrinsic clearance in human liver microsomes,,102164,Homo sapiens,Intermediate,2107.0,9606.0,5639,In vitro,,,,Liver,A,1,BAO_0000251,5007,2,CHEMBL624461,Microsomes,S
,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,50588,Canis lupus familiaris,Intermediate,,9615.0,5640,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL875943,,N
,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,50588,Canis lupus familiaris,Intermediate,,9615.0,5641,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL624462,,N
,,Clearance in dog (dose 1 mg/kg i.v.),,50588,Canis lupus familiaris,Intermediate,,9615.0,5642,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL624463,,N
,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5643,In vivo,,,,,A,1,BAO_0000218,6221,1,CHEMBL624464,,N
,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,5644,In vivo,,,,,A,1,BAO_0000218,5007,1,CHEMBL624465,,N
,,Plasma clearance after peroral administration at 10 mpk in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5645,In vivo,,,,,A,1,BAO_0000218,5668,1,CHEMBL624466,,N
,,Plasma clearance after peroral administration at 5 mpk in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5646,In vivo,,,,,A,1,BAO_0000218,5668,1,CHEMBL624467,,N
,,Plasma clearance after peroral administration at 5 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5647,In vivo,,,,,A,1,BAO_0000218,5668,1,CHEMBL624468,,N
,,Plasma clearance was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5648,In vivo,,,,,A,1,BAO_0000218,15660,1,CHEMBL624469,,N
,,Plasma clearance was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5649,In vivo,,,,,A,1,BAO_0000218,15660,1,CHEMBL624470,,N
,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,50588,Canis lupus familiaris,Intermediate,,9615.0,5650,In vivo,,,,,A,1,BAO_0000218,5983,1,CHEMBL624471,,N
,,Total clearance was determined after 0.1 mg/kg iv administration in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5651,In vivo,,,,,A,1,BAO_0000218,5600,1,CHEMBL624472,,N
,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5652,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL622775,,N
,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5653,In vivo,,,,,A,1,BAO_0000218,6039,1,CHEMBL622776,,N
,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5654,In vivo,,,,,A,1,BAO_0000218,6039,1,CHEMBL622777,,N
,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5655,In vivo,,,,,A,1,BAO_0000218,6039,1,CHEMBL622778,,N
,,Clearance by intravenous administration of 1.2 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5656,In vivo,,,,,A,1,BAO_0000218,4368,1,CHEMBL622779,,N
,,Clearance by iv administration in dogs at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5657,In vivo,,,,,A,1,BAO_0000218,4305,1,CHEMBL622780,,N
,,Clearance value was evaluated in dog plasma,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5658,In vivo,,,,Plasma,A,1,BAO_0000218,1918,1,CHEMBL622781,,N
,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5659,In vivo,,,,,A,1,BAO_0000218,6005,1,CHEMBL622782,,N
,,Compound was tested for plasma clearance in dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5660,In vivo,,,,Plasma,A,1,BAO_0000218,4839,1,CHEMBL622783,,N
,,Pharmacokinetic property (Plasma clearance) was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5661,In vivo,,,,,A,1,BAO_0000218,4239,1,CHEMBL622784,,N
,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5662,,,,,,A,1,BAO_0000218,17729,1,CHEMBL622785,,N
,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5663,,,,,,A,1,BAO_0000218,17728,1,CHEMBL622786,,N
,,Area under curve value in mouse at a dose of 10 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5664,,,,,,A,1,BAO_0000218,5302,1,CHEMBL622787,,N
,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,50594,Mus musculus,Intermediate,,10090.0,5665,,,,,,A,1,BAO_0000218,5506,1,CHEMBL875949,,N
,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,50594,Mus musculus,Intermediate,,10090.0,5666,,,,,,A,1,BAO_0000218,5506,1,CHEMBL622788,,N
,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,5667,,,,,,F,1,BAO_0000218,17764,1,CHEMBL622789,,N
,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,5668,,,,,,F,1,BAO_0000218,17764,1,CHEMBL622790,,N
,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,5669,,,,,,F,1,BAO_0000218,17764,1,CHEMBL622791,,N
,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,5670,,,,,,F,1,BAO_0000218,17764,1,CHEMBL622792,,N
,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,5671,,,,,,A,1,BAO_0000218,17764,1,CHEMBL622793,,N
,,Area under curve was determined for the compound at 24 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,5672,,,,,,A,1,BAO_0000218,17753,1,CHEMBL622794,,N
,,Area under curve was determined for the compound at 40 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,5673,,,,,,A,1,BAO_0000218,17753,1,CHEMBL622795,,N
,,Area under curve was determined for the compound at 5 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,5674,,,,,,A,1,BAO_0000218,17753,1,CHEMBL621803,,N
,,Area under the curve for the compound is obtained at dose 25 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5675,,,,,,A,1,BAO_0000218,3132,1,CHEMBL621804,,N
,,Area under the curve for the compound was obtained when tested in mouse,,50594,Mus musculus,Intermediate,,10090.0,5676,,,,,,A,1,BAO_0000218,3132,1,CHEMBL621805,,N
,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5677,,,,,,A,1,BAO_0000218,17837,1,CHEMBL621806,,N
,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5678,,,,,,A,1,BAO_0000218,17837,1,CHEMBL621807,,N
,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5679,,,,,,A,1,BAO_0000218,6062,1,CHEMBL621808,,N
,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,5680,,,,,,A,1,BAO_0000218,4066,1,CHEMBL621809,,N
,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,50594,Mus musculus,Intermediate,,10090.0,5681,,,,,,A,1,BAO_0000218,16597,1,CHEMBL621810,,N
,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,5682,,,,,,A,1,BAO_0000218,14239,1,CHEMBL875164,,N
,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,5683,,,,,,A,1,BAO_0000218,14239,1,CHEMBL621811,,N
,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,50594,Mus musculus,Intermediate,,10090.0,5684,,,,,,A,1,BAO_0000218,4890,1,CHEMBL621812,,N
,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,50594,Mus musculus,Intermediate,,10090.0,5685,,,,,,A,1,BAO_0000218,429,1,CHEMBL621813,,N
,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,50594,Mus musculus,Intermediate,,10090.0,5686,,,,,,A,1,BAO_0000218,429,1,CHEMBL621814,,N
,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5687,,,,,,A,1,BAO_0000218,5969,1,CHEMBL621815,,N
,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,5688,,,,,,A,1,BAO_0000218,5969,1,CHEMBL621816,,N
,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,50594,Mus musculus,Intermediate,,10090.0,5689,,,,,,A,1,BAO_0000218,5969,1,CHEMBL621817,,N
,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,50594,Mus musculus,Intermediate,,10090.0,5690,,,,,,A,1,BAO_0000218,6091,1,CHEMBL621818,,N
,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,50594,Mus musculus,Intermediate,,10090.0,5691,,,,,,A,1,BAO_0000218,6091,1,CHEMBL621819,,N
,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,5692,,,,,,A,1,BAO_0000218,6091,1,CHEMBL621820,,N
,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,50594,Mus musculus,Intermediate,,10090.0,5693,,,,,,A,1,BAO_0000218,6091,1,CHEMBL621821,,N
,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,5694,,,,,,A,1,BAO_0000218,6178,1,CHEMBL621822,,N
,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,5695,,,,,,A,1,BAO_0000218,6178,1,CHEMBL619474,,N
,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,50594,Mus musculus,Intermediate,,10090.0,5696,,,,,,A,1,BAO_0000218,6619,1,CHEMBL619475,,N
,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,50594,Mus musculus,Intermediate,,10090.0,5697,,,,,,A,1,BAO_0000218,6619,1,CHEMBL619476,,N
,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,50594,Mus musculus,Intermediate,,10090.0,5698,,,,,,A,1,BAO_0000218,3760,1,CHEMBL619477,,N
,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,50594,Mus musculus,Intermediate,,10090.0,5699,,,,,,A,1,BAO_0000218,3760,1,CHEMBL619478,,N
,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,50594,Mus musculus,Intermediate,,10090.0,5700,,,,,,A,1,BAO_0000218,3760,1,CHEMBL619479,,N
,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,50594,Mus musculus,Intermediate,,10090.0,5701,,,,,,A,1,BAO_0000218,3760,1,CHEMBL619480,,N
,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,50594,Mus musculus,Intermediate,,10090.0,5702,,,,,,A,1,BAO_0000218,3192,1,CHEMBL619481,,N
,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,50594,Mus musculus,Intermediate,,10090.0,5703,,,,,,A,1,BAO_0000218,3192,1,CHEMBL619482,,N
,,Area under the curve was evaluated in mice after intravenous administration,,50594,Mus musculus,Intermediate,,10090.0,5704,,,,,,A,1,BAO_0000218,2675,1,CHEMBL619483,,N
,,Area under the curve was evaluated in mice after oral administration,,50594,Mus musculus,Intermediate,,10090.0,5705,,,,,,A,1,BAO_0000218,2675,1,CHEMBL619484,,N
,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,50594,Mus musculus,Intermediate,1969.0,10090.0,5706,,,,,Plasma,A,1,BAO_0000218,16597,1,CHEMBL619485,,N
,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,50594,Mus musculus,Intermediate,1969.0,10090.0,5707,,,,,Plasma,A,1,BAO_0000218,16597,1,CHEMBL619486,,N
,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,50594,Mus musculus,Intermediate,,10090.0,5708,,,,,,A,1,BAO_0000218,16597,1,CHEMBL619487,,N
,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,5709,,,,,,A,1,BAO_0000218,17734,1,CHEMBL619488,,N
,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,178.0,10090.0,5710,In vivo,,,,Blood,A,1,BAO_0000218,7767,1,CHEMBL620106,,N
,,The compound was tested in vitro for anticancer activity against 9L cells,392.0,80653,,Intermediate,,,5711,,9L,,,,F,1,BAO_0000219,15345,1,CHEMBL620107,,N
,,Anti proliferation activity determined; Weak effect,,22226,Rattus norvegicus,Autocuration,,10116.0,5712,,,,,,F,1,BAO_0000019,2181,0,CHEMBL620283,,U
,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,22226,Rattus norvegicus,Autocuration,,10116.0,5713,,,,,,F,1,BAO_0000219,2181,0,CHEMBL875176,,U
,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,22226,Rattus norvegicus,Autocuration,,10116.0,5714,,,,,,F,1,BAO_0000219,2181,0,CHEMBL620284,,U
,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,22226,Rattus norvegicus,Autocuration,,10116.0,5715,,,,,,F,1,BAO_0000219,2181,0,CHEMBL623515,,U
,,The cytotoxic activity was in vitro tested by 9PS assay method,,22226,Mus musculus,Autocuration,,10090.0,5716,,,,,,F,1,BAO_0000019,10486,0,CHEMBL623516,,U
,,The cytotoxic activity was in vitro tested by 9PS assay method.,,22226,Mus musculus,Autocuration,,10090.0,5717,,,,,,F,1,BAO_0000019,10486,0,CHEMBL623517,,U
,,Partition coefficient (logD6.5),,22224,,Autocuration,,,5718,,,,,,A,1,BAO_0000019,15508,0,CHEMBL857878,,U
,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,478.0,81034,Homo sapiens,Expert,,9606.0,5719,,A2780,,,,F,1,BAO_0000219,5242,1,CHEMBL623518,,N
,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),455.0,80018,Homo sapiens,Intermediate,,9606.0,5720,,A-375,,,,F,1,BAO_0000219,16167,1,CHEMBL624195,,N
,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,500.0,80852,Homo sapiens,Expert,,9606.0,5721,,A-431,,,,F,1,BAO_0000219,4782,1,CHEMBL624196,,N
,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,500.0,9,Homo sapiens,Expert,,9606.0,5722,,A-431,,,,F,1,BAO_0000219,16093,9,CHEMBL624197,,D
,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5723,,A498,,,,F,1,BAO_0000219,2596,1,CHEMBL624198,,N
,,in vitro cytotoxicity against A 498 cancer cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5724,,A498,,,,F,1,BAO_0000219,2596,1,CHEMBL621287,,N
,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,624.0,80021,Homo sapiens,Intermediate,,9606.0,5725,,A498,,,,F,1,BAO_0000219,3239,1,CHEMBL621288,,N
,,Cytotoxic activity against A 498 renal cancer cell lines.,624.0,80021,Homo sapiens,Intermediate,,9606.0,5726,,A498,,,,F,1,BAO_0000219,1847,1,CHEMBL876496,,N
,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,624.0,80021,Homo sapiens,Intermediate,,9606.0,5727,,A498,,,,F,1,BAO_0000219,10553,1,CHEMBL621289,,N
,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,22226,Staphylococcus aureus,Autocuration,,1280.0,5728,,,,,,F,1,BAO_0000019,16219,0,CHEMBL621290,,U
,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,22226,Staphylococcus aureus,Autocuration,,1280.0,5729,,,,,,F,1,BAO_0000019,16219,0,CHEMBL621291,,U
,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,22226,Staphylococcus aureus,Autocuration,,1280.0,5730,,,,,,F,1,BAO_0000019,16219,0,CHEMBL621292,,U
,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,22226,Staphylococcus aureus,Autocuration,,1280.0,5731,,,,,,F,1,BAO_0000019,16219,0,CHEMBL621293,,U
,,Inhibitory concentration required against A 549 lung cancer cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5732,,A549,,,,F,1,BAO_0000219,4782,1,CHEMBL621294,,N
,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,646.0,80682,Homo sapiens,Intermediate,,9606.0,5733,,A549,,,,F,1,BAO_0000219,11805,1,CHEMBL621295,,N
,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,646.0,80682,Homo sapiens,Intermediate,,9606.0,5734,,A549,,,,F,1,BAO_0000219,11805,1,CHEMBL884007,,N
,,In vitro cytotoxicity against lung cancer A 549 cell lines,646.0,80682,Homo sapiens,Intermediate,,9606.0,5735,,A549,,,,F,1,BAO_0000219,2007,1,CHEMBL621296,,N
,,Compound was tested for its cytotoxicity against A 549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5736,,A549,,,,F,1,BAO_0000219,4594,1,CHEMBL621297,,N
,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",646.0,80682,Homo sapiens,Expert,,9606.0,5737,,A549,,,,F,1,BAO_0000219,6018,1,CHEMBL839828,,N
,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",646.0,80682,Homo sapiens,Intermediate,,9606.0,5738,,A549,,,,F,1,BAO_0000219,6018,1,CHEMBL620397,,N
,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,646.0,80682,Homo sapiens,Expert,,9606.0,5739,,A549,,,,F,1,BAO_0000219,3599,1,CHEMBL620398,,N
,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5740,,A549,,,,F,1,BAO_0000219,2551,1,CHEMBL620399,,N
,,In vitro inhibition of A549 (human lung cancer) cell growth.,646.0,80682,Homo sapiens,Expert,,9606.0,5741,,A549,,,,F,1,BAO_0000219,16132,1,CHEMBL620400,,N
,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,646.0,80682,Homo sapiens,Intermediate,,9606.0,5742,,A549,,,,F,1,BAO_0000219,16132,1,CHEMBL620401,,N
,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,646.0,80682,Homo sapiens,Expert,,9606.0,5743,,A549,,,,F,1,BAO_0000219,2551,1,CHEMBL620402,,N
,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),646.0,80682,Homo sapiens,Expert,,9606.0,5744,,A549,,,,F,1,BAO_0000219,2551,1,CHEMBL620403,,N
,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,22226,,Autocuration,,,5745,,,,,,F,1,BAO_0000218,11913,0,CHEMBL620404,,U
,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,104694,,Autocuration,,,5746,In vivo,,,,,F,1,BAO_0000218,12621,4,CHEMBL620405,,H
,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,104694,,Autocuration,,,5747,In vivo,,,,,F,1,BAO_0000218,12621,4,CHEMBL620406,,H
,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,104694,,Autocuration,,,5748,In vivo,,,,,F,1,BAO_0000218,12621,4,CHEMBL620407,,H
,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,104694,,Autocuration,,,5749,In vivo,,,,,F,1,BAO_0000218,12621,4,CHEMBL620408,,H
,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,104694,,Autocuration,,,5750,In vivo,,,,,F,1,BAO_0000218,12621,4,CHEMBL620409,,H
,,Inhibition of A-498 human Renal cell proliferation,624.0,80021,Homo sapiens,Expert,,9606.0,5751,,A498,,,,F,1,BAO_0000219,3600,1,CHEMBL620410,,N
,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,22226,Rattus norvegicus,Autocuration,,10116.0,5752,,,,,,F,1,BAO_0000019,1796,0,CHEMBL620411,,U
,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,22226,Rattus norvegicus,Autocuration,,10116.0,5753,,,,,,F,1,BAO_0000019,1796,0,CHEMBL620412,,U
,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,22226,Rattus norvegicus,Autocuration,,10116.0,5754,,,,,,F,1,BAO_0000019,1796,0,CHEMBL876596,,U
,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,622.0,80012,Homo sapiens,Expert,,9606.0,5755,,A 172,,,,F,1,BAO_0000219,16464,1,CHEMBL620413,,N
,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,622.0,80012,Homo sapiens,Intermediate,,9606.0,5756,,A 172,,,,F,1,BAO_0000219,16464,1,CHEMBL620414,,N
,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,622.0,80012,Homo sapiens,Intermediate,,9606.0,5757,,A 172,,,,F,1,BAO_0000219,16464,1,CHEMBL620415,,N
,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,5758,,A549,,,,F,1,BAO_0000219,13617,1,CHEMBL620416,,N
,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,646.0,80682,Homo sapiens,Intermediate,,9606.0,5759,,A549,,,,F,1,BAO_0000219,4584,1,CHEMBL620417,,N
,,Cytotoxic activity evaluated against A549 tumor cells,646.0,80682,Homo sapiens,Expert,,9606.0,5760,,A549,,,,F,1,BAO_0000219,13799,1,CHEMBL620418,,N
,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5761,,A549,,,,F,1,BAO_0000219,16726,1,CHEMBL620419,,N
,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,646.0,80682,Homo sapiens,Intermediate,,9606.0,5762,,A549,,,,F,1,BAO_0000219,16109,1,CHEMBL620420,,N
,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,646.0,80682,Homo sapiens,Intermediate,,9606.0,5763,,A549,,,,F,1,BAO_0000219,16109,1,CHEMBL620421,,N
,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5764,,A549,,,,F,1,BAO_0000219,15474,1,CHEMBL620422,,N
,,Cytotoxicity of compound against A549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5765,,A549,,,,F,1,BAO_0000219,6851,1,CHEMBL620423,,N
,,Cytotoxicity against human lung cell carcinoma A549 cell line,646.0,80682,Homo sapiens,Expert,,9606.0,5766,,A549,,,,F,1,BAO_0000219,17534,1,CHEMBL620424,,N
,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5767,,A549,,,,F,1,BAO_0000219,2621,1,CHEMBL620425,,N
,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,646.0,80682,Homo sapiens,Intermediate,,9606.0,5768,,A549,,,,F,1,BAO_0000219,830,1,CHEMBL620426,,N
,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,646.0,80682,Homo sapiens,Intermediate,,9606.0,5769,,A549,,,,F,1,BAO_0000219,14255,1,CHEMBL620427,,N
,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,5770,,A549,,,,F,1,BAO_0000219,14255,1,CHEMBL620428,,N
,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,5771,,A549,,,,F,1,BAO_0000219,1590,1,CHEMBL620429,,N
,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,646.0,80682,Homo sapiens,Expert,,9606.0,5772,,A549,,,,F,1,BAO_0000219,6146,1,CHEMBL620430,,N
,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,5773,,A549,,,,F,1,BAO_0000219,17427,1,CHEMBL839887,,N
,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,646.0,80682,Homo sapiens,Intermediate,,9606.0,5774,,A549,,,,F,1,BAO_0000219,5280,1,CHEMBL620431,,N
,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,646.0,80682,Homo sapiens,Intermediate,,9606.0,5775,,A549,,,,F,1,BAO_0000219,16786,1,CHEMBL884010,,N
,,In vitro cytotoxicity against A549 (human lung cancer),646.0,80682,Homo sapiens,Intermediate,,9606.0,5776,,A549,,,,F,1,BAO_0000219,5895,1,CHEMBL620538,,N
,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,5777,,A549,,,,F,1,BAO_0000219,14297,1,CHEMBL620539,,N
,,In vivo antiproliferative activity against A549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5778,,A549,,,,F,1,BAO_0000218,17824,1,CHEMBL623373,,N
,,Inhibition of non-small-cell lung adenocarcinoma (A549),646.0,80682,Homo sapiens,Intermediate,,9606.0,5779,,A549,,,,F,1,BAO_0000219,14368,1,CHEMBL623374,,N
,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,646.0,80682,Homo sapiens,Intermediate,,9606.0,5780,,A549,,,,F,1,BAO_0000219,14368,1,CHEMBL623375,,N
,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,646.0,80682,Homo sapiens,Intermediate,,9606.0,5781,,A549,,,,F,1,BAO_0000219,14254,1,CHEMBL623376,,N
,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),646.0,80682,Homo sapiens,Intermediate,,9606.0,5782,,A549,,,,F,1,BAO_0000219,15897,1,CHEMBL623377,,N
,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,646.0,80682,Homo sapiens,Intermediate,,9606.0,5783,,A549,,,,F,1,BAO_0000219,13866,1,CHEMBL623378,,N
,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,646.0,80682,Homo sapiens,Intermediate,,9606.0,5784,,A549,,,,F,1,BAO_0000219,13370,1,CHEMBL623379,,N
,,Inhibitory activity against A549 lung cancer cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5785,,A549,,,,F,1,BAO_0000219,4862,1,CHEMBL623380,,N
,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5786,,A549,,,,F,1,BAO_0000219,4862,1,CHEMBL623381,,N
,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,5787,,A549,,,,F,1,BAO_0000219,4862,1,CHEMBL623382,,N
,,Inhibitory concentration against A549 (lung cancer) cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5788,,A549,,,,F,1,BAO_0000219,15970,1,CHEMBL623383,,N
,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,5789,,A549,,,,F,1,BAO_0000219,17713,1,CHEMBL623384,,N
,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5790,,A549,,,,F,1,BAO_0000219,4833,1,CHEMBL623385,,N
,,Activity against A549 cancer cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,5791,,A549,,,,F,1,BAO_0000219,13736,1,CHEMBL623386,,N
,,The compound was evaluated for cytotoxicity against A549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5792,,A549,,,,F,1,BAO_0000219,4312,1,CHEMBL884105,,N
,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,646.0,80682,Homo sapiens,Intermediate,,9606.0,5793,,A549,,,,F,1,BAO_0000219,5421,1,CHEMBL623387,,N
,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5794,,A549,,,,F,1,BAO_0000219,5421,1,CHEMBL621568,,N
,,Growth inhibitory activity was measured for human A549 tumor cell line.,646.0,80682,Homo sapiens,Intermediate,,9606.0,5795,,A549,,,,F,1,BAO_0000219,14717,1,CHEMBL621569,,N
,,Inhibitory activity against A549 lung cancer cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5796,,A549,,,,F,1,BAO_0000219,4634,1,CHEMBL621570,,N
,,Inhibitory activity against A549 cell line; inactive,646.0,80682,Homo sapiens,Intermediate,,9606.0,5797,,A549,,,,F,1,BAO_0000219,1149,1,CHEMBL621571,,N
,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,646.0,80682,Homo sapiens,Expert,,9606.0,5798,,A549,,,,F,1,BAO_0000219,5421,1,CHEMBL621572,,N
,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,646.0,80682,Homo sapiens,Expert,,9606.0,5799,,A549,,,,F,1,BAO_0000219,5421,1,CHEMBL621573,,N
,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,646.0,80682,Homo sapiens,Intermediate,,9606.0,5800,,A549,,,,F,1,BAO_0000219,5421,1,CHEMBL621574,,N
,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),646.0,80682,Homo sapiens,Intermediate,,9606.0,5801,,A549,,,,F,1,BAO_0000219,3320,1,CHEMBL621575,,N
,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),646.0,80682,Homo sapiens,Intermediate,,9606.0,5802,,A549,,,,F,1,BAO_0000219,3320,1,CHEMBL621576,,N
,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),646.0,80682,Homo sapiens,Intermediate,,9606.0,5803,,A549,,,,F,1,BAO_0000219,3320,1,CHEMBL621577,,N
,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),646.0,80682,Homo sapiens,Intermediate,,9606.0,5804,,A549,,,,F,1,BAO_0000219,3320,1,CHEMBL621578,,N
,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),646.0,80682,Homo sapiens,Intermediate,,9606.0,5805,,A549,,,,F,1,BAO_0000219,3320,1,CHEMBL621579,,N
,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,646.0,80682,Homo sapiens,Intermediate,,9606.0,5806,,A549,,,,F,1,BAO_0000219,5726,1,CHEMBL621580,,N
,,Plasma clearance (in vivo) in mongrel dogs was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5807,In vivo,,,,,A,1,BAO_0000218,17800,1,CHEMBL621581,,N
,,Plasma clearance was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5808,In vivo,,,,,A,1,BAO_0000218,5985,1,CHEMBL621582,,N
,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5809,In vivo,,,,,A,1,BAO_0000218,5530,1,CHEMBL621583,,N
,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5810,In vivo,,,,,A,1,BAO_0000218,5530,1,CHEMBL621584,,N
,,Tested for plasma clearance in dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5811,In vivo,,,,Plasma,A,1,BAO_0000218,4839,1,CHEMBL621585,,N
,,The compound was tested for clearance in dog plasma.,,50588,Canis lupus familiaris,Intermediate,,9615.0,5812,In vivo,,,,,A,1,BAO_0000218,3639,1,CHEMBL621586,,N
,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,50588,Canis lupus familiaris,Intermediate,,9615.0,5813,In vivo,,,,,A,1,BAO_0000218,4838,1,CHEMBL875835,,N
,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5814,In vivo,,,,,A,1,BAO_0000218,4137,1,CHEMBL621587,,N
,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5815,In vivo,,,,Plasma,A,1,BAO_0000218,5017,1,CHEMBL621588,,N
,,In vitro clearance in dog liver microsomes,,50588,Canis lupus familiaris,Intermediate,2107.0,9615.0,5816,In vitro,,,,Liver,A,1,BAO_0000218,17538,1,CHEMBL621589,Microsomes,N
,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5817,In vivo,,,,,A,1,BAO_0000218,6161,1,CHEMBL621590,,N
,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5818,In vivo,,,,,A,1,BAO_0000218,6161,1,CHEMBL621591,,N
,,Plasma clearance in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5819,In vivo,,,,,A,1,BAO_0000218,1696,1,CHEMBL621592,,N
,,Clearance rate in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5820,In vivo,,,,,A,1,BAO_0000218,6762,1,CHEMBL621593,,N
,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5821,In vivo,,,,Plasma,A,1,BAO_0000218,5932,1,CHEMBL621594,,N
,,Clearance in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5822,In vivo,,,,,A,1,BAO_0000218,6305,1,CHEMBL621595,,N
,,Plasma clearance in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5823,In vivo,,,,,A,1,BAO_0000218,4942,1,CHEMBL621596,,N
,,Plasma clearance was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5824,In vivo,,,,,A,1,BAO_0000218,4219,1,CHEMBL621597,,N
,,Lower clearance in dog (i.v.) at 0.5 mpk,,50588,Canis lupus familiaris,Intermediate,,9615.0,5825,In vivo,,,,,A,1,BAO_0000218,17853,1,CHEMBL621598,,N
,,Plasma clearance in Beagle dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5826,In vivo,,,,,A,1,BAO_0000218,4514,1,CHEMBL621599,,N
,,Plasma clearance (Clp) in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5827,In vivo,,,,,A,1,BAO_0000218,6448,1,CHEMBL875836,,N
,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5828,In vivo,,,,,A,1,BAO_0000218,6227,1,CHEMBL621600,,N
,,Plasma clearance (pharmacokinetic parameter) in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5829,In vivo,,,,,A,1,BAO_0000218,6227,1,CHEMBL621601,,N
,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5830,In vivo,,,,,A,1,BAO_0000218,6062,1,CHEMBL618474,,N
,,Plasma clearance of compound was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5831,In vivo,,,,,A,1,BAO_0000218,6821,1,CHEMBL618475,,N
,,Plasma clearance after intravenous administration of 1 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5832,In vivo,,,,,A,1,BAO_0000218,4709,1,CHEMBL624524,,N
,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,5833,In vivo,,,,,A,1,BAO_0000218,4521,1,CHEMBL624525,,N
,,Plasma clearance in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5834,In vivo,,,,,A,1,BAO_0000218,5374,1,CHEMBL624526,,N
,,Plasma clearance was calculated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5835,In vivo,,,,,A,1,BAO_0000218,6057,1,CHEMBL624527,,N
,,Plasma clearance at the dose of 2 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5836,In vivo,,,,,A,1,BAO_0000218,4727,1,CHEMBL624528,,N
,,Plasma clearance in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5837,In vivo,,,,,A,1,BAO_0000218,5145,1,CHEMBL624529,,N
,,Plasma clearance in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5838,In vivo,,,,,A,1,BAO_0000218,17657,1,CHEMBL624530,,N
,,Plasma clearance in dog; Unable to calculate,,50588,Canis lupus familiaris,Intermediate,,9615.0,5839,In vivo,,,,,A,1,BAO_0000218,17657,1,CHEMBL624531,,N
,,Plasma clearance in rhesus monkey,,50588,Canis lupus familiaris,Intermediate,,9615.0,5840,In vivo,,,,,A,1,BAO_0000218,5145,1,CHEMBL624532,,N
,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,50588,Canis lupus familiaris,Intermediate,,9615.0,5841,In vivo,,,,,A,1,BAO_0000218,6642,1,CHEMBL624533,,N
,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588,Canis lupus familiaris,Intermediate,,9615.0,5842,In vivo,,,,,A,1,BAO_0000218,6641,1,CHEMBL624534,,N
,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588,Canis lupus familiaris,Intermediate,,9615.0,5843,In vivo,,,,,A,1,BAO_0000218,6642,1,CHEMBL624535,,N
,,Plasma clearance was evaluated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5844,In vivo,,,,,A,1,BAO_0000218,5472,1,CHEMBL624536,,N
,,Plasma clearance was evaluated in dog; Not tested,,50588,Canis lupus familiaris,Intermediate,,9615.0,5845,In vivo,,,,,A,1,BAO_0000218,5472,1,CHEMBL624537,,N
,,Plasma clearance was evaluated in rhesus,,50588,Canis lupus familiaris,Intermediate,,9615.0,5846,In vivo,,,,,A,1,BAO_0000218,5472,1,CHEMBL624538,,N
,,Plasma clearance was evaluated in rhesus; Not tested,,50588,Canis lupus familiaris,Intermediate,,9615.0,5847,In vivo,,,,,A,1,BAO_0000218,5472,1,CHEMBL624539,,N
,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,50588,Canis lupus familiaris,Intermediate,,9615.0,5848,In vivo,,,,,A,1,BAO_0000218,4257,1,CHEMBL624540,,N
,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,5849,In vivo,,,,,A,1,BAO_0000218,6679,1,CHEMBL624541,,N
,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,5850,In vivo,,,,,A,1,BAO_0000218,5546,1,CHEMBL624542,,N
,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,5851,In vivo,,,,,A,1,BAO_0000218,6348,1,CHEMBL624543,,N
,,Clearance value at a dose of 0.2 mg/kg i.v.,,50588,Canis lupus familiaris,Intermediate,,9615.0,5852,In vivo,,,,,A,1,BAO_0000218,5474,1,CHEMBL624544,,N
,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5853,In vivo,,,,Plasma,A,1,BAO_0000218,6316,1,CHEMBL624545,,N
,,Cmax after oral dose of compound at 3 mg/kg in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5854,In vivo,,,,,A,1,BAO_0000218,17594,1,CHEMBL624546,,N
,,Cmax after single intravenous bolus of 1 mg/kg in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5855,In vivo,,,,,A,1,BAO_0000218,17594,1,CHEMBL875957,,N
,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5856,In vivo,,,,,A,1,BAO_0000218,5802,1,CHEMBL624547,,N
,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,5857,In vivo,,,,,A,1,BAO_0000218,6535,1,CHEMBL624548,,N
,,Cmax in dog after administration of 1 mg/kg iv,,50588,Canis lupus familiaris,Intermediate,,9615.0,5858,In vivo,,,,,A,1,BAO_0000218,6535,1,CHEMBL624549,,N
,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,5859,In vivo,,,,Plasma,A,1,BAO_0000218,1466,1,CHEMBL624550,,N
,,Cmax on p.o. administration of 10 mg/kg was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5860,In vivo,,,,,A,1,BAO_0000218,6505,1,CHEMBL621613,,N
,,Cmax was determine after peroral administration at 10 mpk in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5861,In vivo,,,,,A,1,BAO_0000218,5668,1,CHEMBL621614,,N
,,Cmax was determine after peroral administration at 5 mpk in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5862,In vivo,,,,,A,1,BAO_0000218,5668,1,CHEMBL623431,,N
,,Cmax was determine after peroral administration at 5 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5863,In vivo,,,,,A,1,BAO_0000218,5668,1,CHEMBL623432,,N
,,Cmax after 0.3 mg/kg po administration in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,5864,In vivo,,,,,A,1,BAO_0000218,5600,1,CHEMBL623433,,N
,,Cmax after peroral administration in dogs at 2.4 uM/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5865,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL623434,,N
,,Cmax in dog after oral administration at 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5866,In vivo,,,,,A,1,BAO_0000218,6123,1,CHEMBL623435,,N
,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,50588,Canis lupus familiaris,Intermediate,,9615.0,5867,In vivo,,,,,A,1,BAO_0000218,6123,1,CHEMBL623436,,N
,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,5868,In vivo,,,,,A,1,BAO_0000218,6757,1,CHEMBL875958,,N
,,Cmax value after 15 mg/kg iv dose in Dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5869,In vivo,,,,,A,1,BAO_0000218,16907,1,CHEMBL623437,,N
,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,178.0,10090.0,5870,In vivo,,,,Blood,A,1,BAO_0000218,7767,1,CHEMBL623438,,N
,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,178.0,10090.0,5871,In vivo,,,,Blood,A,1,BAO_0000218,7767,1,CHEMBL623439,,N
,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,10000001.0,10090.0,5872,In vivo,,,,Bone,A,1,BAO_0000218,7767,1,CHEMBL623440,,N
,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,10000001.0,10090.0,5873,In vivo,,,,Bone,A,1,BAO_0000218,7767,1,CHEMBL623441,,N
,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,10000001.0,10090.0,5874,In vivo,,,,Bone,A,1,BAO_0000218,7767,1,CHEMBL623442,,N
,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,,10090.0,5875,In vivo,,,,,A,1,BAO_0000218,7767,1,CHEMBL623469,,N
,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,,10090.0,5876,In vivo,,,,,A,1,BAO_0000218,7767,1,CHEMBL623470,,N
,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,,10090.0,5877,In vivo,,,,,A,1,BAO_0000218,7767,1,CHEMBL623471,,N
,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,948.0,10090.0,5878,In vivo,,,,Heart,A,1,BAO_0000218,7767,1,CHEMBL623472,,N
,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,948.0,10090.0,5879,In vivo,,,,Heart,A,1,BAO_0000218,7767,1,CHEMBL623473,,N
,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,948.0,10090.0,5880,In vivo,,,,Heart,A,1,BAO_0000218,7767,1,CHEMBL623474,,N
,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2113.0,10090.0,5881,In vivo,,,,Kidney,A,1,BAO_0000218,7767,1,CHEMBL623475,,N
,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2113.0,10090.0,5882,In vivo,,,,Kidney,A,1,BAO_0000218,7767,1,CHEMBL623476,,N
,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2113.0,10090.0,5883,In vivo,,,,Kidney,A,1,BAO_0000218,7767,1,CHEMBL623477,,N
,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,160.0,10090.0,5884,In vivo,,,,Intestine,A,1,BAO_0000218,7767,1,CHEMBL621896,,N
,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,160.0,10090.0,5885,In vivo,,,,Intestine,A,1,BAO_0000218,7767,1,CHEMBL621897,,N
,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,160.0,10090.0,5886,In vivo,,,,Intestine,A,1,BAO_0000218,7767,1,CHEMBL621898,,N
,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2107.0,10090.0,5887,In vivo,,,,Liver,A,1,BAO_0000218,7767,1,CHEMBL621899,,N
,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2107.0,10090.0,5888,In vivo,,,,Liver,A,1,BAO_0000218,7767,1,CHEMBL621900,,N
,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2107.0,10090.0,5889,In vivo,,,,Liver,A,1,BAO_0000218,7767,1,CHEMBL621901,,N
,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2048.0,10090.0,5890,In vivo,,,,Lung,A,1,BAO_0000218,7767,1,CHEMBL621902,,N
,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2048.0,10090.0,5891,In vivo,,,,Lung,A,1,BAO_0000218,7767,1,CHEMBL621903,,N
,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2048.0,10090.0,5892,In vivo,,,,Lung,A,1,BAO_0000218,7767,1,CHEMBL622587,,N
,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2385.0,10090.0,5893,In vivo,,,,Muscle tissue,A,1,BAO_0000218,7767,1,CHEMBL620285,,N
,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2385.0,10090.0,5894,In vivo,,,,Muscle tissue,A,1,BAO_0000218,7767,1,CHEMBL875285,,N
,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2385.0,10090.0,5895,In vivo,,,,Muscle tissue,A,1,BAO_0000218,7767,1,CHEMBL620286,,N
,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,,10090.0,5896,In vivo,,,,,A,1,BAO_0000218,7767,1,CHEMBL620287,,N
,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,,10090.0,5897,In vivo,,,,,A,1,BAO_0000218,7767,1,CHEMBL620288,,N
,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,,10090.0,5898,In vivo,,,,,A,1,BAO_0000218,7767,1,CHEMBL620289,,N
,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,160.0,10090.0,5899,In vivo,,,,Intestine,A,1,BAO_0000218,7767,1,CHEMBL620290,,N
,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,160.0,10090.0,5900,In vivo,,,,Intestine,A,1,BAO_0000218,7767,1,CHEMBL620291,,N
,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,160.0,10090.0,5901,In vivo,,,,Intestine,A,1,BAO_0000218,7767,1,CHEMBL620292,,N
,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2106.0,10090.0,5902,In vivo,,,,Spleen,A,1,BAO_0000218,7767,1,CHEMBL620293,,N
,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2106.0,10090.0,5903,In vivo,,,,Spleen,A,1,BAO_0000218,7767,1,CHEMBL620294,,N
,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,2106.0,10090.0,5904,In vivo,,,,Spleen,A,1,BAO_0000218,7767,1,CHEMBL618614,,N
,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,945.0,10090.0,5905,In vivo,,,,Stomach,A,1,BAO_0000218,7767,1,CHEMBL618615,,N
,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,945.0,10090.0,5906,In vivo,,,,Stomach,A,1,BAO_0000218,7767,1,CHEMBL618616,,N
,,Cytotoxicity against A-172 human tumor cell lines,622.0,80012,Homo sapiens,Expert,,9606.0,5907,,A 172,,,,F,1,BAO_0000219,2036,1,CHEMBL618617,,N
,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,622.0,80012,Homo sapiens,Intermediate,,9606.0,5908,,A 172,,,,F,1,BAO_0000219,2357,1,CHEMBL618618,,N
,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,623.0,80014,Homo sapiens,Intermediate,,9606.0,5909,,A204,,,,F,1,BAO_0000219,1457,1,CHEMBL618619,,N
,,Tested for antiproliferative activity against A-2780 tumoral cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,5910,,A2780,,,,F,1,BAO_0000219,4379,1,CHEMBL618620,,N
,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,455.0,80018,Homo sapiens,Intermediate,,9606.0,5911,,A-375,,,,F,1,BAO_0000219,1093,1,CHEMBL618621,,N
,,Tested in vitro against A-375 cell line human melanoma,455.0,80018,Homo sapiens,Intermediate,,9606.0,5912,,A-375,,,,F,1,BAO_0000219,12152,1,CHEMBL618622,,N
,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,797.0,80019,Homo sapiens,Expert,,9606.0,5913,,A-427,,,,F,1,BAO_0000219,16464,1,CHEMBL618623,,N
,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,797.0,80019,Homo sapiens,Intermediate,,9606.0,5914,,A-427,,,,F,1,BAO_0000219,16464,1,CHEMBL618624,,N
,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,797.0,80019,Homo sapiens,Expert,,9606.0,5915,,A-427,,,,F,1,BAO_0000219,16582,1,CHEMBL618625,,N
,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,797.0,80019,Homo sapiens,Intermediate,,9606.0,5916,,A-427,,,,F,1,BAO_0000219,16464,1,CHEMBL618626,,N
,,Antitumor activity on A-427 lung carcinoma cell lines,797.0,80019,Homo sapiens,Intermediate,,9606.0,5917,,A-427,,,,F,1,BAO_0000219,10413,1,CHEMBL618627,,N
,,Cytotoxic activity against human A-427 lung tumor cell line,797.0,80019,Homo sapiens,Intermediate,,9606.0,5918,,A-427,,,,F,1,BAO_0000219,6418,1,CHEMBL618628,,N
,,In vitro antitumor effects against human A-427 cell lines.,797.0,80019,Homo sapiens,Expert,,9606.0,5919,,A-427,,,,F,1,BAO_0000219,17134,1,CHEMBL618629,,N
,,In vitro inhibition of A-427 (human lung cancer) cell growth.,797.0,80019,Homo sapiens,Expert,,9606.0,5920,,A-427,,,,F,1,BAO_0000219,16132,1,CHEMBL618630,,N
,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,797.0,80019,Homo sapiens,Intermediate,,9606.0,5921,,A-427,,,,F,1,BAO_0000219,16132,1,CHEMBL618631,,N
,,Cytotoxic activity of compound against A-427 lung human tumor cell line,797.0,80019,Homo sapiens,Intermediate,,9606.0,5922,,A-427,,,,F,1,BAO_0000219,16780,1,CHEMBL618632,,N
,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,500.0,80852,Homo sapiens,Expert,,9606.0,5923,,A-431,,,,F,1,BAO_0000219,4085,1,CHEMBL618633,,N
,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5924,,A498,,,,F,1,BAO_0000219,1276,1,CHEMBL619315,,N
,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,624.0,80021,Homo sapiens,Expert,,9606.0,5925,,A498,,,,F,1,BAO_0000219,3498,1,CHEMBL619316,,N
,,Cytotoxicity against human kidney carcinoma A-498cell lines,624.0,80021,Homo sapiens,Intermediate,,9606.0,5926,,A498,,,,F,1,BAO_0000219,1169,1,CHEMBL619317,,N
,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,624.0,80021,Homo sapiens,Intermediate,,9606.0,5927,,A498,,,,F,1,BAO_0000219,4450,1,CHEMBL619318,,N
,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,624.0,80021,Homo sapiens,Intermediate,,9606.0,5928,,A498,,,,F,1,BAO_0000219,3311,1,CHEMBL619319,,N
,,Antitumor cytotoxic activity against A-498 cell line was determined,624.0,80021,Homo sapiens,Intermediate,,9606.0,5929,,A498,,,,F,1,BAO_0000219,4461,1,CHEMBL619739,,N
,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,624.0,80021,Homo sapiens,Intermediate,,9606.0,5930,,A498,,,,F,1,BAO_0000219,3311,1,CHEMBL619740,,N
,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,624.0,80021,Homo sapiens,Intermediate,,9606.0,5931,,A498,,,,F,1,BAO_0000219,3311,1,CHEMBL883158,,N
,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,624.0,80021,Homo sapiens,Intermediate,,9606.0,5932,,A498,,,,F,1,BAO_0000219,1457,1,CHEMBL884012,,N
,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,624.0,80021,Homo sapiens,Intermediate,,9606.0,5933,,A498,,,,F,1,BAO_0000219,3664,1,CHEMBL619741,,N
,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",624.0,80021,Homo sapiens,Intermediate,,9606.0,5934,,A498,,,,F,1,BAO_0000219,15895,1,CHEMBL619742,,N
,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5935,,A549,,,,F,1,BAO_0000219,11843,1,CHEMBL876610,,N
,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5936,,A549,,,,F,1,BAO_0000219,11843,1,CHEMBL619743,,N
,,In vitro antiproliferative activity against human A-549 NSCL cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5937,,A549,,,,F,1,BAO_0000219,17705,1,CHEMBL619744,,N
,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,646.0,80682,Homo sapiens,Intermediate,,9606.0,5938,,A549,,,,F,1,BAO_0000219,17705,1,CHEMBL619745,,N
,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5939,,A549,,,,F,1,BAO_0000219,4369,1,CHEMBL619746,,N
,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5940,,A549,,,,F,1,BAO_0000219,4369,1,CHEMBL619747,,N
,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,646.0,80682,Homo sapiens,Intermediate,,9606.0,5941,,A549,,,,F,1,BAO_0000219,4369,1,CHEMBL619748,,N
,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5942,,A549,,,,F,1,BAO_0000219,4369,1,CHEMBL619749,,N
,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,646.0,80682,Homo sapiens,Intermediate,,9606.0,5943,,A549,,,,F,1,BAO_0000219,4369,1,CHEMBL619750,,N
,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5944,,A549,,,,F,1,BAO_0000219,4369,1,CHEMBL624014,,N
,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,646.0,80682,Homo sapiens,Intermediate,,9606.0,5945,,A549,,,,F,1,BAO_0000219,4369,1,CHEMBL624015,,N
,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,646.0,80682,Homo sapiens,Expert,,9606.0,5946,,A549,,,,F,1,BAO_0000219,4787,1,CHEMBL885344,,N
,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,646.0,80682,Homo sapiens,Intermediate,,9606.0,5947,,A549,,,,F,1,BAO_0000219,4787,1,CHEMBL623224,,N
,,Cytotoxic activity against A-549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5948,,A549,,,,F,1,BAO_0000219,6513,1,CHEMBL623225,,N
,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,646.0,80682,Homo sapiens,Intermediate,,9606.0,5949,,A549,,,,F,1,BAO_0000219,6690,1,CHEMBL622698,,N
,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,646.0,80682,Homo sapiens,Intermediate,,9606.0,5950,,A549,,,,F,1,BAO_0000219,6690,1,CHEMBL622699,,N
,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",646.0,80682,Homo sapiens,Expert,,9606.0,5951,,A549,,,,F,1,BAO_0000219,12263,1,CHEMBL622700,,N
,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),646.0,80682,Homo sapiens,Intermediate,,9606.0,5952,,A549,,,,F,1,BAO_0000219,1054,1,CHEMBL622701,,N
,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),646.0,80682,Homo sapiens,Intermediate,,9606.0,5953,,A549,,,,F,1,BAO_0000219,1359,1,CHEMBL622702,,N
,,Cytotoxic activity against human lung carcinoma (A-549) cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5954,,A549,,,,F,1,BAO_0000219,3547,1,CHEMBL622703,,N
,,Cytotoxic activity towards A-549 cells,646.0,80682,Homo sapiens,Expert,,9606.0,5955,,A549,,,,F,1,BAO_0000219,5771,1,CHEMBL622704,,N
,,"In vitro percent inhibition of A549, lung carcinoma.",646.0,80682,Homo sapiens,Intermediate,,9606.0,5956,,A549,,,,F,1,BAO_0000219,14425,1,CHEMBL622705,,N
,,"In vitro percent inhibition of A549, lung carcinoma",646.0,80682,Homo sapiens,Intermediate,,9606.0,5957,,A549,,,,F,1,BAO_0000219,14425,1,CHEMBL622706,,N
,,"In vitro percent inhibition of A549, lung carcinoma.",646.0,80682,Homo sapiens,Intermediate,,9606.0,5958,,A549,,,,F,1,BAO_0000219,14425,1,CHEMBL622707,,N
,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",646.0,80682,Homo sapiens,Intermediate,,9606.0,5959,,A549,,,,F,1,BAO_0000219,14425,1,CHEMBL622708,,N
,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,646.0,80682,Homo sapiens,Intermediate,,9606.0,5960,,A549,,,,F,1,BAO_0000219,5280,1,CHEMBL622709,,N
,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,646.0,80682,Homo sapiens,Intermediate,,9606.0,5961,,A549,,,,F,1,BAO_0000219,15176,1,CHEMBL622710,,N
,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,5962,,A549,,,,F,1,BAO_0000219,15300,1,CHEMBL622711,,N
,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,80682,Homo sapiens,Intermediate,,9606.0,5963,,A549,,,,F,1,BAO_0000218,17824,1,CHEMBL622712,,N
,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,80682,Homo sapiens,Intermediate,,9606.0,5964,,A549,,,,F,1,BAO_0000218,17824,1,CHEMBL622713,,N
,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,80682,Homo sapiens,Intermediate,,9606.0,5965,,A549,,,,F,1,BAO_0000218,17824,1,CHEMBL622714,,N
,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,80682,Homo sapiens,Intermediate,,9606.0,5966,,A549,,,,F,1,BAO_0000218,17824,1,CHEMBL622715,,N
,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,80682,Homo sapiens,Intermediate,,9606.0,5967,,A549,,,,F,1,BAO_0000218,17824,1,CHEMBL622716,,N
,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",646.0,80682,Homo sapiens,Intermediate,,9606.0,5968,,A549,,,,F,1,BAO_0000219,17824,1,CHEMBL622717,,N
,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),646.0,80682,Homo sapiens,Intermediate,,9606.0,5969,,A549,,,,F,1,BAO_0000218,17528,1,CHEMBL622718,,N
,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,646.0,80682,Homo sapiens,Expert,,9606.0,5970,,A549,,,,F,1,BAO_0000219,6870,1,CHEMBL622719,,N
,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,5971,,A549,,,,F,1,BAO_0000219,6870,1,CHEMBL622720,,N
,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,646.0,80682,Homo sapiens,Intermediate,,9606.0,5972,,A549,,,,F,1,BAO_0000219,6870,1,CHEMBL622721,,N
,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,5973,,A549,,,,F,1,BAO_0000219,6870,1,CHEMBL622722,,N
,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,646.0,80682,Homo sapiens,Intermediate,,9606.0,5974,,A549,,,,F,1,BAO_0000219,16726,1,CHEMBL876030,,N
,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",646.0,80682,Homo sapiens,Intermediate,,9606.0,5975,,A549,,,,F,1,BAO_0000219,6170,1,CHEMBL620206,,N
,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,646.0,80682,Homo sapiens,Expert,,9606.0,5976,,A549,,,,F,1,BAO_0000219,6583,1,CHEMBL620207,,N
,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,646.0,80682,Homo sapiens,Expert,,9606.0,5977,,A549,,,,F,1,BAO_0000219,6583,1,CHEMBL620208,,N
,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,646.0,80682,Homo sapiens,Expert,,9606.0,5978,,A549,,,,F,1,BAO_0000219,6583,1,CHEMBL620209,,N
,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,646.0,80682,Homo sapiens,Expert,,9606.0,5979,,A549,,,,F,1,BAO_0000219,6583,1,CHEMBL620210,,N
,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,646.0,80682,Homo sapiens,Expert,,9606.0,5980,,A549,,,,F,1,BAO_0000219,6583,1,CHEMBL621639,,N
,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5981,,A549,,,,F,1,BAO_0000219,17321,1,CHEMBL621640,,N
,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,646.0,80682,Homo sapiens,Expert,,9606.0,5982,,A549,,,,F,1,BAO_0000219,17528,1,CHEMBL621641,,N
,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,646.0,80682,Homo sapiens,Expert,,9606.0,5983,,A549,,,,F,1,BAO_0000219,12888,1,CHEMBL621642,,N
,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5984,,A549,,,,F,1,BAO_0000219,4312,1,CHEMBL621643,,N
,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,5985,,A549,,,,F,1,BAO_0000219,4312,1,CHEMBL621644,,N
,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,646.0,80682,Homo sapiens,Intermediate,,9606.0,5986,,A549,,,,F,1,BAO_0000219,4312,1,CHEMBL621645,,N
,,In vitro antiproliferative activity against A549 cell line,646.0,80682,Mus musculus,Intermediate,,10090.0,5987,,A549,,,,F,1,BAO_0000219,17737,1,CHEMBL621646,,N
,,Synergism with indomethacin in A549 cells,646.0,80682,,Intermediate,,,5988,,A549,,,,F,1,BAO_0000219,6630,1,CHEMBL621647,,N
,,Synergism with tolmetin in A549 cells,646.0,80682,,Intermediate,,,5989,,A549,,,,F,1,BAO_0000219,6630,1,CHEMBL621648,,N
,,Synergism with sulindac in A549 cells,646.0,80682,,Intermediate,,,5990,,A549,,,,F,1,BAO_0000219,6630,1,CHEMBL621649,,N
,,Antagonism of indomethacin in A549 cells,646.0,80682,,Intermediate,,,5991,,A549,,,,F,1,BAO_0000219,6630,1,CHEMBL621650,,N
,,Antagonism of sulindac in A549 cells,646.0,80682,,Intermediate,,,5992,,A549,,,,F,1,BAO_0000219,6630,1,CHEMBL621651,,N
,,Antagonism of tolmetin in A549 cells,646.0,80682,,Intermediate,,,5993,,A549,,,,F,1,BAO_0000219,6630,1,CHEMBL621652,,N
,,Synergism with indomethacin in A549 cells,646.0,80682,,Intermediate,,,5994,,A549,,,,F,1,BAO_0000219,6630,1,CHEMBL621653,,N
,,Synergism with sulindac in A549 cells,646.0,80682,,Intermediate,,,5995,,A549,,,,F,1,BAO_0000219,6630,1,CHEMBL621654,,N
,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,646.0,80682,,Intermediate,,,5996,,A549,,,,F,1,BAO_0000219,6630,1,CHEMBL621655,,N
,,Cmax value after 30 mg/kg po dose in Dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,5997,In vivo,,,,,A,1,BAO_0000218,16907,1,CHEMBL621656,,N
,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,5998,In vivo,,,,,A,1,BAO_0000218,5944,1,CHEMBL621657,,N
,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,5999,In vivo,,,,,A,1,BAO_0000218,5944,1,CHEMBL621658,,N
,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6000,In vivo,,,,,A,1,BAO_0000218,5944,1,CHEMBL621659,,N
,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6001,In vivo,,,,,A,1,BAO_0000218,5944,1,CHEMBL621660,,N
,,Cmax value after administration of 4 mg/Kg oral dose in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6002,In vivo,,,,,A,1,BAO_0000218,2959,1,CHEMBL621661,,N
,,Cmax value in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6003,In vivo,,,,,A,1,BAO_0000218,6241,1,CHEMBL621662,,N
,,Cmax value in dogs after oral administration at 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6004,In vivo,,,,,A,1,BAO_0000218,6241,1,CHEMBL621663,,N
,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,50588,Canis lupus familiaris,Intermediate,,9615.0,6005,In vivo,,,,,A,1,BAO_0000218,2652,1,CHEMBL621664,,N
,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6006,In vivo,,,,Plasma,A,1,BAO_0000218,1806,1,CHEMBL621665,,N
,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6007,In vivo,,,,Plasma,A,1,BAO_0000218,1806,1,CHEMBL621666,,N
,,Concentration maxima after oral dosing in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6008,In vivo,,,,,A,1,BAO_0000218,1021,1,CHEMBL621667,,N
,,Concentration maxima after oral dosing in dogs; not available,,50588,Canis lupus familiaris,Intermediate,,9615.0,6009,In vivo,,,,,A,1,BAO_0000218,1021,1,CHEMBL876738,,N
,,Concentration maxima after oral dosing in dogs; not available,,50588,Canis lupus familiaris,Intermediate,,9615.0,6010,In vivo,,,,,A,1,BAO_0000218,1021,1,CHEMBL621668,,N
,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,50588,Canis lupus familiaris,Intermediate,,9615.0,6011,In vivo,,,,,A,1,BAO_0000218,5444,1,CHEMBL621669,,N
,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,50588,Canis lupus familiaris,Intermediate,,9615.0,6012,In vivo,,,,,A,1,BAO_0000218,5444,1,CHEMBL621670,,N
,,In vivo maximal concentration was calculated at 1 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6013,In vivo,,,,,A,1,BAO_0000218,5444,1,CHEMBL621671,,N
,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,50588,Canis lupus familiaris,Intermediate,,9615.0,6014,In vivo,,,,,A,1,BAO_0000218,5444,1,CHEMBL622360,,N
,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,50588,Canis lupus familiaris,Intermediate,,9615.0,6015,In vivo,,,,,A,1,BAO_0000218,5444,1,CHEMBL622361,,N
,,Cmax in dog plasma after oral dose (1 mg/kg),,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6016,In vivo,,,,Plasma,A,1,BAO_0000218,5130,1,CHEMBL622362,,N
,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6017,In vivo,,,,Plasma,A,1,BAO_0000218,3249,1,CHEMBL622363,,N
,,Maximal plasma concentration at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6018,In vivo,,,,Plasma,A,1,BAO_0000218,5473,1,CHEMBL622364,,N
,,Maximal plasma concentration at a dose of 1 mg/kg (oral),,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6019,In vivo,,,,Plasma,A,1,BAO_0000218,5474,1,CHEMBL622365,,N
,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6020,In vivo,,,,Plasma,A,1,BAO_0000218,4657,1,CHEMBL622533,,N
,,Maximum concentration of compound in dog was evaluated.,,50588,Canis lupus familiaris,Intermediate,,9615.0,6021,In vivo,,,,,A,1,BAO_0000218,3031,1,CHEMBL622534,,N
,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6022,In vivo,,,,,A,1,BAO_0000218,4527,1,CHEMBL622535,,N
,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,50588,Canis lupus familiaris,Intermediate,,9615.0,6023,In vivo,,,,,A,1,BAO_0000218,4186,1,CHEMBL876739,,N
,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6024,In vivo,,,,,A,1,BAO_0000218,5007,1,CHEMBL622536,,N
,,Maximum concentration obtained in dog plasma was determined,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6025,In vivo,,,,Plasma,A,1,BAO_0000218,3132,1,CHEMBL622537,,N
,,Maximum concentration was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6026,In vivo,,,,,A,1,BAO_0000218,5006,1,CHEMBL622538,,N
,,Maximum concentration at the dose of 2 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6027,In vivo,,,,,A,1,BAO_0000218,4727,1,CHEMBL627867,,N
,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6028,In vivo,,,,,A,1,BAO_0000218,1916,1,CHEMBL627868,,N
,,Maximum concentration was evaluated in dog plasma,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6029,In vivo,,,,Plasma,A,1,BAO_0000218,1918,1,CHEMBL627869,,N
,,Maximum concentration was evaluated after 75 min after administration in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6030,In vivo,,,,,A,1,BAO_0000218,3045,1,CHEMBL627870,,N
,,Maximum plasma concentration determined in dog after oral administration of 17b,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6031,In vivo,,,,Plasma,A,1,BAO_0000218,9579,1,CHEMBL627871,,N
,,Maximum plasma concentration determined in dog after oral administration of 2b,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6032,In vivo,,,,Plasma,A,1,BAO_0000218,9579,1,CHEMBL627872,,N
,,Maximum plasma concentration in dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6033,In vivo,,,,Plasma,A,1,BAO_0000218,933,1,CHEMBL627873,,N
,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6034,In vivo,,,,Plasma,A,1,BAO_0000218,17839,1,CHEMBL627874,,N
,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6035,In vivo,,,,Plasma,A,1,BAO_0000218,17839,1,CHEMBL627875,,N
,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6036,In vivo,,,,Plasma,A,1,BAO_0000218,17839,1,CHEMBL627876,,N
,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6037,In vivo,,,,Plasma,A,1,BAO_0000218,17839,1,CHEMBL627877,,N
,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6038,In vivo,,,,Plasma,A,1,BAO_0000218,6348,1,CHEMBL627878,,N
,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6039,In vivo,,,,Plasma,A,1,BAO_0000218,16367,1,CHEMBL627879,,N
,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6040,In vivo,,,,Plasma,A,1,BAO_0000218,1337,1,CHEMBL875355,,N
,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6041,In vivo,,,,Plasma,A,1,BAO_0000218,1337,1,CHEMBL627880,,N
,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6042,In vivo,,,,Plasma,A,1,BAO_0000218,5199,1,CHEMBL627881,,N
,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6043,In vivo,,,,Plasma,A,1,BAO_0000218,17650,1,CHEMBL627882,,N
,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6044,In vivo,,,,Plasma,A,1,BAO_0000218,6679,1,CHEMBL627883,,N
,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6045,In vivo,,,,Plasma,A,1,BAO_0000218,5356,1,CHEMBL628526,,N
,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6046,In vivo,,,,Plasma,A,1,BAO_0000218,5356,1,CHEMBL628527,,N
,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6047,In vivo,,,,Plasma,A,1,BAO_0000218,6227,1,CHEMBL628528,,N
,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6048,In vivo,,,,Plasma,A,1,BAO_0000218,6227,1,CHEMBL628529,,N
,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6049,In vivo,,,,Plasma,A,1,BAO_0000218,6227,1,CHEMBL628530,,N
,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6050,In vivo,,,,Plasma,A,1,BAO_0000218,6227,1,CHEMBL625243,,N
,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,50588,Canis lupus familiaris,Expert,1969.0,9615.0,6051,In vivo,,,,Plasma,A,1,BAO_0000218,3598,1,CHEMBL625244,,N
,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6052,In vivo,,,,,A,1,BAO_0000218,4368,1,CHEMBL625245,,N
,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6053,In vivo,,,,,A,1,BAO_0000218,6265,1,CHEMBL625246,,N
,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,945.0,10090.0,6054,In vivo,,,,Stomach,A,1,BAO_0000218,7767,1,CHEMBL625247,,N
,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,50594,Mus musculus,Intermediate,1088.0,10090.0,6055,In vivo,,,,Urine,A,1,BAO_0000218,7767,1,CHEMBL625248,,N
,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,50594,Mus musculus,Intermediate,1088.0,10090.0,6056,In vivo,,,,Urine,A,1,BAO_0000218,7767,1,CHEMBL625249,,N
,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,50594,Mus musculus,Intermediate,1088.0,10090.0,6057,In vivo,,,,Urine,A,1,BAO_0000218,7767,1,CHEMBL625250,,N
,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,50594,Mus musculus,Intermediate,,10090.0,6058,,,,,,A,1,BAO_0000218,17811,1,CHEMBL625251,,N
,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,50594,Mus musculus,Intermediate,,10090.0,6059,,,,,,A,1,BAO_0000218,17811,1,CHEMBL875356,,N
,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,50594,Mus musculus,Intermediate,,10090.0,6060,,,,,,A,1,BAO_0000218,17827,1,CHEMBL625252,,N
,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,50594,Mus musculus,Intermediate,178.0,10090.0,6061,,,,,Blood,A,1,BAO_0000218,17827,1,CHEMBL625253,,N
,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,50594,Mus musculus,Intermediate,,10090.0,6062,,,,,,A,1,BAO_0000218,17827,1,CHEMBL625254,,N
,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,50594,Mus musculus,Intermediate,,10090.0,6063,,,,,,A,1,BAO_0000218,17827,1,CHEMBL625255,,N
,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,50594,Mus musculus,Intermediate,,10090.0,6064,,,,,,A,1,BAO_0000218,17827,1,CHEMBL625256,,N
,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,50594,Mus musculus,Intermediate,178.0,10090.0,6065,,,,,Blood,A,1,BAO_0000218,17827,1,CHEMBL625257,,N
,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,50594,Mus musculus,Intermediate,178.0,10090.0,6066,,,,,Blood,A,1,BAO_0000218,17827,1,CHEMBL625258,,N
,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,50594,Mus musculus,Intermediate,,10090.0,6067,,,,,,A,1,BAO_0000218,17827,1,CHEMBL625259,,N
,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,50594,Mus musculus,Intermediate,,10090.0,6068,,,,,,A,1,BAO_0000218,17827,1,CHEMBL625260,,N
,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,50594,Mus musculus,Intermediate,,10090.0,6069,,,,,,A,1,BAO_0000218,17827,1,CHEMBL625261,,N
,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,50594,Mus musculus,Intermediate,,10090.0,6070,,,,,,A,1,BAO_0000218,17827,1,CHEMBL625262,,N
,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,50594,Mus musculus,Intermediate,,10090.0,6071,,,,,,A,1,BAO_0000218,17827,1,CHEMBL622639,,N
,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,50594,Mus musculus,Intermediate,,10090.0,6072,,,,,,A,1,BAO_0000218,17257,1,CHEMBL622640,,N
,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,50594,Mus musculus,Intermediate,,10090.0,6073,,,,,,A,1,BAO_0000218,17257,1,CHEMBL622812,,N
,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,50594,Mus musculus,Intermediate,,10090.0,6074,,,,,,A,1,BAO_0000218,17257,1,CHEMBL622813,,N
,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,50594,Mus musculus,Intermediate,,10090.0,6075,,,,,,A,1,BAO_0000218,17257,1,CHEMBL622814,,N
,,Time at maximum activity in mice (Radiolabeled compound),,50594,Mus musculus,Intermediate,,10090.0,6076,,,,,,A,1,BAO_0000218,17827,1,CHEMBL622815,,N
,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,50594,Mus musculus,Intermediate,,10090.0,6077,,,,,,A,1,BAO_0000218,3760,1,CHEMBL625342,,N
,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,50594,Mus musculus,Intermediate,,10090.0,6078,,,,,,A,1,BAO_0000218,3760,1,CHEMBL625343,,N
,,Binding towards mouse plasma protein at 10 uM,,50594,Mus musculus,Intermediate,,10090.0,6079,,,,,,A,1,BAO_0000218,17409,1,CHEMBL877591,,N
,,Binding towards mouse plasma protein at 100 uM,,50594,Mus musculus,Intermediate,,10090.0,6080,,,,,,A,1,BAO_0000218,17409,1,CHEMBL625344,,N
,,Bioavailability was evaluated in mice after intravenous administration,,50594,Mus musculus,Intermediate,,10090.0,6081,In vivo,,,,,A,1,BAO_0000218,2675,1,CHEMBL625345,,N
,,Bioavailability was evaluated in mice after oral administration,,50594,Mus musculus,Intermediate,,10090.0,6082,In vivo,,,,,A,1,BAO_0000218,2675,1,CHEMBL625346,,N
,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,50594,Mus musculus,Intermediate,,10090.0,6083,In vivo,,,,,A,1,BAO_0000218,3132,1,CHEMBL625347,,N
,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,6084,In vivo,,,,,A,1,BAO_0000218,3132,1,CHEMBL625348,,N
,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,50594,Mus musculus,Intermediate,,10090.0,6085,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL625349,,N
,,Oral bioavailability in mouse,,50594,Mus musculus,Intermediate,,10090.0,6086,In vivo,,,,,A,1,BAO_0000218,2862,1,CHEMBL625350,,N
,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,6087,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL882952,,N
,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,955.0,10090.0,6088,In vivo,,,,Brain,A,1,BAO_0000218,846,1,CHEMBL625351,,N
,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,955.0,10090.0,6089,In vivo,,,,Brain,A,1,BAO_0000218,846,1,CHEMBL625352,,N
,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,955.0,10090.0,6090,In vivo,,,,Brain,A,1,BAO_0000218,846,1,CHEMBL877592,,N
,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,955.0,10090.0,6091,In vivo,,,,Brain,A,1,BAO_0000218,846,1,CHEMBL625353,,N
,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,955.0,10090.0,6092,In vivo,,,,Brain,A,1,BAO_0000218,846,1,CHEMBL625354,,N
,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,955.0,10090.0,6093,In vivo,,,,Brain,A,1,BAO_0000218,846,1,CHEMBL626019,,N
,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,948.0,10090.0,6094,In vivo,,,,Heart,A,1,BAO_0000218,846,1,CHEMBL626020,,N
,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,948.0,10090.0,6095,In vivo,,,,Heart,A,1,BAO_0000218,846,1,CHEMBL626021,,N
,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,948.0,10090.0,6096,In vivo,,,,Heart,A,1,BAO_0000218,846,1,CHEMBL626022,,N
,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,948.0,10090.0,6097,In vivo,,,,Heart,A,1,BAO_0000218,846,1,CHEMBL626192,,N
,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),646.0,80682,Homo sapiens,Intermediate,,9606.0,6098,,A549,,,,F,1,BAO_0000219,1276,1,CHEMBL626193,,N
,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,646.0,80682,Homo sapiens,Expert,,9606.0,6099,,A549,,,,F,1,BAO_0000219,3498,1,CHEMBL626194,,N
,,Cytotoxicity against human lung carcinoma A-549 cell lines,646.0,80682,Homo sapiens,Intermediate,,9606.0,6100,,A549,,,,F,1,BAO_0000219,1169,1,CHEMBL626195,,N
,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6101,,A549,,,,F,1,BAO_0000219,4450,1,CHEMBL626196,,N
,,In vitro cytotoxicity against human lung carcinoma cell line A-549,646.0,80682,Homo sapiens,Intermediate,,9606.0,6102,,A549,,,,F,1,BAO_0000219,358,1,CHEMBL626197,,N
,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,646.0,80682,Homo sapiens,Intermediate,,9606.0,6103,,A549,,,,F,1,BAO_0000219,358,1,CHEMBL626198,,N
,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,646.0,80682,Homo sapiens,Intermediate,,9606.0,6104,,A549,,,,F,1,BAO_0000219,358,1,CHEMBL626199,,N
,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,646.0,80682,Homo sapiens,Intermediate,,9606.0,6105,,A549,,,,F,1,BAO_0000219,358,1,CHEMBL626200,,N
,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,646.0,80682,Homo sapiens,Intermediate,,9606.0,6106,,A549,,,,F,1,BAO_0000219,358,1,CHEMBL626201,,N
,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,646.0,80682,Homo sapiens,Intermediate,,9606.0,6107,,A549,,,,F,1,BAO_0000219,358,1,CHEMBL626202,,N
,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,646.0,80682,Homo sapiens,Intermediate,,9606.0,6108,,A549,,,,F,1,BAO_0000219,358,1,CHEMBL626203,,N
,,In vitro cytotoxicity against A-549 human lung cancer cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6109,,A549,,,,F,1,BAO_0000219,15167,1,CHEMBL626204,,N
,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6110,,A549,,,,F,1,BAO_0000219,4139,1,CHEMBL624701,,N
,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,646.0,80682,Homo sapiens,Intermediate,,9606.0,6111,,A549,,,,F,1,BAO_0000219,833,1,CHEMBL624702,,N
,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,646.0,80682,Homo sapiens,Expert,,9606.0,6112,,A549,,,,F,1,BAO_0000219,15718,1,CHEMBL624703,,N
,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6113,,A549,,,,F,1,BAO_0000219,12373,1,CHEMBL624704,,N
,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,646.0,80682,Homo sapiens,Intermediate,,9606.0,6114,,A549,,,,F,1,BAO_0000219,637,1,CHEMBL624705,,N
,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,646.0,80682,Homo sapiens,Expert,,9606.0,6115,,A549,,,,F,1,BAO_0000219,14867,1,CHEMBL624706,,N
,,Antitumor cytotoxic activity against A-549 cell line was determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,6116,,A549,,,,F,1,BAO_0000219,4461,1,CHEMBL624707,,N
,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",646.0,80682,Homo sapiens,Intermediate,,9606.0,6117,,A549,,,,F,1,BAO_0000219,5406,1,CHEMBL624708,,N
,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6118,,A549,,,,F,1,BAO_0000219,4457,1,CHEMBL624709,,N
,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,6119,,A549,,,,F,1,BAO_0000219,1386,1,CHEMBL884107,,N
,,Antitumoral activity was assayed against A-549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6120,,A549,,,,F,1,BAO_0000219,3265,1,CHEMBL624710,,N
,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,646.0,80682,Homo sapiens,Intermediate,,9606.0,6121,,A549,,,,F,1,BAO_0000219,2359,1,CHEMBL624711,,N
,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6122,,A549,,,,F,1,BAO_0000219,4457,1,CHEMBL624712,,N
,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,6123,,A549,,,,F,1,BAO_0000219,12454,1,CHEMBL624713,,N
,,Compound was tested for inhibition of cell growth of A-549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6124,,A549,,,,F,1,BAO_0000219,1481,1,CHEMBL624714,,N
,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,646.0,80682,Homo sapiens,Intermediate,,9606.0,6125,,A549,,,,F,1,BAO_0000219,1750,1,CHEMBL624715,,N
,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,6126,,A549,,,,F,1,BAO_0000219,5065,1,CHEMBL624716,,N
,,In vitro cytotoxicity against A549-human lung carcinoma cells.,646.0,80682,Homo sapiens,Expert,,9606.0,6127,,A549,,,,F,1,BAO_0000219,808,1,CHEMBL619505,,N
,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,646.0,80682,Homo sapiens,Expert,,9606.0,6128,,A549,,,,F,1,BAO_0000219,16364,1,CHEMBL619506,,N
,,Cytotoxic activity against A-549 cell lines.,646.0,80682,Homo sapiens,Intermediate,,9606.0,6129,,A549,,,,F,1,BAO_0000219,1847,1,CHEMBL619507,,N
,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,646.0,80682,Homo sapiens,Expert,,9606.0,6130,,A549,,,,F,1,BAO_0000219,1747,1,CHEMBL619508,,N
,,Cytotoxicity against human A549 non small cell lung cell lines,646.0,80682,Homo sapiens,Intermediate,,9606.0,6131,,A549,,,,F,1,BAO_0000219,1003,1,CHEMBL619509,,N
,,Inhibition of cell growth in (A-549) lung cell line,646.0,80682,Homo sapiens,Expert,,9606.0,6132,,A549,,,,F,1,BAO_0000219,15313,1,CHEMBL619510,,N
,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6133,,A549,,,,F,1,BAO_0000219,3122,1,CHEMBL619511,,N
,,In vitro antitumor activity against A-549 tumor cells.,646.0,80682,Homo sapiens,Intermediate,,9606.0,6134,,A549,,,,F,1,BAO_0000219,16049,1,CHEMBL619512,,N
,,In vitro antitumor effects against human A-549 cell lines.,646.0,80682,Homo sapiens,Expert,,9606.0,6135,,A549,,,,F,1,BAO_0000219,17134,1,CHEMBL619513,,N
,,In vitro cytotoxic activity of compound against A-549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6136,,A549,,,,F,1,BAO_0000219,6406,1,CHEMBL619514,,N
,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6137,,A549,,,,F,1,BAO_0000219,627,1,CHEMBL619515,,N
,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,646.0,80682,Homo sapiens,Intermediate,,9606.0,6138,,A549,,,,F,1,BAO_0000219,12307,1,CHEMBL619516,,N
,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,646.0,80682,Homo sapiens,Intermediate,,9606.0,6139,,A549,,,,F,1,BAO_0000219,17861,1,CHEMBL884005,,N
,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,646.0,80682,Homo sapiens,Expert,,9606.0,6140,,A549,,,,F,1,BAO_0000219,6682,1,CHEMBL619517,,N
,,Inhibitory concentration of compound against A-549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6141,,A549,,,,F,1,BAO_0000219,6663,1,CHEMBL619518,,N
,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6142,,A549,,,,F,1,BAO_0000219,2454,1,CHEMBL619519,,N
,,cytotoxic activity against leukemia (A-549) cancer cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6143,,A549,,,,F,1,BAO_0000219,14709,1,CHEMBL876489,,N
,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,646.0,80682,Homo sapiens,Expert,,9606.0,6144,,A549,,,,F,1,BAO_0000219,15718,1,CHEMBL619520,,N
,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6145,,A549,,,,F,1,BAO_0000219,15718,1,CHEMBL619521,,N
,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),646.0,80682,Homo sapiens,Intermediate,,9606.0,6146,,A549,,,,F,1,BAO_0000219,17130,1,CHEMBL619522,,N
,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),646.0,80682,Homo sapiens,Intermediate,,9606.0,6147,,A549,,,,F,1,BAO_0000219,17130,1,CHEMBL619523,,N
,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),646.0,80682,Homo sapiens,Intermediate,,9606.0,6148,,A549,,,,F,1,BAO_0000219,17130,1,CHEMBL619524,,N
,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),646.0,80682,Homo sapiens,Intermediate,,9606.0,6149,,A549,,,,F,1,BAO_0000219,17130,1,CHEMBL619525,,N
,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,646.0,80682,,Intermediate,,,6150,,A549,,,,F,1,BAO_0000219,6630,1,CHEMBL619526,,N
,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,646.0,80682,Homo sapiens,Intermediate,,9606.0,6151,,A549,,,,F,1,BAO_0000219,16726,1,CHEMBL619527,,N
,,Cytotoxicity against A549 cells; No cytotoxicity,646.0,80682,Homo sapiens,Intermediate,,9606.0,6152,,A549,,,,F,1,BAO_0000219,17846,1,CHEMBL619528,,N
,,Cytotoxicity against human lung carcinoma (A549) cell lines,646.0,80682,Homo sapiens,Expert,,9606.0,6153,,A549,,,,F,1,BAO_0000219,3415,1,CHEMBL619529,,N
,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,646.0,80682,Homo sapiens,Expert,,9606.0,6154,,A549,,,,F,1,BAO_0000219,3415,1,CHEMBL619530,,N
,,In vitro anticancer activity against human lung (A549) cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6155,,A549,,,,F,1,BAO_0000219,5609,1,CHEMBL876490,,N
,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6156,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619531,,N
,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6157,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619532,,N
,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6158,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619533,,N
,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6159,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619534,,N
,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6160,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL620164,,N
,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6161,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL620165,,N
,,Inhibition of A549 human lung tumor cell proliferation,646.0,80682,Homo sapiens,Expert,,9606.0,6162,,A549,,,,F,1,BAO_0000219,16295,1,CHEMBL620166,,N
,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",646.0,80682,Homo sapiens,Intermediate,,9606.0,6163,,A549,,,,F,1,BAO_0000219,16825,1,CHEMBL620167,,N
,,In vitro cytotoxicity against human tumor cell line A549,646.0,80682,Homo sapiens,Expert,,9606.0,6164,,A549,,,,F,1,BAO_0000219,3439,1,CHEMBL620168,,N
,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,646.0,80682,Homo sapiens,Intermediate,,9606.0,6165,,A549,,,,F,1,BAO_0000219,10870,1,CHEMBL620338,,N
,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6166,,A549,,,,F,1,BAO_0000219,4845,1,CHEMBL620339,,N
,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6167,,A549,,,,F,1,BAO_0000219,5822,1,CHEMBL620340,,N
,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6168,,A549,,,,F,1,BAO_0000219,5822,1,CHEMBL620341,,N
,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,646.0,80682,Homo sapiens,Intermediate,,9606.0,6169,,A549,,,,F,1,BAO_0000219,5822,1,CHEMBL876491,,N
,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,646.0,80682,Homo sapiens,Intermediate,,9606.0,6170,,A549,,,,F,1,BAO_0000219,16381,1,CHEMBL620342,,N
,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,646.0,80682,Homo sapiens,Intermediate,,9606.0,6171,,A549,,,,F,1,BAO_0000219,16381,1,CHEMBL620343,,N
,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,646.0,80682,Homo sapiens,Intermediate,,9606.0,6172,,A549,,,,F,1,BAO_0000219,16381,1,CHEMBL620344,,N
,,In vitro anticancer activity against human lung (A549) cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6173,,A549,,,,F,1,BAO_0000219,5609,1,CHEMBL620345,,N
,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,6174,,A549,,,,F,1,BAO_0000219,4644,1,CHEMBL620346,,N
,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,6175,,A549,,,,F,1,BAO_0000219,4644,1,CHEMBL620347,,N
,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,6176,,A549,,,,F,1,BAO_0000219,4644,1,CHEMBL620348,,N
,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,6177,,A549,,,,F,1,BAO_0000219,4644,1,CHEMBL620349,,N
,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,646.0,80682,Homo sapiens,Intermediate,,9606.0,6178,,A549,,,,F,1,BAO_0000219,5822,1,CHEMBL618667,,N
,,Percentage inhibition of human lung carcinoma (A549) cell lines,646.0,80682,Homo sapiens,Expert,,9606.0,6179,,A549,,,,F,1,BAO_0000219,3415,1,CHEMBL618668,,N
,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,646.0,80682,Homo sapiens,Intermediate,,9606.0,6180,,A549,,,,F,1,BAO_0000219,16726,1,CHEMBL876031,,N
,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",646.0,80682,Homo sapiens,Intermediate,,9606.0,6181,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL618759,,N
,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,6182,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL618760,,N
,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,6183,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619000,,N
,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",646.0,80682,Homo sapiens,Intermediate,,9606.0,6184,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619001,,N
,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",646.0,80682,Homo sapiens,Intermediate,,9606.0,6185,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619002,,N
,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",646.0,80682,Homo sapiens,Intermediate,,9606.0,6186,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619003,,N
,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",646.0,80682,Homo sapiens,Intermediate,,9606.0,6187,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619597,,N
,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",646.0,80682,Homo sapiens,Intermediate,,9606.0,6188,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619598,,N
,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6189,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619599,,N
,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6190,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619600,,N
,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,646.0,80682,Homo sapiens,Intermediate,,9606.0,6191,,A549,,,,F,1,BAO_0000219,16726,1,CHEMBL619601,,N
,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6192,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619602,,N
,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6193,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619603,,N
,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6194,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619604,,N
,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6195,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619605,,N
,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6196,In vivo,,,,,A,1,BAO_0000218,6084,1,CHEMBL619606,,N
,,Pharmacokinetic activity (Cmax) in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6197,In vivo,,,,,A,1,BAO_0000218,6084,1,CHEMBL876032,,N
,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6198,In vivo,,,,,A,1,BAO_0000218,4809,1,CHEMBL619607,,N
,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6199,In vivo,,,,,A,1,BAO_0000218,5983,1,CHEMBL619608,,N
,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6200,In vivo,,,,,A,1,BAO_0000218,6251,1,CHEMBL619609,,N
,,Cmax in dog plasma after 30mg/kg oral dose,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6201,In vivo,,,,Plasma,A,1,BAO_0000218,5932,1,CHEMBL619610,,N
,,Tested for the peak blood level in dog,,50588,Canis lupus familiaris,Intermediate,178.0,9615.0,6202,In vivo,,,,Blood,A,1,BAO_0000218,4273,1,CHEMBL619611,,N
,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,50588,Canis lupus familiaris,Intermediate,,9615.0,6203,In vivo,,,,,A,1,BAO_0000218,5313,1,CHEMBL619612,,N
,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,50588,Canis lupus familiaris,Intermediate,,9615.0,6204,In vivo,,,,,A,1,BAO_0000218,5313,1,CHEMBL619613,,N
,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,50588,Canis lupus familiaris,Intermediate,178.0,9615.0,6205,In vivo,,,,Blood,A,1,BAO_0000218,6221,1,CHEMBL619614,,N
,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6206,,,,,,A,1,BAO_0000218,4709,1,CHEMBL619615,,N
,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,50588,Canis lupus familiaris,Intermediate,,9615.0,6207,,,,,,A,1,BAO_0000218,167,1,CHEMBL619616,,N
,,Final plasma concentration in dogs after oral administration at 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6208,,,,,Plasma,A,1,BAO_0000218,6241,1,CHEMBL619617,,N
,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,50588,Canis lupus familiaris,Intermediate,,9615.0,6209,,,,,,A,1,BAO_0000218,344,1,CHEMBL619618,,N
,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,50588,Canis lupus familiaris,Intermediate,,9615.0,6210,,,,,,A,1,BAO_0000218,344,1,CHEMBL876033,,N
,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,50588,Canis lupus familiaris,Intermediate,,9615.0,6211,,,,,,A,1,BAO_0000218,344,1,CHEMBL619619,,N
,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6212,,,,,,A,1,BAO_0000218,2189,1,CHEMBL619620,,N
,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,50588,Canis lupus familiaris,Intermediate,1088.0,9615.0,6213,,,,,Urine,A,1,BAO_0000218,2189,1,CHEMBL619621,,N
,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,50588,Canis lupus familiaris,Intermediate,1088.0,9615.0,6214,,,,,Urine,A,1,BAO_0000218,2189,1,CHEMBL619622,,N
,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,50588,Canis lupus familiaris,Intermediate,1088.0,9615.0,6215,,,,,Urine,A,1,BAO_0000218,2189,1,CHEMBL618874,,N
,,Absolute bioavailability was evaluated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6216,In vivo,,,,,A,1,BAO_0000218,4257,1,CHEMBL618875,,N
,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6217,In vivo,,,,,A,1,BAO_0000218,6221,1,CHEMBL618876,,N
,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6218,In vivo,,,,,A,1,BAO_0000218,6215,1,CHEMBL618877,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6219,In vivo,,,,,A,1,BAO_0000218,17267,1,CHEMBL618878,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6220,In vivo,,,,,A,1,BAO_0000218,6621,1,CHEMBL618879,,N
,,Bioavailability after intravenous administration in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6221,In vivo,,,,,A,1,BAO_0000218,3854,1,CHEMBL618880,,N
,,Bioavailability after peroral administration in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6222,In vivo,,,,,A,1,BAO_0000218,3854,1,CHEMBL618881,,N
,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,50588,Canis lupus familiaris,Intermediate,,9615.0,6223,In vivo,,,,,A,1,BAO_0000218,5007,1,CHEMBL618882,,N
,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,50588,Canis lupus familiaris,Intermediate,,9615.0,6224,In vivo,,,,,A,1,BAO_0000218,4333,1,CHEMBL624226,,N
,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6225,In vivo,,,,Plasma,A,1,BAO_0000218,4333,1,CHEMBL624227,,N
,,Bioavailability,,50588,Canis lupus familiaris,Intermediate,,9615.0,6226,In vivo,,,,,A,1,BAO_0000218,5006,1,CHEMBL624228,,N
,,Bioavailability,,50588,Canis lupus familiaris,Intermediate,,9615.0,6227,In vivo,,,,,A,1,BAO_0000218,5199,1,CHEMBL624229,,N
,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6228,In vivo,,,,,A,1,BAO_0000218,4368,1,CHEMBL624230,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6229,In vivo,,,,,A,1,BAO_0000218,3771,1,CHEMBL624231,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6230,In vivo,,,,,A,1,BAO_0000218,4953,1,CHEMBL624232,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6231,In vivo,,,,,A,1,BAO_0000218,5064,1,CHEMBL625127,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6232,In vivo,,,,,A,1,BAO_0000218,17657,1,CHEMBL625128,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6233,In vivo,,,,,A,1,BAO_0000218,17796,1,CHEMBL621675,,N
,,Bioavailability in dog (p.o.) at 2.0 mpk,,50588,Canis lupus familiaris,Intermediate,,9615.0,6234,In vivo,,,,,A,1,BAO_0000218,17853,1,CHEMBL621676,,N
,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,50588,Canis lupus familiaris,Intermediate,,9615.0,6235,In vivo,,,,,A,1,BAO_0000218,4521,1,CHEMBL621677,,N
,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6236,In vivo,,,,,A,1,BAO_0000218,4521,1,CHEMBL621678,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6237,In vivo,,,,,A,1,BAO_0000218,5006,1,CHEMBL621679,,N
,,Bioavailability was evaluated after oral administration in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6238,In vivo,,,,,A,1,BAO_0000218,16365,1,CHEMBL621680,,N
,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6239,In vivo,,,,,A,1,BAO_0000218,1916,1,CHEMBL621681,,N
,,Bioavailability was evaluated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6240,In vivo,,,,,A,1,BAO_0000218,1918,1,CHEMBL876740,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6241,In vivo,,,,,A,1,BAO_0000218,4239,1,CHEMBL621682,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6242,In vivo,,,,,A,1,BAO_0000218,6505,1,CHEMBL621683,,N
,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,50588,Canis lupus familiaris,Intermediate,,9615.0,6243,In vivo,,,,,A,1,BAO_0000218,5334,1,CHEMBL621684,,N
,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,50588,Canis lupus familiaris,Intermediate,,9615.0,6244,In vivo,,,,,A,1,BAO_0000218,5334,1,CHEMBL621685,,N
,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6245,In vivo,,,,,A,1,BAO_0000218,4809,1,CHEMBL621686,,N
,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6246,In vivo,,,,,A,1,BAO_0000218,6348,1,CHEMBL621687,,N
,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6247,In vivo,,,,,A,1,BAO_0000218,6005,1,CHEMBL621688,,N
,,Bioavailability of compound in dog was determined after peroral administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6248,In vivo,,,,,A,1,BAO_0000218,17804,1,CHEMBL621689,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6249,In vivo,,,,,A,1,BAO_0000218,3184,1,CHEMBL621690,,N
,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6250,In vivo,,,,,A,1,BAO_0000218,1806,1,CHEMBL621691,,N
,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6251,In vivo,,,,,A,1,BAO_0000218,1806,1,CHEMBL875941,,N
,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,50588,Canis lupus familiaris,Intermediate,,9615.0,6252,In vivo,,,,,A,1,BAO_0000218,1806,1,CHEMBL621692,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6253,In vivo,,,,,A,1,BAO_0000218,4839,1,CHEMBL621693,,N
,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,50588,Canis lupus familiaris,Intermediate,,9615.0,6254,In vivo,,,,,A,1,BAO_0000218,5017,1,CHEMBL621694,,N
,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,948.0,10090.0,6255,In vivo,,,,Heart,A,1,BAO_0000218,846,1,CHEMBL621695,,N
,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,948.0,10090.0,6256,In vivo,,,,Heart,A,1,BAO_0000218,846,1,CHEMBL621696,,N
,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2113.0,10090.0,6257,In vivo,,,,Kidney,A,1,BAO_0000218,846,1,CHEMBL621697,,N
,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2113.0,10090.0,6258,In vivo,,,,Kidney,A,1,BAO_0000218,846,1,CHEMBL621698,,N
,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2113.0,10090.0,6259,In vivo,,,,Kidney,A,1,BAO_0000218,846,1,CHEMBL623420,,N
,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2113.0,10090.0,6260,In vivo,,,,Kidney,A,1,BAO_0000218,846,1,CHEMBL623421,,N
,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2113.0,10090.0,6261,In vivo,,,,Kidney,A,1,BAO_0000218,846,1,CHEMBL623422,,N
,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2113.0,10090.0,6262,In vivo,,,,Kidney,A,1,BAO_0000218,846,1,CHEMBL623423,,N
,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2107.0,10090.0,6263,In vivo,,,,Liver,A,1,BAO_0000218,846,1,CHEMBL623424,,N
,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2107.0,10090.0,6264,In vivo,,,,Liver,A,1,BAO_0000218,846,1,CHEMBL623425,,N
,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2107.0,10090.0,6265,In vivo,,,,Liver,A,1,BAO_0000218,846,1,CHEMBL623426,,N
,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2107.0,10090.0,6266,In vivo,,,,Liver,A,1,BAO_0000218,846,1,CHEMBL623427,,N
,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2107.0,10090.0,6267,In vivo,,,,Liver,A,1,BAO_0000218,846,1,CHEMBL623428,,N
,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2107.0,10090.0,6268,In vivo,,,,Liver,A,1,BAO_0000218,846,1,CHEMBL875947,,N
,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2048.0,10090.0,6269,In vivo,,,,Lung,A,1,BAO_0000218,846,1,CHEMBL623429,,N
,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2048.0,10090.0,6270,In vivo,,,,Lung,A,1,BAO_0000218,846,1,CHEMBL623430,,N
,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2048.0,10090.0,6271,In vivo,,,,Lung,A,1,BAO_0000218,846,1,CHEMBL622588,,N
,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2048.0,10090.0,6272,In vivo,,,,Lung,A,1,BAO_0000218,846,1,CHEMBL622589,,N
,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2048.0,10090.0,6273,In vivo,,,,Lung,A,1,BAO_0000218,846,1,CHEMBL622751,,N
,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,50594,Mus musculus,Intermediate,2048.0,10090.0,6274,In vivo,,,,Lung,A,1,BAO_0000218,846,1,CHEMBL622752,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,,10090.0,6275,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL622753,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6276,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL622647,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,,10090.0,6277,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL875163,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6278,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL622648,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6279,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL622649,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,955.0,10090.0,6280,,CCRF S-180,,,Brain,A,1,BAO_0000218,6599,1,CHEMBL622650,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,955.0,10090.0,6281,,CCRF S-180,,,Brain,A,1,BAO_0000218,6599,1,CHEMBL622651,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,955.0,10090.0,6282,,CCRF S-180,,,Brain,A,1,BAO_0000218,6599,1,CHEMBL622652,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,955.0,10090.0,6283,,CCRF S-180,,,Brain,A,1,BAO_0000218,6599,1,CHEMBL622653,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,955.0,10090.0,6284,,CCRF S-180,,,Brain,A,1,BAO_0000218,6599,1,CHEMBL622654,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,948.0,10090.0,6285,,CCRF S-180,,,Heart,A,1,BAO_0000218,6599,1,CHEMBL622655,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,948.0,10090.0,6286,,CCRF S-180,,,Heart,A,1,BAO_0000218,6599,1,CHEMBL622656,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,948.0,10090.0,6287,,CCRF S-180,,,Heart,A,1,BAO_0000218,6599,1,CHEMBL622657,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,948.0,10090.0,6288,,CCRF S-180,,,Heart,A,1,BAO_0000218,6599,1,CHEMBL622658,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,948.0,10090.0,6289,,CCRF S-180,,,Heart,A,1,BAO_0000218,6599,1,CHEMBL622659,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,2113.0,10090.0,6290,,CCRF S-180,,,Kidney,A,1,BAO_0000218,6599,1,CHEMBL624630,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,2113.0,10090.0,6291,,CCRF S-180,,,Kidney,A,1,BAO_0000218,6599,1,CHEMBL624631,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,2113.0,10090.0,6292,,CCRF S-180,,,Kidney,A,1,BAO_0000218,6599,1,CHEMBL624632,,N
,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,646.0,80682,Homo sapiens,Intermediate,,9606.0,6293,,A549,,,,F,1,BAO_0000219,17130,1,CHEMBL624633,,N
,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,646.0,80682,Homo sapiens,Intermediate,,9606.0,6294,,A549,,,,F,1,BAO_0000219,17130,1,CHEMBL624634,,N
,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),646.0,80682,Homo sapiens,Intermediate,,9606.0,6295,,A549,,,,F,1,BAO_0000219,17130,1,CHEMBL624635,,N
,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),646.0,80682,Homo sapiens,Intermediate,,9606.0,6296,,A549,,,,F,1,BAO_0000219,17130,1,CHEMBL624636,,N
,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,6297,,A549,,,,F,1,BAO_0000219,3263,1,CHEMBL857055,,N
,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,646.0,80682,Homo sapiens,Expert,,9606.0,6298,,A549,,,,F,1,BAO_0000219,6663,1,CHEMBL624637,,N
,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,646.0,80682,Homo sapiens,Expert,,9606.0,6299,,A549,,,,F,1,BAO_0000219,6663,1,CHEMBL624638,,N
,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,646.0,80682,Homo sapiens,Expert,,9606.0,6300,,A549,,,,F,1,BAO_0000219,6663,1,CHEMBL874366,,N
,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,646.0,80682,Homo sapiens,Expert,,9606.0,6301,,A549,,,,F,1,BAO_0000219,6663,1,CHEMBL624639,,N
,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,646.0,80682,Homo sapiens,Expert,,9606.0,6302,,A549,,,,F,1,BAO_0000219,6663,1,CHEMBL624640,,N
,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,646.0,80682,Homo sapiens,Intermediate,,9606.0,6303,,A549,,,,F,1,BAO_0000219,6663,1,CHEMBL624641,,N
,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,646.0,80682,Homo sapiens,Intermediate,,9606.0,6304,,A549,,,,F,1,BAO_0000219,6663,1,CHEMBL624642,,N
,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,646.0,80682,Homo sapiens,Intermediate,,9606.0,6305,,A549,,,,F,1,BAO_0000219,6663,1,CHEMBL624643,,N
,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,646.0,80682,Homo sapiens,Intermediate,,9606.0,6306,,A549,,,,F,1,BAO_0000219,6663,1,CHEMBL624644,,N
,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,646.0,80682,Homo sapiens,Intermediate,,9606.0,6307,,A549,,,,F,1,BAO_0000219,6663,1,CHEMBL624645,,N
,,The compound was evaluated for its cytotoxic potency against A-549 cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6308,,A549,,,,F,1,BAO_0000219,3983,1,CHEMBL619445,,N
,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,646.0,80682,Homo sapiens,Expert,,9606.0,6309,,A549,,,,F,1,BAO_0000219,11141,1,CHEMBL839886,,N
,,Cytotoxic activity of compound against A-549 tumor cell line.,646.0,80682,Homo sapiens,Intermediate,,9606.0,6310,,A549,,,,F,1,BAO_0000219,5076,1,CHEMBL619446,,N
,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,646.0,80682,Homo sapiens,Intermediate,,9606.0,6311,,A549,,,,F,1,BAO_0000219,3311,1,CHEMBL619447,,N
,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,646.0,80682,Homo sapiens,Intermediate,,9606.0,6312,,A549,,,,F,1,BAO_0000219,3311,1,CHEMBL619448,,N
,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,646.0,80682,Homo sapiens,Intermediate,,9606.0,6313,,A549,,,,F,1,BAO_0000219,3311,1,CHEMBL619449,,N
,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,646.0,80682,Homo sapiens,Intermediate,,9606.0,6314,,A549,,,,F,1,BAO_0000219,5076,1,CHEMBL619450,,N
,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),646.0,80682,Homo sapiens,Intermediate,,9606.0,6315,,A549,,,,F,1,BAO_0000219,4150,1,CHEMBL619451,,N
,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,646.0,80682,Homo sapiens,Expert,,9606.0,6316,,A549,,,,F,1,BAO_0000219,2150,1,CHEMBL619452,,N
,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6317,,A549,,,,F,1,BAO_0000219,4644,1,CHEMBL619453,,N
,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,646.0,80682,Homo sapiens,Intermediate,,9606.0,6318,,A549,,,,F,1,BAO_0000219,263,1,CHEMBL874367,,N
,,Cytotoxic concentration against A-549 tumor cells.,646.0,80682,Homo sapiens,Intermediate,,9606.0,6319,,A549,,,,F,1,BAO_0000219,11333,1,CHEMBL619454,,N
,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,646.0,80682,Homo sapiens,Intermediate,,9606.0,6320,,A549,,,,F,1,BAO_0000219,11333,1,CHEMBL619455,,N
,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",646.0,80682,Homo sapiens,Intermediate,,9606.0,6321,,A549,,,,F,1,BAO_0000219,15895,1,CHEMBL619456,,N
,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,50191,Acinetobacter baumannii,Expert,,470.0,6322,,,,,,F,1,BAO_0000218,16677,1,CHEMBL619457,,N
,,Activity against Acinetobacter calcoaceticus (AC54),,50192,Acinetobacter calcoaceticus,Intermediate,,471.0,6323,,,,,,F,1,BAO_0000218,10624,1,CHEMBL619458,,N
,,In vitro antifungal activity against Aspergillus flavus CM74,,50274,Aspergillus flavus,Expert,,5059.0,6324,,,,,,F,1,BAO_0000218,16717,1,CHEMBL619459,,N
,,In vitro antifungal activity against Aspergillus flavus CM74,,50274,Aspergillus flavus,Expert,,5059.0,6325,,,,,,F,1,BAO_0000218,16717,1,CHEMBL619460,,N
,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,50416,Aspergillus fumigatus,Intermediate,,746128.0,6326,,,,,,F,1,BAO_0000218,5513,1,CHEMBL619461,,N
,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,50416,Aspergillus fumigatus,Intermediate,,746128.0,6327,,,,,,F,1,BAO_0000218,15962,1,CHEMBL619462,,N
,,Antimicrobial activity against Aspergillus fumigatus (MIC),,50416,Aspergillus fumigatus,Intermediate,,746128.0,6328,,,,,,F,1,BAO_0000218,15962,1,CHEMBL620388,,N
,,Antimicrobial activity against Aspergillus fumigatus (MIC),,50416,Aspergillus fumigatus,Intermediate,,746128.0,6329,,,,,,F,1,BAO_0000218,15962,1,CHEMBL620389,,N
,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,50416,Aspergillus fumigatus,Intermediate,,746128.0,6330,,,,,,F,1,BAO_0000218,15962,1,CHEMBL620390,,N
,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,50416,Aspergillus fumigatus,Expert,,746128.0,6331,,,,,,F,1,BAO_0000218,16717,1,CHEMBL620391,,N
,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,50416,Aspergillus fumigatus,Expert,,746128.0,6332,,,,,,F,1,BAO_0000218,16717,1,CHEMBL621073,,N
,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,50296,Actinomyces naeslundii,Intermediate,,1655.0,6333,,,,,,F,1,BAO_0000218,8117,1,CHEMBL621074,,N
,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,50366,Actinomyces viscosus,Intermediate,,1656.0,6334,,,,,,F,1,BAO_0000218,8117,1,CHEMBL621075,,N
,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,50535,Acanthocheilonema viteae,Intermediate,,6277.0,6335,,,,,,F,1,BAO_0000218,15472,1,CHEMBL619554,,N
,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,50535,Acanthocheilonema viteae,Intermediate,,6277.0,6336,,,,,,F,1,BAO_0000218,15472,1,CHEMBL619555,,N
,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,50169,Aggregatibacter actinomycetemcomitans,Intermediate,,714.0,6337,,,,,,F,1,BAO_0000218,16443,1,CHEMBL619556,,N
,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,50169,Aggregatibacter actinomycetemcomitans,Intermediate,,714.0,6338,,,,,,F,1,BAO_0000218,16443,1,CHEMBL619557,,N
,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,50169,Aggregatibacter actinomycetemcomitans,Intermediate,,714.0,6339,,,,,,F,1,BAO_0000218,16443,1,CHEMBL619558,,N
,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6340,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619559,,N
,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6341,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619560,,N
,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,646.0,80682,Homo sapiens,Intermediate,,9606.0,6342,,A549,,,,F,1,BAO_0000219,16381,1,CHEMBL619561,,N
,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,646.0,80682,Homo sapiens,Intermediate,,9606.0,6343,,A549,,,,F,1,BAO_0000219,16381,1,CHEMBL619562,,N
,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,646.0,80682,Homo sapiens,Intermediate,,9606.0,6344,,A549,,,,F,1,BAO_0000219,16381,1,CHEMBL619563,,N
,,GI values against A549 cells (lung cancer),646.0,80682,Homo sapiens,Intermediate,,9606.0,6345,,A549,,,,F,1,BAO_0000219,16381,1,CHEMBL857457,,N
,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6346,,A549,,,,F,1,BAO_0000219,17206,1,CHEMBL619564,,N
,,Inhibitory activity against A549 human adenocarcinoma,646.0,80682,Homo sapiens,Intermediate,,9606.0,6347,,A549,,,,F,1,BAO_0000219,16325,1,CHEMBL619565,,N
,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,646.0,80682,Homo sapiens,Intermediate,,9606.0,6348,,A549,,,,F,1,BAO_0000218,10708,1,CHEMBL619566,,N
,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,646.0,80682,Homo sapiens,Intermediate,,9606.0,6349,,A549,,,,F,1,BAO_0000218,10708,1,CHEMBL619567,,N
,,Inhibitory activity against A549 lung adenocarcinoma cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6350,,A549,,,,F,1,BAO_0000219,17376,1,CHEMBL619568,,N
,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,646.0,80682,Homo sapiens,Intermediate,,9606.0,6351,,A549,,,,F,1,BAO_0000219,17376,1,CHEMBL619569,,N
,,Cytotoxicity against human A549 lung cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6352,,A549,,,,F,1,BAO_0000219,17488,1,CHEMBL619570,,N
,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,646.0,80682,Homo sapiens,Intermediate,,9606.0,6353,,A549,,,,F,1,BAO_0000218,17404,1,CHEMBL619571,,N
,,Growth inhibition of A549 (human lung carcinoma) cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,6354,,A549,,,,F,1,BAO_0000219,10958,1,CHEMBL619572,,N
,,Effective dose required for inhibitory activity against A549 human tumor cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,6355,,A549,,,,F,1,BAO_0000219,17099,1,CHEMBL619573,,N
,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,646.0,80682,Homo sapiens,Intermediate,,9606.0,6356,,A549,,,,F,1,BAO_0000219,17099,1,CHEMBL619574,,N
,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,646.0,80682,Homo sapiens,Intermediate,,9606.0,6357,,A549,,,,F,1,BAO_0000219,4096,1,CHEMBL619575,,N
,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,646.0,80682,Homo sapiens,Expert,,9606.0,6358,,A549,,,,F,1,BAO_0000219,4096,1,CHEMBL619576,,N
,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,646.0,80682,Homo sapiens,Intermediate,,9606.0,6359,,A549,,,,F,1,BAO_0000219,4096,1,CHEMBL619577,,N
,,In vitro inhibitory activity against A549 tumor cell culture,646.0,80682,Homo sapiens,Intermediate,,9606.0,6360,,A549,,,,F,1,BAO_0000219,2525,1,CHEMBL619578,,N
,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,646.0,80682,Homo sapiens,Intermediate,,9606.0,6361,,A549,,,,F,1,BAO_0000219,2525,1,CHEMBL884009,,N
,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),646.0,80682,Homo sapiens,Intermediate,,9606.0,6362,,A549,,,,F,1,BAO_0000219,5302,1,CHEMBL619579,,N
,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,646.0,80682,Homo sapiens,Intermediate,,9606.0,6363,,A549,,,,F,1,BAO_0000219,16325,1,CHEMBL619580,,N
,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6364,,A549,,,,F,1,BAO_0000219,16939,1,CHEMBL619581,,N
,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,646.0,80682,Homo sapiens,Intermediate,,9606.0,6365,,A549,,,,F,1,BAO_0000219,17229,1,CHEMBL619582,,N
,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,646.0,80682,Homo sapiens,Intermediate,,9606.0,6366,,A549,,,,F,1,BAO_0000219,17380,1,CHEMBL619583,,N
,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,646.0,80682,Homo sapiens,Intermediate,,9606.0,6367,,A549,,,,F,1,BAO_0000219,17380,1,CHEMBL876502,,N
,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,646.0,80682,Homo sapiens,Intermediate,,9606.0,6368,,A549,,,,F,1,BAO_0000219,1903,1,CHEMBL619584,,N
,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,646.0,80682,Homo sapiens,Intermediate,,9606.0,6369,,A549,,,,F,1,BAO_0000219,3838,1,CHEMBL619585,,N
,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6370,,A549,,,,F,1,BAO_0000219,14696,1,CHEMBL619586,,N
,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,646.0,80682,Homo sapiens,Intermediate,,9606.0,6371,,A549,,,,F,1,BAO_0000219,3838,1,CHEMBL619587,,N
,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,646.0,80682,Homo sapiens,Intermediate,,9606.0,6372,,A549,,,,F,1,BAO_0000219,1522,1,CHEMBL619588,,N
,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,646.0,80682,Homo sapiens,Intermediate,,9606.0,6373,,A549,,,,F,1,BAO_0000219,12400,1,CHEMBL619589,,N
,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6374,,A549,,,,F,1,BAO_0000219,14696,1,CHEMBL619590,,N
,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),646.0,80682,Homo sapiens,Intermediate,,9606.0,6375,,A549,,,,F,1,BAO_0000219,14769,1,CHEMBL619591,,N
,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,646.0,80682,Homo sapiens,Intermediate,,9606.0,6376,,A549,,,,F,1,BAO_0000219,14696,1,CHEMBL619592,,N
,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,646.0,80682,Homo sapiens,Intermediate,,9606.0,6377,,A549,,,,F,1,BAO_0000219,1888,1,CHEMBL619593,,N
,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6378,,A549,,,,F,1,BAO_0000219,12016,1,CHEMBL620217,,N
,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,646.0,80682,Homo sapiens,Intermediate,,9606.0,6379,,A549,,,,F,1,BAO_0000219,6058,1,CHEMBL620218,,N
,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6380,,A549,,,,F,1,BAO_0000219,17708,1,CHEMBL620219,,N
,,Antitumor activity against A549/ATCC cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6381,,A549,,,,F,1,BAO_0000219,12301,1,CHEMBL620220,,N
,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,646.0,80682,Homo sapiens,Intermediate,,9606.0,6382,,A549,,,,F,1,BAO_0000219,11970,1,CHEMBL625141,,N
,,In vitro cytotoxicity against A549/ATCC cell line.,646.0,80682,Homo sapiens,Expert,,9606.0,6383,,A549,,,,F,1,BAO_0000219,11818,1,CHEMBL625142,,N
,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,646.0,80682,Homo sapiens,Intermediate,,9606.0,6384,,A549,,,,F,1,BAO_0000219,12400,1,CHEMBL625143,,N
,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,646.0,80682,Homo sapiens,Intermediate,,9606.0,6385,,A549,,,,F,1,BAO_0000219,3381,1,CHEMBL625144,,N
,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,646.0,80682,Homo sapiens,Intermediate,,9606.0,6386,,A549,,,,F,1,BAO_0000219,17376,1,CHEMBL622474,,N
,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,646.0,80682,Homo sapiens,Intermediate,,9606.0,6387,,A549,,,,F,1,BAO_0000219,10708,1,CHEMBL884104,,N
,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,22226,Homo sapiens,Autocuration,,9606.0,6388,,,,,,F,1,BAO_0000219,2964,0,CHEMBL622475,,U
,,Compound was tested for oral bioavailability in dogs,,22224,Canis lupus familiaris,Intermediate,,9615.0,6389,In vivo,,,,,A,1,BAO_0000218,5005,0,CHEMBL622476,,U
,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,50588,Canis lupus familiaris,Intermediate,,9615.0,6390,In vivo,,,,,A,1,BAO_0000218,6229,1,CHEMBL875831,,N
,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,50588,Canis lupus familiaris,Intermediate,,9615.0,6391,In vivo,,,,,A,1,BAO_0000218,6229,1,CHEMBL622477,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6392,In vivo,,,,,A,1,BAO_0000218,5374,1,CHEMBL622478,,N
,,Compound was tested for the oral bioavailability in dog; No availability,,50588,Canis lupus familiaris,Intermediate,,9615.0,6393,In vivo,,,,,A,1,BAO_0000218,5374,1,CHEMBL623172,,N
,,Oral bioavailability in dog (dose 5 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6394,In vivo,,,,,A,1,BAO_0000218,6265,1,CHEMBL623173,,N
,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6395,In vivo,,,,,A,1,BAO_0000218,5654,1,CHEMBL623174,,N
,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6396,In vivo,,,,,A,1,BAO_0000218,5654,1,CHEMBL623175,,N
,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6397,In vivo,,,,,A,1,BAO_0000218,16456,1,CHEMBL623340,,N
,,Oral bioavailability in dog (dose 5 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6398,In vivo,,,,,A,1,BAO_0000218,5302,1,CHEMBL623341,,N
,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,50588,Canis lupus familiaris,Intermediate,,9615.0,6399,In vivo,,,,,A,1,BAO_0000218,3624,1,CHEMBL623342,,N
,,Oral bioavailability of active FTIs in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6400,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL623343,,N
,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,50588,Canis lupus familiaris,Intermediate,,9615.0,6401,In vivo,,,,,A,1,BAO_0000218,5802,1,CHEMBL623344,,N
,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,50588,Canis lupus familiaris,Expert,,9615.0,6402,In vivo,,,,,A,1,BAO_0000218,3598,1,CHEMBL623345,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6403,In vivo,,,,,A,1,BAO_0000218,17839,1,CHEMBL875832,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6404,In vivo,,,,,A,1,BAO_0000218,6762,1,CHEMBL623346,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6405,In vivo,,,,,A,1,BAO_0000218,6821,1,CHEMBL623347,,N
,,Oral bioavailability of compound was determined in dog; Not tested,,50588,Canis lupus familiaris,Intermediate,,9615.0,6406,In vivo,,,,,A,1,BAO_0000218,6821,1,CHEMBL623348,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6407,In vivo,,,,,A,1,BAO_0000218,5210,1,CHEMBL623349,,N
,,Oral bioavailability (10 mg/kg) was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6408,In vivo,,,,,A,1,BAO_0000218,6227,1,CHEMBL623350,,N
,,Oral bioavailability,,50588,Canis lupus familiaris,Intermediate,,9615.0,6409,In vivo,,,,,A,1,BAO_0000218,761,1,CHEMBL623351,,N
,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,50588,Canis lupus familiaris,Intermediate,,9615.0,6410,In vivo,,,,,A,1,BAO_0000218,761,1,CHEMBL623352,,N
,,Oral bioavailability administered in solution in rats,,50588,Canis lupus familiaris,Intermediate,,9615.0,6411,In vivo,,,,,A,1,BAO_0000218,761,1,CHEMBL623353,,N
,,Oral bioavailability after 30 mg/kg po dose in Dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6412,In vivo,,,,,A,1,BAO_0000218,16907,1,CHEMBL875833,,N
,,Oral bioavailability at a dose of 1 mg/kg in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6413,In vivo,,,,,A,1,BAO_0000218,5474,1,CHEMBL623354,,N
,,Oral bioavailability in dog (dose 1 mg/kg p.o.),,50588,Canis lupus familiaris,Intermediate,,9615.0,6414,In vivo,,,,,A,1,BAO_0000218,6535,1,CHEMBL623355,,N
,,Oral bioavailability in Dog; ND = not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6415,In vivo,,,,,A,1,BAO_0000218,6535,1,CHEMBL623356,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6416,In vivo,,,,,A,1,BAO_0000218,3352,1,CHEMBL623357,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6417,In vivo,,,,,A,1,BAO_0000218,6168,1,CHEMBL623358,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6418,In vivo,,,,,A,1,BAO_0000218,5988,1,CHEMBL623359,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6419,In vivo,,,,,A,1,BAO_0000218,4942,1,CHEMBL623360,,N
,,Oral bioavailability in dogs; No data,,50588,Canis lupus familiaris,Intermediate,,9615.0,6420,In vivo,,,,,A,1,BAO_0000218,4942,1,CHEMBL623361,,N
,,Oral bioavailability measured in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6421,In vivo,,,,,A,1,BAO_0000218,14541,1,CHEMBL623362,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6422,In vivo,,,,,A,1,BAO_0000218,4449,1,CHEMBL623363,,N
,,Oral bioavailability was calculated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6423,In vivo,,,,,A,1,BAO_0000218,6057,1,CHEMBL623364,,N
,,Oral bioavailability after 0.3 mg/kg po administration in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6424,In vivo,,,,,A,1,BAO_0000218,5600,1,CHEMBL875834,,N
,,Oral bioavailability in dog (i.v. dosing),,50588,Canis lupus familiaris,Intermediate,,9615.0,6425,In vivo,,,,,A,1,BAO_0000218,5542,1,CHEMBL623365,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6426,In vivo,,,,,A,1,BAO_0000218,5542,1,CHEMBL623366,,N
,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6427,In vivo,,,,,A,1,BAO_0000218,5546,1,CHEMBL623367,,N
,,Oral bioavailability in Beagle dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6428,In vivo,,,,,A,1,BAO_0000218,4514,1,CHEMBL623368,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6429,In vivo,,,,,A,1,BAO_0000218,3624,1,CHEMBL623369,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6430,In vivo,,,,,A,1,BAO_0000218,3854,1,CHEMBL623370,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6431,In vivo,,,,,A,1,BAO_0000218,5836,1,CHEMBL623371,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6432,In vivo,,,,,A,1,BAO_0000218,5940,1,CHEMBL623372,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6433,In vivo,,,,,A,1,BAO_0000218,6168,1,CHEMBL621351,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6434,In vivo,,,,,A,1,BAO_0000218,6227,1,CHEMBL621352,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6435,In vivo,,,,,A,1,BAO_0000218,6251,1,CHEMBL621353,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6436,In vivo,,,,,A,1,BAO_0000218,6448,1,CHEMBL621354,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6437,In vivo,,,,,A,1,BAO_0000218,6647,1,CHEMBL621355,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6438,In vivo,,,,,A,1,BAO_0000218,5940,1,CHEMBL621356,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6439,In vivo,,,,,A,1,BAO_0000218,933,1,CHEMBL621357,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6440,In vivo,,,,,A,1,BAO_0000218,5210,1,CHEMBL621358,,N
,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,50588,Canis lupus familiaris,Intermediate,,9615.0,6441,In vivo,,,,,A,1,BAO_0000218,6642,1,CHEMBL621359,,N
,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,50588,Canis lupus familiaris,Intermediate,,9615.0,6442,In vivo,,,,,A,1,BAO_0000218,6641,1,CHEMBL621360,,N
,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,50588,Canis lupus familiaris,Intermediate,,9615.0,6443,In vivo,,,,,A,1,BAO_0000218,6642,1,CHEMBL621361,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6444,In vivo,,,,,A,1,BAO_0000218,5472,1,CHEMBL621362,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6445,In vivo,,,,,A,1,BAO_0000218,5985,1,CHEMBL621363,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6446,In vivo,,,,,A,1,BAO_0000218,15660,1,CHEMBL621364,,N
,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,50588,Canis lupus familiaris,Intermediate,,9615.0,6447,In vivo,,,,,A,1,BAO_0000218,5530,1,CHEMBL621166,,N
,,Oral bioavailability in dog (dose 1 mg/kg i.v.),,50588,Canis lupus familiaris,Intermediate,,9615.0,6448,In vivo,,,,,A,1,BAO_0000218,5530,1,CHEMBL621167,,N
,,Oral bioavailability (F) in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6449,In vivo,,,,,A,1,BAO_0000218,6305,1,CHEMBL621168,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6450,In vivo,,,,,A,1,BAO_0000218,5210,1,CHEMBL621169,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6451,In vivo,,,,,A,1,BAO_0000218,5238,1,CHEMBL875950,,N
,,Oral bioavailability in dog (dose 10 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6452,In vivo,,,,,A,1,BAO_0000218,5668,1,CHEMBL621170,,N
,,Oral bioavailability after peroral administration at 5 mpk in Dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6453,In vivo,,,,,A,1,BAO_0000218,5668,1,CHEMBL621171,,N
,,Oral bioavailability in dog (dose 5 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6454,In vivo,,,,,A,1,BAO_0000218,5668,1,CHEMBL621172,,N
,,Oral bioavailability in dog (dose 10 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6455,In vivo,,,,,A,1,BAO_0000218,6084,1,CHEMBL621173,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,2113.0,10090.0,6456,,CCRF S-180,,,Kidney,A,1,BAO_0000218,6599,1,CHEMBL621174,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,2113.0,10090.0,6457,,CCRF S-180,,,Kidney,A,1,BAO_0000218,6599,1,CHEMBL621175,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,2107.0,10090.0,6458,,CCRF S-180,,,Liver,A,1,BAO_0000218,6599,1,CHEMBL621176,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,2107.0,10090.0,6459,,CCRF S-180,,,Liver,A,1,BAO_0000218,6599,1,CHEMBL621177,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,2107.0,10090.0,6460,,CCRF S-180,,,Liver,A,1,BAO_0000218,6599,1,CHEMBL621178,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,2107.0,10090.0,6461,,CCRF S-180,,,Liver,A,1,BAO_0000218,6599,1,CHEMBL621179,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,2107.0,10090.0,6462,,CCRF S-180,,,Liver,A,1,BAO_0000218,6599,1,CHEMBL621180,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,2048.0,10090.0,6463,,CCRF S-180,,,Lung,A,1,BAO_0000218,6599,1,CHEMBL875951,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,2048.0,10090.0,6464,,CCRF S-180,,,Lung,A,1,BAO_0000218,6599,1,CHEMBL621181,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,2048.0,10090.0,6465,,CCRF S-180,,,Lung,A,1,BAO_0000218,6599,1,CHEMBL621182,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,2048.0,10090.0,6466,,CCRF S-180,,,Lung,A,1,BAO_0000218,6599,1,CHEMBL621183,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,2048.0,10090.0,6467,,CCRF S-180,,,Lung,A,1,BAO_0000218,6599,1,CHEMBL621184,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,,10090.0,6468,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621185,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6469,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621186,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,,10090.0,6470,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621187,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6471,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621188,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6472,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621189,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,2106.0,10090.0,6473,,CCRF S-180,,,Spleen,A,1,BAO_0000218,6599,1,CHEMBL621190,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,2106.0,10090.0,6474,,CCRF S-180,,,Spleen,A,1,BAO_0000218,6599,1,CHEMBL618520,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,2106.0,10090.0,6475,,CCRF S-180,,,Spleen,A,1,BAO_0000218,6599,1,CHEMBL621739,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,2106.0,10090.0,6476,,CCRF S-180,,,Spleen,A,1,BAO_0000218,6599,1,CHEMBL621740,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,2106.0,10090.0,6477,,CCRF S-180,,,Spleen,A,1,BAO_0000218,6599,1,CHEMBL621741,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,,10090.0,6478,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621742,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6479,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621743,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,,10090.0,6480,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621744,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6481,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621745,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6482,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621746,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,,10090.0,6483,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621747,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6484,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621748,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,,10090.0,6485,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621749,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6486,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621750,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6487,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL621751,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,948.0,10090.0,6488,,CCRF S-180,,,Heart,A,1,BAO_0000218,6599,1,CHEMBL621752,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,948.0,10090.0,6489,,CCRF S-180,,,Heart,A,1,BAO_0000218,6599,1,CHEMBL621753,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,948.0,10090.0,6490,,CCRF S-180,,,Heart,A,1,BAO_0000218,6599,1,CHEMBL875955,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,948.0,10090.0,6491,,CCRF S-180,,,Heart,A,1,BAO_0000218,6599,1,CHEMBL621754,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,948.0,10090.0,6492,,CCRF S-180,,,Heart,A,1,BAO_0000218,6599,1,CHEMBL621755,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,2107.0,10090.0,6493,,CCRF S-180,,,Liver,A,1,BAO_0000218,6599,1,CHEMBL621756,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,2107.0,10090.0,6494,,CCRF S-180,,,Liver,A,1,BAO_0000218,6599,1,CHEMBL624199,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,2107.0,10090.0,6495,,CCRF S-180,,,Liver,A,1,BAO_0000218,6599,1,CHEMBL624200,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,2107.0,10090.0,6496,,CCRF S-180,,,Liver,A,1,BAO_0000218,6599,1,CHEMBL624375,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,2107.0,10090.0,6497,,CCRF S-180,,,Liver,A,1,BAO_0000218,6599,1,CHEMBL624376,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,2048.0,10090.0,6498,,CCRF S-180,,,Lung,A,1,BAO_0000218,6599,1,CHEMBL624377,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,2048.0,10090.0,6499,,CCRF S-180,,,Lung,A,1,BAO_0000218,6599,1,CHEMBL624378,,N
,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,50067,aeinetobacter anitrotap,Intermediate,,107673.0,6500,,,,,,F,1,BAO_0000218,12269,1,CHEMBL857901,,N
,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,50067,Acinetobacter calcoaceticus subsp. anitratus,Intermediate,,107673.0,6501,,,,,,F,1,BAO_0000218,12269,1,CHEMBL875274,,N
,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,50067,Acinetobacter calcoaceticus subsp. anitratus,Intermediate,,107673.0,6502,,,,,,F,1,BAO_0000218,12269,1,CHEMBL624379,,N
,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,50067,aeinetobacter anitrotap,Intermediate,,107673.0,6503,,,,,,F,1,BAO_0000218,12269,1,CHEMBL624380,,N
,,Activity against Acinetobacter calcoaceticus (AC54),,50192,Acinetobacter calcoaceticus,Intermediate,,471.0,6504,,,,,,F,1,BAO_0000218,10624,1,CHEMBL624381,,N
,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,50714,Anolis carolinensis,Intermediate,,28377.0,6505,,,,,,F,1,BAO_0000218,17216,1,CHEMBL624382,,N
,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,50714,Anolis carolinensis,Intermediate,,28377.0,6506,,,,,,F,1,BAO_0000218,17216,1,CHEMBL624383,,N
,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,50296,Actinomyces naeslundii,Intermediate,,1655.0,6507,,,,,,F,1,BAO_0000218,9560,1,CHEMBL624384,,N
,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,50296,Actinomyces naeslundii,Intermediate,,1655.0,6508,,,,,,F,1,BAO_0000218,9560,1,CHEMBL624385,,N
,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,50296,Actinomyces naeslundii,Intermediate,,1655.0,6509,,,,,,F,1,BAO_0000218,9560,1,CHEMBL624386,,N
,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,50296,Actinomyces naeslundii,Intermediate,,1655.0,6510,,,,,,F,1,BAO_0000218,9560,1,CHEMBL624387,,N
,,Plaque bactericidal index against Actinomyces naeslundii 631,,50296,Actinomyces naeslundii,Intermediate,,1655.0,6511,,,,,,F,1,BAO_0000218,9560,1,CHEMBL624388,,N
,,Plaque bactericidal index against Actinomyces naeslundii N/9,,50296,Actinomyces naeslundii,Intermediate,,1655.0,6512,,,,,,F,1,BAO_0000218,9560,1,CHEMBL624389,,N
,,Plaque bactericidal index against Actinomyces naeslundii B74,,50296,Actinomyces naeslundii,Intermediate,,1655.0,6513,,,,,,F,1,BAO_0000218,9560,1,CHEMBL624390,,N
,,Plaque bactericidal index against Actinomyces naeslundii N/3,,50296,Actinomyces naeslundii,Intermediate,,1655.0,6514,,,,,,F,1,BAO_0000218,9560,1,CHEMBL875275,,N
,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,50056,Artemia salina,Intermediate,,85549.0,6515,,,,,,F,1,BAO_0000218,114,1,CHEMBL624391,,N
,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,50056,Artemia salina,Intermediate,,85549.0,6516,,,,,,F,1,BAO_0000218,114,1,CHEMBL623636,,N
,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,50532,Ascaris suum,Intermediate,,6253.0,6517,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623637,,N
,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,50532,Ascaris suum,Intermediate,,6253.0,6518,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623638,,N
,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,50532,Ascaris suum,Intermediate,,6253.0,6519,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623639,,N
,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,50532,Ascaris suum,Intermediate,,6253.0,6520,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623640,,N
,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,50532,Ascaris suum,Intermediate,,6253.0,6521,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623641,,N
,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,50532,Ascaris suum,Intermediate,,6253.0,6522,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623642,,N
,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,50532,Ascaris suum,Intermediate,,6253.0,6523,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623643,,N
,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,50532,Ascaris suum,Intermediate,,6253.0,6524,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623644,,N
,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,50532,Ascaris suum,Intermediate,,6253.0,6525,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623645,,N
,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,50532,Ascaris suum,Intermediate,,6253.0,6526,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623646,,N
,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,50532,Ascaris suum,Intermediate,,6253.0,6527,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623647,,N
,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,50532,Ascaris suum,Intermediate,,6253.0,6528,,,,,,F,1,BAO_0000218,10841,1,CHEMBL623648,,N
,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,50366,Actinomyces viscosus,Intermediate,,1656.0,6529,,,,,,F,1,BAO_0000218,8117,1,CHEMBL623649,,N
,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,50366,Actinomyces viscosus,Intermediate,,1656.0,6530,,,,,,F,1,BAO_0000218,8117,1,CHEMBL623650,,N
,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,50366,Actinomyces viscosus,Intermediate,,1656.0,6531,,,,,,F,1,BAO_0000218,9560,1,CHEMBL623651,,N
,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,50366,Actinomyces viscosus,Expert,,1656.0,6532,,,,,,F,1,BAO_0000218,9560,1,CHEMBL623652,,N
,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,50366,Actinomyces viscosus,Intermediate,,1656.0,6533,,,,,,F,1,BAO_0000218,9560,1,CHEMBL623653,,N
,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,50366,Actinomyces viscosus,Intermediate,,1656.0,6534,,,,,,F,1,BAO_0000218,9560,1,CHEMBL623654,,N
,,Plaque bactericidal index against Actinomyces viscosus 8A06,,50366,Actinomyces viscosus,Intermediate,,1656.0,6535,,,,,,F,1,BAO_0000218,9560,1,CHEMBL623655,,N
,,Plaque bactericidal index against Actinomyces viscosus M-100,,50366,Actinomyces viscosus,Intermediate,,1656.0,6536,,,,,,F,1,BAO_0000218,9560,1,CHEMBL623656,,N
,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,50366,Actinomyces viscosus,Expert,,1656.0,6537,,,,,,F,1,BAO_0000218,9560,1,CHEMBL623657,,N
,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,50366,Actinomyces viscosus,Intermediate,,1656.0,6538,,,,,,F,1,BAO_0000218,9560,1,CHEMBL623658,,N
,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,50366,Actinomyces viscosus,Intermediate,,1656.0,6539,,,,,,F,1,BAO_0000218,9560,1,CHEMBL623659,,N
,,Plaque bactericidal index against Actinomyces viscosus 626,,50366,Actinomyces viscosus,Intermediate,,1656.0,6540,,,,,,F,1,BAO_0000218,9560,1,CHEMBL623660,,N
,,Plaque bactericidal index against Actinomyces viscosus T14V,,50366,Actinomyces viscosus,Intermediate,,1656.0,6541,,,,,,F,1,BAO_0000218,9560,1,CHEMBL623661,,N
,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,50535,Acanthocheilonema viteae,Intermediate,,6277.0,6542,,,,,,F,1,BAO_0000218,10986,1,CHEMBL875281,,N
,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,50535,Acanthocheilonema viteae,Intermediate,,6277.0,6543,,,,,,F,1,BAO_0000218,10986,1,CHEMBL623662,,N
,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,50535,Acanthocheilonema viteae,Intermediate,,6277.0,6544,,,,,,F,1,BAO_0000218,10986,1,CHEMBL623663,,N
,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,50535,Acanthocheilonema viteae,Intermediate,,6277.0,6545,,,,,,F,1,BAO_0000218,10986,1,CHEMBL623664,,N
,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,50535,Acanthocheilonema viteae,Intermediate,,6277.0,6546,,,,,,F,1,BAO_0000218,10986,1,CHEMBL623665,,N
,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,165.0,80023,Homo sapiens,Intermediate,,9606.0,6547,,A673,,,,F,1,BAO_0000219,10708,1,CHEMBL621856,,N
,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,645.0,80661,Homo sapiens,Intermediate,,9606.0,6548,,A704,,,,F,1,BAO_0000219,10708,1,CHEMBL620432,,N
,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,22226,Rattus norvegicus,Autocuration,,10116.0,6549,,,,,,F,1,BAO_0000219,416,0,CHEMBL620433,,U
,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,625.0,80024,Mus musculus,Intermediate,,10090.0,6550,,A9,,,,F,1,BAO_0000219,14354,1,CHEMBL620434,,N
,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,625.0,80024,Mus musculus,Intermediate,,10090.0,6551,,A9,,,,F,1,BAO_0000219,14354,1,CHEMBL620435,,N
,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,625.0,80024,Homo sapiens,Intermediate,,9606.0,6552,,A9,,,,F,1,BAO_0000219,5116,1,CHEMBL620436,,N
,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,625.0,80024,Homo sapiens,Intermediate,,9606.0,6553,,A9,,,,F,1,BAO_0000219,5116,1,CHEMBL876597,,N
,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,874.0,81037,Homo sapiens,Expert,,9606.0,6554,,Human ovarian carcinoma cell line,,,,F,1,BAO_0000219,15694,1,CHEMBL620437,,N
,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",625.0,80024,Mus musculus,Expert,,10090.0,6555,,A9,,,,F,1,BAO_0000219,13038,1,CHEMBL620438,,N
,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,625.0,80024,Mus musculus,Expert,,10090.0,6556,,A9,,,,F,1,BAO_0000219,13038,1,CHEMBL620439,,N
,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,625.0,80024,Mus musculus,Expert,,10090.0,6557,,A9,,,,F,1,BAO_0000219,10923,1,CHEMBL619657,,N
,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,625.0,80024,Mus musculus,Intermediate,,10090.0,6558,,A9,,,,F,1,BAO_0000219,10923,1,CHEMBL619658,,N
,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,625.0,80024,Mus musculus,Intermediate,,10090.0,6559,,A9,,,,F,1,BAO_0000219,10923,1,CHEMBL619659,,N
,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,10649,,Expert,,,6560,,,,,,F,1,BAO_0000019,10923,8,CHEMBL619660,,H
,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,625.0,80024,Mus musculus,Intermediate,,10090.0,6561,,A9,,,,F,1,BAO_0000219,10923,1,CHEMBL619661,,N
,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,625.0,80024,Mus musculus,Intermediate,,10090.0,6562,,A9,,,,F,1,BAO_0000219,10923,1,CHEMBL619662,,N
,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,975.0,80663,Cricetulus griseus,Intermediate,,10029.0,6563,,AA6,,,,F,1,BAO_0000219,8158,1,CHEMBL619663,,N
,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,22226,Homo sapiens,Autocuration,,9606.0,6564,,,,,,F,1,BAO_0000219,15494,0,CHEMBL619664,,U
,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,22226,Homo sapiens,Autocuration,,9606.0,6565,,,,,,F,1,BAO_0000219,15494,0,CHEMBL619665,,U
,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),974.0,80662,Homo sapiens,Intermediate,,9606.0,6566,,AA5,,,,F,1,BAO_0000219,12348,1,CHEMBL883244,,N
,,Cytotoxicity was measured against AA5/HIV-1(IIIB),974.0,80662,Homo sapiens,Intermediate,,9606.0,6567,,AA5,,,,F,1,BAO_0000219,12348,1,CHEMBL884011,,N
,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,974.0,80662,Homo sapiens,Intermediate,,9606.0,6568,,AA5,,,,F,1,BAO_0000219,2726,1,CHEMBL619666,,N
,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,379.0,80566,Homo sapiens,Intermediate,,9606.0,6569,,U-937,,,,F,1,BAO_0000219,2726,1,CHEMBL619667,,N
,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,274.0,80578,Cricetulus griseus,Intermediate,,10029.0,6570,,UV4,,,,F,1,BAO_0000219,10747,1,CHEMBL619668,,N
,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",185.0,80089,Cricetulus griseus,Expert,,10029.0,6571,,CHO-AA8,,,,F,1,BAO_0000219,11005,1,CHEMBL619669,,N
,,Average intracellular compound concentration when the hypoxic SER=1.6,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6572,,CHO-AA8,,,,F,1,BAO_0000219,12687,1,CHEMBL876608,,N
,,Average intracellular compound concentration when the hypoxic SER=1.6.,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6573,,CHO-AA8,,,,F,1,BAO_0000219,12687,1,CHEMBL619670,,N
,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6574,,CHO-AA8,,,,F,1,BAO_0000219,12687,1,CHEMBL619671,,N
,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6575,,CHO-AA8,,,,F,1,BAO_0000219,12687,1,CHEMBL619672,,N
,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6576,,CHO-AA8,,,,F,1,BAO_0000219,12687,1,CHEMBL619673,,N
,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6577,,CHO-AA8,,,,F,1,BAO_0000219,13436,1,CHEMBL619674,,N
,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6578,,CHO-AA8,,,,F,1,BAO_0000219,13435,1,CHEMBL619675,,N
,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6579,,CHO-AA8,,,,F,1,BAO_0000219,13302,1,CHEMBL619676,,N
,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6580,,CHO-AA8,,,,F,1,BAO_0000219,12687,1,CHEMBL619677,,N
,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6581,,CHO-AA8,,,,A,1,BAO_0000219,12687,1,CHEMBL619678,,N
,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6582,,CHO-AA8,,,,A,1,BAO_0000219,12687,1,CHEMBL619679,,N
,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,185.0,80089,Cricetulus griseus,Expert,,10029.0,6583,,CHO-AA8,,,,A,1,BAO_0000219,12878,1,CHEMBL619680,,N
,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6584,,CHO-AA8,,,,A,1,BAO_0000219,12878,1,CHEMBL621457,,N
,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,185.0,80089,Cricetulus griseus,Expert,,10029.0,6585,,CHO-AA8,,,,F,1,BAO_0000219,14367,1,CHEMBL876609,,N
,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6586,,CHO-AA8,,,,F,1,BAO_0000219,14367,1,CHEMBL621458,,N
,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,185.0,80089,hampster,Expert,,36483.0,6587,,CHO-AA8,,,,F,1,BAO_0000219,12398,1,CHEMBL621459,,N
,,Aerobic growth inhibition in Chinese hamster cell line AA8,185.0,80089,Cricetulus griseus,Expert,,10029.0,6588,,CHO-AA8,,,,F,1,BAO_0000219,12878,1,CHEMBL621460,,N
,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,185.0,80089,Cricetulus griseus,Expert,,10029.0,6589,,CHO-AA8,,,,F,1,BAO_0000219,13820,1,CHEMBL621461,,N
,,Inhibition of growth under aerobic conditions in AA8 cells,185.0,80089,Cricetulus griseus,Expert,,10029.0,6590,,CHO-AA8,,,,F,1,BAO_0000219,13436,1,CHEMBL621462,,N
,,Oral bioavailability in dog (dose 10 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6591,In vivo,,,,,A,1,BAO_0000218,6084,1,CHEMBL621463,,N
,,Oral bioavailability in dog at 10 mg/kg of the compound,,50588,Canis lupus familiaris,Intermediate,,9615.0,6592,In vivo,,,,,A,1,BAO_0000218,5711,1,CHEMBL621464,,N
,,Oral bioavailability in dog (dose 5 uM/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6593,In vivo,,,,,A,1,BAO_0000218,4353,1,CHEMBL621465,,N
,,Oral bioavailability in dog (dose 5 uM/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6594,In vivo,,,,,A,1,BAO_0000218,4353,1,CHEMBL621466,,N
,,Oral bioavailability in dog (mongrel),,50588,Canis lupus familiaris,Intermediate,,9615.0,6595,In vivo,,,,,A,1,BAO_0000218,17800,1,CHEMBL621467,,N
,,Oral bioavailability in dog (dose 10 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6596,In vivo,,,,,A,1,BAO_0000218,3994,1,CHEMBL621468,,N
,,Oral bioavailability in dog (dose 10 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6597,In vivo,,,,,F,1,BAO_0000218,3994,1,CHEMBL876734,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6598,In vivo,,,,,A,1,BAO_0000218,5145,1,CHEMBL618476,,N
,,Bioavailability in dog (dose 1 mg/kg i.v.),,50588,Canis lupus familiaris,Intermediate,,9615.0,6599,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL618477,,N
,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,50588,Canis lupus familiaris,Intermediate,,9615.0,6600,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL618478,,N
,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6601,In vivo,,,,,A,1,BAO_0000218,5983,1,CHEMBL618479,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6602,In vivo,,,,,A,1,BAO_0000218,4273,1,CHEMBL618480,,N
,,Bioavailability in dog (dose 3-10 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6603,In vivo,,,,,A,1,BAO_0000218,12500,1,CHEMBL618481,,N
,,The compound was tested for bioavailability of compound in plasma of dog; Complete,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6604,In vivo,,,,Plasma,A,1,BAO_0000218,12500,1,CHEMBL618482,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6605,In vivo,,,,,A,1,BAO_0000218,3639,1,CHEMBL618483,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6606,In vivo,,,,,A,1,BAO_0000218,3880,1,CHEMBL618484,,N
,,Bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6607,In vivo,,,,,A,1,BAO_0000218,4838,1,CHEMBL618485,,N
,,oral bioavailability was measured in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6608,In vivo,,,,,A,1,BAO_0000218,15600,1,CHEMBL618486,,N
,,Compound was tested for plasma protein binding in dog; Not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6609,,,,,,A,1,BAO_0000218,17248,1,CHEMBL618487,,N
,,Compound was tested for plasma protein binding of dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6610,,,,,,A,1,BAO_0000218,17248,1,CHEMBL618488,,N
,,Compound was tested for plasma protein binding of dog; Not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6611,,,,,,A,1,BAO_0000218,17248,1,CHEMBL876735,,N
,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,50588,Canis lupus familiaris,Intermediate,,9615.0,6612,,,,,,A,1,BAO_0000218,17443,1,CHEMBL618489,,N
,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,50588,Canis lupus familiaris,Intermediate,,9615.0,6613,In vivo,,,,,A,1,BAO_0000218,4186,1,CHEMBL618490,,N
,,Half life was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6614,,,,,,A,1,BAO_0000218,3749,1,CHEMBL618491,,N
,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6615,In vivo,,,,,A,1,BAO_0000218,3249,1,CHEMBL618492,,N
,,Half life was evaluated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6616,,,,,,A,1,BAO_0000218,3022,1,CHEMBL873354,,N
,,Half life was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6617,,,,,,A,1,BAO_0000218,3749,1,CHEMBL618493,,N
,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588,Canis lupus familiaris,Intermediate,,9615.0,6618,In vivo,,,,,A,1,BAO_0000218,2517,1,CHEMBL618494,,N
,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588,Canis lupus familiaris,Intermediate,948.0,9615.0,6619,In vivo,,,,Heart,A,1,BAO_0000218,2517,1,CHEMBL618495,,N
,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588,Canis lupus familiaris,Intermediate,2113.0,9615.0,6620,In vivo,,,,Kidney,A,1,BAO_0000218,2517,1,CHEMBL618496,,N
,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588,Canis lupus familiaris,Intermediate,2107.0,9615.0,6621,In vivo,,,,Liver,A,1,BAO_0000218,2517,1,CHEMBL618497,,N
,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588,Canis lupus familiaris,Intermediate,2048.0,9615.0,6622,In vivo,,,,Lung,A,1,BAO_0000218,2517,1,CHEMBL618498,,N
,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,50588,Canis lupus familiaris,Intermediate,2106.0,9615.0,6623,In vivo,,,,Spleen,A,1,BAO_0000218,2517,1,CHEMBL618499,,N
,,LogP in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6624,,,,,,A,1,BAO_0000218,3639,1,CHEMBL876736,,N
,,Partition coefficient (logP),,50588,Canis lupus familiaris,Intermediate,,9615.0,6625,,,,,,A,1,BAO_0000218,6227,1,CHEMBL618500,,N
,,Partition coefficient in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6626,,,,,,A,1,BAO_0000218,6227,1,CHEMBL857831,,N
,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6627,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL618501,,N
,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6628,In vivo,,,,,A,1,BAO_0000218,4809,1,CHEMBL618502,,N
,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,50588,Canis lupus familiaris,Intermediate,,9615.0,6629,,,,,,A,1,BAO_0000218,5600,1,CHEMBL618503,,N
,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,50588,Canis lupus familiaris,Intermediate,,9615.0,6630,,,,,,A,1,BAO_0000218,14294,1,CHEMBL618504,,N
,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,50588,Canis lupus familiaris,Intermediate,,9615.0,6631,,,,,,A,1,BAO_0000218,14294,1,CHEMBL618505,,N
,,Metabolism of compound in dog S9 microsomes; Trace,,50588,Canis lupus familiaris,Intermediate,,9615.0,6632,,,,,,A,1,BAO_0000218,14294,1,CHEMBL618506,,N
,,In vitro metabolic potential in dog liver microsomes,,50588,Canis lupus familiaris,Intermediate,2107.0,9615.0,6633,,,,,Liver,A,1,BAO_0000218,6251,1,CHEMBL618507,,N
,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6634,In vivo,,,,,A,1,BAO_0000218,3748,1,CHEMBL876737,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6635,In vivo,,,,,A,1,BAO_0000218,2713,1,CHEMBL618508,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6636,In vivo,,,,,A,1,BAO_0000218,6512,1,CHEMBL618509,,N
,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6637,In vivo,,,,,A,1,BAO_0000218,6679,1,CHEMBL618510,,N
,,The compound was tested for bioavailability in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6638,In vivo,,,,,A,1,BAO_0000218,3749,1,CHEMBL618511,,N
,,The compound was tested for oral bioavailability in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6639,In vivo,,,,,A,1,BAO_0000218,3749,1,CHEMBL618512,,N
,,Oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6640,In vivo,,,,,A,1,BAO_0000218,6742,1,CHEMBL618513,,N
,,Compound was tested for percent protein binding (PB) in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6641,,,,,,A,1,BAO_0000218,6227,1,CHEMBL618514,,N
,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,50588,Canis lupus familiaris,Intermediate,,9615.0,6642,,,,,,A,1,BAO_0000218,6874,1,CHEMBL620052,,N
,,Compound was evaluated for plasma clearance.,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6643,In vivo,,,,Plasma,A,1,BAO_0000218,2877,1,CHEMBL620053,,N
,,The compound was tested for plasma clearance in dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6644,In vivo,,,,Plasma,A,1,BAO_0000218,12500,1,CHEMBL620054,,N
,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6645,In vivo,,,,Plasma,A,1,BAO_0000218,12500,1,CHEMBL620055,,N
,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6646,,,,,,A,1,BAO_0000218,4709,1,CHEMBL620056,,N
,,In vitro relative rate of metabolism was determined in dog liver microsomes,,50588,Canis lupus familiaris,Intermediate,2107.0,9615.0,6647,,,,,Liver,A,1,BAO_0000218,5542,1,CHEMBL620057,,N
,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6648,In vivo,,,,,A,1,BAO_0000218,17594,1,CHEMBL618939,,N
,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,50588,Canis lupus familiaris,Intermediate,,9615.0,6649,In vivo,,,,,A,1,BAO_0000218,2652,1,CHEMBL618940,,N
,,Half life after intravenous administration in dogs at 1.2 uM/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6650,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL618941,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,2048.0,10090.0,6651,,CCRF S-180,,,Lung,A,1,BAO_0000218,6599,1,CHEMBL624473,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,2048.0,10090.0,6652,,CCRF S-180,,,Lung,A,1,BAO_0000218,6599,1,CHEMBL624474,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,2048.0,10090.0,6653,,CCRF S-180,,,Lung,A,1,BAO_0000218,6599,1,CHEMBL624475,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,42.0,50594,Mus musculus,Intermediate,,10090.0,6654,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL624476,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6655,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL623478,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,42.0,50594,Mus musculus,Intermediate,,10090.0,6656,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL623479,,N
,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6657,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL623480,,N
,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,42.0,50594,Mus musculus,Intermediate,,10090.0,6658,,CCRF S-180,,,,A,1,BAO_0000218,6599,1,CHEMBL623481,,N
,,C2 in brain of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,955.0,10090.0,6659,,,,,Brain,A,1,BAO_0000218,17641,1,CHEMBL623482,,N
,,C2 in kidney of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2113.0,10090.0,6660,,,,,Kidney,A,1,BAO_0000218,17641,1,CHEMBL623483,,N
,,C2 in liver of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2107.0,10090.0,6661,,,,,Liver,A,1,BAO_0000218,17641,1,CHEMBL623484,,N
,,C2 in lungs of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2048.0,10090.0,6662,,,,,Lung,A,1,BAO_0000218,17641,1,CHEMBL623485,,N
,,C2 in spleen of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2106.0,10090.0,6663,,,,,Spleen,A,1,BAO_0000218,17641,1,CHEMBL623486,,N
,,Plasma clearance in mouse,,50594,Mus musculus,Intermediate,,10090.0,6664,In vivo,,,,,A,1,BAO_0000218,17852,1,CHEMBL623487,,N
,,Clearance of compound after intravenous administration in mice at 24 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,6665,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL623488,,N
,,Clearance from mouse blood following i.v. administration of 10 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,6666,In vivo,,,,,A,1,BAO_0000218,17837,1,CHEMBL623489,,N
,,Clearance was evaluated in mice after intravenous administration,,50594,Mus musculus,Intermediate,,10090.0,6667,In vivo,,,,,A,1,BAO_0000218,2675,1,CHEMBL875157,,N
,,Clearance was evaluated in mice after oral administration,,50594,Mus musculus,Intermediate,,10090.0,6668,In vivo,,,,,A,1,BAO_0000218,2675,1,CHEMBL623490,,N
,,Pharmacokinetic property (Plasma clearance) was measured in mouse,,50594,Mus musculus,Intermediate,,10090.0,6669,In vivo,,,,,A,1,BAO_0000218,4239,1,CHEMBL623491,,N
,,Plasma clearance of compound was determined at 40 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,6670,In vivo,,,,,A,1,BAO_0000218,17753,1,CHEMBL623492,,N
,,Plasma clearance of at 24 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,6671,In vivo,,,,,A,1,BAO_0000218,17753,1,CHEMBL623493,,N
,,Plasma clearance at 24 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,6672,In vivo,,,,,A,1,BAO_0000218,17753,1,CHEMBL623494,,N
,,Plasma clearance at 5 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,6673,In vivo,,,,,A,1,BAO_0000218,17753,1,CHEMBL623495,,N
,,Plasma clearance in mice,,50594,Mus musculus,Intermediate,,10090.0,6674,In vivo,,,,,A,1,BAO_0000218,5727,1,CHEMBL623496,,N
,,Plasma clearance value upon iv administration in mouse,,50594,Mus musculus,Intermediate,,10090.0,6675,In vivo,,,,,A,1,BAO_0000218,2862,1,CHEMBL623497,,N
,,Total plasma clearance in mice,,50594,Mus musculus,Intermediate,1969.0,10090.0,6676,In vivo,,,,Plasma,A,1,BAO_0000218,5980,1,CHEMBL623498,,N
,,Clearance in mouse,,50594,Mus musculus,Intermediate,,10090.0,6677,In vivo,,,,,A,1,BAO_0000218,17592,1,CHEMBL623499,,N
,,Clearance value was determined,,50594,Mus musculus,Intermediate,,10090.0,6678,In vivo,,,,,A,1,BAO_0000218,17718,1,CHEMBL623500,,N
,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,50594,Mus musculus,Intermediate,,10090.0,6679,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL623501,,N
,,Calculated partition coefficient (clogP),,22229,,Intermediate,,,6680,,,,,,P,1,BAO_0000100,17384,0,CHEMBL875158,,U
,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,6681,In vivo,,,,,A,1,BAO_0000218,6062,1,CHEMBL623502,,N
,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,6682,In vivo,,,,,A,1,BAO_0000218,17734,1,CHEMBL623503,,N
,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,50594,Mus musculus,Intermediate,,10090.0,6683,In vivo,,,,,A,1,BAO_0000218,6348,1,CHEMBL623504,,N
,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,6684,In vivo,,,,,A,1,BAO_0000218,5969,1,CHEMBL623505,,N
,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,6685,In vivo,,,,,A,1,BAO_0000218,5969,1,CHEMBL623506,,N
,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,50594,Mus musculus,Intermediate,,10090.0,6686,In vivo,,,,,A,1,BAO_0000218,5969,1,CHEMBL623507,,N
,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,50594,Mus musculus,Intermediate,,10090.0,6687,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL623508,,N
,,Cmax after oral administration at 30 mg/kg in ICR mouse,,50594,Mus musculus,Intermediate,,10090.0,6688,In vivo,,,,,A,1,BAO_0000218,5781,1,CHEMBL623509,,N
,,Cmax after peroral administration in mice at 2.4 uM/kg,,50594,Mus musculus,Intermediate,,10090.0,6689,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL875159,,N
,,Cmax in brain of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,955.0,10090.0,6690,In vivo,,,,Brain,A,1,BAO_0000218,17641,1,CHEMBL623510,,N
,,Cmax in kidney of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2113.0,10090.0,6691,In vivo,,,,Kidney,A,1,BAO_0000218,17641,1,CHEMBL623511,,N
,,Cmax in liver of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2107.0,10090.0,6692,In vivo,,,,Liver,A,1,BAO_0000218,17641,1,CHEMBL623512,,N
,,Cmax in lungs of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2048.0,10090.0,6693,In vivo,,,,Lung,A,1,BAO_0000218,17641,1,CHEMBL623513,,N
,,Cmax in mice at 18 uM/kg i.p. administration,,50594,Mus musculus,Intermediate,,10090.0,6694,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL623514,,N
,,Cmax in mice at 23 uM/kg i.v. administration,,50594,Mus musculus,Intermediate,,10090.0,6695,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL622609,,N
,,Cmax in mice at 24 uM/kg i.p. administration,,50594,Mus musculus,Intermediate,,10090.0,6696,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL622610,,N
,,Cmax in mice at 25 uM/kg i.p. administration,,50594,Mus musculus,Intermediate,,10090.0,6697,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL621823,,N
,,Cmax in mice at 26 uM/kg i.p. administration,,50594,Mus musculus,Intermediate,,10090.0,6698,In vivo,,,,,F,1,BAO_0000218,17764,1,CHEMBL621824,,N
,,Cmax in spleen of mice at the oral dose of 50 mg/kg,,50594,Mus musculus,Intermediate,2106.0,10090.0,6699,In vivo,,,,Spleen,A,1,BAO_0000218,17641,1,CHEMBL621825,,N
,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,50594,Mus musculus,Intermediate,,10090.0,6700,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL621826,,N
,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,50594,Mus musculus,Intermediate,,10090.0,6701,In vivo,,,,,A,1,BAO_0000218,16597,1,CHEMBL621827,,N
,,Cmax value was determined,,50594,Mus musculus,Intermediate,,10090.0,6702,In vivo,,,,,A,1,BAO_0000218,5727,1,CHEMBL621828,,N
,,Cmax value in IRC mice,,50594,Mus musculus,Intermediate,,10090.0,6703,In vivo,,,,,A,1,BAO_0000218,5951,1,CHEMBL621829,,N
,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,50594,Mus musculus,Intermediate,,10090.0,6704,In vivo,,,,,A,1,BAO_0000218,5506,1,CHEMBL621830,,N
,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,50594,Mus musculus,Intermediate,,10090.0,6705,In vivo,,,,,A,1,BAO_0000218,5506,1,CHEMBL621831,,N
,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,50594,Mus musculus,Intermediate,1969.0,10090.0,6706,In vivo,,,,Plasma,A,1,BAO_0000218,14239,1,CHEMBL621832,,N
,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,50594,Mus musculus,Intermediate,1969.0,10090.0,6707,In vivo,,,,Plasma,A,1,BAO_0000218,4890,1,CHEMBL624579,,N
,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,6708,In vivo,,,,,A,1,BAO_0000218,429,1,CHEMBL624580,,N
,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,50535,Acanthocheilonema viteae,Intermediate,,6277.0,6709,,,,,,F,1,BAO_0000218,10986,1,CHEMBL624581,,N
,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,50535,Acanthocheilonema viteae,Intermediate,,6277.0,6710,,,,,,F,1,BAO_0000218,10986,1,CHEMBL624582,,N
,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,50535,Acanthocheilonema viteae,Intermediate,,6277.0,6711,,,,,,F,1,BAO_0000218,10986,1,CHEMBL624583,,N
,,Inhibitory activity against human tumor cell line A0375 melanoma.,455.0,80018,Homo sapiens,Intermediate,,9606.0,6712,,A-375,,,,F,1,BAO_0000219,13227,1,CHEMBL624584,,N
,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,12512,Rattus norvegicus,Expert,,10116.0,6713,,,,,,B,1,BAO_0000249,4481,9,CHEMBL624585,Brain membranes,D
,,Forskolin-induced cAMP production at human A1 adenosine receptor,,114,Homo sapiens,Expert,,9606.0,6714,,,,,,F,1,BAO_0000019,16931,9,CHEMBL875165,,D
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,449.0,114,,Autocuration,,,6715,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619490,,H
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,449.0,114,,Autocuration,,,6716,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619491,,H
,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,449.0,114,,Expert,,,6717,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619492,,H
,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,449.0,114,,Expert,,,6718,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619493,,H
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,449.0,114,,Autocuration,,,6719,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619494,,H
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,449.0,114,,Autocuration,,,6720,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619495,,H
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,449.0,114,,Autocuration,,,6721,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619496,,H
,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,449.0,114,Homo sapiens,Expert,,9606.0,6722,,CHO,,,,F,1,BAO_0000219,3850,9,CHEMBL619497,,D
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,449.0,114,,Autocuration,,,6723,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619498,,H
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,449.0,114,,Autocuration,,,6724,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619499,,H
,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,449.0,114,,Expert,,,6725,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619500,,H
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,449.0,114,,Autocuration,,,6726,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619501,,H
,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,449.0,114,,Expert,,,6727,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619502,,H
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,449.0,114,,Autocuration,,,6728,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619503,,H
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,449.0,114,,Autocuration,,,6729,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL619504,,H
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,449.0,114,,Autocuration,,,6730,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL621298,,H
,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,449.0,114,,Expert,,,6731,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL621299,,H
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,449.0,114,,Autocuration,,,6732,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL621300,,H
,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,449.0,114,,Autocuration,,,6733,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL621301,,H
,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,449.0,114,,Expert,,,6734,,CHO,,,,F,1,BAO_0000219,3850,8,CHEMBL621302,,H
,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,164.0,80013,Oryctolagus cuniculus,Intermediate,,9986.0,6735,,A10,,,,F,1,BAO_0000219,12680,1,CHEMBL621303,,N
,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,164.0,22226,Rattus norvegicus,Autocuration,,10116.0,6736,,A10,,,,F,1,BAO_0000219,1313,0,CHEMBL621304,,U
,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,164.0,22226,Rattus norvegicus,Autocuration,,10116.0,6737,,A10,,,,F,1,BAO_0000219,1313,0,CHEMBL621305,,U
,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,164.0,80013,Rattus norvegicus,Intermediate,,10116.0,6738,,A10,,,,F,1,BAO_0000219,17567,1,CHEMBL621306,,N
,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,164.0,80013,Rattus norvegicus,Intermediate,,10116.0,6739,,A10,,,,F,1,BAO_0000219,17567,1,CHEMBL618444,,N
,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,164.0,80013,Rattus norvegicus,Intermediate,,10116.0,6740,,A10,,,,F,1,BAO_0000219,11819,1,CHEMBL618445,,N
,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6741,,CHO-AA8,,,,F,1,BAO_0000219,13436,1,CHEMBL618446,,N
,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6742,,CHO-AA8,,,,F,1,BAO_0000219,12687,1,CHEMBL618447,,N
,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6743,,CHO-AA8,,,,F,1,BAO_0000219,12651,1,CHEMBL618448,,N
,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6744,,CHO-AA8,,,,F,1,BAO_0000219,13300,1,CHEMBL618449,,N
,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6745,,CHO-AA8,,,,F,1,BAO_0000219,15296,1,CHEMBL618637,,N
,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6746,,CHO-AA8,,,,F,1,BAO_0000219,15328,1,CHEMBL618638,,N
,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6747,,CHO-AA8,,,,F,1,BAO_0000219,13302,1,CHEMBL618639,,N
,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",185.0,80089,Cricetulus griseus,Expert,,10029.0,6748,,CHO-AA8,,,,F,1,BAO_0000219,14367,1,CHEMBL618640,,N
,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,185.0,80089,Cricetulus griseus,Expert,,10029.0,6749,,CHO-AA8,,,,F,1,BAO_0000219,17002,1,CHEMBL618641,,N
,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6750,,CHO-AA8,,,,F,1,BAO_0000219,13436,1,CHEMBL618642,,N
,,Inhibitory activity against aerobic growth of AA8 cells.,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6751,,CHO-AA8,,,,F,1,BAO_0000219,13435,1,CHEMBL618643,,N
,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6752,,CHO-AA8,,,,A,1,BAO_0000219,10503,1,CHEMBL884013,,N
,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,185.0,80089,Cricetulus griseus,Expert,,10029.0,6753,,CHO-AA8,,,,F,1,BAO_0000219,10503,1,CHEMBL622723,,N
,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6754,,CHO-AA8,,,,F,1,BAO_0000219,10503,1,CHEMBL622724,,N
,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,185.0,80089,Cricetulus griseus,Expert,,10029.0,6755,,CHO-AA8,,,,F,1,BAO_0000219,15090,1,CHEMBL622725,,N
,,Cytotoxicity against AA8 cell line,185.0,80089,Cricetulus griseus,Expert,,10029.0,6756,,CHO-AA8,,,,F,1,BAO_0000219,10368,1,CHEMBL622726,,N
,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6757,,CHO-AA8,,,,F,1,BAO_0000219,12651,1,CHEMBL622727,,N
,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6758,,CHO-AA8,,,,A,1,BAO_0000219,12687,1,CHEMBL622728,,N
,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6759,,CHO-AA8,,,,F,1,BAO_0000219,12687,1,CHEMBL622729,,N
,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6760,,CHO-AA8,,,,A,1,BAO_0000219,12687,1,CHEMBL622730,,N
,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6761,,CHO-AA8,,,,F,1,BAO_0000219,1890,1,CHEMBL622731,,N
,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6762,,CHO-AA8,,,,F,1,BAO_0000219,10747,1,CHEMBL622732,,N
,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,185.0,80089,Cricetulus griseus,Intermediate,,10029.0,6763,,CHO-AA8,,,,F,1,BAO_0000219,10747,1,CHEMBL622733,,N
,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,22224,Cricetulus griseus,Autocuration,,10029.0,6764,,,,,,F,1,BAO_0000218,11616,0,CHEMBL622734,,U
,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,185.0,80089,Cricetulus griseus,Expert,,10029.0,6765,,CHO-AA8,,,,F,1,BAO_0000219,11616,1,CHEMBL622735,,N
,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6766,,CHO-AA8,,,,F,1,BAO_0000219,3471,0,CHEMBL618746,,U
,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6767,,CHO-AA8,,,,F,1,BAO_0000219,3471,0,CHEMBL618747,,U
,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6768,,CHO-AA8,,,,F,1,BAO_0000219,3471,0,CHEMBL620540,,U
,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6769,,CHO-AA8,,,,F,1,BAO_0000219,3471,0,CHEMBL620541,,U
,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6770,,CHO-AA8,,,,F,1,BAO_0000219,3471,0,CHEMBL620542,,U
,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6771,,CHO-AA8,,,,F,1,BAO_0000219,3471,0,CHEMBL620543,,U
,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6772,,CHO-AA8,,,,F,1,BAO_0000219,3471,0,CHEMBL618832,,U
,,Concentration required to reduce AA8 cell survival by 10%,185.0,80089,Cricetulus griseus,Expert,,10029.0,6773,,CHO-AA8,,,,F,1,BAO_0000219,11616,1,CHEMBL618833,,N
,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6774,,CHO-AA8,,,,F,1,BAO_0000219,2656,0,CHEMBL618834,,U
,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6775,,CHO-AA8,,,,F,1,BAO_0000219,10518,0,CHEMBL618835,,U
,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6776,,CHO-AA8,,,,F,1,BAO_0000219,10518,0,CHEMBL618836,,U
,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6777,,CHO-AA8,,,,F,1,BAO_0000219,10518,0,CHEMBL618837,,U
,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6778,,CHO-AA8,,,,F,1,BAO_0000219,10518,0,CHEMBL618838,,U
,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6779,,CHO-AA8,,,,F,1,BAO_0000219,16156,0,CHEMBL618839,,U
,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6780,,CHO-AA8,,,,F,1,BAO_0000219,2656,0,CHEMBL618840,,U
,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,22224,Cricetulus griseus,Autocuration,,10029.0,6781,,,,,,F,1,BAO_0000019,11005,0,CHEMBL618841,,U
,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6782,,CHO-AA8,,,,F,1,BAO_0000219,11942,0,CHEMBL618842,,U
,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6783,,CHO-AA8,,,,F,1,BAO_0000219,2128,0,CHEMBL618843,,U
,,Half life period after 15 mg/kg iv dose in Dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6784,In vivo,,,,,A,1,BAO_0000218,16907,1,CHEMBL618844,,N
,,Half life period after 30 mg/kg po dose in Dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6785,In vivo,,,,,A,1,BAO_0000218,16907,1,CHEMBL618845,,N
,,Half life was measured after oral 2b administration (tested in 6 dogs),,50588,Canis lupus familiaris,Intermediate,,9615.0,6786,In vivo,,,,,A,1,BAO_0000218,9579,1,CHEMBL618846,,N
,,Half life was measured in dog after oral 17b administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6787,In vivo,,,,,A,1,BAO_0000218,9579,1,CHEMBL618847,,N
,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,50588,Canis lupus familiaris,Intermediate,,9615.0,6788,In vivo,,,,,A,1,BAO_0000218,9579,1,CHEMBL618848,,N
,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,50588,Canis lupus familiaris,Intermediate,,9615.0,6789,In vivo,,,,,A,1,BAO_0000218,9579,1,CHEMBL618849,,N
,,Tmax value after 15 mg/kg iv dose in Dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6790,In vivo,,,,,A,1,BAO_0000218,16907,1,CHEMBL618850,,N
,,Tmax value after 30 mg/kg po dose in Dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6791,In vivo,,,,,A,1,BAO_0000218,16907,1,CHEMBL618851,,N
,,Compound was evaluated for its half life when administered intravenously in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6792,In vivo,,,,,A,1,BAO_0000218,3184,1,CHEMBL873815,,N
,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6793,In vivo,,,,Plasma,A,1,BAO_0000218,5017,1,CHEMBL618852,,N
,,Elimination Half-life of compound was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6794,,,,,,A,1,BAO_0000218,6821,1,CHEMBL618853,,N
,,Half life of compound in dog following oral administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6795,In vivo,,,,,A,1,BAO_0000218,17839,1,CHEMBL618854,,N
,,Half life of compound was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6796,,,,,,A,1,BAO_0000218,17267,1,CHEMBL618855,,N
,,Half life of compound was determined in dog blood,,50588,Canis lupus familiaris,Intermediate,178.0,9615.0,6797,,,,,Blood,A,1,BAO_0000218,4727,1,CHEMBL618856,,N
,,Half life after oral and iv dosing in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6798,In vivo,,,,,A,1,BAO_0000218,5238,1,CHEMBL875827,,N
,,Half life in dogs in hours,,50588,Canis lupus familiaris,Intermediate,,9615.0,6799,,,,,,A,1,BAO_0000218,4942,1,CHEMBL618857,,N
,,Half life on i.v. administration of 2 mg/kg was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6800,In vivo,,,,,A,1,BAO_0000218,6505,1,CHEMBL618858,,N
,,t1/2 in dog after oral dose (1 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6801,In vivo,,,,,A,1,BAO_0000218,5130,1,CHEMBL618859,,N
,,Half life was evaluated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6802,,,,,,A,1,BAO_0000218,1475,1,CHEMBL618860,,N
,,Half life period of compound was determined after intravenous administration at 2 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6803,In vivo,,,,,A,1,BAO_0000218,17804,1,CHEMBL618861,,N
,,Half life period of compound was determined after peroral administration at 2 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6804,In vivo,,,,,A,1,BAO_0000218,17804,1,CHEMBL622539,,N
,,Half life period (10 mg/kg) was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6805,In vivo,,,,,A,1,BAO_0000218,6084,1,CHEMBL622540,,N
,,Half life period (10 mg/kg) was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6806,In vivo,,,,,A,1,BAO_0000218,6084,1,CHEMBL873803,,N
,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6807,In vivo,,,,,A,1,BAO_0000218,5542,1,CHEMBL873804,,N
,,Half life period by po administration in dog at a dose of 0.3 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6808,In vivo,,,,,A,1,BAO_0000218,5542,1,CHEMBL624311,,N
,,Half life period in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6809,,,,,,A,1,BAO_0000218,6084,1,CHEMBL624312,,N
,,Half life period in dogs after oral administration at 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6810,In vivo,,,,,A,1,BAO_0000218,6241,1,CHEMBL624313,,N
,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6811,In vivo,,,,,A,1,BAO_0000218,1916,1,CHEMBL624314,,N
,,Half-life of compound was determined in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6812,,,,,,A,1,BAO_0000218,6621,1,CHEMBL624315,,N
,,Half-life in dog plasma,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6813,,,,,Plasma,A,1,BAO_0000218,1696,1,CHEMBL624316,,N
,,Half-life in mongrel dogs was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6814,,,,,,A,1,BAO_0000218,17800,1,CHEMBL624317,,N
,,Half-life in dog upon oral administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6815,In vivo,,,,,A,1,BAO_0000218,17657,1,CHEMBL624318,,N
,,Half-life in dog upon oral administration; Unable to calculate,,50588,Canis lupus familiaris,Intermediate,,9615.0,6816,In vivo,,,,,A,1,BAO_0000218,17657,1,CHEMBL624319,,N
,,Half-life was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6817,,,,,,A,1,BAO_0000218,4239,1,CHEMBL624496,,N
,,Half-life was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6818,,,,,,A,1,BAO_0000218,5985,1,CHEMBL624497,,N
,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6819,,,,,,A,1,BAO_0000218,9932,1,CHEMBL624498,,N
,,Oral half life was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6820,In vivo,,,,,A,1,BAO_0000218,5199,1,CHEMBL624499,,N
,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6821,In vivo,,,,Plasma,A,1,BAO_0000218,5199,1,CHEMBL624500,,N
,,Plasma half life was evaluated,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6822,,,,,Plasma,A,1,BAO_0000218,1475,1,CHEMBL624501,,N
,,Plasma half life was evaluated in Dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6823,,,,,Plasma,A,1,BAO_0000218,1475,1,CHEMBL623666,,N
,,Plasma half life was evaluated in dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6824,,,,,Plasma,A,1,BAO_0000218,1475,1,CHEMBL623667,,N
,,T1/2 (Half-life) was after oral administration at 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6825,In vivo,,,,,A,1,BAO_0000218,6316,1,CHEMBL623668,,N
,,Tested for the half life value in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6826,,,,,,A,1,BAO_0000218,4883,1,CHEMBL623669,,N
,,Maximum time at the dose of 2 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6827,In vivo,,,,,A,1,BAO_0000218,4727,1,CHEMBL623670,,N
,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6828,In vivo,,,,,A,1,BAO_0000218,1916,1,CHEMBL623671,,N
,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,50588,Canis lupus familiaris,Intermediate,178.0,9615.0,6829,In vivo,,,,Blood,A,1,BAO_0000218,1337,1,CHEMBL875945,,N
,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,50588,Canis lupus familiaris,Intermediate,178.0,9615.0,6830,In vivo,,,,Blood,A,1,BAO_0000218,1337,1,CHEMBL623672,,N
,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6831,In vivo,,,,,A,1,BAO_0000218,6265,1,CHEMBL623673,,N
,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,6832,In vivo,,,,,A,1,BAO_0000218,4809,1,CHEMBL623674,,N
,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,50588,Canis lupus familiaris,Intermediate,,9615.0,6833,In vivo,,,,,A,1,BAO_0000218,5983,1,CHEMBL623675,,N
,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,50588,Canis lupus familiaris,Intermediate,,9615.0,6834,,,,,,A,1,BAO_0000218,5313,1,CHEMBL872526,,N
,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,50588,Canis lupus familiaris,Intermediate,,9615.0,6835,In vivo,,,,,A,1,BAO_0000218,5313,1,CHEMBL623676,,N
,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6836,In vivo,,,,Plasma,A,1,BAO_0000218,17650,1,CHEMBL623677,,N
,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6837,In vivo,,,,Plasma,A,1,BAO_0000218,5199,1,CHEMBL623678,,N
,,Time taken for maximum plasma concentration in dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6838,,,,,Plasma,A,1,BAO_0000218,933,1,CHEMBL623679,,N
,,Time to reach Cmax after oral administration to dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6839,In vivo,,,,,A,1,BAO_0000218,16367,1,CHEMBL623680,,N
,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,6840,In vivo,,,,Plasma,A,1,BAO_0000218,6348,1,CHEMBL623681,,N
,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6841,In vivo,,,,,A,1,BAO_0000218,6316,1,CHEMBL623682,,N
,,Tmax after peroral administration (1 mg/kg) was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6842,In vivo,,,,,A,1,BAO_0000218,6215,1,CHEMBL623683,,N
,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,50588,Canis lupus familiaris,Expert,,9615.0,6843,In vivo,,,,,A,1,BAO_0000218,3598,1,CHEMBL623684,,N
,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,6844,In vivo,,,,,A,1,BAO_0000218,4527,1,CHEMBL622745,,N
,,Tmax after peroral administration in dogs at 2.4 uM/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6845,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL622746,,N
,,In vivo Cmax in mice at dose of 100 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,6846,In vivo,,,,,A,1,BAO_0000218,5969,1,CHEMBL622747,,N
,,In vivo Cmax in mice at dose of 50 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,6847,In vivo,,,,,A,1,BAO_0000218,5969,1,CHEMBL622748,,N
,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,50594,Mus musculus,Intermediate,,10090.0,6848,In vivo,,,,,A,1,BAO_0000218,4573,1,CHEMBL622749,,N
,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,50594,Mus musculus,Intermediate,1969.0,10090.0,6849,In vivo,,,,Plasma,A,1,BAO_0000218,3277,1,CHEMBL622750,,N
,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,50594,Mus musculus,Intermediate,1969.0,10090.0,6850,In vivo,,,,Plasma,A,1,BAO_0000218,17734,1,CHEMBL623411,,N
,,Maximum concentration obtained in mouse plasma was determined,,50594,Mus musculus,Intermediate,1969.0,10090.0,6851,In vivo,,,,Plasma,A,1,BAO_0000218,3132,1,CHEMBL875946,,N
,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,50594,Mus musculus,Intermediate,1969.0,10090.0,6852,In vivo,,,,Plasma,A,1,BAO_0000218,3132,1,CHEMBL623412,,N
,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,50594,Mus musculus,Intermediate,1969.0,10090.0,6853,In vivo,,,,Plasma,A,1,BAO_0000218,6348,1,CHEMBL623413,,N
,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,50594,Mus musculus,Intermediate,1969.0,10090.0,6854,In vivo,,,,Plasma,A,1,BAO_0000218,17729,1,CHEMBL623414,,N
,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,50594,Mus musculus,Intermediate,1969.0,10090.0,6855,In vivo,,,,Plasma,A,1,BAO_0000218,17729,1,CHEMBL623415,,N
,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,50594,Mus musculus,Intermediate,1969.0,10090.0,6856,In vivo,,,,Plasma,A,1,BAO_0000218,17729,1,CHEMBL623416,,N
,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,50594,Mus musculus,Intermediate,1969.0,10090.0,6857,In vivo,,,,Plasma,A,1,BAO_0000218,17728,1,CHEMBL623417,,N
,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,50594,Mus musculus,Intermediate,1969.0,10090.0,6858,In vivo,,,,Plasma,A,1,BAO_0000218,17728,1,CHEMBL623418,,N
,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,50594,Mus musculus,Intermediate,1969.0,10090.0,6859,In vivo,,,,Plasma,A,1,BAO_0000218,17728,1,CHEMBL623419,,N
,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,6860,In vivo,,,,,A,1,BAO_0000218,4066,1,CHEMBL622816,,N
,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,6861,In vivo,,,,,A,1,BAO_0000218,6178,1,CHEMBL623313,,N
,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,50594,Mus musculus,Intermediate,,10090.0,6862,In vivo,,,,,A,1,BAO_0000218,6178,1,CHEMBL623314,,N
,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,50594,Mus musculus,Intermediate,,10090.0,6863,In vivo,,,,,A,1,BAO_0000218,3760,1,CHEMBL876788,,N
,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,50594,Mus musculus,Intermediate,,10090.0,6864,In vivo,,,,,A,1,BAO_0000218,3760,1,CHEMBL623315,,N
,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,50594,Mus musculus,Intermediate,,10090.0,6865,In vivo,,,,,A,1,BAO_0000218,3760,1,CHEMBL623316,,N
,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,50594,Mus musculus,Intermediate,,10090.0,6866,In vivo,,,,,A,1,BAO_0000218,3760,1,CHEMBL623317,,N
,,Cmax in male mice after 2 mg/kg oral dose,,50594,Mus musculus,Intermediate,,10090.0,6868,In vivo,,,,,A,1,BAO_0000218,5961,1,CHEMBL623319,,N
,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,50594,Mus musculus,Intermediate,,10090.0,6869,In vivo,,,,,A,1,BAO_0000218,6137,1,CHEMBL623320,,N
,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,50594,Mus musculus,Intermediate,,10090.0,6870,In vivo,,,,,A,1,BAO_0000218,3802,1,CHEMBL623321,,N
,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,50594,Mus musculus,Intermediate,,10090.0,6871,,,,,,A,1,BAO_0000218,3535,1,CHEMBL623322,,N
,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,50594,Mus musculus,Intermediate,,10090.0,6872,,,,,,A,1,BAO_0000218,3535,1,CHEMBL623323,,N
,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,50594,Mus musculus,Intermediate,,10090.0,6873,,,,,,A,1,BAO_0000218,3535,1,CHEMBL623324,,N
,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,50594,Mus musculus,Intermediate,,10090.0,6874,,,,,,A,1,BAO_0000218,3535,1,CHEMBL623325,,N
,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,50594,Mus musculus,Intermediate,,10090.0,6875,,,,,,A,1,BAO_0000218,3535,1,CHEMBL623326,,N
,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,50594,Mus musculus,Intermediate,,10090.0,6876,,,,,,A,1,BAO_0000218,3535,1,CHEMBL623327,,N
,,Maximum concentration in plasma upon oral administration in mouse,,50594,Mus musculus,Intermediate,1969.0,10090.0,6877,,,,,Plasma,A,1,BAO_0000218,2862,1,CHEMBL623328,,N
,,Maximum plasma concentration was evaluated in mice after oral administration,,50594,Mus musculus,Intermediate,1969.0,10090.0,6878,,,,,Plasma,A,1,BAO_0000218,2675,1,CHEMBL623329,,N
,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,50594,Mus musculus,Intermediate,1969.0,10090.0,6879,In vivo,,,,Plasma,A,1,BAO_0000218,2675,1,CHEMBL623330,,N
,,Dose at which the compound induced fecal excretion in mice,,50594,Mus musculus,Intermediate,,10090.0,6880,,,,,,A,1,BAO_0000218,5399,1,CHEMBL876789,,N
,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,164.0,80013,Rattus norvegicus,Expert,,10116.0,6893,,A10,,,,F,1,BAO_0000219,11819,1,CHEMBL623333,,N
,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,164.0,80013,Rattus norvegicus,Expert,,10116.0,6894,,A10,,,,F,1,BAO_0000219,11819,1,CHEMBL623334,,N
,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,164.0,80013,Rattus norvegicus,Expert,,10116.0,6895,,A10,,,,F,1,BAO_0000219,11819,1,CHEMBL627536,,N
,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,164.0,80013,Rattus norvegicus,Expert,,10116.0,6896,,A10,,,,F,1,BAO_0000219,11819,1,CHEMBL627537,,N
,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),164.0,80013,Rattus norvegicus,Intermediate,,10116.0,6897,,A10,,,,F,1,BAO_0000219,16361,1,CHEMBL627538,,N
,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,393.0,80655,Homo sapiens,Intermediate,,9606.0,6898,,A121,,,,F,1,BAO_0000219,2288,1,CHEMBL884106,,N
,,Anticancer activity against human ovarian carcinoma A121 cells,393.0,80655,Homo sapiens,Intermediate,,9606.0,6899,,A121,,,,F,1,BAO_0000219,10404,1,CHEMBL625294,,N
,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,393.0,80655,Homo sapiens,Intermediate,,9606.0,6900,,A121,,,,F,1,BAO_0000219,14790,1,CHEMBL625295,,N
,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,393.0,80655,Homo sapiens,Intermediate,,9606.0,6901,,A121,,,,F,1,BAO_0000219,14790,1,CHEMBL625296,,N
,,Growth inhibition of human ovarian carcinoma (A121) cell line,393.0,80655,Homo sapiens,Expert,,9606.0,6902,,A121,,,,F,1,BAO_0000219,14253,1,CHEMBL625297,,N
,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,393.0,80655,Homo sapiens,Expert,,9606.0,6903,,A121,,,,F,1,BAO_0000219,13617,1,CHEMBL625298,,N
,,Cytotoxicity against human A121 ovarian cells,393.0,80655,Homo sapiens,Intermediate,,9606.0,6904,,A121,,,,F,1,BAO_0000219,1003,1,CHEMBL625960,,N
,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,393.0,80655,Homo sapiens,Intermediate,,9606.0,6905,,A121,,,,F,1,BAO_0000219,830,1,CHEMBL625961,,N
,,In vitro cytotoxicity against human ovarian carcinoma A21,393.0,80655,Homo sapiens,Intermediate,,9606.0,6906,,A121,,,,F,1,BAO_0000219,12307,1,CHEMBL625962,,N
,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,393.0,80655,Homo sapiens,Intermediate,,9606.0,6907,,A121,,,,F,1,BAO_0000219,14254,1,CHEMBL624717,,N
,,Inhibitory activity of compound against human A121 ovarian cell line.,393.0,80655,Homo sapiens,Intermediate,,9606.0,6908,,A121,,,,F,1,BAO_0000219,13370,1,CHEMBL624718,,N
,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,393.0,80655,Homo sapiens,Intermediate,,9606.0,6909,,A121,,,,F,1,BAO_0000219,14790,1,CHEMBL624719,,N
,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,393.0,80655,Homo sapiens,Intermediate,,9606.0,6910,,A121,,,,F,1,BAO_0000219,3614,1,CHEMBL624720,,N
,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,622.0,80012,Homo sapiens,Intermediate,,9606.0,6911,,A 172,,,,F,1,BAO_0000219,2664,1,CHEMBL624721,,N
,,In vitro cytotoxicity against A172 human tumor cell lines.,622.0,80012,Homo sapiens,Expert,,9606.0,6912,,A 172,,,,F,1,BAO_0000219,2037,1,CHEMBL624722,,N
,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,622.0,80012,Homo sapiens,Intermediate,,9606.0,6913,,A 172,,,,F,1,BAO_0000219,14539,1,CHEMBL877597,,N
,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,622.0,80012,Homo sapiens,Intermediate,,9606.0,6914,,A 172,,,,F,1,BAO_0000219,2836,1,CHEMBL624723,,N
,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,622.0,80012,Homo sapiens,Intermediate,,9606.0,6915,,A 172,,,,F,1,BAO_0000219,10708,1,CHEMBL624724,,N
,,Association constant against A2 adenosine receptor,,104729,Canis lupus familiaris,Autocuration,,9615.0,6916,,,,,,B,1,BAO_0000224,8975,4,CHEMBL624725,,H
,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,1085.0,80656,fish,Intermediate,,,6917,,A2,,,,F,1,BAO_0000219,7645,1,CHEMBL624726,,N
,,Ratio of Ki for adenosine A2 and A1 receptor binding,,104713,Rattus norvegicus,Autocuration,,10116.0,6918,,,,,,B,1,BAO_0000224,11377,5,CHEMBL857535,,D
,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,623.0,80014,Homo sapiens,Expert,,9606.0,6919,,A204,,,,F,1,BAO_0000219,13528,1,CHEMBL624727,,N
,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,623.0,80014,Homo sapiens,Expert,,9606.0,6920,,A204,,,,F,1,BAO_0000219,10160,1,CHEMBL624728,,N
,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,404.0,80015,Homo sapiens,Intermediate,,9606.0,6921,,A2058,,,,F,1,BAO_0000219,15144,1,CHEMBL624729,,N
,,Growth inhibition against Human squamous cell line(A 253),973.0,80657,Homo sapiens,Intermediate,,9606.0,6922,,A253 cell line,,,,F,1,BAO_0000219,13160,1,CHEMBL624730,,N
,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,973.0,80657,Homo sapiens,Intermediate,,9606.0,6923,,A253 cell line,,,,F,1,BAO_0000219,12898,1,CHEMBL624731,,N
,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,973.0,80657,Homo sapiens,Intermediate,,9606.0,6924,,A253 cell line,,,,F,1,BAO_0000219,13069,1,CHEMBL624732,,N
,,Growth inhibition of A253 cell lines.,973.0,80657,Homo sapiens,Intermediate,,9606.0,6925,,A253 cell line,,,,F,1,BAO_0000219,15984,1,CHEMBL883245,,N
,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),973.0,80657,Homo sapiens,Intermediate,,9606.0,6926,,A253 cell line,,,,F,1,BAO_0000219,15564,1,CHEMBL624733,,N
,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,973.0,80657,Homo sapiens,Intermediate,,9606.0,6927,,A253 cell line,,,,F,1,BAO_0000219,15564,1,CHEMBL624734,,N
,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,973.0,80657,Homo sapiens,Intermediate,,9606.0,6928,,A253 cell line,,,,F,1,BAO_0000219,15564,1,CHEMBL624735,,N
,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,6929,,A2780,,,,F,1,BAO_0000219,4720,1,CHEMBL621780,,N
,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,6930,,A2780,,,,F,1,BAO_0000219,16112,1,CHEMBL877598,,N
,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,478.0,81034,Homo sapiens,Expert,,9606.0,6931,,A2780,,,,F,1,BAO_0000219,16597,1,CHEMBL621781,,N
,,Cytotoxicity against human cancer cell lines A2780 (ovarian),478.0,81034,Homo sapiens,Intermediate,,9606.0,6932,,A2780,,,,F,1,BAO_0000219,16378,1,CHEMBL621782,,N
,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,478.0,81034,Homo sapiens,Expert,,9606.0,6933,,A2780,,,,F,1,BAO_0000219,16085,1,CHEMBL621783,,N
,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,478.0,81034,Homo sapiens,Intermediate,,9606.0,6934,,A2780,,,,F,1,BAO_0000219,16317,1,CHEMBL621784,,N
,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),478.0,81034,Homo sapiens,Intermediate,,9606.0,6935,,A2780,,,,F,1,BAO_0000219,15748,1,CHEMBL621785,,N
,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,478.0,81034,Homo sapiens,Expert,,9606.0,6936,,A2780,,,,F,1,BAO_0000219,16597,1,CHEMBL621968,,N
,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,478.0,81034,Homo sapiens,Expert,,9606.0,6937,,A2780,,,,F,1,BAO_0000219,16597,1,CHEMBL621969,,N
,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,478.0,81034,Homo sapiens,Expert,,9606.0,6938,,A2780,,,,F,1,BAO_0000219,16597,1,CHEMBL621970,,N
,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,478.0,81034,Homo sapiens,Intermediate,,9606.0,6939,,A2780,,,,F,1,BAO_0000219,15608,1,CHEMBL621971,,N
,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,478.0,81034,Homo sapiens,Intermediate,,9606.0,6940,,A2780,,,,F,1,BAO_0000219,15608,1,CHEMBL621972,,N
,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,478.0,81034,Homo sapiens,Intermediate,,9606.0,6941,,A2780,,,,F,1,BAO_0000219,15608,1,CHEMBL884108,,N
,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,22224,Cricetulus griseus,Autocuration,,10029.0,6942,,,,,,F,1,BAO_0000019,15296,0,CHEMBL623826,,U
,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6943,,CHO-AA8,,,,A,1,BAO_0000219,10251,0,CHEMBL623827,,U
,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6944,,CHO-AA8,,,,F,1,BAO_0000219,10251,0,CHEMBL623828,,U
,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6945,,CHO-AA8,,,,F,1,BAO_0000219,10251,0,CHEMBL623829,,U
,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6946,,CHO-AA8,,,,F,1,BAO_0000219,10251,0,CHEMBL623830,,U
,,Growth inhibition against CHO-derived cell line AA8,,22224,Cricetulus griseus,Autocuration,,10029.0,6947,,,,,,F,1,BAO_0000019,11858,0,CHEMBL623831,,U
,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6948,,CHO-AA8,,,,F,1,BAO_0000219,11858,0,CHEMBL623832,,U
,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,185.0,80089,hampster,Expert,,36483.0,6949,,CHO-AA8,,,,F,1,BAO_0000219,11616,1,CHEMBL623833,,N
,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,185.0,80089,Cricetulus griseus,Expert,,10029.0,6950,,CHO-AA8,,,,F,1,BAO_0000219,11616,1,CHEMBL623834,,N
,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6951,,CHO-AA8,,,,F,1,BAO_0000219,10518,0,CHEMBL623835,,U
,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6952,,CHO-AA8,,,,F,1,BAO_0000219,11396,0,CHEMBL623836,,U
,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,185.0,22224,Cricetulus griseus,Autocuration,,10029.0,6953,,CHO-AA8,,,,F,1,BAO_0000219,10518,0,CHEMBL623837,,U
,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,185.0,80089,Cricetulus griseus,Expert,,10029.0,6954,,CHO-AA8,,,,F,1,BAO_0000219,11616,1,CHEMBL623838,,N
,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,12675,,Autocuration,,,6955,,,,,,F,1,BAO_0000019,14837,8,CHEMBL623839,,H
,,Number of binding sites (n) of isolated serum protein AAG,,12675,,Autocuration,,,6956,,,,,,F,1,BAO_0000019,14837,8,CHEMBL623840,,H
,,Association constant for binding to AATT duplex,,22222,,Intermediate,,,6957,,,,,,B,1,BAO_0000225,16037,3,CHEMBL623841,,M
,,Inhibition of ABAE human fibroblast cell proliferation,416.0,100090,Homo sapiens,Expert,,9606.0,6958,,ABAE,,,,F,1,BAO_0000219,16597,1,CHEMBL623842,,N
,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",1064.0,80668,Mus musculus,Intermediate,,10090.0,6959,,AC755,,,,F,1,BAO_0000218,8831,1,CHEMBL623843,,N
,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,102444,Oryctolagus cuniculus,Expert,,9986.0,6960,,,,,,F,1,BAO_0000218,13419,9,CHEMBL618669,,D
,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,102444,Oryctolagus cuniculus,Expert,,9986.0,6961,In vivo,,,,,F,1,BAO_0000218,13419,9,CHEMBL618670,,D
,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,69,,Autocuration,,,6962,,,,,,B,1,BAO_0000357,15778,8,CHEMBL618671,,H
,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,69,,Autocuration,,,6963,,,,,,B,1,BAO_0000357,15778,8,CHEMBL618672,,H
,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,978.0,80669,Homo sapiens,Intermediate,,9606.0,6964,,ACH-2 cell line,,,,F,1,BAO_0000219,12988,1,CHEMBL618673,,N
,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),978.0,80669,Homo sapiens,Intermediate,,9606.0,6965,,ACH-2 cell line,,,,F,1,BAO_0000219,12988,1,CHEMBL618674,,N
,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,998.0,22224,Human immunodeficiency virus 1,Autocuration,,11676.0,6966,,T cell line,,,,F,1,BAO_0000219,12988,0,CHEMBL618675,,U
,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),998.0,22224,Human immunodeficiency virus 1,Autocuration,,11676.0,6967,,T cell line,,,,F,1,BAO_0000219,12988,0,CHEMBL618676,,U
,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),998.0,22224,Human immunodeficiency virus 1,Autocuration,,11676.0,6968,,T cell line,,,,F,1,BAO_0000219,12988,0,CHEMBL618677,,U
,,Inhibition of growth of renal cancer ACHN cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,6969,,ACHN,,,,F,1,BAO_0000219,11843,1,CHEMBL618678,,N
,,Inhibition of growth of ACHN renal cancer cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,6970,,ACHN,,,,F,1,BAO_0000219,16939,1,CHEMBL618679,,N
,,Inhibitory concentration required against ACHN renal cancer cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,6971,,ACHN,,,,F,1,BAO_0000219,4782,1,CHEMBL618680,,N
,,Concentration required to inhibit growth of human renal (ACHN) cell line,626.0,80025,Homo sapiens,Expert,,9606.0,6972,,ACHN,,,,F,1,BAO_0000219,6310,1,CHEMBL618681,,N
,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,626.0,80025,Homo sapiens,Intermediate,,9606.0,6973,,ACHN,,,,F,1,BAO_0000219,6310,1,CHEMBL618682,,N
,,Cytotoxic activity against ACHN Renal cancer cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,6974,,ACHN,,,,F,1,BAO_0000219,12858,1,CHEMBL618683,,N
,,Cytotoxicity evaluation against ACHN renal cancer cells,626.0,80025,Homo sapiens,Intermediate,,9606.0,6975,,ACHN,,,,F,1,BAO_0000219,17380,1,CHEMBL618684,,N
,,In vitro antitumor activity against human renal ACHN cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,6976,,ACHN,,,,F,1,BAO_0000219,5858,1,CHEMBL618685,,N
,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,626.0,80025,Homo sapiens,Intermediate,,9606.0,6977,,ACHN,,,,F,1,BAO_0000219,3838,1,CHEMBL876499,,N
,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,626.0,80025,Homo sapiens,Intermediate,,9606.0,6978,,ACHN,,,,F,1,BAO_0000219,3838,1,CHEMBL618686,,N
,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",626.0,80025,Homo sapiens,Intermediate,,9606.0,6979,,ACHN,,,,F,1,BAO_0000219,5406,1,CHEMBL618687,,N
,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,626.0,80025,Homo sapiens,Intermediate,,9606.0,6980,,ACHN,,,,F,1,BAO_0000219,4071,1,CHEMBL618688,,N
,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,626.0,80025,Homo sapiens,Expert,,9606.0,6981,,ACHN,,,,F,1,BAO_0000219,4071,1,CHEMBL618689,,N
,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,626.0,80025,Homo sapiens,Intermediate,,9606.0,6982,,ACHN,,,,F,1,BAO_0000219,4071,1,CHEMBL618690,,N
,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,626.0,80025,Homo sapiens,Intermediate,,9606.0,6983,,ACHN,,,,F,1,BAO_0000219,15002,1,CHEMBL618691,,N
,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),626.0,80025,Homo sapiens,Intermediate,,9606.0,6984,,ACHN,,,,F,1,BAO_0000219,14769,1,CHEMBL619373,,N
,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",626.0,80025,Homo sapiens,Intermediate,,9606.0,6985,,ACHN,,,,F,1,BAO_0000219,13958,1,CHEMBL884008,,N
,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,626.0,80025,Homo sapiens,Intermediate,,9606.0,6986,,ACHN,,,,F,1,BAO_0000219,1665,1,CHEMBL619374,,N
,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,6987,,ACHN,,,,F,1,BAO_0000219,15354,1,CHEMBL619375,,N
,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,626.0,80025,Homo sapiens,Intermediate,,9606.0,6988,,ACHN,,,,F,1,BAO_0000219,15354,1,CHEMBL619376,,N
,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,6989,,ACHN,,,,F,1,BAO_0000219,13978,1,CHEMBL619377,,N
,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,6990,,ACHN,,,,F,1,BAO_0000219,6798,1,CHEMBL619378,,N
,,Tmax value after administration of 4 mg/Kg oral dose in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6991,In vivo,,,,,A,1,BAO_0000218,2959,1,CHEMBL872527,,N
,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,50588,Canis lupus familiaris,Intermediate,,9615.0,6992,,,,,,A,1,BAO_0000218,9932,1,CHEMBL876500,,N
,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,6993,,,,,,A,1,BAO_0000218,5546,1,CHEMBL619379,,N
,,Volume distribution after 15 mg/kg iv dose in Dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6994,In vivo,,,,,A,1,BAO_0000218,16907,1,CHEMBL619538,,N
,,Volume distribution after 30 mg/kg po dose in Dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,6995,In vivo,,,,,A,1,BAO_0000218,16907,1,CHEMBL619539,,N
,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,50588,Canis lupus familiaris,Intermediate,,9615.0,6996,In vivo,,,,,A,1,BAO_0000218,4257,1,CHEMBL619540,,N
,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6997,In vivo,,,,,A,1,BAO_0000218,4305,1,CHEMBL619541,,N
,,Volume of distribution was evaluated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,6998,In vivo,,,,,A,1,BAO_0000218,5472,1,CHEMBL619542,,N
,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,6999,In vivo,,,,,A,1,BAO_0000218,6062,1,CHEMBL619543,,N
,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,50588,Canis lupus familiaris,Expert,,9615.0,7000,,,,,,A,1,BAO_0000218,3598,1,CHEMBL619544,,N
,,The compound was tested for volume of distribution in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7001,In vivo,,,,,A,1,BAO_0000218,12500,1,CHEMBL619545,,N
,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7002,In vivo,,,,,A,1,BAO_0000218,12500,1,CHEMBL619546,,N
,,Vd (1 mg/kg) was determined in dog (in vivo),,50588,Canis lupus familiaris,Intermediate,,9615.0,7003,In vivo,,,,,A,1,BAO_0000218,6227,1,CHEMBL619547,,N
,,Vd in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7004,In vivo,,,,,A,1,BAO_0000218,6227,1,CHEMBL619548,,N
,,Volume distribution was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7005,In vivo,,,,,A,1,BAO_0000218,4219,1,CHEMBL619549,,N
,,Volume of distribution in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7006,In vivo,,,,,A,1,BAO_0000218,1696,1,CHEMBL619550,,N
,,Volume of distribution by as 4 fold increase by iv administration in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,7007,In vivo,,,,,A,1,BAO_0000218,5542,1,CHEMBL876501,,N
,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,50588,Canis lupus familiaris,Intermediate,,9615.0,7008,In vivo,,,,,A,1,BAO_0000218,5199,1,CHEMBL619551,,N
,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,7009,In vivo,,,,,A,1,BAO_0000218,6348,1,CHEMBL619552,,N
,,Volume distribution at the dose of 2 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7010,In vivo,,,,,A,1,BAO_0000218,4727,1,CHEMBL619553,,N
,,Steady state volume of distribution was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7011,In vivo,,,,,A,1,BAO_0000218,16367,1,CHEMBL618722,,N
,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,50588,Canis lupus familiaris,Intermediate,,9615.0,7012,In vivo,,,,,A,1,BAO_0000218,2652,1,CHEMBL618723,,N
,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,50588,Canis lupus familiaris,Intermediate,,9615.0,7013,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL618724,,N
,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,50588,Canis lupus familiaris,Intermediate,,9615.0,7014,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL618725,,N
,,Bioavailability in dog (dose 1 mg/kg i.v.),,50588,Canis lupus familiaris,Intermediate,,9615.0,7015,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL618726,,N
,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,50588,Canis lupus familiaris,Intermediate,,9615.0,7016,In vivo,,,,,A,1,BAO_0000218,5334,1,CHEMBL618727,,N
,,Pharmacokinetic property (vdss) was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7017,In vivo,,,,,A,1,BAO_0000218,4239,1,CHEMBL624233,,N
,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7018,In vivo,,,,,A,1,BAO_0000218,4709,1,CHEMBL624234,,N
,,Vdss was determined after iv 0.1 mg/kg administration in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7019,In vivo,,,,,A,1,BAO_0000218,5600,1,CHEMBL624235,,N
,,Volume displacement was calculated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7020,In vivo,,,,,A,1,BAO_0000218,6057,1,CHEMBL624236,,N
,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7021,In vivo,,,,,A,1,BAO_0000218,5654,1,CHEMBL624237,,N
,,Volume distribution constant was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7022,In vivo,,,,,A,1,BAO_0000218,5505,1,CHEMBL624238,,N
,,Volume distribution at a dose of 1 uM/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7023,In vivo,,,,,A,1,BAO_0000218,4527,1,CHEMBL624239,,N
,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,7024,In vivo,,,,,A,1,BAO_0000218,4521,1,CHEMBL875829,,N
,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7025,In vivo,,,,,A,1,BAO_0000218,4521,1,CHEMBL624240,,N
,,Volume distribution (Vdss) was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7026,In vivo,,,,,A,1,BAO_0000218,15660,1,CHEMBL624241,,N
,,Volume distribution (Vdss) was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7027,In vivo,,,,,A,1,BAO_0000218,15660,1,CHEMBL624242,,N
,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,7028,In vivo,,,,,A,1,BAO_0000218,6679,1,CHEMBL624243,,N
,,Volume of distribution in steady state was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7029,In vivo,,,,,A,1,BAO_0000218,5145,1,CHEMBL624244,,N
,,Volume of distribution of compound was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7030,In vivo,,,,,A,1,BAO_0000218,6821,1,CHEMBL624245,,N
,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7031,In vivo,,,,,A,1,BAO_0000218,4137,1,CHEMBL624246,,N
,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,50588,Canis lupus familiaris,Intermediate,,9615.0,7032,In vivo,,,,,A,1,BAO_0000218,5334,1,CHEMBL624247,,N
,,Volume of distribution (Vdss) was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7033,In vivo,,,,,A,1,BAO_0000218,15660,1,CHEMBL624248,,N
,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,50588,Canis lupus familiaris,Intermediate,,9615.0,7034,In vivo,,,,,A,1,BAO_0000218,6642,1,CHEMBL624249,,N
,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588,Canis lupus familiaris,Intermediate,,9615.0,7035,In vivo,,,,,A,1,BAO_0000218,6641,1,CHEMBL624250,,N
,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588,Canis lupus familiaris,Intermediate,,9615.0,7036,In vivo,,,,,A,1,BAO_0000218,6642,1,CHEMBL624251,,N
,,Maximum rate of depolarization of the upstroke of the action potential,,50588,Canis lupus familiaris,Intermediate,,9615.0,7037,,,,,,A,1,BAO_0000218,11659,1,CHEMBL624252,,N
,,Steady state volume distribution in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7038,In vivo,,,,,A,1,BAO_0000218,6448,1,CHEMBL624253,,N
,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,50588,Canis lupus familiaris,Intermediate,,9615.0,7039,In vivo,,,,,A,1,BAO_0000218,5474,1,CHEMBL624950,,N
,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7040,In vivo,,,,,A,1,BAO_0000218,1466,1,CHEMBL624951,,N
,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7041,In vivo,,,,,A,1,BAO_0000218,6535,1,CHEMBL875830,,N
,,Volume distribution in dog after administration of 1 mg/kg iv,,50588,Canis lupus familiaris,Intermediate,,9615.0,7042,In vivo,,,,,A,1,BAO_0000218,6535,1,CHEMBL624952,,N
,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7043,In vivo,,,,,A,1,BAO_0000218,17764,1,CHEMBL624953,,N
,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7044,In vivo,,,,,A,1,BAO_0000218,6215,1,CHEMBL624954,,N
,,Vss on i.v. administration of 2 mg/kg was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7045,In vivo,,,,,A,1,BAO_0000218,6505,1,CHEMBL624955,,N
,,Vss was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7046,,,,,,A,1,BAO_0000218,3639,1,CHEMBL624956,,N
,,Vss in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7047,,,,,,A,1,BAO_0000218,3639,1,CHEMBL625129,,N
,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7048,In vivo,,,,,A,1,BAO_0000218,6062,1,CHEMBL625130,,N
,,Volume distribution in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,7049,In vivo,,,,,A,1,BAO_0000218,4942,1,CHEMBL625131,,N
,,Volume of distribution in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7050,In vivo,,,,,A,1,BAO_0000218,17796,1,CHEMBL625132,,N
,,Tested for the oral bioavailability in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7051,In vivo,,,,,A,1,BAO_0000218,4883,1,CHEMBL872263,,N
,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,7060,In vivo,,,,,A,1,BAO_0000218,17837,1,CHEMBL624336,,N
,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,50594,Mus musculus,Intermediate,,10090.0,7061,In vivo,,,,,A,1,BAO_0000218,17729,1,CHEMBL624337,,N
,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,50594,Mus musculus,Intermediate,,10090.0,7062,In vivo,,,,,A,1,BAO_0000218,17729,1,CHEMBL624338,,N
,,Bioavailability was measured in mouse,,50594,Mus musculus,Intermediate,,10090.0,7063,In vivo,,,,,A,1,BAO_0000218,4239,1,CHEMBL624339,,N
,,Bioavailability in mouse,,50594,Mus musculus,Intermediate,,10090.0,7064,In vivo,,,,,A,1,BAO_0000218,17592,1,CHEMBL624340,,N
,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,50594,Mus musculus,Intermediate,,10090.0,7065,In vivo,,,,,A,1,BAO_0000218,6348,1,CHEMBL624341,,N
,,Bioavailability in mouse,,50594,Mus musculus,Intermediate,,10090.0,7066,In vivo,,,,,A,1,BAO_0000218,2801,1,CHEMBL624342,,N
,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,50594,Mus musculus,Intermediate,,10090.0,7067,In vivo,,,,,A,1,BAO_0000218,2801,1,CHEMBL624343,,N
,,Oral bioavailability in mouse,,50594,Mus musculus,Intermediate,,10090.0,7068,In vivo,,,,,A,1,BAO_0000218,17718,1,CHEMBL624344,,N
,,Oral availability at 50 mg/kg po in male mice,,50594,Mus musculus,Intermediate,,10090.0,7069,In vivo,,,,,A,1,BAO_0000218,5727,1,CHEMBL624345,,N
,,Oral bioavailability in mouse (dose 10 mg/kg),,50594,Mus musculus,Intermediate,,10090.0,7070,In vivo,,,,,A,1,BAO_0000218,5302,1,CHEMBL624346,,N
,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,50594,Mus musculus,Expert,,10090.0,7071,In vivo,,,,,A,1,BAO_0000218,3598,1,CHEMBL624347,,N
,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,50594,Mus musculus,Intermediate,,10090.0,7072,In vivo,,,,,A,1,BAO_0000218,5961,1,CHEMBL624348,,N
,,Oral bioavailability in mouse,,50594,Mus musculus,Intermediate,,10090.0,7074,In vivo,,,,,A,1,BAO_0000218,6091,1,CHEMBL622754,,N
,,Oral bioavailability in vivo in mice;ND=Not determined,,50594,Mus musculus,Intermediate,,10090.0,7075,In vivo,,,,,A,1,BAO_0000218,6091,1,CHEMBL622755,,N
,,Oral bioavailability in mouse at 10 mg/kg of the compound,,50594,Mus musculus,Intermediate,,10090.0,7076,In vivo,,,,,A,1,BAO_0000218,5711,1,CHEMBL622756,,N
,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,50594,Mus musculus,Intermediate,,10090.0,7077,In vivo,,,,,A,1,BAO_0000218,17728,1,CHEMBL622757,,N
,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,50594,Mus musculus,Intermediate,,10090.0,7078,In vivo,,,,,A,1,BAO_0000218,17728,1,CHEMBL622758,,N
,,Tested for bioavailability of the compound,,50594,Mus musculus,Intermediate,,10090.0,7079,In vivo,,,,,A,1,BAO_0000218,3802,1,CHEMBL622759,,N
,,Tested for half life at the dose of 10 mg/kg when administered intravenously,,50594,Mus musculus,Intermediate,,10090.0,7080,In vivo,,,,,A,1,BAO_0000218,3802,1,CHEMBL622760,,N
,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,50594,Mus musculus,Intermediate,1969.0,10090.0,7081,,,,,Plasma,A,1,BAO_0000218,14029,1,CHEMBL622761,,N
,,The plasma half life of compound was determined on heparin prepared by human plasma. ,,50594,Mus musculus,Intermediate,1969.0,10090.0,7082,,,,,Plasma,A,1,BAO_0000218,14029,1,CHEMBL622762,,N
,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,50594,Mus musculus,Intermediate,1969.0,10090.0,7083,,,,,Plasma,A,1,BAO_0000218,14029,1,CHEMBL622763,,N
,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,50594,Mus musculus,Intermediate,1969.0,10090.0,7084,,,,,Plasma,A,1,BAO_0000218,14029,1,CHEMBL622764,,N
,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,50594,Mus musculus,Intermediate,1969.0,10090.0,7085,,,,,Plasma,A,1,BAO_0000218,14029,1,CHEMBL622765,,N
,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,7086,,,,,,F,1,BAO_0000218,17753,1,CHEMBL622766,,N
,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,7087,,,,,,A,1,BAO_0000218,17753,1,CHEMBL622767,,N
,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,50594,Mus musculus,Intermediate,,10090.0,7088,,,,,,A,1,BAO_0000218,17753,1,CHEMBL622768,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,178.0,10090.0,7089,In vivo,,,,Blood,A,1,BAO_0000218,10107,1,CHEMBL875948,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594,Mus musculus,Intermediate,178.0,10090.0,7090,In vivo,,,,Blood,A,1,BAO_0000218,10107,1,CHEMBL622769,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,178.0,10090.0,7091,In vivo,,,,Blood,A,1,BAO_0000218,10107,1,CHEMBL622770,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,178.0,10090.0,7092,In vivo,,,,Blood,A,1,BAO_0000218,10107,1,CHEMBL622771,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,178.0,10090.0,7093,In vivo,,,,Blood,A,1,BAO_0000218,10107,1,CHEMBL622772,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594,Mus musculus,Intermediate,178.0,10090.0,7094,In vivo,,,,Blood,A,1,BAO_0000218,10107,1,CHEMBL622773,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,178.0,10090.0,7095,In vivo,,,,Blood,A,1,BAO_0000218,10107,1,CHEMBL622774,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,10000001.0,10090.0,7096,In vivo,,,,Bone,A,1,BAO_0000218,10107,1,CHEMBL621725,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,50594,Mus musculus,Intermediate,10000001.0,10090.0,7097,In vivo,,,,Bone,A,1,BAO_0000218,10107,1,CHEMBL621726,,N
,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,478.0,81034,Homo sapiens,Intermediate,,9606.0,7098,,A2780,,,,F,1,BAO_0000219,15608,1,CHEMBL621727,,N
,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,478.0,81034,Homo sapiens,Expert,,9606.0,7099,,A2780,,,,F,1,BAO_0000219,3290,1,CHEMBL622413,,N
,,Compound was evaluated for cytotoxicity against A2780 cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,7100,,A2780,,,,F,1,BAO_0000219,2859,1,CHEMBL622414,,N
,,Inhibition of A2780 cell clonogenic assay,478.0,81034,Homo sapiens,Expert,,9606.0,7101,,A2780,,,,F,1,BAO_0000219,15688,1,CHEMBL622415,,N
,,Cytotoxic effect on ovarian cancer cell line (A2780),478.0,81034,Homo sapiens,Expert,,9606.0,7102,,A2780,,,,F,1,BAO_0000219,5642,1,CHEMBL884001,,N
,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,478.0,81034,Homo sapiens,Intermediate,,9606.0,7103,,A2780,,,,F,1,BAO_0000219,6633,1,CHEMBL622416,,N
,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",478.0,81034,Homo sapiens,Intermediate,,9606.0,7104,,A2780,,,,F,1,BAO_0000219,3906,1,CHEMBL622417,,N
,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,478.0,81034,Homo sapiens,Expert,,9606.0,7105,,A2780,,,,F,1,BAO_0000219,6788,1,CHEMBL622590,,N
,,Antiproliferative activity against human A2780 cells,478.0,81034,Homo sapiens,Expert,,9606.0,7106,,A2780,,,,F,1,BAO_0000219,17582,1,CHEMBL622591,,N
,,Inhibition of human A2780 cell proliferation,478.0,81034,Homo sapiens,Expert,,9606.0,7107,,A2780,,,,F,1,BAO_0000219,17764,1,CHEMBL622592,,N
,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,478.0,81034,Homo sapiens,Expert,,9606.0,7108,,A2780,,,,F,1,BAO_0000219,17764,1,CHEMBL622593,,N
,,Inhibition of human A2780 cell proliferation (No data),478.0,81034,Homo sapiens,Expert,,9606.0,7109,,A2780,,,,F,1,BAO_0000219,17764,1,CHEMBL622594,,N
,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,7110,,A2780,,,,F,1,BAO_0000219,2815,1,CHEMBL622595,,N
,,Compound was evaluated against human Ovarian carcinoma cell line A2780,478.0,81034,Homo sapiens,Intermediate,,9606.0,7111,,A2780,,,,F,1,BAO_0000219,16930,1,CHEMBL622596,,N
,,Growth inhibition against A2780 wild-type ovarian cell lines,478.0,81034,Homo sapiens,Expert,,9606.0,7112,,A2780,,,,F,1,BAO_0000219,17777,1,CHEMBL622597,,N
,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,478.0,81034,Homo sapiens,Intermediate,,9606.0,7113,,A2780,,,,F,1,BAO_0000219,17777,1,CHEMBL622598,,N
,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,104766,Homo sapiens,Autocuration,,9606.0,7114,,,,,,F,1,BAO_0000019,16936,5,CHEMBL622599,,D
,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,478.0,81034,Homo sapiens,Intermediate,,9606.0,7115,,A2780,,,,F,1,BAO_0000219,13759,1,CHEMBL622600,,N
,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,478.0,81034,Homo sapiens,Intermediate,,9606.0,7116,,A2780,,,,F,1,BAO_0000219,13759,1,CHEMBL622601,,N
,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,478.0,81034,Homo sapiens,Intermediate,,9606.0,7117,,A2780,,,,F,1,BAO_0000219,13759,1,CHEMBL622602,,N
,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,478.0,81034,Homo sapiens,Intermediate,,9606.0,7118,,A2780,,,,F,1,BAO_0000219,13759,1,CHEMBL622603,,N
,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,478.0,81034,Homo sapiens,Intermediate,,9606.0,7119,,A2780,,,,F,1,BAO_0000219,15292,1,CHEMBL622604,,N
,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,478.0,81034,Homo sapiens,Intermediate,,9606.0,7120,,A2780,,,,F,1,BAO_0000219,15292,1,CHEMBL622605,,N
,,In vitro inhibition of human ovarian cell line A2780,478.0,81034,Homo sapiens,Expert,,9606.0,7121,,A2780,,,,F,1,BAO_0000219,15069,1,CHEMBL622606,,N
,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",478.0,81034,Homo sapiens,Expert,,9606.0,7122,,A2780,,,,F,1,BAO_0000219,15069,1,CHEMBL619463,,N
,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),478.0,81034,Homo sapiens,Intermediate,,9606.0,7123,,A2780,,,,F,1,BAO_0000219,14073,1,CHEMBL619464,,N
,,Concentration required to inhibit A2780-cell growth by 50%,478.0,81034,Homo sapiens,Expert,,9606.0,7124,,A2780,,,,F,1,BAO_0000219,14553,1,CHEMBL619465,,N
,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,478.0,81034,Homo sapiens,Expert,,9606.0,7125,,A2780,,,,F,1,BAO_0000219,13040,1,CHEMBL619466,,N
,,Cytotoxic effect on human ovarian (A2780) cancer cell line,478.0,81034,Homo sapiens,Expert,,9606.0,7126,,A2780,,,,F,1,BAO_0000219,6891,1,CHEMBL619467,,N
,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,478.0,81034,Homo sapiens,Intermediate,,9606.0,7127,,A2780,,,,F,1,BAO_0000219,15569,1,CHEMBL619468,,N
,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,478.0,81034,Homo sapiens,Expert,,9606.0,7128,,A2780,,,,F,1,BAO_0000219,14190,1,CHEMBL619469,,N
,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,478.0,81034,Homo sapiens,Expert,,9606.0,7129,,A2780,,,,F,1,BAO_0000219,15014,1,CHEMBL619470,,N
,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,478.0,81034,Homo sapiens,Intermediate,,9606.0,7130,,A2780,,,,F,1,BAO_0000219,15014,1,CHEMBL619471,,N
,,Cytotoxicity against human ovarian carcinoma A2780 cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,7131,,A2780,,,,F,1,BAO_0000219,17496,1,CHEMBL619472,,N
,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",478.0,81034,Homo sapiens,Intermediate,,9606.0,7132,,A2780,,,,F,1,BAO_0000219,13617,1,CHEMBL619473,,N
,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",478.0,81034,Homo sapiens,Intermediate,,9606.0,7133,,A2780,,,,F,1,BAO_0000219,13617,1,CHEMBL874368,,N
,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",478.0,81034,Homo sapiens,Intermediate,,9606.0,7134,,A2780,,,,F,1,BAO_0000219,13617,1,CHEMBL884003,,N
,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",478.0,81034,Homo sapiens,Intermediate,,9606.0,7135,,A2780,,,,F,1,BAO_0000219,13617,1,CHEMBL622690,,N
,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,478.0,81034,Homo sapiens,Intermediate,,9606.0,7136,,A2780,,,,F,1,BAO_0000219,17672,1,CHEMBL622691,,N
,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,478.0,81034,Homo sapiens,Intermediate,,9606.0,7137,,A2780,,,,F,1,BAO_0000219,4544,1,CHEMBL622692,,N
,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,478.0,81034,Homo sapiens,Intermediate,,9606.0,7138,,A2780,,,,F,1,BAO_0000219,4544,1,CHEMBL623406,,N
,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",478.0,81034,Homo sapiens,Intermediate,,9606.0,7139,,A2780,,,,F,1,BAO_0000219,16317,1,CHEMBL884004,,N
,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,478.0,81034,Homo sapiens,Intermediate,,9606.0,7140,,A2780,,,,F,1,BAO_0000219,15099,1,CHEMBL623407,,N
,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,7141,,A2780,,,,F,1,BAO_0000219,13978,1,CHEMBL623408,,N
,,In vitro antitumor activity against A2780 cell line.,478.0,81034,Homo sapiens,Expert,,9606.0,7142,,A2780,,,,F,1,BAO_0000219,12989,1,CHEMBL623409,,N
,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,478.0,81034,Homo sapiens,Intermediate,,9606.0,7143,,A2780,,,,F,1,BAO_0000219,5574,1,CHEMBL623410,,N
,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,478.0,81034,Homo sapiens,Expert,,9606.0,7144,,A2780,,,,F,1,BAO_0000219,13528,1,CHEMBL623576,,N
,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,626.0,80025,Homo sapiens,Intermediate,,9606.0,7145,,ACHN,,,,F,1,BAO_0000219,12782,1,CHEMBL623577,,N
,,The IC50 value was measured on ACHN cell line in renal tumor type.,626.0,80025,Homo sapiens,Intermediate,,9606.0,7146,,ACHN,,,,F,1,BAO_0000219,14255,1,CHEMBL623578,,N
,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,626.0,80025,Homo sapiens,Intermediate,,9606.0,7147,,ACHN,,,,F,1,BAO_0000219,16364,1,CHEMBL623579,,N
,,In vitro lethal concentration against most sensitive ACHN cell line,626.0,80025,Homo sapiens,Expert,,9606.0,7148,,ACHN,,,,F,1,BAO_0000219,17376,1,CHEMBL623580,,N
,,Tested for cytotoxic activity against renal cancer ACHN cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,7149,,ACHN,,,,F,1,BAO_0000219,12016,1,CHEMBL623581,,N
,,Compound tested for growth inhibition of renal cancer cell line ACHN,626.0,80025,Homo sapiens,Intermediate,,9606.0,7150,,ACHN,,,,F,1,BAO_0000219,6058,1,CHEMBL857456,,N
,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,7151,,ACHN,,,,F,1,BAO_0000219,17708,1,CHEMBL623582,,N
,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,626.0,80025,Homo sapiens,Intermediate,,9606.0,7152,,ACHN,,,,F,1,BAO_0000219,15176,1,CHEMBL623583,,N
,,In vitro anticancer activity against ACHN renal cancer cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,7153,,ACHN,,,,F,1,BAO_0000219,2806,1,CHEMBL623584,,N
,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,626.0,80025,Homo sapiens,Intermediate,,9606.0,7154,,ACHN,,,,F,1,BAO_0000219,15300,1,CHEMBL623585,,N
,,Percent selectivity was evaluated in renal ACHN cell lines,626.0,80025,Homo sapiens,Intermediate,,9606.0,7155,,ACHN,,,,F,1,BAO_0000219,16364,1,CHEMBL623586,,N
,,In vitro inhibitory activity against renal ACHN cancer cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,7156,,ACHN,,,,F,1,BAO_0000219,13859,1,CHEMBL623587,,N
,,Tested for cytotoxicity against ACHN cell lines in renal cancer,626.0,80025,Homo sapiens,Intermediate,,9606.0,7157,,ACHN,,,,F,1,BAO_0000219,11970,1,CHEMBL875279,,N
,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,7158,,ACHN,,,,F,1,BAO_0000219,2450,1,CHEMBL623588,,N
,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,626.0,80025,Homo sapiens,Intermediate,,9606.0,7159,,ACHN,,,,F,1,BAO_0000219,12696,1,CHEMBL623589,,N
,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,626.0,80025,Homo sapiens,Intermediate,,9606.0,7160,,ACHN,,,,F,1,BAO_0000219,12400,1,CHEMBL623590,,N
,,Cytotoxic effect on renal cancer line ACHN,626.0,80025,Homo sapiens,Expert,,9606.0,7161,,ACHN,,,,F,1,BAO_0000219,12888,1,CHEMBL623591,,N
,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,7162,,ACHN,,,,F,1,BAO_0000219,3156,1,CHEMBL623592,,N
,,In vitro inhibition of Renal Cancer ACHN cell lines,626.0,80025,Homo sapiens,Intermediate,,9606.0,7163,,ACHN,,,,F,1,BAO_0000219,3381,1,CHEMBL623593,,N
,,Antitumor activity against human renal adenocarcinoma ACHN cells,626.0,80025,Homo sapiens,Intermediate,,9606.0,7164,,ACHN,,,,F,1,BAO_0000219,16747,1,CHEMBL623594,,N
,,Antitumor activity against human renal adenocarcinoma ACHN cells.,626.0,80025,Homo sapiens,Expert,,9606.0,7165,,ACHN,,,,F,1,BAO_0000219,16748,1,CHEMBL621833,,N
,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,626.0,80025,Homo sapiens,Intermediate,,9606.0,7166,,ACHN,,,,F,1,BAO_0000219,12062,1,CHEMBL621834,,N
,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),626.0,80025,Homo sapiens,Intermediate,,9606.0,7167,,ACHN,,,,F,1,BAO_0000219,14769,1,CHEMBL621835,,N
,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",626.0,80025,Homo sapiens,Intermediate,,9606.0,7168,,ACHN,,,,F,1,BAO_0000219,15895,1,CHEMBL621836,,N
,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,626.0,80025,Homo sapiens,Intermediate,,9606.0,7169,,ACHN,,,,F,1,BAO_0000219,17376,1,CHEMBL621837,,N
,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,626.0,80025,Homo sapiens,Intermediate,,9606.0,7170,,ACHN,,,,F,1,BAO_0000219,14882,1,CHEMBL875280,,N
,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,626.0,80025,Homo sapiens,Intermediate,,9606.0,7171,,ACHN,,,,F,1,BAO_0000219,14882,1,CHEMBL621838,,N
,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,626.0,80025,Homo sapiens,Intermediate,,9606.0,7172,,ACHN,,,,F,1,BAO_0000219,15661,1,CHEMBL621839,,N
,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,22224,,Autocuration,,,7173,,,,,,A,1,BAO_0000019,9680,0,CHEMBL621840,,U
,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,10647,,Autocuration,,,7174,,,,,,F,1,BAO_0000019,14579,8,CHEMBL621841,,H
,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,468.0,50529,Cytomegalovirus,Expert,,10358.0,7175,,HEL,,,,F,1,BAO_0000218,17290,1,CHEMBL622979,,N
,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,50529,Cytomegalovirus,Intermediate,,10358.0,7176,,,,,,F,1,BAO_0000218,17290,1,CHEMBL876595,,N
,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,12159,,Autocuration,,,7177,,,,,,B,1,BAO_0000357,15891,8,CHEMBL620221,,H
,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,12159,,Autocuration,,,7178,,,,,,B,1,BAO_0000357,15890,8,CHEMBL620222,,H
,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,979.0,80670,Bos taurus,Intermediate,,9913.0,7179,,ADDP cell line,,,,F,1,BAO_0000219,3801,1,CHEMBL620506,,N
,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,980.0,80671,Mus musculus,Intermediate,,10090.0,7180,,ADJ/PC6,,,,F,1,BAO_0000219,9222,1,CHEMBL620507,,N
,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,980.0,80671,Mus musculus,Intermediate,,10090.0,7181,,ADJ/PC6,,,,F,1,BAO_0000219,9222,1,CHEMBL620508,,N
,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",980.0,80671,Mus musculus,Intermediate,,10090.0,7182,,ADJ/PC6,,,,F,1,BAO_0000219,7257,1,CHEMBL620509,,N
,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,980.0,80671,Mus musculus,Intermediate,,10090.0,7183,,ADJ/PC6,,,,F,1,BAO_0000219,7257,1,CHEMBL620510,,N
,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,980.0,80671,Mus musculus,Intermediate,,10090.0,7184,,ADJ/PC6,,,,A,1,BAO_0000219,7257,1,CHEMBL620511,,N
,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,980.0,80671,Mus musculus,Intermediate,,10090.0,7185,,ADJ/PC6,,,,F,1,BAO_0000219,8084,1,CHEMBL620512,,N
,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,22224,Mus musculus,Autocuration,,10090.0,7186,,,,,,F,1,BAO_0000019,14943,0,CHEMBL620513,,U
,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,22224,Mus musculus,Autocuration,,10090.0,7187,,,,,,F,1,BAO_0000019,14943,0,CHEMBL620514,,U
,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,22224,Mus musculus,Autocuration,,10090.0,7188,,,,,,F,1,BAO_0000019,14943,0,CHEMBL620515,,U
,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,22224,Bacillus subtilis,Autocuration,,1423.0,7189,In vivo,,,,,A,1,BAO_0000218,10524,0,CHEMBL620516,,U
,,AUC value in dog after IV administration at a dose of 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7190,,,,,Plasma,A,1,BAO_0000218,3546,1,CHEMBL620517,,N
,,AUC value in dog after oral administration at a dose of 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7191,,,,,Plasma,A,1,BAO_0000218,3546,1,CHEMBL620518,,N
,,Cmax value in dog after oral administration at a dose of 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7192,In vivo,,,,,A,1,BAO_0000218,3546,1,CHEMBL620519,,N
,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7193,In vivo,,,,,A,1,BAO_0000218,3546,1,CHEMBL621386,,N
,,Tmax value in dog after oral administration at a dose of 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7194,In vivo,,,,,A,1,BAO_0000218,3546,1,CHEMBL621387,,N
,,Compound was evaluated for its clearance when administered intravenously in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7195,In vivo,,,,,A,1,BAO_0000218,3184,1,CHEMBL621388,,N
,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7196,In vivo,,,,,A,1,BAO_0000218,16456,1,CHEMBL621389,,N
,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,7197,In vivo,,,,,A,1,BAO_0000218,4809,1,CHEMBL621390,,N
,,Calculated partition coefficient (clogP),,22229,,Intermediate,,,7198,,,,,,P,1,BAO_0000100,4219,0,CHEMBL621391,,U
,,Half life in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7199,,,,,,A,1,BAO_0000218,3748,1,CHEMBL621392,,N
,,Time taken for EC90 was determined when tested in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7200,,,,,,A,1,BAO_0000218,3132,1,CHEMBL621393,,N
,,Half life (iv) was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7201,,,,,,A,1,BAO_0000218,4219,1,CHEMBL621394,,N
,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,50588,Canis lupus familiaris,Intermediate,2107.0,9615.0,7202,,,,,Liver,A,1,BAO_0000218,16907,1,CHEMBL621395,,N
,,Area under the curve was calculated in dog after iv administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,7203,,,,,,A,1,BAO_0000218,6057,1,CHEMBL621396,,N
,,Area under the curve was calculated in dog after peroral administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,7204,,,,,,A,1,BAO_0000218,6057,1,CHEMBL621397,,N
,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,50588,Canis lupus familiaris,Intermediate,,9615.0,7205,,,,,,A,1,BAO_0000218,17853,1,CHEMBL621398,,N
,,pKa was evaluated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7206,,,,,,A,1,BAO_0000218,3639,1,CHEMBL618818,,N
,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,50588,Canis lupus familiaris,Intermediate,,9615.0,7207,,,,,,A,1,BAO_0000218,14541,1,CHEMBL618819,,N
,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7208,In vivo,,,,,A,1,BAO_0000218,16456,1,CHEMBL618820,,N
,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7209,In vivo,,,,,A,1,BAO_0000218,16456,1,CHEMBL873810,,N
,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,50588,Canis lupus familiaris,Intermediate,,9615.0,7210,In vivo,,,,,A,1,BAO_0000218,2652,1,CHEMBL876606,,N
,,Compound was evaluated for the half-life (t 1/2) in hours,,50588,Canis lupus familiaris,Intermediate,,9615.0,7211,,,,,,A,1,BAO_0000218,3624,1,CHEMBL618821,,N
,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,50588,Canis lupus familiaris,Intermediate,178.0,9615.0,7212,In vivo,,,,Blood,A,1,BAO_0000218,1337,1,CHEMBL618822,,N
,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,50588,Canis lupus familiaris,Intermediate,178.0,9615.0,7213,In vivo,,,,Blood,A,1,BAO_0000218,1337,1,CHEMBL618823,,N
,,Half life after intravenous administration of 1 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7214,In vivo,,,,,A,1,BAO_0000218,4709,1,CHEMBL618824,,N
,,Half life was measured in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7215,,,,,,A,1,BAO_0000218,15660,1,CHEMBL618825,,N
,,Half life period in dog after 5 mg/kg dose,,50588,Canis lupus familiaris,Intermediate,,9615.0,7216,In vivo,,,,,A,1,BAO_0000218,5302,1,CHEMBL618826,,N
,,Half life period was evaluated in dog; 4-4.8,,50588,Canis lupus familiaris,Intermediate,,9615.0,7217,,,,,,A,1,BAO_0000218,17791,1,CHEMBL618827,,N
,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,7218,In vivo,,,,,A,1,BAO_0000218,6348,1,CHEMBL618828,,N
,,Half-life was determined in dog after a3 mg/kg of iv dose,,50588,Canis lupus familiaris,Intermediate,,9615.0,7219,In vivo,,,,,A,1,BAO_0000218,4257,1,CHEMBL618829,,N
,,Half-life was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7220,,,,,,A,1,BAO_0000218,3771,1,CHEMBL618830,,N
,,Half life in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,7221,,,,,,A,1,BAO_0000218,6305,1,CHEMBL618831,,N
,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7222,In vivo,,,,Plasma,A,1,BAO_0000218,13501,1,CHEMBL619489,,N
,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,7223,In vivo,,,,,A,1,BAO_0000218,17594,1,CHEMBL619649,,N
,,Compound was evaluated for the half life period after iv administration in Beagle dog.,,50588,Canis lupus familiaris,Intermediate,,9615.0,7224,In vivo,,,,,A,1,BAO_0000218,3045,1,CHEMBL876607,,N
,,Compound was evaluated for the half life period after oral administration in conscious dog.,,50588,Canis lupus familiaris,Intermediate,,9615.0,7225,In vivo,,,,,A,1,BAO_0000218,3043,1,CHEMBL619650,,N
,,Compound was tested for half life in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7226,,,,,,A,1,BAO_0000218,4839,1,CHEMBL619651,,N
,,Compound was tested for its half life in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7227,,,,,,A,1,BAO_0000218,4839,1,CHEMBL619652,,N
,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7228,In vivo,,,,,A,1,BAO_0000218,5802,1,CHEMBL619653,,N
,,Half life of compound in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7229,,,,,,A,1,BAO_0000218,17839,1,CHEMBL619654,,N
,,Half life (iv) was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7230,In vivo,,,,,A,1,BAO_0000218,4219,1,CHEMBL619655,,N
,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,50588,Canis lupus familiaris,Intermediate,178.0,9615.0,7231,,,,,Blood,A,1,BAO_0000218,13966,1,CHEMBL619656,,N
,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7232,In vivo,,,,Plasma,A,1,BAO_0000218,3994,1,CHEMBL873812,,N
,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7233,In vivo,,,,Plasma,F,1,BAO_0000218,3994,1,CHEMBL621365,,N
,,Half life in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7234,,,,,,A,1,BAO_0000218,4453,1,CHEMBL621366,,N
,,Half life in dog plasma,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7235,,,,,Plasma,A,1,BAO_0000218,6535,1,CHEMBL621367,,N
,,Half life in dog plasma after administration of 0.25 mg/kg iv,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7236,In vivo,,,,Plasma,A,1,BAO_0000218,6535,1,CHEMBL621368,,N
,,Half life in dog plasma after administration of 1 mg/kg iv,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7237,In vivo,,,,Plasma,A,1,BAO_0000218,6535,1,CHEMBL621369,,N
,,Half life in dog plasma was determined at dose 10 mg/kg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7238,In vivo,,,,Plasma,A,1,BAO_0000218,3132,1,CHEMBL621370,,N
,,Half life in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7239,,,,,,A,1,BAO_0000218,5374,1,CHEMBL621371,,N
,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,7240,In vivo,,,,,A,1,BAO_0000218,5007,1,CHEMBL621372,,N
,,Half life upon exposure to human plasma,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7241,,,,,Plasma,A,1,BAO_0000218,16907,1,CHEMBL621373,,N
,,Half life was calculated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7242,,,,,,A,1,BAO_0000218,6057,1,CHEMBL621374,,N
,,Half life was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7243,,,,,,A,1,BAO_0000218,5006,1,CHEMBL621375,,N
,,Half life was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7244,,,,,,A,1,BAO_0000218,5473,1,CHEMBL621376,,N
,,Half life by intravenous administration of 1.2 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7245,In vivo,,,,,A,1,BAO_0000218,4368,1,CHEMBL619624,,N
,,Half life in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7246,,,,,,A,1,BAO_0000218,6448,1,CHEMBL875840,,N
,,Half life in dog after intra venous administration of the compound,,50588,Canis lupus familiaris,Intermediate,,9615.0,7247,,,,,,A,1,BAO_0000218,4353,1,CHEMBL619625,,N
,,Half life in dog after intra venous administration of the compound; ND means Not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7248,,,,,,A,1,BAO_0000218,4353,1,CHEMBL619626,,N
,,Half life in dog after po administration of the compound,,50588,Canis lupus familiaris,Intermediate,,9615.0,7249,In vivo,,,,,A,1,BAO_0000218,4353,1,CHEMBL619627,,N
,,Half life in dog after po administration of the compound; ND means Not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7250,In vivo,,,,,A,1,BAO_0000218,4353,1,CHEMBL873817,,N
,,Half life in dog at the single oral dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7251,In vivo,,,,,A,1,BAO_0000218,6265,1,CHEMBL619628,,N
,,Half life in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,7252,,,,,,A,1,BAO_0000218,5006,1,CHEMBL619629,,N
,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,50588,Canis lupus familiaris,Intermediate,,9615.0,7253,In vivo,,,,,A,1,BAO_0000218,5356,1,CHEMBL619630,,N
,,Half life in rat,,50588,Canis lupus familiaris,Intermediate,,9615.0,7254,,,,,,A,1,BAO_0000218,405,1,CHEMBL619631,,N
,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,50588,Canis lupus familiaris,Intermediate,,9615.0,7255,In vivo,,,,,A,1,BAO_0000218,6642,1,CHEMBL619632,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,10000001.0,10090.0,7256,In vivo,,,,Bone,A,1,BAO_0000218,10107,1,CHEMBL619633,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,10000001.0,10090.0,7257,In vivo,,,,Bone,A,1,BAO_0000218,10107,1,CHEMBL875841,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,10000001.0,10090.0,7258,In vivo,,,,Bone,A,1,BAO_0000218,10107,1,CHEMBL619634,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594,Mus musculus,Intermediate,10000001.0,10090.0,7259,In vivo,,,,Bone,A,1,BAO_0000218,10107,1,CHEMBL619635,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,10000001.0,10090.0,7260,In vivo,,,,Bone,A,1,BAO_0000218,10107,1,CHEMBL619636,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,10000004.0,10090.0,7261,In vivo,,,,Gut,A,1,BAO_0000218,10107,1,CHEMBL619637,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594,Mus musculus,Intermediate,10000004.0,10090.0,7262,In vivo,,,,Gut,A,1,BAO_0000218,10107,1,CHEMBL619638,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,10000004.0,10090.0,7263,In vivo,,,,Gut,A,1,BAO_0000218,10107,1,CHEMBL619639,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,10000004.0,10090.0,7264,In vivo,,,,Gut,A,1,BAO_0000218,10107,1,CHEMBL619640,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,10000004.0,10090.0,7265,In vivo,,,,Gut,A,1,BAO_0000218,10107,1,CHEMBL619641,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594,Mus musculus,Intermediate,10000004.0,10090.0,7266,In vivo,,,,Gut,A,1,BAO_0000218,10107,1,CHEMBL619642,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,10000004.0,10090.0,7267,In vivo,,,,Gut,A,1,BAO_0000218,10107,1,CHEMBL619643,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,948.0,10090.0,7268,In vivo,,,,Heart,A,1,BAO_0000218,10107,1,CHEMBL619644,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594,Mus musculus,Intermediate,948.0,10090.0,7269,In vivo,,,,Heart,A,1,BAO_0000218,10107,1,CHEMBL621112,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,948.0,10090.0,7270,In vivo,,,,Heart,A,1,BAO_0000218,10107,1,CHEMBL621113,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,948.0,10090.0,7271,In vivo,,,,Heart,A,1,BAO_0000218,10107,1,CHEMBL621114,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,948.0,10090.0,7272,In vivo,,,,Heart,A,1,BAO_0000218,10107,1,CHEMBL621115,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594,Mus musculus,Intermediate,948.0,10090.0,7273,In vivo,,,,Heart,A,1,BAO_0000218,10107,1,CHEMBL621116,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,948.0,10090.0,7274,In vivo,,,,Heart,A,1,BAO_0000218,10107,1,CHEMBL621117,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,2113.0,10090.0,7275,In vivo,,,,Kidney,A,1,BAO_0000218,10107,1,CHEMBL621118,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,50594,Mus musculus,Intermediate,2113.0,10090.0,7276,In vivo,,,,Kidney,A,1,BAO_0000218,10107,1,CHEMBL621119,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,2113.0,10090.0,7277,In vivo,,,,Kidney,A,1,BAO_0000218,10107,1,CHEMBL621120,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,2113.0,10090.0,7278,In vivo,,,,Kidney,A,1,BAO_0000218,10107,1,CHEMBL621757,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,2113.0,10090.0,7279,In vivo,,,,Kidney,A,1,BAO_0000218,10107,1,CHEMBL621758,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594,Mus musculus,Intermediate,2113.0,10090.0,7280,In vivo,,,,Kidney,A,1,BAO_0000218,10107,1,CHEMBL621759,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,2113.0,10090.0,7281,In vivo,,,,Kidney,A,1,BAO_0000218,10107,1,CHEMBL621760,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,2107.0,10090.0,7282,In vivo,,,,Liver,A,1,BAO_0000218,10107,1,CHEMBL621761,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594,Mus musculus,Intermediate,2107.0,10090.0,7283,In vivo,,,,Liver,A,1,BAO_0000218,10107,1,CHEMBL621762,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,2107.0,10090.0,7284,In vivo,,,,Liver,A,1,BAO_0000218,10107,1,CHEMBL621763,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,2107.0,10090.0,7285,In vivo,,,,Liver,A,1,BAO_0000218,10107,1,CHEMBL624502,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,2107.0,10090.0,7286,In vivo,,,,Liver,A,1,BAO_0000218,10107,1,CHEMBL624503,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594,Mus musculus,Intermediate,2107.0,10090.0,7287,In vivo,,,,Liver,A,1,BAO_0000218,10107,1,CHEMBL624504,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,2107.0,10090.0,7288,In vivo,,,,Liver,A,1,BAO_0000218,10107,1,CHEMBL624505,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,2048.0,10090.0,7289,In vivo,,,,Lung,A,1,BAO_0000218,10107,1,CHEMBL624506,,N
,,In vitro cytotoxicity against A2780 (human ovarian cancer),478.0,81034,Homo sapiens,Intermediate,,9606.0,7290,,A2780,,,,F,1,BAO_0000219,5895,1,CHEMBL624507,,N
,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,478.0,81034,Homo sapiens,Intermediate,,9606.0,7291,,A2780,,,,F,1,BAO_0000219,6338,1,CHEMBL624508,,N
,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,478.0,81034,Homo sapiens,Intermediate,,9606.0,7292,,A2780,,,,F,1,BAO_0000219,15163,1,CHEMBL624509,,N
,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,478.0,81034,Homo sapiens,Intermediate,,9606.0,7293,,A2780,,,,F,1,BAO_0000219,15163,1,CHEMBL624510,,N
,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,478.0,81034,Homo sapiens,Expert,,9606.0,7294,,A2780,,,,F,1,BAO_0000219,15000,1,CHEMBL875956,,N
,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,478.0,81034,Homo sapiens,Expert,,9606.0,7295,,A2780,,,,F,1,BAO_0000219,15000,1,CHEMBL839885,,N
,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,478.0,81034,Homo sapiens,Expert,,9606.0,7296,,A2780,,,,F,1,BAO_0000219,14729,1,CHEMBL624511,,N
,,In vitro cytotoxicity against A2780 cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,7297,,A2780,,,,F,1,BAO_0000219,17270,1,CHEMBL624512,,N
,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,478.0,81034,Homo sapiens,Intermediate,,9606.0,7298,,A2780,,,,F,1,BAO_0000219,5685,1,CHEMBL624513,,N
,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,7299,,A2780,,,,F,1,BAO_0000219,3563,1,CHEMBL624514,,N
,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,478.0,81034,Homo sapiens,Intermediate,,9606.0,7300,,A2780,,,,F,1,BAO_0000218,17753,1,CHEMBL618547,,N
,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",478.0,81034,Homo sapiens,Intermediate,,9606.0,7301,,A2780,,,,F,1,BAO_0000219,16317,1,CHEMBL618548,,N
,,Inhibition of tubulin polymerization in analogy of ca.,478.0,81034,Homo sapiens,Intermediate,,9606.0,7302,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL618549,,N
,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,478.0,81034,Homo sapiens,Intermediate,,9606.0,7303,,A2780,,,,F,1,BAO_0000219,3801,1,CHEMBL618550,,N
,,Cytotoxic effect in ovarian cancer cell line (A2780),478.0,81034,Homo sapiens,Expert,,9606.0,7304,,A2780,,,,F,1,BAO_0000219,6181,1,CHEMBL618551,,N
,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,478.0,81034,Homo sapiens,Intermediate,,9606.0,7305,,A2780,,,,F,1,BAO_0000219,5318,1,CHEMBL618552,,N
,,Tested for the cytotoxicity in A2780 ovarian cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,7306,,A2780,,,,F,1,BAO_0000219,4840,1,CHEMBL618553,,N
,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),478.0,81034,Homo sapiens,Intermediate,,9606.0,7307,,A2780,,,,F,1,BAO_0000219,15748,1,CHEMBL618554,,N
,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,478.0,81034,Homo sapiens,Intermediate,,9606.0,7308,,A2780,,,,F,1,BAO_0000219,15748,1,CHEMBL618555,,N
,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,481.0,80017,,Intermediate,,,7309,,A2780cisR,,,,F,1,BAO_0000219,15748,1,CHEMBL618556,,N
,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),481.0,80017,,Intermediate,,,7310,,A2780cisR,,,,F,1,BAO_0000219,15748,1,CHEMBL618557,,N
,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,481.0,80017,,Intermediate,,,7311,,A2780cisR,,,,F,1,BAO_0000219,15748,1,CHEMBL618558,,N
,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),481.0,80017,,Intermediate,,,7312,,A2780cisR,,,,F,1,BAO_0000219,15748,1,CHEMBL618559,,N
,,In vivo log of cells killed after administration of compound in A2780 cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,7313,,A2780,,,,F,1,BAO_0000218,17753,1,CHEMBL618560,,N
,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,7314,In vivo,A2780,,,,F,1,BAO_0000218,17753,1,CHEMBL618561,,N
,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,478.0,81034,Homo sapiens,Intermediate,,9606.0,7315,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL618562,,N
,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,478.0,81034,Homo sapiens,Intermediate,,9606.0,7316,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL618563,,N
,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,478.0,81034,Homo sapiens,Intermediate,,9606.0,7317,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL618564,,N
,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,478.0,81034,Homo sapiens,Intermediate,,9606.0,7318,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL618565,,N
,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),478.0,81034,Homo sapiens,Intermediate,,9606.0,7319,,A2780,,,,F,1,BAO_0000218,17528,1,CHEMBL618566,,N
,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,478.0,81034,Homo sapiens,Intermediate,,9606.0,7320,,A2780,,,,F,1,BAO_0000219,6633,1,CHEMBL618567,,N
,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,478.0,81034,Homo sapiens,Expert,,9606.0,7321,,A2780,,,,F,1,BAO_0000219,15000,1,CHEMBL618568,,N
,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,478.0,81034,Homo sapiens,Expert,,9606.0,7322,,A2780,,,,F,1,BAO_0000219,17528,1,CHEMBL618569,,N
,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,478.0,81034,Homo sapiens,Intermediate,,9606.0,7323,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL621857,,N
,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,478.0,81034,Homo sapiens,Intermediate,,9606.0,7324,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL621858,,N
,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,478.0,81034,Homo sapiens,Intermediate,,9606.0,7325,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL621859,,N
,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",478.0,81034,Homo sapiens,Intermediate,,9606.0,7326,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL621860,,N
,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),478.0,81034,Homo sapiens,Intermediate,,9606.0,7327,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL621861,,N
,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",478.0,81034,Homo sapiens,Expert,,9606.0,7328,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL621862,,N
,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),478.0,81034,Homo sapiens,Intermediate,,9606.0,7329,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL621863,,N
,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),478.0,81034,Homo sapiens,Intermediate,,9606.0,7330,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL621864,,N
,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),478.0,81034,Homo sapiens,Intermediate,,9606.0,7331,,A2780,,,,F,1,BAO_0000219,16936,1,CHEMBL621865,,N
,,In vitro antiproliferative activity against A2780 cell line,478.0,81034,Mus musculus,Intermediate,,10090.0,7332,,A2780,,,,F,1,BAO_0000219,17737,1,CHEMBL621866,,N
,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,478.0,81034,Mus musculus,Expert,,10090.0,7333,,A2780,,,,F,1,BAO_0000219,17764,1,CHEMBL621867,,N
,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,478.0,81034,Homo sapiens,Intermediate,,9606.0,7334,,A2780,,,,F,1,BAO_0000219,3830,1,CHEMBL621868,,N
,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,478.0,81034,Homo sapiens,Intermediate,,9606.0,7335,,A2780,,,,F,1,BAO_0000219,3829,1,CHEMBL875282,,N
,,Vc value in dog after IV administration at a dose of 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7336,,,,,,A,1,BAO_0000218,3546,1,CHEMBL621869,,N
,,Half life period in dog after IV administration at a dose of 5 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7337,In vivo,,,,,A,1,BAO_0000218,3546,1,CHEMBL621870,,N
,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,22224,Cercopithecidae,Autocuration,,9527.0,7338,,,,,,A,1,BAO_0000019,5668,0,CHEMBL621871,,U
,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,7339,,,,,Plasma,A,1,BAO_0000218,3443,0,CHEMBL621243,,U
,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,1969.0,9527.0,7340,,,,,Plasma,A,1,BAO_0000218,3443,0,CHEMBL621244,,U
,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,22224,Macaca fascicularis,Autocuration,,9541.0,7341,In vivo,,,,,A,1,BAO_0000218,4256,0,CHEMBL621245,,U
,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,22224,Macaca fascicularis,Autocuration,,9541.0,7342,In vivo,,,,,A,1,BAO_0000218,4256,0,CHEMBL621246,,U
,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,22224,Macaca fascicularis,Autocuration,,9541.0,7343,In vivo,,,,,A,1,BAO_0000218,4256,0,CHEMBL621247,,U
,,Oral Bioavailability in rat,,22224,Rattus norvegicus,Autocuration,,10116.0,7344,In vivo,,,,,A,1,BAO_0000218,4256,0,CHEMBL618386,,U
,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,22224,Cercopithecidae,Autocuration,,9527.0,7345,,,,,,A,1,BAO_0000218,1916,0,CHEMBL618387,,U
,,Area under curve value in monkey at a dose of 5 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,7346,,,,,,A,1,BAO_0000218,5302,0,CHEMBL618388,,U
,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,22224,Cercopithecidae,Autocuration,,9527.0,7347,,,,,,A,1,BAO_0000218,4257,0,CHEMBL618389,,U
,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,7348,,,,,,A,1,BAO_0000019,5355,0,CHEMBL618574,,U
,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,7349,,,,,,A,1,BAO_0000019,5355,0,CHEMBL618575,,U
,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,22224,Cercopithecidae,Autocuration,,9527.0,7350,,,,,,A,1,BAO_0000019,5355,0,CHEMBL618576,,U
,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,7351,,,,,,A,1,BAO_0000218,6078,0,CHEMBL618577,,U
,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,7352,,,,,,A,1,BAO_0000218,6078,0,CHEMBL876487,,U
,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,7353,,,,,,A,1,BAO_0000218,6062,0,CHEMBL618578,,U
,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,7354,,,,,,A,1,BAO_0000218,2661,0,CHEMBL618579,,U
,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,7355,,,,,,A,1,BAO_0000019,2661,0,CHEMBL618580,,U
,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,7356,,,,,,A,1,BAO_0000218,5394,0,CHEMBL618581,,U
,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,22224,Cercopithecidae,Autocuration,,9527.0,7357,,,,,,A,1,BAO_0000218,4397,0,CHEMBL618582,,U
,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,7358,,,,,,A,1,BAO_0000218,17509,0,CHEMBL618583,,U
,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,7359,,,,,,A,1,BAO_0000218,17509,0,CHEMBL618584,,U
,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,22224,Cercopithecidae,Autocuration,,9527.0,7360,In vivo,,,,,A,1,BAO_0000218,6641,0,CHEMBL618585,,U
,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,22224,Cercopithecidae,Autocuration,,9527.0,7361,,,,,,A,1,BAO_0000218,5355,0,CHEMBL618586,,U
,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,,9527.0,7362,In vivo,,,,,A,1,BAO_0000218,3443,0,CHEMBL618587,,U
,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,22224,Cercopithecidae,Autocuration,,9527.0,7363,In vivo,,,,,A,1,BAO_0000218,3443,0,CHEMBL618588,,U
,,Binding towards monkey plasma protein at 10 uM,,22224,Cercopithecidae,Autocuration,,9527.0,7364,,,,,,A,1,BAO_0000019,17409,0,CHEMBL618589,,U
,,Binding towards monkey plasma protein at 100 uM,,22224,Cercopithecidae,Autocuration,,9527.0,7365,,,,,,A,1,BAO_0000019,17409,0,CHEMBL618590,,U
,,Apparent bioavailability in squirrel monkey was determined,,22224,Cercopithecidae,Autocuration,,9527.0,7366,In vivo,,,,,A,1,BAO_0000218,1052,0,CHEMBL872262,,U
,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,7367,In vivo,,,,,A,1,BAO_0000218,13501,0,CHEMBL618591,,U
,,Bioavailability in monkey (dose 2 mg/kg),,22224,monkey,Autocuration,,9443.0,7368,In vivo,,,,,A,1,BAO_0000218,17509,0,CHEMBL618592,,U
,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,7369,In vivo,,,,,A,1,BAO_0000218,5394,0,CHEMBL876488,,U
,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,7370,In vivo,,,,,A,1,BAO_0000218,2661,0,CHEMBL618593,,U
,,Bioavailability in monkey (i.d. dosing),,22224,monkey,Autocuration,,9443.0,7371,In vivo,,,,,A,1,BAO_0000218,11219,0,CHEMBL618594,,U
,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,22224,Cercopithecidae,Autocuration,,9527.0,7372,In vivo,,,,,A,1,BAO_0000218,3045,0,CHEMBL618595,,U
,,Clearance of the drug was measured in cynomolgus,,22224,Cercopithecidae,Autocuration,,9527.0,7373,,,,,,A,1,BAO_0000019,17796,0,CHEMBL621469,,U
,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,22224,Cercopithecidae,Autocuration,,9527.0,7374,In vivo,,,,,A,1,BAO_0000218,1399,0,CHEMBL621470,,U
,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,7375,In vivo,,,,,A,1,BAO_0000218,2661,0,CHEMBL621471,,U
,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,22224,Macaca mulatta,Autocuration,1969.0,9544.0,7376,In vivo,,,,Plasma,A,1,BAO_0000218,5005,0,CHEMBL621472,,U
,,Plasma clearance in rhesus monkey was determined,,22224,Cercopithecidae,Autocuration,,9527.0,7377,In vivo,,,,,A,1,BAO_0000218,17267,0,CHEMBL621473,,U
,,Plasma clearance in monkey after administration of 1 mg/kg iv,,22224,Cercopithecidae,Autocuration,,9527.0,7378,In vivo,,,,,A,1,BAO_0000218,6535,0,CHEMBL621474,,U
,,Plasma clearance in cynomolgus monkey,,22224,Cercopithecidae,Autocuration,,9527.0,7379,In vivo,,,,,A,1,BAO_0000218,5922,0,CHEMBL621475,,U
,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,22224,Cercopithecidae,Autocuration,,9527.0,7380,In vivo,,,,,A,1,BAO_0000218,6221,0,CHEMBL621476,,U
,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,22224,Cercopithecidae,Autocuration,,9527.0,7381,In vivo,,,,,A,1,BAO_0000218,5668,0,CHEMBL624290,,U
,,The total clearance was determined after intravenous administration in cynomolgus monkeys,,22224,Cercopithecidae,Autocuration,,9527.0,7382,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL624291,,U
,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,22224,Cercopithecidae,Autocuration,,9527.0,7383,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL624292,,U
,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,22224,Cercopithecidae,Autocuration,,9527.0,7384,In vivo,,,,,A,1,BAO_0000218,5355,0,CHEMBL624293,,U
,,Tested for Clearance upon iv administration to african green monkey,,22224,Cercopithecidae,Autocuration,,9527.0,7385,In vivo,,,,,A,1,BAO_0000218,4578,0,CHEMBL624294,,U
,,Clearance in monkey,,22224,Cercopithecidae,Autocuration,,9527.0,7386,In vivo,,,,,A,1,BAO_0000218,17592,0,CHEMBL624295,,U
,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588,Canis lupus familiaris,Intermediate,,9615.0,7387,In vivo,,,,,A,1,BAO_0000218,6641,1,CHEMBL624296,,N
,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,50588,Canis lupus familiaris,Intermediate,,9615.0,7388,In vivo,,,,,A,1,BAO_0000218,6642,1,CHEMBL624297,,N
,,Half life was evaluated after intravenous administration to dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,7389,In vivo,,,,,A,1,BAO_0000218,16367,1,CHEMBL624298,,N
,,Half life was evaluated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7390,,,,,,A,1,BAO_0000218,5472,1,CHEMBL624299,,N
,,Half life was evaluated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7391,,,,,,A,1,BAO_0000218,5474,1,CHEMBL624300,,N
,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7392,In vivo,,,,,A,1,BAO_0000218,5654,1,CHEMBL624301,,N
,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,50588,Canis lupus familiaris,Intermediate,,9615.0,7393,In vivo,,,,,A,1,BAO_0000218,6227,1,CHEMBL624302,,N
,,Half life period after intravenous administration in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7394,In vivo,,,,,A,1,BAO_0000218,6227,1,CHEMBL876026,,N
,,Half life period after oral administration (2.5 mg/kg) in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7395,In vivo,,,,,A,1,BAO_0000218,6221,1,CHEMBL624303,,N
,,Half life period at a dose of 1 uM/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7396,,,,,,A,1,BAO_0000218,4527,1,CHEMBL624304,,N
,,Half life period was determine after peroral administration at 10 mpk in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7397,In vivo,,,,,A,1,BAO_0000218,5668,1,CHEMBL624305,,N
,,Half life period was determine after peroral administration at 5 mpk in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7398,In vivo,,,,,A,1,BAO_0000218,5668,1,CHEMBL624306,,N
,,Half life period was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7399,,,,,,A,1,BAO_0000218,3854,1,CHEMBL624307,,N
,,Half life period was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7400,,,,,,A,1,BAO_0000218,5505,1,CHEMBL624308,,N
,,Half life period by iv administration in dog at a dose of 6 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7401,In vivo,,,,,A,1,BAO_0000218,6251,1,CHEMBL624309,,N
,,Half life period was evaluated in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7402,,,,,,A,1,BAO_0000218,1918,1,CHEMBL624310,,N
,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,7403,In vivo,,,,,A,1,BAO_0000218,5546,1,CHEMBL625003,,N
,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,7404,In vivo,,,,,A,1,BAO_0000218,4809,1,CHEMBL625004,,N
,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7405,In vivo,,,,,A,1,BAO_0000218,6215,1,CHEMBL625005,,N
,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7406,In vivo,,,,,A,1,BAO_0000218,4527,1,CHEMBL873813,,N
,,Half-life after oral dose of compound at 3 mg/kg in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,7407,In vivo,,,,,A,1,BAO_0000218,17594,1,CHEMBL625006,,N
,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7408,In vivo,,,,,A,1,BAO_0000218,17839,1,CHEMBL625007,,N
,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7409,In vivo,,,,,A,1,BAO_0000218,17839,1,CHEMBL876027,,N
,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7410,In vivo,,,,,A,1,BAO_0000218,17839,1,CHEMBL625008,,N
,,Half-life of compound in dog following p.o. administration of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7411,In vivo,,,,,A,1,BAO_0000218,17839,1,CHEMBL625009,,N
,,Half-life of compound in plasma of dog was determined,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7412,,,,,Plasma,A,1,BAO_0000218,5210,1,CHEMBL625010,,N
,,Half-life of compound was determined in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,7413,,,,,,A,1,BAO_0000218,5210,1,CHEMBL625011,,N
,,Half-life after administration of 4 mg/Kg oral dose in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7414,In vivo,,,,,A,1,BAO_0000218,2959,1,CHEMBL621553,,N
,,Half-life after intravenous administration of 1 mg/kg/h in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7415,In vivo,,,,,A,1,BAO_0000218,4137,1,CHEMBL621554,,N
,,Half-life in Dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7416,,,,,,A,1,BAO_0000218,5064,1,CHEMBL621555,,N
,,Half-life in Dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7417,,,,,,A,1,BAO_0000218,5147,1,CHEMBL621556,,N
,,Half-life in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7418,,,,,,A,1,BAO_0000218,5145,1,CHEMBL621557,,N
,,Half-life in dog after oral administration at 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7419,In vivo,,,,,A,1,BAO_0000218,6123,1,CHEMBL621558,,N
,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7420,In vivo,,,,,A,1,BAO_0000218,6123,1,CHEMBL621559,,N
,,Half-life in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,7421,,,,,,A,1,BAO_0000218,4333,1,CHEMBL621560,,N
,,Half-life in dogs; ND indicates not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7422,,,,,,A,1,BAO_0000218,4333,1,CHEMBL876028,,N
,,Half-life in plasma of dog,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7423,,,,,Plasma,A,1,BAO_0000218,12500,1,CHEMBL621561,,N
,,Half-life in plasma of dog at dose of 3-10 mgkg,,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7424,,,,,Plasma,A,1,BAO_0000218,12500,1,CHEMBL621562,,N
,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7425,In vivo,,,,,A,1,BAO_0000218,6005,1,CHEMBL621563,,N
,,Half-life was measured in dog after an iv dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7426,In vivo,,,,,A,1,BAO_0000218,6062,1,CHEMBL621564,,N
,,Half-life was measured in dogs after an oral dose of 10 uM/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7427,In vivo,,,,,A,1,BAO_0000218,17650,1,CHEMBL621565,,N
,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7428,In vivo,,,,,A,1,BAO_0000218,5530,1,CHEMBL621566,,N
,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,50588,Canis lupus familiaris,Intermediate,,9615.0,7429,In vivo,,,,,A,1,BAO_0000218,5530,1,CHEMBL621567,,N
,,Half-life of the compound after 0.3 mg/kg po administration in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7430,In vivo,,,,,A,1,BAO_0000218,5600,1,CHEMBL622978,,N
,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7431,In vivo,,,,,A,1,BAO_0000218,6039,1,CHEMBL873814,,N
,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7432,In vivo,,,,,A,1,BAO_0000218,6039,1,CHEMBL623219,,N
,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7433,In vivo,,,,,A,1,BAO_0000218,6039,1,CHEMBL624477,,N
,,t1/2 in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7434,,,,,,A,1,BAO_0000218,6227,1,CHEMBL624478,,N
,,Half-life period measured in dogs,,50588,Canis lupus familiaris,Intermediate,,9615.0,7435,,,,,,A,1,BAO_0000218,14541,1,CHEMBL624479,,N
,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,7436,In vivo,,,,,A,1,BAO_0000218,4521,1,CHEMBL624480,,N
,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7437,In vivo,,,,,A,1,BAO_0000218,4521,1,CHEMBL623595,,N
,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,50588,Canis lupus familiaris,Intermediate,,9615.0,7438,In vivo,,,,,A,1,BAO_0000218,6679,1,CHEMBL623596,,N
,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,50588,Canis lupus familiaris,Intermediate,1969.0,9615.0,7439,In vitro,,,,Plasma,A,1,BAO_0000218,1116,1,CHEMBL623597,,N
,,In vivo half life period was calculated at 1 mg/kg in dog,,50588,Canis lupus familiaris,Intermediate,,9615.0,7440,In vivo,,,,,A,1,BAO_0000218,5444,1,CHEMBL623598,,N
,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,50588,Canis lupus familiaris,Intermediate,,9615.0,7441,In vivo,,,,,A,1,BAO_0000218,5444,1,CHEMBL623599,,N
,,Longer half-life in dog (i.v.) at 0.5 mpk,,50588,Canis lupus familiaris,Intermediate,,9615.0,7442,In vivo,,,,,A,1,BAO_0000218,17853,1,CHEMBL623600,,N
,,Oral bioavailability in dog (dose 5 uM/kg),,50588,Canis lupus familiaris,Intermediate,,9615.0,7443,In vivo,,,,,A,1,BAO_0000218,4353,1,CHEMBL623601,,N
,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,50588,Canis lupus familiaris,Intermediate,,9615.0,7444,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL623602,,N
,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,50588,Canis lupus familiaris,Intermediate,,9615.0,7445,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL623603,,N
,,Bioavailability in dog (dose 1 mg/kg i.v.),,50588,Canis lupus familiaris,Intermediate,,9615.0,7446,In vivo,,,,,A,1,BAO_0000218,16452,1,CHEMBL623604,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,50594,Mus musculus,Intermediate,2048.0,10090.0,7447,In vivo,,,,Lung,A,1,BAO_0000218,10107,1,CHEMBL623605,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,2048.0,10090.0,7448,In vivo,,,,Lung,A,1,BAO_0000218,10107,1,CHEMBL623606,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,2048.0,10090.0,7449,In vivo,,,,Lung,A,1,BAO_0000218,10107,1,CHEMBL623607,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,2048.0,10090.0,7450,In vivo,,,,Lung,A,1,BAO_0000218,10107,1,CHEMBL623608,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594,Mus musculus,Intermediate,2048.0,10090.0,7451,In vivo,,,,Lung,A,1,BAO_0000218,10107,1,CHEMBL623609,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,2048.0,10090.0,7452,In vivo,,,,Lung,A,1,BAO_0000218,10107,1,CHEMBL623610,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,2385.0,10090.0,7453,In vivo,,,,Muscle tissue,A,1,BAO_0000218,10107,1,CHEMBL623611,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,50594,Mus musculus,Intermediate,2385.0,10090.0,7454,In vivo,,,,Muscle tissue,A,1,BAO_0000218,10107,1,CHEMBL623612,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,2385.0,10090.0,7455,In vivo,,,,Muscle tissue,A,1,BAO_0000218,10107,1,CHEMBL623613,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,2385.0,10090.0,7456,In vivo,,,,Muscle tissue,A,1,BAO_0000218,10107,1,CHEMBL623614,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,2385.0,10090.0,7457,In vivo,,,,Muscle tissue,A,1,BAO_0000218,10107,1,CHEMBL623615,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594,Mus musculus,Intermediate,2385.0,10090.0,7458,In vivo,,,,Muscle tissue,A,1,BAO_0000218,10107,1,CHEMBL623616,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,2385.0,10090.0,7459,In vivo,,,,Muscle tissue,A,1,BAO_0000218,10107,1,CHEMBL623617,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,14.0,10090.0,7460,In vivo,,,,Zone of skin,A,1,BAO_0000218,10107,1,CHEMBL875944,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594,Mus musculus,Intermediate,14.0,10090.0,7461,In vivo,,,,Zone of skin,A,1,BAO_0000218,10107,1,CHEMBL623618,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,14.0,10090.0,7462,In vivo,,,,Zone of skin,A,1,BAO_0000218,10107,1,CHEMBL623619,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,14.0,10090.0,7463,In vivo,,,,Zone of skin,A,1,BAO_0000218,10107,1,CHEMBL623620,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,14.0,10090.0,7464,In vivo,,,,Zone of skin,A,1,BAO_0000218,10107,1,CHEMBL623621,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594,Mus musculus,Intermediate,14.0,10090.0,7465,In vivo,,,,Zone of skin,A,1,BAO_0000218,10107,1,CHEMBL623622,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,14.0,10090.0,7466,In vivo,,,,Zone of skin,A,1,BAO_0000218,10107,1,CHEMBL623623,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,2106.0,10090.0,7467,In vivo,,,,Spleen,A,1,BAO_0000218,10107,1,CHEMBL623624,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594,Mus musculus,Intermediate,2106.0,10090.0,7468,In vivo,,,,Spleen,A,1,BAO_0000218,10107,1,CHEMBL618521,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,2106.0,10090.0,7469,In vivo,,,,Spleen,A,1,BAO_0000218,10107,1,CHEMBL618522,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,2106.0,10090.0,7470,In vivo,,,,Spleen,A,1,BAO_0000218,10107,1,CHEMBL618523,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,2106.0,10090.0,7471,In vivo,,,,Spleen,A,1,BAO_0000218,10107,1,CHEMBL618524,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594,Mus musculus,Intermediate,2106.0,10090.0,7472,In vivo,,,,Spleen,A,1,BAO_0000218,10107,1,CHEMBL618525,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,2106.0,10090.0,7473,In vivo,,,,Spleen,A,1,BAO_0000218,10107,1,CHEMBL624586,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,50594,Mus musculus,Intermediate,945.0,10090.0,7474,In vivo,,,,Stomach,A,1,BAO_0000218,10107,1,CHEMBL624587,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,50594,Mus musculus,Intermediate,945.0,10090.0,7475,In vivo,,,,Stomach,A,1,BAO_0000218,10107,1,CHEMBL624588,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,50594,Mus musculus,Intermediate,945.0,10090.0,7476,In vivo,,,,Stomach,A,1,BAO_0000218,10107,1,CHEMBL624589,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,50594,Mus musculus,Intermediate,945.0,10090.0,7477,In vivo,,,,Stomach,A,1,BAO_0000218,10107,1,CHEMBL624590,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,50594,Mus musculus,Intermediate,945.0,10090.0,7478,In vivo,,,,Stomach,A,1,BAO_0000218,10107,1,CHEMBL624591,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,50594,Mus musculus,Intermediate,945.0,10090.0,7479,In vivo,,,,Stomach,A,1,BAO_0000218,10107,1,CHEMBL624592,,N
,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,50594,Mus musculus,Intermediate,945.0,10090.0,7480,In vivo,,,,Stomach,A,1,BAO_0000218,10107,1,CHEMBL624593,,N
,,Oral bioavailability in rat,,50597,Rattus norvegicus,Intermediate,,10116.0,7481,In vivo,,,,,A,1,BAO_0000218,4689,1,CHEMBL624594,,N
,,Tested for the bioavailability in rat,,50597,Rattus norvegicus,Intermediate,,10116.0,7482,In vivo,,,,,A,1,BAO_0000218,4950,1,CHEMBL624595,,N
,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,50597,Rattus norvegicus,Intermediate,,10116.0,7483,In vivo,,,,,A,1,BAO_0000218,5328,1,CHEMBL624596,,N
,,Bioavailability in rat,,50597,Rattus norvegicus,Intermediate,,10116.0,7484,In vivo,,,,,A,1,BAO_0000218,406,1,CHEMBL624597,,N
,,Bioavailability in rat,,50597,Rattus norvegicus,Intermediate,,10116.0,7485,In vivo,,,,,A,1,BAO_0000218,12500,1,CHEMBL624598,,N
,,Bioavailability in rat (dose 3-10 mg/kg),,50597,Rattus norvegicus,Intermediate,,10116.0,7486,In vivo,,,,,A,1,BAO_0000218,12500,1,CHEMBL624599,,N
,,Bioavailability in rat,,50597,Rattus norvegicus,Intermediate,,10116.0,7487,In vivo,,,,,A,1,BAO_0000218,5247,1,CHEMBL875166,,N
,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,50597,Rattus norvegicus,Intermediate,1969.0,10116.0,7488,In vivo,,,,Plasma,A,1,BAO_0000218,4186,1,CHEMBL624600,,N
,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,50597,Rattus norvegicus,Intermediate,1969.0,10116.0,7489,In vivo,,,,Plasma,A,1,BAO_0000218,4186,1,CHEMBL624601,,N
,,Half life after oral administration was determined in rats at 6 mg/kg,,50597,Rattus norvegicus,Intermediate,,10116.0,7490,In vivo,,,,,A,1,BAO_0000218,6647,1,CHEMBL624602,,N
,,Half life was determined,,50597,Rattus norvegicus,Intermediate,,10116.0,7491,,,,,,A,1,BAO_0000218,6484,1,CHEMBL624603,,N
,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,50597,Rattus norvegicus,Intermediate,,10116.0,7492,In vivo,,,,,A,1,BAO_0000218,3249,1,CHEMBL624604,,N
,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,50597,Rattus norvegicus,Intermediate,1969.0,10116.0,7493,In vivo,,,,Plasma,A,1,BAO_0000218,6281,1,CHEMBL624605,,N
,,Half life in rats,,50597,Rattus norvegicus,Intermediate,,10116.0,7494,,,,,,A,1,BAO_0000218,3307,1,CHEMBL624606,,N
,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,50597,Rattus norvegicus,Intermediate,178.0,10116.0,7495,In vivo,,,,Blood,A,1,BAO_0000218,12058,1,CHEMBL624607,,N
,,Hill coefficient of the compound,,50597,Rattus norvegicus,Intermediate,,10116.0,7496,,,,,,A,1,BAO_0000218,8833,1,CHEMBL624608,,N
,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,50597,Rattus norvegicus,Intermediate,178.0,10116.0,7497,,,,,Blood,A,1,BAO_0000218,3193,1,CHEMBL624609,,N
,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,50597,Rattus norvegicus,Intermediate,178.0,10116.0,7498,,,,,Blood,A,1,BAO_0000218,3193,1,CHEMBL624610,,N
,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,50597,Rattus norvegicus,Intermediate,178.0,10116.0,7499,,,,,Blood,A,1,BAO_0000218,3193,1,CHEMBL624611,,N
,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,50597,Rattus norvegicus,Intermediate,178.0,10116.0,7500,,,,,Blood,A,1,BAO_0000218,3193,1,CHEMBL624612,,N
,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,50597,Rattus norvegicus,Intermediate,178.0,10116.0,7501,,,,,Blood,A,1,BAO_0000218,3193,1,CHEMBL875167,,N
,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,50597,Rattus norvegicus,Intermediate,178.0,10116.0,7502,,,,,Blood,A,1,BAO_0000218,3193,1,CHEMBL624613,,N
,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,50597,Rattus norvegicus,Intermediate,178.0,10116.0,7503,,,,,Blood,A,1,BAO_0000218,3193,1,CHEMBL624614,,N
,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,50597,Rattus norvegicus,Intermediate,,10116.0,7504,,,,,,A,1,BAO_0000218,5960,1,CHEMBL624392,,N
,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,50597,Rattus norvegicus,Intermediate,955.0,10116.0,7505,In vivo,,,,Brain,A,1,BAO_0000218,13950,1,CHEMBL624393,,N
,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,50597,Rattus norvegicus,Intermediate,955.0,10116.0,7506,In vivo,,,,Brain,A,1,BAO_0000218,13950,1,CHEMBL624394,,N
,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,50597,Rattus norvegicus,Intermediate,955.0,10116.0,7507,In vivo,,,,Brain,A,1,BAO_0000218,13950,1,CHEMBL624395,,N
,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,50597,Rattus norvegicus,Intermediate,955.0,10116.0,7508,In vivo,,,,Brain,A,1,BAO_0000218,13950,1,CHEMBL624396,,N
,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,50597,Rattus norvegicus,Intermediate,955.0,10116.0,7509,In vivo,,,,Brain,A,1,BAO_0000218,13950,1,CHEMBL624397,,N
,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,50597,Rattus norvegicus,Intermediate,2046.0,10116.0,7510,In vivo,,,,Thyroid gland,A,1,BAO_0000218,13950,1,CHEMBL624398,,N
,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,50597,Rattus norvegicus,Intermediate,2046.0,10116.0,7511,In vivo,,,,Thyroid gland,A,1,BAO_0000218,13950,1,CHEMBL624399,,N
,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,50597,Rattus norvegicus,Intermediate,2046.0,10116.0,7512,In vivo,,,,Thyroid gland,A,1,BAO_0000218,13950,1,CHEMBL624400,,N
,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,50597,Rattus norvegicus,Intermediate,2046.0,10116.0,7513,In vivo,,,,Thyroid gland,A,1,BAO_0000218,13950,1,CHEMBL624401,,N
,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,50597,Rattus norvegicus,Intermediate,2046.0,10116.0,7514,In vivo,,,,Thyroid gland,A,1,BAO_0000218,13950,1,CHEMBL624402,,N
,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,50597,Rattus norvegicus,Intermediate,178.0,10116.0,7515,In vivo,,,,Blood,A,1,BAO_0000218,9866,1,CHEMBL624403,,N
,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,50597,Rattus norvegicus,Intermediate,178.0,10116.0,7516,In vivo,,,,Blood,A,1,BAO_0000218,9866,1,CHEMBL624404,,N
,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,50597,Rattus norvegicus,Intermediate,178.0,10116.0,7517,In vivo,,,,Blood,A,1,BAO_0000218,9866,1,CHEMBL624405,,N
,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,50597,Rattus norvegicus,Intermediate,10000001.0,10116.0,7518,In vivo,,,,Bone,A,1,BAO_0000218,9866,1,CHEMBL624406,,N
,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,50597,Rattus norvegicus,Intermediate,10000001.0,10116.0,7519,In vivo,,,,Bone,A,1,BAO_0000218,9866,1,CHEMBL624407,,N
,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,50597,Rattus norvegicus,Intermediate,10000001.0,10116.0,7520,In vivo,,,,Bone,A,1,BAO_0000218,9866,1,CHEMBL624408,,N
,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,50597,Rattus norvegicus,Intermediate,948.0,10116.0,7521,In vivo,,,,Heart,A,1,BAO_0000218,9866,1,CHEMBL618644,,N
,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,50597,Rattus norvegicus,Intermediate,948.0,10116.0,7522,In vivo,,,,Heart,A,1,BAO_0000218,9866,1,CHEMBL618645,,N
,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,50597,Rattus norvegicus,Intermediate,948.0,10116.0,7523,In vivo,,,,Heart,A,1,BAO_0000218,9866,1,CHEMBL618646,,N
